allergic_ID,Adverse-Event,Arm-affected,Arm-at-risk,Category,Trial-Id,URL,Condition,Intervention,Serious-Other,Arm.,Arm_Title,classes_ID,Drug,Class
1107,Drug_hypersensitivity,2,328,Immune_system_disorders,NCT00001213,https://clinicaltrials.gov/show/NCT00001213,Cystinosis,Cysteamine,other_events,arm0,Cysteamine-Topical-Solution,,,
2291,Anaphylaxis,1,38,Immune_system_disorders,NCT00003298,https://clinicaltrials.gov/show/NCT00003298,Gastric_Cancer,cisplatin|fluorouracil|leucovorin_calcium|paclitaxel|surgery|radiation_therapy|,serious_events,arm0,Step-1(Neoadjuvant-Therapy),,,
2415,Allergic_reaction,3,422,Immune_system_disorders,NCT00003389,https://clinicaltrials.gov/show/NCT00003389,Lymphoma,Doxorubicin|Bleomycin|Vinblastine|Dacarbazine|Vincristine|Mechlorethamine|Etoposide|Prednisone|Cyclophosphamide|Radiotherapy|,serious_events,arm1,Arm-B-(Stanford-V),,,
2293,Anaphylaxis,1,1748,Immune_system_disorders,NCT00003782,https://clinicaltrials.gov/show/NCT00003782,Breast_Cancer,cyclophosphamide|docetaxel|doxorubicin|,serious_events,arm0,Doxorubicin-+-Cyclophosphamide-Then-Docetaxel,13,cyclophosphamide,alkylating-agent
2293,Anaphylaxis,1,1748,Immune_system_disorders,NCT00003782,https://clinicaltrials.gov/show/NCT00003782,Breast_Cancer,cyclophosphamide|docetaxel|doxorubicin|,serious_events,arm0,Doxorubicin-+-Cyclophosphamide-Then-Docetaxel,38,doxorubicin,anthracycline-antibiotic
2293,Anaphylaxis,1,1748,Immune_system_disorders,NCT00003782,https://clinicaltrials.gov/show/NCT00003782,Breast_Cancer,cyclophosphamide|docetaxel|doxorubicin|,serious_events,arm0,Doxorubicin-+-Cyclophosphamide-Then-Docetaxel,8,docetaxel,taxane
2292,Anaphylaxis,3,1748,Immune_system_disorders,NCT00003782,https://clinicaltrials.gov/show/NCT00003782,Breast_Cancer,cyclophosphamide|docetaxel|doxorubicin|,serious_events,arm1,Doxorubicin-+-Docetaxel,38,doxorubicin,anthracycline-antibiotic
2292,Anaphylaxis,3,1748,Immune_system_disorders,NCT00003782,https://clinicaltrials.gov/show/NCT00003782,Breast_Cancer,cyclophosphamide|docetaxel|doxorubicin|,serious_events,arm1,Doxorubicin-+-Docetaxel,8,docetaxel,taxane
2376,Allergy,1,90,Immune_system_disorders,NCT00003869,https://clinicaltrials.gov/show/NCT00003869,Stage_IIIA_Non-small_Cell_Lung_Cancer|Stage_IIIB_Non-small_Cell_Lung_Cancer|Stage_IV_Non-small_Cell_Lung_Cancer|,carboxyamidotriazole|placebo|quality-of-life_assessment|laboratory_biomarker_analysis|,serious_events,arm0,Carboxyamidotriazole,,,
2416,Allergic_reaction,5,61,Immune_system_disorders,NCT00003896,https://clinicaltrials.gov/show/NCT00003896,Fallopian_Tube_Cancer|Ovarian_Cancer|Peritoneal_Cavity_Cancer|,cisplatin|liposomal_doxorubicin|paclitaxel|,other_events,arm0,Paclitaxel/CDDP/Liposomal-Doxorubicin,38,doxorubicin,anthracycline-antibiotic
2416,Allergic_reaction,5,61,Immune_system_disorders,NCT00003896,https://clinicaltrials.gov/show/NCT00003896,Fallopian_Tube_Cancer|Ovarian_Cancer|Peritoneal_Cavity_Cancer|,cisplatin|liposomal_doxorubicin|paclitaxel|,other_events,arm0,Paclitaxel/CDDP/Liposomal-Doxorubicin,89,liposomal,Class_Name_Needed
2416,Allergic_reaction,5,61,Immune_system_disorders,NCT00003896,https://clinicaltrials.gov/show/NCT00003896,Fallopian_Tube_Cancer|Ovarian_Cancer|Peritoneal_Cavity_Cancer|,cisplatin|liposomal_doxorubicin|paclitaxel|,other_events,arm0,Paclitaxel/CDDP/Liposomal-Doxorubicin,2,paclitaxel,taxane
2418,Allergic_reaction,16,289,Immune_system_disorders,NCT00004859,https://clinicaltrials.gov/show/NCT00004859,Lung_Cancer,carboplatin|paclitaxel|thalidomide|radiation_therapy|,serious_events,arm0,Arm-A-(Paclitaxel-+-Carboplatin-+-Radiation-),3,carboplatin,alkalating-agent
2418,Allergic_reaction,16,289,Immune_system_disorders,NCT00004859,https://clinicaltrials.gov/show/NCT00004859,Lung_Cancer,carboplatin|paclitaxel|thalidomide|radiation_therapy|,serious_events,arm0,Arm-A-(Paclitaxel-+-Carboplatin-+-Radiation-),2,paclitaxel,taxane
2417,Allergic_reaction,13,288,Immune_system_disorders,NCT00004859,https://clinicaltrials.gov/show/NCT00004859,Lung_Cancer,carboplatin|paclitaxel|thalidomide|radiation_therapy|,serious_events,arm1,Arm-B-(Paclitaxel-+-Carboplatin-+-Radiation-+-Thalidomide),3,carboplatin,alkalating-agent
2417,Allergic_reaction,13,288,Immune_system_disorders,NCT00004859,https://clinicaltrials.gov/show/NCT00004859,Lung_Cancer,carboplatin|paclitaxel|thalidomide|radiation_therapy|,serious_events,arm1,Arm-B-(Paclitaxel-+-Carboplatin-+-Radiation-+-Thalidomide),2,paclitaxel,taxane
2420,Allergic_Reaction,3,41,General_disorders,NCT00004888,https://clinicaltrials.gov/show/NCT00004888,Recurrent_Breast_Cancer|Stage_IV_Breast_Cancer|,pegylated_liposomal_doxorubicin_hydrochloride|docetaxel|trastuzumab|laboratory_biomarker_analysis|,other_events,arm0,Arm-I:-Doxorubicin-and-Taxotere,38,doxorubicin,anthracycline-antibiotic
2419,Allergic_Reaction,8,48,General_disorders,NCT00004888,https://clinicaltrials.gov/show/NCT00004888,Recurrent_Breast_Cancer|Stage_IV_Breast_Cancer|,pegylated_liposomal_doxorubicin_hydrochloride|docetaxel|trastuzumab|laboratory_biomarker_analysis|,other_events,arm1,Arm-II:-Doxorubicin-Taxotere-and-Herceptin,38,doxorubicin,anthracycline-antibiotic
2377,Allergy,4,261,Immune_system_disorders,NCT00006011,https://clinicaltrials.gov/show/NCT00006011,Endometrial_Adenocarcinoma|Endometrial_Adenosquamous_Carcinoma|Endometrial_Clear_Cell_Adenocarcinoma|Endometrial_Endometrioid_Adenocarcinoma_Variant_With_Squamous_Differentiation|Endometrial_Serous_Adenocarcinoma|Stage_III_Uterine_Corpus_Cancer|,Doxorubicin_Hydrochloride|Cisplatin|Filgrastim|Pegfilgrastim|Paclitaxel|,other_events,arm0,Arm-1,,,
2378,Allergy,8,278,Immune_system_disorders,NCT00006011,https://clinicaltrials.gov/show/NCT00006011,Endometrial_Adenocarcinoma|Endometrial_Adenosquamous_Carcinoma|Endometrial_Clear_Cell_Adenocarcinoma|Endometrial_Endometrioid_Adenocarcinoma_Variant_With_Squamous_Differentiation|Endometrial_Serous_Adenocarcinoma|Stage_III_Uterine_Corpus_Cancer|,Doxorubicin_Hydrochloride|Cisplatin|Filgrastim|Pegfilgrastim|Paclitaxel|,other_events,arm1,Arm-2,,,
2422,Allergic_reaction,1,13,Immune_system_disorders,NCT00006721,https://clinicaltrials.gov/show/NCT00006721,Lymphoma,rituximab|cyclophosphamide|doxorubicin_hydrochloride|prednisone|vincristine_sulfate|tositumomab_and_iodine_I_131_tositumomab|,other_events,arm0,CHOP-Only,,,
2421,Allergic_reaction,49,263,Immune_system_disorders,NCT00006721,https://clinicaltrials.gov/show/NCT00006721,Lymphoma,rituximab|cyclophosphamide|doxorubicin_hydrochloride|prednisone|vincristine_sulfate|tositumomab_and_iodine_I_131_tositumomab|,other_events,arm1,CHOP-+-Rituximab,16,rituximab,monoclonal-antibody
2423,Allergic_reaction,4,58,Immune_system_disorders,NCT00008138,https://clinicaltrials.gov/show/NCT00008138,Fallopian_Tube_Cancer|Ovarian_Cancer|Peritoneal_Cavity_Cancer|,carboplatin|paclitaxel|debulking_surgery|,other_events,arm0,Neoadjuvant-Paclitaxel-(IV)-+-Carboplatin-(V),3,carboplatin,alkalating-agent
2423,Allergic_reaction,4,58,Immune_system_disorders,NCT00008138,https://clinicaltrials.gov/show/NCT00008138,Fallopian_Tube_Cancer|Ovarian_Cancer|Peritoneal_Cavity_Cancer|,carboplatin|paclitaxel|debulking_surgery|,other_events,arm0,Neoadjuvant-Paclitaxel-(IV)-+-Carboplatin-(V),2,paclitaxel,taxane
2424,Allergic_Reaction,1,21,Immune_system_disorders,NCT00010257,https://clinicaltrials.gov/show/NCT00010257,Thymoma|Thymic_Carcinoma|,carboplatin|paclitaxel|,serious_events,arm1,Thymic-Carcinoma,,,
2425,Allergic_Reaction,1,21,Immune_system_disorders,NCT00010257,https://clinicaltrials.gov/show/NCT00010257,Thymoma|Thymic_Carcinoma|,carboplatin|paclitaxel|,other_events,arm1,Thymic-Carcinoma,,,
2426,Allergic_Reaction,2,62,Immune_system_disorders,NCT00022659,https://clinicaltrials.gov/show/NCT00022659,Primary_Peritoneal_Cavity_Cancer|Recurrent_Ovarian_Epithelial_Cancer|Stage_IV_Ovarian_Epithelial_Cancer|,bevacizumab|laboratory_biomarker_analysis|,other_events,arm0,Bevacizumab,4,bevacizumab,monoclonal-antibody
2427,Allergic_Reaction,1,62,Immune_system_disorders,NCT00022659,https://clinicaltrials.gov/show/NCT00022659,Primary_Peritoneal_Cavity_Cancer|Recurrent_Ovarian_Epithelial_Cancer|Stage_IV_Ovarian_Epithelial_Cancer|,bevacizumab|laboratory_biomarker_analysis|,serious_events,arm0,Bevacizumab,4,bevacizumab,monoclonal-antibody
2426,Allergic_Reaction,2,62,Immune_system_disorders,NCT00022659,https://clinicaltrials.gov/show/NCT00022659,Primary_Peritoneal_Cavity_Cancer|Recurrent_Ovarian_Epithelial_Cancer|Stage_IV_Ovarian_Epithelial_Cancer|,bevacizumab|laboratory_biomarker_analysis|,other_events,arm0,Bevacizumab,22,bevacizumab,monoclonal-antibody
2427,Allergic_Reaction,1,62,Immune_system_disorders,NCT00022659,https://clinicaltrials.gov/show/NCT00022659,Primary_Peritoneal_Cavity_Cancer|Recurrent_Ovarian_Epithelial_Cancer|Stage_IV_Ovarian_Epithelial_Cancer|,bevacizumab|laboratory_biomarker_analysis|,serious_events,arm0,Bevacizumab,22,bevacizumab,monoclonal-antibody
2428,Allergic_Reaction,3,49,Immune_system_disorders,NCT00025155,https://clinicaltrials.gov/show/NCT00025155,Primary_Peritoneal_Cavity_Cancer|Recurrent_Ovarian_Epithelial_Cancer|,ixabepilone,other_events,arm0,Treatment-(Ixabepilone),82,ixabepilone,antimicrotubule-agent
2429,Allergic_Reaction,1,46,Immune_system_disorders,NCT00025233,https://clinicaltrials.gov/show/NCT00025233,Cervical_Squamous_Cell_Carcinoma|Recurrent_Cervical_Cancer|,bevacizumab|laboratory_biomarker_analysis|,other_events,arm0,Bevacizumab,4,bevacizumab,monoclonal-antibody
2429,Allergic_Reaction,1,46,Immune_system_disorders,NCT00025233,https://clinicaltrials.gov/show/NCT00025233,Cervical_Squamous_Cell_Carcinoma|Recurrent_Cervical_Cancer|,bevacizumab|laboratory_biomarker_analysis|,other_events,arm0,Bevacizumab,22,bevacizumab,monoclonal-antibody
1108,Drug_hypersensitivity,1,8,Immune_system_disorders,NCT00027027,https://clinicaltrials.gov/show/NCT00027027,Neoplasms,rhuMAb_2C4,serious_events,arm4,rhuMAb-2C4:-15-mg/kg,,,
1854,Dermatitis_allergic,1,4814,Skin_and_subcutaneous_tissue_disorders,NCT00036270,https://clinicaltrials.gov/show/NCT00036270,Breast_Neoplasms,exemestane_(Aromasin)|tamoxifen_+_exemestane|,serious_events,arm0,Tamoxifen-Followed-by-Exemestane,56,exemestane,aromatase-inhibitor
11,Hypersensitivity,1,4814,Immune_system_disorders,NCT00036270,https://clinicaltrials.gov/show/NCT00036270,Breast_Neoplasms,exemestane_(Aromasin)|tamoxifen_+_exemestane|,serious_events,arm0,Tamoxifen-Followed-by-Exemestane,56,exemestane,aromatase-inhibitor
10,Hypersensitivity,4,4852,Immune_system_disorders,NCT00036270,https://clinicaltrials.gov/show/NCT00036270,Breast_Neoplasms,exemestane_(Aromasin)|tamoxifen_+_exemestane|,serious_events,arm1,Exemestane,56,exemestane,aromatase-inhibitor
12,Hypersensitivity,1,53,Immune_system_disorders,NCT00038103,https://clinicaltrials.gov/show/NCT00038103,Breast_Neoplasms,Exemestane|Celecoxib_+_Exemestane|,other_events,arm0,Exemestane-(Exemestane-Alone),56,exemestane,aromatase-inhibitor
1855,Dermatitis_allergic,1,56,Skin_and_subcutaneous_tissue_disorders,NCT00038103,https://clinicaltrials.gov/show/NCT00038103,Breast_Neoplasms,Exemestane|Celecoxib_+_Exemestane|,serious_events,arm1,Combination-(Exemestane-+-Celecoxib),56,exemestane,aromatase-inhibitor
1856,Dermatitis_allergic,1,53,Skin_and_subcutaneous_tissue_disorders,NCT00038103,https://clinicaltrials.gov/show/NCT00038103,Breast_Neoplasms,Exemestane|Celecoxib_+_Exemestane|,other_events,arm1,Combination-(Exemestane-+-Celecoxib),56,exemestane,aromatase-inhibitor
15,Hypersensitivity,2,2320,Immune_system_disorders,NCT00038467,https://clinicaltrials.gov/show/NCT00038467,Breast_Neoplasms,Tamoxifen|Exemestane|,serious_events,arm0,Exemestane,56,exemestane,aromatase-inhibitor
16,Hypersensitivity,2,2338,Immune_system_disorders,NCT00038467,https://clinicaltrials.gov/show/NCT00038467,Breast_Neoplasms,Tamoxifen|Exemestane|,serious_events,arm1,Tamoxifen,,,
13,Hypersensitivity,6,105,Immune_system_disorders,NCT00039130,https://clinicaltrials.gov/show/NCT00039130,Leukemia|Lymphoma|,filgrastim|rituximab|cyclophosphamide|cytarabine|dexamethasone|doxorubicin_hydrochloride|etoposide|ifosfamide|leucovorin_calcium|methotrexate|prednisone|vincristine_sulfate|Allopurinol|,other_events,arm0,Rituximab-With-High-Intensity-Chemotherapy,16,rituximab,monoclonal-antibody
14,Hypersensitivity,1,105,Immune_system_disorders,NCT00039130,https://clinicaltrials.gov/show/NCT00039130,Leukemia|Lymphoma|,filgrastim|rituximab|cyclophosphamide|cytarabine|dexamethasone|doxorubicin_hydrochloride|etoposide|ifosfamide|leucovorin_calcium|methotrexate|prednisone|vincristine_sulfate|Allopurinol|,serious_events,arm0,Rituximab-With-High-Intensity-Chemotherapy,16,rituximab,monoclonal-antibody
2431,Allergic_reaction,6,105,Immune_system_disorders,NCT00040937,https://clinicaltrials.gov/show/NCT00040937,Multiple_Myeloma,filgrastim|sargramostim|cyclophosphamide|dexamethasone|melphalan|prednisone|thalidomide|peripheral_blood_stem_cell_transplantation|,other_events,arm1,Autologous-PBSCT,,,
2432,Allergic_reaction,5,49,Immune_system_disorders,NCT00041132,https://clinicaltrials.gov/show/NCT00041132,Lymphoma,filgrastim|rituximab|cyclophosphamide|cytarabine|dexamethasone|doxorubicin|leucovorin|methotrexate|vincristine|,other_events,arm0,Hyper-CVAD-+-MTX/Ara-C-+-Rituximab,86,mtx,Class_Name_Needed
2432,Allergic_reaction,5,49,Immune_system_disorders,NCT00041132,https://clinicaltrials.gov/show/NCT00041132,Lymphoma,filgrastim|rituximab|cyclophosphamide|cytarabine|dexamethasone|doxorubicin|leucovorin|methotrexate|vincristine|,other_events,arm0,Hyper-CVAD-+-MTX/Ara-C-+-Rituximab,16,rituximab,monoclonal-antibody
2433,Allergic_Reaction,1,46,Immune_system_disorders,NCT00042939,https://clinicaltrials.gov/show/NCT00042939,Pancreatic_Cancer,cetuximab|docetaxel|irinotecan_hydrochloride|,serious_events,arm0,Arm-A:-Irinotecan/Docetaxel,46,irinotecan,plant-alkaloid-and-topoisomerase-1-inhibitor
2433,Allergic_Reaction,1,46,Immune_system_disorders,NCT00042939,https://clinicaltrials.gov/show/NCT00042939,Pancreatic_Cancer,cetuximab|docetaxel|irinotecan_hydrochloride|,serious_events,arm0,Arm-A:-Irinotecan/Docetaxel,8,docetaxel,taxane
2434,Allergic_reaction,6,74,Immune_system_disorders,NCT00045630,https://clinicaltrials.gov/show/NCT00045630,Bladder_Cancer|Transitional_Cell_Cancer_of_the_Renal_Pelvis_and_Ureter|Urethral_Cancer|,carboplatin|gemcitabine|paclitaxel|surgery|,other_events,arm0,Gemcitabine-Paclitaxel-Carboplatin-Followed-by-Surgery,3,carboplatin,alkalating-agent
2434,Allergic_reaction,6,74,Immune_system_disorders,NCT00045630,https://clinicaltrials.gov/show/NCT00045630,Bladder_Cancer|Transitional_Cell_Cancer_of_the_Renal_Pelvis_and_Ureter|Urethral_Cancer|,carboplatin|gemcitabine|paclitaxel|surgery|,other_events,arm0,Gemcitabine-Paclitaxel-Carboplatin-Followed-by-Surgery,6,gemcitabine,antimetabolites
2434,Allergic_reaction,6,74,Immune_system_disorders,NCT00045630,https://clinicaltrials.gov/show/NCT00045630,Bladder_Cancer|Transitional_Cell_Cancer_of_the_Renal_Pelvis_and_Ureter|Urethral_Cancer|,carboplatin|gemcitabine|paclitaxel|surgery|,other_events,arm0,Gemcitabine-Paclitaxel-Carboplatin-Followed-by-Surgery,2,paclitaxel,taxane
22,Hypersensitivity,2,104,Immune_system_disorders,NCT00046891,https://clinicaltrials.gov/show/NCT00046891,Breast_Cancer|Neurotoxicity|,Ginkgo_Biloba|Placebo|,other_events,arm0,Ginkgo-Biloba,,,
2435,Allergic_reaction,2,101,Immune_system_disorders,NCT00047320,https://clinicaltrials.gov/show/NCT00047320,Brain_Tumor|Central_Nervous_System_Tumors|Childhood_Germ_Cell_Tumor|,carboplatin|etoposide|ifosfamide|thiotepa|adjuvant_therapy|conventional_surgery|neoadjuvant_therapy|peripheral_blood_stem_cell_transplantation|radiation_therapy|,other_events,arm0,Radiation-Therapy-(CR-From-Induction),,,
2294,Anaphylaxis,1,101,Immune_system_disorders,NCT00047320,https://clinicaltrials.gov/show/NCT00047320,Brain_Tumor|Central_Nervous_System_Tumors|Childhood_Germ_Cell_Tumor|,carboplatin|etoposide|ifosfamide|thiotepa|adjuvant_therapy|conventional_surgery|neoadjuvant_therapy|peripheral_blood_stem_cell_transplantation|radiation_therapy|,other_events,arm0,Radiation-Therapy-(CR-From-Induction),,,
27,Hypersensitivity,1,39,Immune_system_disorders,NCT00049127,https://clinicaltrials.gov/show/NCT00049127,Adult_Anaplastic_Oligodendroglioma|Adult_Mixed_Glioma|Adult_Oligodendroglioma|Recurrent_Adult_Brain_Tumor|,imatinib_mesylate|laboratory_biomarker_analysis|pharmacological_study|,other_events,arm1,Study-2-Arm-B,,,
2436,allergic_reaction,5,58,Immune_system_disorders,NCT00049257,https://clinicaltrials.gov/show/NCT00049257,Prostate_Cancer,carboplatin|paclitaxel|,other_events,arm0,Carboplatin-Paclitaxel,3,carboplatin,alkalating-agent
2436,allergic_reaction,5,58,Immune_system_disorders,NCT00049257,https://clinicaltrials.gov/show/NCT00049257,Prostate_Cancer,carboplatin|paclitaxel|,other_events,arm0,Carboplatin-Paclitaxel,2,paclitaxel,taxane
2437,Allergic_reaction,1,243,Immune_system_disorders,NCT00049543,https://clinicaltrials.gov/show/NCT00049543,Adenocarcinoma_of_the_Lung|Adenosquamous_Cell_Lung_Cancer|Bronchoalveolar_Cell_Lung_Cancer|Large_Cell_Lung_Cancer|Squamous_Cell_Lung_Cancer|Stage_IB_Non-small_Cell_Lung_Cancer|Stage_IIA_Non-small_Cell_Lung_Cancer|Stage_IIB_Non-small_Cell_Lung_Cancer|Stage,gefitinib|placebo|laboratory_biomarker_analysis|,serious_events,arm1,Arm-II-(Placebo),,,
1110,Drug_hypersensitivity,1,300,Immune_system_disorders,NCT00050011,https://clinicaltrials.gov/show/NCT00050011,Breast_Neoplasms|Osteoporosis|,Zoledronic_Acid|Letrozole|,serious_events,arm1,Zoledronic-Acid-Delayed-start,28,zoledronic,bisphosphonates-(supportive-treatment-of-cancer--treats-symptoms-and/or-decreases-complications)
2438,Allergic_reaction,4,297,Immune_system_disorders,NCT00050167,https://clinicaltrials.gov/show/NCT00050167,Breast_Cancer,Paclitaxel|Docetaxel|Capecitabine|,other_events,arm0,Weekly-Paclitaxel-(WP),2,paclitaxel,taxane
2440,Allergic_reaction,2,297,Immune_system_disorders,NCT00050167,https://clinicaltrials.gov/show/NCT00050167,Breast_Cancer,Paclitaxel|Docetaxel|Capecitabine|,serious_events,arm0,Weekly-Paclitaxel-(WP),2,paclitaxel,taxane
2439,Allergic_reaction,6,293,Immune_system_disorders,NCT00050167,https://clinicaltrials.gov/show/NCT00050167,Breast_Cancer,Paclitaxel|Docetaxel|Capecitabine|,other_events,arm1,Docetaxel-and-Capecitabine-(DX),17,capecitabine,antimetabolite
2441,Allergic_reaction,4,293,Immune_system_disorders,NCT00050167,https://clinicaltrials.gov/show/NCT00050167,Breast_Cancer,Paclitaxel|Docetaxel|Capecitabine|,serious_events,arm1,Docetaxel-and-Capecitabine-(DX),17,capecitabine,antimetabolite
2439,Allergic_reaction,6,293,Immune_system_disorders,NCT00050167,https://clinicaltrials.gov/show/NCT00050167,Breast_Cancer,Paclitaxel|Docetaxel|Capecitabine|,other_events,arm1,Docetaxel-and-Capecitabine-(DX),29,capecitabine,antimetabolite
2441,Allergic_reaction,4,293,Immune_system_disorders,NCT00050167,https://clinicaltrials.gov/show/NCT00050167,Breast_Cancer,Paclitaxel|Docetaxel|Capecitabine|,serious_events,arm1,Docetaxel-and-Capecitabine-(DX),29,capecitabine,antimetabolite
2439,Allergic_reaction,6,293,Immune_system_disorders,NCT00050167,https://clinicaltrials.gov/show/NCT00050167,Breast_Cancer,Paclitaxel|Docetaxel|Capecitabine|,other_events,arm1,Docetaxel-and-Capecitabine-(DX),8,docetaxel,taxane
2441,Allergic_reaction,4,293,Immune_system_disorders,NCT00050167,https://clinicaltrials.gov/show/NCT00050167,Breast_Cancer,Paclitaxel|Docetaxel|Capecitabine|,serious_events,arm1,Docetaxel-and-Capecitabine-(DX),8,docetaxel,taxane
1857,Dermatitis_allergic,1,4105,Skin_and_subcutaneous_tissue_disorders,NCT00056407,https://clinicaltrials.gov/show/NCT00056407,Neoplasms_Prostate,Dutasteride|Placebo|,serious_events,arm1,Dutasteride-0.5-mg,,,
2442,Allergic_reaction,5,46,Immune_system_disorders,NCT00057811,https://clinicaltrials.gov/show/NCT00057811,Childhood_Burkitt_Lymphoma|Childhood_Diffuse_Large_Cell_Lymphoma|Childhood_Immunoblastic_Large_Cell_Lymphoma|Stage_I_Childhood_Large_Cell_Lymphoma|Stage_I_Childhood_Small_Noncleaved_Cell_Lymphoma|Stage_II_Childhood_Large_Cell_Lymphoma|Stage_II_Childhood_S,doxorubicin_hydrochloride|cyclophosphamide|methotrexate|rasburicase|leucovorin_calcium|prednisone|methylprednisolone|filgrastim|rituximab|cytarabine|etoposide|vincristine_sulfate|hydrocortisone_sodium_succinate|laboratory_biomarker_analysis|,other_events,arm0,Group-B-(Chemotherapy-Protective-Therapy-Monoclonal-Antib.),,,
2295,Anaphylaxis,1,46,Immune_system_disorders,NCT00057811,https://clinicaltrials.gov/show/NCT00057811,Childhood_Burkitt_Lymphoma|Childhood_Diffuse_Large_Cell_Lymphoma|Childhood_Immunoblastic_Large_Cell_Lymphoma|Stage_I_Childhood_Large_Cell_Lymphoma|Stage_I_Childhood_Small_Noncleaved_Cell_Lymphoma|Stage_II_Childhood_Large_Cell_Lymphoma|Stage_II_Childhood_S,doxorubicin_hydrochloride|cyclophosphamide|methotrexate|rasburicase|leucovorin_calcium|prednisone|methylprednisolone|filgrastim|rituximab|cytarabine|etoposide|vincristine_sulfate|hydrocortisone_sodium_succinate|laboratory_biomarker_analysis|,other_events,arm0,Group-B-(Chemotherapy-Protective-Therapy-Monoclonal-Antib.),,,
2443,Allergic_reaction,2,42,Immune_system_disorders,NCT00057811,https://clinicaltrials.gov/show/NCT00057811,Childhood_Burkitt_Lymphoma|Childhood_Diffuse_Large_Cell_Lymphoma|Childhood_Immunoblastic_Large_Cell_Lymphoma|Stage_I_Childhood_Large_Cell_Lymphoma|Stage_I_Childhood_Small_Noncleaved_Cell_Lymphoma|Stage_II_Childhood_Large_Cell_Lymphoma|Stage_II_Childhood_S,doxorubicin_hydrochloride|cyclophosphamide|methotrexate|rasburicase|leucovorin_calcium|prednisone|methylprednisolone|filgrastim|rituximab|cytarabine|etoposide|vincristine_sulfate|hydrocortisone_sodium_succinate|laboratory_biomarker_analysis|,other_events,arm1,Group-C-(Chemotherapy-Monoclonal-Antibody-Therapy),,,
2296,Anaphylaxis,1,42,Immune_system_disorders,NCT00057811,https://clinicaltrials.gov/show/NCT00057811,Childhood_Burkitt_Lymphoma|Childhood_Diffuse_Large_Cell_Lymphoma|Childhood_Immunoblastic_Large_Cell_Lymphoma|Stage_I_Childhood_Large_Cell_Lymphoma|Stage_I_Childhood_Small_Noncleaved_Cell_Lymphoma|Stage_II_Childhood_Large_Cell_Lymphoma|Stage_II_Childhood_S,doxorubicin_hydrochloride|cyclophosphamide|methotrexate|rasburicase|leucovorin_calcium|prednisone|methylprednisolone|filgrastim|rituximab|cytarabine|etoposide|vincristine_sulfate|hydrocortisone_sodium_succinate|laboratory_biomarker_analysis|,other_events,arm1,Group-C-(Chemotherapy-Monoclonal-Antibody-Therapy),,,
2297,Anaphylaxis,1,42,Immune_system_disorders,NCT00057811,https://clinicaltrials.gov/show/NCT00057811,Childhood_Burkitt_Lymphoma|Childhood_Diffuse_Large_Cell_Lymphoma|Childhood_Immunoblastic_Large_Cell_Lymphoma|Stage_I_Childhood_Large_Cell_Lymphoma|Stage_I_Childhood_Small_Noncleaved_Cell_Lymphoma|Stage_II_Childhood_Large_Cell_Lymphoma|Stage_II_Childhood_S,doxorubicin_hydrochloride|cyclophosphamide|methotrexate|rasburicase|leucovorin_calcium|prednisone|methylprednisolone|filgrastim|rituximab|cytarabine|etoposide|vincristine_sulfate|hydrocortisone_sodium_succinate|laboratory_biomarker_analysis|,serious_events,arm1,Group-C-(Chemotherapy-Monoclonal-Antibody-Therapy),,,
2444,Allergic_reaction,1,16,Immune_system_disorders,NCT00060346,https://clinicaltrials.gov/show/NCT00060346,Lymphoma,rituximab|cyclophosphamide|Doxorubicin|Prednisone|Vincristine|,serious_events,arm0,Rituximab-+-CHOP,16,rituximab,monoclonal-antibody
31,Hypersensitivity,1,119,Immune_system_disorders,NCT00061945,https://clinicaltrials.gov/show/NCT00061945,Acute_Undifferentiated_Leukemia|B-cell_Adult_Acute_Lymphoblastic_Leukemia|B-cell_Childhood_Acute_Lymphoblastic_Leukemia|L1_Adult_Acute_Lymphoblastic_Leukemia|L1_Childhood_Acute_Lymphoblastic_Leukemia|L2_Adult_Acute_Lymphoblastic_Leukemia|L2_Childhood_Acut,allopurinol|cyclophosphamide|daunorubicin_hydrochloride|vincristine_sulfate|dexamethasone|asparaginase|filgrastim|imatinib_mesylate|methotrexate|cytarabine|trimethoprim-sulfamethoxazole|mercaptopurine|leucovorin_calcium|alemtuzumab|acyclovir|laboratory_bi,serious_events,arm0,Phase-I---Alemtuzumab-and-Combination-Chemotherapy,76,alemtuzumab,monoclonal-antibody
32,Hypersensitivity,6,119,Immune_system_disorders,NCT00061945,https://clinicaltrials.gov/show/NCT00061945,Acute_Undifferentiated_Leukemia|B-cell_Adult_Acute_Lymphoblastic_Leukemia|B-cell_Childhood_Acute_Lymphoblastic_Leukemia|L1_Adult_Acute_Lymphoblastic_Leukemia|L1_Childhood_Acute_Lymphoblastic_Leukemia|L2_Adult_Acute_Lymphoblastic_Leukemia|L2_Childhood_Acut,allopurinol|cyclophosphamide|daunorubicin_hydrochloride|vincristine_sulfate|dexamethasone|asparaginase|filgrastim|imatinib_mesylate|methotrexate|cytarabine|trimethoprim-sulfamethoxazole|mercaptopurine|leucovorin_calcium|alemtuzumab|acyclovir|laboratory_bi,other_events,arm0,Phase-I---Alemtuzumab-and-Combination-Chemotherapy,76,alemtuzumab,monoclonal-antibody
33,Hypersensitivity,2,181,Immune_system_disorders,NCT00061945,https://clinicaltrials.gov/show/NCT00061945,Acute_Undifferentiated_Leukemia|B-cell_Adult_Acute_Lymphoblastic_Leukemia|B-cell_Childhood_Acute_Lymphoblastic_Leukemia|L1_Adult_Acute_Lymphoblastic_Leukemia|L1_Childhood_Acute_Lymphoblastic_Leukemia|L2_Adult_Acute_Lymphoblastic_Leukemia|L2_Childhood_Acut,allopurinol|cyclophosphamide|daunorubicin_hydrochloride|vincristine_sulfate|dexamethasone|asparaginase|filgrastim|imatinib_mesylate|methotrexate|cytarabine|trimethoprim-sulfamethoxazole|mercaptopurine|leucovorin_calcium|alemtuzumab|acyclovir|laboratory_bi,serious_events,arm1,Phase-II---Alemtuzumab-and-Combination-Chemotherapy,76,alemtuzumab,monoclonal-antibody
34,Hypersensitivity,10,181,Immune_system_disorders,NCT00061945,https://clinicaltrials.gov/show/NCT00061945,Acute_Undifferentiated_Leukemia|B-cell_Adult_Acute_Lymphoblastic_Leukemia|B-cell_Childhood_Acute_Lymphoblastic_Leukemia|L1_Adult_Acute_Lymphoblastic_Leukemia|L1_Childhood_Acute_Lymphoblastic_Leukemia|L2_Adult_Acute_Lymphoblastic_Leukemia|L2_Childhood_Acut,allopurinol|cyclophosphamide|daunorubicin_hydrochloride|vincristine_sulfate|dexamethasone|asparaginase|filgrastim|imatinib_mesylate|methotrexate|cytarabine|trimethoprim-sulfamethoxazole|mercaptopurine|leucovorin_calcium|alemtuzumab|acyclovir|laboratory_bi,other_events,arm1,Phase-II---Alemtuzumab-and-Combination-Chemotherapy,76,alemtuzumab,monoclonal-antibody
36,HYPERSENSITIVITY,1,43,Immune_system_disorders,NCT00063154,https://clinicaltrials.gov/show/NCT00063154,Non-small_Cell_Lung_Cancer,Pertuzumab,serious_events,arm0,Pertuzumab,40,pertuzumab,monoclonal-antibody
37,Hypersensitivity,3,52,Immune_system_disorders,NCT00063570,https://clinicaltrials.gov/show/NCT00063570,Breast_Cancer|Breast_Neoplasms|,Pemetrexed|Gemcitabine|Gemcitabine|Pemetrexed|,other_events,arm0,Bi-Weekly-Schedule,,,
2445,Allergic_reaction,2,333,Immune_system_disorders,NCT00064350,https://clinicaltrials.gov/show/NCT00064350,Lung_Cancer,Sorafenib|Placebo|,serious_events,arm0,Induction:-Sorafenib,90,sorafenib,Tyrosine-Kinase-inhibitor
2446,ALLERGIC_REACTION,1,200,General_disorders,NCT00065468,https://clinicaltrials.gov/show/NCT00065468,Carcinoma_Renal_Cell|Kidney_Neoplasms|,Interferon_Alfa|CCI-779|Interferon_Alfa_and_CCI-779|,other_events,arm0,Interferon-Alfa,,,
2450,ALLERGIC_REACTION,1,200,General_disorders,NCT00065468,https://clinicaltrials.gov/show/NCT00065468,Carcinoma_Renal_Cell|Kidney_Neoplasms|,Interferon_Alfa|CCI-779|Interferon_Alfa_and_CCI-779|,serious_events,arm0,Interferon-Alfa,,,
2449,ALLERGIC_REACTION,18,208,General_disorders,NCT00065468,https://clinicaltrials.gov/show/NCT00065468,Carcinoma_Renal_Cell|Kidney_Neoplasms|,Interferon_Alfa|CCI-779|Interferon_Alfa_and_CCI-779|,other_events,arm1,Temsirolimus,,,
2447,ALLERGIC_REACTION,11,208,General_disorders,NCT00065468,https://clinicaltrials.gov/show/NCT00065468,Carcinoma_Renal_Cell|Kidney_Neoplasms|,Interferon_Alfa|CCI-779|Interferon_Alfa_and_CCI-779|,other_events,arm2,Interferon-Alfa-and-Temsirolimus,,,
2448,ALLERGIC_REACTION,1,208,General_disorders,NCT00065468,https://clinicaltrials.gov/show/NCT00065468,Carcinoma_Renal_Cell|Kidney_Neoplasms|,Interferon_Alfa|CCI-779|Interferon_Alfa_and_CCI-779|,serious_events,arm2,Interferon-Alfa-and-Temsirolimus,,,
2451,Allergic_reaction,1,3761,Immune_system_disorders,NCT00066573,https://clinicaltrials.gov/show/NCT00066573,Breast_Cancer,anastrozole|exemestane|,serious_events,arm0,Exemestane,56,exemestane,aromatase-inhibitor
2453,Allergic_reaction,2,93,General_disorders,NCT00067808,https://clinicaltrials.gov/show/NCT00067808,Myelodysplastic_Syndrome|Chronic_Myelomonocytic_Leukemia|,Decitabine|Decitabine|Decitabine|,serious_events,arm1,Decitabine-20-mg/m2-IV,,,
2452,Allergic_reaction,1,14,General_disorders,NCT00067808,https://clinicaltrials.gov/show/NCT00067808,Myelodysplastic_Syndrome|Chronic_Myelomonocytic_Leukemia|,Decitabine|Decitabine|Decitabine|,other_events,arm2,Decitabine-20-mg/m2-SQ,,,
38,HYPERSENSITIVITY,2,938,Immune_system_disorders,NCT00069121,https://clinicaltrials.gov/show/NCT00069121,Colorectal_Cancer,capecitabine_[Xeloda]|Oxaliplatin|Oxaliplatin|Leucovorin|5_FU|,serious_events,arm2,XELOX,34,xelox,Combination-drug-with-capecitabine-(Xeloda)-and-Oxaliplatin-(Eloxatin)
1859,Dermatitis_allergic,1,175,Skin_and_subcutaneous_tissue_disorders,NCT00071799,https://clinicaltrials.gov/show/NCT00071799,Myelodysplastic_Syndromes,Azacitidine|Physician_Choice|,other_events,arm0,Azacitidine,,,
1860,Dermatitis_allergic,1,102,Skin_and_subcutaneous_tissue_disorders,NCT00071799,https://clinicaltrials.gov/show/NCT00071799,Myelodysplastic_Syndromes,Azacitidine|Physician_Choice|,other_events,arm1,Best-Supportive-Care-Only,,,
1117,Drug_hypersensitivity,1,102,Immune_system_disorders,NCT00071799,https://clinicaltrials.gov/show/NCT00071799,Myelodysplastic_Syndromes,Azacitidine|Physician_Choice|,serious_events,arm1,Best-Supportive-Care-Only,,,
1861,Dermatitis_allergic,2,19,Skin_and_subcutaneous_tissue_disorders,NCT00071799,https://clinicaltrials.gov/show/NCT00071799,Myelodysplastic_Syndromes,Azacitidine|Physician_Choice|,other_events,arm3,Standard-Chemotherapy,,,
2454,Allergic_reaction,1,38,Immune_system_disorders,NCT00071981,https://clinicaltrials.gov/show/NCT00071981,Melanoma_(Skin),incomplete_Freund's_adjuvant|melanoma_helper_peptide_vaccine|multi-epitope_melanoma_peptide_vaccine|sargramostim|tetanus_peptide_melanoma_vaccine|,serious_events,arm1,Arm-II-(12MP/Tet),,,
2455,Allergic_reaction,2,33,Immune_system_disorders,NCT00072176,https://clinicaltrials.gov/show/NCT00072176,Endometrial_Adenocarcinoma|Endometrial_Adenosquamous_Cell_Carcinoma|Endometrial_Clear_Cell_Carcinoma|Endometrial_Papillary_Serous_Carcinoma|Recurrent_Endometrial_Carcinoma|Stage_IIIA_Endometrial_Carcinoma|Stage_IIIB_Endometrial_Carcinoma|Stage_IIIC_Endome,temsirolimus|laboratory_biomarker_analysis|,other_events,arm0,Group-A,,,
2456,Allergic_reaction,1,27,Immune_system_disorders,NCT00072176,https://clinicaltrials.gov/show/NCT00072176,Endometrial_Adenocarcinoma|Endometrial_Adenosquamous_Cell_Carcinoma|Endometrial_Clear_Cell_Carcinoma|Endometrial_Papillary_Serous_Carcinoma|Recurrent_Endometrial_Carcinoma|Stage_IIIA_Endometrial_Carcinoma|Stage_IIIB_Endometrial_Carcinoma|Stage_IIIC_Endome,temsirolimus|laboratory_biomarker_analysis|,other_events,arm1,Group-B,,,
39,Hypersensitivity,1,153,Immune_system_disorders,NCT00072475,https://clinicaltrials.gov/show/NCT00072475,Leukemia|Myelodysplastic_Syndromes|Myelodysplastic/Myeloproliferative_Neoplasms|,vatalanib,serious_events,arm0,Vatalanib,,,
40,Hypersensitivity,1,153,Immune_system_disorders,NCT00072475,https://clinicaltrials.gov/show/NCT00072475,Leukemia|Myelodysplastic_Syndromes|Myelodysplastic/Myeloproliferative_Neoplasms|,vatalanib,other_events,arm0,Vatalanib,,,
41,Hypersensitivity,3,70,Immune_system_disorders,NCT00072566,https://clinicaltrials.gov/show/NCT00072566,Primary_Peritoneal_Carcinoma|Recurrent_Ovarian_Carcinoma|Stage_IV_Ovarian_Cancer|,Bevacizumab|Cyclophosphamide|Laboratory_Biomarker_Analysis|,other_events,arm0,Treatment-(Bevacizumab-Cyclophosphamide),13,cyclophosphamide,alkylating-agent
41,Hypersensitivity,3,70,Immune_system_disorders,NCT00072566,https://clinicaltrials.gov/show/NCT00072566,Primary_Peritoneal_Carcinoma|Recurrent_Ovarian_Carcinoma|Stage_IV_Ovarian_Cancer|,Bevacizumab|Cyclophosphamide|Laboratory_Biomarker_Analysis|,other_events,arm0,Treatment-(Bevacizumab-Cyclophosphamide),4,bevacizumab,monoclonal-antibody
41,Hypersensitivity,3,70,Immune_system_disorders,NCT00072566,https://clinicaltrials.gov/show/NCT00072566,Primary_Peritoneal_Carcinoma|Recurrent_Ovarian_Carcinoma|Stage_IV_Ovarian_Cancer|,Bevacizumab|Cyclophosphamide|Laboratory_Biomarker_Analysis|,other_events,arm0,Treatment-(Bevacizumab-Cyclophosphamide),22,bevacizumab,monoclonal-antibody
2457,Allergic_Reaction,1,452,Immune_system_disorders,NCT00073307,https://clinicaltrials.gov/show/NCT00073307,Carcinoma_Renal_Cell,Sorafenib_(Nexavar_BAY43-9006)|Placebo|,serious_events,arm2,Sorafenib-(Nexavar-BAY43-9006)-30Jun2008,97,nexavar,Tyrosine-Kinase-inhibitor
2457,Allergic_Reaction,1,452,Immune_system_disorders,NCT00073307,https://clinicaltrials.gov/show/NCT00073307,Carcinoma_Renal_Cell,Sorafenib_(Nexavar_BAY43-9006)|Placebo|,serious_events,arm2,Sorafenib-(Nexavar-BAY43-9006)-30Jun2008,90,sorafenib,Tyrosine-Kinase-inhibitor
2457,Allergic_Reaction,1,452,Immune_system_disorders,NCT00073307,https://clinicaltrials.gov/show/NCT00073307,Carcinoma_Renal_Cell,Sorafenib_(Nexavar_BAY43-9006)|Placebo|,serious_events,arm2,Sorafenib-(Nexavar-BAY43-9006)-30Jun2008,72,bay43,Tyrosine-Kinase-inhibitor
43,Hypersensitivity,2,51,Immune_system_disorders,NCT00074984,https://clinicaltrials.gov/show/NCT00074984,Fabry_Disease,Fabrazyme_(agalsidase_beta)|Placebo|,other_events,arm0,Fabrazyme-(Agalsidase-Beta),,,
42,Hypersensitivity,2,82,Immune_system_disorders,NCT00074984,https://clinicaltrials.gov/show/NCT00074984,Fabry_Disease,Fabrazyme_(agalsidase_beta)|Placebo|,other_events,arm2,Total,,,
1864,Dermatitis_allergic,1,114,Skin_and_subcutaneous_tissue_disorders,NCT00075218,https://clinicaltrials.gov/show/NCT00075218,Gastrointestinal_Stromal_Tumor,Placebo|SU011248|,other_events,arm1,Placebo-Double-Blind-Treatment,,,
44,Hypersensitivity,1,114,Immune_system_disorders,NCT00075218,https://clinicaltrials.gov/show/NCT00075218,Gastrointestinal_Stromal_Tumor,Placebo|SU011248|,other_events,arm1,Placebo-Double-Blind-Treatment,,,
1862,Dermatitis_allergic,2,293,Skin_and_subcutaneous_tissue_disorders,NCT00075270,https://clinicaltrials.gov/show/NCT00075270,Neoplasms_Breast,Paclitaxel|GW572016_(Lapatinib)|,other_events,arm0,Lapatinib-With-Paclitaxel,21,lapatinib,signal-transduction-inhibitor
1118,Drug_hypersensitivity,3,293,Immune_system_disorders,NCT00075270,https://clinicaltrials.gov/show/NCT00075270,Neoplasms_Breast,Paclitaxel|GW572016_(Lapatinib)|,other_events,arm0,Lapatinib-With-Paclitaxel,21,lapatinib,signal-transduction-inhibitor
1862,Dermatitis_allergic,2,293,Skin_and_subcutaneous_tissue_disorders,NCT00075270,https://clinicaltrials.gov/show/NCT00075270,Neoplasms_Breast,Paclitaxel|GW572016_(Lapatinib)|,other_events,arm0,Lapatinib-With-Paclitaxel,2,paclitaxel,taxane
1118,Drug_hypersensitivity,3,293,Immune_system_disorders,NCT00075270,https://clinicaltrials.gov/show/NCT00075270,Neoplasms_Breast,Paclitaxel|GW572016_(Lapatinib)|,other_events,arm0,Lapatinib-With-Paclitaxel,2,paclitaxel,taxane
1863,Dermatitis_allergic,1,286,Skin_and_subcutaneous_tissue_disorders,NCT00075270,https://clinicaltrials.gov/show/NCT00075270,Neoplasms_Breast,Paclitaxel|GW572016_(Lapatinib)|,other_events,arm1,Placebo-With-Paclitaxel,2,paclitaxel,taxane
1119,Drug_hypersensitivity,1,286,Immune_system_disorders,NCT00075270,https://clinicaltrials.gov/show/NCT00075270,Neoplasms_Breast,Paclitaxel|GW572016_(Lapatinib)|,other_events,arm1,Placebo-With-Paclitaxel,2,paclitaxel,taxane
2462,Allergic_reaction,1,215,Immune_system_disorders,NCT00075725,https://clinicaltrials.gov/show/NCT00075725,Leukemia,cyclophosphamide|cytarabine|daunorubicin_hydrochloride|dexamethasone|doxorubicin_hydrochloride|leucovorin_calcium|mercaptopurine|methotrexate|pegaspargase|prednisone|thioguanine|vincristine_sulfate|radiation_therapy|,serious_events,arm0,Dexamethasone-and-Capizzi-Methotrexate-Patients-<-10-Years,23,methotrexate,antimetabolite
2467,Allergic_reaction,1,215,Immune_system_disorders,NCT00075725,https://clinicaltrials.gov/show/NCT00075725,Leukemia,cyclophosphamide|cytarabine|daunorubicin_hydrochloride|dexamethasone|doxorubicin_hydrochloride|leucovorin_calcium|mercaptopurine|methotrexate|pegaspargase|prednisone|thioguanine|vincristine_sulfate|radiation_therapy|,other_events,arm0,Dexamethasone-and-Capizzi-Methotrexate-Patients-<-10-Years,23,methotrexate,antimetabolite
2310,Anaphylaxis,1,215,Immune_system_disorders,NCT00075725,https://clinicaltrials.gov/show/NCT00075725,Leukemia,cyclophosphamide|cytarabine|daunorubicin_hydrochloride|dexamethasone|doxorubicin_hydrochloride|leucovorin_calcium|mercaptopurine|methotrexate|pegaspargase|prednisone|thioguanine|vincristine_sulfate|radiation_therapy|,serious_events,arm0,Dexamethasone-and-Capizzi-Methotrexate-Patients-<-10-Years,23,methotrexate,antimetabolite
2316,Anaphylaxis,30,215,Immune_system_disorders,NCT00075725,https://clinicaltrials.gov/show/NCT00075725,Leukemia,cyclophosphamide|cytarabine|daunorubicin_hydrochloride|dexamethasone|doxorubicin_hydrochloride|leucovorin_calcium|mercaptopurine|methotrexate|pegaspargase|prednisone|thioguanine|vincristine_sulfate|radiation_therapy|,other_events,arm0,Dexamethasone-and-Capizzi-Methotrexate-Patients-<-10-Years,23,methotrexate,antimetabolite
2462,Allergic_reaction,1,215,Immune_system_disorders,NCT00075725,https://clinicaltrials.gov/show/NCT00075725,Leukemia,cyclophosphamide|cytarabine|daunorubicin_hydrochloride|dexamethasone|doxorubicin_hydrochloride|leucovorin_calcium|mercaptopurine|methotrexate|pegaspargase|prednisone|thioguanine|vincristine_sulfate|radiation_therapy|,serious_events,arm0,Dexamethasone-and-Capizzi-Methotrexate-Patients-<-10-Years,68,capizzi,Methotrexate-+-asparaginase
2467,Allergic_reaction,1,215,Immune_system_disorders,NCT00075725,https://clinicaltrials.gov/show/NCT00075725,Leukemia,cyclophosphamide|cytarabine|daunorubicin_hydrochloride|dexamethasone|doxorubicin_hydrochloride|leucovorin_calcium|mercaptopurine|methotrexate|pegaspargase|prednisone|thioguanine|vincristine_sulfate|radiation_therapy|,other_events,arm0,Dexamethasone-and-Capizzi-Methotrexate-Patients-<-10-Years,68,capizzi,Methotrexate-+-asparaginase
2310,Anaphylaxis,1,215,Immune_system_disorders,NCT00075725,https://clinicaltrials.gov/show/NCT00075725,Leukemia,cyclophosphamide|cytarabine|daunorubicin_hydrochloride|dexamethasone|doxorubicin_hydrochloride|leucovorin_calcium|mercaptopurine|methotrexate|pegaspargase|prednisone|thioguanine|vincristine_sulfate|radiation_therapy|,serious_events,arm0,Dexamethasone-and-Capizzi-Methotrexate-Patients-<-10-Years,68,capizzi,Methotrexate-+-asparaginase
2316,Anaphylaxis,30,215,Immune_system_disorders,NCT00075725,https://clinicaltrials.gov/show/NCT00075725,Leukemia,cyclophosphamide|cytarabine|daunorubicin_hydrochloride|dexamethasone|doxorubicin_hydrochloride|leucovorin_calcium|mercaptopurine|methotrexate|pegaspargase|prednisone|thioguanine|vincristine_sulfate|radiation_therapy|,other_events,arm0,Dexamethasone-and-Capizzi-Methotrexate-Patients-<-10-Years,68,capizzi,Methotrexate-+-asparaginase
2462,Allergic_reaction,1,215,Immune_system_disorders,NCT00075725,https://clinicaltrials.gov/show/NCT00075725,Leukemia,cyclophosphamide|cytarabine|daunorubicin_hydrochloride|dexamethasone|doxorubicin_hydrochloride|leucovorin_calcium|mercaptopurine|methotrexate|pegaspargase|prednisone|thioguanine|vincristine_sulfate|radiation_therapy|,serious_events,arm0,Dexamethasone-and-Capizzi-Methotrexate-Patients-<-10-Years,79,dexamethasone,steroid
2467,Allergic_reaction,1,215,Immune_system_disorders,NCT00075725,https://clinicaltrials.gov/show/NCT00075725,Leukemia,cyclophosphamide|cytarabine|daunorubicin_hydrochloride|dexamethasone|doxorubicin_hydrochloride|leucovorin_calcium|mercaptopurine|methotrexate|pegaspargase|prednisone|thioguanine|vincristine_sulfate|radiation_therapy|,other_events,arm0,Dexamethasone-and-Capizzi-Methotrexate-Patients-<-10-Years,79,dexamethasone,steroid
2310,Anaphylaxis,1,215,Immune_system_disorders,NCT00075725,https://clinicaltrials.gov/show/NCT00075725,Leukemia,cyclophosphamide|cytarabine|daunorubicin_hydrochloride|dexamethasone|doxorubicin_hydrochloride|leucovorin_calcium|mercaptopurine|methotrexate|pegaspargase|prednisone|thioguanine|vincristine_sulfate|radiation_therapy|,serious_events,arm0,Dexamethasone-and-Capizzi-Methotrexate-Patients-<-10-Years,79,dexamethasone,steroid
2316,Anaphylaxis,30,215,Immune_system_disorders,NCT00075725,https://clinicaltrials.gov/show/NCT00075725,Leukemia,cyclophosphamide|cytarabine|daunorubicin_hydrochloride|dexamethasone|doxorubicin_hydrochloride|leucovorin_calcium|mercaptopurine|methotrexate|pegaspargase|prednisone|thioguanine|vincristine_sulfate|radiation_therapy|,other_events,arm0,Dexamethasone-and-Capizzi-Methotrexate-Patients-<-10-Years,79,dexamethasone,steroid
2459,Allergic_reaction,2,239,Immune_system_disorders,NCT00075725,https://clinicaltrials.gov/show/NCT00075725,Leukemia,cyclophosphamide|cytarabine|daunorubicin_hydrochloride|dexamethasone|doxorubicin_hydrochloride|leucovorin_calcium|mercaptopurine|methotrexate|pegaspargase|prednisone|thioguanine|vincristine_sulfate|radiation_therapy|,other_events,arm1,Dexamethasone-&-Capizzi-Methotrexate-Patients-=>-10-Years-Old,23,methotrexate,antimetabolite
2461,Allergic_reaction,1,239,Immune_system_disorders,NCT00075725,https://clinicaltrials.gov/show/NCT00075725,Leukemia,cyclophosphamide|cytarabine|daunorubicin_hydrochloride|dexamethasone|doxorubicin_hydrochloride|leucovorin_calcium|mercaptopurine|methotrexate|pegaspargase|prednisone|thioguanine|vincristine_sulfate|radiation_therapy|,serious_events,arm1,Dexamethasone-&-Capizzi-Methotrexate-Patients-=>-10-Years-Old,23,methotrexate,antimetabolite
2307,Anaphylaxis,36,239,Immune_system_disorders,NCT00075725,https://clinicaltrials.gov/show/NCT00075725,Leukemia,cyclophosphamide|cytarabine|daunorubicin_hydrochloride|dexamethasone|doxorubicin_hydrochloride|leucovorin_calcium|mercaptopurine|methotrexate|pegaspargase|prednisone|thioguanine|vincristine_sulfate|radiation_therapy|,other_events,arm1,Dexamethasone-&-Capizzi-Methotrexate-Patients-=>-10-Years-Old,23,methotrexate,antimetabolite
2459,Allergic_reaction,2,239,Immune_system_disorders,NCT00075725,https://clinicaltrials.gov/show/NCT00075725,Leukemia,cyclophosphamide|cytarabine|daunorubicin_hydrochloride|dexamethasone|doxorubicin_hydrochloride|leucovorin_calcium|mercaptopurine|methotrexate|pegaspargase|prednisone|thioguanine|vincristine_sulfate|radiation_therapy|,other_events,arm1,Dexamethasone-&-Capizzi-Methotrexate-Patients-=>-10-Years-Old,68,capizzi,Methotrexate-+-asparaginase
2461,Allergic_reaction,1,239,Immune_system_disorders,NCT00075725,https://clinicaltrials.gov/show/NCT00075725,Leukemia,cyclophosphamide|cytarabine|daunorubicin_hydrochloride|dexamethasone|doxorubicin_hydrochloride|leucovorin_calcium|mercaptopurine|methotrexate|pegaspargase|prednisone|thioguanine|vincristine_sulfate|radiation_therapy|,serious_events,arm1,Dexamethasone-&-Capizzi-Methotrexate-Patients-=>-10-Years-Old,68,capizzi,Methotrexate-+-asparaginase
2307,Anaphylaxis,36,239,Immune_system_disorders,NCT00075725,https://clinicaltrials.gov/show/NCT00075725,Leukemia,cyclophosphamide|cytarabine|daunorubicin_hydrochloride|dexamethasone|doxorubicin_hydrochloride|leucovorin_calcium|mercaptopurine|methotrexate|pegaspargase|prednisone|thioguanine|vincristine_sulfate|radiation_therapy|,other_events,arm1,Dexamethasone-&-Capizzi-Methotrexate-Patients-=>-10-Years-Old,68,capizzi,Methotrexate-+-asparaginase
2459,Allergic_reaction,2,239,Immune_system_disorders,NCT00075725,https://clinicaltrials.gov/show/NCT00075725,Leukemia,cyclophosphamide|cytarabine|daunorubicin_hydrochloride|dexamethasone|doxorubicin_hydrochloride|leucovorin_calcium|mercaptopurine|methotrexate|pegaspargase|prednisone|thioguanine|vincristine_sulfate|radiation_therapy|,other_events,arm1,Dexamethasone-&-Capizzi-Methotrexate-Patients-=>-10-Years-Old,79,dexamethasone,steroid
2461,Allergic_reaction,1,239,Immune_system_disorders,NCT00075725,https://clinicaltrials.gov/show/NCT00075725,Leukemia,cyclophosphamide|cytarabine|daunorubicin_hydrochloride|dexamethasone|doxorubicin_hydrochloride|leucovorin_calcium|mercaptopurine|methotrexate|pegaspargase|prednisone|thioguanine|vincristine_sulfate|radiation_therapy|,serious_events,arm1,Dexamethasone-&-Capizzi-Methotrexate-Patients-=>-10-Years-Old,79,dexamethasone,steroid
2307,Anaphylaxis,36,239,Immune_system_disorders,NCT00075725,https://clinicaltrials.gov/show/NCT00075725,Leukemia,cyclophosphamide|cytarabine|daunorubicin_hydrochloride|dexamethasone|doxorubicin_hydrochloride|leucovorin_calcium|mercaptopurine|methotrexate|pegaspargase|prednisone|thioguanine|vincristine_sulfate|radiation_therapy|,other_events,arm1,Dexamethasone-&-Capizzi-Methotrexate-Patients-=>-10-Years-Old,79,dexamethasone,steroid
2314,Anaphylaxis,1,34,Immune_system_disorders,NCT00075725,https://clinicaltrials.gov/show/NCT00075725,Leukemia,cyclophosphamide|cytarabine|daunorubicin_hydrochloride|dexamethasone|doxorubicin_hydrochloride|leucovorin_calcium|mercaptopurine|methotrexate|pegaspargase|prednisone|thioguanine|vincristine_sulfate|radiation_therapy|,serious_events,arm10,Prenisone-Capezzi-Methotrexate-(Down's-Syndrome),23,methotrexate,antimetabolite
2314,Anaphylaxis,1,34,Immune_system_disorders,NCT00075725,https://clinicaltrials.gov/show/NCT00075725,Leukemia,cyclophosphamide|cytarabine|daunorubicin_hydrochloride|dexamethasone|doxorubicin_hydrochloride|leucovorin_calcium|mercaptopurine|methotrexate|pegaspargase|prednisone|thioguanine|vincristine_sulfate|radiation_therapy|,serious_events,arm10,Prenisone-Capezzi-Methotrexate-(Down's-Syndrome),69,capezzi,Methotrexate-+-asparaginase
2458,Allergic_reaction,1,203,Immune_system_disorders,NCT00075725,https://clinicaltrials.gov/show/NCT00075725,Leukemia,cyclophosphamide|cytarabine|daunorubicin_hydrochloride|dexamethasone|doxorubicin_hydrochloride|leucovorin_calcium|mercaptopurine|methotrexate|pegaspargase|prednisone|thioguanine|vincristine_sulfate|radiation_therapy|,other_events,arm2,Dexamethasone-High-Dose-Methotrexate-(IM)-<-10-Years,23,methotrexate,antimetabolite
2299,Anaphylaxis,29,203,Immune_system_disorders,NCT00075725,https://clinicaltrials.gov/show/NCT00075725,Leukemia,cyclophosphamide|cytarabine|daunorubicin_hydrochloride|dexamethasone|doxorubicin_hydrochloride|leucovorin_calcium|mercaptopurine|methotrexate|pegaspargase|prednisone|thioguanine|vincristine_sulfate|radiation_therapy|,other_events,arm2,Dexamethasone-High-Dose-Methotrexate-(IM)-<-10-Years,23,methotrexate,antimetabolite
2300,Anaphylaxis,1,203,Immune_system_disorders,NCT00075725,https://clinicaltrials.gov/show/NCT00075725,Leukemia,cyclophosphamide|cytarabine|daunorubicin_hydrochloride|dexamethasone|doxorubicin_hydrochloride|leucovorin_calcium|mercaptopurine|methotrexate|pegaspargase|prednisone|thioguanine|vincristine_sulfate|radiation_therapy|,serious_events,arm2,Dexamethasone-High-Dose-Methotrexate-(IM)-<-10-Years,23,methotrexate,antimetabolite
2458,Allergic_reaction,1,203,Immune_system_disorders,NCT00075725,https://clinicaltrials.gov/show/NCT00075725,Leukemia,cyclophosphamide|cytarabine|daunorubicin_hydrochloride|dexamethasone|doxorubicin_hydrochloride|leucovorin_calcium|mercaptopurine|methotrexate|pegaspargase|prednisone|thioguanine|vincristine_sulfate|radiation_therapy|,other_events,arm2,Dexamethasone-High-Dose-Methotrexate-(IM)-<-10-Years,79,dexamethasone,steroid
2299,Anaphylaxis,29,203,Immune_system_disorders,NCT00075725,https://clinicaltrials.gov/show/NCT00075725,Leukemia,cyclophosphamide|cytarabine|daunorubicin_hydrochloride|dexamethasone|doxorubicin_hydrochloride|leucovorin_calcium|mercaptopurine|methotrexate|pegaspargase|prednisone|thioguanine|vincristine_sulfate|radiation_therapy|,other_events,arm2,Dexamethasone-High-Dose-Methotrexate-(IM)-<-10-Years,79,dexamethasone,steroid
2300,Anaphylaxis,1,203,Immune_system_disorders,NCT00075725,https://clinicaltrials.gov/show/NCT00075725,Leukemia,cyclophosphamide|cytarabine|daunorubicin_hydrochloride|dexamethasone|doxorubicin_hydrochloride|leucovorin_calcium|mercaptopurine|methotrexate|pegaspargase|prednisone|thioguanine|vincristine_sulfate|radiation_therapy|,serious_events,arm2,Dexamethasone-High-Dose-Methotrexate-(IM)-<-10-Years,79,dexamethasone,steroid
2301,Anaphylaxis,38,242,Immune_system_disorders,NCT00075725,https://clinicaltrials.gov/show/NCT00075725,Leukemia,cyclophosphamide|cytarabine|daunorubicin_hydrochloride|dexamethasone|doxorubicin_hydrochloride|leucovorin_calcium|mercaptopurine|methotrexate|pegaspargase|prednisone|thioguanine|vincristine_sulfate|radiation_therapy|,other_events,arm3,Dexamethasone-High-Dose-Methotrexate-(IM)->=-10-Years,23,methotrexate,antimetabolite
2304,Anaphylaxis,1,242,Immune_system_disorders,NCT00075725,https://clinicaltrials.gov/show/NCT00075725,Leukemia,cyclophosphamide|cytarabine|daunorubicin_hydrochloride|dexamethasone|doxorubicin_hydrochloride|leucovorin_calcium|mercaptopurine|methotrexate|pegaspargase|prednisone|thioguanine|vincristine_sulfate|radiation_therapy|,serious_events,arm3,Dexamethasone-High-Dose-Methotrexate-(IM)->=-10-Years,23,methotrexate,antimetabolite
2301,Anaphylaxis,38,242,Immune_system_disorders,NCT00075725,https://clinicaltrials.gov/show/NCT00075725,Leukemia,cyclophosphamide|cytarabine|daunorubicin_hydrochloride|dexamethasone|doxorubicin_hydrochloride|leucovorin_calcium|mercaptopurine|methotrexate|pegaspargase|prednisone|thioguanine|vincristine_sulfate|radiation_therapy|,other_events,arm3,Dexamethasone-High-Dose-Methotrexate-(IM)->=-10-Years,79,dexamethasone,steroid
2304,Anaphylaxis,1,242,Immune_system_disorders,NCT00075725,https://clinicaltrials.gov/show/NCT00075725,Leukemia,cyclophosphamide|cytarabine|daunorubicin_hydrochloride|dexamethasone|doxorubicin_hydrochloride|leucovorin_calcium|mercaptopurine|methotrexate|pegaspargase|prednisone|thioguanine|vincristine_sulfate|radiation_therapy|,serious_events,arm3,Dexamethasone-High-Dose-Methotrexate-(IM)->=-10-Years,79,dexamethasone,steroid
2463,Allergic_reaction,2,207,Immune_system_disorders,NCT00075725,https://clinicaltrials.gov/show/NCT00075725,Leukemia,cyclophosphamide|cytarabine|daunorubicin_hydrochloride|dexamethasone|doxorubicin_hydrochloride|leucovorin_calcium|mercaptopurine|methotrexate|pegaspargase|prednisone|thioguanine|vincristine_sulfate|radiation_therapy|,other_events,arm4,Prednisone-Capizzi-Methotrexate-<10-Years,23,methotrexate,antimetabolite
2311,Anaphylaxis,24,207,Immune_system_disorders,NCT00075725,https://clinicaltrials.gov/show/NCT00075725,Leukemia,cyclophosphamide|cytarabine|daunorubicin_hydrochloride|dexamethasone|doxorubicin_hydrochloride|leucovorin_calcium|mercaptopurine|methotrexate|pegaspargase|prednisone|thioguanine|vincristine_sulfate|radiation_therapy|,other_events,arm4,Prednisone-Capizzi-Methotrexate-<10-Years,23,methotrexate,antimetabolite
2313,Anaphylaxis,1,207,Immune_system_disorders,NCT00075725,https://clinicaltrials.gov/show/NCT00075725,Leukemia,cyclophosphamide|cytarabine|daunorubicin_hydrochloride|dexamethasone|doxorubicin_hydrochloride|leucovorin_calcium|mercaptopurine|methotrexate|pegaspargase|prednisone|thioguanine|vincristine_sulfate|radiation_therapy|,serious_events,arm4,Prednisone-Capizzi-Methotrexate-<10-Years,23,methotrexate,antimetabolite
2463,Allergic_reaction,2,207,Immune_system_disorders,NCT00075725,https://clinicaltrials.gov/show/NCT00075725,Leukemia,cyclophosphamide|cytarabine|daunorubicin_hydrochloride|dexamethasone|doxorubicin_hydrochloride|leucovorin_calcium|mercaptopurine|methotrexate|pegaspargase|prednisone|thioguanine|vincristine_sulfate|radiation_therapy|,other_events,arm4,Prednisone-Capizzi-Methotrexate-<10-Years,68,capizzi,Methotrexate-+-asparaginase
2311,Anaphylaxis,24,207,Immune_system_disorders,NCT00075725,https://clinicaltrials.gov/show/NCT00075725,Leukemia,cyclophosphamide|cytarabine|daunorubicin_hydrochloride|dexamethasone|doxorubicin_hydrochloride|leucovorin_calcium|mercaptopurine|methotrexate|pegaspargase|prednisone|thioguanine|vincristine_sulfate|radiation_therapy|,other_events,arm4,Prednisone-Capizzi-Methotrexate-<10-Years,68,capizzi,Methotrexate-+-asparaginase
2313,Anaphylaxis,1,207,Immune_system_disorders,NCT00075725,https://clinicaltrials.gov/show/NCT00075725,Leukemia,cyclophosphamide|cytarabine|daunorubicin_hydrochloride|dexamethasone|doxorubicin_hydrochloride|leucovorin_calcium|mercaptopurine|methotrexate|pegaspargase|prednisone|thioguanine|vincristine_sulfate|radiation_therapy|,serious_events,arm4,Prednisone-Capizzi-Methotrexate-<10-Years,68,capizzi,Methotrexate-+-asparaginase
2463,Allergic_reaction,2,207,Immune_system_disorders,NCT00075725,https://clinicaltrials.gov/show/NCT00075725,Leukemia,cyclophosphamide|cytarabine|daunorubicin_hydrochloride|dexamethasone|doxorubicin_hydrochloride|leucovorin_calcium|mercaptopurine|methotrexate|pegaspargase|prednisone|thioguanine|vincristine_sulfate|radiation_therapy|,other_events,arm4,Prednisone-Capizzi-Methotrexate-<10-Years,85,prednisone,steroid
2311,Anaphylaxis,24,207,Immune_system_disorders,NCT00075725,https://clinicaltrials.gov/show/NCT00075725,Leukemia,cyclophosphamide|cytarabine|daunorubicin_hydrochloride|dexamethasone|doxorubicin_hydrochloride|leucovorin_calcium|mercaptopurine|methotrexate|pegaspargase|prednisone|thioguanine|vincristine_sulfate|radiation_therapy|,other_events,arm4,Prednisone-Capizzi-Methotrexate-<10-Years,85,prednisone,steroid
2313,Anaphylaxis,1,207,Immune_system_disorders,NCT00075725,https://clinicaltrials.gov/show/NCT00075725,Leukemia,cyclophosphamide|cytarabine|daunorubicin_hydrochloride|dexamethasone|doxorubicin_hydrochloride|leucovorin_calcium|mercaptopurine|methotrexate|pegaspargase|prednisone|thioguanine|vincristine_sulfate|radiation_therapy|,serious_events,arm4,Prednisone-Capizzi-Methotrexate-<10-Years,85,prednisone,steroid
2460,Allergic_reaction,1,555,Immune_system_disorders,NCT00075725,https://clinicaltrials.gov/show/NCT00075725,Leukemia,cyclophosphamide|cytarabine|daunorubicin_hydrochloride|dexamethasone|doxorubicin_hydrochloride|leucovorin_calcium|mercaptopurine|methotrexate|pegaspargase|prednisone|thioguanine|vincristine_sulfate|radiation_therapy|,serious_events,arm5,Prednisone-Capezzi-Methotrexate->=-10-Years,23,methotrexate,antimetabolite
2464,Allergic_reaction,9,555,Immune_system_disorders,NCT00075725,https://clinicaltrials.gov/show/NCT00075725,Leukemia,cyclophosphamide|cytarabine|daunorubicin_hydrochloride|dexamethasone|doxorubicin_hydrochloride|leucovorin_calcium|mercaptopurine|methotrexate|pegaspargase|prednisone|thioguanine|vincristine_sulfate|radiation_therapy|,other_events,arm5,Prednisone-Capezzi-Methotrexate->=-10-Years,23,methotrexate,antimetabolite
2308,Anaphylaxis,5,555,Immune_system_disorders,NCT00075725,https://clinicaltrials.gov/show/NCT00075725,Leukemia,cyclophosphamide|cytarabine|daunorubicin_hydrochloride|dexamethasone|doxorubicin_hydrochloride|leucovorin_calcium|mercaptopurine|methotrexate|pegaspargase|prednisone|thioguanine|vincristine_sulfate|radiation_therapy|,serious_events,arm5,Prednisone-Capezzi-Methotrexate->=-10-Years,23,methotrexate,antimetabolite
2312,Anaphylaxis,97,555,Immune_system_disorders,NCT00075725,https://clinicaltrials.gov/show/NCT00075725,Leukemia,cyclophosphamide|cytarabine|daunorubicin_hydrochloride|dexamethasone|doxorubicin_hydrochloride|leucovorin_calcium|mercaptopurine|methotrexate|pegaspargase|prednisone|thioguanine|vincristine_sulfate|radiation_therapy|,other_events,arm5,Prednisone-Capezzi-Methotrexate->=-10-Years,23,methotrexate,antimetabolite
2464,Allergic_reaction,9,555,Immune_system_disorders,NCT00075725,https://clinicaltrials.gov/show/NCT00075725,Leukemia,cyclophosphamide|cytarabine|daunorubicin_hydrochloride|dexamethasone|doxorubicin_hydrochloride|leucovorin_calcium|mercaptopurine|methotrexate|pegaspargase|prednisone|thioguanine|vincristine_sulfate|radiation_therapy|,other_events,arm5,Prednisone-Capezzi-Methotrexate->=-10-Years,69,capezzi,Methotrexate-+-asparaginase
2308,Anaphylaxis,5,555,Immune_system_disorders,NCT00075725,https://clinicaltrials.gov/show/NCT00075725,Leukemia,cyclophosphamide|cytarabine|daunorubicin_hydrochloride|dexamethasone|doxorubicin_hydrochloride|leucovorin_calcium|mercaptopurine|methotrexate|pegaspargase|prednisone|thioguanine|vincristine_sulfate|radiation_therapy|,serious_events,arm5,Prednisone-Capezzi-Methotrexate->=-10-Years,69,capezzi,Methotrexate-+-asparaginase
2312,Anaphylaxis,97,555,Immune_system_disorders,NCT00075725,https://clinicaltrials.gov/show/NCT00075725,Leukemia,cyclophosphamide|cytarabine|daunorubicin_hydrochloride|dexamethasone|doxorubicin_hydrochloride|leucovorin_calcium|mercaptopurine|methotrexate|pegaspargase|prednisone|thioguanine|vincristine_sulfate|radiation_therapy|,other_events,arm5,Prednisone-Capezzi-Methotrexate->=-10-Years,69,capezzi,Methotrexate-+-asparaginase
2460,Allergic_reaction,1,555,Immune_system_disorders,NCT00075725,https://clinicaltrials.gov/show/NCT00075725,Leukemia,cyclophosphamide|cytarabine|daunorubicin_hydrochloride|dexamethasone|doxorubicin_hydrochloride|leucovorin_calcium|mercaptopurine|methotrexate|pegaspargase|prednisone|thioguanine|vincristine_sulfate|radiation_therapy|,serious_events,arm5,Prednisone-Capezzi-Methotrexate->=-10-Years,69,capezzi-,Methotrexate-+-asparaginase
2460,Allergic_reaction,1,555,Immune_system_disorders,NCT00075725,https://clinicaltrials.gov/show/NCT00075725,Leukemia,cyclophosphamide|cytarabine|daunorubicin_hydrochloride|dexamethasone|doxorubicin_hydrochloride|leucovorin_calcium|mercaptopurine|methotrexate|pegaspargase|prednisone|thioguanine|vincristine_sulfate|radiation_therapy|,serious_events,arm5,Prednisone-Capezzi-Methotrexate->=-10-Years,85,prednisone,steroid
2464,Allergic_reaction,9,555,Immune_system_disorders,NCT00075725,https://clinicaltrials.gov/show/NCT00075725,Leukemia,cyclophosphamide|cytarabine|daunorubicin_hydrochloride|dexamethasone|doxorubicin_hydrochloride|leucovorin_calcium|mercaptopurine|methotrexate|pegaspargase|prednisone|thioguanine|vincristine_sulfate|radiation_therapy|,other_events,arm5,Prednisone-Capezzi-Methotrexate->=-10-Years,85,prednisone,steroid
2308,Anaphylaxis,5,555,Immune_system_disorders,NCT00075725,https://clinicaltrials.gov/show/NCT00075725,Leukemia,cyclophosphamide|cytarabine|daunorubicin_hydrochloride|dexamethasone|doxorubicin_hydrochloride|leucovorin_calcium|mercaptopurine|methotrexate|pegaspargase|prednisone|thioguanine|vincristine_sulfate|radiation_therapy|,serious_events,arm5,Prednisone-Capezzi-Methotrexate->=-10-Years,85,prednisone,steroid
2312,Anaphylaxis,97,555,Immune_system_disorders,NCT00075725,https://clinicaltrials.gov/show/NCT00075725,Leukemia,cyclophosphamide|cytarabine|daunorubicin_hydrochloride|dexamethasone|doxorubicin_hydrochloride|leucovorin_calcium|mercaptopurine|methotrexate|pegaspargase|prednisone|thioguanine|vincristine_sulfate|radiation_therapy|,other_events,arm5,Prednisone-Capezzi-Methotrexate->=-10-Years,85,prednisone,steroid
2465,Allergic_reaction,1,203,Immune_system_disorders,NCT00075725,https://clinicaltrials.gov/show/NCT00075725,Leukemia,cyclophosphamide|cytarabine|daunorubicin_hydrochloride|dexamethasone|doxorubicin_hydrochloride|leucovorin_calcium|mercaptopurine|methotrexate|pegaspargase|prednisone|thioguanine|vincristine_sulfate|radiation_therapy|,other_events,arm6,Predisone-and-High-Dose-Methotrexate-<-10-Yrs-Old,23,methotrexate,antimetabolite
2302,Anaphylaxis,24,203,Immune_system_disorders,NCT00075725,https://clinicaltrials.gov/show/NCT00075725,Leukemia,cyclophosphamide|cytarabine|daunorubicin_hydrochloride|dexamethasone|doxorubicin_hydrochloride|leucovorin_calcium|mercaptopurine|methotrexate|pegaspargase|prednisone|thioguanine|vincristine_sulfate|radiation_therapy|,other_events,arm6,Predisone-and-High-Dose-Methotrexate-<-10-Yrs-Old,23,methotrexate,antimetabolite
2468,Allergic_reaction,8,562,Immune_system_disorders,NCT00075725,https://clinicaltrials.gov/show/NCT00075725,Leukemia,cyclophosphamide|cytarabine|daunorubicin_hydrochloride|dexamethasone|doxorubicin_hydrochloride|leucovorin_calcium|mercaptopurine|methotrexate|pegaspargase|prednisone|thioguanine|vincristine_sulfate|radiation_therapy|,other_events,arm7,Prenisone-and-High-Dose-Methotrexate->=10-Years,23,methotrexate,antimetabolite
2303,Anaphylaxis,3,562,Immune_system_disorders,NCT00075725,https://clinicaltrials.gov/show/NCT00075725,Leukemia,cyclophosphamide|cytarabine|daunorubicin_hydrochloride|dexamethasone|doxorubicin_hydrochloride|leucovorin_calcium|mercaptopurine|methotrexate|pegaspargase|prednisone|thioguanine|vincristine_sulfate|radiation_therapy|,serious_events,arm7,Prenisone-and-High-Dose-Methotrexate->=10-Years,23,methotrexate,antimetabolite
2306,Anaphylaxis,81,562,Immune_system_disorders,NCT00075725,https://clinicaltrials.gov/show/NCT00075725,Leukemia,cyclophosphamide|cytarabine|daunorubicin_hydrochloride|dexamethasone|doxorubicin_hydrochloride|leucovorin_calcium|mercaptopurine|methotrexate|pegaspargase|prednisone|thioguanine|vincristine_sulfate|radiation_therapy|,other_events,arm7,Prenisone-and-High-Dose-Methotrexate->=10-Years,23,methotrexate,antimetabolite
2466,Allergic_reaction,2,84,Immune_system_disorders,NCT00075725,https://clinicaltrials.gov/show/NCT00075725,Leukemia,cyclophosphamide|cytarabine|daunorubicin_hydrochloride|dexamethasone|doxorubicin_hydrochloride|leucovorin_calcium|mercaptopurine|methotrexate|pegaspargase|prednisone|thioguanine|vincristine_sulfate|radiation_therapy|,other_events,arm8,Dexamethasone-High-Dose-Methotrexate-(Non-Randomly-Assigned),23,methotrexate,antimetabolite
2305,Anaphylaxis,9,84,Immune_system_disorders,NCT00075725,https://clinicaltrials.gov/show/NCT00075725,Leukemia,cyclophosphamide|cytarabine|daunorubicin_hydrochloride|dexamethasone|doxorubicin_hydrochloride|leucovorin_calcium|mercaptopurine|methotrexate|pegaspargase|prednisone|thioguanine|vincristine_sulfate|radiation_therapy|,other_events,arm8,Dexamethasone-High-Dose-Methotrexate-(Non-Randomly-Assigned),23,methotrexate,antimetabolite
2315,Anaphylaxis,1,84,Immune_system_disorders,NCT00075725,https://clinicaltrials.gov/show/NCT00075725,Leukemia,cyclophosphamide|cytarabine|daunorubicin_hydrochloride|dexamethasone|doxorubicin_hydrochloride|leucovorin_calcium|mercaptopurine|methotrexate|pegaspargase|prednisone|thioguanine|vincristine_sulfate|radiation_therapy|,serious_events,arm8,Dexamethasone-High-Dose-Methotrexate-(Non-Randomly-Assigned),23,methotrexate,antimetabolite
2466,Allergic_reaction,2,84,Immune_system_disorders,NCT00075725,https://clinicaltrials.gov/show/NCT00075725,Leukemia,cyclophosphamide|cytarabine|daunorubicin_hydrochloride|dexamethasone|doxorubicin_hydrochloride|leucovorin_calcium|mercaptopurine|methotrexate|pegaspargase|prednisone|thioguanine|vincristine_sulfate|radiation_therapy|,other_events,arm8,Dexamethasone-High-Dose-Methotrexate-(Non-Randomly-Assigned),79,dexamethasone,steroid
2305,Anaphylaxis,9,84,Immune_system_disorders,NCT00075725,https://clinicaltrials.gov/show/NCT00075725,Leukemia,cyclophosphamide|cytarabine|daunorubicin_hydrochloride|dexamethasone|doxorubicin_hydrochloride|leucovorin_calcium|mercaptopurine|methotrexate|pegaspargase|prednisone|thioguanine|vincristine_sulfate|radiation_therapy|,other_events,arm8,Dexamethasone-High-Dose-Methotrexate-(Non-Randomly-Assigned),79,dexamethasone,steroid
2315,Anaphylaxis,1,84,Immune_system_disorders,NCT00075725,https://clinicaltrials.gov/show/NCT00075725,Leukemia,cyclophosphamide|cytarabine|daunorubicin_hydrochloride|dexamethasone|doxorubicin_hydrochloride|leucovorin_calcium|mercaptopurine|methotrexate|pegaspargase|prednisone|thioguanine|vincristine_sulfate|radiation_therapy|,serious_events,arm8,Dexamethasone-High-Dose-Methotrexate-(Non-Randomly-Assigned),79,dexamethasone,steroid
2309,Anaphylaxis,4,21,Immune_system_disorders,NCT00075725,https://clinicaltrials.gov/show/NCT00075725,Leukemia,cyclophosphamide|cytarabine|daunorubicin_hydrochloride|dexamethasone|doxorubicin_hydrochloride|leucovorin_calcium|mercaptopurine|methotrexate|pegaspargase|prednisone|thioguanine|vincristine_sulfate|radiation_therapy|,other_events,arm9,Prednisone-Capezzi-Methotrexate-(Non-Randomly-Assigned),23,methotrexate,antimetabolite
2309,Anaphylaxis,4,21,Immune_system_disorders,NCT00075725,https://clinicaltrials.gov/show/NCT00075725,Leukemia,cyclophosphamide|cytarabine|daunorubicin_hydrochloride|dexamethasone|doxorubicin_hydrochloride|leucovorin_calcium|mercaptopurine|methotrexate|pegaspargase|prednisone|thioguanine|vincristine_sulfate|radiation_therapy|,other_events,arm9,Prednisone-Capezzi-Methotrexate-(Non-Randomly-Assigned),69,capezzi,Methotrexate-+-asparaginase
2309,Anaphylaxis,4,21,Immune_system_disorders,NCT00075725,https://clinicaltrials.gov/show/NCT00075725,Leukemia,cyclophosphamide|cytarabine|daunorubicin_hydrochloride|dexamethasone|doxorubicin_hydrochloride|leucovorin_calcium|mercaptopurine|methotrexate|pegaspargase|prednisone|thioguanine|vincristine_sulfate|radiation_therapy|,other_events,arm9,Prednisone-Capezzi-Methotrexate-(Non-Randomly-Assigned),85,prednisone,steroid
2298,Anaphylaxis,2,500,Immune_system_disorders,NCT00075946,https://clinicaltrials.gov/show/NCT00075946,Lymphoma,rituximab,serious_events,arm0,Arm-I:-Induction-Rituximab,16,rituximab,monoclonal-antibody
1865,Dermatitis_allergic,1,111,Skin_and_subcutaneous_tissue_disorders,NCT00076024,https://clinicaltrials.gov/show/NCT00076024,Breast_Neoplasms,Placebo|Docetaxel|AG-013736_(axitinib)|Docetaxel|,serious_events,arm1,Axitinib-+-Docetaxel-(Phase-2-Double-blind),10,axitinib,kinase-inhibitor
1865,Dermatitis_allergic,1,111,Skin_and_subcutaneous_tissue_disorders,NCT00076024,https://clinicaltrials.gov/show/NCT00076024,Breast_Neoplasms,Placebo|Docetaxel|AG-013736_(axitinib)|Docetaxel|,serious_events,arm1,Axitinib-+-Docetaxel-(Phase-2-Double-blind),8,docetaxel,taxane
2469,Allergic_reaction,7,64,Immune_system_disorders,NCT00077207,https://clinicaltrials.gov/show/NCT00077207,Brain_Tumor|Central_Nervous_System_Tumor|,carboplatin|temozolomide|vincristine_sulfate|,other_events,arm0,Treatment-(Carboplatin-Vincristine-Sulfate-Temozolomide),3,carboplatin,alkalating-agent
2317,Anaphylaxis,7,64,Immune_system_disorders,NCT00077207,https://clinicaltrials.gov/show/NCT00077207,Brain_Tumor|Central_Nervous_System_Tumor|,carboplatin|temozolomide|vincristine_sulfate|,other_events,arm0,Treatment-(Carboplatin-Vincristine-Sulfate-Temozolomide),3,carboplatin,alkalating-agent
2469,Allergic_reaction,7,64,Immune_system_disorders,NCT00077207,https://clinicaltrials.gov/show/NCT00077207,Brain_Tumor|Central_Nervous_System_Tumor|,carboplatin|temozolomide|vincristine_sulfate|,other_events,arm0,Treatment-(Carboplatin-Vincristine-Sulfate-Temozolomide),98,temozolomide,alkylating-agent
2317,Anaphylaxis,7,64,Immune_system_disorders,NCT00077207,https://clinicaltrials.gov/show/NCT00077207,Brain_Tumor|Central_Nervous_System_Tumor|,carboplatin|temozolomide|vincristine_sulfate|,other_events,arm0,Treatment-(Carboplatin-Vincristine-Sulfate-Temozolomide),98,temozolomide,alkylating-agent
2470,Allergic_reaction,2,59,Immune_system_disorders,NCT00077376,https://clinicaltrials.gov/show/NCT00077376,HER2-positive_Breast_Cancer|Male_Breast_Cancer|Recurrent_Breast_Cancer|Stage_IV_Breast_Cancer|,trastuzumab|ixabepilone|carboplatin|laboratory_biomarker_analysis|,serious_events,arm0,Trastuzumab/Ixabepilone/Carboplatin,3,carboplatin,alkalating-agent
2471,Allergic_reaction,8,59,Immune_system_disorders,NCT00077376,https://clinicaltrials.gov/show/NCT00077376,HER2-positive_Breast_Cancer|Male_Breast_Cancer|Recurrent_Breast_Cancer|Stage_IV_Breast_Cancer|,trastuzumab|ixabepilone|carboplatin|laboratory_biomarker_analysis|,other_events,arm0,Trastuzumab/Ixabepilone/Carboplatin,3,carboplatin,alkalating-agent
2470,Allergic_reaction,2,59,Immune_system_disorders,NCT00077376,https://clinicaltrials.gov/show/NCT00077376,HER2-positive_Breast_Cancer|Male_Breast_Cancer|Recurrent_Breast_Cancer|Stage_IV_Breast_Cancer|,trastuzumab|ixabepilone|carboplatin|laboratory_biomarker_analysis|,serious_events,arm0,Trastuzumab/Ixabepilone/Carboplatin,82,ixabepilone,antimicrotubule-agent
2471,Allergic_reaction,8,59,Immune_system_disorders,NCT00077376,https://clinicaltrials.gov/show/NCT00077376,HER2-positive_Breast_Cancer|Male_Breast_Cancer|Recurrent_Breast_Cancer|Stage_IV_Breast_Cancer|,trastuzumab|ixabepilone|carboplatin|laboratory_biomarker_analysis|,other_events,arm0,Trastuzumab/Ixabepilone/Carboplatin,82,ixabepilone,antimicrotubule-agent
2470,Allergic_reaction,2,59,Immune_system_disorders,NCT00077376,https://clinicaltrials.gov/show/NCT00077376,HER2-positive_Breast_Cancer|Male_Breast_Cancer|Recurrent_Breast_Cancer|Stage_IV_Breast_Cancer|,trastuzumab|ixabepilone|carboplatin|laboratory_biomarker_analysis|,serious_events,arm0,Trastuzumab/Ixabepilone/Carboplatin,18,trastuzumab,monoclonal-antibody
2471,Allergic_reaction,8,59,Immune_system_disorders,NCT00077376,https://clinicaltrials.gov/show/NCT00077376,HER2-positive_Breast_Cancer|Male_Breast_Cancer|Recurrent_Breast_Cancer|Stage_IV_Breast_Cancer|,trastuzumab|ixabepilone|carboplatin|laboratory_biomarker_analysis|,other_events,arm0,Trastuzumab/Ixabepilone/Carboplatin,18,trastuzumab,monoclonal-antibody
47,Hypersensitivity,8,310,Immune_system_disorders,NCT00079001,https://clinicaltrials.gov/show/NCT00079001,Metastatic_Cancer|Prostate_Cancer|,zoledronic_acid|placebo|androgen_deprivation_therapy|GnRH_agonist|Calcium_supplement|Vitamin_D|,other_events,arm0,Zoledronic-Acid-+-Androgen-Deprivation-Therapy,65,deprivation,Androgen-inhibitor
47,Hypersensitivity,8,310,Immune_system_disorders,NCT00079001,https://clinicaltrials.gov/show/NCT00079001,Metastatic_Cancer|Prostate_Cancer|,zoledronic_acid|placebo|androgen_deprivation_therapy|GnRH_agonist|Calcium_supplement|Vitamin_D|,other_events,arm0,Zoledronic-Acid-+-Androgen-Deprivation-Therapy,28,zoledronic,bisphosphonates-(supportive-treatment-of-cancer--treats-symptoms-and/or-decreases-complications)
46,Hypersensitivity,6,308,Immune_system_disorders,NCT00079001,https://clinicaltrials.gov/show/NCT00079001,Metastatic_Cancer|Prostate_Cancer|,zoledronic_acid|placebo|androgen_deprivation_therapy|GnRH_agonist|Calcium_supplement|Vitamin_D|,other_events,arm1,Placebo-+-Androgen-Deprivation-Therapy,65,deprivation,Androgen-inhibitor
2472,Allergic_Reaction,1,64,Immune_system_disorders,NCT00079040,https://clinicaltrials.gov/show/NCT00079040,Extensive_Stage_Small_Cell_Lung_Cancer,cisplatin|etoposide|bevacizumab|laboratory_biomarker_analysis|,serious_events,arm0,Cisplatin-Etoposide-Bevacizumab,9,cisplatin,alkalating-agent
2472,Allergic_Reaction,1,64,Immune_system_disorders,NCT00079040,https://clinicaltrials.gov/show/NCT00079040,Extensive_Stage_Small_Cell_Lung_Cancer,cisplatin|etoposide|bevacizumab|laboratory_biomarker_analysis|,serious_events,arm0,Cisplatin-Etoposide-Bevacizumab,4,bevacizumab,monoclonal-antibody
2472,Allergic_Reaction,1,64,Immune_system_disorders,NCT00079040,https://clinicaltrials.gov/show/NCT00079040,Extensive_Stage_Small_Cell_Lung_Cancer,cisplatin|etoposide|bevacizumab|laboratory_biomarker_analysis|,serious_events,arm0,Cisplatin-Etoposide-Bevacizumab,22,bevacizumab,monoclonal-antibody
2472,Allergic_Reaction,1,64,Immune_system_disorders,NCT00079040,https://clinicaltrials.gov/show/NCT00079040,Extensive_Stage_Small_Cell_Lung_Cancer,cisplatin|etoposide|bevacizumab|laboratory_biomarker_analysis|,serious_events,arm0,Cisplatin-Etoposide-Bevacizumab,26,etoposide,"plant-alkaloid""-and-""topoisomerase-II-inhibitor."""
49,Hypersensitivity,28,1378,Immune_system_disorders,NCT00079274,https://clinicaltrials.gov/show/NCT00079274,Adenocarcinoma_of_the_Colon|Stage_III_Colon_Cancer|,irinotecan_hydrochloride|oxaliplatin|leucovorin_calcium|fluorouracil|cetuximab|Locally_Directed_Therapy|,other_events,arm0,Arm-A-(Combination-Chemotherapy),,,
51,Hypersensitivity,6,1378,Immune_system_disorders,NCT00079274,https://clinicaltrials.gov/show/NCT00079274,Adenocarcinoma_of_the_Colon|Stage_III_Colon_Cancer|,irinotecan_hydrochloride|oxaliplatin|leucovorin_calcium|fluorouracil|cetuximab|Locally_Directed_Therapy|,serious_events,arm0,Arm-A-(Combination-Chemotherapy),,,
48,Hypersensitivity,2,108,Immune_system_disorders,NCT00079274,https://clinicaltrials.gov/show/NCT00079274,Adenocarcinoma_of_the_Colon|Stage_III_Colon_Cancer|,irinotecan_hydrochloride|oxaliplatin|leucovorin_calcium|fluorouracil|cetuximab|Locally_Directed_Therapy|,other_events,arm2,Arm-C-(Combination-Chemotherapy),,,
53,Hypersensitivity,62,1326,Immune_system_disorders,NCT00079274,https://clinicaltrials.gov/show/NCT00079274,Adenocarcinoma_of_the_Colon|Stage_III_Colon_Cancer|,irinotecan_hydrochloride|oxaliplatin|leucovorin_calcium|fluorouracil|cetuximab|Locally_Directed_Therapy|,other_events,arm3,Arm-D-(Combination-Chemotherapy-Monoclonal-Antibody),,,
54,Hypersensitivity,17,1326,Immune_system_disorders,NCT00079274,https://clinicaltrials.gov/show/NCT00079274,Adenocarcinoma_of_the_Colon|Stage_III_Colon_Cancer|,irinotecan_hydrochloride|oxaliplatin|leucovorin_calcium|fluorouracil|cetuximab|Locally_Directed_Therapy|,serious_events,arm3,Arm-D-(Combination-Chemotherapy-Monoclonal-Antibody),,,
52,Hypersensitivity,1,42,Immune_system_disorders,NCT00079274,https://clinicaltrials.gov/show/NCT00079274,Adenocarcinoma_of_the_Colon|Stage_III_Colon_Cancer|,irinotecan_hydrochloride|oxaliplatin|leucovorin_calcium|fluorouracil|cetuximab|Locally_Directed_Therapy|,other_events,arm4,Arm-E-(Combination-Chemotherapy-Monoclonal-Antibody),,,
50,Hypersensitivity,1,44,Immune_system_disorders,NCT00079274,https://clinicaltrials.gov/show/NCT00079274,Adenocarcinoma_of_the_Colon|Stage_III_Colon_Cancer|,irinotecan_hydrochloride|oxaliplatin|leucovorin_calcium|fluorouracil|cetuximab|Locally_Directed_Therapy|,other_events,arm5,Arm-F-(Combination-Chemotherapy-Monoclonal-Antibody),,,
2473,Allergic_Reaction,3,39,Immune_system_disorders,NCT00079326,https://clinicaltrials.gov/show/NCT00079326,HER2-positive_Breast_Cancer|Recurrent_Breast_Cancer|Stage_IV_Breast_Cancer|,trastuzumab|ixabepilone|laboratory_biomarker_analysis|,other_events,arm0,All-Study-Participants,,,
2474,Allergic_reaction,3,69,Immune_system_disorders,NCT00081289,https://clinicaltrials.gov/show/NCT00081289,Colorectal_Cancer,Radiation_Therapy|Capecitabine_1650_mg/m^2/day|Capecitabine_1200_mg/m^2/day|Irinotecan|Oxaliplatin|Surgery|Folinic_Acid|Fluorouracil|Oxaliplatin|,other_events,arm1,Neoadjuvant-Chemoradiation-With-Oxaliplatin,7,oxaliplatin,alkalating-agent
56,Hypersensitivity,1,39,Immune_system_disorders,NCT00081497,https://clinicaltrials.gov/show/NCT00081497,Fabry_Disease,agalsidase_beta,other_events,arm0,Fabrazyme/Fabrazyme,,,
55,Hypersensitivity,1,67,Immune_system_disorders,NCT00081497,https://clinicaltrials.gov/show/NCT00081497,Fabry_Disease,agalsidase_beta,other_events,arm2,Total,,,
58,HYPERSENSITIVITY,4,595,Immune_system_disorders,NCT00082433,https://clinicaltrials.gov/show/NCT00082433,Cancer|Breast_Cancer|,Ixabepilone_+_Capecitabine|Capecitabine|,serious_events,arm1,Ixabepilone-+-Capecitabine,17,capecitabine,antimetabolite
58,HYPERSENSITIVITY,4,595,Immune_system_disorders,NCT00082433,https://clinicaltrials.gov/show/NCT00082433,Cancer|Breast_Cancer|,Ixabepilone_+_Capecitabine|Capecitabine|,serious_events,arm1,Ixabepilone-+-Capecitabine,29,capecitabine,antimetabolite
58,HYPERSENSITIVITY,4,595,Immune_system_disorders,NCT00082433,https://clinicaltrials.gov/show/NCT00082433,Cancer|Breast_Cancer|,Ixabepilone_+_Capecitabine|Capecitabine|,serious_events,arm1,Ixabepilone-+-Capecitabine,82,ixabepilone,antimicrotubule-agent
2319,Anaphylaxis,1,15,Immune_system_disorders,NCT00082758,https://clinicaltrials.gov/show/NCT00082758,Neuroblastoma,hu14.18-Interleukin-2_fusion_protein,serious_events,arm0,Disease-Measurable-by-Standard-Criteria(hu14.18-interleukin-2),,,
2318,Anaphylaxis,3,24,Immune_system_disorders,NCT00082758,https://clinicaltrials.gov/show/NCT00082758,Neuroblastoma,hu14.18-Interleukin-2_fusion_protein,serious_events,arm1,Disease-Eval-by-MIBG-or-BM-Histology-(hu14.18-interleukin-2),,,
59,Hypersensitivity,3,45,Immune_system_disorders,NCT00083122,https://clinicaltrials.gov/show/NCT00083122,Recurrent_Ovarian_Epithelial_Cancer|Recurrent_Primary_Peritoneal_Cavity_Cancer|Stage_IIIA_Ovarian_Epithelial_Cancer|Stage_IIIA_Primary_Peritoneal_Cavity_Cancer|Stage_IIIB_Ovarian_Epithelial_Cancer|Stage_IIIB_Primary_Peritoneal_Cavity_Cancer|Stage_IIIC_Ova,cisplatin|alvocidib|cisplatin/flavopiridol|,serious_events,arm0,Group-1-and-Group-2-Combined,,,
2475,Allergic_reaction,1,2240,Immune_system_disorders,NCT00083174,https://clinicaltrials.gov/show/NCT00083174,Breast_Cancer,exemestane,serious_events,arm0,Exemestane,56,exemestane,aromatase-inhibitor
60,Hypersensitivity,1,182,Immune_system_disorders,NCT00083616,https://clinicaltrials.gov/show/NCT00083616,Colorectal_Cancer|Metastatic_Cancer|,Panitumumab,serious_events,arm0,Panitumumab,30,panitumumab,monoclonal-antibody-and-signal-transduction-inhibitor
61,Hypersensitivity,1,85,Immune_system_disorders,NCT00083720,https://clinicaltrials.gov/show/NCT00083720,Colorectal_Neoplasms|Metastases|Neoplasm|,cetuximab,serious_events,arm0,Cetuximab,5,cetuximab,Epidermal-growth-factor-receptor-inhibitor
1124,Drug_Hypersensitivity,1,17,Immune_system_disorders,NCT00084084,https://clinicaltrials.gov/show/NCT00084084,Fabry_Disease,Agalsidase_alfa,other_events,arm0,Safety-Population-RB,,,
1123,Drug_Hypersensitivity,1,11,Immune_system_disorders,NCT00084084,https://clinicaltrials.gov/show/NCT00084084,Fabry_Disease,Agalsidase_alfa,other_events,arm1,Transition-Safety-Population,,,
2476,Allergic_reaction,1,101,Immune_system_disorders,NCT00085631,https://clinicaltrials.gov/show/NCT00085631,Cervical_Cancer,cisplatin|hyperthermia_treatment|brachytherapy|external_beam_radiation_therapy|,other_events,arm0,Overall-Study,,,
2477,Allergic_reaction,1,101,Immune_system_disorders,NCT00085631,https://clinicaltrials.gov/show/NCT00085631,Cervical_Cancer,cisplatin|hyperthermia_treatment|brachytherapy|external_beam_radiation_therapy|,serious_events,arm0,Overall-Study,,,
1867,Dermatitis_allergic,13,164,Skin_and_subcutaneous_tissue_disorders,NCT00086580,https://clinicaltrials.gov/show/NCT00086580,B-Cell_Chronic_Lymphocytic_Leukemia,FluCAM_[Fludara_+_Campath]|fludarabine_phosphate|,other_events,arm0,Combination-Arm-(FluCAM),,,
1868,Dermatitis_allergic,1,164,Skin_and_subcutaneous_tissue_disorders,NCT00086580,https://clinicaltrials.gov/show/NCT00086580,B-Cell_Chronic_Lymphocytic_Leukemia,FluCAM_[Fludara_+_Campath]|fludarabine_phosphate|,serious_events,arm0,Combination-Arm-(FluCAM),,,
1129,Drug_hypersensitivity,1,164,Immune_system_disorders,NCT00086580,https://clinicaltrials.gov/show/NCT00086580,B-Cell_Chronic_Lymphocytic_Leukemia,FluCAM_[Fludara_+_Campath]|fludarabine_phosphate|,other_events,arm0,Combination-Arm-(FluCAM),,,
64,Hypersensitivity,5,164,Immune_system_disorders,NCT00086580,https://clinicaltrials.gov/show/NCT00086580,B-Cell_Chronic_Lymphocytic_Leukemia,FluCAM_[Fludara_+_Campath]|fludarabine_phosphate|,other_events,arm0,Combination-Arm-(FluCAM),,,
1869,Dermatitis_allergic,4,165,Skin_and_subcutaneous_tissue_disorders,NCT00086580,https://clinicaltrials.gov/show/NCT00086580,B-Cell_Chronic_Lymphocytic_Leukemia,FluCAM_[Fludara_+_Campath]|fludarabine_phosphate|,other_events,arm1,Fludarabine-Alone,66,fludarabine,antimetabolite
65,Hypersensitivity,1,165,Immune_system_disorders,NCT00086580,https://clinicaltrials.gov/show/NCT00086580,B-Cell_Chronic_Lymphocytic_Leukemia,FluCAM_[Fludara_+_Campath]|fludarabine_phosphate|,other_events,arm1,Fludarabine-Alone,66,fludarabine,antimetabolite
2479,Allergic_reaction,1,123,Immune_system_disorders,NCT00087139,https://clinicaltrials.gov/show/NCT00087139,Adenocarcinoma_of_the_Prostate|Recurrent_Prostate_Cancer|Stage_IV_Prostate_Cancer|,ixabepilone,serious_events,arm0,Ixabepilone,82,ixabepilone,antimicrotubule-agent
1132,Drug_hypersensitivity,6,77,Immune_system_disorders,NCT00087698,https://clinicaltrials.gov/show/NCT00087698,Pleural_Neoplasms,pemetrexed|cisplatin|,other_events,arm0,Pemetrexed,15,pemetrexed,antimetabolite
2480,Allergic_reaction,1,62,Immune_system_disorders,NCT00088881,https://clinicaltrials.gov/show/NCT00088881,Contiguous_Stage_II_Adult_Diffuse_Large_Cell_Lymphoma|Extranodal_Marginal_Zone_B-cell_Lymphoma_of_Mucosa-associated_Lymphoid_Tissue|Nodal_Marginal_Zone_B-cell_Lymphoma|Noncontiguous_Stage_II_Adult_Diffuse_Large_Cell_Lymphoma|Splenic_Marginal_Zone_Lymphoma,rituximab|prednisone|cyclophosphamide|doxorubicin|vincristine|indium_In_111_ibritumomab_tiuxetan|radiation_therapy|positron_emission_tomography|,serious_events,arm0,Step-1---R-CHOP,,,
2320,Anaphylaxis,2,129,Immune_system_disorders,NCT00088907,https://clinicaltrials.gov/show/NCT00088907,Recurrent_Head_and_Neck_Cancer|Metastatic_Head_and_Neck_Cancer|,docetaxel|placebo|gefitinib|,serious_events,arm0,Step-1:-Docetaxel+Placebo,8,docetaxel,taxane
2321,Anaphylaxis,1,124,Immune_system_disorders,NCT00088907,https://clinicaltrials.gov/show/NCT00088907,Recurrent_Head_and_Neck_Cancer|Metastatic_Head_and_Neck_Cancer|,docetaxel|placebo|gefitinib|,serious_events,arm1,Step-1:-Docetaxel+ZD1839,8,docetaxel,taxane
2481,Allergic_reaction,3,70,Immune_system_disorders,NCT00089297,https://clinicaltrials.gov/show/NCT00089297,Head_and_Neck_Cancer,Cetuximab|Carboplatin|Paclitaxel|Radiation_therapy|,serious_events,arm0,Cetuximab/Paclitaxel/Carboplatin,3,carboplatin,alkalating-agent
2481,Allergic_reaction,3,70,Immune_system_disorders,NCT00089297,https://clinicaltrials.gov/show/NCT00089297,Head_and_Neck_Cancer,Cetuximab|Carboplatin|Paclitaxel|Radiation_therapy|,serious_events,arm0,Cetuximab/Paclitaxel/Carboplatin,5,cetuximab,Epidermal-growth-factor-receptor-inhibitor
2481,Allergic_reaction,3,70,Immune_system_disorders,NCT00089297,https://clinicaltrials.gov/show/NCT00089297,Head_and_Neck_Cancer,Cetuximab|Carboplatin|Paclitaxel|Radiation_therapy|,serious_events,arm0,Cetuximab/Paclitaxel/Carboplatin,2,paclitaxel,taxane
1133,DRUG_HYPERSENSITIVITY,1,1283,Immune_system_disorders,NCT00089479,https://clinicaltrials.gov/show/NCT00089479,Breast_Cancer,capecitabine_[Xeloda]|Taxotere|Taxotere|,serious_events,arm1,AC-Then-XT,,,
2482,Allergic_reaction,1,15,Immune_system_disorders,NCT00089544,https://clinicaltrials.gov/show/NCT00089544,Recurrent_Adult_Soft_Tissue_Sarcoma|Stage_I_Adult_Soft_Tissue_Sarcoma|Stage_II_Adult_Soft_Tissue_Sarcoma|Stage_III_Adult_Soft_Tissue_Sarcoma|,doxorubicin_hydrochloride|ifosfamide|dacarbazine|filgrastim|radiation_therapy|thalidomide|therapeutic_conventional_surgery|laboratory_biomarker_analysis|,other_events,arm0,Cohort-A-(Chemotherapy-Radiation-Thalidomide-Surgery),,,
70,Hypersensitivity,1,203,Immune_system_disorders,NCT00089635,https://clinicaltrials.gov/show/NCT00089635,Colorectal_Cancer|Metastases|,ABX-EGF_(panitumumab),serious_events,arm0,Panitumumab,30,panitumumab,monoclonal-antibody-and-signal-transduction-inhibitor
1134,Drug_hypersensitivity,1,731,Immune_system_disorders,NCT00089674,https://clinicaltrials.gov/show/NCT00089674,Prostate_Cancer,AMG_162|Placebo|,serious_events,arm1,Denosumab-60-mg-Q6M,,,
1870,Dermatitis_allergic,1,3886,Skin_and_subcutaneous_tissue_disorders,NCT00089791,https://clinicaltrials.gov/show/NCT00089791,Osteoporosis,placebo|Denosumab|,serious_events,arm1,Denosumab-60-mg-Q6M,,,
1137,Drug_hypersensitivity,1,3886,Immune_system_disorders,NCT00089791,https://clinicaltrials.gov/show/NCT00089791,Osteoporosis,placebo|Denosumab|,serious_events,arm1,Denosumab-60-mg-Q6M,,,
71,Hypersensitivity,1,272,Immune_system_disorders,NCT00090051,https://clinicaltrials.gov/show/NCT00090051,Chronic_Lymphocytic_Leukemia,Rituximab|Fludarabine_Phosphate|Cyclophosphamide|,serious_events,arm0,Fludarabine+Cyclophosphamide-(FC),13,cyclophosphamide,alkylating-agent
71,Hypersensitivity,1,272,Immune_system_disorders,NCT00090051,https://clinicaltrials.gov/show/NCT00090051,Chronic_Lymphocytic_Leukemia,Rituximab|Fludarabine_Phosphate|Cyclophosphamide|,serious_events,arm0,Fludarabine+Cyclophosphamide-(FC),66,fludarabine,antimetabolite
1138,Drug_Hypersensitivity,1,274,Immune_system_disorders,NCT00090051,https://clinicaltrials.gov/show/NCT00090051,Chronic_Lymphocytic_Leukemia,Rituximab|Fludarabine_Phosphate|Cyclophosphamide|,serious_events,arm1,Fludarabine+Cyclophosphamide+Rituximab-(FCR),13,cyclophosphamide,alkylating-agent
1138,Drug_Hypersensitivity,1,274,Immune_system_disorders,NCT00090051,https://clinicaltrials.gov/show/NCT00090051,Chronic_Lymphocytic_Leukemia,Rituximab|Fludarabine_Phosphate|Cyclophosphamide|,serious_events,arm1,Fludarabine+Cyclophosphamide+Rituximab-(FCR),66,fludarabine,antimetabolite
1138,Drug_Hypersensitivity,1,274,Immune_system_disorders,NCT00090051,https://clinicaltrials.gov/show/NCT00090051,Chronic_Lymphocytic_Leukemia,Rituximab|Fludarabine_Phosphate|Cyclophosphamide|,serious_events,arm1,Fludarabine+Cyclophosphamide+Rituximab-(FCR),16,rituximab,monoclonal-antibody
72,Hypersensitivity,1,2020,Immune_system_disorders,NCT00090285,https://clinicaltrials.gov/show/NCT00090285,Condylomata_Acuminata,(Gardasil???)_human_papillomavirus_(types_6_11_16_18)_recombinant_vaccine|Comparator:_placebo_(unspecified)|,serious_events,arm0,qHPV-Vaccine:-Base-Study,,,
2484,allergic_reaction,1,75,Immune_system_disorders,NCT00090610,https://clinicaltrials.gov/show/NCT00090610,Ovarian_Cancer,Docetaxel|Carboplatin|,serious_events,arm0,Arm-1,,,
2483,allergic_reaction,1,74,Immune_system_disorders,NCT00090610,https://clinicaltrials.gov/show/NCT00090610,Ovarian_Cancer,Docetaxel|Carboplatin|,serious_events,arm1,Arm2,,,
76,HYPERSENSITIVITY,2,421,Immune_system_disorders,NCT00091572,https://clinicaltrials.gov/show/NCT00091572,Melanoma,Temozolomide|Dacarbazine|,serious_events,arm1,Dacarbazine,,,
1873,Dermatitis_allergic,5,2673,Skin_and_subcutaneous_tissue_disorders,NCT00092521,https://clinicaltrials.gov/show/NCT00092521,Cervical_Cancer|Genital_Warts|,V501|Comparator:_Placebo|Human_Papillomavirus_(HPV)_16_Monovalent|,other_events,arm0,Group-1---Base-Study-Quadrivalent-Human-Papillomavirus-Vaccine,,,
1875,Dermatitis_allergic,3,299,Skin_and_subcutaneous_tissue_disorders,NCT00092521,https://clinicaltrials.gov/show/NCT00092521,Cervical_Cancer|Genital_Warts|,V501|Comparator:_Placebo|Human_Papillomavirus_(HPV)_16_Monovalent|,other_events,arm1,Group-2---Base-Study-Monovalent-HPV-(Type-16)-Vaccine,,,
1874,Dermatitis_allergic,10,2672,Skin_and_subcutaneous_tissue_disorders,NCT00092521,https://clinicaltrials.gov/show/NCT00092521,Cervical_Cancer|Genital_Warts|,V501|Comparator:_Placebo|Human_Papillomavirus_(HPV)_16_Monovalent|,other_events,arm2,Group-3---Base-Study-Placebo,,,
1142,Drug_hypersensitivity,4,32,Immune_system_disorders,NCT00093145,https://clinicaltrials.gov/show/NCT00093145,Breast_Cancer,Albumin-bound_paclitaxel|Carboplatin|Herceptin??|,other_events,arm0,Albumin-bound-Paclitaxel-Carboplatin-+-Herceptin,3,carboplatin,alkalating-agent
1142,Drug_hypersensitivity,4,32,Immune_system_disorders,NCT00093145,https://clinicaltrials.gov/show/NCT00093145,Breast_Cancer,Albumin-bound_paclitaxel|Carboplatin|Herceptin??|,other_events,arm0,Albumin-bound-Paclitaxel-Carboplatin-+-Herceptin,2,paclitaxel,taxane
83,Hypersensitivity,2,27,Immune_system_disorders,NCT00093756,https://clinicaltrials.gov/show/NCT00093756,Recurrent_Non-small_Cell_Lung_Cancer|Stage_IIIA_Non-small_Cell_Lung_Cancer|Stage_IIIB_Non-small_Cell_Lung_Cancer|,3-dimensional_conformal_radiation_therapy|bortezomib|paclitaxel|carboplatin|,other_events,arm1,PhaseII,,,
1144,Drug_hypersensitivity,1,32,Immune_system_disorders,NCT00094107,https://clinicaltrials.gov/show/NCT00094107,Melanoma|Skin_Neoplasms|,Axitinib_[AG-013736],other_events,arm0,Axitinib,10,axitinib,kinase-inhibitor
84,Hypersensitivity,1,6,Immune_system_disorders,NCT00094835,https://clinicaltrials.gov/show/NCT00094835,Lung_Cancer|Non-Small_Cell_Lung_Cancer|,Panitumumab|Motesanib_diphosphate|Paclitaxel|Carboplatin|,other_events,arm2,Paclitaxel/Carboplatin-+-Motesanib-75-mg-BID,3,carboplatin,alkalating-agent
84,Hypersensitivity,1,6,Immune_system_disorders,NCT00094835,https://clinicaltrials.gov/show/NCT00094835,Lung_Cancer|Non-Small_Cell_Lung_Cancer|,Panitumumab|Motesanib_diphosphate|Paclitaxel|Carboplatin|,other_events,arm2,Paclitaxel/Carboplatin-+-Motesanib-75-mg-BID,87,motesanib,angiokinase-inhibitor
84,Hypersensitivity,1,6,Immune_system_disorders,NCT00094835,https://clinicaltrials.gov/show/NCT00094835,Lung_Cancer|Non-Small_Cell_Lung_Cancer|,Panitumumab|Motesanib_diphosphate|Paclitaxel|Carboplatin|,other_events,arm2,Paclitaxel/Carboplatin-+-Motesanib-75-mg-BID,2,paclitaxel,taxane
85,Hypersensitivity,1,6,Immune_system_disorders,NCT00094835,https://clinicaltrials.gov/show/NCT00094835,Lung_Cancer|Non-Small_Cell_Lung_Cancer|,Panitumumab|Motesanib_diphosphate|Paclitaxel|Carboplatin|,other_events,arm6,Panitumumab-+-Paclitaxel/Carboplatin-+-Motesanib-125-mg-QD,3,carboplatin,alkalating-agent
85,Hypersensitivity,1,6,Immune_system_disorders,NCT00094835,https://clinicaltrials.gov/show/NCT00094835,Lung_Cancer|Non-Small_Cell_Lung_Cancer|,Panitumumab|Motesanib_diphosphate|Paclitaxel|Carboplatin|,other_events,arm6,Panitumumab-+-Paclitaxel/Carboplatin-+-Motesanib-125-mg-QD,87,motesanib,angiokinase-inhibitor
85,Hypersensitivity,1,6,Immune_system_disorders,NCT00094835,https://clinicaltrials.gov/show/NCT00094835,Lung_Cancer|Non-Small_Cell_Lung_Cancer|,Panitumumab|Motesanib_diphosphate|Paclitaxel|Carboplatin|,other_events,arm6,Panitumumab-+-Paclitaxel/Carboplatin-+-Motesanib-125-mg-QD,30,panitumumab,monoclonal-antibody-and-signal-transduction-inhibitor
85,Hypersensitivity,1,6,Immune_system_disorders,NCT00094835,https://clinicaltrials.gov/show/NCT00094835,Lung_Cancer|Non-Small_Cell_Lung_Cancer|,Panitumumab|Motesanib_diphosphate|Paclitaxel|Carboplatin|,other_events,arm6,Panitumumab-+-Paclitaxel/Carboplatin-+-Motesanib-125-mg-QD,2,paclitaxel,taxane
88,Hypersensitivity,3,292,Immune_system_disorders,NCT00095199,https://clinicaltrials.gov/show/NCT00095199,Non_Small_Cell_Lung_Cancer,Pemetrexed|Cetuximab|Docetaxel|,serious_events,arm0,Cetuximab-&-Pemetrexed,15,pemetrexed,antimetabolite
88,Hypersensitivity,3,292,Immune_system_disorders,NCT00095199,https://clinicaltrials.gov/show/NCT00095199,Non_Small_Cell_Lung_Cancer,Pemetrexed|Cetuximab|Docetaxel|,serious_events,arm0,Cetuximab-&-Pemetrexed,5,cetuximab,Epidermal-growth-factor-receptor-inhibitor
87,Hypersensitivity,2,159,Immune_system_disorders,NCT00095199,https://clinicaltrials.gov/show/NCT00095199,Non_Small_Cell_Lung_Cancer,Pemetrexed|Cetuximab|Docetaxel|,serious_events,arm2,Cetuximab-and-Docetaxel,5,cetuximab,Epidermal-growth-factor-receptor-inhibitor
87,Hypersensitivity,2,159,Immune_system_disorders,NCT00095199,https://clinicaltrials.gov/show/NCT00095199,Non_Small_Cell_Lung_Cancer,Pemetrexed|Cetuximab|Docetaxel|,serious_events,arm2,Cetuximab-and-Docetaxel,8,docetaxel,taxane
86,Hypersensitivity,1,149,Immune_system_disorders,NCT00095199,https://clinicaltrials.gov/show/NCT00095199,Non_Small_Cell_Lung_Cancer,Pemetrexed|Cetuximab|Docetaxel|,serious_events,arm3,Docetaxel,8,docetaxel,taxane
1146,Drug_hypersensitivity,1,1495,Immune_system_disorders,NCT00095576,https://clinicaltrials.gov/show/NCT00095576,AIDS|HIV_Infections|,Trivalent_MRKAd5_HIV-1_gag/pol/nef_(1.5x10^10_ad-vg/dose)|Comparator:_placebo|,serious_events,arm1,Placebo,,,
2487,Allergic_reaction,1,124,Immune_system_disorders,NCT00096135,https://clinicaltrials.gov/show/NCT00096135,Leukemia,filgrastim|cyclophosphamide|cytarabine|daunorubicin_hydrochloride|dexamethasone|etoposide|leucovorin_calcium|mercaptopurine|methotrexate|pegaspargase|therapeutic_hydrocortisone|vincristine_sulfate|radiation_therapy|,other_events,arm0,CNS-Patients---Treatment-(Combination-Chemotherapy),,,
2324,Anaphylaxis,11,124,Immune_system_disorders,NCT00096135,https://clinicaltrials.gov/show/NCT00096135,Leukemia,filgrastim|cyclophosphamide|cytarabine|daunorubicin_hydrochloride|dexamethasone|etoposide|leucovorin_calcium|mercaptopurine|methotrexate|pegaspargase|therapeutic_hydrocortisone|vincristine_sulfate|radiation_therapy|,other_events,arm0,CNS-Patients---Treatment-(Combination-Chemotherapy),,,
2486,Allergic_reaction,1,42,Immune_system_disorders,NCT00096135,https://clinicaltrials.gov/show/NCT00096135,Leukemia,filgrastim|cyclophosphamide|cytarabine|daunorubicin_hydrochloride|dexamethasone|etoposide|leucovorin_calcium|mercaptopurine|methotrexate|pegaspargase|therapeutic_hydrocortisone|vincristine_sulfate|radiation_therapy|,other_events,arm1,Testicular-Relapse-Patients-(Combination-Chemotherapy),,,
2323,Anaphylaxis,7,42,Immune_system_disorders,NCT00096135,https://clinicaltrials.gov/show/NCT00096135,Leukemia,filgrastim|cyclophosphamide|cytarabine|daunorubicin_hydrochloride|dexamethasone|etoposide|leucovorin_calcium|mercaptopurine|methotrexate|pegaspargase|therapeutic_hydrocortisone|vincristine_sulfate|radiation_therapy|,other_events,arm1,Testicular-Relapse-Patients-(Combination-Chemotherapy),,,
2322,Anaphylaxis,3,29,Immune_system_disorders,NCT00096200,https://clinicaltrials.gov/show/NCT00096200,Recurrent_Fallopian_Tube_Carcinoma|Recurrent_Ovarian_Carcinoma|Recurrent_Primary_Peritoneal_Carcinoma|,Carboplatin|Paclitaxel|Sorafenib_Tosylate|,other_events,arm1,Arm-B,,,
89,Hypersensitivity,7,57,Immune_system_disorders,NCT00096226,https://clinicaltrials.gov/show/NCT00096226,Lung_Cancer,Induction_Carboplatin|Induction_Paclitaxel|Resection|Consolidation_Carboplatin|Radiation_Therapy|Consolidation_Paclitaxel|,other_events,arm0,Chemoradiation-Surgery-Chemotherapy,,,
90,Hypersensitivity,1,57,Immune_system_disorders,NCT00096226,https://clinicaltrials.gov/show/NCT00096226,Lung_Cancer,Induction_Carboplatin|Induction_Paclitaxel|Resection|Consolidation_Carboplatin|Radiation_Therapy|Consolidation_Paclitaxel|,serious_events,arm0,Chemoradiation-Surgery-Chemotherapy,,,
2488,allergic_reaction,1,100,General_disorders,NCT00096356,https://clinicaltrials.gov/show/NCT00096356,Breast_Cancer|Fatigue|,CoQ10_&_Vitamin_E|Placebo_&_Vitamin_E|,serious_events,arm0,Arm-1---CoQ10-&-Vitamin-E,,,
94,HYPERSENSITIVITY,1,65,Immune_system_disorders,NCT00096993,https://clinicaltrials.gov/show/NCT00096993,Ovarian_Cancer|Peritoneal_Cancer|Fallopian_Tube_Cancer|,Placebo|Gemcitabine|Pertuzumab|,other_events,arm0,Placebo-+-Gemcitabine,6,gemcitabine,antimetabolites
92,HYPERSENSITIVITY,4,65,Immune_system_disorders,NCT00096993,https://clinicaltrials.gov/show/NCT00096993,Ovarian_Cancer|Peritoneal_Cancer|Fallopian_Tube_Cancer|,Placebo|Gemcitabine|Pertuzumab|,other_events,arm1,Pertuzumab-+-Gemcitabine,6,gemcitabine,antimetabolites
93,HYPERSENSITIVITY,1,65,Immune_system_disorders,NCT00096993,https://clinicaltrials.gov/show/NCT00096993,Ovarian_Cancer|Peritoneal_Cancer|Fallopian_Tube_Cancer|,Placebo|Gemcitabine|Pertuzumab|,serious_events,arm1,Pertuzumab-+-Gemcitabine,6,gemcitabine,antimetabolites
92,HYPERSENSITIVITY,4,65,Immune_system_disorders,NCT00096993,https://clinicaltrials.gov/show/NCT00096993,Ovarian_Cancer|Peritoneal_Cancer|Fallopian_Tube_Cancer|,Placebo|Gemcitabine|Pertuzumab|,other_events,arm1,Pertuzumab-+-Gemcitabine,40,pertuzumab,monoclonal-antibody
93,HYPERSENSITIVITY,1,65,Immune_system_disorders,NCT00096993,https://clinicaltrials.gov/show/NCT00096993,Ovarian_Cancer|Peritoneal_Cancer|Fallopian_Tube_Cancer|,Placebo|Gemcitabine|Pertuzumab|,serious_events,arm1,Pertuzumab-+-Gemcitabine,40,pertuzumab,monoclonal-antibody
101,Hypersensitivity,9,102,Immune_system_disorders,NCT00098670,https://clinicaltrials.gov/show/NCT00098670,B-cell_Chronic_Lymphocytic_Leukemia|Stage_I_Chronic_Lymphocytic_Leukemia|Stage_II_Chronic_Lymphocytic_Leukemia|Stage_III_Chronic_Lymphocytic_Leukemia|Stage_IV_Chronic_Lymphocytic_Leukemia|,alemtuzumab|rituximab|fludarabine_phosphate|,other_events,arm0,FR-Induction,,,
102,Hypersensitivity,2,102,Immune_system_disorders,NCT00098670,https://clinicaltrials.gov/show/NCT00098670,B-cell_Chronic_Lymphocytic_Leukemia|Stage_I_Chronic_Lymphocytic_Leukemia|Stage_II_Chronic_Lymphocytic_Leukemia|Stage_III_Chronic_Lymphocytic_Leukemia|Stage_IV_Chronic_Lymphocytic_Leukemia|,alemtuzumab|rituximab|fludarabine_phosphate|,serious_events,arm0,FR-Induction,,,
100,Hypersensitivity,4,58,Immune_system_disorders,NCT00098670,https://clinicaltrials.gov/show/NCT00098670,B-cell_Chronic_Lymphocytic_Leukemia|Stage_I_Chronic_Lymphocytic_Leukemia|Stage_II_Chronic_Lymphocytic_Leukemia|Stage_III_Chronic_Lymphocytic_Leukemia|Stage_IV_Chronic_Lymphocytic_Leukemia|,alemtuzumab|rituximab|fludarabine_phosphate|,other_events,arm1,Alemtuzumab-Consolidation,76,alemtuzumab,monoclonal-antibody
103,Hypersensitivity,2,44,Immune_system_disorders,NCT00098774,https://clinicaltrials.gov/show/NCT00098774,Lymphoma,filgrastim|rituximab|cytarabine|etoposide|leucovorin_calcium|methotrexate|temozolomide|,other_events,arm0,Intensive-Combination-Chemo-&-Immunotherapy,,,
2491,Allergic_reaction,7,70,Immune_system_disorders,NCT00098787,https://clinicaltrials.gov/show/NCT00098787,Colorectal_Cancer,bevacizumab|fluorouracil|irinotecan_hydrochloride|leucovorin_calcium|Oxaliplatin|,other_events,arm0,High-TS:-IROX/Bev,,,
2330,Anaphylaxis,2,70,Immune_system_disorders,NCT00098787,https://clinicaltrials.gov/show/NCT00098787,Colorectal_Cancer,bevacizumab|fluorouracil|irinotecan_hydrochloride|leucovorin_calcium|Oxaliplatin|,serious_events,arm0,High-TS:-IROX/Bev,,,
2490,Allergic_reaction,3,73,Immune_system_disorders,NCT00098787,https://clinicaltrials.gov/show/NCT00098787,Colorectal_Cancer,bevacizumab|fluorouracil|irinotecan_hydrochloride|leucovorin_calcium|Oxaliplatin|,other_events,arm1,High-TS:-FOLFOX/Bev,,,
2328,Anaphylaxis,2,73,Immune_system_disorders,NCT00098787,https://clinicaltrials.gov/show/NCT00098787,Colorectal_Cancer,bevacizumab|fluorouracil|irinotecan_hydrochloride|leucovorin_calcium|Oxaliplatin|,serious_events,arm1,High-TS:-FOLFOX/Bev,,,
2329,Anaphylaxis,1,62,Immune_system_disorders,NCT00098787,https://clinicaltrials.gov/show/NCT00098787,Colorectal_Cancer,bevacizumab|fluorouracil|irinotecan_hydrochloride|leucovorin_calcium|Oxaliplatin|,serious_events,arm2,Low-or-Indeterminate-TS:-FOLFOX/Bev,,,
2325,Anaphylaxis,1,54,Immune_system_disorders,NCT00098839,https://clinicaltrials.gov/show/NCT00098839,Recurrent_Childhood_Acute_Lymphoblastic_Leukemia,L-asparaginase|doxorubicin_hydrochloride|therapeutic_hydrocortisone|vincristine_sulfate|epratuzumab|cytarabine|prednisone|pegaspargase|dexrazoxane_hydrochloride|methotrexate|etoposide|cyclophosphamide|leucovorin_calcium|filgrastim|,serious_events,arm0,Reinduction-Chemoimmunotherapy-With-Epratuzumab-Once-Weekly,58,epratuzumab,monoclonal-antibody
2326,Anaphylaxis,2,54,Immune_system_disorders,NCT00098839,https://clinicaltrials.gov/show/NCT00098839,Recurrent_Childhood_Acute_Lymphoblastic_Leukemia,L-asparaginase|doxorubicin_hydrochloride|therapeutic_hydrocortisone|vincristine_sulfate|epratuzumab|cytarabine|prednisone|pegaspargase|dexrazoxane_hydrochloride|methotrexate|etoposide|cyclophosphamide|leucovorin_calcium|filgrastim|,other_events,arm0,Reinduction-Chemoimmunotherapy-With-Epratuzumab-Once-Weekly,58,epratuzumab,monoclonal-antibody
2327,Anaphylaxis,1,60,Immune_system_disorders,NCT00098839,https://clinicaltrials.gov/show/NCT00098839,Recurrent_Childhood_Acute_Lymphoblastic_Leukemia,L-asparaginase|doxorubicin_hydrochloride|therapeutic_hydrocortisone|vincristine_sulfate|epratuzumab|cytarabine|prednisone|pegaspargase|dexrazoxane_hydrochloride|methotrexate|etoposide|cyclophosphamide|leucovorin_calcium|filgrastim|,serious_events,arm1,Reinduction-Chemoimmunotherapy-With-Epratuzumab-Twice-Weekly,58,epratuzumab,monoclonal-antibody
2489,Allergic_reaction,1,15,Immune_system_disorders,NCT00098865,https://clinicaltrials.gov/show/NCT00098865,Central_Nervous_System_Tumor_Pediatric|Neuroblastoma|,temozolomide|thalidomide|,serious_events,arm0,Thalidomide-and-Temzolomide,,,
106,Hypersensitivity,1,94,Immune_system_disorders,NCT00101582,https://clinicaltrials.gov/show/NCT00101582,Mucositis|Solid_Tumors|Stomatitis|Head_and_Neck_Cancer|Squamous_Cell_Carcinoma|,Placebo|palifermin|cisplatin_chemotherapy|Radiotherapy|,serious_events,arm1,Palifermin,,,
107,HYPERSENSITIVITY,1,99,Immune_system_disorders,NCT00101660,https://clinicaltrials.gov/show/NCT00101660,Chronic_Myeloid_Leukemia|Philadelphia-Positive_Myeloid_Leukemia|,Dasatinib,serious_events,arm0,Intolerant,,,
108,HYPERSENSITIVITY,2,288,Immune_system_disorders,NCT00101660,https://clinicaltrials.gov/show/NCT00101660,Chronic_Myeloid_Leukemia|Philadelphia-Positive_Myeloid_Leukemia|,Dasatinib,serious_events,arm1,Resistant,,,
1159,Drug_hypersensitivity,1,137,Immune_system_disorders,NCT00101686,https://clinicaltrials.gov/show/NCT00101686,Colorectal_Neoplasms,Modified_Bolus_5-FU/LV_with_Irinotecan|FOLFIRI_+_bevacizumab|miFL_+_bevacizumab|Infusional_5-FU/LV_with_Irinotecan|Oral_Capecitabine_with_Irinotecan|,serious_events,arm0,FOLFIRI,45,folfiri,combination-drug-with-Irinotecan--Flourouracil--and-Leucovorin
109,Hypersensitivity,1,137,Immune_system_disorders,NCT00101686,https://clinicaltrials.gov/show/NCT00101686,Colorectal_Neoplasms,Modified_Bolus_5-FU/LV_with_Irinotecan|FOLFIRI_+_bevacizumab|miFL_+_bevacizumab|Infusional_5-FU/LV_with_Irinotecan|Oral_Capecitabine_with_Irinotecan|,serious_events,arm0,FOLFIRI,45,folfiri,combination-drug-with-Irinotecan--Flourouracil--and-Leucovorin
110,Hypersensitivity,6,438,Immune_system_disorders,NCT00102804,https://clinicaltrials.gov/show/NCT00102804,Non-Small_Cell_Lung_Cancer,Pemetrexed|Placebo|Best_Supportive_Care|,other_events,arm0,Pemetrexed-and-BSC,15,pemetrexed,antimetabolite
111,Hypersensitivity,1,218,Immune_system_disorders,NCT00102804,https://clinicaltrials.gov/show/NCT00102804,Non-Small_Cell_Lung_Cancer,Pemetrexed|Placebo|Best_Supportive_Care|,other_events,arm1,Placebo-and-BSC,,,
2492,Allergic_reaction,4,72,Immune_system_disorders,NCT00103207,https://clinicaltrials.gov/show/NCT00103207,Lung_Cancer,cetuximab,other_events,arm0,Cetuximab,5,cetuximab,Epidermal-growth-factor-receptor-inhibitor
2493,Allergic_reaction,1,72,Immune_system_disorders,NCT00103207,https://clinicaltrials.gov/show/NCT00103207,Lung_Cancer,cetuximab,serious_events,arm0,Cetuximab,5,cetuximab,Epidermal-growth-factor-receptor-inhibitor
112,Hypersensitivity,1,318,Immune_system_disorders,NCT00103506,https://clinicaltrials.gov/show/NCT00103506,Multiple_Myeloma,Bortezomib_(VELCADE)|Bortezomib_(VELCADE)|Doxorubicin_hydrochloride_(DOXIL/CAELYX)|,serious_events,arm1,Doxil/Caelyx-Plus-Velcade-(Bortezomib),70,bortezomib,proteasome-inhibitor
2494,Allergic_reaction,1,3,General_disorders,NCT00106353,https://clinicaltrials.gov/show/NCT00106353,Adenocarcinoma|Neoplasms|,Torisel,other_events,arm2,Temsirolimus-75-mg/m^2:-Part-1,,,
2495,Allergic_reaction,1,7,General_disorders,NCT00106353,https://clinicaltrials.gov/show/NCT00106353,Adenocarcinoma|Neoplasms|,Torisel,other_events,arm3,Temsirolimus-150-mg/m^2:-Part-1,,,
120,Hypersensitivity,2,19,Immune_system_disorders,NCT00106353,https://clinicaltrials.gov/show/NCT00106353,Adenocarcinoma|Neoplasms|,Torisel,other_events,arm5,Neuroblastoma:-Part-2,,,
1883,Dermatitis_allergic,1,16,Skin_and_subcutaneous_tissue_disorders,NCT00106353,https://clinicaltrials.gov/show/NCT00106353,Adenocarcinoma|Neoplasms|,Torisel,other_events,arm6,Rhabdomyosarcoma:-Part-2,,,
121,Hypersensitivity,1,16,Immune_system_disorders,NCT00107315,https://clinicaltrials.gov/show/NCT00107315,Colorectal_Cancer,bevacizumab|capecitabine|,other_events,arm0,Combination-of-Capecitabine-and-Bevacizumab,17,capecitabine,antimetabolite
121,Hypersensitivity,1,16,Immune_system_disorders,NCT00107315,https://clinicaltrials.gov/show/NCT00107315,Colorectal_Cancer,bevacizumab|capecitabine|,other_events,arm0,Combination-of-Capecitabine-and-Bevacizumab,29,capecitabine,antimetabolite
121,Hypersensitivity,1,16,Immune_system_disorders,NCT00107315,https://clinicaltrials.gov/show/NCT00107315,Colorectal_Cancer,bevacizumab|capecitabine|,other_events,arm0,Combination-of-Capecitabine-and-Bevacizumab,4,bevacizumab,monoclonal-antibody
121,Hypersensitivity,1,16,Immune_system_disorders,NCT00107315,https://clinicaltrials.gov/show/NCT00107315,Colorectal_Cancer,bevacizumab|capecitabine|,other_events,arm0,Combination-of-Capecitabine-and-Bevacizumab,22,bevacizumab,monoclonal-antibody
122,Hypersensitivity,1,11,Immune_system_disorders,NCT00109031,https://clinicaltrials.gov/show/NCT00109031,Cancer|Lymphoma|Leukemia|,palifermin|Total_Body_Irradiation|Cyclophosphamide|Etoposide|Placebo|,other_events,arm1,Palifermin-180-?_g/kg-on-Day-???1-(B),,,
1885,Dermatitis_allergic,1,12,Skin_and_subcutaneous_tissue_disorders,NCT00109031,https://clinicaltrials.gov/show/NCT00109031,Cancer|Lymphoma|Leukemia|,palifermin|Total_Body_Irradiation|Cyclophosphamide|Etoposide|Placebo|,other_events,arm3,Palifermin-180-?_g/kg-on-Day-?_?3-(D),,,
125,Hypersensitivity,3,48,Immune_system_disorders,NCT00109967,https://clinicaltrials.gov/show/NCT00109967,Recurrent_Mantle_Cell_Lymphoma,rituximab|temsirolimus|,other_events,arm0,Group-I:-Rituximab-Sensitive,16,rituximab,monoclonal-antibody
126,Hypersensitivity,1,48,Immune_system_disorders,NCT00109967,https://clinicaltrials.gov/show/NCT00109967,Recurrent_Mantle_Cell_Lymphoma,rituximab|temsirolimus|,serious_events,arm0,Group-I:-Rituximab-Sensitive,16,rituximab,monoclonal-antibody
124,Hypersensitivity,1,21,Immune_system_disorders,NCT00109967,https://clinicaltrials.gov/show/NCT00109967,Recurrent_Mantle_Cell_Lymphoma,rituximab|temsirolimus|,other_events,arm1,Group-II:-Rituximab-Refractory,16,rituximab,monoclonal-antibody
2498,Allergic_reaction,20,393,Immune_system_disorders,NCT00110019,https://clinicaltrials.gov/show/NCT00110019,Mucosal_Melanoma|Recurrent_Melanoma|Stage_IIIA_Skin_Melanoma|Stage_IIIB_Skin_Melanoma|Stage_IIIC_Skin_Melanoma|Stage_IV_Skin_Melanoma|,Carboplatin|Laboratory_Biomarker_Analysis|Paclitaxel|Pharmacological_Study|Placebo|Sorafenib_Tosylate|,serious_events,arm0,Arm-I-(Carboplatin-+-Paclitaxel-+-Sorafenib),3,carboplatin,alkalating-agent
2498,Allergic_reaction,20,393,Immune_system_disorders,NCT00110019,https://clinicaltrials.gov/show/NCT00110019,Mucosal_Melanoma|Recurrent_Melanoma|Stage_IIIA_Skin_Melanoma|Stage_IIIB_Skin_Melanoma|Stage_IIIC_Skin_Melanoma|Stage_IV_Skin_Melanoma|,Carboplatin|Laboratory_Biomarker_Analysis|Paclitaxel|Pharmacological_Study|Placebo|Sorafenib_Tosylate|,serious_events,arm0,Arm-I-(Carboplatin-+-Paclitaxel-+-Sorafenib),2,paclitaxel,taxane
2498,Allergic_reaction,20,393,Immune_system_disorders,NCT00110019,https://clinicaltrials.gov/show/NCT00110019,Mucosal_Melanoma|Recurrent_Melanoma|Stage_IIIA_Skin_Melanoma|Stage_IIIB_Skin_Melanoma|Stage_IIIC_Skin_Melanoma|Stage_IV_Skin_Melanoma|,Carboplatin|Laboratory_Biomarker_Analysis|Paclitaxel|Pharmacological_Study|Placebo|Sorafenib_Tosylate|,serious_events,arm0,Arm-I-(Carboplatin-+-Paclitaxel-+-Sorafenib),90,sorafenib,Tyrosine-Kinase-inhibitor
2497,Allergic_reaction,11,397,Immune_system_disorders,NCT00110019,https://clinicaltrials.gov/show/NCT00110019,Mucosal_Melanoma|Recurrent_Melanoma|Stage_IIIA_Skin_Melanoma|Stage_IIIB_Skin_Melanoma|Stage_IIIC_Skin_Melanoma|Stage_IV_Skin_Melanoma|,Carboplatin|Laboratory_Biomarker_Analysis|Paclitaxel|Pharmacological_Study|Placebo|Sorafenib_Tosylate|,serious_events,arm1,Arm-II-(Carboplatin-+-Paclitaxel+Placebo),3,carboplatin,alkalating-agent
2497,Allergic_reaction,11,397,Immune_system_disorders,NCT00110019,https://clinicaltrials.gov/show/NCT00110019,Mucosal_Melanoma|Recurrent_Melanoma|Stage_IIIA_Skin_Melanoma|Stage_IIIB_Skin_Melanoma|Stage_IIIC_Skin_Melanoma|Stage_IV_Skin_Melanoma|,Carboplatin|Laboratory_Biomarker_Analysis|Paclitaxel|Pharmacological_Study|Placebo|Sorafenib_Tosylate|,serious_events,arm1,Arm-II-(Carboplatin-+-Paclitaxel+Placebo),2,paclitaxel,taxane
127,Hypersensitivity,1,50,Immune_system_disorders,NCT00110084,https://clinicaltrials.gov/show/NCT00110084,Breast_Cancer,Gemcitabine|Paclitaxel_protein-bound_particles_for_injectable_suspension_(albumin-bound)|,other_events,arm0,Nab-paclitaxel/Gemcitabine,6,gemcitabine,antimetabolites
127,Hypersensitivity,1,50,Immune_system_disorders,NCT00110084,https://clinicaltrials.gov/show/NCT00110084,Breast_Cancer,Gemcitabine|Paclitaxel_protein-bound_particles_for_injectable_suspension_(albumin-bound)|,other_events,arm0,Nab-paclitaxel/Gemcitabine,2,paclitaxel,taxane
128,HYPERSENSITIVITY,2,14,Immune_system_disorders,NCT00110357,https://clinicaltrials.gov/show/NCT00110357,Cancer|Refractory_Solid_Tumor|,Cetuximab_+_Irinotecan|Cetuximab_+_Irinotecan|,serious_events,arm0,01-75-mg/m2-CET-+-20-mg/m2-IRI,,,
131,HYPERSENSITIVITY,1,10,Immune_system_disorders,NCT00110357,https://clinicaltrials.gov/show/NCT00110357,Cancer|Refractory_Solid_Tumor|,Cetuximab_+_Irinotecan|Cetuximab_+_Irinotecan|,serious_events,arm1,02-150-mg/m2-CET-+-20-mg/m2-IRI,,,
129,HYPERSENSITIVITY,1,3,Immune_system_disorders,NCT00110357,https://clinicaltrials.gov/show/NCT00110357,Cancer|Refractory_Solid_Tumor|,Cetuximab_+_Irinotecan|Cetuximab_+_Irinotecan|,other_events,arm2,03-150-mg/m2-CET-+-16-mg/m2-IRI,,,
130,HYPERSENSITIVITY,1,12,Immune_system_disorders,NCT00110357,https://clinicaltrials.gov/show/NCT00110357,Cancer|Refractory_Solid_Tumor|,Cetuximab_+_Irinotecan|Cetuximab_+_Irinotecan|,other_events,arm3,04-250-mg/m2-CET-+-16-mg/m2-IRI,,,
2499,allergic_reaction,3,51,Immune_system_disorders,NCT00110994,https://clinicaltrials.gov/show/NCT00110994,Cancer|Melanoma|,Sorafenib_(Nexavar_BAY43-9006)|Placebo|Dacarbazine|,other_events,arm0,Sorafenib-(Nexavar-BAY43-9006)-+-Dacarbazine,97,nexavar,Tyrosine-Kinase-inhibitor
2499,allergic_reaction,3,51,Immune_system_disorders,NCT00110994,https://clinicaltrials.gov/show/NCT00110994,Cancer|Melanoma|,Sorafenib_(Nexavar_BAY43-9006)|Placebo|Dacarbazine|,other_events,arm0,Sorafenib-(Nexavar-BAY43-9006)-+-Dacarbazine,90,sorafenib,Tyrosine-Kinase-inhibitor
2499,allergic_reaction,3,51,Immune_system_disorders,NCT00110994,https://clinicaltrials.gov/show/NCT00110994,Cancer|Melanoma|,Sorafenib_(Nexavar_BAY43-9006)|Placebo|Dacarbazine|,other_events,arm0,Sorafenib-(Nexavar-BAY43-9006)-+-Dacarbazine,72,bay43,Tyrosine-Kinase-inhibitor
2501,allergic_reaction,4,134,Immune_system_disorders,NCT00111007,https://clinicaltrials.gov/show/NCT00111007,Melanoma,Sorafenib_(Nexavar_BAY43-9006)|Carboplatin/Paclitaxel|Placebo|,serious_events,arm0,Sorafenib-(Nexavar-BAY43-9006),97,nexavar,Tyrosine-Kinase-inhibitor
2503,allergic_reaction,8,134,Immune_system_disorders,NCT00111007,https://clinicaltrials.gov/show/NCT00111007,Melanoma,Sorafenib_(Nexavar_BAY43-9006)|Carboplatin/Paclitaxel|Placebo|,other_events,arm0,Sorafenib-(Nexavar-BAY43-9006),97,nexavar,Tyrosine-Kinase-inhibitor
2501,allergic_reaction,4,134,Immune_system_disorders,NCT00111007,https://clinicaltrials.gov/show/NCT00111007,Melanoma,Sorafenib_(Nexavar_BAY43-9006)|Carboplatin/Paclitaxel|Placebo|,serious_events,arm0,Sorafenib-(Nexavar-BAY43-9006),90,sorafenib,Tyrosine-Kinase-inhibitor
2503,allergic_reaction,8,134,Immune_system_disorders,NCT00111007,https://clinicaltrials.gov/show/NCT00111007,Melanoma,Sorafenib_(Nexavar_BAY43-9006)|Carboplatin/Paclitaxel|Placebo|,other_events,arm0,Sorafenib-(Nexavar-BAY43-9006),90,sorafenib,Tyrosine-Kinase-inhibitor
2501,allergic_reaction,4,134,Immune_system_disorders,NCT00111007,https://clinicaltrials.gov/show/NCT00111007,Melanoma,Sorafenib_(Nexavar_BAY43-9006)|Carboplatin/Paclitaxel|Placebo|,serious_events,arm0,Sorafenib-(Nexavar-BAY43-9006),72,bay43,Tyrosine-Kinase-inhibitor
2503,allergic_reaction,8,134,Immune_system_disorders,NCT00111007,https://clinicaltrials.gov/show/NCT00111007,Melanoma,Sorafenib_(Nexavar_BAY43-9006)|Carboplatin/Paclitaxel|Placebo|,other_events,arm0,Sorafenib-(Nexavar-BAY43-9006),72,bay43,Tyrosine-Kinase-inhibitor
2500,allergic_reaction,2,134,Immune_system_disorders,NCT00111007,https://clinicaltrials.gov/show/NCT00111007,Melanoma,Sorafenib_(Nexavar_BAY43-9006)|Carboplatin/Paclitaxel|Placebo|,serious_events,arm1,Carboplatin/Paclitaxel-(C/P),3,carboplatin,alkalating-agent
2502,allergic_reaction,10,134,Immune_system_disorders,NCT00111007,https://clinicaltrials.gov/show/NCT00111007,Melanoma,Sorafenib_(Nexavar_BAY43-9006)|Carboplatin/Paclitaxel|Placebo|,other_events,arm1,Carboplatin/Paclitaxel-(C/P),3,carboplatin,alkalating-agent
2500,allergic_reaction,2,134,Immune_system_disorders,NCT00111007,https://clinicaltrials.gov/show/NCT00111007,Melanoma,Sorafenib_(Nexavar_BAY43-9006)|Carboplatin/Paclitaxel|Placebo|,serious_events,arm1,Carboplatin/Paclitaxel-(C/P),2,paclitaxel,taxane
2502,allergic_reaction,10,134,Immune_system_disorders,NCT00111007,https://clinicaltrials.gov/show/NCT00111007,Melanoma,Sorafenib_(Nexavar_BAY43-9006)|Carboplatin/Paclitaxel|Placebo|,other_events,arm1,Carboplatin/Paclitaxel-(C/P),2,paclitaxel,taxane
135,Hypersensitivity,11,325,Immune_system_disorders,NCT00112294,https://clinicaltrials.gov/show/NCT00112294,Non-Small-Cell_Lung_Carcinoma,Paclitaxel_(Taxane)|Docetaxel_(Taxane)|Carboplatin|Cetuximab|,serious_events,arm0,Cetuximab+Taxane+Carboplatin,3,carboplatin,alkalating-agent
137,Hypersensitivity,22,325,Immune_system_disorders,NCT00112294,https://clinicaltrials.gov/show/NCT00112294,Non-Small-Cell_Lung_Carcinoma,Paclitaxel_(Taxane)|Docetaxel_(Taxane)|Carboplatin|Cetuximab|,other_events,arm0,Cetuximab+Taxane+Carboplatin,3,carboplatin,alkalating-agent
135,Hypersensitivity,11,325,Immune_system_disorders,NCT00112294,https://clinicaltrials.gov/show/NCT00112294,Non-Small-Cell_Lung_Carcinoma,Paclitaxel_(Taxane)|Docetaxel_(Taxane)|Carboplatin|Cetuximab|,serious_events,arm0,Cetuximab+Taxane+Carboplatin,5,cetuximab,Epidermal-growth-factor-receptor-inhibitor
137,Hypersensitivity,22,325,Immune_system_disorders,NCT00112294,https://clinicaltrials.gov/show/NCT00112294,Non-Small-Cell_Lung_Carcinoma,Paclitaxel_(Taxane)|Docetaxel_(Taxane)|Carboplatin|Cetuximab|,other_events,arm0,Cetuximab+Taxane+Carboplatin,5,cetuximab,Epidermal-growth-factor-receptor-inhibitor
135,Hypersensitivity,11,325,Immune_system_disorders,NCT00112294,https://clinicaltrials.gov/show/NCT00112294,Non-Small-Cell_Lung_Carcinoma,Paclitaxel_(Taxane)|Docetaxel_(Taxane)|Carboplatin|Cetuximab|,serious_events,arm0,Cetuximab+Taxane+Carboplatin,93,taxane,
137,Hypersensitivity,22,325,Immune_system_disorders,NCT00112294,https://clinicaltrials.gov/show/NCT00112294,Non-Small-Cell_Lung_Carcinoma,Paclitaxel_(Taxane)|Docetaxel_(Taxane)|Carboplatin|Cetuximab|,other_events,arm0,Cetuximab+Taxane+Carboplatin,93,taxane,
1170,Drug_hypersensitivity,1,320,Immune_system_disorders,NCT00112294,https://clinicaltrials.gov/show/NCT00112294,Non-Small-Cell_Lung_Carcinoma,Paclitaxel_(Taxane)|Docetaxel_(Taxane)|Carboplatin|Cetuximab|,serious_events,arm1,Taxane+Carboplatin,3,carboplatin,alkalating-agent
134,Hypersensitivity,1,320,Immune_system_disorders,NCT00112294,https://clinicaltrials.gov/show/NCT00112294,Non-Small-Cell_Lung_Carcinoma,Paclitaxel_(Taxane)|Docetaxel_(Taxane)|Carboplatin|Cetuximab|,serious_events,arm1,Taxane+Carboplatin,3,carboplatin,alkalating-agent
136,Hypersensitivity,8,320,Immune_system_disorders,NCT00112294,https://clinicaltrials.gov/show/NCT00112294,Non-Small-Cell_Lung_Carcinoma,Paclitaxel_(Taxane)|Docetaxel_(Taxane)|Carboplatin|Cetuximab|,other_events,arm1,Taxane+Carboplatin,3,carboplatin,alkalating-agent
1170,Drug_hypersensitivity,1,320,Immune_system_disorders,NCT00112294,https://clinicaltrials.gov/show/NCT00112294,Non-Small-Cell_Lung_Carcinoma,Paclitaxel_(Taxane)|Docetaxel_(Taxane)|Carboplatin|Cetuximab|,serious_events,arm1,Taxane+Carboplatin,93,taxane,
134,Hypersensitivity,1,320,Immune_system_disorders,NCT00112294,https://clinicaltrials.gov/show/NCT00112294,Non-Small-Cell_Lung_Carcinoma,Paclitaxel_(Taxane)|Docetaxel_(Taxane)|Carboplatin|Cetuximab|,serious_events,arm1,Taxane+Carboplatin,93,taxane,
136,Hypersensitivity,8,320,Immune_system_disorders,NCT00112294,https://clinicaltrials.gov/show/NCT00112294,Non-Small-Cell_Lung_Carcinoma,Paclitaxel_(Taxane)|Docetaxel_(Taxane)|Carboplatin|Cetuximab|,other_events,arm1,Taxane+Carboplatin,93,taxane,
1178,Drug_Hypersensitivity,1,21,Immune_system_disorders,NCT00112437,https://clinicaltrials.gov/show/NCT00112437,Osteoporosis,MK0822|MK0822|MK0822|MK0822|Vitamin_D3|Calcium_Carbonate|Placebo|,other_events,arm12,MK0822-25-mg-/-MK0822-50-mg,,,
1177,Drug_Hypersensitivity,1,20,Immune_system_disorders,NCT00112437,https://clinicaltrials.gov/show/NCT00112437,Osteoporosis,MK0822|MK0822|MK0822|MK0822|Vitamin_D3|Calcium_Carbonate|Placebo|,other_events,arm14,MK0822-50-mg-/-MK0822-50-mg,,,
2382,Allergy,3,46,Immune_system_disorders,NCT00112489,https://clinicaltrials.gov/show/NCT00112489,Sarcoma,carboplatin|paclitaxel|,other_events,arm0,Paclitaxel-Followed-by-Carboplatin,3,carboplatin,alkalating-agent
2382,Allergy,3,46,Immune_system_disorders,NCT00112489,https://clinicaltrials.gov/show/NCT00112489,Sarcoma,carboplatin|paclitaxel|,other_events,arm0,Paclitaxel-Followed-by-Carboplatin,2,paclitaxel,taxane
138,Hypersensitivity,3,45,Immune_system_disorders,NCT00112840,https://clinicaltrials.gov/show/NCT00112840,Clear_Cell_Renal_Cell_Carcinoma|Recurrent_Renal_Cell_Cancer|Stage_IV_Renal_Cell_Cancer|,CCI-779|Bevacizumab|,other_events,arm2,Phase-II,,,
1171,Drug_hypersensitivity,5,1126,Immune_system_disorders,NCT00112918,https://clinicaltrials.gov/show/NCT00112918,Colorectal_Cancer,Bevacizumab|Capecitabine|5-Fluorouracil_(5-FU)|Leucovorin_calcium|Oxaliplatin|,serious_events,arm0,FOLFOX4,,,
1173,Drug_hypersensitivity,66,1126,Immune_system_disorders,NCT00112918,https://clinicaltrials.gov/show/NCT00112918,Colorectal_Cancer,Bevacizumab|Capecitabine|5-Fluorouracil_(5-FU)|Leucovorin_calcium|Oxaliplatin|,other_events,arm0,FOLFOX4,,,
1172,Drug_hypersensitivity,3,1145,Immune_system_disorders,NCT00112918,https://clinicaltrials.gov/show/NCT00112918,Colorectal_Cancer,Bevacizumab|Capecitabine|5-Fluorouracil_(5-FU)|Leucovorin_calcium|Oxaliplatin|,serious_events,arm1,FOLFOX4-+-Bv,,,
1174,Drug_hypersensitivity,72,1145,Immune_system_disorders,NCT00112918,https://clinicaltrials.gov/show/NCT00112918,Colorectal_Cancer,Bevacizumab|Capecitabine|5-Fluorouracil_(5-FU)|Leucovorin_calcium|Oxaliplatin|,other_events,arm1,FOLFOX4-+-Bv,,,
1175,Drug_hypersensitivity,1,1135,Immune_system_disorders,NCT00112918,https://clinicaltrials.gov/show/NCT00112918,Colorectal_Cancer,Bevacizumab|Capecitabine|5-Fluorouracil_(5-FU)|Leucovorin_calcium|Oxaliplatin|,serious_events,arm2,XELOX+Bv,34,xelox,Combination-drug-with-capecitabine-(Xeloda)-and-Oxaliplatin-(Eloxatin)
1176,Drug_hypersensitivity,32,1135,Immune_system_disorders,NCT00112918,https://clinicaltrials.gov/show/NCT00112918,Colorectal_Cancer,Bevacizumab|Capecitabine|5-Fluorouracil_(5-FU)|Leucovorin_calcium|Oxaliplatin|,other_events,arm2,XELOX+Bv,34,xelox,Combination-drug-with-capecitabine-(Xeloda)-and-Oxaliplatin-(Eloxatin)
2504,Allergic_reaction,2,50,Immune_system_disorders,NCT00113217,https://clinicaltrials.gov/show/NCT00113217,Renal_Cell_Carcinoma|Kidney_Cancer|,Bevacizumab,serious_events,arm0,Bevacizumab,4,bevacizumab,monoclonal-antibody
2504,Allergic_reaction,2,50,Immune_system_disorders,NCT00113217,https://clinicaltrials.gov/show/NCT00113217,Renal_Cell_Carcinoma|Kidney_Cancer|,Bevacizumab,serious_events,arm0,Bevacizumab,22,bevacizumab,monoclonal-antibody
2505,Allergic_reaction,1,9,Immune_system_disorders,NCT00113386,https://clinicaltrials.gov/show/NCT00113386,Lung_Cancer,filgrastim|pegfilgrastim|cisplatin|docetaxel|adjuvant_therapy|conventional_surgery|neoadjuvant_therapy|radiation_therapy|,other_events,arm0,Preoperative-Cisplatin/Docetaxel,9,cisplatin,alkalating-agent
2505,Allergic_reaction,1,9,Immune_system_disorders,NCT00113386,https://clinicaltrials.gov/show/NCT00113386,Lung_Cancer,filgrastim|pegfilgrastim|cisplatin|docetaxel|adjuvant_therapy|conventional_surgery|neoadjuvant_therapy|radiation_therapy|,other_events,arm0,Preoperative-Cisplatin/Docetaxel,8,docetaxel,taxane
2506,Allergic_reaction,1,7,Immune_system_disorders,NCT00113399,https://clinicaltrials.gov/show/NCT00113399,Head_and_Neck_Cancer,filgrastim|cisplatin|docetaxel|fluorouracil|paclitaxel|radiation_therapy|,serious_events,arm1,Chemotherapy-Alone,,,
139,HYPERSENSITIVITY,1,66,Immune_system_disorders,NCT00113490,https://clinicaltrials.gov/show/NCT00113490,Motavizumab_Administration_for_a_Second_Season_for_RSV_Prophylaxis,motavizumab_(MEDI-524)|palivizumab_15_mg/kg|,serious_events,arm0,Motavizumab-(MEDI-524)-15-mg/kg,,,
142,Hypersensitivity,1,84,Immune_system_disorders,NCT00113516,https://clinicaltrials.gov/show/NCT00113516,Non-small_Cell_Lung_Cancer,carboplatin|paclitaxel|sunitinib|,serious_events,arm0,Carboplatin-Plus-Paclitaxel-172-225-mg/m2-(Part-1),3,carboplatin,alkalating-agent
142,Hypersensitivity,1,84,Immune_system_disorders,NCT00113516,https://clinicaltrials.gov/show/NCT00113516,Non-small_Cell_Lung_Cancer,carboplatin|paclitaxel|sunitinib|,serious_events,arm0,Carboplatin-Plus-Paclitaxel-172-225-mg/m2-(Part-1),2,paclitaxel,taxane
141,Hypersensitivity,2,333,Immune_system_disorders,NCT00113607,https://clinicaltrials.gov/show/NCT00113607,Ovarian_Cancer,Trabectedin|DOXIL|Dexamethasone|,serious_events,arm0,Trabectedin/DOXIL,,,
1179,Drug_Hypersensitivity,1,330,Immune_system_disorders,NCT00113607,https://clinicaltrials.gov/show/NCT00113607,Ovarian_Cancer,Trabectedin|DOXIL|Dexamethasone|,serious_events,arm1,DOXIL,,,
140,Hypersensitivity,3,330,Immune_system_disorders,NCT00113607,https://clinicaltrials.gov/show/NCT00113607,Ovarian_Cancer,Trabectedin|DOXIL|Dexamethasone|,serious_events,arm1,DOXIL,,,
1892,DERMATITIS_ALLERGIC,1,229,Skin_and_subcutaneous_tissue_disorders,NCT00113763,https://clinicaltrials.gov/show/NCT00113763,Colorectal_Cancer|Metastases|,Best_supportive_care|Panitumumab|,serious_events,arm0,Panitumumab-Plus-BSC,30,panitumumab,monoclonal-antibody-and-signal-transduction-inhibitor
143,HYPERSENSITIVITY,1,229,Immune_system_disorders,NCT00113763,https://clinicaltrials.gov/show/NCT00113763,Colorectal_Cancer|Metastases|,Best_supportive_care|Panitumumab|,serious_events,arm0,Panitumumab-Plus-BSC,30,panitumumab,monoclonal-antibody-and-signal-transduction-inhibitor
144,Hypersensitivity,1,15,Immune_system_disorders,NCT00114244,https://clinicaltrials.gov/show/NCT00114244,Stage_IV_Pancreatic_Cancer,sorafenib_tosylate|gemcitabine_hydrochloride|laboratory_biomarker_analysis|,other_events,arm0,Arm-I-(Sorafenib-Tosylate),90,sorafenib,Tyrosine-Kinase-inhibitor
1180,DRUG_HYPERSENSITIVITY,2,518,Immune_system_disorders,NCT00115765,https://clinicaltrials.gov/show/NCT00115765,Colorectal_Cancer,Oxaliplatin_Based_Chemotherapy|Panitumumab|Irinotecan_Based_Chemotherapy|Bevacizumab|,serious_events,arm0,Panit.-Plus-Bevacizumab-With-Chemotherapy,4,bevacizumab,monoclonal-antibody
145,HYPERSENSITIVITY,4,518,Immune_system_disorders,NCT00115765,https://clinicaltrials.gov/show/NCT00115765,Colorectal_Cancer,Oxaliplatin_Based_Chemotherapy|Panitumumab|Irinotecan_Based_Chemotherapy|Bevacizumab|,serious_events,arm0,Panit.-Plus-Bevacizumab-With-Chemotherapy,4,bevacizumab,monoclonal-antibody
1180,DRUG_HYPERSENSITIVITY,2,518,Immune_system_disorders,NCT00115765,https://clinicaltrials.gov/show/NCT00115765,Colorectal_Cancer,Oxaliplatin_Based_Chemotherapy|Panitumumab|Irinotecan_Based_Chemotherapy|Bevacizumab|,serious_events,arm0,Panit.-Plus-Bevacizumab-With-Chemotherapy,22,bevacizumab,monoclonal-antibody
145,HYPERSENSITIVITY,4,518,Immune_system_disorders,NCT00115765,https://clinicaltrials.gov/show/NCT00115765,Colorectal_Cancer,Oxaliplatin_Based_Chemotherapy|Panitumumab|Irinotecan_Based_Chemotherapy|Bevacizumab|,serious_events,arm0,Panit.-Plus-Bevacizumab-With-Chemotherapy,22,bevacizumab,monoclonal-antibody
1181,DRUG_HYPERSENSITIVITY,1,510,Immune_system_disorders,NCT00115765,https://clinicaltrials.gov/show/NCT00115765,Colorectal_Cancer,Oxaliplatin_Based_Chemotherapy|Panitumumab|Irinotecan_Based_Chemotherapy|Bevacizumab|,serious_events,arm1,Bevacizumab-With-Chemotherapy,4,bevacizumab,monoclonal-antibody
146,HYPERSENSITIVITY,1,510,Immune_system_disorders,NCT00115765,https://clinicaltrials.gov/show/NCT00115765,Colorectal_Cancer,Oxaliplatin_Based_Chemotherapy|Panitumumab|Irinotecan_Based_Chemotherapy|Bevacizumab|,serious_events,arm1,Bevacizumab-With-Chemotherapy,4,bevacizumab,monoclonal-antibody
1181,DRUG_HYPERSENSITIVITY,1,510,Immune_system_disorders,NCT00115765,https://clinicaltrials.gov/show/NCT00115765,Colorectal_Cancer,Oxaliplatin_Based_Chemotherapy|Panitumumab|Irinotecan_Based_Chemotherapy|Bevacizumab|,serious_events,arm1,Bevacizumab-With-Chemotherapy,22,bevacizumab,monoclonal-antibody
146,HYPERSENSITIVITY,1,510,Immune_system_disorders,NCT00115765,https://clinicaltrials.gov/show/NCT00115765,Colorectal_Cancer,Oxaliplatin_Based_Chemotherapy|Panitumumab|Irinotecan_Based_Chemotherapy|Bevacizumab|,serious_events,arm1,Bevacizumab-With-Chemotherapy,22,bevacizumab,monoclonal-antibody
2507,Allergic_reaction,5,26,Immune_system_disorders,NCT00117156,https://clinicaltrials.gov/show/NCT00117156,Lymphoma_Non-Hodgkin|MALT_Lymphoma|,Fludarabine|Rituximab|,other_events,arm0,Fludarabine-and-Rituximab,66,fludarabine,antimetabolite
2508,Allergic_reaction,1,26,Immune_system_disorders,NCT00117156,https://clinicaltrials.gov/show/NCT00117156,Lymphoma_Non-Hodgkin|MALT_Lymphoma|,Fludarabine|Rituximab|,serious_events,arm0,Fludarabine-and-Rituximab,66,fludarabine,antimetabolite
2507,Allergic_reaction,5,26,Immune_system_disorders,NCT00117156,https://clinicaltrials.gov/show/NCT00117156,Lymphoma_Non-Hodgkin|MALT_Lymphoma|,Fludarabine|Rituximab|,other_events,arm0,Fludarabine-and-Rituximab,16,rituximab,monoclonal-antibody
2508,Allergic_reaction,1,26,Immune_system_disorders,NCT00117156,https://clinicaltrials.gov/show/NCT00117156,Lymphoma_Non-Hodgkin|MALT_Lymphoma|,Fludarabine|Rituximab|,serious_events,arm0,Fludarabine-and-Rituximab,16,rituximab,monoclonal-antibody
2510,allergic_reaction,1,97,Immune_system_disorders,NCT00117637,https://clinicaltrials.gov/show/NCT00117637,Carcinoma_Renal_Cell,Sorafenib_(Nexavar_BAY43-9006)|Interferon|,serious_events,arm0,Sorafenib-400-mg-in-Period-1,90,sorafenib,Tyrosine-Kinase-inhibitor
2509,allergic_reaction,1,90,Immune_system_disorders,NCT00117637,https://clinicaltrials.gov/show/NCT00117637,Carcinoma_Renal_Cell,Sorafenib_(Nexavar_BAY43-9006)|Interferon|,serious_events,arm1,Interferon-Therapy-in-Period-1,,,
147,Hypersensitivity,1,50,Immune_system_disorders,NCT00117962,https://clinicaltrials.gov/show/NCT00117962,Lung_Cancer,cetuximab|carboplatin|pemetrexed_disodium|radiation_therapy|,serious_events,arm0,Std-Tx-+-Pemetrexed,15,pemetrexed,antimetabolite
150,Hypersensitivity,1,50,Immune_system_disorders,NCT00117962,https://clinicaltrials.gov/show/NCT00117962,Lung_Cancer,cetuximab|carboplatin|pemetrexed_disodium|radiation_therapy|,other_events,arm0,Std-Tx-+-Pemetrexed,15,pemetrexed,antimetabolite
148,Hypersensitivity,3,53,Immune_system_disorders,NCT00117962,https://clinicaltrials.gov/show/NCT00117962,Lung_Cancer,cetuximab|carboplatin|pemetrexed_disodium|radiation_therapy|,serious_events,arm1,Std-Tx-+-Pemetrexed-and-Cetuximab,15,pemetrexed,antimetabolite
149,Hypersensitivity,3,53,Immune_system_disorders,NCT00117962,https://clinicaltrials.gov/show/NCT00117962,Lung_Cancer,cetuximab|carboplatin|pemetrexed_disodium|radiation_therapy|,other_events,arm1,Std-Tx-+-Pemetrexed-and-Cetuximab,15,pemetrexed,antimetabolite
148,Hypersensitivity,3,53,Immune_system_disorders,NCT00117962,https://clinicaltrials.gov/show/NCT00117962,Lung_Cancer,cetuximab|carboplatin|pemetrexed_disodium|radiation_therapy|,serious_events,arm1,Std-Tx-+-Pemetrexed-and-Cetuximab,5,cetuximab,Epidermal-growth-factor-receptor-inhibitor
149,Hypersensitivity,3,53,Immune_system_disorders,NCT00117962,https://clinicaltrials.gov/show/NCT00117962,Lung_Cancer,cetuximab|carboplatin|pemetrexed_disodium|radiation_therapy|,other_events,arm1,Std-Tx-+-Pemetrexed-and-Cetuximab,5,cetuximab,Epidermal-growth-factor-receptor-inhibitor
151,Hypersensitivity,1,42,Immune_system_disorders,NCT00118144,https://clinicaltrials.gov/show/NCT00118144,Adenocarcinoma_of_the_Lung|Bronchoalveolar_Cell_Lung_Cancer|Non-small_Cell_Lung_Cancer|Recurrent_Non-small_Cell_Lung_Cancer|Stage_IIIB_Non-small_Cell_Lung_Cancer|Stage_IV_Non-small_Cell_Lung_Cancer|,bortezomib,other_events,arm0,Arm-I,,,
152,Hypersensitivity,1,208,Immune_system_disorders,NCT00118755,https://clinicaltrials.gov/show/NCT00118755,Colorectal_Cancer,capecitabine|Oxaliplatin|bevacizumab|capecitabine|Oxaliplatin|bevacizumab|,serious_events,arm0,XELOX-Q3W-+-Bevacizumab,34,xelox,Combination-drug-with-capecitabine-(Xeloda)-and-Oxaliplatin-(Eloxatin)
152,Hypersensitivity,1,208,Immune_system_disorders,NCT00118755,https://clinicaltrials.gov/show/NCT00118755,Colorectal_Cancer,capecitabine|Oxaliplatin|bevacizumab|capecitabine|Oxaliplatin|bevacizumab|,serious_events,arm0,XELOX-Q3W-+-Bevacizumab,4,bevacizumab,monoclonal-antibody
152,Hypersensitivity,1,208,Immune_system_disorders,NCT00118755,https://clinicaltrials.gov/show/NCT00118755,Colorectal_Cancer,capecitabine|Oxaliplatin|bevacizumab|capecitabine|Oxaliplatin|bevacizumab|,serious_events,arm0,XELOX-Q3W-+-Bevacizumab,22,bevacizumab,monoclonal-antibody
1182,Drug_Hypersensitivity,1,211,Immune_system_disorders,NCT00118755,https://clinicaltrials.gov/show/NCT00118755,Colorectal_Cancer,capecitabine|Oxaliplatin|bevacizumab|capecitabine|Oxaliplatin|bevacizumab|,serious_events,arm1,XELOX-Q2W-+-Bevacizumab,34,xelox,Combination-drug-with-capecitabine-(Xeloda)-and-Oxaliplatin-(Eloxatin)
1182,Drug_Hypersensitivity,1,211,Immune_system_disorders,NCT00118755,https://clinicaltrials.gov/show/NCT00118755,Colorectal_Cancer,capecitabine|Oxaliplatin|bevacizumab|capecitabine|Oxaliplatin|bevacizumab|,serious_events,arm1,XELOX-Q2W-+-Bevacizumab,4,bevacizumab,monoclonal-antibody
1182,Drug_Hypersensitivity,1,211,Immune_system_disorders,NCT00118755,https://clinicaltrials.gov/show/NCT00118755,Colorectal_Cancer,capecitabine|Oxaliplatin|bevacizumab|capecitabine|Oxaliplatin|bevacizumab|,serious_events,arm1,XELOX-Q2W-+-Bevacizumab,22,bevacizumab,monoclonal-antibody
2511,Allergic_reaction,4,103,Immune_system_disorders,NCT00119262,https://clinicaltrials.gov/show/NCT00119262,Male_Breast_Cancer|Stage_II_Breast_Cancer|Stage_IIIA_Breast_Cancer|Stage_IIIB_Breast_Cancer|,doxorubicin_hydrochloride|cyclophosphamide|bevacizumab|paclitaxel|filgrastim|pegfilgrastim|radiation_therapy|tamoxifen_citrate|aromatase_inhibition_therapy|,serious_events,arm0,Arm-A-(ddBAC->-BT->-B),,,
2514,Allergic_Reaction,1,41,Immune_system_disorders,NCT00121134,https://clinicaltrials.gov/show/NCT00121134,Breast_Cancer,Bevacizumab|Cyclophosphamide|Methotrexate|Capecitabine|,other_events,arm1,Group-B-Bevacizumab+Cyclophosphamide+Methotrexate,13,cyclophosphamide,alkylating-agent
2514,Allergic_Reaction,1,41,Immune_system_disorders,NCT00121134,https://clinicaltrials.gov/show/NCT00121134,Breast_Cancer,Bevacizumab|Cyclophosphamide|Methotrexate|Capecitabine|,other_events,arm1,Group-B-Bevacizumab+Cyclophosphamide+Methotrexate,23,methotrexate,antimetabolite
2514,Allergic_Reaction,1,41,Immune_system_disorders,NCT00121134,https://clinicaltrials.gov/show/NCT00121134,Breast_Cancer,Bevacizumab|Cyclophosphamide|Methotrexate|Capecitabine|,other_events,arm1,Group-B-Bevacizumab+Cyclophosphamide+Methotrexate,4,bevacizumab,monoclonal-antibody
2514,Allergic_Reaction,1,41,Immune_system_disorders,NCT00121134,https://clinicaltrials.gov/show/NCT00121134,Breast_Cancer,Bevacizumab|Cyclophosphamide|Methotrexate|Capecitabine|,other_events,arm1,Group-B-Bevacizumab+Cyclophosphamide+Methotrexate,22,bevacizumab,monoclonal-antibody
2512,Allergic_Reaction,1,41,Immune_system_disorders,NCT00121134,https://clinicaltrials.gov/show/NCT00121134,Breast_Cancer,Bevacizumab|Cyclophosphamide|Methotrexate|Capecitabine|,other_events,arm2,Group-C-Bevacizumab-+-Capcitabine(18-Wks),4,bevacizumab,monoclonal-antibody
2512,Allergic_Reaction,1,41,Immune_system_disorders,NCT00121134,https://clinicaltrials.gov/show/NCT00121134,Breast_Cancer,Bevacizumab|Cyclophosphamide|Methotrexate|Capecitabine|,other_events,arm2,Group-C-Bevacizumab-+-Capcitabine(18-Wks),22,bevacizumab,monoclonal-antibody
2513,Allergic_Reaction,2,40,Immune_system_disorders,NCT00121134,https://clinicaltrials.gov/show/NCT00121134,Breast_Cancer,Bevacizumab|Cyclophosphamide|Methotrexate|Capecitabine|,other_events,arm3,Group-D-bevacizumab-+-Capecitibine-(24wks),4,bevacizumab,monoclonal-antibody
2513,Allergic_Reaction,2,40,Immune_system_disorders,NCT00121134,https://clinicaltrials.gov/show/NCT00121134,Breast_Cancer,Bevacizumab|Cyclophosphamide|Methotrexate|Capecitabine|,other_events,arm3,Group-D-bevacizumab-+-Capecitibine-(24wks),22,bevacizumab,monoclonal-antibody
154,Hypersensitivity,4,219,Immune_system_disorders,NCT00122460,https://clinicaltrials.gov/show/NCT00122460,Head_and_Neck_Cancer,Cetuximab_+_Platinum_(Cisplatin_or_Carboplatin)_+_5Fluorouracil_(5-FU)|Platinum_(Cisplatin_or_Carboplatin)_+_5-FU|,serious_events,arm0,Cetuximab-Plus-Chemotherapy,5,cetuximab,Epidermal-growth-factor-receptor-inhibitor
157,Hypersensitivity,1,163,Immune_system_disorders,NCT00123474,https://clinicaltrials.gov/show/NCT00123474,Myeloid_Leukemia_Chronic_Chronic-Phase,dasatinib|dasatinib|dasatinib|dasatinib|,serious_events,arm1,140mg-QD,,,
158,Hypersensitivity,1,167,Immune_system_disorders,NCT00123474,https://clinicaltrials.gov/show/NCT00123474,Myeloid_Leukemia_Chronic_Chronic-Phase,dasatinib|dasatinib|dasatinib|dasatinib|,serious_events,arm3,70mg-BID,,,
1196,Drug_hypersensitivity,1,305,Immune_system_disorders,NCT00123487,https://clinicaltrials.gov/show/NCT00123487,Myeloid_Leukemia_Chronic_Accelerated_Phase|Leukemia_Lymphoblastic_Acute_Philadelphia-Positive|,dasatinib|dasatinib|,serious_events,arm1,Dasatinib-70-mg-BID,24,dasatinib,signal-transduction-inhibitor---tyrosine-kinase-inhibitor
159,Hypersensitivity,4,58,Immune_system_disorders,NCT00124618,https://clinicaltrials.gov/show/NCT00124618,Lung_Cancer,cetuximab|radiation_therapy|,other_events,arm0,Cetuximab/Radiation,5,cetuximab,Epidermal-growth-factor-receptor-inhibitor
1894,Dermatitis_allergic,1,157,Skin_and_subcutaneous_tissue_disorders,NCT00124748,https://clinicaltrials.gov/show/NCT00124748,Leukemia_Myeloid_Chronic_Phase,Imatinib_mesylate,serious_events,arm0,Imatinib-400mg,,,
161,HYPERSENSITIVITY,13,170,Immune_system_disorders,NCT00125034,https://clinicaltrials.gov/show/NCT00125034,Neoplasm_Metastasis|Colorectal_Cancer|,Cetuximab|Oxaliplatin|,other_events,arm0,Cetuximab-Plus-FOLFOX-4,5,cetuximab,Epidermal-growth-factor-receptor-inhibitor
163,HYPERSENSITIVITY,5,170,Immune_system_disorders,NCT00125034,https://clinicaltrials.gov/show/NCT00125034,Neoplasm_Metastasis|Colorectal_Cancer|,Cetuximab|Oxaliplatin|,serious_events,arm0,Cetuximab-Plus-FOLFOX-4,5,cetuximab,Epidermal-growth-factor-receptor-inhibitor
162,HYPERSENSITIVITY,2,168,Immune_system_disorders,NCT00125034,https://clinicaltrials.gov/show/NCT00125034,Neoplasm_Metastasis|Colorectal_Cancer|,Cetuximab|Oxaliplatin|,serious_events,arm1,FOLFOX-4-Alone,,,
164,HYPERSENSITIVITY,1,168,Immune_system_disorders,NCT00125034,https://clinicaltrials.gov/show/NCT00125034,Neoplasm_Metastasis|Colorectal_Cancer|,Cetuximab|Oxaliplatin|,other_events,arm1,FOLFOX-4-Alone,,,
2515,Allergic_reaction,2,22,Immune_system_disorders,NCT00126555,https://clinicaltrials.gov/show/NCT00126555,Recurrent_Skin_Cancer|Squamous_Cell_Carcinoma_of_the_Skin|,Gefitinib|Radiotherapy|Conventional_surgery|laboratory_biomarker_analysis|,other_events,arm0,Gefitinib-Radiotherapy-Surgery,,,
1895,Dermatitis_Allergic,1,5,Skin_and_subcutaneous_tissue_disorders,NCT00127101,https://clinicaltrials.gov/show/NCT00127101,Lymphoma,vorinostat|Comparator:_bexarotene|,other_events,arm1,Cohort-2,,,
165,Hypersensitivity,1,5,Immune_system_disorders,NCT00127101,https://clinicaltrials.gov/show/NCT00127101,Lymphoma,vorinostat|Comparator:_bexarotene|,serious_events,arm1,Cohort-2,,,
167,Hypersensitivity,1,93,Immune_system_disorders,NCT00131911,https://clinicaltrials.gov/show/NCT00131911,Gastrinoma|Glucagonoma|Insulinoma|Metastatic_Gastrointestinal_Carcinoid_Tumor|Neuroendocrine_Tumor|Pancreatic_Polypeptide_Tumor|Recurrent_Gastrointestinal_Carcinoid_Tumor|Recurrent_Islet_Cell_Carcinoma|Somatostatinoma|WDHA_Syndrome|,sorafenib_tosylate,serious_events,arm0,All-Patients,,,
168,Hypersensitivity,1,93,Immune_system_disorders,NCT00131911,https://clinicaltrials.gov/show/NCT00131911,Gastrinoma|Glucagonoma|Insulinoma|Metastatic_Gastrointestinal_Carcinoid_Tumor|Neuroendocrine_Tumor|Pancreatic_Polypeptide_Tumor|Recurrent_Gastrointestinal_Carcinoid_Tumor|Recurrent_Islet_Cell_Carcinoma|Somatostatinoma|WDHA_Syndrome|,sorafenib_tosylate,other_events,arm0,All-Patients,,,
2517,Allergic_reaction,1,14,Immune_system_disorders,NCT00131937,https://clinicaltrials.gov/show/NCT00131937,Anaplastic_Large_Cell_Lymphoma|Angioimmunoblastic_T-cell_Lymphoma|Hepatosplenic_T-cell_Lymphoma|Peripheral_T-cell_Lymphoma|Recurrent_Adult_Diffuse_Large_Cell_Lymphoma|Recurrent_Adult_Immunoblastic_Large_Cell_Lymphoma|Recurrent_Adult_T-cell_Leukemia/Lympho,sorafenib_tosylate,other_events,arm0,Treatment-(Sorafenib),90,sorafenib,Tyrosine-Kinase-inhibitor
169,Hypersensitivity,1,198,Immune_system_disorders,NCT00132808,https://clinicaltrials.gov/show/NCT00132808,Osteopenia,Zoledronic_Acid|Placebo|,serious_events,arm0,Zoledronic-Acid-2x5-mg,28,zoledronic,bisphosphonates-(supportive-treatment-of-cancer--treats-symptoms-and/or-decreases-complications)
1896,Dermatitis_allergic,1,53,Skin_and_subcutaneous_tissue_disorders,NCT00137423,https://clinicaltrials.gov/show/NCT00137423,Carcinoma_Renal_Cell_Metastasis,SU011248_(sunitinib),serious_events,arm1,PM-Dose-Sunitinib-Malate-(SU011248),27,sunitinib,tyrosine-kinase-inhibitor-and-angiogenesis-inhibitor
171,Hypersensitivity,1,55,Immune_system_disorders,NCT00137436,https://clinicaltrials.gov/show/NCT00137436,Prostatic_Neoplasms,Docetaxel|Prednisone|SU011248|,serious_events,arm0,SU011248-37.5-mg-+-Docetaxel-75-mg/m^2-+-Prednisone-5-mg,85,prednisone,steroid
171,Hypersensitivity,1,55,Immune_system_disorders,NCT00137436,https://clinicaltrials.gov/show/NCT00137436,Prostatic_Neoplasms,Docetaxel|Prednisone|SU011248|,serious_events,arm0,SU011248-37.5-mg-+-Docetaxel-75-mg/m^2-+-Prednisone-5-mg,8,docetaxel,taxane
1900,Dermatitis_allergic,1,8,Skin_and_subcutaneous_tissue_disorders,NCT00144781,https://clinicaltrials.gov/show/NCT00144781,Mucopolysaccharidosis_I|Hurler's_Syndrome|Hurler-Scheie_Syndrome|Scheie_Syndrome|,Aldurazyme_(Recombinant_Human_Alpha-L-Iduronidase)|Aldurazyme_(Recombinant_Human_Alpha-L-Iduronidase)|Aldurazyme_(Recombinant_Human_Alpha-L-Iduronidase)|Aldurazyme_(Recombinant_Human_Alpha-L-Iduronidase)|,other_events,arm0,Aldurazyme|Every-Other|Week-1.2-mg/kg***Check-Title***,,,
1201,drug_hypersensitivity,1,7,General_disorders,NCT00145041,https://clinicaltrials.gov/show/NCT00145041,Malignant_Melanoma,Vincristine_Sulfate_Liposomes_Injection,other_events,arm0,Overall-Study,,,
1902,Dermatitis_allergic,1,613,Skin_and_subcutaneous_tissue_disorders,NCT00145327,https://clinicaltrials.gov/show/NCT00145327,Osteoporosis,Zoledronic_Acid|Placebo|,serious_events,arm0,Zoledronic-Acid-6,28,zoledronic,bisphosphonates-(supportive-treatment-of-cancer--treats-symptoms-and/or-decreases-complications)
181,Hypersensitivity,1,616,Immune_system_disorders,NCT00145327,https://clinicaltrials.gov/show/NCT00145327,Osteoporosis,Zoledronic_Acid|Placebo|,serious_events,arm1,Zoledronic-Acid-3-Placebo-3,28,zoledronic,bisphosphonates-(supportive-treatment-of-cancer--treats-symptoms-and/or-decreases-complications)
182,Hypersensitivity,2,1221,Immune_system_disorders,NCT00145327,https://clinicaltrials.gov/show/NCT00145327,Osteoporosis,Zoledronic_Acid|Placebo|,serious_events,arm2,Placebo-3-Zoledronic-Acid-3,28,zoledronic,bisphosphonates-(supportive-treatment-of-cancer--treats-symptoms-and/or-decreases-complications)
1903,Dermatitis_allergic,1,23,Skin_and_subcutaneous_tissue_disorders,NCT00146770,https://clinicaltrials.gov/show/NCT00146770,Mucopolysaccharidosis_I|Hurler's_Syndrome|Hurler-Scheie_Syndrome|Scheie_Syndrome|,Aldurazyme|Aldurazyme|placebo|,other_events,arm0,Placebo/|Aldurazyme***Check-Title***,,,
183,Hypersensitivity,1,56,Immune_system_disorders,NCT00147537,https://clinicaltrials.gov/show/NCT00147537,Carcinoma_Non-Small-Cell_Lung,CP-751871|paclitaxel|carboplatin|CP-751871|paclitaxel|carboplatin|erlotinib|,other_events,arm10,Paclitaxel-+-Carboplatin-(Phase-2),3,carboplatin,alkalating-agent
183,Hypersensitivity,1,56,Immune_system_disorders,NCT00147537,https://clinicaltrials.gov/show/NCT00147537,Carcinoma_Non-Small-Cell_Lung,CP-751871|paclitaxel|carboplatin|CP-751871|paclitaxel|carboplatin|erlotinib|,other_events,arm10,Paclitaxel-+-Carboplatin-(Phase-2),2,paclitaxel,taxane
1203,Drug_hypersensitivity,1,17,Immune_system_disorders,NCT00147537,https://clinicaltrials.gov/show/NCT00147537,Carcinoma_Non-Small-Cell_Lung,CP-751871|paclitaxel|carboplatin|CP-751871|paclitaxel|carboplatin|erlotinib|,other_events,arm6,CP-751871-10-mg/kg-+-Paclitaxel-+-Carboplatin-(Phase-1b),3,carboplatin,alkalating-agent
1203,Drug_hypersensitivity,1,17,Immune_system_disorders,NCT00147537,https://clinicaltrials.gov/show/NCT00147537,Carcinoma_Non-Small-Cell_Lung,CP-751871|paclitaxel|carboplatin|CP-751871|paclitaxel|carboplatin|erlotinib|,other_events,arm6,CP-751871-10-mg/kg-+-Paclitaxel-+-Carboplatin-(Phase-1b),2,paclitaxel,taxane
1204,Drug_hypersensitivity,2,163,Immune_system_disorders,NCT00147537,https://clinicaltrials.gov/show/NCT00147537,Carcinoma_Non-Small-Cell_Lung,CP-751871|paclitaxel|carboplatin|CP-751871|paclitaxel|carboplatin|erlotinib|,other_events,arm9,CP-751871-+-Paclitaxel-+-Carboplatin-(Phase-2),3,carboplatin,alkalating-agent
184,Hypersensitivity,5,163,Immune_system_disorders,NCT00147537,https://clinicaltrials.gov/show/NCT00147537,Carcinoma_Non-Small-Cell_Lung,CP-751871|paclitaxel|carboplatin|CP-751871|paclitaxel|carboplatin|erlotinib|,other_events,arm9,CP-751871-+-Paclitaxel-+-Carboplatin-(Phase-2),3,carboplatin,alkalating-agent
1204,Drug_hypersensitivity,2,163,Immune_system_disorders,NCT00147537,https://clinicaltrials.gov/show/NCT00147537,Carcinoma_Non-Small-Cell_Lung,CP-751871|paclitaxel|carboplatin|CP-751871|paclitaxel|carboplatin|erlotinib|,other_events,arm9,CP-751871-+-Paclitaxel-+-Carboplatin-(Phase-2),2,paclitaxel,taxane
184,Hypersensitivity,5,163,Immune_system_disorders,NCT00147537,https://clinicaltrials.gov/show/NCT00147537,Carcinoma_Non-Small-Cell_Lung,CP-751871|paclitaxel|carboplatin|CP-751871|paclitaxel|carboplatin|erlotinib|,other_events,arm9,CP-751871-+-Paclitaxel-+-Carboplatin-(Phase-2),2,paclitaxel,taxane
1205,Drug_hypersensitivity,1,548,Immune_system_disorders,NCT00148798,https://clinicaltrials.gov/show/NCT00148798,Non_Small_Cell_Lung_Cancer_(NSCLC),cetuximab_+_cisplatin_+_vinorelbine|cisplatin_+_vinorelbine|,serious_events,arm0,Cetuximab-Plus-Chemotherapy,5,cetuximab,Epidermal-growth-factor-receptor-inhibitor
185,Hypersensitivity,5,548,Immune_system_disorders,NCT00148798,https://clinicaltrials.gov/show/NCT00148798,Non_Small_Cell_Lung_Cancer_(NSCLC),cetuximab_+_cisplatin_+_vinorelbine|cisplatin_+_vinorelbine|,serious_events,arm0,Cetuximab-Plus-Chemotherapy,5,cetuximab,Epidermal-growth-factor-receptor-inhibitor
186,Hypersensitivity,1,562,Immune_system_disorders,NCT00148798,https://clinicaltrials.gov/show/NCT00148798,Non_Small_Cell_Lung_Cancer_(NSCLC),cetuximab_+_cisplatin_+_vinorelbine|cisplatin_+_vinorelbine|,serious_events,arm1,Chemotherapy-Alone,,,
2520,Allergic_reaction,2,415,Immune_system_disorders,NCT00153816,https://clinicaltrials.gov/show/NCT00153816,Colorectal_Cancer|Polyps|Adenomas|,Calcium_Carbonate|Vitamin_D3|placebo|,serious_events,arm0,Full-Factorial-Placebo,,,
193,HYPERSENSITIVITY,4,600,Immune_system_disorders,NCT00154102,https://clinicaltrials.gov/show/NCT00154102,Epidermal_Growth_Factor_Receptor_(EGFR)_Expressing_Metastatic_Colorectal_Cancer,Cetuximab|FOLFIRI_(5-Fluorouracil_Folinic_acid_Irinotecan)|,serious_events,arm0,Cetuximab-Plus-FOLFIRI,45,folfiri,combination-drug-with-Irinotecan--Flourouracil--and-Leucovorin
193,HYPERSENSITIVITY,4,600,Immune_system_disorders,NCT00154102,https://clinicaltrials.gov/show/NCT00154102,Epidermal_Growth_Factor_Receptor_(EGFR)_Expressing_Metastatic_Colorectal_Cancer,Cetuximab|FOLFIRI_(5-Fluorouracil_Folinic_acid_Irinotecan)|,serious_events,arm0,Cetuximab-Plus-FOLFIRI,5,cetuximab,Epidermal-growth-factor-receptor-inhibitor
196,Hypersensitivity,2,90,Immune_system_disorders,NCT00158600,https://clinicaltrials.gov/show/NCT00158600,Pompe_Disease_(Late-onset)|Glycogen_Storage_Disease_Type_II_(GSD-II)|Acid_Maltase_Deficiency_Disease|Glycogenosis_2|,alglucosidase_alfa|Placebo|,serious_events,arm2,Overall,,,
197,Hypersensitivity,2,90,Immune_system_disorders,NCT00158600,https://clinicaltrials.gov/show/NCT00158600,Pompe_Disease_(Late-onset)|Glycogen_Storage_Disease_Type_II_(GSD-II)|Acid_Maltase_Deficiency_Disease|Glycogenosis_2|,alglucosidase_alfa|Placebo|,other_events,arm2,Overall,,,
199,Hypersensitivity,1,53,Immune_system_disorders,NCT00162123,https://clinicaltrials.gov/show/NCT00162123,Melanoma,Ipilimumab,other_events,arm0,First-Reinduction:-Ipilimumab-10-to-10-mg/kg,64,ipilimumab,monoclonal-antibody
201,Hypersensitivity,1,34,Immune_system_disorders,NCT00162123,https://clinicaltrials.gov/show/NCT00162123,Melanoma,Ipilimumab,other_events,arm1,First-Reinduction:-Ipilimumab-3-to-10-mg/kg,64,ipilimumab,monoclonal-antibody
203,Hypersensitivity,1,33,Immune_system_disorders,NCT00162123,https://clinicaltrials.gov/show/NCT00162123,Melanoma,Ipilimumab,other_events,arm4,Extended-Maintenance-Only:-Ipilimumab-10-mg/kg,88,maintenance,Class_Name_Needed
204,Hypersensitivity,1,33,Immune_system_disorders,NCT00162123,https://clinicaltrials.gov/show/NCT00162123,Melanoma,Ipilimumab,serious_events,arm4,Extended-Maintenance-Only:-Ipilimumab-10-mg/kg,88,maintenance,Class_Name_Needed
203,Hypersensitivity,1,33,Immune_system_disorders,NCT00162123,https://clinicaltrials.gov/show/NCT00162123,Melanoma,Ipilimumab,other_events,arm4,Extended-Maintenance-Only:-Ipilimumab-10-mg/kg,64,ipilimumab,monoclonal-antibody
204,Hypersensitivity,1,33,Immune_system_disorders,NCT00162123,https://clinicaltrials.gov/show/NCT00162123,Melanoma,Ipilimumab,serious_events,arm4,Extended-Maintenance-Only:-Ipilimumab-10-mg/kg,64,ipilimumab,monoclonal-antibody
200,Hypersensitivity,1,12,Immune_system_disorders,NCT00162123,https://clinicaltrials.gov/show/NCT00162123,Melanoma,Ipilimumab,serious_events,arm5,Extended-Maintenance-Only:-Ipilimumab-3-mg/kg,88,maintenance,Class_Name_Needed
202,Hypersensitivity,1,12,Immune_system_disorders,NCT00162123,https://clinicaltrials.gov/show/NCT00162123,Melanoma,Ipilimumab,other_events,arm5,Extended-Maintenance-Only:-Ipilimumab-3-mg/kg,88,maintenance,Class_Name_Needed
200,Hypersensitivity,1,12,Immune_system_disorders,NCT00162123,https://clinicaltrials.gov/show/NCT00162123,Melanoma,Ipilimumab,serious_events,arm5,Extended-Maintenance-Only:-Ipilimumab-3-mg/kg,64,ipilimumab,monoclonal-antibody
202,Hypersensitivity,1,12,Immune_system_disorders,NCT00162123,https://clinicaltrials.gov/show/NCT00162123,Melanoma,Ipilimumab,other_events,arm5,Extended-Maintenance-Only:-Ipilimumab-3-mg/kg,64,ipilimumab,monoclonal-antibody
1907,Dermatitis_allergic,1,93,Skin_and_subcutaneous_tissue_disorders,NCT00165646,https://clinicaltrials.gov/show/NCT00165646,Non-erosive_Gastroesophageal_Reflux_Disease,E3810|E3810|Placebo|,other_events,arm1,E3810-5-mg,,,
209,Hypersensitivity,1,110,Immune_system_disorders,NCT00170157,https://clinicaltrials.gov/show/NCT00170157,Prostatic_Neoplasms,Combination_Androgen_Ablative_Therapy|MDX-010_therapy|,serious_events,arm0,Entire-Study-Population,,,
210,Hypersensitivity,3,110,Immune_system_disorders,NCT00170157,https://clinicaltrials.gov/show/NCT00170157,Prostatic_Neoplasms,Combination_Androgen_Ablative_Therapy|MDX-010_therapy|,other_events,arm0,Entire-Study-Population,,,
213,Hypersensitivity,1,535,Immune_system_disorders,NCT00171340,https://clinicaltrials.gov/show/NCT00171340,Bone_Loss|Breast_Cancer|,Zoledronic_acid|Letrozole|,serious_events,arm1,Zolendronic-Acid-4mg-Delayed,,,
214,Hypersensitivity,1,6,Immune_system_disorders,NCT00171834,https://clinicaltrials.gov/show/NCT00171834,Carcinoma_Non-Small-Cell_Lung,Patupilone,other_events,arm0,Patupilone-??_7.0-mg/m^2-(Phase-I),,,
2522,Allergic_reaction,3,25,Immune_system_disorders,NCT00179309,https://clinicaltrials.gov/show/NCT00179309,Breast_Cancer,Docetaxel|PANVAC-V|PANVAC-F|Sargramostim|,other_events,arm0,Arm-I---PANVAC-+-Docetaxel,8,docetaxel,taxane
1218,DRUG_HYPERSENSITIVITY,1,1913,Immune_system_disorders,NCT00179647,https://clinicaltrials.gov/show/NCT00179647,Multiple_Myeloma,lenalidomide|dexamethasone|,serious_events,arm0,Lenalidomide,25,lenalidomide,immunomodulatory-agent-or-antiangiogenic-agent
218,Hypersensitivity,3,42,Immune_system_disorders,NCT00190671,https://clinicaltrials.gov/show/NCT00190671,Breast_Cancer,pemetrexed|cyclophosphamide|pemetrexed|,other_events,arm0,Pemetrexed-600mg/m2,15,pemetrexed,antimetabolite
1219,Drug_hypersensitivity,3,32,Immune_system_disorders,NCT00191139,https://clinicaltrials.gov/show/NCT00191139,Non-small_Cell_Lung_Cancer,gemcitabine|docetaxel|cisplatin|etoposide|radiation_therapy|,other_events,arm0,Gemcitabine,6,gemcitabine,antimetabolites
1220,Drug_hypersensitivity,2,32,Immune_system_disorders,NCT00191139,https://clinicaltrials.gov/show/NCT00191139,Non-small_Cell_Lung_Cancer,gemcitabine|docetaxel|cisplatin|etoposide|radiation_therapy|,other_events,arm1,Gemcitabine-Plus-Docetaxel,6,gemcitabine,antimetabolites
1220,Drug_hypersensitivity,2,32,Immune_system_disorders,NCT00191139,https://clinicaltrials.gov/show/NCT00191139,Non-small_Cell_Lung_Cancer,gemcitabine|docetaxel|cisplatin|etoposide|radiation_therapy|,other_events,arm1,Gemcitabine-Plus-Docetaxel,8,docetaxel,taxane
220,Hypersensitivity,1,48,Immune_system_disorders,NCT00191451,https://clinicaltrials.gov/show/NCT00191451,Breast_Cancer,Gemcitabine|Carboplatin|Herceptin|,serious_events,arm1,HER2--(Taxane-),93,taxane,
1911,Dermatitis_allergic,1,166,Skin_and_subcutaneous_tissue_disorders,NCT00191477,https://clinicaltrials.gov/show/NCT00191477,Bladder_Neoplasms,Gemcitabine|Placebo|,other_events,arm0,Gemcitabine,6,gemcitabine,antimetabolites
1223,Drug_hypersensitivity,1,412,Immune_system_disorders,NCT00191646,https://clinicaltrials.gov/show/NCT00191646,Genital_Neoplasms_Female|Fallopian_Tube_Neoplasms|Ovarian_Neoplasms|Pelvic_Neoplasms|Peritoneal_Neoplasms|,Gemcitabine|Paclitaxel|Carboplatin|,serious_events,arm0,Gemcitabine/Carboplatin-Induction,3,carboplatin,alkalating-agent
1223,Drug_hypersensitivity,1,412,Immune_system_disorders,NCT00191646,https://clinicaltrials.gov/show/NCT00191646,Genital_Neoplasms_Female|Fallopian_Tube_Neoplasms|Ovarian_Neoplasms|Pelvic_Neoplasms|Peritoneal_Neoplasms|,Gemcitabine|Paclitaxel|Carboplatin|,serious_events,arm0,Gemcitabine/Carboplatin-Induction,6,gemcitabine,antimetabolites
1222,Drug_hypersensitivity,2,408,Immune_system_disorders,NCT00191646,https://clinicaltrials.gov/show/NCT00191646,Genital_Neoplasms_Female|Fallopian_Tube_Neoplasms|Ovarian_Neoplasms|Pelvic_Neoplasms|Peritoneal_Neoplasms|,Gemcitabine|Paclitaxel|Carboplatin|,serious_events,arm1,Paclitaxel/Carboplatin-Induction,3,carboplatin,alkalating-agent
1222,Drug_hypersensitivity,2,408,Immune_system_disorders,NCT00191646,https://clinicaltrials.gov/show/NCT00191646,Genital_Neoplasms_Female|Fallopian_Tube_Neoplasms|Ovarian_Neoplasms|Pelvic_Neoplasms|Peritoneal_Neoplasms|,Gemcitabine|Paclitaxel|Carboplatin|,serious_events,arm1,Paclitaxel/Carboplatin-Induction,2,paclitaxel,taxane
221,Hypersensitivity,1,44,Immune_system_disorders,NCT00191984,https://clinicaltrials.gov/show/NCT00191984,Metastatic_Colorectal_Cancer,pemetrexed|irinotecan|,serious_events,arm0,Pemetrexed-+-Irinotecan,15,pemetrexed,antimetabolite
221,Hypersensitivity,1,44,Immune_system_disorders,NCT00191984,https://clinicaltrials.gov/show/NCT00191984,Metastatic_Colorectal_Cancer,pemetrexed|irinotecan|,serious_events,arm0,Pemetrexed-+-Irinotecan,46,irinotecan,plant-alkaloid-and-topoisomerase-1-inhibitor
2526,Allergic_reaction,2,37,General_disorders,NCT00193180,https://clinicaltrials.gov/show/NCT00193180,Breast_Cancer,Imatinib|Docetaxel|,other_events,arm0,Docetaxel+Imatinib,8,docetaxel,taxane
2527,Allergic_Reaction,2,31,Immune_system_disorders,NCT00193219,https://clinicaltrials.gov/show/NCT00193219,Colon_Cancer,Bevacizumab|Cetuximab|5-fluorouracil|Leucovorin|Oxaliplatin|,serious_events,arm0,Bevacizumab/Cetuximab/FOLFOX,5,cetuximab,Epidermal-growth-factor-receptor-inhibitor
2527,Allergic_Reaction,2,31,Immune_system_disorders,NCT00193219,https://clinicaltrials.gov/show/NCT00193219,Colon_Cancer,Bevacizumab|Cetuximab|5-fluorouracil|Leucovorin|Oxaliplatin|,serious_events,arm0,Bevacizumab/Cetuximab/FOLFOX,4,bevacizumab,monoclonal-antibody
2527,Allergic_Reaction,2,31,Immune_system_disorders,NCT00193219,https://clinicaltrials.gov/show/NCT00193219,Colon_Cancer,Bevacizumab|Cetuximab|5-fluorouracil|Leucovorin|Oxaliplatin|,serious_events,arm0,Bevacizumab/Cetuximab/FOLFOX,22,bevacizumab,monoclonal-antibody
222,Hypersensitivity,5,94,Immune_system_disorders,NCT00193258,https://clinicaltrials.gov/show/NCT00193258,Clear_Cell_Renal_Cell_Carcinoma,Bevacizumab|Erlotinib|Imatinib|,other_events,arm0,Bevacizumab/Erlotinib/Imatinib,31,erlotinib,epidermal-growth-factor-receptor-(EGFR)-inhibitor---protein-tyrosine-kinase-inhibitor
222,Hypersensitivity,5,94,Immune_system_disorders,NCT00193258,https://clinicaltrials.gov/show/NCT00193258,Clear_Cell_Renal_Cell_Carcinoma,Bevacizumab|Erlotinib|Imatinib|,other_events,arm0,Bevacizumab/Erlotinib/Imatinib,4,bevacizumab,monoclonal-antibody
222,Hypersensitivity,5,94,Immune_system_disorders,NCT00193258,https://clinicaltrials.gov/show/NCT00193258,Clear_Cell_Renal_Cell_Carcinoma,Bevacizumab|Erlotinib|Imatinib|,other_events,arm0,Bevacizumab/Erlotinib/Imatinib,22,bevacizumab,monoclonal-antibody
2528,Allergic_Reaction,8,69,Immune_system_disorders,NCT00193453,https://clinicaltrials.gov/show/NCT00193453,Lung_Cancer,Gemcitabine|Docetaxel|Cetuximab|,other_events,arm0,Intervention,,,
2529,Allergic_Reaction,3,69,Immune_system_disorders,NCT00193453,https://clinicaltrials.gov/show/NCT00193453,Lung_Cancer,Gemcitabine|Docetaxel|Cetuximab|,serious_events,arm0,Intervention,,,
2531,Allergic_reaction,8,31,Immune_system_disorders,NCT00193492,https://clinicaltrials.gov/show/NCT00193492,Lymphoma_Follicular,Bevacizumab|Rituximab|,other_events,arm0,Rituximab,16,rituximab,monoclonal-antibody
2530,Allergic_reaction,2,29,Immune_system_disorders,NCT00193492,https://clinicaltrials.gov/show/NCT00193492,Lymphoma_Follicular,Bevacizumab|Rituximab|,other_events,arm1,Rituximab/Bevacizumab,16,rituximab,monoclonal-antibody
2530,Allergic_reaction,2,29,Immune_system_disorders,NCT00193492,https://clinicaltrials.gov/show/NCT00193492,Lymphoma_Follicular,Bevacizumab|Rituximab|,other_events,arm1,Rituximab/Bevacizumab,4,bevacizumab,monoclonal-antibody
2530,Allergic_reaction,2,29,Immune_system_disorders,NCT00193492,https://clinicaltrials.gov/show/NCT00193492,Lymphoma_Follicular,Bevacizumab|Rituximab|,other_events,arm1,Rituximab/Bevacizumab,22,bevacizumab,monoclonal-antibody
2532,Allergic_Reaction,1,93,Immune_system_disorders,NCT00193596,https://clinicaltrials.gov/show/NCT00193596,Neoplasms_Unknown_Primary,Etoposide|Gemcitabine|Irinotecan|Paclitaxel|Carboplatin|,serious_events,arm0,Paclitaxel/Carboplatin/Etoposide/Gefitinib,3,carboplatin,alkalating-agent
2532,Allergic_Reaction,1,93,Immune_system_disorders,NCT00193596,https://clinicaltrials.gov/show/NCT00193596,Neoplasms_Unknown_Primary,Etoposide|Gemcitabine|Irinotecan|Paclitaxel|Carboplatin|,serious_events,arm0,Paclitaxel/Carboplatin/Etoposide/Gefitinib,26,etoposide,"plant-alkaloid""-and-""topoisomerase-II-inhibitor."""
2532,Allergic_Reaction,1,93,Immune_system_disorders,NCT00193596,https://clinicaltrials.gov/show/NCT00193596,Neoplasms_Unknown_Primary,Etoposide|Gemcitabine|Irinotecan|Paclitaxel|Carboplatin|,serious_events,arm0,Paclitaxel/Carboplatin/Etoposide/Gefitinib,2,paclitaxel,taxane
2533,Allergic_Reaction,3,48,Immune_system_disorders,NCT00193609,https://clinicaltrials.gov/show/NCT00193609,Neoplasms_Unknown_Primary,Oxaliplatin|Capecitabine|,other_events,arm0,Intervention,,,
1226,Drug_hypersensitivity,1,199,Immune_system_disorders,NCT00203047,https://clinicaltrials.gov/show/NCT00203047,Relapsing_Remitting_Multiple_Sclerosis,Glatiramer_Acetate|Placebo|Prednisone|,other_events,arm0,GA-+-Placebo,,,
1916,Dermatitis_allergic,1,1885,Skin_and_subcutaneous_tissue_disorders,NCT00205777,https://clinicaltrials.gov/show/NCT00205777,Osteoporosis,Bazedoxifene_Acetate|Placebo|,serious_events,arm3,Placebo,,,
1917,Dermatitis_allergic,1,57,Skin_and_subcutaneous_tissue_disorders,NCT00206726,https://clinicaltrials.gov/show/NCT00206726,Leukemia_Lymphocytic_Chronic_B-Cell,Alemtuzumab_plus_Fludarabine,other_events,arm0,Alemtuzumab-Plus-Fludarabine,66,fludarabine,antimetabolite
1917,Dermatitis_allergic,1,57,Skin_and_subcutaneous_tissue_disorders,NCT00206726,https://clinicaltrials.gov/show/NCT00206726,Leukemia_Lymphocytic_Chronic_B-Cell,Alemtuzumab_plus_Fludarabine,other_events,arm0,Alemtuzumab-Plus-Fludarabine,76,alemtuzumab,monoclonal-antibody
229,HYPERSENSITIVITY,1,15,Immune_system_disorders,NCT00207090,https://clinicaltrials.gov/show/NCT00207090,Advanced_Solid_Tumors|Neoplasms|,ixabepilone|Rifampin|,serious_events,arm0,All-Participants,,,
230,HYPERSENSITIVITY,1,15,Immune_system_disorders,NCT00207090,https://clinicaltrials.gov/show/NCT00207090,Advanced_Solid_Tumors|Neoplasms|,ixabepilone|Rifampin|,other_events,arm0,All-Participants,,,
239,Hypersensitivity,1,68,Immune_system_disorders,NCT00219557,https://clinicaltrials.gov/show/NCT00219557,Pancreatic_Neoplasms,Gemcitabine|AG-013736|Gemcitabine|,other_events,arm1,Axitinib-+-Gemcitabine,6,gemcitabine,antimetabolites
239,Hypersensitivity,1,68,Immune_system_disorders,NCT00219557,https://clinicaltrials.gov/show/NCT00219557,Pancreatic_Neoplasms,Gemcitabine|AG-013736|Gemcitabine|,other_events,arm1,Axitinib-+-Gemcitabine,10,axitinib,kinase-inhibitor
238,Hypersensitivity,1,31,Immune_system_disorders,NCT00219557,https://clinicaltrials.gov/show/NCT00219557,Pancreatic_Neoplasms,Gemcitabine|AG-013736|Gemcitabine|,other_events,arm2,Gemcitabine,6,gemcitabine,antimetabolites
1923,Dermatitis_Allergic,2,31,Skin_and_subcutaneous_tissue_disorders,NCT00229723,https://clinicaltrials.gov/show/NCT00229723,Neoplasms_Squamous_Cell,gefitinib_(Iressa)|cisplatin|radiotherapy|Gefitinib_(Iressa)|,other_events,arm3,250mg/250mg,,,
242,Hypersensitivity,1,34,Immune_system_disorders,NCT00229723,https://clinicaltrials.gov/show/NCT00229723,Neoplasms_Squamous_Cell,gefitinib_(Iressa)|cisplatin|radiotherapy|Gefitinib_(Iressa)|,serious_events,arm5,Placebo/250mg,,,
1232,Drug_hypersensitivity,1,92,Immune_system_disorders,NCT00230178,https://clinicaltrials.gov/show/NCT00230178,Tumor_Lysis_Syndrome|Cancer|Hyperuricemia|,Rasburicase_(SR29142)|Allopurinol|,serious_events,arm1,Rasburicase-+-Allopurinol,,,
2538,allergic_reaction,2,13,Injury_poisoning_and_procedural_complications,NCT00238615,https://clinicaltrials.gov/show/NCT00238615,Lung_Cancer|Carcinoma_Non-Small-Cell_Lung|,Docetaxel|Carboplatin|Radiation_therapy|Surgical_resection|,serious_events,arm0,Docetaxel-/-Carboplatin-/-XRT-+-Surgical-Resection,3,carboplatin,alkalating-agent
2538,allergic_reaction,2,13,Injury_poisoning_and_procedural_complications,NCT00238615,https://clinicaltrials.gov/show/NCT00238615,Lung_Cancer|Carcinoma_Non-Small-Cell_Lung|,Docetaxel|Carboplatin|Radiation_therapy|Surgical_resection|,serious_events,arm0,Docetaxel-/-Carboplatin-/-XRT-+-Surgical-Resection,8,docetaxel,taxane
249,Hypersensitivity,10,361,Immune_system_disorders,NCT00242710,https://clinicaltrials.gov/show/NCT00242710,Endometrial_Hyperplasia|Osteoporosis|,Bazedoxifene/Conjugated_Estrogen|Bazedoxifene/Conjugated_Estrogen|CE_0.45_mg/MPA_1.5mg|Placebo|,other_events,arm0,Bazedoxifene-20-mg/Conjugated-Estrogen-0.45-mg,,,
246,Hypersensitivity,9,349,Immune_system_disorders,NCT00242710,https://clinicaltrials.gov/show/NCT00242710,Endometrial_Hyperplasia|Osteoporosis|,Bazedoxifene/Conjugated_Estrogen|Bazedoxifene/Conjugated_Estrogen|CE_0.45_mg/MPA_1.5mg|Placebo|,other_events,arm1,Bazedoxifene-20-mg/Conjugated-Estrogen-0.625-mg,,,
247,Hypersensitivity,2,172,Immune_system_disorders,NCT00242710,https://clinicaltrials.gov/show/NCT00242710,Endometrial_Hyperplasia|Osteoporosis|,Bazedoxifene/Conjugated_Estrogen|Bazedoxifene/Conjugated_Estrogen|CE_0.45_mg/MPA_1.5mg|Placebo|,other_events,arm3,Placebo,,,
251,Hypersensitivity,1,46,Immune_system_disorders,NCT00245466,https://clinicaltrials.gov/show/NCT00245466,Prostate_Cancer,Degarelix|Degarelix|Degarelix|,serious_events,arm1,Degarelix-40/40-+-40,,,
252,Hypersensitivity,1,32,Immune_system_disorders,NCT00246012,https://clinicaltrials.gov/show/NCT00246012,Melanoma,Intetumumab|Dacarbazine|Placebo|,serious_events,arm8,Dacarbazine-+-Intetumumab-10-mg/kg-[Phase-2],,,
1930,Dermatitis_allergic,1,110,Skin_and_subcutaneous_tissue_disorders,NCT00246571,https://clinicaltrials.gov/show/NCT00246571,Breast_Neoplasms,SU011248|Chemotherapy|,other_events,arm0,Sunitinib,27,sunitinib,tyrosine-kinase-inhibitor-and-angiogenesis-inhibitor
253,Hypersensitivity,1,110,Immune_system_disorders,NCT00246571,https://clinicaltrials.gov/show/NCT00246571,Breast_Neoplasms,SU011248|Chemotherapy|,other_events,arm0,Sunitinib,27,sunitinib,tyrosine-kinase-inhibitor-and-angiogenesis-inhibitor
1931,Dermatitis_allergic,1,103,Skin_and_subcutaneous_tissue_disorders,NCT00246571,https://clinicaltrials.gov/show/NCT00246571,Breast_Neoplasms,SU011248|Chemotherapy|,other_events,arm1,Standard-of-Care,,,
1240,Drug_hypersensitivity,2,2049,Immune_system_disorders,NCT00248170,https://clinicaltrials.gov/show/NCT00248170,Breast_Cancer,Letrozole|Anastrozole|,serious_events,arm0,Letrozole,,,
254,Hypersensitivity,1,2049,Immune_system_disorders,NCT00248170,https://clinicaltrials.gov/show/NCT00248170,Breast_Cancer,Letrozole|Anastrozole|,serious_events,arm0,Letrozole,,,
1241,Drug_hypersensitivity,1,2062,Immune_system_disorders,NCT00248170,https://clinicaltrials.gov/show/NCT00248170,Breast_Cancer,Letrozole|Anastrozole|,serious_events,arm1,Anastrozole,,,
2539,ALLERGIC_REACTION,9,118,Immune_system_disorders,NCT00252564,https://clinicaltrials.gov/show/NCT00252564,Colorectal_Cancer_Metastatic,Bevacizumab|Oxaliplatin|Leucovorin|Fluorouracil|Cetuximab|,other_events,arm0,Arm-A,,,
2541,ALLERGIC_REACTION,1,118,Immune_system_disorders,NCT00252564,https://clinicaltrials.gov/show/NCT00252564,Colorectal_Cancer_Metastatic,Bevacizumab|Oxaliplatin|Leucovorin|Fluorouracil|Cetuximab|,serious_events,arm0,Arm-A,,,
257,HYPERSENSITIVITY,20,118,Immune_system_disorders,NCT00252564,https://clinicaltrials.gov/show/NCT00252564,Colorectal_Cancer_Metastatic,Bevacizumab|Oxaliplatin|Leucovorin|Fluorouracil|Cetuximab|,other_events,arm0,Arm-A,,,
2540,ALLERGIC_REACTION,4,121,Immune_system_disorders,NCT00252564,https://clinicaltrials.gov/show/NCT00252564,Colorectal_Cancer_Metastatic,Bevacizumab|Oxaliplatin|Leucovorin|Fluorouracil|Cetuximab|,other_events,arm1,Arm-B,,,
2542,Allergic_reaction,1,44,Immune_system_disorders,NCT00253370,https://clinicaltrials.gov/show/NCT00253370,Adenocarcinoma_of_the_Gastroesophageal_Junction|Metastatic_Gastric_Cancer|Advanced_Unresectable_Gastric_Cancer|,BAY_43-9006|docetaxel|cisplatin|,serious_events,arm0,BAY-43-9006-Docetaxel-Cisplatin,9,cisplatin,alkalating-agent
2542,Allergic_reaction,1,44,Immune_system_disorders,NCT00253370,https://clinicaltrials.gov/show/NCT00253370,Adenocarcinoma_of_the_Gastroesophageal_Junction|Metastatic_Gastric_Cancer|Advanced_Unresectable_Gastric_Cancer|,BAY_43-9006|docetaxel|cisplatin|,serious_events,arm0,BAY-43-9006-Docetaxel-Cisplatin,8,docetaxel,taxane
1249,Drug_hypersensitivity,1,288,Immune_system_disorders,NCT00261846,https://clinicaltrials.gov/show/NCT00261846,Chronic_Myeloid_Leukemia,Bosutinib,serious_events,arm0,CP2L-CML,,,
1248,Drug_hypersensitivity,1,118,Immune_system_disorders,NCT00261846,https://clinicaltrials.gov/show/NCT00261846,Chronic_Myeloid_Leukemia,Bosutinib,serious_events,arm1,CP3L-CML,,,
1250,Drug_hypersensitivity,1,164,Immune_system_disorders,NCT00261846,https://clinicaltrials.gov/show/NCT00261846,Chronic_Myeloid_Leukemia,Bosutinib,serious_events,arm2,Advanced-Phase,,,
263,Hypersensitivity,1,413,Immune_system_disorders,NCT00262067,https://clinicaltrials.gov/show/NCT00262067,Metastatic_Breast_Cancer,Bevacizumab|Placebo|Chemotherapy|,serious_events,arm0,Bevacizumab-15-mg/kg-+-Taxane-or-Anthracycline-based-Regimen,73,anthracycline,anthracycline
263,Hypersensitivity,1,413,Immune_system_disorders,NCT00262067,https://clinicaltrials.gov/show/NCT00262067,Metastatic_Breast_Cancer,Bevacizumab|Placebo|Chemotherapy|,serious_events,arm0,Bevacizumab-15-mg/kg-+-Taxane-or-Anthracycline-based-Regimen,4,bevacizumab,monoclonal-antibody
263,Hypersensitivity,1,413,Immune_system_disorders,NCT00262067,https://clinicaltrials.gov/show/NCT00262067,Metastatic_Breast_Cancer,Bevacizumab|Placebo|Chemotherapy|,serious_events,arm0,Bevacizumab-15-mg/kg-+-Taxane-or-Anthracycline-based-Regimen,22,bevacizumab,monoclonal-antibody
263,Hypersensitivity,1,413,Immune_system_disorders,NCT00262067,https://clinicaltrials.gov/show/NCT00262067,Metastatic_Breast_Cancer,Bevacizumab|Placebo|Chemotherapy|,serious_events,arm0,Bevacizumab-15-mg/kg-+-Taxane-or-Anthracycline-based-Regimen,93,taxane,
271,Hypersensitivity,2,64,Immune_system_disorders,NCT00265317,https://clinicaltrials.gov/show/NCT00265317,Carcinoma_Non-Small-Cell_Lung,erlotinib|sunitinib|erlotinib|placebo|,other_events,arm2,Sunitinib-+-Erlotinib,31,erlotinib,epidermal-growth-factor-receptor-(EGFR)-inhibitor---protein-tyrosine-kinase-inhibitor
271,Hypersensitivity,2,64,Immune_system_disorders,NCT00265317,https://clinicaltrials.gov/show/NCT00265317,Carcinoma_Non-Small-Cell_Lung,erlotinib|sunitinib|erlotinib|placebo|,other_events,arm2,Sunitinib-+-Erlotinib,27,sunitinib,tyrosine-kinase-inhibitor-and-angiogenesis-inhibitor
272,HYPERSENSITIVITY,10,98,Immune_system_disorders,NCT00266799,https://clinicaltrials.gov/show/NCT00266799,Breast_Cancer,Pegylated_liposomal_doxorubicin_(SCH_200746)|Capecitabine|,other_events,arm0,Pegylated-Liposomal-Doxorubicin-(PLD),38,doxorubicin,anthracycline-antibiotic
274,HYPERSENSITIVITY,2,98,Immune_system_disorders,NCT00266799,https://clinicaltrials.gov/show/NCT00266799,Breast_Cancer,Pegylated_liposomal_doxorubicin_(SCH_200746)|Capecitabine|,serious_events,arm0,Pegylated-Liposomal-Doxorubicin-(PLD),38,doxorubicin,anthracycline-antibiotic
272,HYPERSENSITIVITY,10,98,Immune_system_disorders,NCT00266799,https://clinicaltrials.gov/show/NCT00266799,Breast_Cancer,Pegylated_liposomal_doxorubicin_(SCH_200746)|Capecitabine|,other_events,arm0,Pegylated-Liposomal-Doxorubicin-(PLD),89,liposomal,Class_Name_Needed
274,HYPERSENSITIVITY,2,98,Immune_system_disorders,NCT00266799,https://clinicaltrials.gov/show/NCT00266799,Breast_Cancer,Pegylated_liposomal_doxorubicin_(SCH_200746)|Capecitabine|,serious_events,arm0,Pegylated-Liposomal-Doxorubicin-(PLD),89,liposomal,Class_Name_Needed
273,HYPERSENSITIVITY,1,102,Immune_system_disorders,NCT00266799,https://clinicaltrials.gov/show/NCT00266799,Breast_Cancer,Pegylated_liposomal_doxorubicin_(SCH_200746)|Capecitabine|,other_events,arm1,Capecitabine,17,capecitabine,antimetabolite
273,HYPERSENSITIVITY,1,102,Immune_system_disorders,NCT00266799,https://clinicaltrials.gov/show/NCT00266799,Breast_Cancer,Pegylated_liposomal_doxorubicin_(SCH_200746)|Capecitabine|,other_events,arm1,Capecitabine,29,capecitabine,antimetabolite
1258,Drug_Hypersensitivity,1,19,Immune_system_disorders,NCT00267007,https://clinicaltrials.gov/show/NCT00267007,Peripheral_Neuropathy_Chemotherapy-induced,PROCRIT_40000_IU_QW|Placebo|,other_events,arm0,PROCRIT-40000-IU-QW,,,
275,Hypersensitivity,1,143,Immune_system_disorders,NCT00267748,https://clinicaltrials.gov/show/NCT00267748,Carcinoma_Renal_Cell,Sunitinib_Malate_Continuous_Daily_Dosing|Sunitinib_Malate_Schedule_4/2|,serious_events,arm2,Sunitinib-37.5-mg,27,sunitinib,tyrosine-kinase-inhibitor-and-angiogenesis-inhibitor
1937,Dermatitis_allergic,1,765,Skin_and_subcutaneous_tissue_disorders,NCT00268203,https://clinicaltrials.gov/show/NCT00268203,Lymphoma_Non-Hodgkin,Iodine_I_131_Tositumomab_Therapeutic_Regimen,other_events,arm0,Tositumomab-and-Iodine-I-131-Tositumomab,53,iodine,Class_Name_Needed
276,Hypersensitivity,4,765,Immune_system_disorders,NCT00268203,https://clinicaltrials.gov/show/NCT00268203,Lymphoma_Non-Hodgkin,Iodine_I_131_Tositumomab_Therapeutic_Regimen,other_events,arm0,Tositumomab-and-Iodine-I-131-Tositumomab,53,iodine,Class_Name_Needed
277,Hypersensitivity,1,8,Immune_system_disorders,NCT00268983,https://clinicaltrials.gov/show/NCT00268983,Lymphoma_Non-Hodgkin,Tositumomab_and_Iodine_I_131_Tositumomab|Rituximab|,serious_events,arm1,TST/I-131-TST,,,
2384,Allergy,1,183,Immune_system_disorders,NCT00269113,https://clinicaltrials.gov/show/NCT00269113,Non-Hodgkin's_Lymphoma,rituximab_[MabThera/Rituxan]|Standard_chemotherapy|,serious_events,arm1,Rituximab-+-MCP,16,rituximab,monoclonal-antibody
1262,Drug_hypersensitivity,1,14,Immune_system_disorders,NCT00272987,https://clinicaltrials.gov/show/NCT00272987,Neoplasms_Breast,lapatinib|paclitaxel|trastuzumab|,serious_events,arm1,Paclitaxel-70-mg/Trastuzumab-4-mg/Lapatinib-1000-mg,18,trastuzumab,monoclonal-antibody
280,Hypersensitivity,1,14,Nervous_system_disorders,NCT00272987,https://clinicaltrials.gov/show/NCT00272987,Neoplasms_Breast,lapatinib|paclitaxel|trastuzumab|,other_events,arm1,Paclitaxel-70-mg/Trastuzumab-4-mg/Lapatinib-1000-mg,18,trastuzumab,monoclonal-antibody
1262,Drug_hypersensitivity,1,14,Immune_system_disorders,NCT00272987,https://clinicaltrials.gov/show/NCT00272987,Neoplasms_Breast,lapatinib|paclitaxel|trastuzumab|,serious_events,arm1,Paclitaxel-70-mg/Trastuzumab-4-mg/Lapatinib-1000-mg,21,lapatinib,signal-transduction-inhibitor
280,Hypersensitivity,1,14,Nervous_system_disorders,NCT00272987,https://clinicaltrials.gov/show/NCT00272987,Neoplasms_Breast,lapatinib|paclitaxel|trastuzumab|,other_events,arm1,Paclitaxel-70-mg/Trastuzumab-4-mg/Lapatinib-1000-mg,21,lapatinib,signal-transduction-inhibitor
1262,Drug_hypersensitivity,1,14,Immune_system_disorders,NCT00272987,https://clinicaltrials.gov/show/NCT00272987,Neoplasms_Breast,lapatinib|paclitaxel|trastuzumab|,serious_events,arm1,Paclitaxel-70-mg/Trastuzumab-4-mg/Lapatinib-1000-mg,2,paclitaxel,taxane
280,Hypersensitivity,1,14,Nervous_system_disorders,NCT00272987,https://clinicaltrials.gov/show/NCT00272987,Neoplasms_Breast,lapatinib|paclitaxel|trastuzumab|,other_events,arm1,Paclitaxel-70-mg/Trastuzumab-4-mg/Lapatinib-1000-mg,2,paclitaxel,taxane
1261,Drug_hypersensitivity,2,20,Immune_system_disorders,NCT00272987,https://clinicaltrials.gov/show/NCT00272987,Neoplasms_Breast,lapatinib|paclitaxel|trastuzumab|,other_events,arm2,Paclitaxel-80-mg/Trastuzumab-4-mg/Lapatinib-750-mg,18,trastuzumab,monoclonal-antibody
1261,Drug_hypersensitivity,2,20,Immune_system_disorders,NCT00272987,https://clinicaltrials.gov/show/NCT00272987,Neoplasms_Breast,lapatinib|paclitaxel|trastuzumab|,other_events,arm2,Paclitaxel-80-mg/Trastuzumab-4-mg/Lapatinib-750-mg,21,lapatinib,signal-transduction-inhibitor
1261,Drug_hypersensitivity,2,20,Immune_system_disorders,NCT00272987,https://clinicaltrials.gov/show/NCT00272987,Neoplasms_Breast,lapatinib|paclitaxel|trastuzumab|,other_events,arm2,Paclitaxel-80-mg/Trastuzumab-4-mg/Lapatinib-750-mg,2,paclitaxel,taxane
282,Hypersensitivity,1,560,Immune_system_disorders,NCT00274261,https://clinicaltrials.gov/show/NCT00274261,Pregnancy,C31G|nonoxynol-9_(N-9)|,serious_events,arm1,Conceptrol,,,
283,Hypersensitivity,1,76,Immune_system_disorders,NCT00274456,https://clinicaltrials.gov/show/NCT00274456,Metastatic_Breast_Cancer,ABI-007|Docetaxel|,serious_events,arm1,ABI-007-100-mg/m^2-Weekly,,,
284,Hypersensitivity,2,24,Immune_system_disorders,NCT00274651,https://clinicaltrials.gov/show/NCT00274651,Cutaneous_T-Cell_Lymphoma|Peripheral_T-Cell_Lymphoma|Non-Hodgkin's_Lymphoma|,belinostat,other_events,arm1,Arm-B-(PTCL-ITT-Population),,,
1264,Drug_Hypersensitivity,4,70,Immune_system_disorders,NCT00278889,https://clinicaltrials.gov/show/NCT00278889,Colorectal_Cancer,AZD2171|5-fluorouracil|Leucovorin|Oxaliplatin|Bevacizumab|,other_events,arm0,FOLFOX-+-Cediranib-20-mg,19,folfox,combination-drug-with-Leucovorin-(Folinic-Acid)--Fluorouracil--and-Oxaliplatin
1264,Drug_Hypersensitivity,4,70,Immune_system_disorders,NCT00278889,https://clinicaltrials.gov/show/NCT00278889,Colorectal_Cancer,AZD2171|5-fluorouracil|Leucovorin|Oxaliplatin|Bevacizumab|,other_events,arm0,FOLFOX-+-Cediranib-20-mg,14,cediranib,endothelial-growith-factor-receptor-tyrosine-kinase-inhibitor?
1263,Drug_Hypersensitivity,1,73,Immune_system_disorders,NCT00278889,https://clinicaltrials.gov/show/NCT00278889,Colorectal_Cancer,AZD2171|5-fluorouracil|Leucovorin|Oxaliplatin|Bevacizumab|,serious_events,arm1,FOLFOX-+-Cediranib-30-mg,19,folfox,combination-drug-with-Leucovorin-(Folinic-Acid)--Fluorouracil--and-Oxaliplatin
1266,Drug_Hypersensitivity,2,73,Immune_system_disorders,NCT00278889,https://clinicaltrials.gov/show/NCT00278889,Colorectal_Cancer,AZD2171|5-fluorouracil|Leucovorin|Oxaliplatin|Bevacizumab|,other_events,arm1,FOLFOX-+-Cediranib-30-mg,19,folfox,combination-drug-with-Leucovorin-(Folinic-Acid)--Fluorouracil--and-Oxaliplatin
1263,Drug_Hypersensitivity,1,73,Immune_system_disorders,NCT00278889,https://clinicaltrials.gov/show/NCT00278889,Colorectal_Cancer,AZD2171|5-fluorouracil|Leucovorin|Oxaliplatin|Bevacizumab|,serious_events,arm1,FOLFOX-+-Cediranib-30-mg,14,cediranib,endothelial-growith-factor-receptor-tyrosine-kinase-inhibitor?
1266,Drug_Hypersensitivity,2,73,Immune_system_disorders,NCT00278889,https://clinicaltrials.gov/show/NCT00278889,Colorectal_Cancer,AZD2171|5-fluorouracil|Leucovorin|Oxaliplatin|Bevacizumab|,other_events,arm1,FOLFOX-+-Cediranib-30-mg,14,cediranib,endothelial-growith-factor-receptor-tyrosine-kinase-inhibitor?
1265,Drug_Hypersensitivity,5,66,Immune_system_disorders,NCT00278889,https://clinicaltrials.gov/show/NCT00278889,Colorectal_Cancer,AZD2171|5-fluorouracil|Leucovorin|Oxaliplatin|Bevacizumab|,other_events,arm2,FOLFOX-+-Bevacizumab-10-mg/kg,19,folfox,combination-drug-with-Leucovorin-(Folinic-Acid)--Fluorouracil--and-Oxaliplatin
1267,Drug_Hypersensitivity,1,66,Immune_system_disorders,NCT00278889,https://clinicaltrials.gov/show/NCT00278889,Colorectal_Cancer,AZD2171|5-fluorouracil|Leucovorin|Oxaliplatin|Bevacizumab|,serious_events,arm2,FOLFOX-+-Bevacizumab-10-mg/kg,19,folfox,combination-drug-with-Leucovorin-(Folinic-Acid)--Fluorouracil--and-Oxaliplatin
1265,Drug_Hypersensitivity,5,66,Immune_system_disorders,NCT00278889,https://clinicaltrials.gov/show/NCT00278889,Colorectal_Cancer,AZD2171|5-fluorouracil|Leucovorin|Oxaliplatin|Bevacizumab|,other_events,arm2,FOLFOX-+-Bevacizumab-10-mg/kg,4,bevacizumab,monoclonal-antibody
1267,Drug_Hypersensitivity,1,66,Immune_system_disorders,NCT00278889,https://clinicaltrials.gov/show/NCT00278889,Colorectal_Cancer,AZD2171|5-fluorouracil|Leucovorin|Oxaliplatin|Bevacizumab|,serious_events,arm2,FOLFOX-+-Bevacizumab-10-mg/kg,4,bevacizumab,monoclonal-antibody
1265,Drug_Hypersensitivity,5,66,Immune_system_disorders,NCT00278889,https://clinicaltrials.gov/show/NCT00278889,Colorectal_Cancer,AZD2171|5-fluorouracil|Leucovorin|Oxaliplatin|Bevacizumab|,other_events,arm2,FOLFOX-+-Bevacizumab-10-mg/kg,22,bevacizumab,monoclonal-antibody
1267,Drug_Hypersensitivity,1,66,Immune_system_disorders,NCT00278889,https://clinicaltrials.gov/show/NCT00278889,Colorectal_Cancer,AZD2171|5-fluorouracil|Leucovorin|Oxaliplatin|Bevacizumab|,serious_events,arm2,FOLFOX-+-Bevacizumab-10-mg/kg,22,bevacizumab,monoclonal-antibody
287,Hypersensitivity,1,75,Immune_system_disorders,NCT00281528,https://clinicaltrials.gov/show/NCT00281528,Breast_Neoplasms|Neoplasm_Metastasis|,ABI-007_(Abraxane)|bevacizumab|,other_events,arm0,260-mg/m^2-ABI-007-Every-3-Weeks,,,
286,Hypersensitivity,3,54,Immune_system_disorders,NCT00281528,https://clinicaltrials.gov/show/NCT00281528,Breast_Neoplasms|Neoplasm_Metastasis|,ABI-007_(Abraxane)|bevacizumab|,other_events,arm1,260-mg/m^2-ABI-007-Every-2-Weeks,,,
1941,Dermatitis_Allergic,1,402,Skin_and_subcutaneous_tissue_disorders,NCT00281918,https://clinicaltrials.gov/show/NCT00281918,Leukemia,Rituximab|Cyclophosphamide|Fludarabine_Phosphate|,serious_events,arm1,Fludarabine+Cyclophosphamide+Rituximab-(FCR),13,cyclophosphamide,alkylating-agent
1268,Drug_Hypersensitivity,2,402,Immune_system_disorders,NCT00281918,https://clinicaltrials.gov/show/NCT00281918,Leukemia,Rituximab|Cyclophosphamide|Fludarabine_Phosphate|,serious_events,arm1,Fludarabine+Cyclophosphamide+Rituximab-(FCR),13,cyclophosphamide,alkylating-agent
1941,Dermatitis_Allergic,1,402,Skin_and_subcutaneous_tissue_disorders,NCT00281918,https://clinicaltrials.gov/show/NCT00281918,Leukemia,Rituximab|Cyclophosphamide|Fludarabine_Phosphate|,serious_events,arm1,Fludarabine+Cyclophosphamide+Rituximab-(FCR),66,fludarabine,antimetabolite
1268,Drug_Hypersensitivity,2,402,Immune_system_disorders,NCT00281918,https://clinicaltrials.gov/show/NCT00281918,Leukemia,Rituximab|Cyclophosphamide|Fludarabine_Phosphate|,serious_events,arm1,Fludarabine+Cyclophosphamide+Rituximab-(FCR),66,fludarabine,antimetabolite
1941,Dermatitis_Allergic,1,402,Skin_and_subcutaneous_tissue_disorders,NCT00281918,https://clinicaltrials.gov/show/NCT00281918,Leukemia,Rituximab|Cyclophosphamide|Fludarabine_Phosphate|,serious_events,arm1,Fludarabine+Cyclophosphamide+Rituximab-(FCR),16,rituximab,monoclonal-antibody
1268,Drug_Hypersensitivity,2,402,Immune_system_disorders,NCT00281918,https://clinicaltrials.gov/show/NCT00281918,Leukemia,Rituximab|Cyclophosphamide|Fludarabine_Phosphate|,serious_events,arm1,Fludarabine+Cyclophosphamide+Rituximab-(FCR),16,rituximab,monoclonal-antibody
289,Hypersensitivity,3,62,Immune_system_disorders,NCT00282048,https://clinicaltrials.gov/show/NCT00282048,Kidney_Neoplasms|Carcinoma_Renal_Cell|,AG-013736_(axitinib),other_events,arm0,Axitinib,10,axitinib,kinase-inhibitor
288,Hypersensitivity,10,47,Immune_system_disorders,NCT00282087,https://clinicaltrials.gov/show/NCT00282087,Leiomyosarcoma|Uterine_Neoplasm|,gemcitabine_docetaxel_doxorubicin,other_events,arm0,Women-Treated-With-Adjuvant-Regimen-for-High-Risk-Uterine-LMS,,,
290,Hypersensitivity,1,50,Immune_system_disorders,NCT00283062,https://clinicaltrials.gov/show/NCT00283062,Prostatic_Neoplasms,Docetaxel_(TAXOTERE??)_Chemotherapy|Leuprolide_acetate_(_ELIGARD??)_Hormonal_Therapy|Docetaxel_(TAXOTERE??)_Chemotherapy|Leuprolide_acetate_(_ELIGARD??)_Hormonal_Therapy|Leuprolide_acetate_(_ELIGARD??)_Hormonal_Therapy|,other_events,arm0,Docetaxel-/-Leuprolide-Acetate---Immediate-Treatment-(I-CHT),78,acetate,Class_Name_Needed
290,Hypersensitivity,1,50,Immune_system_disorders,NCT00283062,https://clinicaltrials.gov/show/NCT00283062,Prostatic_Neoplasms,Docetaxel_(TAXOTERE??)_Chemotherapy|Leuprolide_acetate_(_ELIGARD??)_Hormonal_Therapy|Docetaxel_(TAXOTERE??)_Chemotherapy|Leuprolide_acetate_(_ELIGARD??)_Hormonal_Therapy|Leuprolide_acetate_(_ELIGARD??)_Hormonal_Therapy|,other_events,arm0,Docetaxel-/-Leuprolide-Acetate---Immediate-Treatment-(I-CHT),8,docetaxel,taxane
1270,Drug_hypersensitivity,1,17,Immune_system_disorders,NCT00283062,https://clinicaltrials.gov/show/NCT00283062,Prostatic_Neoplasms,Docetaxel_(TAXOTERE??)_Chemotherapy|Leuprolide_acetate_(_ELIGARD??)_Hormonal_Therapy|Docetaxel_(TAXOTERE??)_Chemotherapy|Leuprolide_acetate_(_ELIGARD??)_Hormonal_Therapy|Leuprolide_acetate_(_ELIGARD??)_Hormonal_Therapy|,other_events,arm3,Leuprolide-Acetate---Deferred-Treatment-(D-HT),78,acetate,Class_Name_Needed
2547,Allergic_Reaction,1,32,Immune_system_disorders,NCT00288067,https://clinicaltrials.gov/show/NCT00288067,Adult_Nodular_Lymphocyte_Predominant_Hodgkin_Lymphoma|B-cell_Chronic_Lymphocytic_Leukemia|Contiguous_Stage_II_Adult_Burkitt_Lymphoma|Contiguous_Stage_II_Adult_Diffuse_Large_Cell_Lymphoma|Contiguous_Stage_II_Adult_Lymphoblastic_Lymphoma|Contiguous_Stage_II,fenretinide|rituximab|,serious_events,arm0,Fenretinide-and-Rituximab,16,rituximab,monoclonal-antibody
2548,Allergic_Reaction,3,32,Immune_system_disorders,NCT00288067,https://clinicaltrials.gov/show/NCT00288067,Adult_Nodular_Lymphocyte_Predominant_Hodgkin_Lymphoma|B-cell_Chronic_Lymphocytic_Leukemia|Contiguous_Stage_II_Adult_Burkitt_Lymphoma|Contiguous_Stage_II_Adult_Diffuse_Large_Cell_Lymphoma|Contiguous_Stage_II_Adult_Lymphoblastic_Lymphoma|Contiguous_Stage_II,fenretinide|rituximab|,other_events,arm0,Fenretinide-and-Rituximab,16,rituximab,monoclonal-antibody
2549,Allergic_reaction,1,28,Immune_system_disorders,NCT00293462,https://clinicaltrials.gov/show/NCT00293462,Head_and_Neck_Cancer|Mucositis|Radiation_Toxicity|,sargramostim|oral_salt_and_soda_mouthwash|,serious_events,arm1,Arm-II:-Salt-&-Soda-Group-(SS),,,
298,Hypersensitivity,8,132,Immune_system_disorders,NCT00296816,https://clinicaltrials.gov/show/NCT00296816,Ovarian_Cancer,Bevacizumab_(Avastin??)|Docetaxel_(Taxotere??)|Oxaliplatin_(Eloxatin??)|,other_events,arm0,Oxaliplatin/Docetaxel/Bevacizumab,7,oxaliplatin,alkalating-agent
298,Hypersensitivity,8,132,Immune_system_disorders,NCT00296816,https://clinicaltrials.gov/show/NCT00296816,Ovarian_Cancer,Bevacizumab_(Avastin??)|Docetaxel_(Taxotere??)|Oxaliplatin_(Eloxatin??)|,other_events,arm0,Oxaliplatin/Docetaxel/Bevacizumab,4,bevacizumab,monoclonal-antibody
298,Hypersensitivity,8,132,Immune_system_disorders,NCT00296816,https://clinicaltrials.gov/show/NCT00296816,Ovarian_Cancer,Bevacizumab_(Avastin??)|Docetaxel_(Taxotere??)|Oxaliplatin_(Eloxatin??)|,other_events,arm0,Oxaliplatin/Docetaxel/Bevacizumab,22,bevacizumab,monoclonal-antibody
298,Hypersensitivity,8,132,Immune_system_disorders,NCT00296816,https://clinicaltrials.gov/show/NCT00296816,Ovarian_Cancer,Bevacizumab_(Avastin??)|Docetaxel_(Taxotere??)|Oxaliplatin_(Eloxatin??)|,other_events,arm0,Oxaliplatin/Docetaxel/Bevacizumab,8,docetaxel,taxane
1279,Drug_hypersensitivity,1,1094,Immune_system_disorders,NCT00297232,https://clinicaltrials.gov/show/NCT00297232,Relapsing-Remitting_Multiple_Sclerosis,Natalizumab,serious_events,arm0,Natalizumab,,,
2550,Allergic_Reaction,1,25,General_disorders,NCT00297596,https://clinicaltrials.gov/show/NCT00297596,Breast_Cancer,Trastuzumab|Oxaliplatin|,serious_events,arm0,Oxaliplatin/Trastuzumab,7,oxaliplatin,alkalating-agent
2551,Allergic_Reaction,2,25,General_disorders,NCT00297596,https://clinicaltrials.gov/show/NCT00297596,Breast_Cancer,Trastuzumab|Oxaliplatin|,other_events,arm0,Oxaliplatin/Trastuzumab,7,oxaliplatin,alkalating-agent
2550,Allergic_Reaction,1,25,General_disorders,NCT00297596,https://clinicaltrials.gov/show/NCT00297596,Breast_Cancer,Trastuzumab|Oxaliplatin|,serious_events,arm0,Oxaliplatin/Trastuzumab,18,trastuzumab,monoclonal-antibody
2551,Allergic_Reaction,2,25,General_disorders,NCT00297596,https://clinicaltrials.gov/show/NCT00297596,Breast_Cancer,Trastuzumab|Oxaliplatin|,other_events,arm0,Oxaliplatin/Trastuzumab,18,trastuzumab,monoclonal-antibody
2554,Allergic_reaction,29,463,Immune_system_disorders,NCT00300885,https://clinicaltrials.gov/show/NCT00300885,Carcinoma_Non-Small_Cell_Lung,Nexavar_(Sorafenib_BAY43-9006)_+_carboplatin_+_paclitaxel|Carboplatin_plus_Paclitaxel|,other_events,arm0,Sorafenib-+-C/P,90,sorafenib,Tyrosine-Kinase-inhibitor
2556,Allergic_reaction,11,463,Immune_system_disorders,NCT00300885,https://clinicaltrials.gov/show/NCT00300885,Carcinoma_Non-Small_Cell_Lung,Nexavar_(Sorafenib_BAY43-9006)_+_carboplatin_+_paclitaxel|Carboplatin_plus_Paclitaxel|,serious_events,arm0,Sorafenib-+-C/P,90,sorafenib,Tyrosine-Kinase-inhibitor
2553,Allergic_reaction,30,459,Immune_system_disorders,NCT00300885,https://clinicaltrials.gov/show/NCT00300885,Carcinoma_Non-Small_Cell_Lung,Nexavar_(Sorafenib_BAY43-9006)_+_carboplatin_+_paclitaxel|Carboplatin_plus_Paclitaxel|,other_events,arm1,Placebo-+-C/P,,,
2555,Allergic_reaction,4,459,Immune_system_disorders,NCT00300885,https://clinicaltrials.gov/show/NCT00300885,Carcinoma_Non-Small_Cell_Lung,Nexavar_(Sorafenib_BAY43-9006)_+_carboplatin_+_paclitaxel|Carboplatin_plus_Paclitaxel|,serious_events,arm1,Placebo-+-C/P,,,
2552,Allergic_reaction,2,47,Investigations,NCT00301028,https://clinicaltrials.gov/show/NCT00301028,Head_and_Neck_Cancer,Cetuximab|Carboplatin|Paclitaxel|Conventional_Surgery|Radiation_Therapy|,serious_events,arm0,Cetuximab-+-Carboplatin/Paclitaxel,3,carboplatin,alkalating-agent
2552,Allergic_reaction,2,47,Investigations,NCT00301028,https://clinicaltrials.gov/show/NCT00301028,Head_and_Neck_Cancer,Cetuximab|Carboplatin|Paclitaxel|Conventional_Surgery|Radiation_Therapy|,serious_events,arm0,Cetuximab-+-Carboplatin/Paclitaxel,5,cetuximab,Epidermal-growth-factor-receptor-inhibitor
2552,Allergic_reaction,2,47,Investigations,NCT00301028,https://clinicaltrials.gov/show/NCT00301028,Head_and_Neck_Cancer,Cetuximab|Carboplatin|Paclitaxel|Conventional_Surgery|Radiation_Therapy|,serious_events,arm0,Cetuximab-+-Carboplatin/Paclitaxel,2,paclitaxel,taxane
302,Hypersensitivity,2,106,Immune_system_disorders,NCT00301821,https://clinicaltrials.gov/show/NCT00301821,Lymphoma,epratuzumab|rituximab|cyclophosphamide|doxorubicin_hydrochloride|prednisone|vincristine_sulfate|,other_events,arm0,Epratuzumab-+-Rituximab-+-CHOP,16,rituximab,monoclonal-antibody
302,Hypersensitivity,2,106,Immune_system_disorders,NCT00301821,https://clinicaltrials.gov/show/NCT00301821,Lymphoma,epratuzumab|rituximab|cyclophosphamide|doxorubicin_hydrochloride|prednisone|vincristine_sulfate|,other_events,arm0,Epratuzumab-+-Rituximab-+-CHOP,58,epratuzumab,monoclonal-antibody
2561,Allergic_reaction,1,7,Immune_system_disorders,NCT00305864,https://clinicaltrials.gov/show/NCT00305864,Adult_Giant_Cell_Glioblastoma|Adult_Glioblastoma|Adult_Gliosarcoma|,3-dimensional_conformal_radiation_therapy|temozolomide|motexafin_gadolinium|,other_events,arm0,Phase-I:-MGd-3-mg/kg,,,
2560,Allergic_reaction,1,9,Immune_system_disorders,NCT00305864,https://clinicaltrials.gov/show/NCT00305864,Adult_Giant_Cell_Glioblastoma|Adult_Glioblastoma|Adult_Gliosarcoma|,3-dimensional_conformal_radiation_therapy|temozolomide|motexafin_gadolinium|,serious_events,arm1,Phase-I:-MGd-4-mg/kg,,,
2558,Allergic_reaction,3,6,Immune_system_disorders,NCT00305864,https://clinicaltrials.gov/show/NCT00305864,Adult_Giant_Cell_Glioblastoma|Adult_Glioblastoma|Adult_Gliosarcoma|,3-dimensional_conformal_radiation_therapy|temozolomide|motexafin_gadolinium|,other_events,arm2,Phase-I:-MGd-5-mg/kg,,,
2557,Allergic_reaction,4,81,Immune_system_disorders,NCT00305864,https://clinicaltrials.gov/show/NCT00305864,Adult_Giant_Cell_Glioblastoma|Adult_Glioblastoma|Adult_Gliosarcoma|,3-dimensional_conformal_radiation_therapy|temozolomide|motexafin_gadolinium|,serious_events,arm3,Phase-II:-MGd-5-mg/kg,,,
2559,Allergic_reaction,11,81,Immune_system_disorders,NCT00305864,https://clinicaltrials.gov/show/NCT00305864,Adult_Giant_Cell_Glioblastoma|Adult_Glioblastoma|Adult_Gliosarcoma|,3-dimensional_conformal_radiation_therapy|temozolomide|motexafin_gadolinium|,other_events,arm3,Phase-II:-MGd-5-mg/kg,,,
2562,Allergic_reaction,1,67,Immune_system_disorders,NCT00305877,https://clinicaltrials.gov/show/NCT00305877,Stage_IA_Pancreatic_Cancer|Stage_IB_Pancreatic_Cancer|Stage_IIA_Pancreatic_Cancer|Stage_IIB_Pancreatic_Cancer|,cetuximab|gemcitabine_hydrochloride|capecitabine|radiation_therapy|bevacizumab|laboratory_biomarker_analysis|,serious_events,arm0,Arm-A-(Cetuximab-Gemcitabine-Capecitabine-Radiation),17,capecitabine,antimetabolite
2562,Allergic_reaction,1,67,Immune_system_disorders,NCT00305877,https://clinicaltrials.gov/show/NCT00305877,Stage_IA_Pancreatic_Cancer|Stage_IB_Pancreatic_Cancer|Stage_IIA_Pancreatic_Cancer|Stage_IIB_Pancreatic_Cancer|,cetuximab|gemcitabine_hydrochloride|capecitabine|radiation_therapy|bevacizumab|laboratory_biomarker_analysis|,serious_events,arm0,Arm-A-(Cetuximab-Gemcitabine-Capecitabine-Radiation),29,capecitabine,antimetabolite
2562,Allergic_reaction,1,67,Immune_system_disorders,NCT00305877,https://clinicaltrials.gov/show/NCT00305877,Stage_IA_Pancreatic_Cancer|Stage_IB_Pancreatic_Cancer|Stage_IIA_Pancreatic_Cancer|Stage_IIB_Pancreatic_Cancer|,cetuximab|gemcitabine_hydrochloride|capecitabine|radiation_therapy|bevacizumab|laboratory_biomarker_analysis|,serious_events,arm0,Arm-A-(Cetuximab-Gemcitabine-Capecitabine-Radiation),6,gemcitabine,antimetabolites
2562,Allergic_reaction,1,67,Immune_system_disorders,NCT00305877,https://clinicaltrials.gov/show/NCT00305877,Stage_IA_Pancreatic_Cancer|Stage_IB_Pancreatic_Cancer|Stage_IIA_Pancreatic_Cancer|Stage_IIB_Pancreatic_Cancer|,cetuximab|gemcitabine_hydrochloride|capecitabine|radiation_therapy|bevacizumab|laboratory_biomarker_analysis|,serious_events,arm0,Arm-A-(Cetuximab-Gemcitabine-Capecitabine-Radiation),5,cetuximab,Epidermal-growth-factor-receptor-inhibitor
308,Hypersensitivity,1,37,Immune_system_disorders,NCT00308087,https://clinicaltrials.gov/show/NCT00308087,Lymphoma_Follicular,Sargramostim_(Leukine)|Rituximab|,other_events,arm0,Rituximab,16,rituximab,monoclonal-antibody
1286,Drug_hypersensitivity,1,38,Immune_system_disorders,NCT00308087,https://clinicaltrials.gov/show/NCT00308087,Lymphoma_Follicular,Sargramostim_(Leukine)|Rituximab|,other_events,arm1,Rituximab-+-Sargramostim,16,rituximab,monoclonal-antibody
309,Hypersensitivity,3,38,Immune_system_disorders,NCT00308087,https://clinicaltrials.gov/show/NCT00308087,Lymphoma_Follicular,Sargramostim_(Leukine)|Rituximab|,other_events,arm1,Rituximab-+-Sargramostim,16,rituximab,monoclonal-antibody
2333,Anaphylaxis,1,51,Immune_system_disorders,NCT00309946,https://clinicaltrials.gov/show/NCT00309946,Advanced_Malignant_Mesothelioma|Epithelial_Mesothelioma|Localized_Malignant_Mesothelioma|Recurrent_Malignant_Mesothelioma|Sarcomatous_Mesothelioma|,cediranib_maleate,serious_events,arm0,Treatment-(Enzyme-Inhibitor-Therapy),,,
2565,Allergic_reaction,7,1634,General_disorders,NCT00312208,https://clinicaltrials.gov/show/NCT00312208,Breast_Cancer,docetaxel_doxorubicin_cyclophosphamide|Docetaxeldoxorubicin_cyclophosphamide|,serious_events,arm0,Doxorubicin-+-Cyclophosphamide-Followed-by-Docetaxel-(AC-->-T),13,cyclophosphamide,alkylating-agent
2566,Allergic_reaction,172,1634,General_disorders,NCT00312208,https://clinicaltrials.gov/show/NCT00312208,Breast_Cancer,docetaxel_doxorubicin_cyclophosphamide|Docetaxeldoxorubicin_cyclophosphamide|,other_events,arm0,Doxorubicin-+-Cyclophosphamide-Followed-by-Docetaxel-(AC-->-T),13,cyclophosphamide,alkylating-agent
2565,Allergic_reaction,7,1634,General_disorders,NCT00312208,https://clinicaltrials.gov/show/NCT00312208,Breast_Cancer,docetaxel_doxorubicin_cyclophosphamide|Docetaxeldoxorubicin_cyclophosphamide|,serious_events,arm0,Doxorubicin-+-Cyclophosphamide-Followed-by-Docetaxel-(AC-->-T),38,doxorubicin,anthracycline-antibiotic
2566,Allergic_reaction,172,1634,General_disorders,NCT00312208,https://clinicaltrials.gov/show/NCT00312208,Breast_Cancer,docetaxel_doxorubicin_cyclophosphamide|Docetaxeldoxorubicin_cyclophosphamide|,other_events,arm0,Doxorubicin-+-Cyclophosphamide-Followed-by-Docetaxel-(AC-->-T),38,doxorubicin,anthracycline-antibiotic
2565,Allergic_reaction,7,1634,General_disorders,NCT00312208,https://clinicaltrials.gov/show/NCT00312208,Breast_Cancer,docetaxel_doxorubicin_cyclophosphamide|Docetaxeldoxorubicin_cyclophosphamide|,serious_events,arm0,Doxorubicin-+-Cyclophosphamide-Followed-by-Docetaxel-(AC-->-T),8,docetaxel,taxane
2566,Allergic_reaction,172,1634,General_disorders,NCT00312208,https://clinicaltrials.gov/show/NCT00312208,Breast_Cancer,docetaxel_doxorubicin_cyclophosphamide|Docetaxeldoxorubicin_cyclophosphamide|,other_events,arm0,Doxorubicin-+-Cyclophosphamide-Followed-by-Docetaxel-(AC-->-T),8,docetaxel,taxane
2563,Allergic_reaction,190,1635,General_disorders,NCT00312208,https://clinicaltrials.gov/show/NCT00312208,Breast_Cancer,docetaxel_doxorubicin_cyclophosphamide|Docetaxeldoxorubicin_cyclophosphamide|,other_events,arm1,Docetaxel-+-Doxorubicin-and-Cyclophosphamide-(TAC),13,cyclophosphamide,alkylating-agent
2564,Allergic_reaction,5,1635,General_disorders,NCT00312208,https://clinicaltrials.gov/show/NCT00312208,Breast_Cancer,docetaxel_doxorubicin_cyclophosphamide|Docetaxeldoxorubicin_cyclophosphamide|,serious_events,arm1,Docetaxel-+-Doxorubicin-and-Cyclophosphamide-(TAC),13,cyclophosphamide,alkylating-agent
2563,Allergic_reaction,190,1635,General_disorders,NCT00312208,https://clinicaltrials.gov/show/NCT00312208,Breast_Cancer,docetaxel_doxorubicin_cyclophosphamide|Docetaxeldoxorubicin_cyclophosphamide|,other_events,arm1,Docetaxel-+-Doxorubicin-and-Cyclophosphamide-(TAC),38,doxorubicin,anthracycline-antibiotic
2564,Allergic_reaction,5,1635,General_disorders,NCT00312208,https://clinicaltrials.gov/show/NCT00312208,Breast_Cancer,docetaxel_doxorubicin_cyclophosphamide|Docetaxeldoxorubicin_cyclophosphamide|,serious_events,arm1,Docetaxel-+-Doxorubicin-and-Cyclophosphamide-(TAC),38,doxorubicin,anthracycline-antibiotic
2563,Allergic_reaction,190,1635,General_disorders,NCT00312208,https://clinicaltrials.gov/show/NCT00312208,Breast_Cancer,docetaxel_doxorubicin_cyclophosphamide|Docetaxeldoxorubicin_cyclophosphamide|,other_events,arm1,Docetaxel-+-Doxorubicin-and-Cyclophosphamide-(TAC),8,docetaxel,taxane
2564,Allergic_reaction,5,1635,General_disorders,NCT00312208,https://clinicaltrials.gov/show/NCT00312208,Breast_Cancer,docetaxel_doxorubicin_cyclophosphamide|Docetaxeldoxorubicin_cyclophosphamide|,serious_events,arm1,Docetaxel-+-Doxorubicin-and-Cyclophosphamide-(TAC),8,docetaxel,taxane
1287,Drug_Hypersensitivity,2,694,Immune_system_disorders,NCT00312377,https://clinicaltrials.gov/show/NCT00312377,Non-small_Cell_Lung_Cancer|Lung_Cancer|,Docetaxel|Vandetanib|,serious_events,arm0,Vandetanib-100-mg-Plus-Docetaxel,8,docetaxel,taxane
1287,Drug_Hypersensitivity,2,694,Immune_system_disorders,NCT00312377,https://clinicaltrials.gov/show/NCT00312377,Non-small_Cell_Lung_Cancer|Lung_Cancer|,Docetaxel|Vandetanib|,serious_events,arm0,Vandetanib-100-mg-Plus-Docetaxel,33,vandetanib,tyrosine-kinase-inhibitor
1288,Drug_Hypersensitivity,1,697,Immune_system_disorders,NCT00312377,https://clinicaltrials.gov/show/NCT00312377,Non-small_Cell_Lung_Cancer|Lung_Cancer|,Docetaxel|Vandetanib|,serious_events,arm1,Placebo-Plus-Docetaxel,8,docetaxel,taxane
313,Hypersensitivity,4,334,Immune_system_disorders,NCT00312845,https://clinicaltrials.gov/show/NCT00312845,Non-Hodgkin's_Lymphoma,Bortezomib_+_Rituximab|Rituximab|,serious_events,arm0,Bortezomib-+-Rituximab,16,rituximab,monoclonal-antibody
313,Hypersensitivity,4,334,Immune_system_disorders,NCT00312845,https://clinicaltrials.gov/show/NCT00312845,Non-Hodgkin's_Lymphoma,Bortezomib_+_Rituximab|Rituximab|,serious_events,arm0,Bortezomib-+-Rituximab,70,bortezomib,proteasome-inhibitor
1950,Dermatitis_allergic,1,339,Skin_and_subcutaneous_tissue_disorders,NCT00312845,https://clinicaltrials.gov/show/NCT00312845,Non-Hodgkin's_Lymphoma,Bortezomib_+_Rituximab|Rituximab|,serious_events,arm1,Rituximab,16,rituximab,monoclonal-antibody
312,Hypersensitivity,1,339,Immune_system_disorders,NCT00312845,https://clinicaltrials.gov/show/NCT00312845,Non-Hodgkin's_Lymphoma,Bortezomib_+_Rituximab|Rituximab|,serious_events,arm1,Rituximab,16,rituximab,monoclonal-antibody
1956,Dermatitis_allergic,1,97,Skin_and_subcutaneous_tissue_disorders,NCT00313781,https://clinicaltrials.gov/show/NCT00313781,Prostatic_Neoplasms,CP-751871|docetaxel|prednisone|docetaxel|prednisone|,other_events,arm0,CP-751871+Docetaxel+Prednisone,85,prednisone,steroid
316,Hypersensitivity,2,97,Immune_system_disorders,NCT00313781,https://clinicaltrials.gov/show/NCT00313781,Prostatic_Neoplasms,CP-751871|docetaxel|prednisone|docetaxel|prednisone|,other_events,arm0,CP-751871+Docetaxel+Prednisone,85,prednisone,steroid
317,Hypersensitivity,1,97,Immune_system_disorders,NCT00313781,https://clinicaltrials.gov/show/NCT00313781,Prostatic_Neoplasms,CP-751871|docetaxel|prednisone|docetaxel|prednisone|,serious_events,arm0,CP-751871+Docetaxel+Prednisone,85,prednisone,steroid
1956,Dermatitis_allergic,1,97,Skin_and_subcutaneous_tissue_disorders,NCT00313781,https://clinicaltrials.gov/show/NCT00313781,Prostatic_Neoplasms,CP-751871|docetaxel|prednisone|docetaxel|prednisone|,other_events,arm0,CP-751871+Docetaxel+Prednisone,8,docetaxel,taxane
316,Hypersensitivity,2,97,Immune_system_disorders,NCT00313781,https://clinicaltrials.gov/show/NCT00313781,Prostatic_Neoplasms,CP-751871|docetaxel|prednisone|docetaxel|prednisone|,other_events,arm0,CP-751871+Docetaxel+Prednisone,8,docetaxel,taxane
317,Hypersensitivity,1,97,Immune_system_disorders,NCT00313781,https://clinicaltrials.gov/show/NCT00313781,Prostatic_Neoplasms,CP-751871|docetaxel|prednisone|docetaxel|prednisone|,serious_events,arm0,CP-751871+Docetaxel+Prednisone,8,docetaxel,taxane
1955,Dermatitis_allergic,1,102,Skin_and_subcutaneous_tissue_disorders,NCT00313781,https://clinicaltrials.gov/show/NCT00313781,Prostatic_Neoplasms,CP-751871|docetaxel|prednisone|docetaxel|prednisone|,other_events,arm1,Docetaxel+Prednisone,85,prednisone,steroid
1290,Drug_hypersensitivity,1,102,Immune_system_disorders,NCT00313781,https://clinicaltrials.gov/show/NCT00313781,Prostatic_Neoplasms,CP-751871|docetaxel|prednisone|docetaxel|prednisone|,other_events,arm1,Docetaxel+Prednisone,85,prednisone,steroid
315,Hypersensitivity,1,102,Immune_system_disorders,NCT00313781,https://clinicaltrials.gov/show/NCT00313781,Prostatic_Neoplasms,CP-751871|docetaxel|prednisone|docetaxel|prednisone|,serious_events,arm1,Docetaxel+Prednisone,85,prednisone,steroid
1955,Dermatitis_allergic,1,102,Skin_and_subcutaneous_tissue_disorders,NCT00313781,https://clinicaltrials.gov/show/NCT00313781,Prostatic_Neoplasms,CP-751871|docetaxel|prednisone|docetaxel|prednisone|,other_events,arm1,Docetaxel+Prednisone,8,docetaxel,taxane
1290,Drug_hypersensitivity,1,102,Immune_system_disorders,NCT00313781,https://clinicaltrials.gov/show/NCT00313781,Prostatic_Neoplasms,CP-751871|docetaxel|prednisone|docetaxel|prednisone|,other_events,arm1,Docetaxel+Prednisone,8,docetaxel,taxane
315,Hypersensitivity,1,102,Immune_system_disorders,NCT00313781,https://clinicaltrials.gov/show/NCT00313781,Prostatic_Neoplasms,CP-751871|docetaxel|prednisone|docetaxel|prednisone|,serious_events,arm1,Docetaxel+Prednisone,8,docetaxel,taxane
318,Hypersensitivity,1,18,Immune_system_disorders,NCT00314106,https://clinicaltrials.gov/show/NCT00314106,Metastatic_Melanoma,Melanoma_Reactive_TIL|Cyclophosphamide|IL-2|Fludarabine|1200_total_body_irradiation_(TBI)|,serious_events,arm0,TBI-1200-cGy-+-TIL-+HD-IL-2-Prior-IL-2,,,
1295,Drug_hypersensitivity,1,3,Immune_system_disorders,NCT00315705,https://clinicaltrials.gov/show/NCT00315705,Acute_Lymphoblastic_Leukemia|Acute_Myelogenous_Leukemia|Relapsed_Leukemia|,clofarabine|Etoposide|Cyclophosphamide|,serious_events,arm1,Phase-1---Cohort-2,,,
1293,Drug_hypersensitivity,2,10,Immune_system_disorders,NCT00315705,https://clinicaltrials.gov/show/NCT00315705,Acute_Lymphoblastic_Leukemia|Acute_Myelogenous_Leukemia|Relapsed_Leukemia|,clofarabine|Etoposide|Cyclophosphamide|,other_events,arm3,Phase-1---Cohort-4,,,
1292,Drug_hypersensitivity,2,25,Immune_system_disorders,NCT00315705,https://clinicaltrials.gov/show/NCT00315705,Acute_Lymphoblastic_Leukemia|Acute_Myelogenous_Leukemia|Relapsed_Leukemia|,clofarabine|Etoposide|Cyclophosphamide|,other_events,arm5,Phase-1---Total,,,
1294,Drug_hypersensitivity,1,25,Immune_system_disorders,NCT00315705,https://clinicaltrials.gov/show/NCT00315705,Acute_Lymphoblastic_Leukemia|Acute_Myelogenous_Leukemia|Relapsed_Leukemia|,clofarabine|Etoposide|Cyclophosphamide|,serious_events,arm5,Phase-1---Total,,,
319,Hypersensitivity,1,15,Immune_system_disorders,NCT00315731,https://clinicaltrials.gov/show/NCT00315731,Lymphoma_Follicular,Follicular_Lymphoma,other_events,arm0,Tositumomab-and-Fission-derived-Iodine-I-131-Tositumomab,53,iodine,Class_Name_Needed
1296,Drug_hypersensitivity,2,22,Immune_system_disorders,NCT00316173,https://clinicaltrials.gov/show/NCT00316173,Ovarian_Cancer|Neoplasms_Ovarian|,topotecan|CARBOPLATIN|,other_events,arm0,Dose-finding-Phase,,,
1297,Drug_hypersensitivity,1,55,Immune_system_disorders,NCT00316173,https://clinicaltrials.gov/show/NCT00316173,Ovarian_Cancer|Neoplasms_Ovarian|,topotecan|CARBOPLATIN|,serious_events,arm1,Activity-Assessment-Phase,,,
1298,Drug_hypersensitivity,12,55,Immune_system_disorders,NCT00316173,https://clinicaltrials.gov/show/NCT00316173,Ovarian_Cancer|Neoplasms_Ovarian|,topotecan|CARBOPLATIN|,other_events,arm1,Activity-Assessment-Phase,,,
320,Hypersensitivity,4,50,Immune_system_disorders,NCT00316914,https://clinicaltrials.gov/show/NCT00316914,Colorectal_Cancer|Neurotoxicity|,calcium_gluconate|magnesium_sulfate|placebo|,other_events,arm0,Ca/Mg,,,
1958,Dermatitis_allergic,1,161,Skin_and_subcutaneous_tissue_disorders,NCT00317642,https://clinicaltrials.gov/show/NCT00317642,Acute_Myelogenous_Leukemia,clofarabine_(IV_formulation)|placebo|cytarabine|,other_events,arm0,Clofarabine-(IV-Formulation)-and-Cytarabine,37,clofarabine,antimetabolite
1301,Drug_hypersensitivity,9,161,Immune_system_disorders,NCT00317642,https://clinicaltrials.gov/show/NCT00317642,Acute_Myelogenous_Leukemia,clofarabine_(IV_formulation)|placebo|cytarabine|,other_events,arm0,Clofarabine-(IV-Formulation)-and-Cytarabine,37,clofarabine,antimetabolite
1958,Dermatitis_allergic,1,161,Skin_and_subcutaneous_tissue_disorders,NCT00317642,https://clinicaltrials.gov/show/NCT00317642,Acute_Myelogenous_Leukemia,clofarabine_(IV_formulation)|placebo|cytarabine|,other_events,arm0,Clofarabine-(IV-Formulation)-and-Cytarabine,52,cytarabine,antimetabolite
1301,Drug_hypersensitivity,9,161,Immune_system_disorders,NCT00317642,https://clinicaltrials.gov/show/NCT00317642,Acute_Myelogenous_Leukemia,clofarabine_(IV_formulation)|placebo|cytarabine|,other_events,arm0,Clofarabine-(IV-Formulation)-and-Cytarabine,52,cytarabine,antimetabolite
1300,Drug_hypersensitivity,1,155,Immune_system_disorders,NCT00317642,https://clinicaltrials.gov/show/NCT00317642,Acute_Myelogenous_Leukemia,clofarabine_(IV_formulation)|placebo|cytarabine|,other_events,arm1,Placebo-and-Cytarabine,52,cytarabine,antimetabolite
1959,Dermatitis_allergic,1,316,Skin_and_subcutaneous_tissue_disorders,NCT00317642,https://clinicaltrials.gov/show/NCT00317642,Acute_Myelogenous_Leukemia,clofarabine_(IV_formulation)|placebo|cytarabine|,other_events,arm2,Overall,,,
1302,Drug_hypersensitivity,10,316,Immune_system_disorders,NCT00317642,https://clinicaltrials.gov/show/NCT00317642,Acute_Myelogenous_Leukemia,clofarabine_(IV_formulation)|placebo|cytarabine|,other_events,arm2,Overall,,,
1957,Dermatitis_allergic,1,65,Skin_and_subcutaneous_tissue_disorders,NCT00317941,https://clinicaltrials.gov/show/NCT00317941,Relapsing-remitting_Multiple_Sclerosis,Betaferon/Betaseron|Rebif|Betaferon/Betaseron|,other_events,arm1,IFNB-1a-44-Mcg-(Rebif)-Via-Rebiject-II,,,
321,Hypersensitivity,3,54,Immune_system_disorders,NCT00318370,https://clinicaltrials.gov/show/NCT00318370,Ovarian_Cancer|Fallopian_Tube_Cancer|Peritoneal_Neoplasms|,Farletuzumab|Chemo_Plus_Far|,other_events,arm0,Far-Only-and-Chemo-Plus-Far-and-Maintenance-Far-Only,88,maintenance,Class_Name_Needed
322,Hypersensitivity,1,58,Injury_poisoning_and_procedural_complications,NCT00320411,https://clinicaltrials.gov/show/NCT00320411,Neoplasms_Breast,lapatinib,other_events,arm0,Lapatinib-Monotherapy,21,lapatinib,signal-transduction-inhibitor
1303,Drug_hypersensitivity,1,1013,Immune_system_disorders,NCT00321464,https://clinicaltrials.gov/show/NCT00321464,Bone_Metastases,Denosumab|Zoledronic_Acid|,serious_events,arm0,Zoledronic-Acid-4-mg-Q4W,28,zoledronic,bisphosphonates-(supportive-treatment-of-cancer--treats-symptoms-and/or-decreases-complications)
2567,Allergic_reaction,1,41,Immune_system_disorders,NCT00321646,https://clinicaltrials.gov/show/NCT00321646,Prostate_Cancer|Adenocarcinoma_of_the_Prostate|,Bevacizumab|Docetaxel|,serious_events,arm0,Chemotherapy,,,
2568,Allergic_reaction,5,41,Immune_system_disorders,NCT00321646,https://clinicaltrials.gov/show/NCT00321646,Prostate_Cancer|Adenocarcinoma_of_the_Prostate|,Bevacizumab|Docetaxel|,other_events,arm0,Chemotherapy,,,
2569,Allergic_reaction,1,55,Immune_system_disorders,NCT00321685,https://clinicaltrials.gov/show/NCT00321685,Adenocarcinoma_of_the_Rectum|Stage_II_Rectal_Cancer|Stage_III_Rectal_Cancer|,radiation_therapy|capecitabine|oxaliplatin|bevacizumab|surgery|leucovorin_calcium|fluorouracil|,serious_events,arm0,Arm-I,,,
1304,Drug_hypersensitivity,1,14,Immune_system_disorders,NCT00321711,https://clinicaltrials.gov/show/NCT00321711,MDS|Myelodysplastic_Syndromes|Thrombocytopenia|,Placebo|AMG_531_(Romiplostim)|Azacitidine|Decitabine|,other_events,arm2,Part-A-Romiplostim-750-??g,84,romiplostim,Class_Name_Needed
323,Hypersensitivity,1,14,Immune_system_disorders,NCT00321711,https://clinicaltrials.gov/show/NCT00321711,MDS|Myelodysplastic_Syndromes|Thrombocytopenia|,Placebo|AMG_531_(Romiplostim)|Azacitidine|Decitabine|,other_events,arm2,Part-A-Romiplostim-750-??g,84,romiplostim,Class_Name_Needed
324,Hypersensitivity,1,14,Immune_system_disorders,NCT00321711,https://clinicaltrials.gov/show/NCT00321711,MDS|Myelodysplastic_Syndromes|Thrombocytopenia|,Placebo|AMG_531_(Romiplostim)|Azacitidine|Decitabine|,serious_events,arm2,Part-A-Romiplostim-750-??g,84,romiplostim,Class_Name_Needed
1961,Dermatitis_allergic,1,15,Skin_and_subcutaneous_tissue_disorders,NCT00321711,https://clinicaltrials.gov/show/NCT00321711,MDS|Myelodysplastic_Syndromes|Thrombocytopenia|,Placebo|AMG_531_(Romiplostim)|Azacitidine|Decitabine|,other_events,arm4,Part-B-Romiplostim-750-??g,84,romiplostim,Class_Name_Needed
2334,Anaphylaxis,9,89,Immune_system_disorders,NCT00321828,https://clinicaltrials.gov/show/NCT00321828,Colorectal_Cancer,bevacizumab|fluorouracil|leucovorin|oxaliplatin|,other_events,arm0,Oxaliplatin-+-Leucovorin-+-5-Fluorouracil-+-Bevacizumab,7,oxaliplatin,alkalating-agent
2334,Anaphylaxis,9,89,Immune_system_disorders,NCT00321828,https://clinicaltrials.gov/show/NCT00321828,Colorectal_Cancer,bevacizumab|fluorouracil|leucovorin|oxaliplatin|,other_events,arm0,Oxaliplatin-+-Leucovorin-+-5-Fluorouracil-+-Bevacizumab,11,fluorouracil,antimetabolites
2334,Anaphylaxis,9,89,Immune_system_disorders,NCT00321828,https://clinicaltrials.gov/show/NCT00321828,Colorectal_Cancer,bevacizumab|fluorouracil|leucovorin|oxaliplatin|,other_events,arm0,Oxaliplatin-+-Leucovorin-+-5-Fluorouracil-+-Bevacizumab,20,leucovorin,chemoprotectant
2334,Anaphylaxis,9,89,Immune_system_disorders,NCT00321828,https://clinicaltrials.gov/show/NCT00321828,Colorectal_Cancer,bevacizumab|fluorouracil|leucovorin|oxaliplatin|,other_events,arm0,Oxaliplatin-+-Leucovorin-+-5-Fluorouracil-+-Bevacizumab,4,bevacizumab,monoclonal-antibody
2334,Anaphylaxis,9,89,Immune_system_disorders,NCT00321828,https://clinicaltrials.gov/show/NCT00321828,Colorectal_Cancer,bevacizumab|fluorouracil|leucovorin|oxaliplatin|,other_events,arm0,Oxaliplatin-+-Leucovorin-+-5-Fluorouracil-+-Bevacizumab,22,bevacizumab,monoclonal-antibody
2570,Allergic_Reaction,1,98,Immune_system_disorders,NCT00321893,https://clinicaltrials.gov/show/NCT00321893,Lung_Cancer,Budesonide|Placebo|,other_events,arm0,Arm-I:-Budesonide,,,
325,HYPERSENSITIVITY,1,6,Immune_system_disorders,NCT00322374,https://clinicaltrials.gov/show/NCT00322374,Metastatic_Breast_Cancer,Ixabepilone|Epirubicin|,serious_events,arm0,Ixabepilone-25-mg^m2-+-Epirubicin-75-mg^m2,59,epirubicin,anthracyline-antitumor-antibiotic
325,HYPERSENSITIVITY,1,6,Immune_system_disorders,NCT00322374,https://clinicaltrials.gov/show/NCT00322374,Metastatic_Breast_Cancer,Ixabepilone|Epirubicin|,serious_events,arm0,Ixabepilone-25-mg^m2-+-Epirubicin-75-mg^m2,82,ixabepilone,antimicrotubule-agent
326,HYPERSENSITIVITY,3,30,Immune_system_disorders,NCT00322374,https://clinicaltrials.gov/show/NCT00322374,Metastatic_Breast_Cancer,Ixabepilone|Epirubicin|,other_events,arm1,Ixabepilone-30-mg^m2-+-Epirubicin-75-mg^m2,59,epirubicin,anthracyline-antitumor-antibiotic
326,HYPERSENSITIVITY,3,30,Immune_system_disorders,NCT00322374,https://clinicaltrials.gov/show/NCT00322374,Metastatic_Breast_Cancer,Ixabepilone|Epirubicin|,other_events,arm1,Ixabepilone-30-mg^m2-+-Epirubicin-75-mg^m2,82,ixabepilone,antimicrotubule-agent
1306,Drug_Hypersensitivity,1,607,Immune_system_disorders,NCT00322452,https://clinicaltrials.gov/show/NCT00322452,Non-Small_Cell_Lung_Cancer,Gefitinib|Carboplatin|Paclitaxel|,serious_events,arm0,Gefitinib,,,
1305,Drug_Hypersensitivity,3,589,Immune_system_disorders,NCT00322452,https://clinicaltrials.gov/show/NCT00322452,Non-Small_Cell_Lung_Cancer,Gefitinib|Carboplatin|Paclitaxel|,serious_events,arm1,Carboplatin/Paclitaxel,3,carboplatin,alkalating-agent
1305,Drug_Hypersensitivity,3,589,Immune_system_disorders,NCT00322452,https://clinicaltrials.gov/show/NCT00322452,Non-Small_Cell_Lung_Cancer,Gefitinib|Carboplatin|Paclitaxel|,serious_events,arm1,Carboplatin/Paclitaxel,2,paclitaxel,taxane
330,Hypersensitivity,13,247,Immune_system_disorders,NCT00324155,https://clinicaltrials.gov/show/NCT00324155,Melanoma,Ipilimumab|Placebo|Dacarbazine|,other_events,arm0,10-mg/kg-Ipilimumab-+-Dacarbazine,64,ipilimumab,monoclonal-antibody
331,Hypersensitivity,2,247,Immune_system_disorders,NCT00324155,https://clinicaltrials.gov/show/NCT00324155,Melanoma,Ipilimumab|Placebo|Dacarbazine|,serious_events,arm0,10-mg/kg-Ipilimumab-+-Dacarbazine,64,ipilimumab,monoclonal-antibody
329,Hypersensitivity,6,251,Immune_system_disorders,NCT00324155,https://clinicaltrials.gov/show/NCT00324155,Melanoma,Ipilimumab|Placebo|Dacarbazine|,other_events,arm1,Placebo-+-Dacarbazine,,,
2571,Allergic_reaction,1,50,Immune_system_disorders,NCT00326495,https://clinicaltrials.gov/show/NCT00326495,Metastatic_Colorectal_Cancer,Cetuximab|BAY_43-9006|,other_events,arm0,BAY-43-9006-&-Cetuximab,5,cetuximab,Epidermal-growth-factor-receptor-inhibitor
2335,Anaphylaxis,1,50,Immune_system_disorders,NCT00326495,https://clinicaltrials.gov/show/NCT00326495,Metastatic_Colorectal_Cancer,Cetuximab|BAY_43-9006|,serious_events,arm0,BAY-43-9006-&-Cetuximab,5,cetuximab,Epidermal-growth-factor-receptor-inhibitor
333,Hypersensitivity,1,26,Immune_system_disorders,NCT00326872,https://clinicaltrials.gov/show/NCT00326872,Neurofibromatosis_Type_1|Plexiform_Neurofibroma|Spinal_Cord_Neurofibroma|,Cediranib_Maleate,other_events,arm0,Treatment-(Cediranib-Maleate),14,cediranib,endothelial-growith-factor-receptor-tyrosine-kinase-inhibitor?
1308,Drug_hypersensitivity,1,107,Immune_system_disorders,NCT00327470,https://clinicaltrials.gov/show/NCT00327470,Age_Related_Macular_Degeneration_(AMD)|Macular_Degeneration|Choroidal_Neovascularization_(CNV)|,Pegaptanib_Sodium_0.3_mg,other_events,arm0,Early-AMD,,,
1309,Drug_hypersensitivity,2,179,Immune_system_disorders,NCT00327470,https://clinicaltrials.gov/show/NCT00327470,Age_Related_Macular_Degeneration_(AMD)|Macular_Degeneration|Choroidal_Neovascularization_(CNV)|,Pegaptanib_Sodium_0.3_mg,other_events,arm1,Established-AMD,,,
334,Hypersensitivity,1,179,Immune_system_disorders,NCT00327470,https://clinicaltrials.gov/show/NCT00327470,Age_Related_Macular_Degeneration_(AMD)|Macular_Degeneration|Choroidal_Neovascularization_(CNV)|,Pegaptanib_Sodium_0.3_mg,other_events,arm1,Established-AMD,,,
1964,Dermatitis_allergic,1,86,Skin_and_subcutaneous_tissue_disorders,NCT00328198,https://clinicaltrials.gov/show/NCT00328198,B-Cell_Chronic_Lymphocytic_Leukemia_(B-CLL),Alemtuzumab|Alemtuzumab|,other_events,arm0,Alemtuzumab-30mg,76,alemtuzumab,monoclonal-antibody
1310,Drug_hypersensitivity,1,86,Immune_system_disorders,NCT00328198,https://clinicaltrials.gov/show/NCT00328198,B-Cell_Chronic_Lymphocytic_Leukemia_(B-CLL),Alemtuzumab|Alemtuzumab|,other_events,arm0,Alemtuzumab-30mg,76,alemtuzumab,monoclonal-antibody
335,Hypersensitivity,1,86,Immune_system_disorders,NCT00328198,https://clinicaltrials.gov/show/NCT00328198,B-Cell_Chronic_Lymphocytic_Leukemia_(B-CLL),Alemtuzumab|Alemtuzumab|,serious_events,arm0,Alemtuzumab-30mg,76,alemtuzumab,monoclonal-antibody
336,Hypersensitivity,1,86,Immune_system_disorders,NCT00328198,https://clinicaltrials.gov/show/NCT00328198,B-Cell_Chronic_Lymphocytic_Leukemia_(B-CLL),Alemtuzumab|Alemtuzumab|,other_events,arm0,Alemtuzumab-30mg,76,alemtuzumab,monoclonal-antibody
337,hypersensitivity,1,14,Immune_system_disorders,NCT00329108,https://clinicaltrials.gov/show/NCT00329108,Acute_Mania|Bipolar_Disorder_Manic|,ziprasidone_hydrochloride|olanzapine|,other_events,arm1,Olanzapine,,,
339,Hypersensitivity,2,29,General_disorders,NCT00330161,https://clinicaltrials.gov/show/NCT00330161,Recurrent_Prostate_Cancer|Stage_IV_Prostate_Cancer|,vorinostat|laboratory_biomarker_analysis|,other_events,arm0,Treatment-(Vorinostat),,,
1315,Drug_hypersensitivity,3,878,Immune_system_disorders,NCT00330759,https://clinicaltrials.gov/show/NCT00330759,Bone_Metastases,Denosumab|Zoledronic_Acid|,serious_events,arm1,Denosumab-120-mg-Q4W,,,
340,Hypersensitivity,1,878,Immune_system_disorders,NCT00330759,https://clinicaltrials.gov/show/NCT00330759,Bone_Metastases,Denosumab|Zoledronic_Acid|,serious_events,arm1,Denosumab-120-mg-Q4W,,,
1316,Drug_hypersensitivity,1,551,Immune_system_disorders,NCT00333840,https://clinicaltrials.gov/show/NCT00333840,Chronic_Myelogenous_Leukemia,imatinib_mesilate|interferon-alpha_(INF-a)|cytarabine_(ARA-C)|,serious_events,arm0,Imatinib-(STI571),,,
341,Hypersensitivity,1,544,Immune_system_disorders,NCT00337103,https://clinicaltrials.gov/show/NCT00337103,Metastatic_Breast_Cancer,Eribulin_Mesylate|Capecitabine|,serious_events,arm0,Eribulin-Mesylate-1.4-mg/m^2,,,
342,Hypersensitivity,1,546,Immune_system_disorders,NCT00337103,https://clinicaltrials.gov/show/NCT00337103,Metastatic_Breast_Cancer,Eribulin_Mesylate|Capecitabine|,serious_events,arm1,Capecitabine-2.5-g/m^2/Day,17,capecitabine,antimetabolite
342,Hypersensitivity,1,546,Immune_system_disorders,NCT00337103,https://clinicaltrials.gov/show/NCT00337103,Metastatic_Breast_Cancer,Eribulin_Mesylate|Capecitabine|,serious_events,arm1,Capecitabine-2.5-g/m^2/Day,29,capecitabine,antimetabolite
343,Hypersensitivity,2,23,Immune_system_disorders,NCT00337194,https://clinicaltrials.gov/show/NCT00337194,Adult_Lymphocyte_Depletion_Hodgkin_Lymphoma|Adult_Lymphocyte_Predominant_Hodgkin_Lymphoma|Adult_Mixed_Cellularity_Hodgkin_Lymphoma|Adult_Nodular_Sclerosis_Hodgkin_Lymphoma|Recurrent_Adult_Hodgkin_Lymphoma|,monoclonal_antibody_SGN-30|placebo|vinorelbine_tartrate|pegylated_liposomal_doxorubicin_hydrochloride|gemcitabine_hydrochloride|laboratory_biomarker_analysis|pharmacological_study|,other_events,arm0,Arm-I-(SGN-30-Chemotherapy),,,
2572,Allergic_Reaction,1,18,Immune_system_disorders,NCT00338988,https://clinicaltrials.gov/show/NCT00338988,Cancer_of_the_Gallbladder|Cancer_of_the_Biliary_Tract|,Capecitabine|Oxaliplatin|,serious_events,arm0,Stratum:-1-Prior-Regimen,,,
1318,Drug_hypersensitivity,1,9,Immune_system_disorders,NCT00339144,https://clinicaltrials.gov/show/NCT00339144,Tumors,Dasatinib|Dasatinib|Dasatinib|,other_events,arm0,Dasatinib-100-mg,24,dasatinib,signal-transduction-inhibitor---tyrosine-kinase-inhibitor
1319,Drug_hypersensitivity,1,594,Immune_system_disorders,NCT00339183,https://clinicaltrials.gov/show/NCT00339183,Metastatic_Colorectal_Cancer,Panitumumab|FOLFIRI|,serious_events,arm1,FOLFIRI-Alone,45,folfiri,combination-drug-with-Irinotecan--Flourouracil--and-Leucovorin
345,Hypersensitivity,1,58,Immune_system_disorders,NCT00343291,https://clinicaltrials.gov/show/NCT00343291,Non-Small_Cell_Lung_Cancer,Cetuximab|Bevacizumab|Paclitaxel|Carboplatin|,serious_events,arm0,Cetuximab-+-Bevacizumab-+-Paclitaxel-+-Carboplatin-(6/6),3,carboplatin,alkalating-agent
346,Hypersensitivity,2,58,Immune_system_disorders,NCT00343291,https://clinicaltrials.gov/show/NCT00343291,Non-Small_Cell_Lung_Cancer,Cetuximab|Bevacizumab|Paclitaxel|Carboplatin|,other_events,arm0,Cetuximab-+-Bevacizumab-+-Paclitaxel-+-Carboplatin-(6/6),3,carboplatin,alkalating-agent
345,Hypersensitivity,1,58,Immune_system_disorders,NCT00343291,https://clinicaltrials.gov/show/NCT00343291,Non-Small_Cell_Lung_Cancer,Cetuximab|Bevacizumab|Paclitaxel|Carboplatin|,serious_events,arm0,Cetuximab-+-Bevacizumab-+-Paclitaxel-+-Carboplatin-(6/6),5,cetuximab,Epidermal-growth-factor-receptor-inhibitor
346,Hypersensitivity,2,58,Immune_system_disorders,NCT00343291,https://clinicaltrials.gov/show/NCT00343291,Non-Small_Cell_Lung_Cancer,Cetuximab|Bevacizumab|Paclitaxel|Carboplatin|,other_events,arm0,Cetuximab-+-Bevacizumab-+-Paclitaxel-+-Carboplatin-(6/6),5,cetuximab,Epidermal-growth-factor-receptor-inhibitor
345,Hypersensitivity,1,58,Immune_system_disorders,NCT00343291,https://clinicaltrials.gov/show/NCT00343291,Non-Small_Cell_Lung_Cancer,Cetuximab|Bevacizumab|Paclitaxel|Carboplatin|,serious_events,arm0,Cetuximab-+-Bevacizumab-+-Paclitaxel-+-Carboplatin-(6/6),4,bevacizumab,monoclonal-antibody
346,Hypersensitivity,2,58,Immune_system_disorders,NCT00343291,https://clinicaltrials.gov/show/NCT00343291,Non-Small_Cell_Lung_Cancer,Cetuximab|Bevacizumab|Paclitaxel|Carboplatin|,other_events,arm0,Cetuximab-+-Bevacizumab-+-Paclitaxel-+-Carboplatin-(6/6),4,bevacizumab,monoclonal-antibody
345,Hypersensitivity,1,58,Immune_system_disorders,NCT00343291,https://clinicaltrials.gov/show/NCT00343291,Non-Small_Cell_Lung_Cancer,Cetuximab|Bevacizumab|Paclitaxel|Carboplatin|,serious_events,arm0,Cetuximab-+-Bevacizumab-+-Paclitaxel-+-Carboplatin-(6/6),22,bevacizumab,monoclonal-antibody
346,Hypersensitivity,2,58,Immune_system_disorders,NCT00343291,https://clinicaltrials.gov/show/NCT00343291,Non-Small_Cell_Lung_Cancer,Cetuximab|Bevacizumab|Paclitaxel|Carboplatin|,other_events,arm0,Cetuximab-+-Bevacizumab-+-Paclitaxel-+-Carboplatin-(6/6),22,bevacizumab,monoclonal-antibody
345,Hypersensitivity,1,58,Immune_system_disorders,NCT00343291,https://clinicaltrials.gov/show/NCT00343291,Non-Small_Cell_Lung_Cancer,Cetuximab|Bevacizumab|Paclitaxel|Carboplatin|,serious_events,arm0,Cetuximab-+-Bevacizumab-+-Paclitaxel-+-Carboplatin-(6/6),2,paclitaxel,taxane
346,Hypersensitivity,2,58,Immune_system_disorders,NCT00343291,https://clinicaltrials.gov/show/NCT00343291,Non-Small_Cell_Lung_Cancer,Cetuximab|Bevacizumab|Paclitaxel|Carboplatin|,other_events,arm0,Cetuximab-+-Bevacizumab-+-Paclitaxel-+-Carboplatin-(6/6),2,paclitaxel,taxane
344,Hypersensitivity,3,58,Immune_system_disorders,NCT00343291,https://clinicaltrials.gov/show/NCT00343291,Non-Small_Cell_Lung_Cancer,Cetuximab|Bevacizumab|Paclitaxel|Carboplatin|,serious_events,arm1,Cetuximab-+-Bevacizumab-+-Paclitaxel-+-Carboplatin-(6/3),3,carboplatin,alkalating-agent
347,Hypersensitivity,5,58,Immune_system_disorders,NCT00343291,https://clinicaltrials.gov/show/NCT00343291,Non-Small_Cell_Lung_Cancer,Cetuximab|Bevacizumab|Paclitaxel|Carboplatin|,other_events,arm1,Cetuximab-+-Bevacizumab-+-Paclitaxel-+-Carboplatin-(6/3),3,carboplatin,alkalating-agent
344,Hypersensitivity,3,58,Immune_system_disorders,NCT00343291,https://clinicaltrials.gov/show/NCT00343291,Non-Small_Cell_Lung_Cancer,Cetuximab|Bevacizumab|Paclitaxel|Carboplatin|,serious_events,arm1,Cetuximab-+-Bevacizumab-+-Paclitaxel-+-Carboplatin-(6/3),5,cetuximab,Epidermal-growth-factor-receptor-inhibitor
347,Hypersensitivity,5,58,Immune_system_disorders,NCT00343291,https://clinicaltrials.gov/show/NCT00343291,Non-Small_Cell_Lung_Cancer,Cetuximab|Bevacizumab|Paclitaxel|Carboplatin|,other_events,arm1,Cetuximab-+-Bevacizumab-+-Paclitaxel-+-Carboplatin-(6/3),5,cetuximab,Epidermal-growth-factor-receptor-inhibitor
344,Hypersensitivity,3,58,Immune_system_disorders,NCT00343291,https://clinicaltrials.gov/show/NCT00343291,Non-Small_Cell_Lung_Cancer,Cetuximab|Bevacizumab|Paclitaxel|Carboplatin|,serious_events,arm1,Cetuximab-+-Bevacizumab-+-Paclitaxel-+-Carboplatin-(6/3),4,bevacizumab,monoclonal-antibody
347,Hypersensitivity,5,58,Immune_system_disorders,NCT00343291,https://clinicaltrials.gov/show/NCT00343291,Non-Small_Cell_Lung_Cancer,Cetuximab|Bevacizumab|Paclitaxel|Carboplatin|,other_events,arm1,Cetuximab-+-Bevacizumab-+-Paclitaxel-+-Carboplatin-(6/3),4,bevacizumab,monoclonal-antibody
344,Hypersensitivity,3,58,Immune_system_disorders,NCT00343291,https://clinicaltrials.gov/show/NCT00343291,Non-Small_Cell_Lung_Cancer,Cetuximab|Bevacizumab|Paclitaxel|Carboplatin|,serious_events,arm1,Cetuximab-+-Bevacizumab-+-Paclitaxel-+-Carboplatin-(6/3),22,bevacizumab,monoclonal-antibody
347,Hypersensitivity,5,58,Immune_system_disorders,NCT00343291,https://clinicaltrials.gov/show/NCT00343291,Non-Small_Cell_Lung_Cancer,Cetuximab|Bevacizumab|Paclitaxel|Carboplatin|,other_events,arm1,Cetuximab-+-Bevacizumab-+-Paclitaxel-+-Carboplatin-(6/3),22,bevacizumab,monoclonal-antibody
344,Hypersensitivity,3,58,Immune_system_disorders,NCT00343291,https://clinicaltrials.gov/show/NCT00343291,Non-Small_Cell_Lung_Cancer,Cetuximab|Bevacizumab|Paclitaxel|Carboplatin|,serious_events,arm1,Cetuximab-+-Bevacizumab-+-Paclitaxel-+-Carboplatin-(6/3),2,paclitaxel,taxane
347,Hypersensitivity,5,58,Immune_system_disorders,NCT00343291,https://clinicaltrials.gov/show/NCT00343291,Non-Small_Cell_Lung_Cancer,Cetuximab|Bevacizumab|Paclitaxel|Carboplatin|,other_events,arm1,Cetuximab-+-Bevacizumab-+-Paclitaxel-+-Carboplatin-(6/3),2,paclitaxel,taxane
2573,Allergic_reaction,2,32,Immune_system_disorders,NCT00343512,https://clinicaltrials.gov/show/NCT00343512,Breast_Cancer,docetaxel|protein_expression_analysis|laboratory_biomarker_analysis|biopsy|conventional_surgery|neoadjuvant_therapy|,other_events,arm0,Therapeutic-Intervention,,,
348,Hypersensitivity,2,15,Immune_system_disorders,NCT00345540,https://clinicaltrials.gov/show/NCT00345540,Ovarian_Cancer,NOV-002|Carboplatin|,other_events,arm0,NOV-002-Plus-Carboplatin,3,carboplatin,alkalating-agent
351,Hypersensitivity,1,76,Immune_system_disorders,NCT00347919,https://clinicaltrials.gov/show/NCT00347919,Neoplasms_Breast,pazopanib_(GW786034)_400_mg|lapatinib_(GW572016)_1500_mg|lapatinib_(GW572016)_1000_mg|pazopanib_(GW786034)_800_mg|,serious_events,arm1,Cohort-1:-Lapatinib-1000-mg/Pazopanib-400-mg,21,lapatinib,signal-transduction-inhibitor
352,Hypersensitivity,4,32,Immune_system_disorders,NCT00349336,https://clinicaltrials.gov/show/NCT00349336,Colorectal_Cancer,bevacizumab_[Avastin]|XELOX|bevacizumab_[Avastin]|FOLFOX-4|,other_events,arm1,FOLFOX-4+Bevacizumab,4,bevacizumab,monoclonal-antibody
353,Hypersensitivity,2,32,Immune_system_disorders,NCT00349336,https://clinicaltrials.gov/show/NCT00349336,Colorectal_Cancer,bevacizumab_[Avastin]|XELOX|bevacizumab_[Avastin]|FOLFOX-4|,serious_events,arm1,FOLFOX-4+Bevacizumab,4,bevacizumab,monoclonal-antibody
352,Hypersensitivity,4,32,Immune_system_disorders,NCT00349336,https://clinicaltrials.gov/show/NCT00349336,Colorectal_Cancer,bevacizumab_[Avastin]|XELOX|bevacizumab_[Avastin]|FOLFOX-4|,other_events,arm1,FOLFOX-4+Bevacizumab,22,bevacizumab,monoclonal-antibody
353,Hypersensitivity,2,32,Immune_system_disorders,NCT00349336,https://clinicaltrials.gov/show/NCT00349336,Colorectal_Cancer,bevacizumab_[Avastin]|XELOX|bevacizumab_[Avastin]|FOLFOX-4|,serious_events,arm1,FOLFOX-4+Bevacizumab,22,bevacizumab,monoclonal-antibody
354,Hypersensitivity,1,95,Immune_system_disorders,NCT00349349,https://clinicaltrials.gov/show/NCT00349349,Leukaemia_Lymphocytic_Chronic,ofatumumab,serious_events,arm0,2000-mg-Ofatumumab-+-DR,42,ofatumumab,monoclonal-antibody
1322,Drug_hypersensitivity,1,62,Immune_system_disorders,NCT00350792,https://clinicaltrials.gov/show/NCT00350792,Non_Small_Cell_Lung_Cancer,pemetrexed|carboplatin|,serious_events,arm0,Pemetrexed-+-Carboplatin,3,carboplatin,alkalating-agent
1322,Drug_hypersensitivity,1,62,Immune_system_disorders,NCT00350792,https://clinicaltrials.gov/show/NCT00350792,Non_Small_Cell_Lung_Cancer,pemetrexed|carboplatin|,serious_events,arm0,Pemetrexed-+-Carboplatin,15,pemetrexed,antimetabolite
2336,Anaphylaxis,3,108,Immune_system_disorders,NCT00354744,https://clinicaltrials.gov/show/NCT00354744,Sarcoma,dactinomycin|cyclophosphamide|doxorubicin_hydrochloride|etoposide|ifosfamide|irinotecan_hydrochloride|vincristine_sulfate|conventional_surgery|radiation_therapy|filgrastim|,other_events,arm0,High_Risk_Rhabdomyosarcoma,,,
356,HYPERSENSITIVITY,5,52,Immune_system_disorders,NCT00356122,https://clinicaltrials.gov/show/NCT00356122,Non-Small_Cell_Lung_Cancer,Docetaxel|Oxaliplatin|Bevacizumab|,other_events,arm0,Docetaxel/Oxaliplatin/Bevacizumab,7,oxaliplatin,alkalating-agent
356,HYPERSENSITIVITY,5,52,Immune_system_disorders,NCT00356122,https://clinicaltrials.gov/show/NCT00356122,Non-Small_Cell_Lung_Cancer,Docetaxel|Oxaliplatin|Bevacizumab|,other_events,arm0,Docetaxel/Oxaliplatin/Bevacizumab,4,bevacizumab,monoclonal-antibody
356,HYPERSENSITIVITY,5,52,Immune_system_disorders,NCT00356122,https://clinicaltrials.gov/show/NCT00356122,Non-Small_Cell_Lung_Cancer,Docetaxel|Oxaliplatin|Bevacizumab|,other_events,arm0,Docetaxel/Oxaliplatin/Bevacizumab,22,bevacizumab,monoclonal-antibody
356,HYPERSENSITIVITY,5,52,Immune_system_disorders,NCT00356122,https://clinicaltrials.gov/show/NCT00356122,Non-Small_Cell_Lung_Cancer,Docetaxel|Oxaliplatin|Bevacizumab|,other_events,arm0,Docetaxel/Oxaliplatin/Bevacizumab,8,docetaxel,taxane
1324,Drug_hypersensitivity,1,11,Immune_system_disorders,NCT00356525,https://clinicaltrials.gov/show/NCT00356525,Lung_Neoplasms,pemetrexed|gemcitabine|carboplatin|Pemetrexed|,other_events,arm1,Less-Than-One-Year:-Pemetrexed-+-Gemcitabine,15,pemetrexed,antimetabolite
1324,Drug_hypersensitivity,1,11,Immune_system_disorders,NCT00356525,https://clinicaltrials.gov/show/NCT00356525,Lung_Neoplasms,pemetrexed|gemcitabine|carboplatin|Pemetrexed|,other_events,arm1,Less-Than-One-Year:-Pemetrexed-+-Gemcitabine,6,gemcitabine,antimetabolites
1325,Drug_hypersensitivity,1,9,Immune_system_disorders,NCT00356525,https://clinicaltrials.gov/show/NCT00356525,Lung_Neoplasms,pemetrexed|gemcitabine|carboplatin|Pemetrexed|,other_events,arm3,One-Year-or-Greater:-Pemetrexed-+-Gemcitabine,15,pemetrexed,antimetabolite
1325,Drug_hypersensitivity,1,9,Immune_system_disorders,NCT00356525,https://clinicaltrials.gov/show/NCT00356525,Lung_Neoplasms,pemetrexed|gemcitabine|carboplatin|Pemetrexed|,other_events,arm3,One-Year-or-Greater:-Pemetrexed-+-Gemcitabine,6,gemcitabine,antimetabolites
357,Hypersensitivity,4,57,Immune_system_disorders,NCT00356811,https://clinicaltrials.gov/show/NCT00356811,Neoplasms_Breast,Lapatinib_oral_tablets|Paclitaxel_infusion|,other_events,arm0,Lapatinib-Plus-Paclitaxel,21,lapatinib,signal-transduction-inhibitor
357,Hypersensitivity,4,57,Immune_system_disorders,NCT00356811,https://clinicaltrials.gov/show/NCT00356811,Neoplasms_Breast,Lapatinib_oral_tablets|Paclitaxel_infusion|,other_events,arm0,Lapatinib-Plus-Paclitaxel,2,paclitaxel,taxane
358,Hypersensitivity,2,21,Immune_system_disorders,NCT00357162,https://clinicaltrials.gov/show/NCT00357162,de_Novo_Myelodysplastic_Syndromes|Previously_Treated_Myelodysplastic_Syndromes|Secondary_Myelodysplastic_Syndromes|,belinostat,other_events,arm0,Treatment-(Enzyme-Inhibitor-Therapy),,,
2574,Allergic_reaction,1,97,Immune_system_disorders,NCT00357500,https://clinicaltrials.gov/show/NCT00357500,Central_Nervous_System_Tumor_Pediatric|Leukemia|Lymphoma|Neuroblastoma|Sarcoma|Unspecified_Childhood_Solid_Tumor_Protocol_Specific|,celecoxib|cyclophosphamide|etoposide|fenofibrate|thalidomide|,other_events,arm0,5-drug-Metronomic-Antiangiogenic-Regimen,,,
1968,Dermatitis_allergic,1,6,Skin_and_subcutaneous_tissue_disorders,NCT00358150,https://clinicaltrials.gov/show/NCT00358150,Gaucher_Disease_Type_1|Cerebroside_Lipidosis_Syndrome|Glucocerebrosidase_Deficiency_Disease|Glucosylceramide_Beta-Glucosidase_Deficiency_Disease|Gaucher_Disease_Non-Neuronopathic_Form|,Eliglustat_tartrate,other_events,arm0,Eliglustat-50-mg,,,
1967,Dermatitis_allergic,1,26,Skin_and_subcutaneous_tissue_disorders,NCT00358150,https://clinicaltrials.gov/show/NCT00358150,Gaucher_Disease_Type_1|Cerebroside_Lipidosis_Syndrome|Glucocerebrosidase_Deficiency_Disease|Glucosylceramide_Beta-Glucosidase_Deficiency_Disease|Gaucher_Disease_Non-Neuronopathic_Form|,Eliglustat_tartrate,other_events,arm2,Eliglustat-All-Participants,,,
1969,Dermatitis_Allergic,1,55,Skin_and_subcutaneous_tissue_disorders,NCT00358644,https://clinicaltrials.gov/show/NCT00358644,Acute_Myeloid_Leukemia,Decitabine,serious_events,arm0,Decitabine-20-mg/m2-Intravenous,,,
361,Hypersensitivity,1,41,Immune_system_disorders,NCT00362882,https://clinicaltrials.gov/show/NCT00362882,Non-small_Cell_Lung_Cancer|Recurrent_Non-small_Cell_Lung_Cancer|Stage_IV_Non-small_Cell_Lung_Cancer|,docetaxel|bortezomib|laboratory_biomarker_analysis|immunoenzyme_technique|immunohistochemistry_staining_method|pharmacological_study|,other_events,arm1,Arm-2,,,
1335,Drug_hypersensitivity,1,447,Immune_system_disorders,NCT00363415,https://clinicaltrials.gov/show/NCT00363415,Small_Cell_Lung_Cancer,pemetrexed|etoposide|carboplatin|,serious_events,arm1,Etoposide-+-Carboplatin,3,carboplatin,alkalating-agent
362,Hypersensitivity,1,447,Immune_system_disorders,NCT00363415,https://clinicaltrials.gov/show/NCT00363415,Small_Cell_Lung_Cancer,pemetrexed|etoposide|carboplatin|,serious_events,arm1,Etoposide-+-Carboplatin,3,carboplatin,alkalating-agent
1335,Drug_hypersensitivity,1,447,Immune_system_disorders,NCT00363415,https://clinicaltrials.gov/show/NCT00363415,Small_Cell_Lung_Cancer,pemetrexed|etoposide|carboplatin|,serious_events,arm1,Etoposide-+-Carboplatin,26,etoposide,"plant-alkaloid""-and-""topoisomerase-II-inhibitor."""
362,Hypersensitivity,1,447,Immune_system_disorders,NCT00363415,https://clinicaltrials.gov/show/NCT00363415,Small_Cell_Lung_Cancer,pemetrexed|etoposide|carboplatin|,serious_events,arm1,Etoposide-+-Carboplatin,26,etoposide,"plant-alkaloid""-and-""topoisomerase-II-inhibitor."""
1973,Dermatitis_allergic,1,585,Skin_and_subcutaneous_tissue_disorders,NCT00364013,https://clinicaltrials.gov/show/NCT00364013,Metastatic_Colorectal_Cancer,Panitumumab|FOLFOX_regimen|,serious_events,arm0,Panitumumab-Plus-FOLFOX,30,panitumumab,monoclonal-antibody-and-signal-transduction-inhibitor
1336,Drug_hypersensitivity,2,585,Immune_system_disorders,NCT00364013,https://clinicaltrials.gov/show/NCT00364013,Metastatic_Colorectal_Cancer,Panitumumab|FOLFOX_regimen|,serious_events,arm0,Panitumumab-Plus-FOLFOX,30,panitumumab,monoclonal-antibody-and-signal-transduction-inhibitor
363,Hypersensitivity,4,585,Immune_system_disorders,NCT00364013,https://clinicaltrials.gov/show/NCT00364013,Metastatic_Colorectal_Cancer,Panitumumab|FOLFOX_regimen|,serious_events,arm0,Panitumumab-Plus-FOLFOX,30,panitumumab,monoclonal-antibody-and-signal-transduction-inhibitor
1974,Dermatitis_allergic,1,584,Skin_and_subcutaneous_tissue_disorders,NCT00364013,https://clinicaltrials.gov/show/NCT00364013,Metastatic_Colorectal_Cancer,Panitumumab|FOLFOX_regimen|,serious_events,arm1,FOLFOX-Alone,19,folfox,combination-drug-with-Leucovorin-(Folinic-Acid)--Fluorouracil--and-Oxaliplatin
1337,Drug_hypersensitivity,2,584,Immune_system_disorders,NCT00364013,https://clinicaltrials.gov/show/NCT00364013,Metastatic_Colorectal_Cancer,Panitumumab|FOLFOX_regimen|,serious_events,arm1,FOLFOX-Alone,19,folfox,combination-drug-with-Leucovorin-(Folinic-Acid)--Fluorouracil--and-Oxaliplatin
364,Hypersensitivity,4,584,Immune_system_disorders,NCT00364013,https://clinicaltrials.gov/show/NCT00364013,Metastatic_Colorectal_Cancer,Panitumumab|FOLFOX_regimen|,serious_events,arm1,FOLFOX-Alone,19,folfox,combination-drug-with-Leucovorin-(Folinic-Acid)--Fluorouracil--and-Oxaliplatin
366,Hypersensitivity,1,62,Immune_system_disorders,NCT00364858,https://clinicaltrials.gov/show/NCT00364858,Gaucher_Disease_Type_1|Cerebroside_Lipidosis_Syndrome|Glucocerebrosidase_Deficiency_Disease|Glucosylceramide_Beta-Glucosidase_Deficiency_Disease|Gaucher_Disease_Non-Neuronopathic_Form|,Cerezyme,other_events,arm1,Q4-Cerezyme,,,
365,Hypersensitivity,1,95,Immune_system_disorders,NCT00364858,https://clinicaltrials.gov/show/NCT00364858,Gaucher_Disease_Type_1|Cerebroside_Lipidosis_Syndrome|Glucocerebrosidase_Deficiency_Disease|Glucosylceramide_Beta-Glucosidase_Deficiency_Disease|Gaucher_Disease_Non-Neuronopathic_Form|,Cerezyme,other_events,arm2,Total,,,
367,Hypersensitivity,2,13,Immune_system_disorders,NCT00365053,https://clinicaltrials.gov/show/NCT00365053,Advanced_Malignant_Mesothelioma|Epithelial_Mesothelioma|Recurrent_Malignant_Mesothelioma|Sarcomatous_Mesothelioma|,belinostat|laboratory_biomarker_analysis|,other_events,arm0,Treatment-(Belinostat),49,belinostat,histone-deacetylase-(HDAC)-inhibitor
368,Hypersensitivity,1,405,Immune_system_disorders,NCT00365456,https://clinicaltrials.gov/show/NCT00365456,Osteoporosis,Parathyroid_Hormone_(PTH)|Risedronate|,serious_events,arm0,PTH-(1-84),,,
1340,Drug_hypersensitivity,1,460,Immune_system_disorders,NCT00367484,https://clinicaltrials.gov/show/NCT00367484,Relapsing_Remitting_Multiple_Sclerosis,Rebif??_(clone_484-39),serious_events,arm0,Rebif??-(Clone-484-39),,,
2576,Allergic_reaction,1,59,Immune_system_disorders,NCT00369122,https://clinicaltrials.gov/show/NCT00369122,Cervical_Adenocarcinoma|Cervical_Adenosquamous_Cell_Carcinoma|Cervical_Squamous_Cell_Carcinoma|Stage_IB_Cervical_Cancer|Stage_IIA_Cervical_Cancer|Stage_IIB_Cervical_Cancer|Stage_III_Cervical_Cancer|,external_beam_radiation_therapy|brachytherapy|bevacizumab|cisplatin|,serious_events,arm0,Treatment-(Radiation-Therapy-Bevacizumab-Cisplatin),9,cisplatin,alkalating-agent
2576,Allergic_reaction,1,59,Immune_system_disorders,NCT00369122,https://clinicaltrials.gov/show/NCT00369122,Cervical_Adenocarcinoma|Cervical_Adenosquamous_Cell_Carcinoma|Cervical_Squamous_Cell_Carcinoma|Stage_IB_Cervical_Cancer|Stage_IIA_Cervical_Cancer|Stage_IIB_Cervical_Cancer|Stage_III_Cervical_Cancer|,external_beam_radiation_therapy|brachytherapy|bevacizumab|cisplatin|,serious_events,arm0,Treatment-(Radiation-Therapy-Bevacizumab-Cisplatin),4,bevacizumab,monoclonal-antibody
2576,Allergic_reaction,1,59,Immune_system_disorders,NCT00369122,https://clinicaltrials.gov/show/NCT00369122,Cervical_Adenocarcinoma|Cervical_Adenosquamous_Cell_Carcinoma|Cervical_Squamous_Cell_Carcinoma|Stage_IB_Cervical_Cancer|Stage_IIA_Cervical_Cancer|Stage_IIB_Cervical_Cancer|Stage_III_Cervical_Cancer|,external_beam_radiation_therapy|brachytherapy|bevacizumab|cisplatin|,serious_events,arm0,Treatment-(Radiation-Therapy-Bevacizumab-Cisplatin),22,bevacizumab,monoclonal-antibody
2337,Anaphylaxis,5,204,Immune_system_disorders,NCT00369317,https://clinicaltrials.gov/show/NCT00369317,Childhood_Acute_Basophilic_Leukemia|Childhood_Acute_Eosinophilic_Leukemia|Childhood_Acute_Erythroleukemia_(M6)|Childhood_Acute_Megakaryocytic_Leukemia_(M7)|Childhood_Acute_Minimally_Differentiated_Myeloid_Leukemia_(M0)|Childhood_Acute_Monoblastic_Leukemia,asparaginase|daunorubicin_hydrochloride|cytarabine|thioguanine|etoposide|laboratory_biomarker_analysis|,other_events,arm0,Treatment-(Combination-Chemotherapy),,,
370,Hypersensitivity,1,21,Immune_system_disorders,NCT00369655,https://clinicaltrials.gov/show/NCT00369655,Metastatic_Breast_Cancer|Recurrent_Breast_Cancer|Stage_IV_Breast_Cancer|,ziv-aflibercept,other_events,arm0,Treatment-(Ziv-afibercept),,,
1341,Drug_hypersensitivity,1,214,Immune_system_disorders,NCT00369824,https://clinicaltrials.gov/show/NCT00369824,Human_Papillomavirus_Type-16/-18_Infection|Papillomavirus_Vaccines|Cervical_Neoplasia|,Different_formulations_of_GSK_Biologicals'_HPV_vaccine_(580299)|Menactra_TM|Boostrix_TM|,serious_events,arm4,Menactra/Cervarix-Group,,,
1342,Drug_hypersensitivity,2,32,Immune_system_disorders,NCT00370552,https://clinicaltrials.gov/show/NCT00370552,Metastatic_Breast_Cancer,Ixabepilone_16_mg/m^2_+_Bevacizumab_10_mg/kg|Ixabepilone_40_mg/m^2_+_Bevacizumab_15_mg/kg|Paclitaxel_90_mg/m^2_+_Bevacizumab_10_mg/kg|,other_events,arm2,Paclitaxel-90-mg/m^2-+-Bevacizumab-10-mg/kg,4,bevacizumab,monoclonal-antibody
1342,Drug_hypersensitivity,2,32,Immune_system_disorders,NCT00370552,https://clinicaltrials.gov/show/NCT00370552,Metastatic_Breast_Cancer,Ixabepilone_16_mg/m^2_+_Bevacizumab_10_mg/kg|Ixabepilone_40_mg/m^2_+_Bevacizumab_15_mg/kg|Paclitaxel_90_mg/m^2_+_Bevacizumab_10_mg/kg|,other_events,arm2,Paclitaxel-90-mg/m^2-+-Bevacizumab-10-mg/kg,22,bevacizumab,monoclonal-antibody
1342,Drug_hypersensitivity,2,32,Immune_system_disorders,NCT00370552,https://clinicaltrials.gov/show/NCT00370552,Metastatic_Breast_Cancer,Ixabepilone_16_mg/m^2_+_Bevacizumab_10_mg/kg|Ixabepilone_40_mg/m^2_+_Bevacizumab_15_mg/kg|Paclitaxel_90_mg/m^2_+_Bevacizumab_10_mg/kg|,other_events,arm2,Paclitaxel-90-mg/m^2-+-Bevacizumab-10-mg/kg,2,paclitaxel,taxane
1343,Drug_hypersensitivity,3,25,Immune_system_disorders,NCT00372424,https://clinicaltrials.gov/show/NCT00372424,Breast_Cancer,Herceptin|Sunitinib|Taxotere|,other_events,arm0,Sunitinib-+-Docetaxel-+-Trastuzumab,18,trastuzumab,monoclonal-antibody
371,Hypersensitivity,2,25,Immune_system_disorders,NCT00372424,https://clinicaltrials.gov/show/NCT00372424,Breast_Cancer,Herceptin|Sunitinib|Taxotere|,other_events,arm0,Sunitinib-+-Docetaxel-+-Trastuzumab,18,trastuzumab,monoclonal-antibody
1343,Drug_hypersensitivity,3,25,Immune_system_disorders,NCT00372424,https://clinicaltrials.gov/show/NCT00372424,Breast_Cancer,Herceptin|Sunitinib|Taxotere|,other_events,arm0,Sunitinib-+-Docetaxel-+-Trastuzumab,8,docetaxel,taxane
371,Hypersensitivity,2,25,Immune_system_disorders,NCT00372424,https://clinicaltrials.gov/show/NCT00372424,Breast_Cancer,Herceptin|Sunitinib|Taxotere|,other_events,arm0,Sunitinib-+-Docetaxel-+-Trastuzumab,8,docetaxel,taxane
1343,Drug_hypersensitivity,3,25,Immune_system_disorders,NCT00372424,https://clinicaltrials.gov/show/NCT00372424,Breast_Cancer,Herceptin|Sunitinib|Taxotere|,other_events,arm0,Sunitinib-+-Docetaxel-+-Trastuzumab,27,sunitinib,tyrosine-kinase-inhibitor-and-angiogenesis-inhibitor
371,Hypersensitivity,2,25,Immune_system_disorders,NCT00372424,https://clinicaltrials.gov/show/NCT00372424,Breast_Cancer,Herceptin|Sunitinib|Taxotere|,other_events,arm0,Sunitinib-+-Docetaxel-+-Trastuzumab,27,sunitinib,tyrosine-kinase-inhibitor-and-angiogenesis-inhibitor
2342,Anaphylaxis,25,511,Immune_system_disorders,NCT00372593,https://clinicaltrials.gov/show/NCT00372593,Leukemia,asparaginase|cytarabine|daunorubicin_hydrochloride|etoposide|gemtuzumab_ozogamicin|mitoxantrone_hydrochloride|,other_events,arm0,Arm-A:-Standard-Arm---No-GMTZ-AML-Pts-w/Out-Down-Syndrome,,,
2341,Anaphylaxis,32,511,Immune_system_disorders,NCT00372593,https://clinicaltrials.gov/show/NCT00372593,Leukemia,asparaginase|cytarabine|daunorubicin_hydrochloride|etoposide|gemtuzumab_ozogamicin|mitoxantrone_hydrochloride|,other_events,arm1,Arm-B:-Experimental---With-GMTZ-AML-Pts-w/Out-Down-Syndrome,,,
2579,Allergic_reaction,1,6,Immune_system_disorders,NCT00372593,https://clinicaltrials.gov/show/NCT00372593,Leukemia,asparaginase|cytarabine|daunorubicin_hydrochloride|etoposide|gemtuzumab_ozogamicin|mitoxantrone_hydrochloride|,other_events,arm2,Arm-A:-Standard-Arm---No-GMTZ-AML-Patients-With-Down-Syndrome,,,
2340,Anaphylaxis,1,6,Immune_system_disorders,NCT00372593,https://clinicaltrials.gov/show/NCT00372593,Leukemia,asparaginase|cytarabine|daunorubicin_hydrochloride|etoposide|gemtuzumab_ozogamicin|mitoxantrone_hydrochloride|,other_events,arm2,Arm-A:-Standard-Arm---No-GMTZ-AML-Patients-With-Down-Syndrome,,,
2338,Anaphylaxis,1,7,Immune_system_disorders,NCT00372619,https://clinicaltrials.gov/show/NCT00372619,Leukemia,clofarabine|cytarabine|methotrexate|laboratory_biomarker_analysis|,other_events,arm4,Clofarabine-52-mg/m?_-to-Assess-Feasibility-in-AML-Patients.,37,clofarabine,antimetabolite
2578,Allergic_reaction,2,40,Immune_system_disorders,NCT00372619,https://clinicaltrials.gov/show/NCT00372619,Leukemia,clofarabine|cytarabine|methotrexate|laboratory_biomarker_analysis|,other_events,arm5,Clofarabine-52-mg/m?_-to-Assess-Efficacy-in-AML-Patients,37,clofarabine,antimetabolite
2339,Anaphylaxis,3,40,Immune_system_disorders,NCT00372619,https://clinicaltrials.gov/show/NCT00372619,Leukemia,clofarabine|cytarabine|methotrexate|laboratory_biomarker_analysis|,other_events,arm5,Clofarabine-52-mg/m?_-to-Assess-Efficacy-in-AML-Patients,37,clofarabine,antimetabolite
372,Hypersensitivity,1,115,Immune_system_disorders,NCT00372996,https://clinicaltrials.gov/show/NCT00372996,Breast_Neoplasms,CP-751871|exemestane|exemestane|Fulvestrant|,serious_events,arm0,CP-751871-+-Exemestane,56,exemestane,aromatase-inhibitor
1344,Drug_hypersensitivity,1,238,Immune_system_disorders,NCT00373113,https://clinicaltrials.gov/show/NCT00373113,Breast_Neoplasms,Capecitabine|Sunitinib_malate|,other_events,arm0,Sunitinib,27,sunitinib,tyrosine-kinase-inhibitor-and-angiogenesis-inhibitor
373,Hypersensitivity,3,238,Immune_system_disorders,NCT00373113,https://clinicaltrials.gov/show/NCT00373113,Breast_Neoplasms,Capecitabine|Sunitinib_malate|,other_events,arm0,Sunitinib,27,sunitinib,tyrosine-kinase-inhibitor-and-angiogenesis-inhibitor
1983,Dermatitis_allergic,1,240,Skin_and_subcutaneous_tissue_disorders,NCT00373113,https://clinicaltrials.gov/show/NCT00373113,Breast_Neoplasms,Capecitabine|Sunitinib_malate|,other_events,arm1,Capecitabine,17,capecitabine,antimetabolite
1983,Dermatitis_allergic,1,240,Skin_and_subcutaneous_tissue_disorders,NCT00373113,https://clinicaltrials.gov/show/NCT00373113,Breast_Neoplasms,Capecitabine|Sunitinib_malate|,other_events,arm1,Capecitabine,29,capecitabine,antimetabolite
1985,Dermatitis_allergic,1,235,Skin_and_subcutaneous_tissue_disorders,NCT00373256,https://clinicaltrials.gov/show/NCT00373256,Breast_Neoplasms,Sunitinib|paclitaxel|bevacizumab|paclitaxel|,other_events,arm0,Sunitinib-+-Paclitaxel,2,paclitaxel,taxane
1346,Drug_hypersensitivity,1,235,Immune_system_disorders,NCT00373256,https://clinicaltrials.gov/show/NCT00373256,Breast_Neoplasms,Sunitinib|paclitaxel|bevacizumab|paclitaxel|,serious_events,arm0,Sunitinib-+-Paclitaxel,2,paclitaxel,taxane
1347,Drug_hypersensitivity,4,235,Immune_system_disorders,NCT00373256,https://clinicaltrials.gov/show/NCT00373256,Breast_Neoplasms,Sunitinib|paclitaxel|bevacizumab|paclitaxel|,other_events,arm0,Sunitinib-+-Paclitaxel,2,paclitaxel,taxane
375,Hypersensitivity,7,235,Immune_system_disorders,NCT00373256,https://clinicaltrials.gov/show/NCT00373256,Breast_Neoplasms,Sunitinib|paclitaxel|bevacizumab|paclitaxel|,other_events,arm0,Sunitinib-+-Paclitaxel,2,paclitaxel,taxane
1985,Dermatitis_allergic,1,235,Skin_and_subcutaneous_tissue_disorders,NCT00373256,https://clinicaltrials.gov/show/NCT00373256,Breast_Neoplasms,Sunitinib|paclitaxel|bevacizumab|paclitaxel|,other_events,arm0,Sunitinib-+-Paclitaxel,27,sunitinib,tyrosine-kinase-inhibitor-and-angiogenesis-inhibitor
1346,Drug_hypersensitivity,1,235,Immune_system_disorders,NCT00373256,https://clinicaltrials.gov/show/NCT00373256,Breast_Neoplasms,Sunitinib|paclitaxel|bevacizumab|paclitaxel|,serious_events,arm0,Sunitinib-+-Paclitaxel,27,sunitinib,tyrosine-kinase-inhibitor-and-angiogenesis-inhibitor
1347,Drug_hypersensitivity,4,235,Immune_system_disorders,NCT00373256,https://clinicaltrials.gov/show/NCT00373256,Breast_Neoplasms,Sunitinib|paclitaxel|bevacizumab|paclitaxel|,other_events,arm0,Sunitinib-+-Paclitaxel,27,sunitinib,tyrosine-kinase-inhibitor-and-angiogenesis-inhibitor
375,Hypersensitivity,7,235,Immune_system_disorders,NCT00373256,https://clinicaltrials.gov/show/NCT00373256,Breast_Neoplasms,Sunitinib|paclitaxel|bevacizumab|paclitaxel|,other_events,arm0,Sunitinib-+-Paclitaxel,27,sunitinib,tyrosine-kinase-inhibitor-and-angiogenesis-inhibitor
1984,Dermatitis_allergic,2,242,Skin_and_subcutaneous_tissue_disorders,NCT00373256,https://clinicaltrials.gov/show/NCT00373256,Breast_Neoplasms,Sunitinib|paclitaxel|bevacizumab|paclitaxel|,other_events,arm1,Bevacizumab-+-Paclitaxel,4,bevacizumab,monoclonal-antibody
1345,Drug_hypersensitivity,4,242,Immune_system_disorders,NCT00373256,https://clinicaltrials.gov/show/NCT00373256,Breast_Neoplasms,Sunitinib|paclitaxel|bevacizumab|paclitaxel|,other_events,arm1,Bevacizumab-+-Paclitaxel,4,bevacizumab,monoclonal-antibody
374,Hypersensitivity,7,242,Immune_system_disorders,NCT00373256,https://clinicaltrials.gov/show/NCT00373256,Breast_Neoplasms,Sunitinib|paclitaxel|bevacizumab|paclitaxel|,other_events,arm1,Bevacizumab-+-Paclitaxel,4,bevacizumab,monoclonal-antibody
1984,Dermatitis_allergic,2,242,Skin_and_subcutaneous_tissue_disorders,NCT00373256,https://clinicaltrials.gov/show/NCT00373256,Breast_Neoplasms,Sunitinib|paclitaxel|bevacizumab|paclitaxel|,other_events,arm1,Bevacizumab-+-Paclitaxel,22,bevacizumab,monoclonal-antibody
1345,Drug_hypersensitivity,4,242,Immune_system_disorders,NCT00373256,https://clinicaltrials.gov/show/NCT00373256,Breast_Neoplasms,Sunitinib|paclitaxel|bevacizumab|paclitaxel|,other_events,arm1,Bevacizumab-+-Paclitaxel,22,bevacizumab,monoclonal-antibody
374,Hypersensitivity,7,242,Immune_system_disorders,NCT00373256,https://clinicaltrials.gov/show/NCT00373256,Breast_Neoplasms,Sunitinib|paclitaxel|bevacizumab|paclitaxel|,other_events,arm1,Bevacizumab-+-Paclitaxel,22,bevacizumab,monoclonal-antibody
1984,Dermatitis_allergic,2,242,Skin_and_subcutaneous_tissue_disorders,NCT00373256,https://clinicaltrials.gov/show/NCT00373256,Breast_Neoplasms,Sunitinib|paclitaxel|bevacizumab|paclitaxel|,other_events,arm1,Bevacizumab-+-Paclitaxel,2,paclitaxel,taxane
1345,Drug_hypersensitivity,4,242,Immune_system_disorders,NCT00373256,https://clinicaltrials.gov/show/NCT00373256,Breast_Neoplasms,Sunitinib|paclitaxel|bevacizumab|paclitaxel|,other_events,arm1,Bevacizumab-+-Paclitaxel,2,paclitaxel,taxane
374,Hypersensitivity,7,242,Immune_system_disorders,NCT00373256,https://clinicaltrials.gov/show/NCT00373256,Breast_Neoplasms,Sunitinib|paclitaxel|bevacizumab|paclitaxel|,other_events,arm1,Bevacizumab-+-Paclitaxel,2,paclitaxel,taxane
1986,Dermatitis_allergic,1,112,Skin_and_subcutaneous_tissue_disorders,NCT00373529,https://clinicaltrials.gov/show/NCT00373529,Acute_Myelogenous_Leukemia|Acute_Myeloid_Leukemia|,clofarabine,other_events,arm0,Clofarabine,37,clofarabine,antimetabolite
1348,Drug_hypersensitivity,6,112,Immune_system_disorders,NCT00373529,https://clinicaltrials.gov/show/NCT00373529,Acute_Myelogenous_Leukemia|Acute_Myeloid_Leukemia|,clofarabine,other_events,arm0,Clofarabine,37,clofarabine,antimetabolite
376,Hypersensitivity,1,112,Immune_system_disorders,NCT00373529,https://clinicaltrials.gov/show/NCT00373529,Acute_Myelogenous_Leukemia|Acute_Myeloid_Leukemia|,clofarabine,other_events,arm0,Clofarabine,37,clofarabine,antimetabolite
1350,Drug_hypersensitivity,1,1573,Immune_system_disorders,NCT00374322,https://clinicaltrials.gov/show/NCT00374322,Neoplasms_Breast,lapatinib|placebo|,serious_events,arm0,Lapatinib-1500-mg,21,lapatinib,signal-transduction-inhibitor
380,Hypersensitivity,1,1573,Immune_system_disorders,NCT00374322,https://clinicaltrials.gov/show/NCT00374322,Neoplasms_Breast,lapatinib|placebo|,serious_events,arm0,Lapatinib-1500-mg,21,lapatinib,signal-transduction-inhibitor
1351,DRUG_HYPERSENSITIVITY,1,34,Immune_system_disorders,NCT00375505,https://clinicaltrials.gov/show/NCT00375505,Breast_Cancer,Zoledronic_acid|Placebo|,serious_events,arm1,Zometa,,,
1989,Dermatitis_allergic,3,480,Skin_and_subcutaneous_tissue_disorders,NCT00378560,https://clinicaltrials.gov/show/NCT00378560,HPV_Infections,Quadrivalent_Human_Papillomavirus_(Types_6_11_16_18)_Recombinant_Vaccine|Comparator:_Placebo|,other_events,arm0,V501,,,
1352,Drug_Hypersensitivity,1,17,Immune_system_disorders,NCT00378573,https://clinicaltrials.gov/show/NCT00378573,Non-small_Cell_Lung_Cancer,docetaxel|gemcitabine|bevacizumab|,other_events,arm0,Docetaxel-Gemcitabine-and-Bevacizumab,6,gemcitabine,antimetabolites
1352,Drug_Hypersensitivity,1,17,Immune_system_disorders,NCT00378573,https://clinicaltrials.gov/show/NCT00378573,Non-small_Cell_Lung_Cancer,docetaxel|gemcitabine|bevacizumab|,other_events,arm0,Docetaxel-Gemcitabine-and-Bevacizumab,4,bevacizumab,monoclonal-antibody
1352,Drug_Hypersensitivity,1,17,Immune_system_disorders,NCT00378573,https://clinicaltrials.gov/show/NCT00378573,Non-small_Cell_Lung_Cancer,docetaxel|gemcitabine|bevacizumab|,other_events,arm0,Docetaxel-Gemcitabine-and-Bevacizumab,22,bevacizumab,monoclonal-antibody
1352,Drug_Hypersensitivity,1,17,Immune_system_disorders,NCT00378573,https://clinicaltrials.gov/show/NCT00378573,Non-small_Cell_Lung_Cancer,docetaxel|gemcitabine|bevacizumab|,other_events,arm0,Docetaxel-Gemcitabine-and-Bevacizumab,8,docetaxel,taxane
2580,Allergic_reaction,5,86,Immune_system_disorders,NCT00378703,https://clinicaltrials.gov/show/NCT00378703,Clear_Cell_Renal_Cell_Carcinoma|Recurrent_Renal_Cell_Cancer|Stage_IV_Renal_Cell_Cancer|,Sorafenib|temsirolimus|bevacizumab|,other_events,arm1,Arm-B-(Bevacizumab-and-Temsirolimus),4,bevacizumab,monoclonal-antibody
2580,Allergic_reaction,5,86,Immune_system_disorders,NCT00378703,https://clinicaltrials.gov/show/NCT00378703,Clear_Cell_Renal_Cell_Carcinoma|Recurrent_Renal_Cell_Cancer|Stage_IV_Renal_Cell_Cancer|,Sorafenib|temsirolimus|bevacizumab|,other_events,arm1,Arm-B-(Bevacizumab-and-Temsirolimus),22,bevacizumab,monoclonal-antibody
2581,Allergic_reaction,1,91,Immune_system_disorders,NCT00378703,https://clinicaltrials.gov/show/NCT00378703,Clear_Cell_Renal_Cell_Carcinoma|Recurrent_Renal_Cell_Cancer|Stage_IV_Renal_Cell_Cancer|,Sorafenib|temsirolimus|bevacizumab|,serious_events,arm3,Arm-D-(Sorafenib-and-Temsirolimus),90,sorafenib,Tyrosine-Kinase-inhibitor
2582,Allergic_reaction,4,91,Immune_system_disorders,NCT00378703,https://clinicaltrials.gov/show/NCT00378703,Clear_Cell_Renal_Cell_Carcinoma|Recurrent_Renal_Cell_Cancer|Stage_IV_Renal_Cell_Cancer|,Sorafenib|temsirolimus|bevacizumab|,other_events,arm3,Arm-D-(Sorafenib-and-Temsirolimus),90,sorafenib,Tyrosine-Kinase-inhibitor
1355,Drug_hypersensitivity,2,32,Immune_system_disorders,NCT00380874,https://clinicaltrials.gov/show/NCT00380874,Chemotherapy-Induced_Peripheral_Neuropathy,Pregabalin|Placebo|,other_events,arm0,Pregabalin,,,
388,Hypersensitivity,1,32,Immune_system_disorders,NCT00380874,https://clinicaltrials.gov/show/NCT00380874,Chemotherapy-Induced_Peripheral_Neuropathy,Pregabalin|Placebo|,other_events,arm0,Pregabalin,,,
1356,Drug_hypersensitivity,3,29,Immune_system_disorders,NCT00380874,https://clinicaltrials.gov/show/NCT00380874,Chemotherapy-Induced_Peripheral_Neuropathy,Pregabalin|Placebo|,other_events,arm1,Placebo,,,
389,Hypersensitivity,1,29,Immune_system_disorders,NCT00380874,https://clinicaltrials.gov/show/NCT00380874,Chemotherapy-Induced_Peripheral_Neuropathy,Pregabalin|Placebo|,other_events,arm1,Placebo,,,
2583,Allergic_reaction,5,35,General_disorders,NCT00381550,https://clinicaltrials.gov/show/NCT00381550,Accelerated_Phase_Chronic_Myelogenous_Leukemia|Atypical_Chronic_Myeloid_Leukemia_BCR-ABL1_Negative|Blastic_Phase_Chronic_Myelogenous_Leukemia|Chronic_Eosinophilic_Leukemia|Chronic_Myelomonocytic_Leukemia|Essential_Thrombocythemia|Philadelphia_Chromosome_N,fludarabine_phosphate|triapine|laboratory_biomarker_analysis|,other_events,arm0,Arm-I,,,
2343,Anaphylaxis,2,35,General_disorders,NCT00381550,https://clinicaltrials.gov/show/NCT00381550,Accelerated_Phase_Chronic_Myelogenous_Leukemia|Atypical_Chronic_Myeloid_Leukemia_BCR-ABL1_Negative|Blastic_Phase_Chronic_Myelogenous_Leukemia|Chronic_Eosinophilic_Leukemia|Chronic_Myelomonocytic_Leukemia|Essential_Thrombocythemia|Philadelphia_Chromosome_N,fludarabine_phosphate|triapine|laboratory_biomarker_analysis|,other_events,arm0,Arm-I,,,
2344,Anaphylaxis,1,25,Immune_system_disorders,NCT00381940,https://clinicaltrials.gov/show/NCT00381940,Adult_Lymphocyte_Depletion_Hodgkin_Lymphoma|Adult_Lymphocyte_Predominant_Hodgkin_Lymphoma|Adult_Mixed_Cellularity_Hodgkin_Lymphoma|Adult_Nodular_Lymphocyte_Predominant_Hodgkin_Lymphoma|Adult_Nodular_Sclerosis_Hodgkin_Lymphoma|Childhood_Lymphocyte_Depletio,ifosfamide|bortezomib|vinorelbine_tartrate|filgrastim|,serious_events,arm0,Treatment-(Ifosfamide-Vinorelbine-Bortezomib),70,bortezomib,proteasome-inhibitor
392,Hypersensitivity,1,53,Immune_system_disorders,NCT00382174,https://clinicaltrials.gov/show/NCT00382174,Pressure_Ulcers,Placebo|Thymosin_Beta_4|,other_events,arm1,T?_4-at-3-Doses,,,
393,Hypersensitivity,1,71,Immune_system_disorders,NCT00382174,https://clinicaltrials.gov/show/NCT00382174,Pressure_Ulcers,Placebo|Thymosin_Beta_4|,other_events,arm2,Placebo-vs.-Thymosin-Beta-4-at-3-Doses,,,
394,HYPERSENSITIVITY,3,54,Immune_system_disorders,NCT00383149,https://clinicaltrials.gov/show/NCT00383149,Metastatic_Pancreatic_Cancer,Ixabepilone|Cetuximab|,serious_events,arm0,Ixabepilone-+-Cetuximab,82,ixabepilone,antimicrotubule-agent
395,HYPERSENSITIVITY,5,54,Immune_system_disorders,NCT00383149,https://clinicaltrials.gov/show/NCT00383149,Metastatic_Pancreatic_Cancer,Ixabepilone|Cetuximab|,other_events,arm0,Ixabepilone-+-Cetuximab,82,ixabepilone,antimicrotubule-agent
394,HYPERSENSITIVITY,3,54,Immune_system_disorders,NCT00383149,https://clinicaltrials.gov/show/NCT00383149,Metastatic_Pancreatic_Cancer,Ixabepilone|Cetuximab|,serious_events,arm0,Ixabepilone-+-Cetuximab,5,cetuximab,Epidermal-growth-factor-receptor-inhibitor
395,HYPERSENSITIVITY,5,54,Immune_system_disorders,NCT00383149,https://clinicaltrials.gov/show/NCT00383149,Metastatic_Pancreatic_Cancer,Ixabepilone|Cetuximab|,other_events,arm0,Ixabepilone-+-Cetuximab,5,cetuximab,Epidermal-growth-factor-receptor-inhibitor
1362,Drug_Hypersensitivity,41,705,Immune_system_disorders,NCT00384176,https://clinicaltrials.gov/show/NCT00384176,Colorectal_Cancer,Cediranib|Bevacizumab|5-fluorouracil_(_in_FOLFOX)|Leucovorin_(in_FOLFOX)|Oxaliplatin_(in_FOLFOX)|,other_events,arm0,Cediranib-20-mg,14,cediranib,endothelial-growith-factor-receptor-tyrosine-kinase-inhibitor?
1365,Drug_Hypersensitivity,2,705,Immune_system_disorders,NCT00384176,https://clinicaltrials.gov/show/NCT00384176,Colorectal_Cancer,Cediranib|Bevacizumab|5-fluorouracil_(_in_FOLFOX)|Leucovorin_(in_FOLFOX)|Oxaliplatin_(in_FOLFOX)|,serious_events,arm0,Cediranib-20-mg,14,cediranib,endothelial-growith-factor-receptor-tyrosine-kinase-inhibitor?
1361,Drug_Hypersensitivity,1,191,Immune_system_disorders,NCT00384176,https://clinicaltrials.gov/show/NCT00384176,Colorectal_Cancer,Cediranib|Bevacizumab|5-fluorouracil_(_in_FOLFOX)|Leucovorin_(in_FOLFOX)|Oxaliplatin_(in_FOLFOX)|,serious_events,arm1,Cediranib-30-mg,14,cediranib,endothelial-growith-factor-receptor-tyrosine-kinase-inhibitor?
1364,Drug_Hypersensitivity,10,191,Immune_system_disorders,NCT00384176,https://clinicaltrials.gov/show/NCT00384176,Colorectal_Cancer,Cediranib|Bevacizumab|5-fluorouracil_(_in_FOLFOX)|Leucovorin_(in_FOLFOX)|Oxaliplatin_(in_FOLFOX)|,other_events,arm1,Cediranib-30-mg,14,cediranib,endothelial-growith-factor-receptor-tyrosine-kinase-inhibitor?
1360,Drug_Hypersensitivity,50,704,Immune_system_disorders,NCT00384176,https://clinicaltrials.gov/show/NCT00384176,Colorectal_Cancer,Cediranib|Bevacizumab|5-fluorouracil_(_in_FOLFOX)|Leucovorin_(in_FOLFOX)|Oxaliplatin_(in_FOLFOX)|,other_events,arm2,1Bevacizumab-5mg/kg,4,bevacizumab,monoclonal-antibody
1363,Drug_Hypersensitivity,5,704,Immune_system_disorders,NCT00384176,https://clinicaltrials.gov/show/NCT00384176,Colorectal_Cancer,Cediranib|Bevacizumab|5-fluorouracil_(_in_FOLFOX)|Leucovorin_(in_FOLFOX)|Oxaliplatin_(in_FOLFOX)|,serious_events,arm2,1Bevacizumab-5mg/kg,4,bevacizumab,monoclonal-antibody
1360,Drug_Hypersensitivity,50,704,Immune_system_disorders,NCT00384176,https://clinicaltrials.gov/show/NCT00384176,Colorectal_Cancer,Cediranib|Bevacizumab|5-fluorouracil_(_in_FOLFOX)|Leucovorin_(in_FOLFOX)|Oxaliplatin_(in_FOLFOX)|,other_events,arm2,1Bevacizumab-5mg/kg,22,bevacizumab,monoclonal-antibody
1363,Drug_Hypersensitivity,5,704,Immune_system_disorders,NCT00384176,https://clinicaltrials.gov/show/NCT00384176,Colorectal_Cancer,Cediranib|Bevacizumab|5-fluorouracil_(_in_FOLFOX)|Leucovorin_(in_FOLFOX)|Oxaliplatin_(in_FOLFOX)|,serious_events,arm2,1Bevacizumab-5mg/kg,22,bevacizumab,monoclonal-antibody
397,Hypersensitivity,1,212,Immune_system_disorders,NCT00384930,https://clinicaltrials.gov/show/NCT00384930,Benign_Prostatic_Hyperplasia,tadalafil|tadalafil|tadalafil|tadalafil|placebo|,other_events,arm2,5-mg-Tadalafil,,,
396,Hypersensitivity,1,209,Immune_system_disorders,NCT00384930,https://clinicaltrials.gov/show/NCT00384930,Benign_Prostatic_Hyperplasia,tadalafil|tadalafil|tadalafil|tadalafil|placebo|,other_events,arm4,20-mg-Tadalafil,,,
2584,Allergic_reaction,1,62,Immune_system_disorders,NCT00387790,https://clinicaltrials.gov/show/NCT00387790,Untreated_Childhood_Brain_Stem_Glioma,motexafin_gadolinium|3-dimensional_conformal_radiation_therapy|,other_events,arm0,Radiation-and-Motexafin-Gadolinium,80,motexafin,Class_Name_Needed
2345,Anaphylaxis,1,62,Immune_system_disorders,NCT00387790,https://clinicaltrials.gov/show/NCT00387790,Untreated_Childhood_Brain_Stem_Glioma,motexafin_gadolinium|3-dimensional_conformal_radiation_therapy|,serious_events,arm0,Radiation-and-Motexafin-Gadolinium,80,motexafin,Class_Name_Needed
2346,Anaphylaxis,1,62,Immune_system_disorders,NCT00387790,https://clinicaltrials.gov/show/NCT00387790,Untreated_Childhood_Brain_Stem_Glioma,motexafin_gadolinium|3-dimensional_conformal_radiation_therapy|,other_events,arm0,Radiation-and-Motexafin-Gadolinium,80,motexafin,Class_Name_Needed
2386,Allergy,1,20,Immune_system_disorders,NCT00388154,https://clinicaltrials.gov/show/NCT00388154,Endometrial_Cancer,Gemcitabine|Cisplatin|,other_events,arm0,Gemcitabine-+-Cisplatin,9,cisplatin,alkalating-agent
2386,Allergy,1,20,Immune_system_disorders,NCT00388154,https://clinicaltrials.gov/show/NCT00388154,Endometrial_Cancer,Gemcitabine|Cisplatin|,other_events,arm0,Gemcitabine-+-Cisplatin,6,gemcitabine,antimetabolites
399,Hypersensitivity,1,52,Immune_system_disorders,NCT00389441,https://clinicaltrials.gov/show/NCT00389441,Thyroid_Neoplasms,AG-013736,serious_events,arm0,Axitinib,10,axitinib,kinase-inhibitor
2585,Allergic_reaction,7,43,Immune_system_disorders,NCT00390611,https://clinicaltrials.gov/show/NCT00390611,Ovarian_Cancer,Sorafenib|Paclitaxel|Carboplatin|,other_events,arm0,Paclitaxel/Carboplatin/Sorafenib,3,carboplatin,alkalating-agent
2587,Allergic_reaction,4,43,Immune_system_disorders,NCT00390611,https://clinicaltrials.gov/show/NCT00390611,Ovarian_Cancer,Sorafenib|Paclitaxel|Carboplatin|,serious_events,arm0,Paclitaxel/Carboplatin/Sorafenib,3,carboplatin,alkalating-agent
2585,Allergic_reaction,7,43,Immune_system_disorders,NCT00390611,https://clinicaltrials.gov/show/NCT00390611,Ovarian_Cancer,Sorafenib|Paclitaxel|Carboplatin|,other_events,arm0,Paclitaxel/Carboplatin/Sorafenib,2,paclitaxel,taxane
2587,Allergic_reaction,4,43,Immune_system_disorders,NCT00390611,https://clinicaltrials.gov/show/NCT00390611,Ovarian_Cancer,Sorafenib|Paclitaxel|Carboplatin|,serious_events,arm0,Paclitaxel/Carboplatin/Sorafenib,2,paclitaxel,taxane
2585,Allergic_reaction,7,43,Immune_system_disorders,NCT00390611,https://clinicaltrials.gov/show/NCT00390611,Ovarian_Cancer,Sorafenib|Paclitaxel|Carboplatin|,other_events,arm0,Paclitaxel/Carboplatin/Sorafenib,90,sorafenib,Tyrosine-Kinase-inhibitor
2587,Allergic_reaction,4,43,Immune_system_disorders,NCT00390611,https://clinicaltrials.gov/show/NCT00390611,Ovarian_Cancer,Sorafenib|Paclitaxel|Carboplatin|,serious_events,arm0,Paclitaxel/Carboplatin/Sorafenib,90,sorafenib,Tyrosine-Kinase-inhibitor
2586,Allergic_reaction,1,42,Immune_system_disorders,NCT00390611,https://clinicaltrials.gov/show/NCT00390611,Ovarian_Cancer,Sorafenib|Paclitaxel|Carboplatin|,serious_events,arm1,Paclitaxel/Carboplatin,3,carboplatin,alkalating-agent
2586,Allergic_reaction,1,42,Immune_system_disorders,NCT00390611,https://clinicaltrials.gov/show/NCT00390611,Ovarian_Cancer,Sorafenib|Paclitaxel|Carboplatin|,serious_events,arm1,Paclitaxel/Carboplatin,2,paclitaxel,taxane
1993,Dermatitis_allergic,1,233,Skin_and_subcutaneous_tissue_disorders,NCT00390806,https://clinicaltrials.gov/show/NCT00390806,Lung_Cancer_Non-Small_Cell,HYCAMTIN_oral_capsules|Radiation|,other_events,arm1,Radiation:-WBRT-Alone,,,
401,Hypersensitivity,1,206,Immune_system_disorders,NCT00391092,https://clinicaltrials.gov/show/NCT00391092,Breast_Cancer,bevacizumab_[Avastin]|Docetaxel|Herceptin|,serious_events,arm0,Trastuzumab-+-Docetaxel,18,trastuzumab,monoclonal-antibody
403,Hypersensitivity,14,206,Immune_system_disorders,NCT00391092,https://clinicaltrials.gov/show/NCT00391092,Breast_Cancer,bevacizumab_[Avastin]|Docetaxel|Herceptin|,other_events,arm0,Trastuzumab-+-Docetaxel,18,trastuzumab,monoclonal-antibody
401,Hypersensitivity,1,206,Immune_system_disorders,NCT00391092,https://clinicaltrials.gov/show/NCT00391092,Breast_Cancer,bevacizumab_[Avastin]|Docetaxel|Herceptin|,serious_events,arm0,Trastuzumab-+-Docetaxel,8,docetaxel,taxane
403,Hypersensitivity,14,206,Immune_system_disorders,NCT00391092,https://clinicaltrials.gov/show/NCT00391092,Breast_Cancer,bevacizumab_[Avastin]|Docetaxel|Herceptin|,other_events,arm0,Trastuzumab-+-Docetaxel,8,docetaxel,taxane
402,Hypersensitivity,10,215,Immune_system_disorders,NCT00391092,https://clinicaltrials.gov/show/NCT00391092,Breast_Cancer,bevacizumab_[Avastin]|Docetaxel|Herceptin|,other_events,arm1,Trastuzumab-+-Bevacizumab-+-Docetaxel,4,bevacizumab,monoclonal-antibody
402,Hypersensitivity,10,215,Immune_system_disorders,NCT00391092,https://clinicaltrials.gov/show/NCT00391092,Breast_Cancer,bevacizumab_[Avastin]|Docetaxel|Herceptin|,other_events,arm1,Trastuzumab-+-Bevacizumab-+-Docetaxel,22,bevacizumab,monoclonal-antibody
402,Hypersensitivity,10,215,Immune_system_disorders,NCT00391092,https://clinicaltrials.gov/show/NCT00391092,Breast_Cancer,bevacizumab_[Avastin]|Docetaxel|Herceptin|,other_events,arm1,Trastuzumab-+-Bevacizumab-+-Docetaxel,18,trastuzumab,monoclonal-antibody
402,Hypersensitivity,10,215,Immune_system_disorders,NCT00391092,https://clinicaltrials.gov/show/NCT00391092,Breast_Cancer,bevacizumab_[Avastin]|Docetaxel|Herceptin|,other_events,arm1,Trastuzumab-+-Bevacizumab-+-Docetaxel,8,docetaxel,taxane
1369,Drug_hypersensitivity,2,10,Immune_system_disorders,NCT00391625,https://clinicaltrials.gov/show/NCT00391625,Gaucher_Disease_Type_1,GA-GCB,other_events,arm0,GA-GCB,,,
404,Hypersensitivity,1,10,Immune_system_disorders,NCT00391625,https://clinicaltrials.gov/show/NCT00391625,Gaucher_Disease_Type_1,GA-GCB,other_events,arm0,GA-GCB,,,
2588,Allergic_Reaction,2,29,Immune_system_disorders,NCT00392392,https://clinicaltrials.gov/show/NCT00392392,Breast_Cancer,nab-paclitaxel|Bevacizumab|Trastuzumab|,other_events,arm0,Nab-Paclitaxel/Bevacizumab/Trastuzumab,4,bevacizumab,monoclonal-antibody
2588,Allergic_Reaction,2,29,Immune_system_disorders,NCT00392392,https://clinicaltrials.gov/show/NCT00392392,Breast_Cancer,nab-paclitaxel|Bevacizumab|Trastuzumab|,other_events,arm0,Nab-Paclitaxel/Bevacizumab/Trastuzumab,22,bevacizumab,monoclonal-antibody
2588,Allergic_Reaction,2,29,Immune_system_disorders,NCT00392392,https://clinicaltrials.gov/show/NCT00392392,Breast_Cancer,nab-paclitaxel|Bevacizumab|Trastuzumab|,other_events,arm0,Nab-Paclitaxel/Bevacizumab/Trastuzumab,18,trastuzumab,monoclonal-antibody
2588,Allergic_Reaction,2,29,Immune_system_disorders,NCT00392392,https://clinicaltrials.gov/show/NCT00392392,Breast_Cancer,nab-paclitaxel|Bevacizumab|Trastuzumab|,other_events,arm0,Nab-Paclitaxel/Bevacizumab/Trastuzumab,2,paclitaxel,taxane
412,Hypersensitivity,1,295,Immune_system_disorders,NCT00393939,https://clinicaltrials.gov/show/NCT00393939,Breast_Neoplasms,Sunitinib_malate|Taxotere|,serious_events,arm0,Docetaxel-+-Sunitinib,8,docetaxel,taxane
412,Hypersensitivity,1,295,Immune_system_disorders,NCT00393939,https://clinicaltrials.gov/show/NCT00393939,Breast_Neoplasms,Sunitinib_malate|Taxotere|,serious_events,arm0,Docetaxel-+-Sunitinib,27,sunitinib,tyrosine-kinase-inhibitor-and-angiogenesis-inhibitor
414,Hypersensitivity,3,30,Immune_system_disorders,NCT00394836,https://clinicaltrials.gov/show/NCT00394836,Lymphoma_Follicular,Ofatumumab|Ofatumumab|,other_events,arm0,Ofatumumab-500-mg,42,ofatumumab,monoclonal-antibody
1372,Drug_hypersensitivity,1,86,Immune_system_disorders,NCT00394836,https://clinicaltrials.gov/show/NCT00394836,Lymphoma_Follicular,Ofatumumab|Ofatumumab|,serious_events,arm1,Ofatumumab-1000-mg,42,ofatumumab,monoclonal-antibody
413,Hypersensitivity,6,86,Immune_system_disorders,NCT00394836,https://clinicaltrials.gov/show/NCT00394836,Lymphoma_Follicular,Ofatumumab|Ofatumumab|,other_events,arm1,Ofatumumab-1000-mg,42,ofatumumab,monoclonal-antibody
1376,Drug_Hypersensitivity,1,246,Immune_system_disorders,NCT00396318,https://clinicaltrials.gov/show/NCT00396318,Dysfunctional_Central_Venous_Access_Catheters,tenecteplase,other_events,arm0,Tenecteplase,,,
1381,Drug_Hypersensitivity,1,214,Immune_system_disorders,NCT00399035,https://clinicaltrials.gov/show/NCT00399035,Metastatic_Colorectal_Cancer,Cediranib|FOLFOX_(5-fluorouracil_Leucovorin_Oxaliplatin)|XELOX_(Capecitabine_and_Oxaliplatin)|Cediranib_Placebo|,serious_events,arm0,Cediranib-30mg,14,cediranib,endothelial-growith-factor-receptor-tyrosine-kinase-inhibitor?
1382,Drug_Hypersensitivity,6,214,Immune_system_disorders,NCT00399035,https://clinicaltrials.gov/show/NCT00399035,Metastatic_Colorectal_Cancer,Cediranib|FOLFOX_(5-fluorouracil_Leucovorin_Oxaliplatin)|XELOX_(Capecitabine_and_Oxaliplatin)|Cediranib_Placebo|,other_events,arm0,Cediranib-30mg,14,cediranib,endothelial-growith-factor-receptor-tyrosine-kinase-inhibitor?
1380,Drug_Hypersensitivity,24,500,Immune_system_disorders,NCT00399035,https://clinicaltrials.gov/show/NCT00399035,Metastatic_Colorectal_Cancer,Cediranib|FOLFOX_(5-fluorouracil_Leucovorin_Oxaliplatin)|XELOX_(Capecitabine_and_Oxaliplatin)|Cediranib_Placebo|,other_events,arm1,Cediranib-20mg,14,cediranib,endothelial-growith-factor-receptor-tyrosine-kinase-inhibitor?
1384,Drug_Hypersensitivity,3,500,Immune_system_disorders,NCT00399035,https://clinicaltrials.gov/show/NCT00399035,Metastatic_Colorectal_Cancer,Cediranib|FOLFOX_(5-fluorouracil_Leucovorin_Oxaliplatin)|XELOX_(Capecitabine_and_Oxaliplatin)|Cediranib_Placebo|,serious_events,arm1,Cediranib-20mg,14,cediranib,endothelial-growith-factor-receptor-tyrosine-kinase-inhibitor?
1383,Drug_Hypersensitivity,2,358,Immune_system_disorders,NCT00399035,https://clinicaltrials.gov/show/NCT00399035,Metastatic_Colorectal_Cancer,Cediranib|FOLFOX_(5-fluorouracil_Leucovorin_Oxaliplatin)|XELOX_(Capecitabine_and_Oxaliplatin)|Cediranib_Placebo|,serious_events,arm2,Placebo,,,
1385,Drug_Hypersensitivity,19,358,Immune_system_disorders,NCT00399035,https://clinicaltrials.gov/show/NCT00399035,Metastatic_Colorectal_Cancer,Cediranib|FOLFOX_(5-fluorouracil_Leucovorin_Oxaliplatin)|XELOX_(Capecitabine_and_Oxaliplatin)|Cediranib_Placebo|,other_events,arm2,Placebo,,,
1386,DRUG_HYPERSENSITIVITY,2,26,Immune_system_disorders,NCT00400764,https://clinicaltrials.gov/show/NCT00400764,Non-Hodgkin's_Lymphoma,Dulanermin|Rituximab|,other_events,arm3,Phase-II---Combination-Therapy,,,
420,Hypersensitivity,1,66,Immune_system_disorders,NCT00400829,https://clinicaltrials.gov/show/NCT00400829,Recurrent_Non-small_Cell_Lung_Cancer|Stage_IIIB_Non-small_Cell_Lung_Cancer|Stage_IV_Non-small_Cell_Lung_Cancer|,eribulin_mesylate,serious_events,arm0,Arm-I,,,
1387,Drug_hypersensitivity,1,66,Immune_system_disorders,NCT00404495,https://clinicaltrials.gov/show/NCT00404495,Glioma|Medulloblastoma|,Irinotecan|Temozolomide|,serious_events,arm0,Temozolomide-+-Irinotecan-for-Medulloblastoma,98,temozolomide,alkylating-agent
1387,Drug_hypersensitivity,1,66,Immune_system_disorders,NCT00404495,https://clinicaltrials.gov/show/NCT00404495,Glioma|Medulloblastoma|,Irinotecan|Temozolomide|,serious_events,arm0,Temozolomide-+-Irinotecan-for-Medulloblastoma,46,irinotecan,plant-alkaloid-and-topoisomerase-1-inhibitor
1388,Drug_hypersensitivity,1,17,Immune_system_disorders,NCT00404495,https://clinicaltrials.gov/show/NCT00404495,Glioma|Medulloblastoma|,Irinotecan|Temozolomide|,other_events,arm1,Temozolomide-+-Irinotecan-for-High-Grade-Glioma,98,temozolomide,alkylating-agent
1388,Drug_hypersensitivity,1,17,Immune_system_disorders,NCT00404495,https://clinicaltrials.gov/show/NCT00404495,Glioma|Medulloblastoma|,Irinotecan|Temozolomide|,other_events,arm1,Temozolomide-+-Irinotecan-for-High-Grade-Glioma,46,irinotecan,plant-alkaloid-and-topoisomerase-1-inhibitor
1997,Dermatitis_Allergic,1,619,Skin_and_subcutaneous_tissue_disorders,NCT00404924,https://clinicaltrials.gov/show/NCT00404924,Non-Small-Cell_Lung_Carcinoma,ZD6474_(vandetanib)|Best_Supportive_Care|,serious_events,arm0,Vandetanib,33,vandetanib,tyrosine-kinase-inhibitor
1389,Drug_Hypersensitivity,2,619,Immune_system_disorders,NCT00404924,https://clinicaltrials.gov/show/NCT00404924,Non-Small-Cell_Lung_Carcinoma,ZD6474_(vandetanib)|Best_Supportive_Care|,serious_events,arm0,Vandetanib,33,vandetanib,tyrosine-kinase-inhibitor
422,Hypersensitivity,1,150,Immune_system_disorders,NCT00405756,https://clinicaltrials.gov/show/NCT00405756,Newly_Diagnosed_Multiple_Myeloma,Lenalidomide:_Double-blind_Induction|Melphalan|Prednisone|Aspirin|Placebo|Lenalidomide:_Double-blind_Maintenance|Lenalidomide:_Open-label|,serious_events,arm0,MPR+R,,,
423,Hypersensitivity,2,48,Immune_system_disorders,NCT00407563,https://clinicaltrials.gov/show/NCT00407563,Epithelial_Ovarian_Cancer|Primary_Peritoneal_Carcinoma|,Bevacizumab|Abraxane|,other_events,arm0,Bevacizumab-and-Abraxane,4,bevacizumab,monoclonal-antibody
423,Hypersensitivity,2,48,Immune_system_disorders,NCT00407563,https://clinicaltrials.gov/show/NCT00407563,Epithelial_Ovarian_Cancer|Primary_Peritoneal_Carcinoma|,Bevacizumab|Abraxane|,other_events,arm0,Bevacizumab-and-Abraxane,22,bevacizumab,monoclonal-antibody
2591,Allergic_reaction,1,44,Immune_system_disorders,NCT00408694,https://clinicaltrials.gov/show/NCT00408694,Stage_II_Squamous_Cell_Carcinoma_of_the_Nasopharynx|Stage_III_Lymphoepithelioma_of_the_Nasopharynx|Stage_III_Squamous_Cell_Carcinoma_of_the_Nasopharynx|Stage_IV_Lymphoepithelioma_of_the_Nasopharynx|Stage_IV_Squamous_Cell_Carcinoma_of_the_Nasopharynx|,3-dimensional_conformal_radiation_therapy|intensity-modulated_radiation_therapy|bevacizumab|cisplatin|fluorouracil|,other_events,arm0,Treatment-(Bevacizumab-Cisplatin-Fluorouracil-IMRT-3D-CRT),9,cisplatin,alkalating-agent
2591,Allergic_reaction,1,44,Immune_system_disorders,NCT00408694,https://clinicaltrials.gov/show/NCT00408694,Stage_II_Squamous_Cell_Carcinoma_of_the_Nasopharynx|Stage_III_Lymphoepithelioma_of_the_Nasopharynx|Stage_III_Squamous_Cell_Carcinoma_of_the_Nasopharynx|Stage_IV_Lymphoepithelioma_of_the_Nasopharynx|Stage_IV_Squamous_Cell_Carcinoma_of_the_Nasopharynx|,3-dimensional_conformal_radiation_therapy|intensity-modulated_radiation_therapy|bevacizumab|cisplatin|fluorouracil|,other_events,arm0,Treatment-(Bevacizumab-Cisplatin-Fluorouracil-IMRT-3D-CRT),11,fluorouracil,antimetabolites
2591,Allergic_reaction,1,44,Immune_system_disorders,NCT00408694,https://clinicaltrials.gov/show/NCT00408694,Stage_II_Squamous_Cell_Carcinoma_of_the_Nasopharynx|Stage_III_Lymphoepithelioma_of_the_Nasopharynx|Stage_III_Squamous_Cell_Carcinoma_of_the_Nasopharynx|Stage_IV_Lymphoepithelioma_of_the_Nasopharynx|Stage_IV_Squamous_Cell_Carcinoma_of_the_Nasopharynx|,3-dimensional_conformal_radiation_therapy|intensity-modulated_radiation_therapy|bevacizumab|cisplatin|fluorouracil|,other_events,arm0,Treatment-(Bevacizumab-Cisplatin-Fluorouracil-IMRT-3D-CRT),4,bevacizumab,monoclonal-antibody
2591,Allergic_reaction,1,44,Immune_system_disorders,NCT00408694,https://clinicaltrials.gov/show/NCT00408694,Stage_II_Squamous_Cell_Carcinoma_of_the_Nasopharynx|Stage_III_Lymphoepithelioma_of_the_Nasopharynx|Stage_III_Squamous_Cell_Carcinoma_of_the_Nasopharynx|Stage_IV_Lymphoepithelioma_of_the_Nasopharynx|Stage_IV_Squamous_Cell_Carcinoma_of_the_Nasopharynx|,3-dimensional_conformal_radiation_therapy|intensity-modulated_radiation_therapy|bevacizumab|cisplatin|fluorouracil|,other_events,arm0,Treatment-(Bevacizumab-Cisplatin-Fluorouracil-IMRT-3D-CRT),22,bevacizumab,monoclonal-antibody
427,Hypersensitivity,1,274,Immune_system_disorders,NCT00410124,https://clinicaltrials.gov/show/NCT00410124,Metastatic_Renal_Cell_Carcinoma,RAD001|Placebo|,serious_events,arm0,Randomized-to-RAD001+-BSC-(-Blinded-+-Open-Label),,,
426,Hypersensitivity,1,111,Immune_system_disorders,NCT00410124,https://clinicaltrials.gov/show/NCT00410124,Metastatic_Renal_Cell_Carcinoma,RAD001|Placebo|,serious_events,arm1,Randomized-to-Placebo-+-BSC-(Open-Label),,,
2592,Allergic_reaction,1,40,Immune_system_disorders,NCT00410904,https://clinicaltrials.gov/show/NCT00410904,Recurrent_Non-small_Cell_Lung_Cancer,cediranib_maleate|pemetrexed_disodium|,serious_events,arm0,Arm-I---Cohort-A,,,
2347,Anaphylaxis,1,40,Immune_system_disorders,NCT00410904,https://clinicaltrials.gov/show/NCT00410904,Recurrent_Non-small_Cell_Lung_Cancer,cediranib_maleate|pemetrexed_disodium|,serious_events,arm0,Arm-I---Cohort-A,,,
1394,Drug_hypersensitivity,1,170,Immune_system_disorders,NCT00412061,https://clinicaltrials.gov/show/NCT00412061,Carcinoid_Tumor|Malignant_Carcinoid_Syndrome|,Octreotide|Placebo|Everolimus|,serious_events,arm2,Everolimus-Open-Label,32,everolimus,mTOR?inhibitor-(blocks-gene-translation)
429,Hypersensitivity,1,112,Immune_system_disorders,NCT00412971,https://clinicaltrials.gov/show/NCT00412971,Bladder_Cancer,Hexvix|Standard_white_light_cystoscopy|,other_events,arm0,Hexvix-Cystoscopy-Group,,,
430,Hypersensitivity,1,118,Immune_system_disorders,NCT00412971,https://clinicaltrials.gov/show/NCT00412971,Bladder_Cancer,Hexvix|Standard_white_light_cystoscopy|,other_events,arm1,White-Light,,,
2000,Dermatitis_allergic,1,16,Skin_and_subcutaneous_tissue_disorders,NCT00413283,https://clinicaltrials.gov/show/NCT00413283,Lung_Cancer|Chemotherapy-Induced_Thrombocytopenia|Non-Small_Cell_Lung_Cancer|Cancer|Lung_Neoplasms|Oncology|Solid_Tumors|Thrombocytopenia|,Romiplostim|Placebo|Gemcitabine|Carboplatin|Cisplatin|,other_events,arm1,Romiplostim-250-??g,84,romiplostim,Class_Name_Needed
433,Hypersensitivity,2,385,Immune_system_disorders,NCT00415194,https://clinicaltrials.gov/show/NCT00415194,Head_and_Neck_Neoplasms,pemetrexed|cisplatin|placebo|,serious_events,arm1,Placebo/Cisplatin,9,cisplatin,alkalating-agent
2593,Allergic_reaction,1,19,Immune_system_disorders,NCT00416494,https://clinicaltrials.gov/show/NCT00416494,Colorectal_Cancer,bevacizumab|oxaliplatin|Capecitabine|Capecitabine|,other_events,arm0,Initial-Cohort,,,
437,Hypersensitivity,1,273,Immune_system_disorders,NCT00418886,https://clinicaltrials.gov/show/NCT00418886,Non_Small_Cell_Lung_Cancer|Lung_Cancer|,Vandetanib|Pemetrexed|,serious_events,arm1,Placebo-Plus-Pemetrexed,15,pemetrexed,antimetabolite
2003,Dermatitis_Allergic,1,408,Skin_and_subcutaneous_tissue_disorders,NCT00420212,https://clinicaltrials.gov/show/NCT00420212,Relapsing-Remitting_Multiple_Sclerosis,BG00012|Placebo|,serious_events,arm0,Placebo,,,
439,Hypersensitivity,1,410,Immune_system_disorders,NCT00420212,https://clinicaltrials.gov/show/NCT00420212,Relapsing-Remitting_Multiple_Sclerosis,BG00012|Placebo|,serious_events,arm1,BG00012-240-mg-Twice-Daily-(BID),,,
438,Hypersensitivity,1,416,Immune_system_disorders,NCT00420212,https://clinicaltrials.gov/show/NCT00420212,Relapsing-Remitting_Multiple_Sclerosis,BG00012|Placebo|,serious_events,arm2,BG00012-240-mg-3-Times-Daily-(TID),,,
440,Hypersensitivity,2,826,Immune_system_disorders,NCT00420212,https://clinicaltrials.gov/show/NCT00420212,Relapsing-Remitting_Multiple_Sclerosis,BG00012|Placebo|,serious_events,arm3,Total-BG00012,,,
1398,Drug_hypersensitivity,1,587,Immune_system_disorders,NCT00420849,https://clinicaltrials.gov/show/NCT00420849,Multiple_Myeloma,Lenalidomide|Dexamethasone|,serious_events,arm0,Lenalidomide-Plus-Dexamethasone,25,lenalidomide,immunomodulatory-agent-or-antiangiogenic-agent
1398,Drug_hypersensitivity,1,587,Immune_system_disorders,NCT00420849,https://clinicaltrials.gov/show/NCT00420849,Multiple_Myeloma,Lenalidomide|Dexamethasone|,serious_events,arm0,Lenalidomide-Plus-Dexamethasone,79,dexamethasone,steroid
1399,Drug_hypersensitivity,1,23,Immune_system_disorders,NCT00421889,https://clinicaltrials.gov/show/NCT00421889,Ovarian_Cancer|Epithelial_Ovarian_Cancer|Fallopian_Tube_Cancer|Bladder_Cancer|,belinostat|Paclitaxel|Carboplatin|,serious_events,arm0,Part-A:-Dose-Escalation-(N=23),,,
1402,Drug_hypersensitivity,2,23,Immune_system_disorders,NCT00421889,https://clinicaltrials.gov/show/NCT00421889,Ovarian_Cancer|Epithelial_Ovarian_Cancer|Fallopian_Tube_Cancer|Bladder_Cancer|,belinostat|Paclitaxel|Carboplatin|,other_events,arm0,Part-A:-Dose-Escalation-(N=23),,,
442,Hypersensitivity,1,23,Immune_system_disorders,NCT00421889,https://clinicaltrials.gov/show/NCT00421889,Ovarian_Cancer|Epithelial_Ovarian_Cancer|Fallopian_Tube_Cancer|Bladder_Cancer|,belinostat|Paclitaxel|Carboplatin|,other_events,arm0,Part-A:-Dose-Escalation-(N=23),,,
1400,Drug_hypersensitivity,2,35,Immune_system_disorders,NCT00421889,https://clinicaltrials.gov/show/NCT00421889,Ovarian_Cancer|Epithelial_Ovarian_Cancer|Fallopian_Tube_Cancer|Bladder_Cancer|,belinostat|Paclitaxel|Carboplatin|,serious_events,arm1,Part-B:-Ovarian-Cancer-MTD-(N=35),,,
1404,Drug_hypersensitivity,8,35,Immune_system_disorders,NCT00421889,https://clinicaltrials.gov/show/NCT00421889,Ovarian_Cancer|Epithelial_Ovarian_Cancer|Fallopian_Tube_Cancer|Bladder_Cancer|,belinostat|Paclitaxel|Carboplatin|,other_events,arm1,Part-B:-Ovarian-Cancer-MTD-(N=35),,,
441,Hypersensitivity,1,35,Immune_system_disorders,NCT00421889,https://clinicaltrials.gov/show/NCT00421889,Ovarian_Cancer|Epithelial_Ovarian_Cancer|Fallopian_Tube_Cancer|Bladder_Cancer|,belinostat|Paclitaxel|Carboplatin|,serious_events,arm1,Part-B:-Ovarian-Cancer-MTD-(N=35),,,
443,Hypersensitivity,2,35,Immune_system_disorders,NCT00421889,https://clinicaltrials.gov/show/NCT00421889,Ovarian_Cancer|Epithelial_Ovarian_Cancer|Fallopian_Tube_Cancer|Bladder_Cancer|,belinostat|Paclitaxel|Carboplatin|,other_events,arm1,Part-B:-Ovarian-Cancer-MTD-(N=35),,,
1401,Drug_hypersensitivity,3,7,Immune_system_disorders,NCT00421889,https://clinicaltrials.gov/show/NCT00421889,Ovarian_Cancer|Epithelial_Ovarian_Cancer|Fallopian_Tube_Cancer|Bladder_Cancer|,belinostat|Paclitaxel|Carboplatin|,other_events,arm2,Part-C:-3-6-Hours-Infusion-(N=7),,,
2006,Dermatitis_allergic,1,15,Skin_and_subcutaneous_tissue_disorders,NCT00421889,https://clinicaltrials.gov/show/NCT00421889,Ovarian_Cancer|Epithelial_Ovarian_Cancer|Fallopian_Tube_Cancer|Bladder_Cancer|,belinostat|Paclitaxel|Carboplatin|,other_events,arm3,Part-D:-Bladder-Cancer-MTD-(N=15),,,
1403,Drug_hypersensitivity,4,15,Immune_system_disorders,NCT00421889,https://clinicaltrials.gov/show/NCT00421889,Ovarian_Cancer|Epithelial_Ovarian_Cancer|Fallopian_Tube_Cancer|Bladder_Cancer|,belinostat|Paclitaxel|Carboplatin|,other_events,arm3,Part-D:-Bladder-Cancer-MTD-(N=15),,,
2594,Allergic_reaction,2,52,Immune_system_disorders,NCT00423293,https://clinicaltrials.gov/show/NCT00423293,Anal_Cancer,fluorouracil|mitomycin_C|Intensity-modulated_radiation_therapy|,other_events,arm0,5-FU-+-Mitomycin-+-IMRT,,,
1406,Drug_hypersensitivity,1,18,Immune_system_disorders,NCT00423449,https://clinicaltrials.gov/show/NCT00423449,Non-Small_Cell_Lung_Cancer,vorinostat|Gemcitabine|Platinum-based_agent|,other_events,arm2,MK-0683-400-mg-7d/21d-+-Gemcitabine-1250-mg/m^2-+-Cisplatin,9,cisplatin,alkalating-agent
1406,Drug_hypersensitivity,1,18,Immune_system_disorders,NCT00423449,https://clinicaltrials.gov/show/NCT00423449,Non-Small_Cell_Lung_Cancer,vorinostat|Gemcitabine|Platinum-based_agent|,other_events,arm2,MK-0683-400-mg-7d/21d-+-Gemcitabine-1250-mg/m^2-+-Cisplatin,6,gemcitabine,antimetabolites
446,Hypersensitivity,1,131,Immune_system_disorders,NCT00426764,https://clinicaltrials.gov/show/NCT00426764,Peripheral_T-cell_Lymphoma,Romidepsin,serious_events,arm0,Romidepsin,,,
1411,Drug_Hypersensitivity,1,65,Immune_system_disorders,NCT00428584,https://clinicaltrials.gov/show/NCT00428584,Relapsing_Remitting_Multiple_Sclerosis_(RRMS),New_Formulation_of_rebif_-_human_interferon_beta-1a|Interferon_beta_-1b|,other_events,arm0,New-Formulation-of-Rebif,,,
448,Hypersensitivity,1,65,Immune_system_disorders,NCT00428584,https://clinicaltrials.gov/show/NCT00428584,Relapsing_Remitting_Multiple_Sclerosis_(RRMS),New_Formulation_of_rebif_-_human_interferon_beta-1a|Interferon_beta_-1b|,other_events,arm0,New-Formulation-of-Rebif,,,
449,Hypersensitivity,1,25,Immune_system_disorders,NCT00428844,https://clinicaltrials.gov/show/NCT00428844,Osteomyelitis,daptomycin|daptomycin|vancomycin|teicoplanin|nafcillin|oxacillin|flucloxacillin|,serious_events,arm2,Comparator,,,
450,Hypersensitivity,2,8,Immune_system_disorders,NCT00430027,https://clinicaltrials.gov/show/NCT00430027,Esophageal_Adenocarcinoma,Capecitabine|Oxaliplatin|Cetuximab|,other_events,arm0,Capecitabine-Oxaliplatin-Cetuximab-and-Radiation-Therapy,7,oxaliplatin,alkalating-agent
450,Hypersensitivity,2,8,Immune_system_disorders,NCT00430027,https://clinicaltrials.gov/show/NCT00430027,Esophageal_Adenocarcinoma,Capecitabine|Oxaliplatin|Cetuximab|,other_events,arm0,Capecitabine-Oxaliplatin-Cetuximab-and-Radiation-Therapy,17,capecitabine,antimetabolite
450,Hypersensitivity,2,8,Immune_system_disorders,NCT00430027,https://clinicaltrials.gov/show/NCT00430027,Esophageal_Adenocarcinoma,Capecitabine|Oxaliplatin|Cetuximab|,other_events,arm0,Capecitabine-Oxaliplatin-Cetuximab-and-Radiation-Therapy,29,capecitabine,antimetabolite
450,Hypersensitivity,2,8,Immune_system_disorders,NCT00430027,https://clinicaltrials.gov/show/NCT00430027,Esophageal_Adenocarcinoma,Capecitabine|Oxaliplatin|Cetuximab|,other_events,arm0,Capecitabine-Oxaliplatin-Cetuximab-and-Radiation-Therapy,5,cetuximab,Epidermal-growth-factor-receptor-inhibitor
2595,Allergic_reaction,1,60,Immune_system_disorders,NCT00433381,https://clinicaltrials.gov/show/NCT00433381,Adult_Glioblastoma|Adult_Gliosarcoma|Recurrent_Adult_Brain_Tumor|,irinotecan_hydrochloride|bevacizumab|temozolomide|,other_events,arm0,Arm-I-(Bevacizumab-and-Temozolomide),98,temozolomide,alkylating-agent
2595,Allergic_reaction,1,60,Immune_system_disorders,NCT00433381,https://clinicaltrials.gov/show/NCT00433381,Adult_Glioblastoma|Adult_Gliosarcoma|Recurrent_Adult_Brain_Tumor|,irinotecan_hydrochloride|bevacizumab|temozolomide|,other_events,arm0,Arm-I-(Bevacizumab-and-Temozolomide),4,bevacizumab,monoclonal-antibody
2595,Allergic_reaction,1,60,Immune_system_disorders,NCT00433381,https://clinicaltrials.gov/show/NCT00433381,Adult_Glioblastoma|Adult_Gliosarcoma|Recurrent_Adult_Brain_Tumor|,irinotecan_hydrochloride|bevacizumab|temozolomide|,other_events,arm0,Arm-I-(Bevacizumab-and-Temozolomide),22,bevacizumab,monoclonal-antibody
2596,Allergic_reaction,1,57,Immune_system_disorders,NCT00433381,https://clinicaltrials.gov/show/NCT00433381,Adult_Glioblastoma|Adult_Gliosarcoma|Recurrent_Adult_Brain_Tumor|,irinotecan_hydrochloride|bevacizumab|temozolomide|,other_events,arm1,Arm-II-(Bevacizumab-and-Irinotecan-Hydrochloride),4,bevacizumab,monoclonal-antibody
2596,Allergic_reaction,1,57,Immune_system_disorders,NCT00433381,https://clinicaltrials.gov/show/NCT00433381,Adult_Glioblastoma|Adult_Gliosarcoma|Recurrent_Adult_Brain_Tumor|,irinotecan_hydrochloride|bevacizumab|temozolomide|,other_events,arm1,Arm-II-(Bevacizumab-and-Irinotecan-Hydrochloride),22,bevacizumab,monoclonal-antibody
2596,Allergic_reaction,1,57,Immune_system_disorders,NCT00433381,https://clinicaltrials.gov/show/NCT00433381,Adult_Glioblastoma|Adult_Gliosarcoma|Recurrent_Adult_Brain_Tumor|,irinotecan_hydrochloride|bevacizumab|temozolomide|,other_events,arm1,Arm-II-(Bevacizumab-and-Irinotecan-Hydrochloride),46,irinotecan,plant-alkaloid-and-topoisomerase-1-inhibitor
2597,Allergic_reaction,1,77,Immune_system_disorders,NCT00433537,https://clinicaltrials.gov/show/NCT00433537,Contiguous_Stage_II_Mantle_Cell_Lymphoma|Noncontiguous_Stage_II_Mantle_Cell_Lymphoma|Stage_I_Mantle_Cell_Lymphoma|Stage_III_Mantle_Cell_Lymphoma|Stage_IV_Mantle_Cell_Lymphoma|,bortezomib|rituximab|cyclophosphamide|doxorubicin_hydrochloride|vincristine|dexamethasone|filgrastim|pegfilgrastim|Autologous_stem_cell_transplantation_(ASCT)|,serious_events,arm0,Step-1---VcR-CVAD-Induction,,,
1417,Drug_Hypersensitivity,1,69,Immune_system_disorders,NCT00434252,https://clinicaltrials.gov/show/NCT00434252,Melanoma,bevacizumab|carboplatin|paclitaxel|placebo|,serious_events,arm0,Carboplatin+Paclitaxel+Placebo,3,carboplatin,alkalating-agent
453,Hypersensitivity,4,69,Immune_system_disorders,NCT00434252,https://clinicaltrials.gov/show/NCT00434252,Melanoma,bevacizumab|carboplatin|paclitaxel|placebo|,other_events,arm0,Carboplatin+Paclitaxel+Placebo,3,carboplatin,alkalating-agent
1417,Drug_Hypersensitivity,1,69,Immune_system_disorders,NCT00434252,https://clinicaltrials.gov/show/NCT00434252,Melanoma,bevacizumab|carboplatin|paclitaxel|placebo|,serious_events,arm0,Carboplatin+Paclitaxel+Placebo,2,paclitaxel,taxane
453,Hypersensitivity,4,69,Immune_system_disorders,NCT00434252,https://clinicaltrials.gov/show/NCT00434252,Melanoma,bevacizumab|carboplatin|paclitaxel|placebo|,other_events,arm0,Carboplatin+Paclitaxel+Placebo,2,paclitaxel,taxane
454,Hypersensitivity,7,143,Immune_system_disorders,NCT00434252,https://clinicaltrials.gov/show/NCT00434252,Melanoma,bevacizumab|carboplatin|paclitaxel|placebo|,other_events,arm1,Carboplatin+Paclitaxel+Bevacizumab,3,carboplatin,alkalating-agent
454,Hypersensitivity,7,143,Immune_system_disorders,NCT00434252,https://clinicaltrials.gov/show/NCT00434252,Melanoma,bevacizumab|carboplatin|paclitaxel|placebo|,other_events,arm1,Carboplatin+Paclitaxel+Bevacizumab,4,bevacizumab,monoclonal-antibody
454,Hypersensitivity,7,143,Immune_system_disorders,NCT00434252,https://clinicaltrials.gov/show/NCT00434252,Melanoma,bevacizumab|carboplatin|paclitaxel|placebo|,other_events,arm1,Carboplatin+Paclitaxel+Bevacizumab,22,bevacizumab,monoclonal-antibody
454,Hypersensitivity,7,143,Immune_system_disorders,NCT00434252,https://clinicaltrials.gov/show/NCT00434252,Melanoma,bevacizumab|carboplatin|paclitaxel|placebo|,other_events,arm1,Carboplatin+Paclitaxel+Bevacizumab,2,paclitaxel,taxane
1418,Drug_Hypersensitivity,1,23,Immune_system_disorders,NCT00434356,https://clinicaltrials.gov/show/NCT00434356,Metastatic_Breast_Cancer,bevacizumab|sunitinib|paclitaxel|,serious_events,arm1,Bevacizumab-+-Paclitaxel,4,bevacizumab,monoclonal-antibody
1418,Drug_Hypersensitivity,1,23,Immune_system_disorders,NCT00434356,https://clinicaltrials.gov/show/NCT00434356,Metastatic_Breast_Cancer,bevacizumab|sunitinib|paclitaxel|,serious_events,arm1,Bevacizumab-+-Paclitaxel,22,bevacizumab,monoclonal-antibody
1418,Drug_Hypersensitivity,1,23,Immune_system_disorders,NCT00434356,https://clinicaltrials.gov/show/NCT00434356,Metastatic_Breast_Cancer,bevacizumab|sunitinib|paclitaxel|,serious_events,arm1,Bevacizumab-+-Paclitaxel,2,paclitaxel,taxane
1420,Drug_Hypersensitivity,26,247,Immune_system_disorders,NCT00434642,https://clinicaltrials.gov/show/NCT00434642,Ovarian_Cancer,Carboplatin|Gemcitabine|Bevacizumab|Placebo|,other_events,arm0,Carboplatin-and-Gemcitabine-+-Bevacizumab,3,carboplatin,alkalating-agent
1421,Drug_Hypersensitivity,4,247,Immune_system_disorders,NCT00434642,https://clinicaltrials.gov/show/NCT00434642,Ovarian_Cancer,Carboplatin|Gemcitabine|Bevacizumab|Placebo|,serious_events,arm0,Carboplatin-and-Gemcitabine-+-Bevacizumab,3,carboplatin,alkalating-agent
456,Hypersensitivity,16,247,Immune_system_disorders,NCT00434642,https://clinicaltrials.gov/show/NCT00434642,Ovarian_Cancer,Carboplatin|Gemcitabine|Bevacizumab|Placebo|,other_events,arm0,Carboplatin-and-Gemcitabine-+-Bevacizumab,3,carboplatin,alkalating-agent
457,Hypersensitivity,1,247,Immune_system_disorders,NCT00434642,https://clinicaltrials.gov/show/NCT00434642,Ovarian_Cancer,Carboplatin|Gemcitabine|Bevacizumab|Placebo|,serious_events,arm0,Carboplatin-and-Gemcitabine-+-Bevacizumab,3,carboplatin,alkalating-agent
1420,Drug_Hypersensitivity,26,247,Immune_system_disorders,NCT00434642,https://clinicaltrials.gov/show/NCT00434642,Ovarian_Cancer,Carboplatin|Gemcitabine|Bevacizumab|Placebo|,other_events,arm0,Carboplatin-and-Gemcitabine-+-Bevacizumab,6,gemcitabine,antimetabolites
1421,Drug_Hypersensitivity,4,247,Immune_system_disorders,NCT00434642,https://clinicaltrials.gov/show/NCT00434642,Ovarian_Cancer,Carboplatin|Gemcitabine|Bevacizumab|Placebo|,serious_events,arm0,Carboplatin-and-Gemcitabine-+-Bevacizumab,6,gemcitabine,antimetabolites
456,Hypersensitivity,16,247,Immune_system_disorders,NCT00434642,https://clinicaltrials.gov/show/NCT00434642,Ovarian_Cancer,Carboplatin|Gemcitabine|Bevacizumab|Placebo|,other_events,arm0,Carboplatin-and-Gemcitabine-+-Bevacizumab,6,gemcitabine,antimetabolites
457,Hypersensitivity,1,247,Immune_system_disorders,NCT00434642,https://clinicaltrials.gov/show/NCT00434642,Ovarian_Cancer,Carboplatin|Gemcitabine|Bevacizumab|Placebo|,serious_events,arm0,Carboplatin-and-Gemcitabine-+-Bevacizumab,6,gemcitabine,antimetabolites
1420,Drug_Hypersensitivity,26,247,Immune_system_disorders,NCT00434642,https://clinicaltrials.gov/show/NCT00434642,Ovarian_Cancer,Carboplatin|Gemcitabine|Bevacizumab|Placebo|,other_events,arm0,Carboplatin-and-Gemcitabine-+-Bevacizumab,4,bevacizumab,monoclonal-antibody
1421,Drug_Hypersensitivity,4,247,Immune_system_disorders,NCT00434642,https://clinicaltrials.gov/show/NCT00434642,Ovarian_Cancer,Carboplatin|Gemcitabine|Bevacizumab|Placebo|,serious_events,arm0,Carboplatin-and-Gemcitabine-+-Bevacizumab,4,bevacizumab,monoclonal-antibody
456,Hypersensitivity,16,247,Immune_system_disorders,NCT00434642,https://clinicaltrials.gov/show/NCT00434642,Ovarian_Cancer,Carboplatin|Gemcitabine|Bevacizumab|Placebo|,other_events,arm0,Carboplatin-and-Gemcitabine-+-Bevacizumab,4,bevacizumab,monoclonal-antibody
457,Hypersensitivity,1,247,Immune_system_disorders,NCT00434642,https://clinicaltrials.gov/show/NCT00434642,Ovarian_Cancer,Carboplatin|Gemcitabine|Bevacizumab|Placebo|,serious_events,arm0,Carboplatin-and-Gemcitabine-+-Bevacizumab,4,bevacizumab,monoclonal-antibody
1420,Drug_Hypersensitivity,26,247,Immune_system_disorders,NCT00434642,https://clinicaltrials.gov/show/NCT00434642,Ovarian_Cancer,Carboplatin|Gemcitabine|Bevacizumab|Placebo|,other_events,arm0,Carboplatin-and-Gemcitabine-+-Bevacizumab,22,bevacizumab,monoclonal-antibody
1421,Drug_Hypersensitivity,4,247,Immune_system_disorders,NCT00434642,https://clinicaltrials.gov/show/NCT00434642,Ovarian_Cancer,Carboplatin|Gemcitabine|Bevacizumab|Placebo|,serious_events,arm0,Carboplatin-and-Gemcitabine-+-Bevacizumab,22,bevacizumab,monoclonal-antibody
456,Hypersensitivity,16,247,Immune_system_disorders,NCT00434642,https://clinicaltrials.gov/show/NCT00434642,Ovarian_Cancer,Carboplatin|Gemcitabine|Bevacizumab|Placebo|,other_events,arm0,Carboplatin-and-Gemcitabine-+-Bevacizumab,22,bevacizumab,monoclonal-antibody
457,Hypersensitivity,1,247,Immune_system_disorders,NCT00434642,https://clinicaltrials.gov/show/NCT00434642,Ovarian_Cancer,Carboplatin|Gemcitabine|Bevacizumab|Placebo|,serious_events,arm0,Carboplatin-and-Gemcitabine-+-Bevacizumab,22,bevacizumab,monoclonal-antibody
1419,Drug_Hypersensitivity,3,233,Immune_system_disorders,NCT00434642,https://clinicaltrials.gov/show/NCT00434642,Ovarian_Cancer,Carboplatin|Gemcitabine|Bevacizumab|Placebo|,serious_events,arm1,Carboplatin-and-Gemcitabine-+-Placebo,3,carboplatin,alkalating-agent
1422,Drug_Hypersensitivity,15,233,Immune_system_disorders,NCT00434642,https://clinicaltrials.gov/show/NCT00434642,Ovarian_Cancer,Carboplatin|Gemcitabine|Bevacizumab|Placebo|,other_events,arm1,Carboplatin-and-Gemcitabine-+-Placebo,3,carboplatin,alkalating-agent
455,Hypersensitivity,1,233,Immune_system_disorders,NCT00434642,https://clinicaltrials.gov/show/NCT00434642,Ovarian_Cancer,Carboplatin|Gemcitabine|Bevacizumab|Placebo|,serious_events,arm1,Carboplatin-and-Gemcitabine-+-Placebo,3,carboplatin,alkalating-agent
458,Hypersensitivity,12,233,Immune_system_disorders,NCT00434642,https://clinicaltrials.gov/show/NCT00434642,Ovarian_Cancer,Carboplatin|Gemcitabine|Bevacizumab|Placebo|,other_events,arm1,Carboplatin-and-Gemcitabine-+-Placebo,3,carboplatin,alkalating-agent
1419,Drug_Hypersensitivity,3,233,Immune_system_disorders,NCT00434642,https://clinicaltrials.gov/show/NCT00434642,Ovarian_Cancer,Carboplatin|Gemcitabine|Bevacizumab|Placebo|,serious_events,arm1,Carboplatin-and-Gemcitabine-+-Placebo,6,gemcitabine,antimetabolites
1422,Drug_Hypersensitivity,15,233,Immune_system_disorders,NCT00434642,https://clinicaltrials.gov/show/NCT00434642,Ovarian_Cancer,Carboplatin|Gemcitabine|Bevacizumab|Placebo|,other_events,arm1,Carboplatin-and-Gemcitabine-+-Placebo,6,gemcitabine,antimetabolites
455,Hypersensitivity,1,233,Immune_system_disorders,NCT00434642,https://clinicaltrials.gov/show/NCT00434642,Ovarian_Cancer,Carboplatin|Gemcitabine|Bevacizumab|Placebo|,serious_events,arm1,Carboplatin-and-Gemcitabine-+-Placebo,6,gemcitabine,antimetabolites
458,Hypersensitivity,12,233,Immune_system_disorders,NCT00434642,https://clinicaltrials.gov/show/NCT00434642,Ovarian_Cancer,Carboplatin|Gemcitabine|Bevacizumab|Placebo|,other_events,arm1,Carboplatin-and-Gemcitabine-+-Placebo,6,gemcitabine,antimetabolites
2012,Dermatitis_allergic,3,215,Skin_and_subcutaneous_tissue_disorders,NCT00435409,https://clinicaltrials.gov/show/NCT00435409,Breast_Neoplasms,Sunitinib_+_Capecitabine|Capecitabine|,other_events,arm1,Capecitabine,17,capecitabine,antimetabolite
1423,Drug_hypersensitivity,1,215,Immune_system_disorders,NCT00435409,https://clinicaltrials.gov/show/NCT00435409,Breast_Neoplasms,Sunitinib_+_Capecitabine|Capecitabine|,other_events,arm1,Capecitabine,17,capecitabine,antimetabolite
460,Hypersensitivity,1,215,Immune_system_disorders,NCT00435409,https://clinicaltrials.gov/show/NCT00435409,Breast_Neoplasms,Sunitinib_+_Capecitabine|Capecitabine|,other_events,arm1,Capecitabine,17,capecitabine,antimetabolite
2012,Dermatitis_allergic,3,215,Skin_and_subcutaneous_tissue_disorders,NCT00435409,https://clinicaltrials.gov/show/NCT00435409,Breast_Neoplasms,Sunitinib_+_Capecitabine|Capecitabine|,other_events,arm1,Capecitabine,29,capecitabine,antimetabolite
1423,Drug_hypersensitivity,1,215,Immune_system_disorders,NCT00435409,https://clinicaltrials.gov/show/NCT00435409,Breast_Neoplasms,Sunitinib_+_Capecitabine|Capecitabine|,other_events,arm1,Capecitabine,29,capecitabine,antimetabolite
460,Hypersensitivity,1,215,Immune_system_disorders,NCT00435409,https://clinicaltrials.gov/show/NCT00435409,Breast_Neoplasms,Sunitinib_+_Capecitabine|Capecitabine|,other_events,arm1,Capecitabine,29,capecitabine,antimetabolite
2598,Allergic_reaction,1,55,Immune_system_disorders,NCT00436215,https://clinicaltrials.gov/show/NCT00436215,Ovarian_Neoplasm|Fallopian_Tube_Cancer|Primary_Peritoneal_Cancer|,Bevacizumab|BAY_43-9006|,serious_events,arm0,BAY-43-9006-+-Bevacizumab,4,bevacizumab,monoclonal-antibody
2599,Allergic_reaction,2,55,Immune_system_disorders,NCT00436215,https://clinicaltrials.gov/show/NCT00436215,Ovarian_Neoplasm|Fallopian_Tube_Cancer|Primary_Peritoneal_Cancer|,Bevacizumab|BAY_43-9006|,other_events,arm0,BAY-43-9006-+-Bevacizumab,4,bevacizumab,monoclonal-antibody
2348,Anaphylaxis,1,55,Immune_system_disorders,NCT00436215,https://clinicaltrials.gov/show/NCT00436215,Ovarian_Neoplasm|Fallopian_Tube_Cancer|Primary_Peritoneal_Cancer|,Bevacizumab|BAY_43-9006|,other_events,arm0,BAY-43-9006-+-Bevacizumab,4,bevacizumab,monoclonal-antibody
2598,Allergic_reaction,1,55,Immune_system_disorders,NCT00436215,https://clinicaltrials.gov/show/NCT00436215,Ovarian_Neoplasm|Fallopian_Tube_Cancer|Primary_Peritoneal_Cancer|,Bevacizumab|BAY_43-9006|,serious_events,arm0,BAY-43-9006-+-Bevacizumab,22,bevacizumab,monoclonal-antibody
2599,Allergic_reaction,2,55,Immune_system_disorders,NCT00436215,https://clinicaltrials.gov/show/NCT00436215,Ovarian_Neoplasm|Fallopian_Tube_Cancer|Primary_Peritoneal_Cancer|,Bevacizumab|BAY_43-9006|,other_events,arm0,BAY-43-9006-+-Bevacizumab,22,bevacizumab,monoclonal-antibody
2348,Anaphylaxis,1,55,Immune_system_disorders,NCT00436215,https://clinicaltrials.gov/show/NCT00436215,Ovarian_Neoplasm|Fallopian_Tube_Cancer|Primary_Peritoneal_Cancer|,Bevacizumab|BAY_43-9006|,other_events,arm0,BAY-43-9006-+-Bevacizumab,22,bevacizumab,monoclonal-antibody
461,Hypersensitivity,1,108,Immune_system_disorders,NCT00436566,https://clinicaltrials.gov/show/NCT00436566,Breast_Cancer|Cardiac_Toxicity|,trastuzumab|cyclophosphamide|doxorubicin_hydrochloride|lapatinib_ditosylate|paclitaxel|gene_expression_analysis|reverse_transcriptase-polymerase_chain_reaction|fluorophotometry|laboratory_biomarker_analysis|mass_spectrometry|adjuvant_therapy|quality-of-li,other_events,arm0,AC/PTL,,,
462,Hypersensitivity,1,114,Immune_system_disorders,NCT00436618,https://clinicaltrials.gov/show/NCT00436618,Leukemia|Lymphoma|Lymphoproliferative_Disorder|,Everolimus,serious_events,arm0,Relapsed-Aggressive-Non-Hodgkin-Lymphoma,,,
463,Hypersensitivity,3,30,Immune_system_disorders,NCT00436904,https://clinicaltrials.gov/show/NCT00436904,Leukemia,Alemtuzumab|Rituximab|,other_events,arm0,Alemtuzumab-+-Rituximab,16,rituximab,monoclonal-antibody
463,Hypersensitivity,3,30,Immune_system_disorders,NCT00436904,https://clinicaltrials.gov/show/NCT00436904,Leukemia,Alemtuzumab|Rituximab|,other_events,arm0,Alemtuzumab-+-Rituximab,76,alemtuzumab,monoclonal-antibody
464,Hypersensitivity,1,4,Immune_system_disorders,NCT00437203,https://clinicaltrials.gov/show/NCT00437203,Neoplasms,PF-00477736|gemcitabine|,serious_events,arm9,PF-00477736-225-mg-24-Hrs-+-Gemcitabine-1000-mg/m^2-(cohort10),6,gemcitabine,antimetabolites
1427,Drug_hypersensitivity,1,34,Immune_system_disorders,NCT00439270,https://clinicaltrials.gov/show/NCT00439270,Metastatic_Prostate_Cancer,Dasatinib|Docetaxel|,serious_events,arm0,Dasatinib-100-mg-+-Docetaxel-75-mg/m^2,24,dasatinib,signal-transduction-inhibitor---tyrosine-kinase-inhibitor
469,Hypersensitivity,4,34,Immune_system_disorders,NCT00439270,https://clinicaltrials.gov/show/NCT00439270,Metastatic_Prostate_Cancer,Dasatinib|Docetaxel|,other_events,arm0,Dasatinib-100-mg-+-Docetaxel-75-mg/m^2,24,dasatinib,signal-transduction-inhibitor---tyrosine-kinase-inhibitor
1427,Drug_hypersensitivity,1,34,Immune_system_disorders,NCT00439270,https://clinicaltrials.gov/show/NCT00439270,Metastatic_Prostate_Cancer,Dasatinib|Docetaxel|,serious_events,arm0,Dasatinib-100-mg-+-Docetaxel-75-mg/m^2,8,docetaxel,taxane
469,Hypersensitivity,4,34,Immune_system_disorders,NCT00439270,https://clinicaltrials.gov/show/NCT00439270,Metastatic_Prostate_Cancer,Dasatinib|Docetaxel|,other_events,arm0,Dasatinib-100-mg-+-Docetaxel-75-mg/m^2,8,docetaxel,taxane
467,Hypersensitivity,2,3,Immune_system_disorders,NCT00439270,https://clinicaltrials.gov/show/NCT00439270,Metastatic_Prostate_Cancer,Dasatinib|Docetaxel|,other_events,arm2,Dasatinib-50-mg-+-Docetaxel-60-mg/m^2,24,dasatinib,signal-transduction-inhibitor---tyrosine-kinase-inhibitor
467,Hypersensitivity,2,3,Immune_system_disorders,NCT00439270,https://clinicaltrials.gov/show/NCT00439270,Metastatic_Prostate_Cancer,Dasatinib|Docetaxel|,other_events,arm2,Dasatinib-50-mg-+-Docetaxel-60-mg/m^2,8,docetaxel,taxane
468,Hypersensitivity,1,3,Immune_system_disorders,NCT00439270,https://clinicaltrials.gov/show/NCT00439270,Metastatic_Prostate_Cancer,Dasatinib|Docetaxel|,other_events,arm3,Dasatinib-50-mg-+-Docetaxel-75-mg/m^2,24,dasatinib,signal-transduction-inhibitor---tyrosine-kinase-inhibitor
468,Hypersensitivity,1,3,Immune_system_disorders,NCT00439270,https://clinicaltrials.gov/show/NCT00439270,Metastatic_Prostate_Cancer,Dasatinib|Docetaxel|,other_events,arm3,Dasatinib-50-mg-+-Docetaxel-75-mg/m^2,8,docetaxel,taxane
1431,Drug_hypersensitivity,12,151,Immune_system_disorders,NCT00439517,https://clinicaltrials.gov/show/NCT00439517,Previously_Untreated_Metastatic_Colorectal_Cancer,UFOX_+_Cetuximab|FOLFOX4_+_Cetuximab|,other_events,arm0,UFOX-+-Cetuximab,5,cetuximab,Epidermal-growth-factor-receptor-inhibitor
471,Hypersensitivity,3,151,Immune_system_disorders,NCT00439517,https://clinicaltrials.gov/show/NCT00439517,Previously_Untreated_Metastatic_Colorectal_Cancer,UFOX_+_Cetuximab|FOLFOX4_+_Cetuximab|,other_events,arm0,UFOX-+-Cetuximab,5,cetuximab,Epidermal-growth-factor-receptor-inhibitor
1429,Drug_hypersensitivity,2,150,Immune_system_disorders,NCT00439517,https://clinicaltrials.gov/show/NCT00439517,Previously_Untreated_Metastatic_Colorectal_Cancer,UFOX_+_Cetuximab|FOLFOX4_+_Cetuximab|,serious_events,arm1,FOLFOX4-+-Cetuximab,5,cetuximab,Epidermal-growth-factor-receptor-inhibitor
1430,Drug_hypersensitivity,10,150,Immune_system_disorders,NCT00439517,https://clinicaltrials.gov/show/NCT00439517,Previously_Untreated_Metastatic_Colorectal_Cancer,UFOX_+_Cetuximab|FOLFOX4_+_Cetuximab|,other_events,arm1,FOLFOX4-+-Cetuximab,5,cetuximab,Epidermal-growth-factor-receptor-inhibitor
470,Hypersensitivity,8,150,Immune_system_disorders,NCT00439517,https://clinicaltrials.gov/show/NCT00439517,Previously_Untreated_Metastatic_Colorectal_Cancer,UFOX_+_Cetuximab|FOLFOX4_+_Cetuximab|,other_events,arm1,FOLFOX4-+-Cetuximab,5,cetuximab,Epidermal-growth-factor-receptor-inhibitor
474,Hypersensitivity,1,131,Immune_system_disorders,NCT00440011,https://clinicaltrials.gov/show/NCT00440011,Glaucoma|Ocular_Hypertension|,bimatoprost_0.03_PERCENT_eye_drops|travoprost_0.004_PERCENT_eye_drops|,other_events,arm0,Bimatoprost,,,
1432,Drug_Hypersensitivity,1,133,Immune_system_disorders,NCT00440011,https://clinicaltrials.gov/show/NCT00440011,Glaucoma|Ocular_Hypertension|,bimatoprost_0.03_PERCENT_eye_drops|travoprost_0.004_PERCENT_eye_drops|,other_events,arm1,Travoprost,,,
476,Hypersensitivity,2,222,Immune_system_disorders,NCT00440310,https://clinicaltrials.gov/show/NCT00440310,Liver_Metastases|Colorectal_Neoplasms|Neoplasm_Metastasis|Neoplasm_Recurrence_Local|,Talaporfin_sodium|Percutaneous_placement_of_device_in_liver_metastases|Interstitial_light_emitting_diodes|FOLFOX4_regimen|FOLFIRI_regimen|,serious_events,arm0,Litx-+-Chemotherapy,,,
480,Hypersensitivity,1,6,Immune_system_disorders,NCT00441337,https://clinicaltrials.gov/show/NCT00441337,Carcinoma_Non-Small-Cell_Lung|Colorectal_Cancer|Malignant_Melanoma|Renal_Cancer|Prostate_Cancer|,MDX-1106,other_events,arm2,3-mg/kg-Nivolumab,,,
1446,DRUG_HYPERSENSITIVITY,2,92,Immune_system_disorders,NCT00446030,https://clinicaltrials.gov/show/NCT00446030,Breast_Neoplasms,Docetaxel|Doxorubicin|Carboplatin|Cyclophosphamide|Trastuzumab|Bevacizumab|,other_events,arm0,Stratum-1:-TAC-+-Bevacizumab,4,bevacizumab,monoclonal-antibody
1446,DRUG_HYPERSENSITIVITY,2,92,Immune_system_disorders,NCT00446030,https://clinicaltrials.gov/show/NCT00446030,Breast_Neoplasms,Docetaxel|Doxorubicin|Carboplatin|Cyclophosphamide|Trastuzumab|Bevacizumab|,other_events,arm0,Stratum-1:-TAC-+-Bevacizumab,22,bevacizumab,monoclonal-antibody
1445,DRUG_HYPERSENSITIVITY,2,34,Immune_system_disorders,NCT00446030,https://clinicaltrials.gov/show/NCT00446030,Breast_Neoplasms,Docetaxel|Doxorubicin|Carboplatin|Cyclophosphamide|Trastuzumab|Bevacizumab|,other_events,arm1,Stratum-2:-TCH-+-Bevacizumab,4,bevacizumab,monoclonal-antibody
484,HYPERSENSITIVITY,3,34,Immune_system_disorders,NCT00446030,https://clinicaltrials.gov/show/NCT00446030,Breast_Neoplasms,Docetaxel|Doxorubicin|Carboplatin|Cyclophosphamide|Trastuzumab|Bevacizumab|,other_events,arm1,Stratum-2:-TCH-+-Bevacizumab,4,bevacizumab,monoclonal-antibody
1445,DRUG_HYPERSENSITIVITY,2,34,Immune_system_disorders,NCT00446030,https://clinicaltrials.gov/show/NCT00446030,Breast_Neoplasms,Docetaxel|Doxorubicin|Carboplatin|Cyclophosphamide|Trastuzumab|Bevacizumab|,other_events,arm1,Stratum-2:-TCH-+-Bevacizumab,22,bevacizumab,monoclonal-antibody
484,HYPERSENSITIVITY,3,34,Immune_system_disorders,NCT00446030,https://clinicaltrials.gov/show/NCT00446030,Breast_Neoplasms,Docetaxel|Doxorubicin|Carboplatin|Cyclophosphamide|Trastuzumab|Bevacizumab|,other_events,arm1,Stratum-2:-TCH-+-Bevacizumab,22,bevacizumab,monoclonal-antibody
485,Hypersensitivity,1,102,Immune_system_disorders,NCT00447057,https://clinicaltrials.gov/show/NCT00447057,Histological_or_Cytological_Diagnosis_of_Locally_Advanced_or_Metastatic_NSCLC_of_Nonsquamous_Histology_and_Not_Amenable_to_Curative_Therapy.,Pemetrexed|Erlotinib|Pemetrexed|Erlotinib|,serious_events,arm1,Pemetrexed-+-Erlotinib-(Nonsquamous-and-Squamous),15,pemetrexed,antimetabolite
485,Hypersensitivity,1,102,Immune_system_disorders,NCT00447057,https://clinicaltrials.gov/show/NCT00447057,Histological_or_Cytological_Diagnosis_of_Locally_Advanced_or_Metastatic_NSCLC_of_Nonsquamous_Histology_and_Not_Amenable_to_Curative_Therapy.,Pemetrexed|Erlotinib|Pemetrexed|Erlotinib|,serious_events,arm1,Pemetrexed-+-Erlotinib-(Nonsquamous-and-Squamous),31,erlotinib,epidermal-growth-factor-receptor-(EGFR)-inhibitor---protein-tyrosine-kinase-inhibitor
2601,Allergic_reaction,1,58,Immune_system_disorders,NCT00447330,https://clinicaltrials.gov/show/NCT00447330,Esophageal_Neoplasms|Stomach_Neoplasms|Neoplasm_Metastasis|,capecitabine_(Xeloda)_oxaliplatin_and_bevacizumab_(Avastin),other_events,arm0,1---Capecitabine-(Xeloda)-Oxaliplatin-and-Bevacizumab-(Avasti,7,oxaliplatin,alkalating-agent
2601,Allergic_reaction,1,58,Immune_system_disorders,NCT00447330,https://clinicaltrials.gov/show/NCT00447330,Esophageal_Neoplasms|Stomach_Neoplasms|Neoplasm_Metastasis|,capecitabine_(Xeloda)_oxaliplatin_and_bevacizumab_(Avastin),other_events,arm0,1---Capecitabine-(Xeloda)-Oxaliplatin-and-Bevacizumab-(Avasti,17,capecitabine,antimetabolite
2601,Allergic_reaction,1,58,Immune_system_disorders,NCT00447330,https://clinicaltrials.gov/show/NCT00447330,Esophageal_Neoplasms|Stomach_Neoplasms|Neoplasm_Metastasis|,capecitabine_(Xeloda)_oxaliplatin_and_bevacizumab_(Avastin),other_events,arm0,1---Capecitabine-(Xeloda)-Oxaliplatin-and-Bevacizumab-(Avasti,29,capecitabine,antimetabolite
2601,Allergic_reaction,1,58,Immune_system_disorders,NCT00447330,https://clinicaltrials.gov/show/NCT00447330,Esophageal_Neoplasms|Stomach_Neoplasms|Neoplasm_Metastasis|,capecitabine_(Xeloda)_oxaliplatin_and_bevacizumab_(Avastin),other_events,arm0,1---Capecitabine-(Xeloda)-Oxaliplatin-and-Bevacizumab-(Avasti,4,bevacizumab,monoclonal-antibody
2601,Allergic_reaction,1,58,Immune_system_disorders,NCT00447330,https://clinicaltrials.gov/show/NCT00447330,Esophageal_Neoplasms|Stomach_Neoplasms|Neoplasm_Metastasis|,capecitabine_(Xeloda)_oxaliplatin_and_bevacizumab_(Avastin),other_events,arm0,1---Capecitabine-(Xeloda)-Oxaliplatin-and-Bevacizumab-(Avasti,22,bevacizumab,monoclonal-antibody
2387,Allergy,1,28,Immune_system_disorders,NCT00448279,https://clinicaltrials.gov/show/NCT00448279,Breast_Cancer,trastuzumab|Chemotherapy|,other_events,arm1,Chemotherapy-+-Trastuzumab,18,trastuzumab,monoclonal-antibody
486,Hypersensitivity,3,2264,Immune_system_disorders,NCT00448591,https://clinicaltrials.gov/show/NCT00448591,Breast_Cancer,bevacizumab_[Avastin]|Taxane-based_chemotherapy|,serious_events,arm0,Bevacizumab,4,bevacizumab,monoclonal-antibody
486,Hypersensitivity,3,2264,Immune_system_disorders,NCT00448591,https://clinicaltrials.gov/show/NCT00448591,Breast_Cancer,bevacizumab_[Avastin]|Taxane-based_chemotherapy|,serious_events,arm0,Bevacizumab,22,bevacizumab,monoclonal-antibody
2602,Allergic_reaction,1,452,Immune_system_disorders,NCT00449033,https://clinicaltrials.gov/show/NCT00449033,Carcinoma_Non-Small-Cell_Lung,Sorafenib_(Nexavar_BAY43-9006)|Placebo|Gemcitabine|Cisplatin|,serious_events,arm0,Sorafenib-(Nexavar-BAY43-9006)-+-GC,97,nexavar,Tyrosine-Kinase-inhibitor
2602,Allergic_reaction,1,452,Immune_system_disorders,NCT00449033,https://clinicaltrials.gov/show/NCT00449033,Carcinoma_Non-Small-Cell_Lung,Sorafenib_(Nexavar_BAY43-9006)|Placebo|Gemcitabine|Cisplatin|,serious_events,arm0,Sorafenib-(Nexavar-BAY43-9006)-+-GC,90,sorafenib,Tyrosine-Kinase-inhibitor
2602,Allergic_reaction,1,452,Immune_system_disorders,NCT00449033,https://clinicaltrials.gov/show/NCT00449033,Carcinoma_Non-Small-Cell_Lung,Sorafenib_(Nexavar_BAY43-9006)|Placebo|Gemcitabine|Cisplatin|,serious_events,arm0,Sorafenib-(Nexavar-BAY43-9006)-+-GC,72,bay43,Tyrosine-Kinase-inhibitor
2603,Allergic_Reaction,1,37,Injury_poisoning_and_procedural_complications,NCT00450372,https://clinicaltrials.gov/show/NCT00450372,Melanoma_(Skin),ADI-PEG-20|Pharmacology_Studies|,serious_events,arm0,Single-Arm,,,
2604,Allergic_reaction,1,22,Immune_system_disorders,NCT00450619,https://clinicaltrials.gov/show/NCT00450619,Prostate_Cancer,Samarium_Sm_153_lexidronam_pentasodium|Sargramostim|Recombinant_vaccinia-TRICOM_vaccine|Recombinant_fowlpox-TRICOM_vaccine|,other_events,arm1,Arm-B---153SmEDTMP-With-Vaccine,,,
490,Hypersensitivity,1,3,Immune_system_disorders,NCT00454649,https://clinicaltrials.gov/show/NCT00454649,Neoplasms,Axitinib_+_Paclitaxel_+_Carboplatin_(Cohort_1)|Axitinib_+_Paclitaxel_+_Carboplatin_(Cohort_2)|Axitinib_+_Paclitaxel_+_Carboplatin_(Cohort_3)|Axitinib_+_Paclitaxel_(Cohort_4)|Axitinib_+_Docetaxel_+_Carboplatin_(Cohort_4a)|Axitinib_+_Docetaxel_(Cohort_5)|Ax,serious_events,arm0,Axitinib-+-Paclitaxel-+-Carboplatin-(Cohort-1),3,carboplatin,alkalating-agent
491,Hypersensitivity,1,3,Immune_system_disorders,NCT00454649,https://clinicaltrials.gov/show/NCT00454649,Neoplasms,Axitinib_+_Paclitaxel_+_Carboplatin_(Cohort_1)|Axitinib_+_Paclitaxel_+_Carboplatin_(Cohort_2)|Axitinib_+_Paclitaxel_+_Carboplatin_(Cohort_3)|Axitinib_+_Paclitaxel_(Cohort_4)|Axitinib_+_Docetaxel_+_Carboplatin_(Cohort_4a)|Axitinib_+_Docetaxel_(Cohort_5)|Ax,other_events,arm0,Axitinib-+-Paclitaxel-+-Carboplatin-(Cohort-1),3,carboplatin,alkalating-agent
490,Hypersensitivity,1,3,Immune_system_disorders,NCT00454649,https://clinicaltrials.gov/show/NCT00454649,Neoplasms,Axitinib_+_Paclitaxel_+_Carboplatin_(Cohort_1)|Axitinib_+_Paclitaxel_+_Carboplatin_(Cohort_2)|Axitinib_+_Paclitaxel_+_Carboplatin_(Cohort_3)|Axitinib_+_Paclitaxel_(Cohort_4)|Axitinib_+_Docetaxel_+_Carboplatin_(Cohort_4a)|Axitinib_+_Docetaxel_(Cohort_5)|Ax,serious_events,arm0,Axitinib-+-Paclitaxel-+-Carboplatin-(Cohort-1),10,axitinib,kinase-inhibitor
491,Hypersensitivity,1,3,Immune_system_disorders,NCT00454649,https://clinicaltrials.gov/show/NCT00454649,Neoplasms,Axitinib_+_Paclitaxel_+_Carboplatin_(Cohort_1)|Axitinib_+_Paclitaxel_+_Carboplatin_(Cohort_2)|Axitinib_+_Paclitaxel_+_Carboplatin_(Cohort_3)|Axitinib_+_Paclitaxel_(Cohort_4)|Axitinib_+_Docetaxel_+_Carboplatin_(Cohort_4a)|Axitinib_+_Docetaxel_(Cohort_5)|Ax,other_events,arm0,Axitinib-+-Paclitaxel-+-Carboplatin-(Cohort-1),10,axitinib,kinase-inhibitor
490,Hypersensitivity,1,3,Immune_system_disorders,NCT00454649,https://clinicaltrials.gov/show/NCT00454649,Neoplasms,Axitinib_+_Paclitaxel_+_Carboplatin_(Cohort_1)|Axitinib_+_Paclitaxel_+_Carboplatin_(Cohort_2)|Axitinib_+_Paclitaxel_+_Carboplatin_(Cohort_3)|Axitinib_+_Paclitaxel_(Cohort_4)|Axitinib_+_Docetaxel_+_Carboplatin_(Cohort_4a)|Axitinib_+_Docetaxel_(Cohort_5)|Ax,serious_events,arm0,Axitinib-+-Paclitaxel-+-Carboplatin-(Cohort-1),2,paclitaxel,taxane
491,Hypersensitivity,1,3,Immune_system_disorders,NCT00454649,https://clinicaltrials.gov/show/NCT00454649,Neoplasms,Axitinib_+_Paclitaxel_+_Carboplatin_(Cohort_1)|Axitinib_+_Paclitaxel_+_Carboplatin_(Cohort_2)|Axitinib_+_Paclitaxel_+_Carboplatin_(Cohort_3)|Axitinib_+_Paclitaxel_(Cohort_4)|Axitinib_+_Docetaxel_+_Carboplatin_(Cohort_4a)|Axitinib_+_Docetaxel_(Cohort_5)|Ax,other_events,arm0,Axitinib-+-Paclitaxel-+-Carboplatin-(Cohort-1),2,paclitaxel,taxane
1454,Drug_hypersensitivity,1,5,Immune_system_disorders,NCT00454649,https://clinicaltrials.gov/show/NCT00454649,Neoplasms,Axitinib_+_Paclitaxel_+_Carboplatin_(Cohort_1)|Axitinib_+_Paclitaxel_+_Carboplatin_(Cohort_2)|Axitinib_+_Paclitaxel_+_Carboplatin_(Cohort_3)|Axitinib_+_Paclitaxel_(Cohort_4)|Axitinib_+_Docetaxel_+_Carboplatin_(Cohort_4a)|Axitinib_+_Docetaxel_(Cohort_5)|Ax,other_events,arm1,Axitinib-+-Paclitaxel-+-Carboplatin-(Cohort-2),3,carboplatin,alkalating-agent
492,Hypersensitivity,1,5,Immune_system_disorders,NCT00454649,https://clinicaltrials.gov/show/NCT00454649,Neoplasms,Axitinib_+_Paclitaxel_+_Carboplatin_(Cohort_1)|Axitinib_+_Paclitaxel_+_Carboplatin_(Cohort_2)|Axitinib_+_Paclitaxel_+_Carboplatin_(Cohort_3)|Axitinib_+_Paclitaxel_(Cohort_4)|Axitinib_+_Docetaxel_+_Carboplatin_(Cohort_4a)|Axitinib_+_Docetaxel_(Cohort_5)|Ax,other_events,arm1,Axitinib-+-Paclitaxel-+-Carboplatin-(Cohort-2),3,carboplatin,alkalating-agent
1454,Drug_hypersensitivity,1,5,Immune_system_disorders,NCT00454649,https://clinicaltrials.gov/show/NCT00454649,Neoplasms,Axitinib_+_Paclitaxel_+_Carboplatin_(Cohort_1)|Axitinib_+_Paclitaxel_+_Carboplatin_(Cohort_2)|Axitinib_+_Paclitaxel_+_Carboplatin_(Cohort_3)|Axitinib_+_Paclitaxel_(Cohort_4)|Axitinib_+_Docetaxel_+_Carboplatin_(Cohort_4a)|Axitinib_+_Docetaxel_(Cohort_5)|Ax,other_events,arm1,Axitinib-+-Paclitaxel-+-Carboplatin-(Cohort-2),10,axitinib,kinase-inhibitor
492,Hypersensitivity,1,5,Immune_system_disorders,NCT00454649,https://clinicaltrials.gov/show/NCT00454649,Neoplasms,Axitinib_+_Paclitaxel_+_Carboplatin_(Cohort_1)|Axitinib_+_Paclitaxel_+_Carboplatin_(Cohort_2)|Axitinib_+_Paclitaxel_+_Carboplatin_(Cohort_3)|Axitinib_+_Paclitaxel_(Cohort_4)|Axitinib_+_Docetaxel_+_Carboplatin_(Cohort_4a)|Axitinib_+_Docetaxel_(Cohort_5)|Ax,other_events,arm1,Axitinib-+-Paclitaxel-+-Carboplatin-(Cohort-2),10,axitinib,kinase-inhibitor
1454,Drug_hypersensitivity,1,5,Immune_system_disorders,NCT00454649,https://clinicaltrials.gov/show/NCT00454649,Neoplasms,Axitinib_+_Paclitaxel_+_Carboplatin_(Cohort_1)|Axitinib_+_Paclitaxel_+_Carboplatin_(Cohort_2)|Axitinib_+_Paclitaxel_+_Carboplatin_(Cohort_3)|Axitinib_+_Paclitaxel_(Cohort_4)|Axitinib_+_Docetaxel_+_Carboplatin_(Cohort_4a)|Axitinib_+_Docetaxel_(Cohort_5)|Ax,other_events,arm1,Axitinib-+-Paclitaxel-+-Carboplatin-(Cohort-2),2,paclitaxel,taxane
492,Hypersensitivity,1,5,Immune_system_disorders,NCT00454649,https://clinicaltrials.gov/show/NCT00454649,Neoplasms,Axitinib_+_Paclitaxel_+_Carboplatin_(Cohort_1)|Axitinib_+_Paclitaxel_+_Carboplatin_(Cohort_2)|Axitinib_+_Paclitaxel_+_Carboplatin_(Cohort_3)|Axitinib_+_Paclitaxel_(Cohort_4)|Axitinib_+_Docetaxel_+_Carboplatin_(Cohort_4a)|Axitinib_+_Docetaxel_(Cohort_5)|Ax,other_events,arm1,Axitinib-+-Paclitaxel-+-Carboplatin-(Cohort-2),2,paclitaxel,taxane
1453,Drug_hypersensitivity,1,7,Immune_system_disorders,NCT00454649,https://clinicaltrials.gov/show/NCT00454649,Neoplasms,Axitinib_+_Paclitaxel_+_Carboplatin_(Cohort_1)|Axitinib_+_Paclitaxel_+_Carboplatin_(Cohort_2)|Axitinib_+_Paclitaxel_+_Carboplatin_(Cohort_3)|Axitinib_+_Paclitaxel_(Cohort_4)|Axitinib_+_Docetaxel_+_Carboplatin_(Cohort_4a)|Axitinib_+_Docetaxel_(Cohort_5)|Ax,other_events,arm3,Axitinib-+-Paclitaxel-(Cohort-4),10,axitinib,kinase-inhibitor
1453,Drug_hypersensitivity,1,7,Immune_system_disorders,NCT00454649,https://clinicaltrials.gov/show/NCT00454649,Neoplasms,Axitinib_+_Paclitaxel_+_Carboplatin_(Cohort_1)|Axitinib_+_Paclitaxel_+_Carboplatin_(Cohort_2)|Axitinib_+_Paclitaxel_+_Carboplatin_(Cohort_3)|Axitinib_+_Paclitaxel_(Cohort_4)|Axitinib_+_Docetaxel_+_Carboplatin_(Cohort_4a)|Axitinib_+_Docetaxel_(Cohort_5)|Ax,other_events,arm3,Axitinib-+-Paclitaxel-(Cohort-4),2,paclitaxel,taxane
496,Hypersensitivity,2,86,Immune_system_disorders,NCT00455195,https://clinicaltrials.gov/show/NCT00455195,Pompe_Disease_(Late-Onset)|Glycogen_Storage_Disease_Type_II_(GSD-II)|Glycogenesis_Type_II|Acid_Maltase_Deficiency_(AMD)|,alglucosidase_alfa,serious_events,arm2,Overall,,,
497,Hypersensitivity,3,86,Immune_system_disorders,NCT00455195,https://clinicaltrials.gov/show/NCT00455195,Pompe_Disease_(Late-Onset)|Glycogen_Storage_Disease_Type_II_(GSD-II)|Glycogenesis_Type_II|Acid_Maltase_Deficiency_(AMD)|,alglucosidase_alfa,other_events,arm2,Overall,,,
2606,Allergic_reaction,4,58,Immune_system_disorders,NCT00455975,https://clinicaltrials.gov/show/NCT00455975,Renal_Cancer|Kidney_Cancer|,Bevacizumab,other_events,arm0,Weekly-Avastin,,,
2605,Allergic_reaction,9,61,Immune_system_disorders,NCT00455975,https://clinicaltrials.gov/show/NCT00455975,Renal_Cancer|Kidney_Cancer|,Bevacizumab,other_events,arm1,Bi-weekly-Avastin,,,
1456,Drug_hypersensitivity,2,477,Immune_system_disorders,NCT00457392,https://clinicaltrials.gov/show/NCT00457392,Carcinoma_Non-Small_Cell_Lung,erlotinib|sunitinib|erlotinib|placebo|,other_events,arm1,Erlotinib,31,erlotinib,epidermal-growth-factor-receptor-(EGFR)-inhibitor---protein-tyrosine-kinase-inhibitor
499,Hypersensitivity,1,477,Immune_system_disorders,NCT00457392,https://clinicaltrials.gov/show/NCT00457392,Carcinoma_Non-Small_Cell_Lung,erlotinib|sunitinib|erlotinib|placebo|,other_events,arm1,Erlotinib,31,erlotinib,epidermal-growth-factor-receptor-(EGFR)-inhibitor---protein-tyrosine-kinase-inhibitor
1455,DRUG_HYPERSENSITIVITY,1,32,Immune_system_disorders,NCT00457418,https://clinicaltrials.gov/show/NCT00457418,Melanoma,PEG-Intron,serious_events,arm0,PEG-Intron,,,
500,Hypersensitivity,1,25,Immune_system_disorders,NCT00459108,https://clinicaltrials.gov/show/NCT00459108,Adult_Primary_Hepatocellular_Carcinoma|Advanced_Adult_Primary_Liver_Cancer|Recurrent_Adult_Primary_Liver_Cancer|,dasatinib,serious_events,arm0,Oral-Dasatinib,24,dasatinib,signal-transduction-inhibitor---tyrosine-kinase-inhibitor
501,Hypersensitivity,1,25,Immune_system_disorders,NCT00459108,https://clinicaltrials.gov/show/NCT00459108,Adult_Primary_Hepatocellular_Carcinoma|Advanced_Adult_Primary_Liver_Cancer|Recurrent_Adult_Primary_Liver_Cancer|,dasatinib,other_events,arm0,Oral-Dasatinib,24,dasatinib,signal-transduction-inhibitor---tyrosine-kinase-inhibitor
502,Hypersensitivity,2,325,Immune_system_disorders,NCT00460265,https://clinicaltrials.gov/show/NCT00460265,Recurrent_and/or_Metastatic_Head_and_Neck_Cancer,ARM_2|ARM_1|,serious_events,arm0,Panitumumab-Plus-Chemotherapy,30,panitumumab,monoclonal-antibody-and-signal-transduction-inhibitor
506,Hypersensitivity,1,43,Immune_system_disorders,NCT00460603,https://clinicaltrials.gov/show/NCT00460603,Colorectal_Neoplasms,bevacizumab|AG-013726|AG-013736_(axitinib)|,other_events,arm10,Phase-2:-Bevacizumab-+-FOLFOX,4,bevacizumab,monoclonal-antibody
506,Hypersensitivity,1,43,Immune_system_disorders,NCT00460603,https://clinicaltrials.gov/show/NCT00460603,Colorectal_Neoplasms,bevacizumab|AG-013726|AG-013736_(axitinib)|,other_events,arm10,Phase-2:-Bevacizumab-+-FOLFOX,22,bevacizumab,monoclonal-antibody
508,Hypersensitivity,2,41,Immune_system_disorders,NCT00460603,https://clinicaltrials.gov/show/NCT00460603,Colorectal_Neoplasms,bevacizumab|AG-013726|AG-013736_(axitinib)|,other_events,arm11,Phase-2:-Axitinib-+-Bevacizumab-+-FOLFOX,10,axitinib,kinase-inhibitor
508,Hypersensitivity,2,41,Immune_system_disorders,NCT00460603,https://clinicaltrials.gov/show/NCT00460603,Colorectal_Neoplasms,bevacizumab|AG-013726|AG-013736_(axitinib)|,other_events,arm11,Phase-2:-Axitinib-+-Bevacizumab-+-FOLFOX,4,bevacizumab,monoclonal-antibody
508,Hypersensitivity,2,41,Immune_system_disorders,NCT00460603,https://clinicaltrials.gov/show/NCT00460603,Colorectal_Neoplasms,bevacizumab|AG-013726|AG-013736_(axitinib)|,other_events,arm11,Phase-2:-Axitinib-+-Bevacizumab-+-FOLFOX,22,bevacizumab,monoclonal-antibody
507,Hypersensitivity,1,6,Immune_system_disorders,NCT00460603,https://clinicaltrials.gov/show/NCT00460603,Colorectal_Neoplasms,bevacizumab|AG-013726|AG-013736_(axitinib)|,serious_events,arm4,Phase-1:-Axitinib-+-FOLFOX-(Cohort-5),19,folfox,combination-drug-with-Leucovorin-(Folinic-Acid)--Fluorouracil--and-Oxaliplatin
507,Hypersensitivity,1,6,Immune_system_disorders,NCT00460603,https://clinicaltrials.gov/show/NCT00460603,Colorectal_Neoplasms,bevacizumab|AG-013726|AG-013736_(axitinib)|,serious_events,arm4,Phase-1:-Axitinib-+-FOLFOX-(Cohort-5),10,axitinib,kinase-inhibitor
505,Hypersensitivity,1,39,Immune_system_disorders,NCT00460603,https://clinicaltrials.gov/show/NCT00460603,Colorectal_Neoplasms,bevacizumab|AG-013726|AG-013736_(axitinib)|,other_events,arm9,Phase-2:-Axitinib-+-FOLFOX,10,axitinib,kinase-inhibitor
2607,Allergic_reaction,1,115,Immune_system_disorders,NCT00461708,https://clinicaltrials.gov/show/NCT00461708,Pancreatic_Cancer,Erlotinib|Gemcitabine|,other_events,arm0,Erlotinib-Gemcitabine:-Rash-Grade-<-2,6,gemcitabine,antimetabolites
2607,Allergic_reaction,1,115,Immune_system_disorders,NCT00461708,https://clinicaltrials.gov/show/NCT00461708,Pancreatic_Cancer,Erlotinib|Gemcitabine|,other_events,arm0,Erlotinib-Gemcitabine:-Rash-Grade-<-2,31,erlotinib,epidermal-growth-factor-receptor-(EGFR)-inhibitor---protein-tyrosine-kinase-inhibitor
1457,Drug_Hypersensitivity,1,114,Immune_system_disorders,NCT00463788,https://clinicaltrials.gov/show/NCT00463788,Breast_Neoplasm,cetuximab_cisplatin|cisplatin|,serious_events,arm0,Cisplatin-and-Cetuximab,9,cisplatin,alkalating-agent
1458,Drug_Hypersensitivity,6,114,Immune_system_disorders,NCT00463788,https://clinicaltrials.gov/show/NCT00463788,Breast_Neoplasm,cetuximab_cisplatin|cisplatin|,other_events,arm0,Cisplatin-and-Cetuximab,9,cisplatin,alkalating-agent
1457,Drug_Hypersensitivity,1,114,Immune_system_disorders,NCT00463788,https://clinicaltrials.gov/show/NCT00463788,Breast_Neoplasm,cetuximab_cisplatin|cisplatin|,serious_events,arm0,Cisplatin-and-Cetuximab,5,cetuximab,Epidermal-growth-factor-receptor-inhibitor
1458,Drug_Hypersensitivity,6,114,Immune_system_disorders,NCT00463788,https://clinicaltrials.gov/show/NCT00463788,Breast_Neoplasm,cetuximab_cisplatin|cisplatin|,other_events,arm0,Cisplatin-and-Cetuximab,5,cetuximab,Epidermal-growth-factor-receptor-inhibitor
2608,allergic_reaction,3,17,General_disorders,NCT00466505,https://clinicaltrials.gov/show/NCT00466505,Colorectal_Cancer,cetuximab|celecoxib|proteomic_profiling|immunohistochemistry_staining_method|laboratory_biomarker_analysis|mass_spectrometry|,other_events,arm0,Therapeutic-Intervention,,,
2349,Anaphylaxis,1,10,Immune_system_disorders,NCT00470275,https://clinicaltrials.gov/show/NCT00470275,Sarcoma,cytarabine,other_events,arm0,Cytarabine,52,cytarabine,antimetabolite
2028,Dermatitis_allergic,1,304,Skin_and_subcutaneous_tissue_disorders,NCT00471146,https://clinicaltrials.gov/show/NCT00471146,Carcinoma_Pancreatic_Ductal,AG-013736|Gemcitabine|Gemcitabine|placebo|,other_events,arm0,Axitinib-+-Gemcitabine,6,gemcitabine,antimetabolites
515,Hypersensitivity,2,304,Immune_system_disorders,NCT00471146,https://clinicaltrials.gov/show/NCT00471146,Carcinoma_Pancreatic_Ductal,AG-013736|Gemcitabine|Gemcitabine|placebo|,other_events,arm0,Axitinib-+-Gemcitabine,6,gemcitabine,antimetabolites
2028,Dermatitis_allergic,1,304,Skin_and_subcutaneous_tissue_disorders,NCT00471146,https://clinicaltrials.gov/show/NCT00471146,Carcinoma_Pancreatic_Ductal,AG-013736|Gemcitabine|Gemcitabine|placebo|,other_events,arm0,Axitinib-+-Gemcitabine,10,axitinib,kinase-inhibitor
515,Hypersensitivity,2,304,Immune_system_disorders,NCT00471146,https://clinicaltrials.gov/show/NCT00471146,Carcinoma_Pancreatic_Ductal,AG-013736|Gemcitabine|Gemcitabine|placebo|,other_events,arm0,Axitinib-+-Gemcitabine,10,axitinib,kinase-inhibitor
516,Hypersensitivity,1,309,Immune_system_disorders,NCT00471146,https://clinicaltrials.gov/show/NCT00471146,Carcinoma_Pancreatic_Ductal,AG-013736|Gemcitabine|Gemcitabine|placebo|,other_events,arm1,Placebo-+-Gemcitabine,6,gemcitabine,antimetabolites
517,Hypersensitivity,1,124,Immune_system_disorders,NCT00473889,https://clinicaltrials.gov/show/NCT00473889,Stage_IIIB_or_IV_Non-Small_Cell_Lung_Cancer,vorinostat|Comparator:_paclitaxel|Comparator:_carboplatin|Comparator:_placebo|,serious_events,arm1,Placebo-+-Paclitaxel-+-Carboplatin,3,carboplatin,alkalating-agent
517,Hypersensitivity,1,124,Immune_system_disorders,NCT00473889,https://clinicaltrials.gov/show/NCT00473889,Stage_IIIB_or_IV_Non-Small_Cell_Lung_Cancer,vorinostat|Comparator:_paclitaxel|Comparator:_carboplatin|Comparator:_placebo|,serious_events,arm1,Placebo-+-Paclitaxel-+-Carboplatin,2,paclitaxel,taxane
1466,Drug_hypersensitivity,1,252,Immune_system_disorders,NCT00474786,https://clinicaltrials.gov/show/NCT00474786,Renal_Cell_Carcinoma,Sorafenib|temsirolimus_(Torisel)|,serious_events,arm1,Sorafenib,90,sorafenib,Tyrosine-Kinase-inhibitor
518,Hypersensitivity,1,30,Immune_system_disorders,NCT00474903,https://clinicaltrials.gov/show/NCT00474903,Barrett_Esophagus|Esophageal_Cancer|,acetylsalicylic_acid|esomeprazole_magnesium|placebo|,other_events,arm0,Arm-I-(Placebo-Esomeprazole-Magnesium),,,
2029,Dermatitis_allergic,3,41,Skin_and_subcutaneous_tissue_disorders,NCT00475670,https://clinicaltrials.gov/show/NCT00475670,Breast_Cancer,Trastuzumab|Taxane_(docetaxel_or_paclitaxel)|,other_events,arm1,Trastuzumab-Taxane,18,trastuzumab,monoclonal-antibody
2029,Dermatitis_allergic,3,41,Skin_and_subcutaneous_tissue_disorders,NCT00475670,https://clinicaltrials.gov/show/NCT00475670,Breast_Cancer,Trastuzumab|Taxane_(docetaxel_or_paclitaxel)|,other_events,arm1,Trastuzumab-Taxane,93,taxane,
521,Hypersensitivity,1,26,Immune_system_disorders,NCT00477750,https://clinicaltrials.gov/show/NCT00477750,Multiple_Myeloma_and_Plasma_Cell_Neoplasm,lenalidomide|melphalan|prednisone|,other_events,arm0,Treatment-(Lenalidomide-Melphalan-Prednisone),25,lenalidomide,immunomodulatory-agent-or-antiangiogenic-agent
521,Hypersensitivity,1,26,Immune_system_disorders,NCT00477750,https://clinicaltrials.gov/show/NCT00477750,Multiple_Myeloma_and_Plasma_Cell_Neoplasm,lenalidomide|melphalan|prednisone|,other_events,arm0,Treatment-(Lenalidomide-Melphalan-Prednisone),85,prednisone,steroid
1469,Drug_hypersensitivity,1,40,Immune_system_disorders,NCT00478647,https://clinicaltrials.gov/show/NCT00478647,Gaucher_Disease_Type_1,GA-GCB_(velaglucerase_alfa),serious_events,arm0,GA-GCB-(Velaglucerase-Alfa),,,
2611,Allergic_reaction,1,41,Immune_system_disorders,NCT00479674,https://clinicaltrials.gov/show/NCT00479674,Breast_Cancer,Abraxane|Bevacizumab|Carboplatin|,serious_events,arm0,Abraxane-Carboplatin-Bevacizumab,3,carboplatin,alkalating-agent
2612,Allergic_reaction,3,41,Immune_system_disorders,NCT00479674,https://clinicaltrials.gov/show/NCT00479674,Breast_Cancer,Abraxane|Bevacizumab|Carboplatin|,other_events,arm0,Abraxane-Carboplatin-Bevacizumab,3,carboplatin,alkalating-agent
2611,Allergic_reaction,1,41,Immune_system_disorders,NCT00479674,https://clinicaltrials.gov/show/NCT00479674,Breast_Cancer,Abraxane|Bevacizumab|Carboplatin|,serious_events,arm0,Abraxane-Carboplatin-Bevacizumab,4,bevacizumab,monoclonal-antibody
2612,Allergic_reaction,3,41,Immune_system_disorders,NCT00479674,https://clinicaltrials.gov/show/NCT00479674,Breast_Cancer,Abraxane|Bevacizumab|Carboplatin|,other_events,arm0,Abraxane-Carboplatin-Bevacizumab,4,bevacizumab,monoclonal-antibody
2611,Allergic_reaction,1,41,Immune_system_disorders,NCT00479674,https://clinicaltrials.gov/show/NCT00479674,Breast_Cancer,Abraxane|Bevacizumab|Carboplatin|,serious_events,arm0,Abraxane-Carboplatin-Bevacizumab,22,bevacizumab,monoclonal-antibody
2612,Allergic_reaction,3,41,Immune_system_disorders,NCT00479674,https://clinicaltrials.gov/show/NCT00479674,Breast_Cancer,Abraxane|Bevacizumab|Carboplatin|,other_events,arm0,Abraxane-Carboplatin-Bevacizumab,22,bevacizumab,monoclonal-antibody
525,Hypersensitivity,2,32,Immune_system_disorders,NCT00481078,https://clinicaltrials.gov/show/NCT00481078,Recurrent_Non-small_Cell_Lung_Cancer|Stage_IIIB_Non-small_Cell_Lung_Cancer|Stage_IV_Non-small_Cell_Lung_Cancer|,vorinostat|paclitaxel|carboplatin|placebo|laboratory_biomarker_analysis|,other_events,arm1,Arm-II-(Placebo-Paclitaxel-Carboplatin),3,carboplatin,alkalating-agent
525,Hypersensitivity,2,32,Immune_system_disorders,NCT00481078,https://clinicaltrials.gov/show/NCT00481078,Recurrent_Non-small_Cell_Lung_Cancer|Stage_IIIB_Non-small_Cell_Lung_Cancer|Stage_IV_Non-small_Cell_Lung_Cancer|,vorinostat|paclitaxel|carboplatin|placebo|laboratory_biomarker_analysis|,other_events,arm1,Arm-II-(Placebo-Paclitaxel-Carboplatin),2,paclitaxel,taxane
529,Hypersensitivity,1,395,Immune_system_disorders,NCT00486759,https://clinicaltrials.gov/show/NCT00486759,B-cell_Lymphoma,Bevacizumab|Rituximab|CHOP|Placebo|,serious_events,arm0,Bevacizumab-+-Rituximab-+-CHOP,16,rituximab,monoclonal-antibody
529,Hypersensitivity,1,395,Immune_system_disorders,NCT00486759,https://clinicaltrials.gov/show/NCT00486759,B-cell_Lymphoma,Bevacizumab|Rituximab|CHOP|Placebo|,serious_events,arm0,Bevacizumab-+-Rituximab-+-CHOP,4,bevacizumab,monoclonal-antibody
529,Hypersensitivity,1,395,Immune_system_disorders,NCT00486759,https://clinicaltrials.gov/show/NCT00486759,B-cell_Lymphoma,Bevacizumab|Rituximab|CHOP|Placebo|,serious_events,arm0,Bevacizumab-+-Rituximab-+-CHOP,22,bevacizumab,monoclonal-antibody
528,Hypersensitivity,2,386,Immune_system_disorders,NCT00486759,https://clinicaltrials.gov/show/NCT00486759,B-cell_Lymphoma,Bevacizumab|Rituximab|CHOP|Placebo|,serious_events,arm1,Placebo-+-Rituximab-+-CHOP,16,rituximab,monoclonal-antibody
1482,Drug_hypersensitivity,1,4,Immune_system_disorders,NCT00489359,https://clinicaltrials.gov/show/NCT00489359,Ovarian_Cancer|Primary_Peritoneal_Cancer|,Pemetrexed_-_Phase_1|Carboplatin_-_Phase_1|Pemetrexed_-_Phase_2|Carboplatin_-_Phase_2|,other_events,arm0,Pemetrexed-500-+-Carboplatin-AUC-5-(Phase-1),3,carboplatin,alkalating-agent
534,Hypersensitivity,1,4,Immune_system_disorders,NCT00489359,https://clinicaltrials.gov/show/NCT00489359,Ovarian_Cancer|Primary_Peritoneal_Cancer|,Pemetrexed_-_Phase_1|Carboplatin_-_Phase_1|Pemetrexed_-_Phase_2|Carboplatin_-_Phase_2|,other_events,arm0,Pemetrexed-500-+-Carboplatin-AUC-5-(Phase-1),3,carboplatin,alkalating-agent
1482,Drug_hypersensitivity,1,4,Immune_system_disorders,NCT00489359,https://clinicaltrials.gov/show/NCT00489359,Ovarian_Cancer|Primary_Peritoneal_Cancer|,Pemetrexed_-_Phase_1|Carboplatin_-_Phase_1|Pemetrexed_-_Phase_2|Carboplatin_-_Phase_2|,other_events,arm0,Pemetrexed-500-+-Carboplatin-AUC-5-(Phase-1),15,pemetrexed,antimetabolite
534,Hypersensitivity,1,4,Immune_system_disorders,NCT00489359,https://clinicaltrials.gov/show/NCT00489359,Ovarian_Cancer|Primary_Peritoneal_Cancer|,Pemetrexed_-_Phase_1|Carboplatin_-_Phase_1|Pemetrexed_-_Phase_2|Carboplatin_-_Phase_2|,other_events,arm0,Pemetrexed-500-+-Carboplatin-AUC-5-(Phase-1),15,pemetrexed,antimetabolite
533,Hypersensitivity,1,3,Immune_system_disorders,NCT00489359,https://clinicaltrials.gov/show/NCT00489359,Ovarian_Cancer|Primary_Peritoneal_Cancer|,Pemetrexed_-_Phase_1|Carboplatin_-_Phase_1|Pemetrexed_-_Phase_2|Carboplatin_-_Phase_2|,other_events,arm1,Pemetrexed-600-+-Carboplatin-AUC-5-(Phase-1),3,carboplatin,alkalating-agent
533,Hypersensitivity,1,3,Immune_system_disorders,NCT00489359,https://clinicaltrials.gov/show/NCT00489359,Ovarian_Cancer|Primary_Peritoneal_Cancer|,Pemetrexed_-_Phase_1|Carboplatin_-_Phase_1|Pemetrexed_-_Phase_2|Carboplatin_-_Phase_2|,other_events,arm1,Pemetrexed-600-+-Carboplatin-AUC-5-(Phase-1),15,pemetrexed,antimetabolite
535,Hypersensitivity,1,3,Immune_system_disorders,NCT00489359,https://clinicaltrials.gov/show/NCT00489359,Ovarian_Cancer|Primary_Peritoneal_Cancer|,Pemetrexed_-_Phase_1|Carboplatin_-_Phase_1|Pemetrexed_-_Phase_2|Carboplatin_-_Phase_2|,other_events,arm3,Pemetrexed-700-+-Carboplatin-AUC-6-(Phase-1),3,carboplatin,alkalating-agent
535,Hypersensitivity,1,3,Immune_system_disorders,NCT00489359,https://clinicaltrials.gov/show/NCT00489359,Ovarian_Cancer|Primary_Peritoneal_Cancer|,Pemetrexed_-_Phase_1|Carboplatin_-_Phase_1|Pemetrexed_-_Phase_2|Carboplatin_-_Phase_2|,other_events,arm3,Pemetrexed-700-+-Carboplatin-AUC-6-(Phase-1),15,pemetrexed,antimetabolite
1480,Drug_hypersensitivity,1,3,Immune_system_disorders,NCT00489359,https://clinicaltrials.gov/show/NCT00489359,Ovarian_Cancer|Primary_Peritoneal_Cancer|,Pemetrexed_-_Phase_1|Carboplatin_-_Phase_1|Pemetrexed_-_Phase_2|Carboplatin_-_Phase_2|,other_events,arm5,Pemetrexed-900-+-Carboplatin-AUC-6-(Phase-1),3,carboplatin,alkalating-agent
532,Hypersensitivity,1,3,Immune_system_disorders,NCT00489359,https://clinicaltrials.gov/show/NCT00489359,Ovarian_Cancer|Primary_Peritoneal_Cancer|,Pemetrexed_-_Phase_1|Carboplatin_-_Phase_1|Pemetrexed_-_Phase_2|Carboplatin_-_Phase_2|,other_events,arm5,Pemetrexed-900-+-Carboplatin-AUC-6-(Phase-1),3,carboplatin,alkalating-agent
1480,Drug_hypersensitivity,1,3,Immune_system_disorders,NCT00489359,https://clinicaltrials.gov/show/NCT00489359,Ovarian_Cancer|Primary_Peritoneal_Cancer|,Pemetrexed_-_Phase_1|Carboplatin_-_Phase_1|Pemetrexed_-_Phase_2|Carboplatin_-_Phase_2|,other_events,arm5,Pemetrexed-900-+-Carboplatin-AUC-6-(Phase-1),15,pemetrexed,antimetabolite
532,Hypersensitivity,1,3,Immune_system_disorders,NCT00489359,https://clinicaltrials.gov/show/NCT00489359,Ovarian_Cancer|Primary_Peritoneal_Cancer|,Pemetrexed_-_Phase_1|Carboplatin_-_Phase_1|Pemetrexed_-_Phase_2|Carboplatin_-_Phase_2|,other_events,arm5,Pemetrexed-900-+-Carboplatin-AUC-6-(Phase-1),15,pemetrexed,antimetabolite
1479,Drug_hypersensitivity,17,66,Immune_system_disorders,NCT00489359,https://clinicaltrials.gov/show/NCT00489359,Ovarian_Cancer|Primary_Peritoneal_Cancer|,Pemetrexed_-_Phase_1|Carboplatin_-_Phase_1|Pemetrexed_-_Phase_2|Carboplatin_-_Phase_2|,other_events,arm6,Pemetrexed-500-+-Carboplatin-AUC-6-(Phase-2),3,carboplatin,alkalating-agent
1481,Drug_hypersensitivity,3,66,Immune_system_disorders,NCT00489359,https://clinicaltrials.gov/show/NCT00489359,Ovarian_Cancer|Primary_Peritoneal_Cancer|,Pemetrexed_-_Phase_1|Carboplatin_-_Phase_1|Pemetrexed_-_Phase_2|Carboplatin_-_Phase_2|,serious_events,arm6,Pemetrexed-500-+-Carboplatin-AUC-6-(Phase-2),3,carboplatin,alkalating-agent
531,Hypersensitivity,1,66,Immune_system_disorders,NCT00489359,https://clinicaltrials.gov/show/NCT00489359,Ovarian_Cancer|Primary_Peritoneal_Cancer|,Pemetrexed_-_Phase_1|Carboplatin_-_Phase_1|Pemetrexed_-_Phase_2|Carboplatin_-_Phase_2|,other_events,arm6,Pemetrexed-500-+-Carboplatin-AUC-6-(Phase-2),3,carboplatin,alkalating-agent
1479,Drug_hypersensitivity,17,66,Immune_system_disorders,NCT00489359,https://clinicaltrials.gov/show/NCT00489359,Ovarian_Cancer|Primary_Peritoneal_Cancer|,Pemetrexed_-_Phase_1|Carboplatin_-_Phase_1|Pemetrexed_-_Phase_2|Carboplatin_-_Phase_2|,other_events,arm6,Pemetrexed-500-+-Carboplatin-AUC-6-(Phase-2),15,pemetrexed,antimetabolite
1481,Drug_hypersensitivity,3,66,Immune_system_disorders,NCT00489359,https://clinicaltrials.gov/show/NCT00489359,Ovarian_Cancer|Primary_Peritoneal_Cancer|,Pemetrexed_-_Phase_1|Carboplatin_-_Phase_1|Pemetrexed_-_Phase_2|Carboplatin_-_Phase_2|,serious_events,arm6,Pemetrexed-500-+-Carboplatin-AUC-6-(Phase-2),15,pemetrexed,antimetabolite
531,Hypersensitivity,1,66,Immune_system_disorders,NCT00489359,https://clinicaltrials.gov/show/NCT00489359,Ovarian_Cancer|Primary_Peritoneal_Cancer|,Pemetrexed_-_Phase_1|Carboplatin_-_Phase_1|Pemetrexed_-_Phase_2|Carboplatin_-_Phase_2|,other_events,arm6,Pemetrexed-500-+-Carboplatin-AUC-6-(Phase-2),15,pemetrexed,antimetabolite
1485,Drug_Hypersensitivity,1,2061,Immune_system_disorders,NCT00490139,https://clinicaltrials.gov/show/NCT00490139,Neoplasms_Breast,Lapatinib|Trastuzumab|,serious_events,arm0,Lapatinib-plusTrastuzumab,18,trastuzumab,monoclonal-antibody
1485,Drug_Hypersensitivity,1,2061,Immune_system_disorders,NCT00490139,https://clinicaltrials.gov/show/NCT00490139,Neoplasms_Breast,Lapatinib|Trastuzumab|,serious_events,arm0,Lapatinib-plusTrastuzumab,21,lapatinib,signal-transduction-inhibitor
1484,Drug_Hypersensitivity,2,2057,Immune_system_disorders,NCT00490139,https://clinicaltrials.gov/show/NCT00490139,Neoplasms_Breast,Lapatinib|Trastuzumab|,serious_events,arm2,Lapatinib,21,lapatinib,signal-transduction-inhibitor
1483,DRUG_HYPERSENSITIVITY,2,24,Immune_system_disorders,NCT00490646,https://clinicaltrials.gov/show/NCT00490646,Metastatic_Breast_Cancer,ixabepilone|docetaxel|trastuzumab|,other_events,arm0,Trastuzumab-2-mg/kg-+-Docetaxel-100-mg/m^2-IV,18,trastuzumab,monoclonal-antibody
1483,DRUG_HYPERSENSITIVITY,2,24,Immune_system_disorders,NCT00490646,https://clinicaltrials.gov/show/NCT00490646,Metastatic_Breast_Cancer,ixabepilone|docetaxel|trastuzumab|,other_events,arm0,Trastuzumab-2-mg/kg-+-Docetaxel-100-mg/m^2-IV,8,docetaxel,taxane
2618,Allergic_Reaction,2,149,Immune_system_disorders,NCT00492752,https://clinicaltrials.gov/show/NCT00492752,Carcinoma_Hepatocellular,Sorafenib_(Nexavar_BAY43-9006)|Placebo|,other_events,arm0,Sorafenib-All-(Double-Blind-and-Open-Label-Phase),90,sorafenib,Tyrosine-Kinase-inhibitor
2617,Allergic_Reaction,4,75,Immune_system_disorders,NCT00492752,https://clinicaltrials.gov/show/NCT00492752,Carcinoma_Hepatocellular,Sorafenib_(Nexavar_BAY43-9006)|Placebo|,other_events,arm1,Placebo-All-(Double-Blind-and-Open-Label-Phase),,,
1490,Drug_hypersensitivity,2,76,Immune_system_disorders,NCT00494091,https://clinicaltrials.gov/show/NCT00494091,Advanced_Renal_Cell_Carcinoma,Temsirolimus_(CCI-779)|Temsirolimus_(CCI-779)|,other_events,arm1,Temsirolimus-25-mg,,,
1487,Drug_Hypersensitivity,6,58,Immune_system_disorders,NCT00494221,https://clinicaltrials.gov/show/NCT00494221,Metastatic_Colorectal_Cancer,AZD2171|FOLFOX_(5-fluorouracil_Leucovorin_Oxaliplatin)|Placebo_Cediranib|,other_events,arm0,Cediranib-20-mg,14,cediranib,endothelial-growith-factor-receptor-tyrosine-kinase-inhibitor?
1488,Drug_Hypersensitivity,9,56,Immune_system_disorders,NCT00494221,https://clinicaltrials.gov/show/NCT00494221,Metastatic_Colorectal_Cancer,AZD2171|FOLFOX_(5-fluorouracil_Leucovorin_Oxaliplatin)|Placebo_Cediranib|,other_events,arm1,Cediranib-30-mg,14,cediranib,endothelial-growith-factor-receptor-tyrosine-kinase-inhibitor?
1489,Drug_Hypersensitivity,12,58,Immune_system_disorders,NCT00494221,https://clinicaltrials.gov/show/NCT00494221,Metastatic_Colorectal_Cancer,AZD2171|FOLFOX_(5-fluorouracil_Leucovorin_Oxaliplatin)|Placebo_Cediranib|,other_events,arm2,Placebo,,,
537,Hypersensitivity,1,29,Immune_system_disorders,NCT00494780,https://clinicaltrials.gov/show/NCT00494780,Lymphoma_Follicular,Ofatumumab|Cyclophosphamide|Doxorubicin|Vincristine|Prednisolone_Prednisone_or_equivalent|,serious_events,arm0,500-mg-Ofatumumab-+-CHOP,42,ofatumumab,monoclonal-antibody
536,Hypersensitivity,1,29,Immune_system_disorders,NCT00494780,https://clinicaltrials.gov/show/NCT00494780,Lymphoma_Follicular,Ofatumumab|Cyclophosphamide|Doxorubicin|Vincristine|Prednisolone_Prednisone_or_equivalent|,serious_events,arm1,1000-mg-Ofatumumab-+-CHOP,42,ofatumumab,monoclonal-antibody
2621,Allergic_Reaction,1,30,Immune_system_disorders,NCT00499694,https://clinicaltrials.gov/show/NCT00499694,Prostate_Cancer,bevacizumab|satraplatin|,serious_events,arm0,Bevacizumab-and-Satraplatin,4,bevacizumab,monoclonal-antibody
2622,Allergic_Reaction,2,30,Immune_system_disorders,NCT00499694,https://clinicaltrials.gov/show/NCT00499694,Prostate_Cancer,bevacizumab|satraplatin|,other_events,arm0,Bevacizumab-and-Satraplatin,4,bevacizumab,monoclonal-antibody
2621,Allergic_Reaction,1,30,Immune_system_disorders,NCT00499694,https://clinicaltrials.gov/show/NCT00499694,Prostate_Cancer,bevacizumab|satraplatin|,serious_events,arm0,Bevacizumab-and-Satraplatin,22,bevacizumab,monoclonal-antibody
2622,Allergic_Reaction,2,30,Immune_system_disorders,NCT00499694,https://clinicaltrials.gov/show/NCT00499694,Prostate_Cancer,bevacizumab|satraplatin|,other_events,arm0,Bevacizumab-and-Satraplatin,22,bevacizumab,monoclonal-antibody
1491,Drug_Hypersensitivity,3,32,Immune_system_disorders,NCT00500292,https://clinicaltrials.gov/show/NCT00500292,Colorectal|Cancer|,Vandetanib|FOLFOX_regimen=oxaliplatin_fluorouracil_&_folinic_acid|,other_events,arm0,Vandetanib-100-mg-Plus-FOLFOX,33,vandetanib,tyrosine-kinase-inhibitor
1492,Drug_Hypersensitivity,4,35,Immune_system_disorders,NCT00500292,https://clinicaltrials.gov/show/NCT00500292,Colorectal|Cancer|,Vandetanib|FOLFOX_regimen=oxaliplatin_fluorouracil_&_folinic_acid|,other_events,arm1,Vandetanib-300-mg-Plus-FOLFOX,33,vandetanib,tyrosine-kinase-inhibitor
1493,Drug_Hypersensitivity,5,37,Immune_system_disorders,NCT00500292,https://clinicaltrials.gov/show/NCT00500292,Colorectal|Cancer|,Vandetanib|FOLFOX_regimen=oxaliplatin_fluorouracil_&_folinic_acid|,other_events,arm2,Placebo-Plus-FOLFOX,,,
2623,Allergic_Reaction,2,23,General_disorders,NCT00502203,https://clinicaltrials.gov/show/NCT00502203,Mixed_Tumor_Mullerian,Carboplatin|Paclitaxel|,other_events,arm0,Paclitaxel-+-Carboplatin,3,carboplatin,alkalating-agent
2623,Allergic_Reaction,2,23,General_disorders,NCT00502203,https://clinicaltrials.gov/show/NCT00502203,Mixed_Tumor_Mullerian,Carboplatin|Paclitaxel|,other_events,arm0,Paclitaxel-+-Carboplatin,2,paclitaxel,taxane
2388,Allergy,1,196,Immune_system_disorders,NCT00502905,https://clinicaltrials.gov/show/NCT00502905,Leukemia,Busulfan|Fludarabine|,other_events,arm0,Busulfan-+-Fludarabine,66,fludarabine,antimetabolite
2624,Allergic_Reaction,1,33,Immune_system_disorders,NCT00506597,https://clinicaltrials.gov/show/NCT00506597,Leukemia,Erwinase,other_events,arm0,Erwinase,,,
2049,Dermatitis_allergic,1,158,Skin_and_subcutaneous_tissue_disorders,NCT00507416,https://clinicaltrials.gov/show/NCT00507416,Multiple_Myeloma,Bortezomib|Dexamethasone|Melphalan|Prednisone|Thalidomide|,other_events,arm1,Bortezomib-Thalidomide-and-Dexamethasone,70,bortezomib,proteasome-inhibitor
2049,Dermatitis_allergic,1,158,Skin_and_subcutaneous_tissue_disorders,NCT00507416,https://clinicaltrials.gov/show/NCT00507416,Multiple_Myeloma,Bortezomib|Dexamethasone|Melphalan|Prednisone|Thalidomide|,other_events,arm1,Bortezomib-Thalidomide-and-Dexamethasone,79,dexamethasone,steroid
541,Hypersensitivity,1,43,Immune_system_disorders,NCT00509041,https://clinicaltrials.gov/show/NCT00509041,Malignant_Mesothelioma,dasatinib,other_events,arm0,Dasatinib,24,dasatinib,signal-transduction-inhibitor---tyrosine-kinase-inhibitor
2626,Allergic_reaction,1,16,Immune_system_disorders,NCT00509366,https://clinicaltrials.gov/show/NCT00509366,Non_Small_Cell_Lung_Cancer,Cisplatin_&_Gemcitabine|Cisplatin_&_Pemetrexed|Docetaxel_&_Gemcitabine|Pemetrexed_&_Gemcitabine|,serious_events,arm0,Cisplatin-Sensitive-(Pre-Amendment),9,cisplatin,alkalating-agent
2625,Allergic_reaction,1,17,Immune_system_disorders,NCT00509366,https://clinicaltrials.gov/show/NCT00509366,Non_Small_Cell_Lung_Cancer,Cisplatin_&_Gemcitabine|Cisplatin_&_Pemetrexed|Docetaxel_&_Gemcitabine|Pemetrexed_&_Gemcitabine|,other_events,arm2,Cisplatin-Resistant-(Pre-Amendment),9,cisplatin,alkalating-agent
1497,Drug_hypersensitivity,1,203,Immune_system_disorders,NCT00510068,https://clinicaltrials.gov/show/NCT00510068,Advanced_Neuroendocrine_Tumors_of_Pancreatic_Origin,Everolimus|Everolimus_Placebo|,serious_events,arm1,Placebo,,,
542,Hypersensitivity,1,266,Immune_system_disorders,NCT00511238,https://clinicaltrials.gov/show/NCT00511238,Multiple_Myeloma,carfilzomib|carfilzomib|,serious_events,arm1,Carfilzomib-(A1),,,
2627,allergic_reaction,1,23,Immune_system_disorders,NCT00512096,https://clinicaltrials.gov/show/NCT00512096,Penile_Cancer,Ifosfamide|Paclitaxel_(Taxol)|Cisplatin|,serious_events,arm0,Cisplatin-+-Ifosfamide-+-Paclitaxel,9,cisplatin,alkalating-agent
2627,allergic_reaction,1,23,Immune_system_disorders,NCT00512096,https://clinicaltrials.gov/show/NCT00512096,Penile_Cancer,Ifosfamide|Paclitaxel_(Taxol)|Cisplatin|,serious_events,arm0,Cisplatin-+-Ifosfamide-+-Paclitaxel,2,paclitaxel,taxane
545,Hypersensitivity,2,138,Immune_system_disorders,NCT00513292,https://clinicaltrials.gov/show/NCT00513292,HER2/Neu_Positive|Stage_IA_Breast_Cancer|Stage_IB_Breast_Cancer|Stage_II_Breast_Cancer|Stage_IIIA_Breast_Cancer|,Cyclophosphamide|Epirubicin_Hydrochloride|Laboratory_Biomarker_Analysis|Paclitaxel|Therapeutic_Conventional_Surgery|Trastuzumab|,other_events,arm0,Arm-A,,,
546,Hypersensitivity,4,142,Immune_system_disorders,NCT00513292,https://clinicaltrials.gov/show/NCT00513292,HER2/Neu_Positive|Stage_IA_Breast_Cancer|Stage_IB_Breast_Cancer|Stage_II_Breast_Cancer|Stage_IIIA_Breast_Cancer|,Cyclophosphamide|Epirubicin_Hydrochloride|Laboratory_Biomarker_Analysis|Paclitaxel|Therapeutic_Conventional_Surgery|Trastuzumab|,other_events,arm1,Arm-B,,,
2628,Allergic_reaction,1,26,Immune_system_disorders,NCT00513604,https://clinicaltrials.gov/show/NCT00513604,Melanoma|Malignant_Melanoma|Melanoma_Experimental|Experimental_Melanomas|,aldesleukin|therapeutic_autologous_lymphocytes|Cyclophosphamide|Fludarabine_phosphate|Total_body_irradiation|,other_events,arm0,Cohort-1---NMA-TIL-Aldesleukin,,,
2052,Dermatitis_allergic,1,15,Skin_and_subcutaneous_tissue_disorders,NCT00514813,https://clinicaltrials.gov/show/NCT00514813,Anemia|Kidney_Failure_Chronic|,Dynepo,other_events,arm0,Dynepo-(Epoetin-Delta)-Twice-Weekly-(BIW),,,
547,Hypersensitivity,1,60,Immune_system_disorders,NCT00514943,https://clinicaltrials.gov/show/NCT00514943,Head_and_Neck_Neoplasms|Carcinoma_Squamous_Cell|,BIBW_2992|Cetuximab|,serious_events,arm1,Cetuximab-mg/m2---Stage-1,5,cetuximab,Epidermal-growth-factor-receptor-inhibitor
1498,Drug_Hypersensitivity,1,6,Immune_system_disorders,NCT00515086,https://clinicaltrials.gov/show/NCT00515086,Glioblastoma_Multiforme,Everolimus|Surgery|,other_events,arm0,Everolimus-10-mg-+-Surgery,32,everolimus,mTOR?inhibitor-(blocks-gene-translation)
549,Hypersensitivity,1,29,Immune_system_disorders,NCT00516217,https://clinicaltrials.gov/show/NCT00516217,Lymphoma,galiximab,serious_events,arm0,Galaximab,,,
2629,Allergic_reaction,1,6,Immune_system_disorders,NCT00516295,https://clinicaltrials.gov/show/NCT00516295,Ewing_Sarcoma_of_Bone|Extraosseous_Ewing_Sarcoma|Peripheral_Primitive_Neuroectodermal_Tumor|Recurrent_Ewing_Sarcoma/Peripheral_Primitive_Neuroectodermal_Tumor|,topotecan_hydrochloride|vincristine_sulfate|cyclophosphamide|bevacizumab|,other_events,arm0,Arm-I-(Feasibility-Assessment-of-VTCB),,,
1500,Drug_hypersensitivity,1,598,Immune_system_disorders,NCT00519285,https://clinicaltrials.gov/show/NCT00519285,Prostatic_Neoplasms|Neoplasm_Metastasis|,Aflibercept|Placebo_(for_aflibercept)|Docetaxel|Prednisone_or_Prednisolone|,serious_events,arm0,Placebo,,,
1499,Drug_hypersensitivity,3,611,Immune_system_disorders,NCT00519285,https://clinicaltrials.gov/show/NCT00519285,Prostatic_Neoplasms|Neoplasm_Metastasis|,Aflibercept|Placebo_(for_aflibercept)|Docetaxel|Prednisone_or_Prednisolone|,serious_events,arm1,Aflibercept,39,aflibercept,vascular-endothelial-growth-factor-(VEGF)-inhibitor
2389,allergy,1,23,Respiratory_thoracic_and_mediastinal_disorders,NCT00520845,https://clinicaltrials.gov/show/NCT00520845,Lung_Cancer,celecoxib|Docetaxel|pemetrexed_disodium|laboratory_biomarker_analysis|,serious_events,arm0,Treatment-Arm,,,
2054,Dermatitis_allergic,1,6,Skin_and_subcutaneous_tissue_disorders,NCT00524459,https://clinicaltrials.gov/show/NCT00524459,Breast_Cancer,docetaxel|pegylated_liposomal_doxorubicin_hydrochloride|conventional_surgery|neoadjuvant_therapy|,other_events,arm0,DOXIL-(Pegylated-Liposomal-Doxorubicin)-and-Docetaxel,38,doxorubicin,anthracycline-antibiotic
555,Hypersensitivity,1,6,Immune_system_disorders,NCT00524459,https://clinicaltrials.gov/show/NCT00524459,Breast_Cancer,docetaxel|pegylated_liposomal_doxorubicin_hydrochloride|conventional_surgery|neoadjuvant_therapy|,serious_events,arm0,DOXIL-(Pegylated-Liposomal-Doxorubicin)-and-Docetaxel,38,doxorubicin,anthracycline-antibiotic
2054,Dermatitis_allergic,1,6,Skin_and_subcutaneous_tissue_disorders,NCT00524459,https://clinicaltrials.gov/show/NCT00524459,Breast_Cancer,docetaxel|pegylated_liposomal_doxorubicin_hydrochloride|conventional_surgery|neoadjuvant_therapy|,other_events,arm0,DOXIL-(Pegylated-Liposomal-Doxorubicin)-and-Docetaxel,89,liposomal,Class_Name_Needed
555,Hypersensitivity,1,6,Immune_system_disorders,NCT00524459,https://clinicaltrials.gov/show/NCT00524459,Breast_Cancer,docetaxel|pegylated_liposomal_doxorubicin_hydrochloride|conventional_surgery|neoadjuvant_therapy|,serious_events,arm0,DOXIL-(Pegylated-Liposomal-Doxorubicin)-and-Docetaxel,89,liposomal,Class_Name_Needed
2054,Dermatitis_allergic,1,6,Skin_and_subcutaneous_tissue_disorders,NCT00524459,https://clinicaltrials.gov/show/NCT00524459,Breast_Cancer,docetaxel|pegylated_liposomal_doxorubicin_hydrochloride|conventional_surgery|neoadjuvant_therapy|,other_events,arm0,DOXIL-(Pegylated-Liposomal-Doxorubicin)-and-Docetaxel,8,docetaxel,taxane
555,Hypersensitivity,1,6,Immune_system_disorders,NCT00524459,https://clinicaltrials.gov/show/NCT00524459,Breast_Cancer,docetaxel|pegylated_liposomal_doxorubicin_hydrochloride|conventional_surgery|neoadjuvant_therapy|,serious_events,arm0,DOXIL-(Pegylated-Liposomal-Doxorubicin)-and-Docetaxel,8,docetaxel,taxane
1502,Drug_hypersensitivity,1,99,Immune_system_disorders,NCT00525148,https://clinicaltrials.gov/show/NCT00525148,Carcinoma_Non-Small-Cell_Lung,BIBW_2992,serious_events,arm1,Afatinib-50-mg,,,
556,Hypersensitivity,1,2331,Immune_system_disorders,NCT00525798,https://clinicaltrials.gov/show/NCT00525798,Osteoporosis,SMC021_Oral_calcitonin|SMC021_Placebo|,serious_events,arm1,Placebo,,,
2630,Allergic_Reaction,1,16,Skin_and_subcutaneous_tissue_disorders,NCT00525876,https://clinicaltrials.gov/show/NCT00525876,Lymphoma,Cyclophosphamide|Fludarabine|Rituximab|Alemtuzumab|Allogeneic_Stem_Cell_Infusion|,serious_events,arm0,Matched-Sibling-Transplant,,,
561,HYPERSENSITIVITY,1,71,Immune_system_disorders,NCT00527735,https://clinicaltrials.gov/show/NCT00527735,Lung_Cancer|Small_Cell_Lung_Cancer|Carcinoma_Non-Small-Cell_Lung|,Ipilimumab|Placebo|Paclitaxel|Carboplatin|,serious_events,arm0,Ipilimubab+Paclitaxel/Carboplatin-(Concurrent)-NSCLC,3,carboplatin,alkalating-agent
561,HYPERSENSITIVITY,1,71,Immune_system_disorders,NCT00527735,https://clinicaltrials.gov/show/NCT00527735,Lung_Cancer|Small_Cell_Lung_Cancer|Carcinoma_Non-Small-Cell_Lung|,Ipilimumab|Placebo|Paclitaxel|Carboplatin|,serious_events,arm0,Ipilimubab+Paclitaxel/Carboplatin-(Concurrent)-NSCLC,2,paclitaxel,taxane
559,HYPERSENSITIVITY,1,67,Immune_system_disorders,NCT00527735,https://clinicaltrials.gov/show/NCT00527735,Lung_Cancer|Small_Cell_Lung_Cancer|Carcinoma_Non-Small-Cell_Lung|,Ipilimumab|Placebo|Paclitaxel|Carboplatin|,serious_events,arm1,Placebo/Ipilimumab+-Paclitaxel/Carboplatin-(Sequential)-NSCLC,3,carboplatin,alkalating-agent
559,HYPERSENSITIVITY,1,67,Immune_system_disorders,NCT00527735,https://clinicaltrials.gov/show/NCT00527735,Lung_Cancer|Small_Cell_Lung_Cancer|Carcinoma_Non-Small-Cell_Lung|,Ipilimumab|Placebo|Paclitaxel|Carboplatin|,serious_events,arm1,Placebo/Ipilimumab+-Paclitaxel/Carboplatin-(Sequential)-NSCLC,64,ipilimumab,monoclonal-antibody
559,HYPERSENSITIVITY,1,67,Immune_system_disorders,NCT00527735,https://clinicaltrials.gov/show/NCT00527735,Lung_Cancer|Small_Cell_Lung_Cancer|Carcinoma_Non-Small-Cell_Lung|,Ipilimumab|Placebo|Paclitaxel|Carboplatin|,serious_events,arm1,Placebo/Ipilimumab+-Paclitaxel/Carboplatin-(Sequential)-NSCLC,2,paclitaxel,taxane
560,HYPERSENSITIVITY,1,65,Immune_system_disorders,NCT00527735,https://clinicaltrials.gov/show/NCT00527735,Lung_Cancer|Small_Cell_Lung_Cancer|Carcinoma_Non-Small-Cell_Lung|,Ipilimumab|Placebo|Paclitaxel|Carboplatin|,serious_events,arm2,Placebo-+-Paclitaxel/Carboplatin-NSCLC,3,carboplatin,alkalating-agent
560,HYPERSENSITIVITY,1,65,Immune_system_disorders,NCT00527735,https://clinicaltrials.gov/show/NCT00527735,Lung_Cancer|Small_Cell_Lung_Cancer|Carcinoma_Non-Small-Cell_Lung|,Ipilimumab|Placebo|Paclitaxel|Carboplatin|,serious_events,arm2,Placebo-+-Paclitaxel/Carboplatin-NSCLC,2,paclitaxel,taxane
564,Hypersensitivity,1,1271,Immune_system_disorders,NCT00528567,https://clinicaltrials.gov/show/NCT00528567,Breast_Cancer,Bevacizumab|Standard_adjuvant_chemotherapy|,serious_events,arm1,Chemotherapy-(0-18-Months),,,
565,Hypersensitivity,1,81,Immune_system_disorders,NCT00529659,https://clinicaltrials.gov/show/NCT00529659,Sarcopenia,Comparator:_MK-0773|Comparator:_Placebo|,other_events,arm0,MK-0773,,,
566,Hypersensitivity,1,60,Immune_system_disorders,NCT00531960,https://clinicaltrials.gov/show/NCT00531960,Non-Small_Cell_Lung_Cancer,Erlotinib|Bevacizumab|Standard_platinum-based_chemotherapy|,other_events,arm0,Bevacizumab-+-Chemotherapy,4,bevacizumab,monoclonal-antibody
566,Hypersensitivity,1,60,Immune_system_disorders,NCT00531960,https://clinicaltrials.gov/show/NCT00531960,Non-Small_Cell_Lung_Cancer,Erlotinib|Bevacizumab|Standard_platinum-based_chemotherapy|,other_events,arm0,Bevacizumab-+-Chemotherapy,22,bevacizumab,monoclonal-antibody
1510,Drug_hypersensitivity,1,452,Immune_system_disorders,NCT00532155,https://clinicaltrials.gov/show/NCT00532155,Carcinoma|Non_Small_Cell_Lung|,Aflibercept_(ziv-aflibercept_AVE0005_VEGF_trap_ZALTRAP??)|Placebo|Docetaxel_(Taxotere??)|Dexamethasone_(pre-_and_post-medication_for_docetaxel)|,serious_events,arm1,Aflibercept/Docetaxel,8,docetaxel,taxane
1510,Drug_hypersensitivity,1,452,Immune_system_disorders,NCT00532155,https://clinicaltrials.gov/show/NCT00532155,Carcinoma|Non_Small_Cell_Lung|,Aflibercept_(ziv-aflibercept_AVE0005_VEGF_trap_ZALTRAP??)|Placebo|Docetaxel_(Taxotere??)|Dexamethasone_(pre-_and_post-medication_for_docetaxel)|,serious_events,arm1,Aflibercept/Docetaxel,39,aflibercept,vascular-endothelial-growth-factor-(VEGF)-inhibitor
569,Hypersensitivity,1,41,Immune_system_disorders,NCT00534417,https://clinicaltrials.gov/show/NCT00534417,Metastatic_Breast_Cancer,capecitabine|fulvestrant|,other_events,arm0,Treatment-Group:-Capecitabine/Fulvestrant,17,capecitabine,antimetabolite
569,Hypersensitivity,1,41,Immune_system_disorders,NCT00534417,https://clinicaltrials.gov/show/NCT00534417,Metastatic_Breast_Cancer,capecitabine|fulvestrant|,other_events,arm0,Treatment-Group:-Capecitabine/Fulvestrant,29,capecitabine,antimetabolite
2631,Allergic_reaction,3,55,Immune_system_disorders,NCT00537030,https://clinicaltrials.gov/show/NCT00537030,Adult_Acute_Lymphoblastic_Leukemia|Childhood_Acute_Lymphoblastic_Leukemia|,laboratory_biomarker_analysis|pharmacological_study|asparaginase|,other_events,arm0,Erwinia-Asparaginase,,,
1512,Drug_hypersensitivity,1,43,Immune_system_disorders,NCT00537329,https://clinicaltrials.gov/show/NCT00537329,Candidemia,Anidulafungin,other_events,arm0,Anidulafungin,,,
574,Hypersensitivity,1,6,Immune_system_disorders,NCT00537511,https://clinicaltrials.gov/show/NCT00537511,Carcinoma_Small_Cell,Pomalidomide|Cisplatin|Etoposide|,other_events,arm0,Pomalidomide-1-mg,,,
575,Hypersensitivity,1,4,Immune_system_disorders,NCT00537511,https://clinicaltrials.gov/show/NCT00537511,Carcinoma_Small_Cell,Pomalidomide|Cisplatin|Etoposide|,other_events,arm1,Pomalidomide-3-mg,,,
573,Hypersensitivity,2,22,Immune_system_disorders,NCT00537511,https://clinicaltrials.gov/show/NCT00537511,Carcinoma_Small_Cell,Pomalidomide|Cisplatin|Etoposide|,other_events,arm4,Pomalidomide-(Overall),,,
1514,Drug_hypersensitivity,1,524,Immune_system_disorders,NCT00540514,https://clinicaltrials.gov/show/NCT00540514,Non-Small_Cell_Lung_Carcinoma,Albumin-bound_paclitaxel|Paclitaxel|Carboplatin|,serious_events,arm1,Paclitaxel-+-Carboplatin,3,carboplatin,alkalating-agent
1514,Drug_hypersensitivity,1,524,Immune_system_disorders,NCT00540514,https://clinicaltrials.gov/show/NCT00540514,Non-Small_Cell_Lung_Carcinoma,Albumin-bound_paclitaxel|Paclitaxel|Carboplatin|,serious_events,arm1,Paclitaxel-+-Carboplatin,2,paclitaxel,taxane
2632,Allergic_Reaction,1,8,Immune_system_disorders,NCT00541099,https://clinicaltrials.gov/show/NCT00541099,Lung_Cancer,bevacizumab|docetaxel|,other_events,arm0,Avastin-&-Docetaxel,8,docetaxel,taxane
2066,Dermatitis_allergic,1,14,Skin_and_subcutaneous_tissue_disorders,NCT00542828,https://clinicaltrials.gov/show/NCT00542828,Myelodysplastic_Syndrome_(MDS),Thymoglobulin??_Rabbit_Anti-thymocyte_Globulin_(rATG),other_events,arm0,Thymoglobulin,,,
580,Hypersensitivity,1,7071,Immune_system_disorders,NCT00543543,https://clinicaltrials.gov/show/NCT00543543,Cervical_Cancer|Vulvar_Cancer|Vaginal_Cancer|Genital_Warts|Human_Papillomavirus_Infection|,Comparator:_GARDASIL|Experimental:_V503|,serious_events,arm1,Mid-dose-V503,,,
2633,Allergic_reaction,1,8,Immune_system_disorders,NCT00545948,https://clinicaltrials.gov/show/NCT00545948,Carcinoma_Non-Small-Cell_Lung,Vinorelbine_followed_by_Cisplatin|Pemetrexed_followed_by_Cisplatin|,other_events,arm0,Arm-A-Vinorelbine,,,
2634,Allergic_Reaction,10,104,Immune_system_disorders,NCT00546156,https://clinicaltrials.gov/show/NCT00546156,Breast_Cancer,Doxorubicin|Cyclophosphamide|Paclitaxel|Bevacizumab|,other_events,arm0,All-Study-Participants,,,
585,HYPERSENSITIVITY,2,20,Immune_system_disorders,NCT00546364,https://clinicaltrials.gov/show/NCT00546364,Breast_Neoplasms,Ixabepilone_40_mg/m^2_+_Capecitabine_1000_mg/m^2|Ixabepilone_32_mg/m^2_+_Capecitabine_1000_mg/m^2|Docetaxel_75_mg/m^2_+_Capecitabine_1000_mg/m^2|,other_events,arm0,Docetaxel,8,docetaxel,taxane
2635,Allergic_reaction,4,30,Infections_and_infestations,NCT00547534,https://clinicaltrials.gov/show/NCT00547534,Non-Hodgkin's_Lymphoma,bortezomib|bendamustine|rituximab|,other_events,arm0,Lymphoma-Subjects,,,
2390,Allergy,3,27,Immune_system_disorders,NCT00548418,https://clinicaltrials.gov/show/NCT00548418,Cervical_Cancer,Topotecan|Cisplatin|Bevacizumab|,other_events,arm0,Treatment-(Cisplatin-Topotecan-Bevacizumab),9,cisplatin,alkalating-agent
2390,Allergy,3,27,Immune_system_disorders,NCT00548418,https://clinicaltrials.gov/show/NCT00548418,Cervical_Cancer,Topotecan|Cisplatin|Bevacizumab|,other_events,arm0,Treatment-(Cisplatin-Topotecan-Bevacizumab),4,bevacizumab,monoclonal-antibody
2390,Allergy,3,27,Immune_system_disorders,NCT00548418,https://clinicaltrials.gov/show/NCT00548418,Cervical_Cancer,Topotecan|Cisplatin|Bevacizumab|,other_events,arm0,Treatment-(Cisplatin-Topotecan-Bevacizumab),22,bevacizumab,monoclonal-antibody
2390,Allergy,3,27,Immune_system_disorders,NCT00548418,https://clinicaltrials.gov/show/NCT00548418,Cervical_Cancer,Topotecan|Cisplatin|Bevacizumab|,other_events,arm0,Treatment-(Cisplatin-Topotecan-Bevacizumab),44,topotecan,topoisomerase-1-inhibitor
587,HYPERSENSITIVITY,1,381,Immune_system_disorders,NCT00548548,https://clinicaltrials.gov/show/NCT00548548,Adenocarcinoma,Bevacizumab|Capecitabine|Cisplatin|Placebo|5-fluorouracil|,serious_events,arm1,Placebo,,,
591,HYPERSENSITIVITY,9,120,Immune_system_disorders,NCT00550771,https://clinicaltrials.gov/show/NCT00550771,Breast_Neoplasm,doxorubicin_cyclophosphamide_paclitaxel_trastuzumab|PLD_cyclophosphamide_trastuzumab_paclitaxel|,other_events,arm0,PLD-Based-Regimen,,,
590,HYPERSENSITIVITY,3,59,Immune_system_disorders,NCT00550771,https://clinicaltrials.gov/show/NCT00550771,Breast_Neoplasm,doxorubicin_cyclophosphamide_paclitaxel_trastuzumab|PLD_cyclophosphamide_trastuzumab_paclitaxel|,other_events,arm1,Doxorubicin-Based-Regimen,38,doxorubicin,anthracycline-antibiotic
2636,Allergic_reaction,1,22,Immune_system_disorders,NCT00551759,https://clinicaltrials.gov/show/NCT00551759,Esophageal_Cancer,5-Fluorouracil|Oxaliplatin|Cetuximab|Docetaxel|Surgery|Radiotherapy|,serious_events,arm0,Neoadjuvant-Therapy-Surgery-Adjuvant-Therapy,,,
593,Hypersensitivity,1,59,Immune_system_disorders,NCT00553501,https://clinicaltrials.gov/show/NCT00553501,Lymphoma,epratuzumab|rituximab|,serious_events,arm0,Epratuzumab-Plus-Rituximab,16,rituximab,monoclonal-antibody
594,Hypersensitivity,2,59,Immune_system_disorders,NCT00553501,https://clinicaltrials.gov/show/NCT00553501,Lymphoma,epratuzumab|rituximab|,other_events,arm0,Epratuzumab-Plus-Rituximab,16,rituximab,monoclonal-antibody
593,Hypersensitivity,1,59,Immune_system_disorders,NCT00553501,https://clinicaltrials.gov/show/NCT00553501,Lymphoma,epratuzumab|rituximab|,serious_events,arm0,Epratuzumab-Plus-Rituximab,58,epratuzumab,monoclonal-antibody
594,Hypersensitivity,2,59,Immune_system_disorders,NCT00553501,https://clinicaltrials.gov/show/NCT00553501,Lymphoma,epratuzumab|rituximab|,other_events,arm0,Epratuzumab-Plus-Rituximab,58,epratuzumab,monoclonal-antibody
2070,Dermatitis_allergic,1,17,Skin_and_subcutaneous_tissue_disorders,NCT00553631,https://clinicaltrials.gov/show/NCT00553631,Gaucher_Disease_Type_1,velaglucerase_alfa|imiglucerase|,serious_events,arm0,Gene-Activated-Human-Glucocerebrosidase-(GA-GCB),,,
2071,Dermatitis_allergic,1,17,Skin_and_subcutaneous_tissue_disorders,NCT00553631,https://clinicaltrials.gov/show/NCT00553631,Gaucher_Disease_Type_1,velaglucerase_alfa|imiglucerase|,other_events,arm0,Gene-Activated-Human-Glucocerebrosidase-(GA-GCB),,,
595,Hypersensitivity,2,17,Immune_system_disorders,NCT00553631,https://clinicaltrials.gov/show/NCT00553631,Gaucher_Disease_Type_1,velaglucerase_alfa|imiglucerase|,other_events,arm0,Gene-Activated-Human-Glucocerebrosidase-(GA-GCB),,,
596,Hypersensitivity,1,53,Immune_system_disorders,NCT00553644,https://clinicaltrials.gov/show/NCT00553644,Recurrent_Mantle_Cell_Lymphoma,Bortezomib|Laboratory_Biomarker_Analysis|Lenalidomide|,other_events,arm0,Treatment-(Antiangiogenesis-Therapy-Enzyme-Inhibitor-Therapy),,,
599,Hypersensitivity,2,23,Immune_system_disorders,NCT00555620,https://clinicaltrials.gov/show/NCT00555620,Stomach_Neoplasms,capecitabine|oxaliplatin|sunitinib_malate|capecitabine|cisplatin|sunitinib_malate|,other_events,arm3,SU-37.5-mg-OXA-110-mg/m^2-CAP-1600-mg/m^2,,,
600,Hypersensitivity,1,30,Immune_system_disorders,NCT00555906,https://clinicaltrials.gov/show/NCT00555906,Multiple_Myeloma,Bortezomib|Dexamethasone|PD_0332991|,serious_events,arm4,Palbociclib-100mg+Bortezomib+Dexamethasone(Phase2:ScheduleB),70,bortezomib,proteasome-inhibitor
600,Hypersensitivity,1,30,Immune_system_disorders,NCT00555906,https://clinicaltrials.gov/show/NCT00555906,Multiple_Myeloma,Bortezomib|Dexamethasone|PD_0332991|,serious_events,arm4,Palbociclib-100mg+Bortezomib+Dexamethasone(Phase2:ScheduleB),79,dexamethasone,steroid
602,Hypersensitivity,1,46,General_disorders,NCT00556452,https://clinicaltrials.gov/show/NCT00556452,Leukemia|Hodgkin_Lymphoma|Non-Hodgkin_Lymphoma|Multiple_Myeloma|Myelodysplastic_Syndrome|,Clofarabine/Busulfan_x_4|Peripheral_blood_stem_cell_transplant|Total_Lymphoid_Irradiation|,other_events,arm0,Clo/Bu4,,,
603,Hypersensitivity,1,68,Immune_system_disorders,NCT00557856,https://clinicaltrials.gov/show/NCT00557856,Advanced_Solid_Tumors,PF-03446962,serious_events,arm0,PF-03446962,,,
2639,Allergic_reaction,6,47,Immune_system_disorders,NCT00558636,https://clinicaltrials.gov/show/NCT00558636,Carcinoma_Non-Small-Cell_Lung,Sorafenib_+_Paclitaxel_+_Carboplatin|Placebo_+_Paclitaxel_+_Carboplatin|,other_events,arm0,Sorafenib-+-Paclitaxel-+-Carboplatin,3,carboplatin,alkalating-agent
2639,Allergic_reaction,6,47,Immune_system_disorders,NCT00558636,https://clinicaltrials.gov/show/NCT00558636,Carcinoma_Non-Small-Cell_Lung,Sorafenib_+_Paclitaxel_+_Carboplatin|Placebo_+_Paclitaxel_+_Carboplatin|,other_events,arm0,Sorafenib-+-Paclitaxel-+-Carboplatin,2,paclitaxel,taxane
2639,Allergic_reaction,6,47,Immune_system_disorders,NCT00558636,https://clinicaltrials.gov/show/NCT00558636,Carcinoma_Non-Small-Cell_Lung,Sorafenib_+_Paclitaxel_+_Carboplatin|Placebo_+_Paclitaxel_+_Carboplatin|,other_events,arm0,Sorafenib-+-Paclitaxel-+-Carboplatin,90,sorafenib,Tyrosine-Kinase-inhibitor
2637,Allergic_reaction,1,44,Immune_system_disorders,NCT00558636,https://clinicaltrials.gov/show/NCT00558636,Carcinoma_Non-Small-Cell_Lung,Sorafenib_+_Paclitaxel_+_Carboplatin|Placebo_+_Paclitaxel_+_Carboplatin|,serious_events,arm1,Placebo-+-Paclitaxel-+-Carboplatin,3,carboplatin,alkalating-agent
2638,Allergic_reaction,2,44,Immune_system_disorders,NCT00558636,https://clinicaltrials.gov/show/NCT00558636,Carcinoma_Non-Small-Cell_Lung,Sorafenib_+_Paclitaxel_+_Carboplatin|Placebo_+_Paclitaxel_+_Carboplatin|,other_events,arm1,Placebo-+-Paclitaxel-+-Carboplatin,3,carboplatin,alkalating-agent
2637,Allergic_reaction,1,44,Immune_system_disorders,NCT00558636,https://clinicaltrials.gov/show/NCT00558636,Carcinoma_Non-Small-Cell_Lung,Sorafenib_+_Paclitaxel_+_Carboplatin|Placebo_+_Paclitaxel_+_Carboplatin|,serious_events,arm1,Placebo-+-Paclitaxel-+-Carboplatin,2,paclitaxel,taxane
2638,Allergic_reaction,2,44,Immune_system_disorders,NCT00558636,https://clinicaltrials.gov/show/NCT00558636,Carcinoma_Non-Small-Cell_Lung,Sorafenib_+_Paclitaxel_+_Carboplatin|Placebo_+_Paclitaxel_+_Carboplatin|,other_events,arm1,Placebo-+-Paclitaxel-+-Carboplatin,2,paclitaxel,taxane
604,Hypersensitivity,1,60,Immune_system_disorders,NCT00558896,https://clinicaltrials.gov/show/NCT00558896,Multiple_Myeloma_and_Plasma_Cell_Neoplasm,dexamethasone|pomalidomide|,other_events,arm4,Relapsed-Myeloma-(<-4-Prior-Regimens):-High-Dose,,,
605,Hypersensitivity,2,21,Immune_system_disorders,NCT00560235,https://clinicaltrials.gov/show/NCT00560235,Ewing's_Sarcoma_Family_of_Tumors,CP-751871,other_events,arm2,Figitumumab-30-mg/kg-Dose-Extension-(Phase-1B),,,
606,Hypersensitivity,1,107,Immune_system_disorders,NCT00560235,https://clinicaltrials.gov/show/NCT00560235,Ewing's_Sarcoma_Family_of_Tumors,CP-751871,other_events,arm6,Figitumumab-30mg/kg-(Phase-2),,,
1530,Drug_hypersensitivity,1,83,Immune_system_disorders,NCT00560560,https://clinicaltrials.gov/show/NCT00560560,Colorectal_Neoplasm,CP-751_871,other_events,arm1,Figitumumab-30-mg/kg,,,
607,Hypersensitivity,1,6,Immune_system_disorders,NCT00560573,https://clinicaltrials.gov/show/NCT00560573,Carcinoma_Non-Small-Cell_Lung,CP-751871|Cisplatin|Gemcitabine|Pemetrexed|,other_events,arm0,Figitumumab-6-mg/kg,,,
608,Hypersensitivity,2,605,Immune_system_disorders,NCT00561470,https://clinicaltrials.gov/show/NCT00561470,Colorectal_Neoplasms|Neoplasm_Metastasis|,Placebo|Aflibercept_(ziv-aflibercept_AVE0005_VEGF_trap_ZALTRAP??)|FOLFIRI_(Irinotecan_5-Fluorouracil_and_Leucovorin)|FOLFIRI_(Irinotecan_5-Fluorouracil_and_Leucovorin)|,serious_events,arm0,Placebo/FOLFIRI,45,folfiri,combination-drug-with-Irinotecan--Flourouracil--and-Leucovorin
1531,Drug_hypersensitivity,1,6,Immune_system_disorders,NCT00561795,https://clinicaltrials.gov/show/NCT00561795,Primary_Peritoneal_Carcinoma|Tumor|Epithelial_Ovarian_Cancer|Uterine_Disease|Cervix_Diseases|Neoplasms_Ovarian|Cancer|,pazopanib_(GW786034)|carboplatin|paclitaxel|,other_events,arm1,42410,,,
611,Hypersensitivity,1,33,Immune_system_disorders,NCT00562328,https://clinicaltrials.gov/show/NCT00562328,Leukemia,Alemtuzumab|Rituximab|Sargramostim|,other_events,arm0,Alemtuzumab-+-Rituximab-+-GM-CSF,16,rituximab,monoclonal-antibody
611,Hypersensitivity,1,33,Immune_system_disorders,NCT00562328,https://clinicaltrials.gov/show/NCT00562328,Leukemia,Alemtuzumab|Rituximab|Sargramostim|,other_events,arm0,Alemtuzumab-+-Rituximab-+-GM-CSF,76,alemtuzumab,monoclonal-antibody
612,HYPERSENSITIVITY,4,50,Immune_system_disorders,NCT00565448,https://clinicaltrials.gov/show/NCT00565448,Nasopharyngeal_Neoplasms|Carcinoma|,docetaxel|cisplatin|5-fluorouracil|,other_events,arm1,Docetaxel-/Cisplatin/5-FU,9,cisplatin,alkalating-agent
613,HYPERSENSITIVITY,1,50,Immune_system_disorders,NCT00565448,https://clinicaltrials.gov/show/NCT00565448,Nasopharyngeal_Neoplasms|Carcinoma|,docetaxel|cisplatin|5-fluorouracil|,serious_events,arm1,Docetaxel-/Cisplatin/5-FU,9,cisplatin,alkalating-agent
612,HYPERSENSITIVITY,4,50,Immune_system_disorders,NCT00565448,https://clinicaltrials.gov/show/NCT00565448,Nasopharyngeal_Neoplasms|Carcinoma|,docetaxel|cisplatin|5-fluorouracil|,other_events,arm1,Docetaxel-/Cisplatin/5-FU,8,docetaxel,taxane
613,HYPERSENSITIVITY,1,50,Immune_system_disorders,NCT00565448,https://clinicaltrials.gov/show/NCT00565448,Nasopharyngeal_Neoplasms|Carcinoma|,docetaxel|cisplatin|5-fluorouracil|,serious_events,arm1,Docetaxel-/Cisplatin/5-FU,8,docetaxel,taxane
2075,Dermatitis_allergic,1,407,Skin_and_subcutaneous_tissue_disorders,NCT00567190,https://clinicaltrials.gov/show/NCT00567190,Metastatic_Breast_Cancer,Pertuzumab|Placebo|Trastuzumab|Docetaxel|,serious_events,arm0,Pertuzumab-+-Trastuzumab-+-Docetaxel,40,pertuzumab,monoclonal-antibody
1535,Drug_hypersensitivity,3,407,Immune_system_disorders,NCT00567190,https://clinicaltrials.gov/show/NCT00567190,Metastatic_Breast_Cancer,Pertuzumab|Placebo|Trastuzumab|Docetaxel|,serious_events,arm0,Pertuzumab-+-Trastuzumab-+-Docetaxel,40,pertuzumab,monoclonal-antibody
614,Hypersensitivity,24,407,Immune_system_disorders,NCT00567190,https://clinicaltrials.gov/show/NCT00567190,Metastatic_Breast_Cancer,Pertuzumab|Placebo|Trastuzumab|Docetaxel|,other_events,arm0,Pertuzumab-+-Trastuzumab-+-Docetaxel,40,pertuzumab,monoclonal-antibody
616,Hypersensitivity,3,407,Immune_system_disorders,NCT00567190,https://clinicaltrials.gov/show/NCT00567190,Metastatic_Breast_Cancer,Pertuzumab|Placebo|Trastuzumab|Docetaxel|,serious_events,arm0,Pertuzumab-+-Trastuzumab-+-Docetaxel,40,pertuzumab,monoclonal-antibody
2075,Dermatitis_allergic,1,407,Skin_and_subcutaneous_tissue_disorders,NCT00567190,https://clinicaltrials.gov/show/NCT00567190,Metastatic_Breast_Cancer,Pertuzumab|Placebo|Trastuzumab|Docetaxel|,serious_events,arm0,Pertuzumab-+-Trastuzumab-+-Docetaxel,18,trastuzumab,monoclonal-antibody
1535,Drug_hypersensitivity,3,407,Immune_system_disorders,NCT00567190,https://clinicaltrials.gov/show/NCT00567190,Metastatic_Breast_Cancer,Pertuzumab|Placebo|Trastuzumab|Docetaxel|,serious_events,arm0,Pertuzumab-+-Trastuzumab-+-Docetaxel,18,trastuzumab,monoclonal-antibody
614,Hypersensitivity,24,407,Immune_system_disorders,NCT00567190,https://clinicaltrials.gov/show/NCT00567190,Metastatic_Breast_Cancer,Pertuzumab|Placebo|Trastuzumab|Docetaxel|,other_events,arm0,Pertuzumab-+-Trastuzumab-+-Docetaxel,18,trastuzumab,monoclonal-antibody
616,Hypersensitivity,3,407,Immune_system_disorders,NCT00567190,https://clinicaltrials.gov/show/NCT00567190,Metastatic_Breast_Cancer,Pertuzumab|Placebo|Trastuzumab|Docetaxel|,serious_events,arm0,Pertuzumab-+-Trastuzumab-+-Docetaxel,18,trastuzumab,monoclonal-antibody
2075,Dermatitis_allergic,1,407,Skin_and_subcutaneous_tissue_disorders,NCT00567190,https://clinicaltrials.gov/show/NCT00567190,Metastatic_Breast_Cancer,Pertuzumab|Placebo|Trastuzumab|Docetaxel|,serious_events,arm0,Pertuzumab-+-Trastuzumab-+-Docetaxel,8,docetaxel,taxane
1535,Drug_hypersensitivity,3,407,Immune_system_disorders,NCT00567190,https://clinicaltrials.gov/show/NCT00567190,Metastatic_Breast_Cancer,Pertuzumab|Placebo|Trastuzumab|Docetaxel|,serious_events,arm0,Pertuzumab-+-Trastuzumab-+-Docetaxel,8,docetaxel,taxane
614,Hypersensitivity,24,407,Immune_system_disorders,NCT00567190,https://clinicaltrials.gov/show/NCT00567190,Metastatic_Breast_Cancer,Pertuzumab|Placebo|Trastuzumab|Docetaxel|,other_events,arm0,Pertuzumab-+-Trastuzumab-+-Docetaxel,8,docetaxel,taxane
616,Hypersensitivity,3,407,Immune_system_disorders,NCT00567190,https://clinicaltrials.gov/show/NCT00567190,Metastatic_Breast_Cancer,Pertuzumab|Placebo|Trastuzumab|Docetaxel|,serious_events,arm0,Pertuzumab-+-Trastuzumab-+-Docetaxel,8,docetaxel,taxane
1534,Drug_hypersensitivity,3,397,Immune_system_disorders,NCT00567190,https://clinicaltrials.gov/show/NCT00567190,Metastatic_Breast_Cancer,Pertuzumab|Placebo|Trastuzumab|Docetaxel|,serious_events,arm1,Placebo-+-Trastuzumab-+-Docetaxel,18,trastuzumab,monoclonal-antibody
615,Hypersensitivity,20,397,Immune_system_disorders,NCT00567190,https://clinicaltrials.gov/show/NCT00567190,Metastatic_Breast_Cancer,Pertuzumab|Placebo|Trastuzumab|Docetaxel|,other_events,arm1,Placebo-+-Trastuzumab-+-Docetaxel,18,trastuzumab,monoclonal-antibody
1534,Drug_hypersensitivity,3,397,Immune_system_disorders,NCT00567190,https://clinicaltrials.gov/show/NCT00567190,Metastatic_Breast_Cancer,Pertuzumab|Placebo|Trastuzumab|Docetaxel|,serious_events,arm1,Placebo-+-Trastuzumab-+-Docetaxel,8,docetaxel,taxane
615,Hypersensitivity,20,397,Immune_system_disorders,NCT00567190,https://clinicaltrials.gov/show/NCT00567190,Metastatic_Breast_Cancer,Pertuzumab|Placebo|Trastuzumab|Docetaxel|,other_events,arm1,Placebo-+-Trastuzumab-+-Docetaxel,8,docetaxel,taxane
617,Hypersensitivity,1,73,Immune_system_disorders,NCT00570713,https://clinicaltrials.gov/show/NCT00570713,Pancreatic_Cancer,MORAb-009|Placebo|Gemcitabine|,serious_events,arm0,MORAb-009-Plus-Gemcitabine-(???MORAb-009???),6,gemcitabine,antimetabolites
1536,Drug_hypersensitivity,1,75,Immune_system_disorders,NCT00570713,https://clinicaltrials.gov/show/NCT00570713,Pancreatic_Cancer,MORAb-009|Placebo|Gemcitabine|,serious_events,arm1,Placebo-Plus-Gemcitabine-(_??Placebo_??),6,gemcitabine,antimetabolites
1538,Drug_hypersensitivity,1,248,Immune_system_disorders,NCT00574873,https://clinicaltrials.gov/show/NCT00574873,Chronic_Myeloid_Leukemia,Bosutinib|imatinib|,serious_events,arm0,Bosutinib,43,bosutinib,oral-receptor-tyrosine-kinase-inhibitor
621,Hypersensitivity,2,23,Immune_system_disorders,NCT00576901,https://clinicaltrials.gov/show/NCT00576901,Breast_Cancer,bevacizumab_[Avastin]|Docetaxel|Xeloda|,other_events,arm0,Bevacizumab+Docetaxel+Capecitabine,17,capecitabine,antimetabolite
621,Hypersensitivity,2,23,Immune_system_disorders,NCT00576901,https://clinicaltrials.gov/show/NCT00576901,Breast_Cancer,bevacizumab_[Avastin]|Docetaxel|Xeloda|,other_events,arm0,Bevacizumab+Docetaxel+Capecitabine,29,capecitabine,antimetabolite
621,Hypersensitivity,2,23,Immune_system_disorders,NCT00576901,https://clinicaltrials.gov/show/NCT00576901,Breast_Cancer,bevacizumab_[Avastin]|Docetaxel|Xeloda|,other_events,arm0,Bevacizumab+Docetaxel+Capecitabine,4,bevacizumab,monoclonal-antibody
621,Hypersensitivity,2,23,Immune_system_disorders,NCT00576901,https://clinicaltrials.gov/show/NCT00576901,Breast_Cancer,bevacizumab_[Avastin]|Docetaxel|Xeloda|,other_events,arm0,Bevacizumab+Docetaxel+Capecitabine,22,bevacizumab,monoclonal-antibody
621,Hypersensitivity,2,23,Immune_system_disorders,NCT00576901,https://clinicaltrials.gov/show/NCT00576901,Breast_Cancer,bevacizumab_[Avastin]|Docetaxel|Xeloda|,other_events,arm0,Bevacizumab+Docetaxel+Capecitabine,8,docetaxel,taxane
1541,Drug_hypersensitivity,4,197,Immune_system_disorders,NCT00577031,https://clinicaltrials.gov/show/NCT00577031,Colorectal_Cancer,bevacizumab_[Avastin]|Oxaliplatin|Xeloda|,other_events,arm0,Bevacizumab+Oxaliplatin+Capecitabine/Bevacizumab,7,oxaliplatin,alkalating-agent
1542,Drug_hypersensitivity,1,197,Immune_system_disorders,NCT00577031,https://clinicaltrials.gov/show/NCT00577031,Colorectal_Cancer,bevacizumab_[Avastin]|Oxaliplatin|Xeloda|,serious_events,arm0,Bevacizumab+Oxaliplatin+Capecitabine/Bevacizumab,7,oxaliplatin,alkalating-agent
622,Hypersensitivity,4,197,Immune_system_disorders,NCT00577031,https://clinicaltrials.gov/show/NCT00577031,Colorectal_Cancer,bevacizumab_[Avastin]|Oxaliplatin|Xeloda|,other_events,arm0,Bevacizumab+Oxaliplatin+Capecitabine/Bevacizumab,7,oxaliplatin,alkalating-agent
623,Hypersensitivity,3,197,Immune_system_disorders,NCT00577031,https://clinicaltrials.gov/show/NCT00577031,Colorectal_Cancer,bevacizumab_[Avastin]|Oxaliplatin|Xeloda|,serious_events,arm0,Bevacizumab+Oxaliplatin+Capecitabine/Bevacizumab,7,oxaliplatin,alkalating-agent
1541,Drug_hypersensitivity,4,197,Immune_system_disorders,NCT00577031,https://clinicaltrials.gov/show/NCT00577031,Colorectal_Cancer,bevacizumab_[Avastin]|Oxaliplatin|Xeloda|,other_events,arm0,Bevacizumab+Oxaliplatin+Capecitabine/Bevacizumab,17,capecitabine,antimetabolite
1542,Drug_hypersensitivity,1,197,Immune_system_disorders,NCT00577031,https://clinicaltrials.gov/show/NCT00577031,Colorectal_Cancer,bevacizumab_[Avastin]|Oxaliplatin|Xeloda|,serious_events,arm0,Bevacizumab+Oxaliplatin+Capecitabine/Bevacizumab,17,capecitabine,antimetabolite
622,Hypersensitivity,4,197,Immune_system_disorders,NCT00577031,https://clinicaltrials.gov/show/NCT00577031,Colorectal_Cancer,bevacizumab_[Avastin]|Oxaliplatin|Xeloda|,other_events,arm0,Bevacizumab+Oxaliplatin+Capecitabine/Bevacizumab,17,capecitabine,antimetabolite
623,Hypersensitivity,3,197,Immune_system_disorders,NCT00577031,https://clinicaltrials.gov/show/NCT00577031,Colorectal_Cancer,bevacizumab_[Avastin]|Oxaliplatin|Xeloda|,serious_events,arm0,Bevacizumab+Oxaliplatin+Capecitabine/Bevacizumab,17,capecitabine,antimetabolite
1541,Drug_hypersensitivity,4,197,Immune_system_disorders,NCT00577031,https://clinicaltrials.gov/show/NCT00577031,Colorectal_Cancer,bevacizumab_[Avastin]|Oxaliplatin|Xeloda|,other_events,arm0,Bevacizumab+Oxaliplatin+Capecitabine/Bevacizumab,29,capecitabine,antimetabolite
1542,Drug_hypersensitivity,1,197,Immune_system_disorders,NCT00577031,https://clinicaltrials.gov/show/NCT00577031,Colorectal_Cancer,bevacizumab_[Avastin]|Oxaliplatin|Xeloda|,serious_events,arm0,Bevacizumab+Oxaliplatin+Capecitabine/Bevacizumab,29,capecitabine,antimetabolite
622,Hypersensitivity,4,197,Immune_system_disorders,NCT00577031,https://clinicaltrials.gov/show/NCT00577031,Colorectal_Cancer,bevacizumab_[Avastin]|Oxaliplatin|Xeloda|,other_events,arm0,Bevacizumab+Oxaliplatin+Capecitabine/Bevacizumab,29,capecitabine,antimetabolite
623,Hypersensitivity,3,197,Immune_system_disorders,NCT00577031,https://clinicaltrials.gov/show/NCT00577031,Colorectal_Cancer,bevacizumab_[Avastin]|Oxaliplatin|Xeloda|,serious_events,arm0,Bevacizumab+Oxaliplatin+Capecitabine/Bevacizumab,29,capecitabine,antimetabolite
1541,Drug_hypersensitivity,4,197,Immune_system_disorders,NCT00577031,https://clinicaltrials.gov/show/NCT00577031,Colorectal_Cancer,bevacizumab_[Avastin]|Oxaliplatin|Xeloda|,other_events,arm0,Bevacizumab+Oxaliplatin+Capecitabine/Bevacizumab,4,bevacizumab,monoclonal-antibody
1542,Drug_hypersensitivity,1,197,Immune_system_disorders,NCT00577031,https://clinicaltrials.gov/show/NCT00577031,Colorectal_Cancer,bevacizumab_[Avastin]|Oxaliplatin|Xeloda|,serious_events,arm0,Bevacizumab+Oxaliplatin+Capecitabine/Bevacizumab,4,bevacizumab,monoclonal-antibody
622,Hypersensitivity,4,197,Immune_system_disorders,NCT00577031,https://clinicaltrials.gov/show/NCT00577031,Colorectal_Cancer,bevacizumab_[Avastin]|Oxaliplatin|Xeloda|,other_events,arm0,Bevacizumab+Oxaliplatin+Capecitabine/Bevacizumab,4,bevacizumab,monoclonal-antibody
623,Hypersensitivity,3,197,Immune_system_disorders,NCT00577031,https://clinicaltrials.gov/show/NCT00577031,Colorectal_Cancer,bevacizumab_[Avastin]|Oxaliplatin|Xeloda|,serious_events,arm0,Bevacizumab+Oxaliplatin+Capecitabine/Bevacizumab,4,bevacizumab,monoclonal-antibody
1541,Drug_hypersensitivity,4,197,Immune_system_disorders,NCT00577031,https://clinicaltrials.gov/show/NCT00577031,Colorectal_Cancer,bevacizumab_[Avastin]|Oxaliplatin|Xeloda|,other_events,arm0,Bevacizumab+Oxaliplatin+Capecitabine/Bevacizumab,22,bevacizumab,monoclonal-antibody
1542,Drug_hypersensitivity,1,197,Immune_system_disorders,NCT00577031,https://clinicaltrials.gov/show/NCT00577031,Colorectal_Cancer,bevacizumab_[Avastin]|Oxaliplatin|Xeloda|,serious_events,arm0,Bevacizumab+Oxaliplatin+Capecitabine/Bevacizumab,22,bevacizumab,monoclonal-antibody
622,Hypersensitivity,4,197,Immune_system_disorders,NCT00577031,https://clinicaltrials.gov/show/NCT00577031,Colorectal_Cancer,bevacizumab_[Avastin]|Oxaliplatin|Xeloda|,other_events,arm0,Bevacizumab+Oxaliplatin+Capecitabine/Bevacizumab,22,bevacizumab,monoclonal-antibody
623,Hypersensitivity,3,197,Immune_system_disorders,NCT00577031,https://clinicaltrials.gov/show/NCT00577031,Colorectal_Cancer,bevacizumab_[Avastin]|Oxaliplatin|Xeloda|,serious_events,arm0,Bevacizumab+Oxaliplatin+Capecitabine/Bevacizumab,22,bevacizumab,monoclonal-antibody
1543,Drug_hypersensitivity,2,199,Immune_system_disorders,NCT00577863,https://clinicaltrials.gov/show/NCT00577863,Osteoporosis,teriparatide,other_events,arm0,Teriparatide,,,
624,Hypersensitivity,1,29,Immune_system_disorders,NCT00579501,https://clinicaltrials.gov/show/NCT00579501,LiposarcomaMyxoid,Trabectedin|Dexamethasone|,other_events,arm0,Trabectedin,,,
2640,Allergic_reaction,6,95,Immune_system_disorders,NCT00586495,https://clinicaltrials.gov/show/NCT00586495,Carcinoma_Renal_Cell,Sorafenib_(Nexavar_BAY43-9006),other_events,arm0,Sorafenib-(Nexavar-BAY43-9006),97,nexavar,Tyrosine-Kinase-inhibitor
2640,Allergic_reaction,6,95,Immune_system_disorders,NCT00586495,https://clinicaltrials.gov/show/NCT00586495,Carcinoma_Renal_Cell,Sorafenib_(Nexavar_BAY43-9006),other_events,arm0,Sorafenib-(Nexavar-BAY43-9006),90,sorafenib,Tyrosine-Kinase-inhibitor
2640,Allergic_reaction,6,95,Immune_system_disorders,NCT00586495,https://clinicaltrials.gov/show/NCT00586495,Carcinoma_Renal_Cell,Sorafenib_(Nexavar_BAY43-9006),other_events,arm0,Sorafenib-(Nexavar-BAY43-9006),72,bay43,Tyrosine-Kinase-inhibitor
625,Hypersensitivity,1,3,Immune_system_disorders,NCT00587990,https://clinicaltrials.gov/show/NCT00587990,Stem_Cell_Transplantation|Ventricular_Dysfunction_Left|,Lower_dose_mesenchymal_stem_cell_(MSC)_injection|Placebo|Higher_dose_MSC_injection|,serious_events,arm2,(3)-Placebo-Injection,,,
2641,Allergic_reaction,5,47,Immune_system_disorders,NCT00588809,https://clinicaltrials.gov/show/NCT00588809,Adult_Acute_Myeloid_Leukemia_With_t(15;17)(q22;q12)|Adult_Acute_Promyelocytic_Leukemia_(M3)|Myelodysplastic_Syndromes|Myelodysplastic/Myeloproliferative_Neoplasms|Recurrent_Adult_Acute_Myeloid_Leukemia|Secondary_Acute_Myeloid_Leukemia|,selumetinib,other_events,arm0,Selumetinib,,,
2642,Allergic_reaction,8,41,Immune_system_disorders,NCT00589290,https://clinicaltrials.gov/show/NCT00589290,Thymoma|Thymic_Carcinoma|,Belinostat_(PDX101),other_events,arm0,Belinostat-Treatment,49,belinostat,histone-deacetylase-(HDAC)-inhibitor
626,Hypersensitivity,3,31,Immune_system_disorders,NCT00589563,https://clinicaltrials.gov/show/NCT00589563,Chronic_Myeloproliferative_Disorders|Graft_Versus_Host_Disease|Infection|Leukemia|Lymphoma|Multiple_Myeloma_and_Plasma_Cell_Neoplasm|Myelodysplastic_Syndromes|Myelodysplastic/Myeloproliferative_Neoplasms|Precancerous_Condition|Secondary_Myelofibrosis|Smal,anti-thymocyte_globulin|cyclophosphamide|etoposide|fludarabine_phosphate|melphalan|methotrexate|sirolimus|tacrolimus|allogeneic_hematopoietic_stem_cell_transplantation|hematopoietic_stem_cell_transplantation|nonmyeloablative_allogeneic_hematopoietic_stem_,other_events,arm0,All-Patients,,,
2643,Allergic_Reaction,4,57,Immune_system_disorders,NCT00591734,https://clinicaltrials.gov/show/NCT00591734,Metastatic_Melanoma,Bevacizumab|Everolimus|,other_events,arm0,Intervention,,,
2645,allergic_reaction,5,82,Immune_system_disorders,NCT00593827,https://clinicaltrials.gov/show/NCT00593827,Metastatic_Breast_Cancer,Ixabepilone|Ixabepilone|,other_events,arm0,Ixabepilone-16-mg/m^2,82,ixabepilone,antimicrotubule-agent
2644,allergic_reaction,6,89,Immune_system_disorders,NCT00593827,https://clinicaltrials.gov/show/NCT00593827,Metastatic_Breast_Cancer,Ixabepilone|Ixabepilone|,other_events,arm1,Ixabepilone-40-mg/m^2,82,ixabepilone,antimicrotubule-agent
2351,Anaphylaxis,1,150,Immune_system_disorders,NCT00602641,https://clinicaltrials.gov/show/NCT00602641,Stage_I_Multiple_Myeloma|Stage_II_Multiple_Myeloma|Stage_III_Multiple_Myeloma|,melphalan|prednisone|thalidomide|lenalidomide|,serious_events,arm1,mPR-R,,,
632,Hypersensitivity,3,44,Immune_system_disorders,NCT00602836,https://clinicaltrials.gov/show/NCT00602836,Leukemia|Lymphoma|,Rituximab|Cyclophosphamide|Lenalidomide|Pentostatin|,other_events,arm0,PCR-Lenalidomide,25,lenalidomide,immunomodulatory-agent-or-antiangiogenic-agent
1547,Drug_hypersensitivity,1,8,Immune_system_disorders,NCT00603447,https://clinicaltrials.gov/show/NCT00603447,Relapsed_Multiple_Myeloma,Carfilzomib|Lenalidomide|Dexamethasone|,other_events,arm5,6:-CFZ-20/27-mg/m?_-+-LEN-25-mg,,,
1548,Drug_hypersensitivity,1,44,Immune_system_disorders,NCT00603447,https://clinicaltrials.gov/show/NCT00603447,Relapsed_Multiple_Myeloma,Carfilzomib|Lenalidomide|Dexamethasone|,other_events,arm6,7:-CFZ-20/27-mg/m?_-+-LEN-25-mg,,,
634,Hypersensitivity,1,7,Immune_system_disorders,NCT00603538,https://clinicaltrials.gov/show/NCT00603538,Carcinoma_Non-Small-Cell_Lung,CP-751871_+_carboplatin_+_paclitaxel,serious_events,arm1,CP-751871-10-mg/kg-in-Combination-With-Chemotherapy-Agents,,,
2079,Dermatitis_allergic,1,3,Skin_and_subcutaneous_tissue_disorders,NCT00607048,https://clinicaltrials.gov/show/NCT00607048,Neoplasms,Paclitaxel_+_Carboplatin_+_CP-870893|Paclitaxel_+_Carboplatin_+_CP-870893|,other_events,arm0,Schedule-A---CP-870893-0.1-mg/kg,,,
637,Hypersensitivity,1,6,Immune_system_disorders,NCT00607048,https://clinicaltrials.gov/show/NCT00607048,Neoplasms,Paclitaxel_+_Carboplatin_+_CP-870893|Paclitaxel_+_Carboplatin_+_CP-870893|,serious_events,arm4,Schedule-B---CP-870893-0.2-mg/kg-(Escalation-Cohort),,,
638,Hypersensitivity,1,6,Immune_system_disorders,NCT00607048,https://clinicaltrials.gov/show/NCT00607048,Neoplasms,Paclitaxel_+_Carboplatin_+_CP-870893|Paclitaxel_+_Carboplatin_+_CP-870893|,other_events,arm4,Schedule-B---CP-870893-0.2-mg/kg-(Escalation-Cohort),,,
1549,Drug_hypersensitivity,1,7,Immune_system_disorders,NCT00607048,https://clinicaltrials.gov/show/NCT00607048,Neoplasms,Paclitaxel_+_Carboplatin_+_CP-870893|Paclitaxel_+_Carboplatin_+_CP-870893|,other_events,arm5,Schedule-B---CP-870893-0.2-mg/kg-(Expansion-Cohort),,,
2080,Dermatitis_allergic,1,28,Skin_and_subcutaneous_tissue_disorders,NCT00607386,https://clinicaltrials.gov/show/NCT00607386,Hunter_Syndrome|Mucopolysaccharidosis_II|MPS_II|,Idursulfase,other_events,arm0,Idursulfase,,,
1550,Drug_hypersensitivity,1,14,Immune_system_disorders,NCT00607724,https://clinicaltrials.gov/show/NCT00607724,Unspecified_Adult_Solid_Tumor_Protocol_Specific,GDC-0449,other_events,arm4,Stage-2:-Basal-Cell-Carcinoma-[GDC-0449-(270-mg)],,,
1551,Drug_hypersensitivity,1,96,Immune_system_disorders,NCT00609622,https://clinicaltrials.gov/show/NCT00609622,Colorectal_Neoplasms,sunitinib|mFOLFOX6|bevacizumab|mFOLFOX6|,serious_events,arm0,Sunitinib-+-mFOLFOX6,47,mfolfox6,combination-therapy-with-leucovorin-calcium--fluorouracil-and-oxaliplatin
640,Hypersensitivity,2,96,Immune_system_disorders,NCT00609622,https://clinicaltrials.gov/show/NCT00609622,Colorectal_Neoplasms,sunitinib|mFOLFOX6|bevacizumab|mFOLFOX6|,other_events,arm0,Sunitinib-+-mFOLFOX6,47,mfolfox6,combination-therapy-with-leucovorin-calcium--fluorouracil-and-oxaliplatin
1551,Drug_hypersensitivity,1,96,Immune_system_disorders,NCT00609622,https://clinicaltrials.gov/show/NCT00609622,Colorectal_Neoplasms,sunitinib|mFOLFOX6|bevacizumab|mFOLFOX6|,serious_events,arm0,Sunitinib-+-mFOLFOX6,27,sunitinib,tyrosine-kinase-inhibitor-and-angiogenesis-inhibitor
640,Hypersensitivity,2,96,Immune_system_disorders,NCT00609622,https://clinicaltrials.gov/show/NCT00609622,Colorectal_Neoplasms,sunitinib|mFOLFOX6|bevacizumab|mFOLFOX6|,other_events,arm0,Sunitinib-+-mFOLFOX6,27,sunitinib,tyrosine-kinase-inhibitor-and-angiogenesis-inhibitor
639,Hypersensitivity,5,93,Immune_system_disorders,NCT00609622,https://clinicaltrials.gov/show/NCT00609622,Colorectal_Neoplasms,sunitinib|mFOLFOX6|bevacizumab|mFOLFOX6|,other_events,arm1,Bevacizumab-+-mFOLFOX6,47,mfolfox6,combination-therapy-with-leucovorin-calcium--fluorouracil-and-oxaliplatin
639,Hypersensitivity,5,93,Immune_system_disorders,NCT00609622,https://clinicaltrials.gov/show/NCT00609622,Colorectal_Neoplasms,sunitinib|mFOLFOX6|bevacizumab|mFOLFOX6|,other_events,arm1,Bevacizumab-+-mFOLFOX6,4,bevacizumab,monoclonal-antibody
639,Hypersensitivity,5,93,Immune_system_disorders,NCT00609622,https://clinicaltrials.gov/show/NCT00609622,Colorectal_Neoplasms,sunitinib|mFOLFOX6|bevacizumab|mFOLFOX6|,other_events,arm1,Bevacizumab-+-mFOLFOX6,22,bevacizumab,monoclonal-antibody
1552,Drug_Hypersensitivity,4,105,Immune_system_disorders,NCT00610714,https://clinicaltrials.gov/show/NCT00610714,Ovarian_Neoplasms|Ovarian_Cancer|,AZD0530|Carboplatin|Paclitaxel|,serious_events,arm0,AZD0530--Paclitaxel--Carboplatin-i.v.,3,carboplatin,alkalating-agent
1553,Drug_Hypersensitivity,16,105,Immune_system_disorders,NCT00610714,https://clinicaltrials.gov/show/NCT00610714,Ovarian_Neoplasms|Ovarian_Cancer|,AZD0530|Carboplatin|Paclitaxel|,other_events,arm0,AZD0530--Paclitaxel--Carboplatin-i.v.,3,carboplatin,alkalating-agent
1552,Drug_Hypersensitivity,4,105,Immune_system_disorders,NCT00610714,https://clinicaltrials.gov/show/NCT00610714,Ovarian_Neoplasms|Ovarian_Cancer|,AZD0530|Carboplatin|Paclitaxel|,serious_events,arm0,AZD0530--Paclitaxel--Carboplatin-i.v.,2,paclitaxel,taxane
1553,Drug_Hypersensitivity,16,105,Immune_system_disorders,NCT00610714,https://clinicaltrials.gov/show/NCT00610714,Ovarian_Neoplasms|Ovarian_Cancer|,AZD0530|Carboplatin|Paclitaxel|,other_events,arm0,AZD0530--Paclitaxel--Carboplatin-i.v.,2,paclitaxel,taxane
1554,Drug_Hypersensitivity,5,106,Immune_system_disorders,NCT00610714,https://clinicaltrials.gov/show/NCT00610714,Ovarian_Neoplasms|Ovarian_Cancer|,AZD0530|Carboplatin|Paclitaxel|,serious_events,arm1,Carboplatin-Paclitaxel,3,carboplatin,alkalating-agent
1555,Drug_Hypersensitivity,24,106,Immune_system_disorders,NCT00610714,https://clinicaltrials.gov/show/NCT00610714,Ovarian_Neoplasms|Ovarian_Cancer|,AZD0530|Carboplatin|Paclitaxel|,other_events,arm1,Carboplatin-Paclitaxel,3,carboplatin,alkalating-agent
1554,Drug_Hypersensitivity,5,106,Immune_system_disorders,NCT00610714,https://clinicaltrials.gov/show/NCT00610714,Ovarian_Neoplasms|Ovarian_Cancer|,AZD0530|Carboplatin|Paclitaxel|,serious_events,arm1,Carboplatin-Paclitaxel,2,paclitaxel,taxane
1555,Drug_Hypersensitivity,24,106,Immune_system_disorders,NCT00610714,https://clinicaltrials.gov/show/NCT00610714,Ovarian_Neoplasms|Ovarian_Cancer|,AZD0530|Carboplatin|Paclitaxel|,other_events,arm1,Carboplatin-Paclitaxel,2,paclitaxel,taxane
2646,Allergic_reaction,5,68,Immune_system_disorders,NCT00613080,https://clinicaltrials.gov/show/NCT00613080,Colorectal_Cancer,capecitabine|oxaliplatin|resection|radiation_therapy|FOLFOX|,other_events,arm0,IMRT-+-Chemotherapy--Resection-Postoperative-Chemotherapy,,,
2083,Dermatitis_allergic,1,46,Skin_and_subcutaneous_tissue_disorders,NCT00615056,https://clinicaltrials.gov/show/NCT00615056,Colorectal_Neoplasms,Bevacizumab_(avastin)|FOLFIRI_(Irinotecan_leucovorin_5-fluorouracil_[5FU])|AG-013736_(axitinib)|FOLFOX_(oxaliplatin_leucovorin_5-fluorouracil_[5FU])|AG-013736_(axitinib)|FOLFIRI_(irinotecan_leucovorin_5-fluorouracil_[5FU])|Bevacizumab_(avastin)|FOLFOX_(ox,other_events,arm0,Axitinib-+-FOLFIRI,45,folfiri,combination-drug-with-Irinotecan--Flourouracil--and-Leucovorin
2083,Dermatitis_allergic,1,46,Skin_and_subcutaneous_tissue_disorders,NCT00615056,https://clinicaltrials.gov/show/NCT00615056,Colorectal_Neoplasms,Bevacizumab_(avastin)|FOLFIRI_(Irinotecan_leucovorin_5-fluorouracil_[5FU])|AG-013736_(axitinib)|FOLFOX_(oxaliplatin_leucovorin_5-fluorouracil_[5FU])|AG-013736_(axitinib)|FOLFIRI_(irinotecan_leucovorin_5-fluorouracil_[5FU])|Bevacizumab_(avastin)|FOLFOX_(ox,other_events,arm0,Axitinib-+-FOLFIRI,10,axitinib,kinase-inhibitor
642,Hypersensitivity,1,51,Immune_system_disorders,NCT00615056,https://clinicaltrials.gov/show/NCT00615056,Colorectal_Neoplasms,Bevacizumab_(avastin)|FOLFIRI_(Irinotecan_leucovorin_5-fluorouracil_[5FU])|AG-013736_(axitinib)|FOLFOX_(oxaliplatin_leucovorin_5-fluorouracil_[5FU])|AG-013736_(axitinib)|FOLFIRI_(irinotecan_leucovorin_5-fluorouracil_[5FU])|Bevacizumab_(avastin)|FOLFOX_(ox,other_events,arm1,Bevacizumab-+-FOLFIRI,45,folfiri,combination-drug-with-Irinotecan--Flourouracil--and-Leucovorin
642,Hypersensitivity,1,51,Immune_system_disorders,NCT00615056,https://clinicaltrials.gov/show/NCT00615056,Colorectal_Neoplasms,Bevacizumab_(avastin)|FOLFIRI_(Irinotecan_leucovorin_5-fluorouracil_[5FU])|AG-013736_(axitinib)|FOLFOX_(oxaliplatin_leucovorin_5-fluorouracil_[5FU])|AG-013736_(axitinib)|FOLFIRI_(irinotecan_leucovorin_5-fluorouracil_[5FU])|Bevacizumab_(avastin)|FOLFOX_(ox,other_events,arm1,Bevacizumab-+-FOLFIRI,4,bevacizumab,monoclonal-antibody
642,Hypersensitivity,1,51,Immune_system_disorders,NCT00615056,https://clinicaltrials.gov/show/NCT00615056,Colorectal_Neoplasms,Bevacizumab_(avastin)|FOLFIRI_(Irinotecan_leucovorin_5-fluorouracil_[5FU])|AG-013736_(axitinib)|FOLFOX_(oxaliplatin_leucovorin_5-fluorouracil_[5FU])|AG-013736_(axitinib)|FOLFIRI_(irinotecan_leucovorin_5-fluorouracil_[5FU])|Bevacizumab_(avastin)|FOLFOX_(ox,other_events,arm1,Bevacizumab-+-FOLFIRI,22,bevacizumab,monoclonal-antibody
2084,Dermatitis_allergic,1,36,Skin_and_subcutaneous_tissue_disorders,NCT00615056,https://clinicaltrials.gov/show/NCT00615056,Colorectal_Neoplasms,Bevacizumab_(avastin)|FOLFIRI_(Irinotecan_leucovorin_5-fluorouracil_[5FU])|AG-013736_(axitinib)|FOLFOX_(oxaliplatin_leucovorin_5-fluorouracil_[5FU])|AG-013736_(axitinib)|FOLFIRI_(irinotecan_leucovorin_5-fluorouracil_[5FU])|Bevacizumab_(avastin)|FOLFOX_(ox,other_events,arm2,Axitinib-+-FOLFOX,10,axitinib,kinase-inhibitor
1556,Drug_hypersensitivity,1,36,Immune_system_disorders,NCT00615056,https://clinicaltrials.gov/show/NCT00615056,Colorectal_Neoplasms,Bevacizumab_(avastin)|FOLFIRI_(Irinotecan_leucovorin_5-fluorouracil_[5FU])|AG-013736_(axitinib)|FOLFOX_(oxaliplatin_leucovorin_5-fluorouracil_[5FU])|AG-013736_(axitinib)|FOLFIRI_(irinotecan_leucovorin_5-fluorouracil_[5FU])|Bevacizumab_(avastin)|FOLFOX_(ox,other_events,arm2,Axitinib-+-FOLFOX,10,axitinib,kinase-inhibitor
643,Hypersensitivity,5,36,Immune_system_disorders,NCT00615056,https://clinicaltrials.gov/show/NCT00615056,Colorectal_Neoplasms,Bevacizumab_(avastin)|FOLFIRI_(Irinotecan_leucovorin_5-fluorouracil_[5FU])|AG-013736_(axitinib)|FOLFOX_(oxaliplatin_leucovorin_5-fluorouracil_[5FU])|AG-013736_(axitinib)|FOLFIRI_(irinotecan_leucovorin_5-fluorouracil_[5FU])|Bevacizumab_(avastin)|FOLFOX_(ox,other_events,arm2,Axitinib-+-FOLFOX,10,axitinib,kinase-inhibitor
2085,Dermatitis_allergic,1,35,Skin_and_subcutaneous_tissue_disorders,NCT00615056,https://clinicaltrials.gov/show/NCT00615056,Colorectal_Neoplasms,Bevacizumab_(avastin)|FOLFIRI_(Irinotecan_leucovorin_5-fluorouracil_[5FU])|AG-013736_(axitinib)|FOLFOX_(oxaliplatin_leucovorin_5-fluorouracil_[5FU])|AG-013736_(axitinib)|FOLFIRI_(irinotecan_leucovorin_5-fluorouracil_[5FU])|Bevacizumab_(avastin)|FOLFOX_(ox,other_events,arm3,Bevacizumab-+-FOLFOX,4,bevacizumab,monoclonal-antibody
644,Hypersensitivity,1,35,Immune_system_disorders,NCT00615056,https://clinicaltrials.gov/show/NCT00615056,Colorectal_Neoplasms,Bevacizumab_(avastin)|FOLFIRI_(Irinotecan_leucovorin_5-fluorouracil_[5FU])|AG-013736_(axitinib)|FOLFOX_(oxaliplatin_leucovorin_5-fluorouracil_[5FU])|AG-013736_(axitinib)|FOLFIRI_(irinotecan_leucovorin_5-fluorouracil_[5FU])|Bevacizumab_(avastin)|FOLFOX_(ox,other_events,arm3,Bevacizumab-+-FOLFOX,4,bevacizumab,monoclonal-antibody
2085,Dermatitis_allergic,1,35,Skin_and_subcutaneous_tissue_disorders,NCT00615056,https://clinicaltrials.gov/show/NCT00615056,Colorectal_Neoplasms,Bevacizumab_(avastin)|FOLFIRI_(Irinotecan_leucovorin_5-fluorouracil_[5FU])|AG-013736_(axitinib)|FOLFOX_(oxaliplatin_leucovorin_5-fluorouracil_[5FU])|AG-013736_(axitinib)|FOLFIRI_(irinotecan_leucovorin_5-fluorouracil_[5FU])|Bevacizumab_(avastin)|FOLFOX_(ox,other_events,arm3,Bevacizumab-+-FOLFOX,22,bevacizumab,monoclonal-antibody
644,Hypersensitivity,1,35,Immune_system_disorders,NCT00615056,https://clinicaltrials.gov/show/NCT00615056,Colorectal_Neoplasms,Bevacizumab_(avastin)|FOLFIRI_(Irinotecan_leucovorin_5-fluorouracil_[5FU])|AG-013736_(axitinib)|FOLFOX_(oxaliplatin_leucovorin_5-fluorouracil_[5FU])|AG-013736_(axitinib)|FOLFIRI_(irinotecan_leucovorin_5-fluorouracil_[5FU])|Bevacizumab_(avastin)|FOLFOX_(ox,other_events,arm3,Bevacizumab-+-FOLFOX,22,bevacizumab,monoclonal-antibody
2648,Allergic_reaction,10,31,Immune_system_disorders,NCT00616967,https://clinicaltrials.gov/show/NCT00616967,Breast_Cancer,carboplatin|paclitaxel_albumin-stabilized_nanoparticle_formulation|vorinostat|placebo|,other_events,arm1,Arm-I,,,
2647,Allergic_reaction,1,31,Immune_system_disorders,NCT00616967,https://clinicaltrials.gov/show/NCT00616967,Breast_Cancer,carboplatin|paclitaxel_albumin-stabilized_nanoparticle_formulation|vorinostat|placebo|,other_events,arm2,Arm-II,,,
1557,Drug_Hypersensitivity,2,522,Immune_system_disorders,NCT00617669,https://clinicaltrials.gov/show/NCT00617669,Prostate_Cancer,Docetaxel|ZD4054|Placebo|,serious_events,arm0,ZD4054-+-Docetaxel,8,docetaxel,taxane
649,Hypersensitivity,1,522,Immune_system_disorders,NCT00617669,https://clinicaltrials.gov/show/NCT00617669,Prostate_Cancer,Docetaxel|ZD4054|Placebo|,serious_events,arm0,ZD4054-+-Docetaxel,8,docetaxel,taxane
650,Hypersensitivity,1,525,Immune_system_disorders,NCT00617669,https://clinicaltrials.gov/show/NCT00617669,Prostate_Cancer,Docetaxel|ZD4054|Placebo|,serious_events,arm1,Placebo-+-Docetaxel,8,docetaxel,taxane
648,Hypersensitivity,3,31,Immune_system_disorders,NCT00617773,https://clinicaltrials.gov/show/NCT00617773,Fallopian_Tube_Cancer|Ovarian_Cancer|Primary_Peritoneal_Cancer|,hu3S193,other_events,arm0,hu3S193,,,
2649,Allergic_reaction,1,83,Immune_system_disorders,NCT00618982,https://clinicaltrials.gov/show/NCT00618982,Carcinoma_Renal_Cell,Sorafenib_(Nexavar_BAY43-9006),serious_events,arm0,Sorafenib-(Nexavar-BAY43-9006),97,nexavar,Tyrosine-Kinase-inhibitor
2649,Allergic_reaction,1,83,Immune_system_disorders,NCT00618982,https://clinicaltrials.gov/show/NCT00618982,Carcinoma_Renal_Cell,Sorafenib_(Nexavar_BAY43-9006),serious_events,arm0,Sorafenib-(Nexavar-BAY43-9006),90,sorafenib,Tyrosine-Kinase-inhibitor
2649,Allergic_reaction,1,83,Immune_system_disorders,NCT00618982,https://clinicaltrials.gov/show/NCT00618982,Carcinoma_Renal_Cell,Sorafenib_(Nexavar_BAY43-9006),serious_events,arm0,Sorafenib-(Nexavar-BAY43-9006),72,bay43,Tyrosine-Kinase-inhibitor
2650,Allergic_reaction,4,55,Immune_system_disorders,NCT00621049,https://clinicaltrials.gov/show/NCT00621049,Non-Small_Cell_Lung_Cancer,Docetaxel/Carboplatin/Bevacizumab/Erlotinib|Docetaxel/Carboplatin|,other_events,arm0,Docetaxel/Carboplatin/Bevacizumab/Erlotinib,3,carboplatin,alkalating-agent
2650,Allergic_reaction,4,55,Immune_system_disorders,NCT00621049,https://clinicaltrials.gov/show/NCT00621049,Non-Small_Cell_Lung_Cancer,Docetaxel/Carboplatin/Bevacizumab/Erlotinib|Docetaxel/Carboplatin|,other_events,arm0,Docetaxel/Carboplatin/Bevacizumab/Erlotinib,31,erlotinib,epidermal-growth-factor-receptor-(EGFR)-inhibitor---protein-tyrosine-kinase-inhibitor
2650,Allergic_reaction,4,55,Immune_system_disorders,NCT00621049,https://clinicaltrials.gov/show/NCT00621049,Non-Small_Cell_Lung_Cancer,Docetaxel/Carboplatin/Bevacizumab/Erlotinib|Docetaxel/Carboplatin|,other_events,arm0,Docetaxel/Carboplatin/Bevacizumab/Erlotinib,4,bevacizumab,monoclonal-antibody
2650,Allergic_reaction,4,55,Immune_system_disorders,NCT00621049,https://clinicaltrials.gov/show/NCT00621049,Non-Small_Cell_Lung_Cancer,Docetaxel/Carboplatin/Bevacizumab/Erlotinib|Docetaxel/Carboplatin|,other_events,arm0,Docetaxel/Carboplatin/Bevacizumab/Erlotinib,22,bevacizumab,monoclonal-antibody
2650,Allergic_reaction,4,55,Immune_system_disorders,NCT00621049,https://clinicaltrials.gov/show/NCT00621049,Non-Small_Cell_Lung_Cancer,Docetaxel/Carboplatin/Bevacizumab/Erlotinib|Docetaxel/Carboplatin|,other_events,arm0,Docetaxel/Carboplatin/Bevacizumab/Erlotinib,8,docetaxel,taxane
2651,Allergic_reaction,2,57,Immune_system_disorders,NCT00621049,https://clinicaltrials.gov/show/NCT00621049,Non-Small_Cell_Lung_Cancer,Docetaxel/Carboplatin/Bevacizumab/Erlotinib|Docetaxel/Carboplatin|,other_events,arm1,Docetaxel-and-Carboplatin,3,carboplatin,alkalating-agent
2651,Allergic_reaction,2,57,Immune_system_disorders,NCT00621049,https://clinicaltrials.gov/show/NCT00621049,Non-Small_Cell_Lung_Cancer,Docetaxel/Carboplatin/Bevacizumab/Erlotinib|Docetaxel/Carboplatin|,other_events,arm1,Docetaxel-and-Carboplatin,8,docetaxel,taxane
652,Hypersensitivity,6,81,Immune_system_disorders,NCT00622388,https://clinicaltrials.gov/show/NCT00622388,Lymphoma_Large-Cell_Diffuse,Ofatumumab,other_events,arm0,Ofatumumab,42,ofatumumab,monoclonal-antibody
655,Hypersensitivity,1,21,Immune_system_disorders,NCT00623766,https://clinicaltrials.gov/show/NCT00623766,Melanoma,Ipilimumab|Corticosteroid:_Betamethasone|Corticosteroid:_Dexamethasone|Corticosteroid:_Fludrocortisone|Corticosteroid:_Hydrocortisone|Corticosteroid:_Meprednisone|Corticosteroid:_Methylprednisolone|Corticosteroid:_Prednisolone|Corticosteroid:_Prednisone|C,serious_events,arm0,Ipilimumab-10-mg/kg-IV-in-Corticosteroid-dependent-Patients,64,ipilimumab,monoclonal-antibody
656,Hypersensitivity,1,5,Immune_system_disorders,NCT00625183,https://clinicaltrials.gov/show/NCT00625183,Colorectal_Cancer,selenomethionine|capecitabine|oxaliplatin|laboratory_biomarker_analysis|pharmacological_study|adjuvant_therapy|neoadjuvant_therapy|therapeutic_conventional_surgery|radiation_therapy|,other_events,arm0,Capecitabine-Oxaliplatin-Selenomethionine-and-Radiation-Ther,7,oxaliplatin,alkalating-agent
656,Hypersensitivity,1,5,Immune_system_disorders,NCT00625183,https://clinicaltrials.gov/show/NCT00625183,Colorectal_Cancer,selenomethionine|capecitabine|oxaliplatin|laboratory_biomarker_analysis|pharmacological_study|adjuvant_therapy|neoadjuvant_therapy|therapeutic_conventional_surgery|radiation_therapy|,other_events,arm0,Capecitabine-Oxaliplatin-Selenomethionine-and-Radiation-Ther,17,capecitabine,antimetabolite
656,Hypersensitivity,1,5,Immune_system_disorders,NCT00625183,https://clinicaltrials.gov/show/NCT00625183,Colorectal_Cancer,selenomethionine|capecitabine|oxaliplatin|laboratory_biomarker_analysis|pharmacological_study|adjuvant_therapy|neoadjuvant_therapy|therapeutic_conventional_surgery|radiation_therapy|,other_events,arm0,Capecitabine-Oxaliplatin-Selenomethionine-and-Radiation-Ther,29,capecitabine,antimetabolite
2652,Allergic_reaction,1,3017,Immune_system_disorders,NCT00626821,https://clinicaltrials.gov/show/NCT00626821,Stoma,SenSura,other_events,arm0,SenSura,,,
659,HYPERSENSITIVITY,1,42,Immune_system_disorders,NCT00627042,https://clinicaltrials.gov/show/NCT00627042,Hepatocellular_Carcinoma,Ramucirumab_(IMC-1121B),serious_events,arm0,Ramucirumab-(IMC-1121B),,,
661,Hypersensitivity,2,30,Immune_system_disorders,NCT00628901,https://clinicaltrials.gov/show/NCT00628901,Leiomyoma|Uterine_Fibroids|Uterine_Neoplasms|Menorrhagia|Leiomyomatosis|,Uterine_Fibroid_Embolization_(UFE)|Contour_SE???_Microspheres|Embosphere??_Microspheres|,other_events,arm1,Embosphere-Microspheres,,,
2089,Dermatitis_allergic,1,393,Skin_and_subcutaneous_tissue_disorders,NCT00631371,https://clinicaltrials.gov/show/NCT00631371,Renal_Cell_Carcinoma,Bevacizumab|Temsirolimus|Bevacizumab|Interferon-Alfa_9MU|,serious_events,arm0,Bevacizumab+Temsirolimus,4,bevacizumab,monoclonal-antibody
1560,Drug_hypersensitivity,1,393,Immune_system_disorders,NCT00631371,https://clinicaltrials.gov/show/NCT00631371,Renal_Cell_Carcinoma,Bevacizumab|Temsirolimus|Bevacizumab|Interferon-Alfa_9MU|,serious_events,arm0,Bevacizumab+Temsirolimus,4,bevacizumab,monoclonal-antibody
2089,Dermatitis_allergic,1,393,Skin_and_subcutaneous_tissue_disorders,NCT00631371,https://clinicaltrials.gov/show/NCT00631371,Renal_Cell_Carcinoma,Bevacizumab|Temsirolimus|Bevacizumab|Interferon-Alfa_9MU|,serious_events,arm0,Bevacizumab+Temsirolimus,22,bevacizumab,monoclonal-antibody
1560,Drug_hypersensitivity,1,393,Immune_system_disorders,NCT00631371,https://clinicaltrials.gov/show/NCT00631371,Renal_Cell_Carcinoma,Bevacizumab|Temsirolimus|Bevacizumab|Interferon-Alfa_9MU|,serious_events,arm0,Bevacizumab+Temsirolimus,22,bevacizumab,monoclonal-antibody
663,Hypersensitivity,1,6,Immune_system_disorders,NCT00631410,https://clinicaltrials.gov/show/NCT00631410,Colorectal_Neoplasms,sunitinib_+_mFOLFOX6|sunitinib_+_mFOLFOX6|,other_events,arm0,Treatment-Arm-A-37.5-mg/Day-(4/2),,,
667,Hypersensitivity,1,7,Immune_system_disorders,NCT00632749,https://clinicaltrials.gov/show/NCT00632749,Leukemia_Myeloid_Acute,BI_811283_(d_1_and_15)|Cytarabine|BI_811283_(d1)|Cytarabine|,other_events,arm5,120-mg-BI-811283-+-20-mg-Cytarabine---Treatment-Schedule-A,52,cytarabine,antimetabolite
668,Hypersensitivity,1,4,Immune_system_disorders,NCT00632749,https://clinicaltrials.gov/show/NCT00632749,Leukemia_Myeloid_Acute,BI_811283_(d_1_and_15)|Cytarabine|BI_811283_(d1)|Cytarabine|,other_events,arm7,40-mg-BI-811283-+-20-mg-Cytarabine---Treatment-Schedule-B,52,cytarabine,antimetabolite
665,HYPERSENSITIVITY,2,40,Immune_system_disorders,NCT00633464,https://clinicaltrials.gov/show/NCT00633464,Triple_Negative_Locally_Advanced_Non-resectable_Breast_Cancer|Metastatic_Breast_Cancer|,ixabepilone|ixabepilone_+_cetuximab|,other_events,arm0,Ixabepilone-40-mg/m^2,82,ixabepilone,antimicrotubule-agent
666,HYPERSENSITIVITY,2,37,Immune_system_disorders,NCT00633464,https://clinicaltrials.gov/show/NCT00633464,Triple_Negative_Locally_Advanced_Non-resectable_Breast_Cancer|Metastatic_Breast_Cancer|,ixabepilone|ixabepilone_+_cetuximab|,other_events,arm1,Cetuximab-250-mg/m^2-+-Ixabepilone-40-mg/m^2,82,ixabepilone,antimicrotubule-agent
666,HYPERSENSITIVITY,2,37,Immune_system_disorders,NCT00633464,https://clinicaltrials.gov/show/NCT00633464,Triple_Negative_Locally_Advanced_Non-resectable_Breast_Cancer|Metastatic_Breast_Cancer|,ixabepilone|ixabepilone_+_cetuximab|,other_events,arm1,Cetuximab-250-mg/m^2-+-Ixabepilone-40-mg/m^2,5,cetuximab,Epidermal-growth-factor-receptor-inhibitor
1561,DRUG_HYPERSENSITIVITY,2,6,Immune_system_disorders,NCT00634088,https://clinicaltrials.gov/show/NCT00634088,Locally_Advanced_or_Metastatic_Breast_Cancer,Ixabepilone_32_mg/m^2_+_Lapatinib_1000_mg|Ixabepilone_32_mg/m^2_+_Lapatinib_1250_mg|Ixabepilone_40_mg/m^2_+_Lapatinib_1250_mg|Ixabepilone_+_Lapatinib_+_Capecitabine|,other_events,arm0,Ixabepilone-32-mg/m^2-+-Lapatinib-1000-mg/d,82,ixabepilone,antimicrotubule-agent
1561,DRUG_HYPERSENSITIVITY,2,6,Immune_system_disorders,NCT00634088,https://clinicaltrials.gov/show/NCT00634088,Locally_Advanced_or_Metastatic_Breast_Cancer,Ixabepilone_32_mg/m^2_+_Lapatinib_1000_mg|Ixabepilone_32_mg/m^2_+_Lapatinib_1250_mg|Ixabepilone_40_mg/m^2_+_Lapatinib_1250_mg|Ixabepilone_+_Lapatinib_+_Capecitabine|,other_events,arm0,Ixabepilone-32-mg/m^2-+-Lapatinib-1000-mg/d,21,lapatinib,signal-transduction-inhibitor
669,Hypersensitivity,3,54,Immune_system_disorders,NCT00635154,https://clinicaltrials.gov/show/NCT00635154,Multiple_Myeloma_and_Plasma_Cell_Neoplasm,Anakinra_(IL-1Ra)|Dexamethasone_acetate|,other_events,arm0,Anakinra-With/Without-Dexamethasone,79,dexamethasone,steroid
2091,Dermatitis_allergic,2,38,Skin_and_subcutaneous_tissue_disorders,NCT00635427,https://clinicaltrials.gov/show/NCT00635427,Gaucher_Disease_Type_1,VPRIV??,other_events,arm0,VPRIV-15-60-U/kg-(Parent-Study-VPRIV-(15-60-U/kg)-TKT034),,,
1562,Drug_hypersensitivity,1,471,Immune_system_disorders,NCT00636168,https://clinicaltrials.gov/show/NCT00636168,High_Risk_Stage_III_Melanoma,ipilimumab|Placebo|,serious_events,arm0,Ipilimumab-10mg/kg,64,ipilimumab,monoclonal-antibody
670,Hypersensitivity,3,471,Immune_system_disorders,NCT00636168,https://clinicaltrials.gov/show/NCT00636168,High_Risk_Stage_III_Melanoma,ipilimumab|Placebo|,serious_events,arm0,Ipilimumab-10mg/kg,64,ipilimumab,monoclonal-antibody
2657,Allergic_reaction,2,7,Immune_system_disorders,NCT00636441,https://clinicaltrials.gov/show/NCT00636441,Early-Stage_Breast_Cancer,Doxorubicin/Cyclophosphamide_(AC)_or_Docetaxel/Cyclophosphamide_(TC),other_events,arm1,Guided-TC-Sensitive,,,
2658,Allergic_reaction,1,6,Immune_system_disorders,NCT00636441,https://clinicaltrials.gov/show/NCT00636441,Early-Stage_Breast_Cancer,Doxorubicin/Cyclophosphamide_(AC)_or_Docetaxel/Cyclophosphamide_(TC),other_events,arm2,Guided-AC-Non-sensitive,,,
2656,Allergic_reaction,1,6,Immune_system_disorders,NCT00636441,https://clinicaltrials.gov/show/NCT00636441,Early-Stage_Breast_Cancer,Doxorubicin/Cyclophosphamide_(AC)_or_Docetaxel/Cyclophosphamide_(TC),other_events,arm3,Guided-TC-Non-Sensitive,,,
2654,Allergic_reaction,2,7,Immune_system_disorders,NCT00636441,https://clinicaltrials.gov/show/NCT00636441,Early-Stage_Breast_Cancer,Doxorubicin/Cyclophosphamide_(AC)_or_Docetaxel/Cyclophosphamide_(TC),other_events,arm5,Non-guided-TC,,,
2655,Allergic_reaction,1,7,Immune_system_disorders,NCT00636441,https://clinicaltrials.gov/show/NCT00636441,Early-Stage_Breast_Cancer,Doxorubicin/Cyclophosphamide_(AC)_or_Docetaxel/Cyclophosphamide_(TC),serious_events,arm5,Non-guided-TC,,,
2659,Allergic_reaction,1,67,Immune_system_disorders,NCT00637247,https://clinicaltrials.gov/show/NCT00637247,Pancreatic_Neoplasms,imexon_in_combination_with_gemcitabine|imexon_placebo_+_gemcitabine|,serious_events,arm0,Amplimexon-(Imexon)-+-Gemcitabine,6,gemcitabine,antimetabolites
671,Hypersensitivity,1,17,Immune_system_disorders,NCT00641537,https://clinicaltrials.gov/show/NCT00641537,Relapsing-Remitting_Multiple_Sclerosis,Cladribine|Placebo|Cladribine|Cladribine|Placebo|,other_events,arm6,Cladribine-3.5-mg/kg/No-Treatment,,,
2660,Allergic_reaction,1,18,Immune_system_disorders,NCT00643097,https://clinicaltrials.gov/show/NCT00643097,Malignant_Neoplasms_of_Brain,PEP-3_vaccine|sargramostim|Temozolomide|,serious_events,arm0,Arm-I-(ACTIVATE),,,
2661,Allergic_reaction,4,30,Immune_system_disorders,NCT00645333,https://clinicaltrials.gov/show/NCT00645333,Metastatic_Breast_Cancer,MK-0752_Docetaxel_Pegfilgrastim,other_events,arm0,MK-0752,,,
673,Hypersensitivity,2,30,General_disorders,NCT00645333,https://clinicaltrials.gov/show/NCT00645333,Metastatic_Breast_Cancer,MK-0752_Docetaxel_Pegfilgrastim,serious_events,arm0,MK-0752,,,
1565,Drug_Hypersensitivity,1,29,Immune_system_disorders,NCT00653939,https://clinicaltrials.gov/show/NCT00653939,Tumors,Fosbretabulin|Carboplatin|Paclitaxel|Bevacizumab|,other_events,arm0,Arm-1:-Chemotherapy+Bevacizumab,4,bevacizumab,monoclonal-antibody
1565,Drug_Hypersensitivity,1,29,Immune_system_disorders,NCT00653939,https://clinicaltrials.gov/show/NCT00653939,Tumors,Fosbretabulin|Carboplatin|Paclitaxel|Bevacizumab|,other_events,arm0,Arm-1:-Chemotherapy+Bevacizumab,22,bevacizumab,monoclonal-antibody
1566,Drug_Hypersensitivity,2,31,Immune_system_disorders,NCT00653939,https://clinicaltrials.gov/show/NCT00653939,Tumors,Fosbretabulin|Carboplatin|Paclitaxel|Bevacizumab|,other_events,arm1,Arm-2:-Active-Comparator+Fosbretabulin,,,
2094,Dermatitis_allergic,1,390,Skin_and_subcutaneous_tissue_disorders,NCT00656136,https://clinicaltrials.gov/show/NCT00656136,Carcinoma_Non-Small-Cell_Lung,placebo|BIBW_2992|,serious_events,arm1,Afatinib-50-mg/Day-Plus-Best-Supportive-Care-(BSC),,,
2663,Allergic_reaction,8,41,Immune_system_disorders,NCT00658697,https://clinicaltrials.gov/show/NCT00658697,Prostate_Cancer,Docetaxel|Bevacizumab|ADT|Bicalutamide|,other_events,arm0,Docetaxel-Bevacizumab-and-ADT,4,bevacizumab,monoclonal-antibody
2664,Allergic_reaction,1,41,Immune_system_disorders,NCT00658697,https://clinicaltrials.gov/show/NCT00658697,Prostate_Cancer,Docetaxel|Bevacizumab|ADT|Bicalutamide|,serious_events,arm0,Docetaxel-Bevacizumab-and-ADT,4,bevacizumab,monoclonal-antibody
2663,Allergic_reaction,8,41,Immune_system_disorders,NCT00658697,https://clinicaltrials.gov/show/NCT00658697,Prostate_Cancer,Docetaxel|Bevacizumab|ADT|Bicalutamide|,other_events,arm0,Docetaxel-Bevacizumab-and-ADT,22,bevacizumab,monoclonal-antibody
2664,Allergic_reaction,1,41,Immune_system_disorders,NCT00658697,https://clinicaltrials.gov/show/NCT00658697,Prostate_Cancer,Docetaxel|Bevacizumab|ADT|Bicalutamide|,serious_events,arm0,Docetaxel-Bevacizumab-and-ADT,22,bevacizumab,monoclonal-antibody
2663,Allergic_reaction,8,41,Immune_system_disorders,NCT00658697,https://clinicaltrials.gov/show/NCT00658697,Prostate_Cancer,Docetaxel|Bevacizumab|ADT|Bicalutamide|,other_events,arm0,Docetaxel-Bevacizumab-and-ADT,8,docetaxel,taxane
2664,Allergic_reaction,1,41,Immune_system_disorders,NCT00658697,https://clinicaltrials.gov/show/NCT00658697,Prostate_Cancer,Docetaxel|Bevacizumab|ADT|Bicalutamide|,serious_events,arm0,Docetaxel-Bevacizumab-and-ADT,8,docetaxel,taxane
676,Hypersensitivity,1,164,Immune_system_disorders,NCT00661999,https://clinicaltrials.gov/show/NCT00661999,Anemia|Leukemia|Lymphoma|Lymphoproliferative_Disorder|Multiple_Myeloma_and_Plasma_Cell_Neoplasm|Precancerous_Condition|Unspecified_Adult_Solid_Tumor_Protocol_Specific|,darbepoetin_alfa|ferrous_sulfate|sodium_ferric_gluconate_complex_in_sucrose|placebo|,other_events,arm0,DA-+-IV-Iron,,,
2667,Allergic_Reaction,4,49,Immune_system_disorders,NCT00664326,https://clinicaltrials.gov/show/NCT00664326,Carcinoma_Renal_Cell,Regorafenib_(Stivarga_BAY73-4506),other_events,arm0,Regorafenib-(Stivarga-BAY73-4506),,,
2668,Allergic_reaction,1,20,Immune_system_disorders,NCT00666588,https://clinicaltrials.gov/show/NCT00666588,Adult_Acute_Monoblastic_Leukemia_(M5a)|Adult_Acute_Monocytic_Leukemia_(M5b)|Adult_Acute_Myeloblastic_Leukemia_With_Maturation_(M2)|Adult_Acute_Myeloblastic_Leukemia_Without_Maturation_(M1)|Adult_Acute_Myeloid_Leukemia_With_11q23_(MLL)_Abnormalities|Adult_,idarubicin|cytarabine|bortezomib|etoposide|laboratory_biomarker_analysis|,other_events,arm3,Bortezomib-1.3-mg/m2-assess-Efficacy-High-Anthracycline-Exp,73,anthracycline,anthracycline
2352,Anaphylaxis,1,20,Immune_system_disorders,NCT00666588,https://clinicaltrials.gov/show/NCT00666588,Adult_Acute_Monoblastic_Leukemia_(M5a)|Adult_Acute_Monocytic_Leukemia_(M5b)|Adult_Acute_Myeloblastic_Leukemia_With_Maturation_(M2)|Adult_Acute_Myeloblastic_Leukemia_Without_Maturation_(M1)|Adult_Acute_Myeloid_Leukemia_With_11q23_(MLL)_Abnormalities|Adult_,idarubicin|cytarabine|bortezomib|etoposide|laboratory_biomarker_analysis|,other_events,arm3,Bortezomib-1.3-mg/m2-assess-Efficacy-High-Anthracycline-Exp,73,anthracycline,anthracycline
2668,Allergic_reaction,1,20,Immune_system_disorders,NCT00666588,https://clinicaltrials.gov/show/NCT00666588,Adult_Acute_Monoblastic_Leukemia_(M5a)|Adult_Acute_Monocytic_Leukemia_(M5b)|Adult_Acute_Myeloblastic_Leukemia_With_Maturation_(M2)|Adult_Acute_Myeloblastic_Leukemia_Without_Maturation_(M1)|Adult_Acute_Myeloid_Leukemia_With_11q23_(MLL)_Abnormalities|Adult_,idarubicin|cytarabine|bortezomib|etoposide|laboratory_biomarker_analysis|,other_events,arm3,Bortezomib-1.3-mg/m2-assess-Efficacy-High-Anthracycline-Exp,70,bortezomib,proteasome-inhibitor
2352,Anaphylaxis,1,20,Immune_system_disorders,NCT00666588,https://clinicaltrials.gov/show/NCT00666588,Adult_Acute_Monoblastic_Leukemia_(M5a)|Adult_Acute_Monocytic_Leukemia_(M5b)|Adult_Acute_Myeloblastic_Leukemia_With_Maturation_(M2)|Adult_Acute_Myeloblastic_Leukemia_Without_Maturation_(M1)|Adult_Acute_Myeloid_Leukemia_With_11q23_(MLL)_Abnormalities|Adult_,idarubicin|cytarabine|bortezomib|etoposide|laboratory_biomarker_analysis|,other_events,arm3,Bortezomib-1.3-mg/m2-assess-Efficacy-High-Anthracycline-Exp,70,bortezomib,proteasome-inhibitor
2670,Allergic_reaction,31,322,Immune_system_disorders,NCT00667251,https://clinicaltrials.gov/show/NCT00667251,Breast_Cancer,trastuzumab|docetaxel|lapatinib_ditosylate|paclitaxel|,other_events,arm0,Lapatinib,21,lapatinib,signal-transduction-inhibitor
2669,Allergic_reaction,43,325,Immune_system_disorders,NCT00667251,https://clinicaltrials.gov/show/NCT00667251,Breast_Cancer,trastuzumab|docetaxel|lapatinib_ditosylate|paclitaxel|,other_events,arm1,Trastuzumab,18,trastuzumab,monoclonal-antibody
680,Hypersensitivity,1,65,Immune_system_disorders,NCT00669578,https://clinicaltrials.gov/show/NCT00669578,Chronic_Myeloproliferative_Disorders|Secondary_Myelofibrosis|,CC-4047,other_events,arm0,Phase-II,,,
681,Hypersensitivity,1,65,Immune_system_disorders,NCT00669578,https://clinicaltrials.gov/show/NCT00669578,Chronic_Myeloproliferative_Disorders|Secondary_Myelofibrosis|,CC-4047,serious_events,arm0,Phase-II,,,
2671,Allergic_Reaction,2,29,General_disorders,NCT00670982,https://clinicaltrials.gov/show/NCT00670982,Breast_Cancer,bevacizumab|vinorelbine|trastuzumab|,other_events,arm0,All-Study-Participants,,,
1570,Drug_hypersensitivity,1,289,Immune_system_disorders,NCT00673049,https://clinicaltrials.gov/show/NCT00673049,Carcinoma_Large_Cell|Carcinoma_Non-Small-Cell_Lung|Carcinoma_Squamous_Cell|Carcinoma_Adenosquamous_Cell|,CP_751871_(Figitumumab)|Erlotinib|Erlotinib|,other_events,arm0,Figitumumab-+-Erlotinib,31,erlotinib,epidermal-growth-factor-receptor-(EGFR)-inhibitor---protein-tyrosine-kinase-inhibitor
682,Hypersensitivity,5,289,Immune_system_disorders,NCT00673049,https://clinicaltrials.gov/show/NCT00673049,Carcinoma_Large_Cell|Carcinoma_Non-Small-Cell_Lung|Carcinoma_Squamous_Cell|Carcinoma_Adenosquamous_Cell|,CP_751871_(Figitumumab)|Erlotinib|Erlotinib|,other_events,arm0,Figitumumab-+-Erlotinib,31,erlotinib,epidermal-growth-factor-receptor-(EGFR)-inhibitor---protein-tyrosine-kinase-inhibitor
683,Hypersensitivity,1,289,Immune_system_disorders,NCT00673049,https://clinicaltrials.gov/show/NCT00673049,Carcinoma_Large_Cell|Carcinoma_Non-Small-Cell_Lung|Carcinoma_Squamous_Cell|Carcinoma_Adenosquamous_Cell|,CP_751871_(Figitumumab)|Erlotinib|Erlotinib|,serious_events,arm0,Figitumumab-+-Erlotinib,31,erlotinib,epidermal-growth-factor-receptor-(EGFR)-inhibitor---protein-tyrosine-kinase-inhibitor
2098,Dermatitis_allergic,1,290,Skin_and_subcutaneous_tissue_disorders,NCT00673049,https://clinicaltrials.gov/show/NCT00673049,Carcinoma_Large_Cell|Carcinoma_Non-Small-Cell_Lung|Carcinoma_Squamous_Cell|Carcinoma_Adenosquamous_Cell|,CP_751871_(Figitumumab)|Erlotinib|Erlotinib|,other_events,arm1,Erlotinib,31,erlotinib,epidermal-growth-factor-receptor-(EGFR)-inhibitor---protein-tyrosine-kinase-inhibitor
686,Hypersensitivity,1,359,Immune_system_disorders,NCT00678392,https://clinicaltrials.gov/show/NCT00678392,Kidney_Neoplasms,Axitinib_(AG-013736)|Sorafenib|,serious_events,arm0,Axitinib,10,axitinib,kinase-inhibitor
685,Hypersensitivity,4,446,Immune_system_disorders,NCT00678535,https://clinicaltrials.gov/show/NCT00678535,Gastric_Cancer,Cetuximab|Capecitabine|Cisplatin|,serious_events,arm0,Cetuximab-Plus-Capecitabine-Plus-Cisplatin,9,cisplatin,alkalating-agent
685,Hypersensitivity,4,446,Immune_system_disorders,NCT00678535,https://clinicaltrials.gov/show/NCT00678535,Gastric_Cancer,Cetuximab|Capecitabine|Cisplatin|,serious_events,arm0,Cetuximab-Plus-Capecitabine-Plus-Cisplatin,17,capecitabine,antimetabolite
685,Hypersensitivity,4,446,Immune_system_disorders,NCT00678535,https://clinicaltrials.gov/show/NCT00678535,Gastric_Cancer,Cetuximab|Capecitabine|Cisplatin|,serious_events,arm0,Cetuximab-Plus-Capecitabine-Plus-Cisplatin,29,capecitabine,antimetabolite
685,Hypersensitivity,4,446,Immune_system_disorders,NCT00678535,https://clinicaltrials.gov/show/NCT00678535,Gastric_Cancer,Cetuximab|Capecitabine|Cisplatin|,serious_events,arm0,Cetuximab-Plus-Capecitabine-Plus-Cisplatin,5,cetuximab,Epidermal-growth-factor-receptor-inhibitor
687,Hypersensitivity,1,66,Immune_system_disorders,NCT00679341,https://clinicaltrials.gov/show/NCT00679341,Breast_Cancer,Trastuzumab_emtansine_[Kadcyla]|Trastuzumab|Docetaxel|,serious_events,arm1,Trastuzumab-+-Docetaxel,18,trastuzumab,monoclonal-antibody
687,Hypersensitivity,1,66,Immune_system_disorders,NCT00679341,https://clinicaltrials.gov/show/NCT00679341,Breast_Cancer,Trastuzumab_emtansine_[Kadcyla]|Trastuzumab|Docetaxel|,serious_events,arm1,Trastuzumab-+-Docetaxel,8,docetaxel,taxane
2672,Allergic_reaction,1,29,Immune_system_disorders,NCT00679354,https://clinicaltrials.gov/show/NCT00679354,Childhood_High-grade_Cerebellar_Astrocytoma|Childhood_High-grade_Cerebral_Astrocytoma|Recurrent_Childhood_Anaplastic_Astrocytoma|Recurrent_Childhood_Anaplastic_Oligoastrocytoma|Recurrent_Childhood_Anaplastic_Oligodendroglioma|Recurrent_Childhood_Brain_Tum,cilengitide|laboratory_biomarker_analysis|pharmacological_study|,other_events,arm0,Treatment-(Cilengitide),41,cilengitide,"first-anti-angiogenic-small-molecule-targeting-the-integrins-??v??3--??v??5-and-??5??1""Moruno-et-al--Cilengitide:--The-First-Anti-Angiogenic-Small-Molecule-Drug-Candidate.-Design--Synthesis-and-Clinical-Evaluations.--Anticancer-Agents-Med-Chem.-2010-Dec;;"
1573,Drug_hypersensitivity,1,270,Immune_system_disorders,NCT00680901,https://clinicaltrials.gov/show/NCT00680901,Neoplasms_Gastrointestinal_Tract,Lapatinib|Placebo|Capecitabine|Oxaliplatin|,serious_events,arm0,CapeOx-+-Lapatinib,21,lapatinib,signal-transduction-inhibitor
689,Hypersensitivity,1,270,Immune_system_disorders,NCT00680901,https://clinicaltrials.gov/show/NCT00680901,Neoplasms_Gastrointestinal_Tract,Lapatinib|Placebo|Capecitabine|Oxaliplatin|,serious_events,arm0,CapeOx-+-Lapatinib,21,lapatinib,signal-transduction-inhibitor
693,Hypersensitivity,1,152,Immune_system_disorders,NCT00684307,https://clinicaltrials.gov/show/NCT00684307,Nonvalvular_Atrial_Fibrillation,AZD0837|Vitamin-K_antagonist_at_INR_2-3|AZD0837|,serious_events,arm1,AZD0837-300-mg-od,,,
694,Hypersensitivity,2,19,Immune_system_disorders,NCT00684983,https://clinicaltrials.gov/show/NCT00684983,HER2/Neu_Positive|Stage_IIIB_Breast_Cancer|Stage_IIIC_Breast_Cancer|Stage_IV_Breast_Cancer|,Capecitabine|Cixutumumab|Laboratory_Biomarker_Analysis|Lapatinib_Ditosylate|Quality-of-Life_Assessment|,other_events,arm0,Arm-A,,,
695,Hypersensitivity,1,45,Immune_system_disorders,NCT00684983,https://clinicaltrials.gov/show/NCT00684983,HER2/Neu_Positive|Stage_IIIB_Breast_Cancer|Stage_IIIC_Breast_Cancer|Stage_IV_Breast_Cancer|,Capecitabine|Cixutumumab|Laboratory_Biomarker_Analysis|Lapatinib_Ditosylate|Quality-of-Life_Assessment|,other_events,arm1,Arm-B,,,
2673,Allergic_Reaction,3,157,Immune_system_disorders,NCT00687297,https://clinicaltrials.gov/show/NCT00687297,Lung_Cancer|Non_Small_Cell_Lung_Cancer|,vandetanib_induction|Docetaxel|Carboplatin|Placebo|Vandetanib_maintenance|,serious_events,arm2,All-Treated-Patients---Induction,,,
697,Hypersensitivity,4,744,Immune_system_disorders,NCT00688740,https://clinicaltrials.gov/show/NCT00688740,Breast_Cancer,Docetaxel|5-fluorouracil|Doxorubicin|Cyclophosphamide|,serious_events,arm0,TAC-(Docetaxel),8,docetaxel,taxane
698,Hypersensitivity,82,744,Immune_system_disorders,NCT00688740,https://clinicaltrials.gov/show/NCT00688740,Breast_Cancer,Docetaxel|5-fluorouracil|Doxorubicin|Cyclophosphamide|,other_events,arm0,TAC-(Docetaxel),8,docetaxel,taxane
699,Hypersensitivity,21,736,Immune_system_disorders,NCT00688740,https://clinicaltrials.gov/show/NCT00688740,Breast_Cancer,Docetaxel|5-fluorouracil|Doxorubicin|Cyclophosphamide|,other_events,arm1,FAC-(5-fluorouracil),11,fluorouracil,antimetabolites
1580,DRUG_HYPERSENSITIVITY,1,263,Immune_system_disorders,NCT00689221,https://clinicaltrials.gov/show/NCT00689221,Glioblastoma,Cilengitide|Temozolomide|Radiotherapy|,serious_events,arm0,Cilengitide-+-Temozolomide-+-Radiotherapy,98,temozolomide,alkylating-agent
700,HYPERSENSITIVITY,1,263,Immune_system_disorders,NCT00689221,https://clinicaltrials.gov/show/NCT00689221,Glioblastoma,Cilengitide|Temozolomide|Radiotherapy|,serious_events,arm0,Cilengitide-+-Temozolomide-+-Radiotherapy,98,temozolomide,alkylating-agent
1580,DRUG_HYPERSENSITIVITY,1,263,Immune_system_disorders,NCT00689221,https://clinicaltrials.gov/show/NCT00689221,Glioblastoma,Cilengitide|Temozolomide|Radiotherapy|,serious_events,arm0,Cilengitide-+-Temozolomide-+-Radiotherapy,41,cilengitide,"first-anti-angiogenic-small-molecule-targeting-the-integrins-??v??3--??v??5-and-??5??1""Moruno-et-al--Cilengitide:--The-First-Anti-Angiogenic-Small-Molecule-Drug-Candidate.-Design--Synthesis-and-Clinical-Evaluations.--Anticancer-Agents-Med-Chem.-2010-Dec;;"
700,HYPERSENSITIVITY,1,263,Immune_system_disorders,NCT00689221,https://clinicaltrials.gov/show/NCT00689221,Glioblastoma,Cilengitide|Temozolomide|Radiotherapy|,serious_events,arm0,Cilengitide-+-Temozolomide-+-Radiotherapy,41,cilengitide,"first-anti-angiogenic-small-molecule-targeting-the-integrins-??v??3--??v??5-and-??5??1""Moruno-et-al--Cilengitide:--The-First-Anti-Angiogenic-Small-Molecule-Drug-Candidate.-Design--Synthesis-and-Clinical-Evaluations.--Anticancer-Agents-Med-Chem.-2010-Dec;;"
701,Hypersensitivity,1,6,Immune_system_disorders,NCT00690430,https://clinicaltrials.gov/show/NCT00690430,Symptomatic_Refractory_Resistant_Carcinoid_Disease,Pasireotide|Octreotide|,other_events,arm3,Extension-Phase-Octreotide-LAR,,,
2103,Dermatitis_allergic,1,559,Skin_and_subcutaneous_tissue_disorders,NCT00692770,https://clinicaltrials.gov/show/NCT00692770,Carcinoma_Hepatocellular,Nexavar_(Sorafenib_BAY43-9006)|Placebo|,serious_events,arm0,Sorafenib-(Nexavar-BAY43-9006),97,nexavar,Tyrosine-Kinase-inhibitor
2103,Dermatitis_allergic,1,559,Skin_and_subcutaneous_tissue_disorders,NCT00692770,https://clinicaltrials.gov/show/NCT00692770,Carcinoma_Hepatocellular,Nexavar_(Sorafenib_BAY43-9006)|Placebo|,serious_events,arm0,Sorafenib-(Nexavar-BAY43-9006),90,sorafenib,Tyrosine-Kinase-inhibitor
2103,Dermatitis_allergic,1,559,Skin_and_subcutaneous_tissue_disorders,NCT00692770,https://clinicaltrials.gov/show/NCT00692770,Carcinoma_Hepatocellular,Nexavar_(Sorafenib_BAY43-9006)|Placebo|,serious_events,arm0,Sorafenib-(Nexavar-BAY43-9006),72,bay43,Tyrosine-Kinase-inhibitor
702,Hypersensitivity,1,8,Immune_system_disorders,NCT00695396,https://clinicaltrials.gov/show/NCT00695396,Myelodysplastic_Syndromes|Anemia|,Placebo|Epoetin_alfa|Placebo|Epoetin_alfa|,other_events,arm1,Epoetin-Alfa-40000-IU,,,
703,Hypersensitivity,5,54,Immune_system_disorders,NCT00698451,https://clinicaltrials.gov/show/NCT00698451,Ovarian_Neoplasms|Fallopian_Tube_Neoplasms|Peritoneal_Neoplasms|,doxorubicin_HCL_liposome;_bevacizumab;_carboplatin,other_events,arm0,DOXIL/CARBOPLATIN/BEVACIZUMAB,3,carboplatin,alkalating-agent
703,Hypersensitivity,5,54,Immune_system_disorders,NCT00698451,https://clinicaltrials.gov/show/NCT00698451,Ovarian_Neoplasms|Fallopian_Tube_Neoplasms|Peritoneal_Neoplasms|,doxorubicin_HCL_liposome;_bevacizumab;_carboplatin,other_events,arm0,DOXIL/CARBOPLATIN/BEVACIZUMAB,4,bevacizumab,monoclonal-antibody
703,Hypersensitivity,5,54,Immune_system_disorders,NCT00698451,https://clinicaltrials.gov/show/NCT00698451,Ovarian_Neoplasms|Fallopian_Tube_Neoplasms|Peritoneal_Neoplasms|,doxorubicin_HCL_liposome;_bevacizumab;_carboplatin,other_events,arm0,DOXIL/CARBOPLATIN/BEVACIZUMAB,22,bevacizumab,monoclonal-antibody
704,Hypersensitivity,1,542,Immune_system_disorders,NCT00699374,https://clinicaltrials.gov/show/NCT00699374,Carcinoma_Hepatocellular,sunitinib_malate|sorafenib|,serious_events,arm1,Sorafenib,90,sorafenib,Tyrosine-Kinase-inhibitor
706,Hypersensitivity,1,3,Immune_system_disorders,NCT00699491,https://clinicaltrials.gov/show/NCT00699491,Male_Breast_Cancer|Recurrent_Breast_Cancer|Stage_IV_Breast_Cancer|,cixutumumab|temsirolimus|laboratory_biomarker_analysis|,other_events,arm0,Dose-Level-1,,,
705,Hypersensitivity,1,22,Immune_system_disorders,NCT00699491,https://clinicaltrials.gov/show/NCT00699491,Male_Breast_Cancer|Recurrent_Breast_Cancer|Stage_IV_Breast_Cancer|,cixutumumab|temsirolimus|laboratory_biomarker_analysis|,other_events,arm5,Phase-II,,,
1582,Drug_hypersensitivity,1,409,Immune_system_disorders,NCT00700102,https://clinicaltrials.gov/show/NCT00700102,Colorectal_Cancer,Chemotherapy|Bevacizumab|,serious_events,arm0,Chemotherapy,,,
709,Hypersensitivity,1,409,Immune_system_disorders,NCT00700102,https://clinicaltrials.gov/show/NCT00700102,Colorectal_Cancer,Chemotherapy|Bevacizumab|,serious_events,arm0,Chemotherapy,,,
1581,Drug_hypersensitivity,6,401,Immune_system_disorders,NCT00700102,https://clinicaltrials.gov/show/NCT00700102,Colorectal_Cancer,Chemotherapy|Bevacizumab|,serious_events,arm1,Chemotherapy-+-Bevacizumab,4,bevacizumab,monoclonal-antibody
708,Hypersensitivity,1,401,Immune_system_disorders,NCT00700102,https://clinicaltrials.gov/show/NCT00700102,Colorectal_Cancer,Chemotherapy|Bevacizumab|,serious_events,arm1,Chemotherapy-+-Bevacizumab,4,bevacizumab,monoclonal-antibody
1581,Drug_hypersensitivity,6,401,Immune_system_disorders,NCT00700102,https://clinicaltrials.gov/show/NCT00700102,Colorectal_Cancer,Chemotherapy|Bevacizumab|,serious_events,arm1,Chemotherapy-+-Bevacizumab,22,bevacizumab,monoclonal-antibody
708,Hypersensitivity,1,401,Immune_system_disorders,NCT00700102,https://clinicaltrials.gov/show/NCT00700102,Colorectal_Cancer,Chemotherapy|Bevacizumab|,serious_events,arm1,Chemotherapy-+-Bevacizumab,22,bevacizumab,monoclonal-antibody
707,Hypersensitivity,1,143,Immune_system_disorders,NCT00700180,https://clinicaltrials.gov/show/NCT00700180,Non-Small_Cell_Lung_Cancer,bevacizumab_[Avastin]|bevacizumab_[Avastin]|Carboplatin-based_chemotherapy|,serious_events,arm1,Bevacizumab-15-mg-Plus-Chemotherapy,4,bevacizumab,monoclonal-antibody
707,Hypersensitivity,1,143,Immune_system_disorders,NCT00700180,https://clinicaltrials.gov/show/NCT00700180,Non-Small_Cell_Lung_Cancer,bevacizumab_[Avastin]|bevacizumab_[Avastin]|Carboplatin-based_chemotherapy|,serious_events,arm1,Bevacizumab-15-mg-Plus-Chemotherapy,22,bevacizumab,monoclonal-antibody
1585,Drug_hypersensitivity,1,11,Immune_system_disorders,NCT00702520,https://clinicaltrials.gov/show/NCT00702520,Pregnancy|Neonates|,Corifollitropin_alpha_(MK-8962_Org_36286)_100_ug|Corifollitropin_alpha_(MK-8962_Org_36286)_150_ug|Triptorelin|Recombinant_follicle_stimulating_hormone_(recFSH)|Human_chorionic_gonadotprophin_(hCG).|,other_events,arm3,Fetuses/Infants-From-Mothers-Administered-Cori.-Alpha-150-ug,,,
2105,Dermatitis_allergic,1,752,Skin_and_subcutaneous_tissue_disorders,NCT00703326,https://clinicaltrials.gov/show/NCT00703326,Breast_Cancer,ramucirumab_(IMC-1121B)|docetaxel|Placebo|,serious_events,arm0,Ramucirumab-(IMC-1121B)-+-Docetaxel,8,docetaxel,taxane
712,Hypersensitivity,4,752,Immune_system_disorders,NCT00703326,https://clinicaltrials.gov/show/NCT00703326,Breast_Cancer,ramucirumab_(IMC-1121B)|docetaxel|Placebo|,serious_events,arm0,Ramucirumab-(IMC-1121B)-+-Docetaxel,8,docetaxel,taxane
713,Hypersensitivity,3,382,Immune_system_disorders,NCT00703326,https://clinicaltrials.gov/show/NCT00703326,Breast_Cancer,ramucirumab_(IMC-1121B)|docetaxel|Placebo|,serious_events,arm1,Placebo-+-Docetaxel,8,docetaxel,taxane
716,Hypersensitivity,1,214,Immune_system_disorders,NCT00704730,https://clinicaltrials.gov/show/NCT00704730,Thyroid_Cancer,XL184|Placebo|,serious_events,arm0,XL184-(Cabozantinib),,,
1588,Drug_Hypersensitivity,2,61,Immune_system_disorders,NCT00705016,https://clinicaltrials.gov/show/NCT00705016,Squamous_Cell_Cancer,Cilengitide_2000_mg_once_weekly|Cilengitide_2000_mg_twice_weekly|Cetuximab|5-fluorouracil_(5-FU)|Cisplatin|,serious_events,arm0,Cilengitide-2000-mg-Once-Weekly+Cetuximab+5-FU+Cisplatin,9,cisplatin,alkalating-agent
1589,Drug_Hypersensitivity,3,61,Immune_system_disorders,NCT00705016,https://clinicaltrials.gov/show/NCT00705016,Squamous_Cell_Cancer,Cilengitide_2000_mg_once_weekly|Cilengitide_2000_mg_twice_weekly|Cetuximab|5-fluorouracil_(5-FU)|Cisplatin|,other_events,arm0,Cilengitide-2000-mg-Once-Weekly+Cetuximab+5-FU+Cisplatin,9,cisplatin,alkalating-agent
1588,Drug_Hypersensitivity,2,61,Immune_system_disorders,NCT00705016,https://clinicaltrials.gov/show/NCT00705016,Squamous_Cell_Cancer,Cilengitide_2000_mg_once_weekly|Cilengitide_2000_mg_twice_weekly|Cetuximab|5-fluorouracil_(5-FU)|Cisplatin|,serious_events,arm0,Cilengitide-2000-mg-Once-Weekly+Cetuximab+5-FU+Cisplatin,5,cetuximab,Epidermal-growth-factor-receptor-inhibitor
1589,Drug_Hypersensitivity,3,61,Immune_system_disorders,NCT00705016,https://clinicaltrials.gov/show/NCT00705016,Squamous_Cell_Cancer,Cilengitide_2000_mg_once_weekly|Cilengitide_2000_mg_twice_weekly|Cetuximab|5-fluorouracil_(5-FU)|Cisplatin|,other_events,arm0,Cilengitide-2000-mg-Once-Weekly+Cetuximab+5-FU+Cisplatin,5,cetuximab,Epidermal-growth-factor-receptor-inhibitor
1588,Drug_Hypersensitivity,2,61,Immune_system_disorders,NCT00705016,https://clinicaltrials.gov/show/NCT00705016,Squamous_Cell_Cancer,Cilengitide_2000_mg_once_weekly|Cilengitide_2000_mg_twice_weekly|Cetuximab|5-fluorouracil_(5-FU)|Cisplatin|,serious_events,arm0,Cilengitide-2000-mg-Once-Weekly+Cetuximab+5-FU+Cisplatin,41,cilengitide,"first-anti-angiogenic-small-molecule-targeting-the-integrins-??v??3--??v??5-and-??5??1""Moruno-et-al--Cilengitide:--The-First-Anti-Angiogenic-Small-Molecule-Drug-Candidate.-Design--Synthesis-and-Clinical-Evaluations.--Anticancer-Agents-Med-Chem.-2010-Dec;;"
1589,Drug_Hypersensitivity,3,61,Immune_system_disorders,NCT00705016,https://clinicaltrials.gov/show/NCT00705016,Squamous_Cell_Cancer,Cilengitide_2000_mg_once_weekly|Cilengitide_2000_mg_twice_weekly|Cetuximab|5-fluorouracil_(5-FU)|Cisplatin|,other_events,arm0,Cilengitide-2000-mg-Once-Weekly+Cetuximab+5-FU+Cisplatin,41,cilengitide,"first-anti-angiogenic-small-molecule-targeting-the-integrins-??v??3--??v??5-and-??5??1""Moruno-et-al--Cilengitide:--The-First-Anti-Angiogenic-Small-Molecule-Drug-Candidate.-Design--Synthesis-and-Clinical-Evaluations.--Anticancer-Agents-Med-Chem.-2010-Dec;;"
1587,Drug_Hypersensitivity,2,59,Immune_system_disorders,NCT00705016,https://clinicaltrials.gov/show/NCT00705016,Squamous_Cell_Cancer,Cilengitide_2000_mg_once_weekly|Cilengitide_2000_mg_twice_weekly|Cetuximab|5-fluorouracil_(5-FU)|Cisplatin|,serious_events,arm1,Cilengitide-2000-mg-Twice-Weekly+Cetuximab+5-FU+Cisplatin,9,cisplatin,alkalating-agent
1590,Drug_Hypersensitivity,2,59,Immune_system_disorders,NCT00705016,https://clinicaltrials.gov/show/NCT00705016,Squamous_Cell_Cancer,Cilengitide_2000_mg_once_weekly|Cilengitide_2000_mg_twice_weekly|Cetuximab|5-fluorouracil_(5-FU)|Cisplatin|,other_events,arm1,Cilengitide-2000-mg-Twice-Weekly+Cetuximab+5-FU+Cisplatin,9,cisplatin,alkalating-agent
1587,Drug_Hypersensitivity,2,59,Immune_system_disorders,NCT00705016,https://clinicaltrials.gov/show/NCT00705016,Squamous_Cell_Cancer,Cilengitide_2000_mg_once_weekly|Cilengitide_2000_mg_twice_weekly|Cetuximab|5-fluorouracil_(5-FU)|Cisplatin|,serious_events,arm1,Cilengitide-2000-mg-Twice-Weekly+Cetuximab+5-FU+Cisplatin,5,cetuximab,Epidermal-growth-factor-receptor-inhibitor
1590,Drug_Hypersensitivity,2,59,Immune_system_disorders,NCT00705016,https://clinicaltrials.gov/show/NCT00705016,Squamous_Cell_Cancer,Cilengitide_2000_mg_once_weekly|Cilengitide_2000_mg_twice_weekly|Cetuximab|5-fluorouracil_(5-FU)|Cisplatin|,other_events,arm1,Cilengitide-2000-mg-Twice-Weekly+Cetuximab+5-FU+Cisplatin,5,cetuximab,Epidermal-growth-factor-receptor-inhibitor
1587,Drug_Hypersensitivity,2,59,Immune_system_disorders,NCT00705016,https://clinicaltrials.gov/show/NCT00705016,Squamous_Cell_Cancer,Cilengitide_2000_mg_once_weekly|Cilengitide_2000_mg_twice_weekly|Cetuximab|5-fluorouracil_(5-FU)|Cisplatin|,serious_events,arm1,Cilengitide-2000-mg-Twice-Weekly+Cetuximab+5-FU+Cisplatin,41,cilengitide,"first-anti-angiogenic-small-molecule-targeting-the-integrins-??v??3--??v??5-and-??5??1""Moruno-et-al--Cilengitide:--The-First-Anti-Angiogenic-Small-Molecule-Drug-Candidate.-Design--Synthesis-and-Clinical-Evaluations.--Anticancer-Agents-Med-Chem.-2010-Dec;;"
1590,Drug_Hypersensitivity,2,59,Immune_system_disorders,NCT00705016,https://clinicaltrials.gov/show/NCT00705016,Squamous_Cell_Cancer,Cilengitide_2000_mg_once_weekly|Cilengitide_2000_mg_twice_weekly|Cetuximab|5-fluorouracil_(5-FU)|Cisplatin|,other_events,arm1,Cilengitide-2000-mg-Twice-Weekly+Cetuximab+5-FU+Cisplatin,41,cilengitide,"first-anti-angiogenic-small-molecule-targeting-the-integrins-??v??3--??v??5-and-??5??1""Moruno-et-al--Cilengitide:--The-First-Anti-Angiogenic-Small-Molecule-Drug-Candidate.-Design--Synthesis-and-Clinical-Evaluations.--Anticancer-Agents-Med-Chem.-2010-Dec;;"
1586,Drug_Hypersensitivity,5,62,Immune_system_disorders,NCT00705016,https://clinicaltrials.gov/show/NCT00705016,Squamous_Cell_Cancer,Cilengitide_2000_mg_once_weekly|Cilengitide_2000_mg_twice_weekly|Cetuximab|5-fluorouracil_(5-FU)|Cisplatin|,other_events,arm2,Cetuximab+5-FU+Cisplatin,9,cisplatin,alkalating-agent
1586,Drug_Hypersensitivity,5,62,Immune_system_disorders,NCT00705016,https://clinicaltrials.gov/show/NCT00705016,Squamous_Cell_Cancer,Cilengitide_2000_mg_once_weekly|Cilengitide_2000_mg_twice_weekly|Cetuximab|5-fluorouracil_(5-FU)|Cisplatin|,other_events,arm2,Cetuximab+5-FU+Cisplatin,5,cetuximab,Epidermal-growth-factor-receptor-inhibitor
720,Hypersensitivity,1,21,Immune_system_disorders,NCT00711828,https://clinicaltrials.gov/show/NCT00711828,Extranodal_Marginal_Zone_Lymphoma_of_Mucosa-Associated_Lymphoid_Tissue|Nodal_Marginal_Zone_Lymphoma|Recurrent_Grade_1_Follicular_Lymphoma|Recurrent_Grade_2_Follicular_Lymphoma|Recurrent_Mantle_Cell_Lymphoma|Recurrent_Small_Lymphocytic_Lymphoma|Refractory_,Bortezomib|Rituximab|Cyclophosphamide|Dexamethasone|Questionnaire_Administration|Quality-of-Life_Assessment|,other_events,arm0,Treatment,,,
723,Hypersensitivity,1,6,Immune_system_disorders,NCT00715403,https://clinicaltrials.gov/show/NCT00715403,Neoplasms,BIBF_1120,other_events,arm4,200mg-BID,,,
1593,Drug_hypersensitivity,1,11,Immune_system_disorders,NCT00716417,https://clinicaltrials.gov/show/NCT00716417,Neoplasms,BIBW_2992|BIBW_2992|,other_events,arm3,Pac175-+-Cis75-+-Afatinib40,,,
2107,Dermatitis_allergic,1,7,Skin_and_subcutaneous_tissue_disorders,NCT00717522,https://clinicaltrials.gov/show/NCT00717522,Soft_Tissue_Sarcoma,Pomalidomide,other_events,arm0,Pomalidomide,,,
726,Hypersensitivity,1,7,Immune_system_disorders,NCT00717522,https://clinicaltrials.gov/show/NCT00717522,Soft_Tissue_Sarcoma,Pomalidomide,other_events,arm0,Pomalidomide,,,
727,Hypersensitivity,1,168,Immune_system_disorders,NCT00719563,https://clinicaltrials.gov/show/NCT00719563,Chronic_Myeloproliferative_Disorders|Fatigue|Leukemia|Lymphoma|Lymphoproliferative_Disorder|Multiple_Myeloma_and_Plasma_Cell_Neoplasm|Myelodysplastic_Syndromes|Myelodysplastic/Myeloproliferative_Neoplasms|Precancerous_Condition|Unspecified_Adult_Solid_Tum,American_ginseng|placebo|,other_events,arm0,Ginseng,,,
728,Hypersensitivity,1,10,Immune_system_disorders,NCT00719901,https://clinicaltrials.gov/show/NCT00719901,Refractory_Multiple_Myeloma|Stage_I_Multiple_Myeloma|Stage_II_Multiple_Myeloma|Stage_III_Multiple_Myeloma|,obatoclax_mesylate|bortezomib|laboratory_biomarker_analysis|,other_events,arm0,Treatment-(Enzyme-Inhibitor-Therapy),,,
2675,Allergic_reaction,1,16,Immune_system_disorders,NCT00720083,https://clinicaltrials.gov/show/NCT00720083,Head_and_Neck_Cancer,cisplatin|vandetanib|radiation_therapy|,serious_events,arm0,RT+-Cisplatin,9,cisplatin,alkalating-agent
2353,Anaphylaxis,1,149,Immune_system_disorders,NCT00723073,https://clinicaltrials.gov/show/NCT00723073,Febrile_Neutropenia,Null,serious_events,arm0,Caspofungin-Arm,,,
731,Hypersensitivity,1,16,Immune_system_disorders,NCT00723203,https://clinicaltrials.gov/show/NCT00723203,Leukemia,panobinostat|gene_expression_analysis|reverse_transcriptase-polymerase_chain_reaction|laboratory_biomarker_analysis|,other_events,arm0,Treatment-(Panobinostat),,,
733,HYPERSENSITIVITY,2,95,Immune_system_disorders,NCT00723957,https://clinicaltrials.gov/show/NCT00723957,Advanced/Metastatic_Non-Small_Cell_Lung_Cancer,Ixabepilone_32_mg/m^2|Paclitaxel_200_mg/m^2|Carboplatin_(area_under_the_concentration_curve_[AUC]_6)|,other_events,arm0,Ixabepilone-32-mg/m^2-+-Carboplatin-(AUC),3,carboplatin,alkalating-agent
733,HYPERSENSITIVITY,2,95,Immune_system_disorders,NCT00723957,https://clinicaltrials.gov/show/NCT00723957,Advanced/Metastatic_Non-Small_Cell_Lung_Cancer,Ixabepilone_32_mg/m^2|Paclitaxel_200_mg/m^2|Carboplatin_(area_under_the_concentration_curve_[AUC]_6)|,other_events,arm0,Ixabepilone-32-mg/m^2-+-Carboplatin-(AUC),82,ixabepilone,antimicrotubule-agent
732,HYPERSENSITIVITY,6,96,Immune_system_disorders,NCT00723957,https://clinicaltrials.gov/show/NCT00723957,Advanced/Metastatic_Non-Small_Cell_Lung_Cancer,Ixabepilone_32_mg/m^2|Paclitaxel_200_mg/m^2|Carboplatin_(area_under_the_concentration_curve_[AUC]_6)|,other_events,arm1,Paclitaxel-200-mg/m^2-+-Carboplatin-(AUC-6),3,carboplatin,alkalating-agent
732,HYPERSENSITIVITY,6,96,Immune_system_disorders,NCT00723957,https://clinicaltrials.gov/show/NCT00723957,Advanced/Metastatic_Non-Small_Cell_Lung_Cancer,Ixabepilone_32_mg/m^2|Paclitaxel_200_mg/m^2|Carboplatin_(area_under_the_concentration_curve_[AUC]_6)|,other_events,arm1,Paclitaxel-200-mg/m^2-+-Carboplatin-(AUC-6),2,paclitaxel,taxane
739,Hypersensitivity,1,97,Immune_system_disorders,NCT00738374,https://clinicaltrials.gov/show/NCT00738374,Lymphocytic_Leukemia_Chronic,rituximab_[MabThera/Rituxan]|chlorambucil|,other_events,arm0,CLB-+-R:-Induction-Treatment,,,
738,Hypersensitivity,1,34,Immune_system_disorders,NCT00738374,https://clinicaltrials.gov/show/NCT00738374,Lymphocytic_Leukemia_Chronic,rituximab_[MabThera/Rituxan]|chlorambucil|,other_events,arm1,CLB-+-R:-Maintenance-Treatment,88,maintenance,Class_Name_Needed
740,Hypersensitivity,1,40,Immune_system_disorders,NCT00739934,https://clinicaltrials.gov/show/NCT00739934,Candidiasis|Candidemia|,voriconazole_(Vfend),other_events,arm0,Voriconazole-IV,,,
2108,Dermatitis_allergic,1,3,Skin_and_subcutaneous_tissue_disorders,NCT00741338,https://clinicaltrials.gov/show/NCT00741338,Mucopolysaccharidosis_I,Laronidase|Cyclosporine_A_(CsA)|Azathioprine_(Aza)|,other_events,arm0,Cohort-1,,,
1600,Drug_hypersensitivity,1,3,Immune_system_disorders,NCT00741338,https://clinicaltrials.gov/show/NCT00741338,Mucopolysaccharidosis_I,Laronidase|Cyclosporine_A_(CsA)|Azathioprine_(Aza)|,other_events,arm0,Cohort-1,,,
2676,Allergic_Reaction,1,40,Immune_system_disorders,NCT00741988,https://clinicaltrials.gov/show/NCT00741988,Non-Small_Cell_Lung_Cancer,Ixabepilone|Carboplatin|Bevacizumab|,serious_events,arm1,Ixabepilone/Carboplatin/Bevacizumab,3,carboplatin,alkalating-agent
2676,Allergic_Reaction,1,40,Immune_system_disorders,NCT00741988,https://clinicaltrials.gov/show/NCT00741988,Non-Small_Cell_Lung_Cancer,Ixabepilone|Carboplatin|Bevacizumab|,serious_events,arm1,Ixabepilone/Carboplatin/Bevacizumab,82,ixabepilone,antimicrotubule-agent
2676,Allergic_Reaction,1,40,Immune_system_disorders,NCT00741988,https://clinicaltrials.gov/show/NCT00741988,Non-Small_Cell_Lung_Cancer,Ixabepilone|Carboplatin|Bevacizumab|,serious_events,arm1,Ixabepilone/Carboplatin/Bevacizumab,4,bevacizumab,monoclonal-antibody
2676,Allergic_Reaction,1,40,Immune_system_disorders,NCT00741988,https://clinicaltrials.gov/show/NCT00741988,Non-Small_Cell_Lung_Cancer,Ixabepilone|Carboplatin|Bevacizumab|,serious_events,arm1,Ixabepilone/Carboplatin/Bevacizumab,22,bevacizumab,monoclonal-antibody
1601,Drug_hypersensitivity,2,761,Immune_system_disorders,NCT00744497,https://clinicaltrials.gov/show/NCT00744497,Prostatic_Neoplasms,Placebo|Dasatinib|Docetaxel|Prednisone|,serious_events,arm0,Dasatinib,24,dasatinib,signal-transduction-inhibitor---tyrosine-kinase-inhibitor
741,Hypersensitivity,2,37,Immune_system_disorders,NCT00744757,https://clinicaltrials.gov/show/NCT00744757,Myelodysplastic_Syndrome,Decitabine,other_events,arm0,Decitabine,,,
2112,Dermatitis_allergic,1,217,Skin_and_subcutaneous_tissue_disorders,NCT00748189,https://clinicaltrials.gov/show/NCT00748189,Leukaemia_Lymphocytic_Chronic,chlorambucil_tablets|ofatumumab_(GSK1841157)_infusion|,serious_events,arm1,Ofatumumab-+-Chlorambucil,42,ofatumumab,monoclonal-antibody
1602,Drug_hypersensitivity,1,217,Immune_system_disorders,NCT00748189,https://clinicaltrials.gov/show/NCT00748189,Leukaemia_Lymphocytic_Chronic,chlorambucil_tablets|ofatumumab_(GSK1841157)_infusion|,serious_events,arm1,Ofatumumab-+-Chlorambucil,42,ofatumumab,monoclonal-antibody
2114,Dermatitis_allergic,1,59,Skin_and_subcutaneous_tissue_disorders,NCT00753675,https://clinicaltrials.gov/show/NCT00753675,Biliary_Tract_Cancer|Gallbladder_Cancer|Cancer_Of_The_Extrahepatic_Bile_Duct|Ampullary_Carcinoma|,ZD6474_Vandetanib|ZD6474_Vandetanib|Gemcitabine|Placebo_matching_ZD6474|,other_events,arm0,Arm-A-Vandetanib-300-mg,33,vandetanib,tyrosine-kinase-inhibitor
2115,Dermatitis_allergic,1,58,Skin_and_subcutaneous_tissue_disorders,NCT00753675,https://clinicaltrials.gov/show/NCT00753675,Biliary_Tract_Cancer|Gallbladder_Cancer|Cancer_Of_The_Extrahepatic_Bile_Duct|Ampullary_Carcinoma|,ZD6474_Vandetanib|ZD6474_Vandetanib|Gemcitabine|Placebo_matching_ZD6474|,other_events,arm1,Arm-B-Vandetanib-100mg-+-Gemcitab,33,vandetanib,tyrosine-kinase-inhibitor
746,Hypersensitivity,1,240,Immune_system_disorders,NCT00753688,https://clinicaltrials.gov/show/NCT00753688,Sarcoma_Soft_Tissue,PAZOPANIB|Placebo|,serious_events,arm1,Pazopanib,,,
749,Hypersensitivity,13,70,Immune_system_disorders,NCT00757172,https://clinicaltrials.gov/show/NCT00757172,Adenocarcinoma_of_the_Gastroesophageal_Junction|Esophageal_Cancer|,panitumumab|cisplatin|docetaxel|neoadjuvant_therapy|therapeutic_conventional_surgery|radiation_therapy|,other_events,arm0,Docetaxel-+-Cisplatin-+-Panitumumab-+-RT,9,cisplatin,alkalating-agent
749,Hypersensitivity,13,70,Immune_system_disorders,NCT00757172,https://clinicaltrials.gov/show/NCT00757172,Adenocarcinoma_of_the_Gastroesophageal_Junction|Esophageal_Cancer|,panitumumab|cisplatin|docetaxel|neoadjuvant_therapy|therapeutic_conventional_surgery|radiation_therapy|,other_events,arm0,Docetaxel-+-Cisplatin-+-Panitumumab-+-RT,30,panitumumab,monoclonal-antibody-and-signal-transduction-inhibitor
749,Hypersensitivity,13,70,Immune_system_disorders,NCT00757172,https://clinicaltrials.gov/show/NCT00757172,Adenocarcinoma_of_the_Gastroesophageal_Junction|Esophageal_Cancer|,panitumumab|cisplatin|docetaxel|neoadjuvant_therapy|therapeutic_conventional_surgery|radiation_therapy|,other_events,arm0,Docetaxel-+-Cisplatin-+-Panitumumab-+-RT,8,docetaxel,taxane
752,Hypersensitivity,1,292,Immune_system_disorders,NCT00762034,https://clinicaltrials.gov/show/NCT00762034,Non-small_Cell_Lung_Cancer,Pemetrexed|Pemetrexed|Paclitaxel|Carboplatin|Bevacizumab|Bevacizumab|,serious_events,arm1,Pem/Carbo/Bev;-Maintenance-Phase,88,maintenance,Class_Name_Needed
1604,Drug_hypersensitivity,1,443,Immune_system_disorders,NCT00762034,https://clinicaltrials.gov/show/NCT00762034,Non-small_Cell_Lung_Cancer,Pemetrexed|Pemetrexed|Paclitaxel|Carboplatin|Bevacizumab|Bevacizumab|,serious_events,arm2,Pac/Carbo/Bev;-Induction-Phase,,,
753,Hypersensitivity,1,32,Immune_system_disorders,NCT00765102,https://clinicaltrials.gov/show/NCT00765102,Multiple_Myeloma,Bortezomib|Romidepsin|,serious_events,arm0,Romidepsin-+-Bortezomib,70,bortezomib,proteasome-inhibitor
2681,Allergic_reaction,1,36,Immune_system_disorders,NCT00768144,https://clinicaltrials.gov/show/NCT00768144,Ovarian_Cancer|Fallopian_Tube_Cancer|Peritoneal_Cancer|,Sunitinib,serious_events,arm0,Sunitinib,27,sunitinib,tyrosine-kinase-inhibitor-and-angiogenesis-inhibitor
759,Hypersensitivity,11,115,Immune_system_disorders,NCT00770809,https://clinicaltrials.gov/show/NCT00770809,HER2/Neu_Positive|Male_Breast_Carcinoma|Stage_IIA_Breast_Cancer|Stage_IIB_Breast_Cancer|Stage_IIIA_Breast_Cancer|Stage_IIIB_Breast_Cancer|Stage_IIIC_Breast_Cancer|,Lapatinib_Ditosylate|Trastuzumab|Paclitaxel|Laboratory_Biomarker_Analysis|,other_events,arm0,Arm-I-(THL),,,
760,Hypersensitivity,1,115,Immune_system_disorders,NCT00770809,https://clinicaltrials.gov/show/NCT00770809,HER2/Neu_Positive|Male_Breast_Carcinoma|Stage_IIA_Breast_Cancer|Stage_IIB_Breast_Cancer|Stage_IIIA_Breast_Cancer|Stage_IIIB_Breast_Cancer|Stage_IIIC_Breast_Cancer|,Lapatinib_Ditosylate|Trastuzumab|Paclitaxel|Laboratory_Biomarker_Analysis|,serious_events,arm0,Arm-I-(THL),,,
761,Hypersensitivity,14,115,Immune_system_disorders,NCT00770809,https://clinicaltrials.gov/show/NCT00770809,HER2/Neu_Positive|Male_Breast_Carcinoma|Stage_IIA_Breast_Cancer|Stage_IIB_Breast_Cancer|Stage_IIIA_Breast_Cancer|Stage_IIIB_Breast_Cancer|Stage_IIIC_Breast_Cancer|,Lapatinib_Ditosylate|Trastuzumab|Paclitaxel|Laboratory_Biomarker_Analysis|,other_events,arm1,Arm-II-(TH),,,
762,Hypersensitivity,1,115,Immune_system_disorders,NCT00770809,https://clinicaltrials.gov/show/NCT00770809,HER2/Neu_Positive|Male_Breast_Carcinoma|Stage_IIA_Breast_Cancer|Stage_IIB_Breast_Cancer|Stage_IIIA_Breast_Cancer|Stage_IIIB_Breast_Cancer|Stage_IIIC_Breast_Cancer|,Lapatinib_Ditosylate|Trastuzumab|Paclitaxel|Laboratory_Biomarker_Analysis|,serious_events,arm1,Arm-II-(TH),,,
758,Hypersensitivity,8,65,Immune_system_disorders,NCT00770809,https://clinicaltrials.gov/show/NCT00770809,HER2/Neu_Positive|Male_Breast_Carcinoma|Stage_IIA_Breast_Cancer|Stage_IIB_Breast_Cancer|Stage_IIIA_Breast_Cancer|Stage_IIIB_Breast_Cancer|Stage_IIIC_Breast_Cancer|,Lapatinib_Ditosylate|Trastuzumab|Paclitaxel|Laboratory_Biomarker_Analysis|,other_events,arm2,Arm-III-(TL),,,
768,Hypersensitivity,1,123,Immune_system_disorders,NCT00777153,https://clinicaltrials.gov/show/NCT00777153,Recurrent_Glioblastoma,Cediranib|Cediranib|Lomustine_Chemotherapy|Placebo_Cediranib|,serious_events,arm1,Cediranib-20mg-+-Lomustine-110mg,14,cediranib,endothelial-growith-factor-receptor-tyrosine-kinase-inhibitor?
767,Hypersensitivity,5,42,Immune_system_disorders,NCT00777179,https://clinicaltrials.gov/show/NCT00777179,NSCLC,Vandetanib|Placebo|,other_events,arm1,Placebo,,,
1608,Drug_hypersensitivity,1,37,Immune_system_disorders,NCT00778102,https://clinicaltrials.gov/show/NCT00778102,Colorectal_Cancer,5-FU|5-FU|5-FU|Irinotecan|Leucovorin|Leucovorin|Oxaliplatin|bevacizumab_[Avastin]|,serious_events,arm0,Bevacizumab-+-mFOLFOX-6,4,bevacizumab,monoclonal-antibody
769,Hypersensitivity,3,37,Immune_system_disorders,NCT00778102,https://clinicaltrials.gov/show/NCT00778102,Colorectal_Cancer,5-FU|5-FU|5-FU|Irinotecan|Leucovorin|Leucovorin|Oxaliplatin|bevacizumab_[Avastin]|,other_events,arm0,Bevacizumab-+-mFOLFOX-6,4,bevacizumab,monoclonal-antibody
1608,Drug_hypersensitivity,1,37,Immune_system_disorders,NCT00778102,https://clinicaltrials.gov/show/NCT00778102,Colorectal_Cancer,5-FU|5-FU|5-FU|Irinotecan|Leucovorin|Leucovorin|Oxaliplatin|bevacizumab_[Avastin]|,serious_events,arm0,Bevacizumab-+-mFOLFOX-6,22,bevacizumab,monoclonal-antibody
769,Hypersensitivity,3,37,Immune_system_disorders,NCT00778102,https://clinicaltrials.gov/show/NCT00778102,Colorectal_Cancer,5-FU|5-FU|5-FU|Irinotecan|Leucovorin|Leucovorin|Oxaliplatin|bevacizumab_[Avastin]|,other_events,arm0,Bevacizumab-+-mFOLFOX-6,22,bevacizumab,monoclonal-antibody
770,Hypersensitivity,3,40,Immune_system_disorders,NCT00778102,https://clinicaltrials.gov/show/NCT00778102,Colorectal_Cancer,5-FU|5-FU|5-FU|Irinotecan|Leucovorin|Leucovorin|Oxaliplatin|bevacizumab_[Avastin]|,other_events,arm1,Bevacizumab-+-FOLFOXIRI,4,bevacizumab,monoclonal-antibody
770,Hypersensitivity,3,40,Immune_system_disorders,NCT00778102,https://clinicaltrials.gov/show/NCT00778102,Colorectal_Cancer,5-FU|5-FU|5-FU|Irinotecan|Leucovorin|Leucovorin|Oxaliplatin|bevacizumab_[Avastin]|,other_events,arm1,Bevacizumab-+-FOLFOXIRI,22,bevacizumab,monoclonal-antibody
1609,Drug_hypersensitivity,1,101,Immune_system_disorders,NCT00778830,https://clinicaltrials.gov/show/NCT00778830,Metastatic_Colorectal_Cancer,Cetuximab|FOLFIRI|FOLFOX|,other_events,arm0,Cetuximab-Plus-FOLFIRI,45,folfiri,combination-drug-with-Irinotecan--Flourouracil--and-Leucovorin
1609,Drug_hypersensitivity,1,101,Immune_system_disorders,NCT00778830,https://clinicaltrials.gov/show/NCT00778830,Metastatic_Colorectal_Cancer,Cetuximab|FOLFIRI|FOLFOX|,other_events,arm0,Cetuximab-Plus-FOLFIRI,5,cetuximab,Epidermal-growth-factor-receptor-inhibitor
1610,Drug_hypersensitivity,17,188,Immune_system_disorders,NCT00778830,https://clinicaltrials.gov/show/NCT00778830,Metastatic_Colorectal_Cancer,Cetuximab|FOLFIRI|FOLFOX|,other_events,arm1,Cetuximab-Plus-FOLFOX,5,cetuximab,Epidermal-growth-factor-receptor-inhibitor
1611,Drug_hypersensitivity,3,188,Immune_system_disorders,NCT00778830,https://clinicaltrials.gov/show/NCT00778830,Metastatic_Colorectal_Cancer,Cetuximab|FOLFIRI|FOLFOX|,serious_events,arm1,Cetuximab-Plus-FOLFOX,5,cetuximab,Epidermal-growth-factor-receptor-inhibitor
775,Hypersensitivity,23,272,Immune_system_disorders,NCT00785291,https://clinicaltrials.gov/show/NCT00785291,Estrogen_Receptor_Negative|Estrogen_Receptor_Positive|HER2/Neu_Negative|HER2/Neu_Positive|Male_Breast_Carcinoma|Progesterone_Receptor_Negative|Progesterone_Receptor_Positive|Recurrent_Breast_Carcinoma|Stage_IIIC_Breast_Cancer_AJCC_v6|Stage_IV_Breast_Cance,Paclitaxel|Paclitaxel_Albumin-Stabilized_Nanoparticle_Formulation|Ixabepilone|Bevacizumab|Questionnaire_Administration|Laboratory_Biomarker_Analysis|,other_events,arm0,Arm-A-(Paclitaxel),2,paclitaxel,taxane
776,Hypersensitivity,3,272,Immune_system_disorders,NCT00785291,https://clinicaltrials.gov/show/NCT00785291,Estrogen_Receptor_Negative|Estrogen_Receptor_Positive|HER2/Neu_Negative|HER2/Neu_Positive|Male_Breast_Carcinoma|Progesterone_Receptor_Negative|Progesterone_Receptor_Positive|Recurrent_Breast_Carcinoma|Stage_IIIC_Breast_Cancer_AJCC_v6|Stage_IV_Breast_Cance,Paclitaxel|Paclitaxel_Albumin-Stabilized_Nanoparticle_Formulation|Ixabepilone|Bevacizumab|Questionnaire_Administration|Laboratory_Biomarker_Analysis|,serious_events,arm0,Arm-A-(Paclitaxel),2,paclitaxel,taxane
777,Hypersensitivity,2,264,Immune_system_disorders,NCT00785291,https://clinicaltrials.gov/show/NCT00785291,Estrogen_Receptor_Negative|Estrogen_Receptor_Positive|HER2/Neu_Negative|HER2/Neu_Positive|Male_Breast_Carcinoma|Progesterone_Receptor_Negative|Progesterone_Receptor_Positive|Recurrent_Breast_Carcinoma|Stage_IIIC_Breast_Cancer_AJCC_v6|Stage_IV_Breast_Cance,Paclitaxel|Paclitaxel_Albumin-Stabilized_Nanoparticle_Formulation|Ixabepilone|Bevacizumab|Questionnaire_Administration|Laboratory_Biomarker_Analysis|,serious_events,arm1,Arm-B-(Nab-paclitaxel),2,paclitaxel,taxane
780,Hypersensitivity,28,264,Immune_system_disorders,NCT00785291,https://clinicaltrials.gov/show/NCT00785291,Estrogen_Receptor_Negative|Estrogen_Receptor_Positive|HER2/Neu_Negative|HER2/Neu_Positive|Male_Breast_Carcinoma|Progesterone_Receptor_Negative|Progesterone_Receptor_Positive|Recurrent_Breast_Carcinoma|Stage_IIIC_Breast_Cancer_AJCC_v6|Stage_IV_Breast_Cance,Paclitaxel|Paclitaxel_Albumin-Stabilized_Nanoparticle_Formulation|Ixabepilone|Bevacizumab|Questionnaire_Administration|Laboratory_Biomarker_Analysis|,other_events,arm1,Arm-B-(Nab-paclitaxel),2,paclitaxel,taxane
778,Hypersensitivity,2,238,Immune_system_disorders,NCT00785291,https://clinicaltrials.gov/show/NCT00785291,Estrogen_Receptor_Negative|Estrogen_Receptor_Positive|HER2/Neu_Negative|HER2/Neu_Positive|Male_Breast_Carcinoma|Progesterone_Receptor_Negative|Progesterone_Receptor_Positive|Recurrent_Breast_Carcinoma|Stage_IIIC_Breast_Cancer_AJCC_v6|Stage_IV_Breast_Cance,Paclitaxel|Paclitaxel_Albumin-Stabilized_Nanoparticle_Formulation|Ixabepilone|Bevacizumab|Questionnaire_Administration|Laboratory_Biomarker_Analysis|,serious_events,arm2,Arm-C-(Ixabepilone),82,ixabepilone,antimicrotubule-agent
779,Hypersensitivity,17,238,Immune_system_disorders,NCT00785291,https://clinicaltrials.gov/show/NCT00785291,Estrogen_Receptor_Negative|Estrogen_Receptor_Positive|HER2/Neu_Negative|HER2/Neu_Positive|Male_Breast_Carcinoma|Progesterone_Receptor_Negative|Progesterone_Receptor_Positive|Recurrent_Breast_Carcinoma|Stage_IIIC_Breast_Cancer_AJCC_v6|Stage_IV_Breast_Cance,Paclitaxel|Paclitaxel_Albumin-Stabilized_Nanoparticle_Formulation|Ixabepilone|Bevacizumab|Questionnaire_Administration|Laboratory_Biomarker_Analysis|,other_events,arm2,Arm-C-(Ixabepilone),82,ixabepilone,antimicrotubule-agent
781,Hypersensitivity,1,20,Immune_system_disorders,NCT00786643,https://clinicaltrials.gov/show/NCT00786643,Colorectal_Cancer,5-Fluorouracil|Leucovorin_(LV)|Gamma-Interferon-1b_(IFN-?_)|Bevacizumab|,other_events,arm0,Stratum-1,,,
1623,Drug_hypersensitivity,1,11,Immune_system_disorders,NCT00788957,https://clinicaltrials.gov/show/NCT00788957,Colon_Cancer|Colorectal_Cancer|Gastrointestinal_Cancer|Metastatic_Colorectal_Cancer|Rectal_Cancer|,Panitumumab|Ganitumab|Rilotumumab|Placebo|,other_events,arm0,Part-1:-Panitumumab-+-Rilotumumab,30,panitumumab,monoclonal-antibody-and-signal-transduction-inhibitor
783,Hypersensitivity,1,37,Immune_system_disorders,NCT00789685,https://clinicaltrials.gov/show/NCT00789685,Acute_Lung_Injury|Acute_Respiratory_Distress_Syndrome|,Interferon_Beta,serious_events,arm0,Safety-Population,,,
784,Hypersensitivity,1,78,Immune_system_disorders,NCT00789828,https://clinicaltrials.gov/show/NCT00789828,Tuberous_Sclerosis|Subependymal_Giant_Cell_Astrocytoma|,Everolimus|Placebo|,serious_events,arm0,Everolimus,32,everolimus,mTOR?inhibitor-(blocks-gene-translation)
785,Hypersensitivity,1,6,Immune_system_disorders,NCT00790218,https://clinicaltrials.gov/show/NCT00790218,Hepatocellular_Carcinoma,CF102,other_events,arm0,CF102-1mg,,,
786,Hypersensitivity,1,79,Immune_system_disorders,NCT00790400,https://clinicaltrials.gov/show/NCT00790400,Tuberous_Sclerosis_Complex_(TSC)|Lymphangioleiomyomatosis_(LAM)|,Everolimus_(RAD001)|Placebo|,serious_events,arm0,Everolimus,32,everolimus,mTOR?inhibitor-(blocks-gene-translation)
787,Hypersensitivity,1,44,Immune_system_disorders,NCT00791492,https://clinicaltrials.gov/show/NCT00791492,Familial_Amyloid_Polyneuropathy|ATTR-PN|,Fx-1006A,serious_events,arm0,Tafamidis-Tafamidis,,,
2684,Allergic_reaction,1,123,Immune_system_disorders,NCT00791778,https://clinicaltrials.gov/show/NCT00791778,Ovarian_Neoplasms,Sorafenib_(Nexavar_BAY43-9006)|Placebo|,serious_events,arm0,Sorafenib-(Nexavar-BAY43-9006),97,nexavar,Tyrosine-Kinase-inhibitor
2686,Allergic_reaction,7,123,Immune_system_disorders,NCT00791778,https://clinicaltrials.gov/show/NCT00791778,Ovarian_Neoplasms,Sorafenib_(Nexavar_BAY43-9006)|Placebo|,other_events,arm0,Sorafenib-(Nexavar-BAY43-9006),97,nexavar,Tyrosine-Kinase-inhibitor
2684,Allergic_reaction,1,123,Immune_system_disorders,NCT00791778,https://clinicaltrials.gov/show/NCT00791778,Ovarian_Neoplasms,Sorafenib_(Nexavar_BAY43-9006)|Placebo|,serious_events,arm0,Sorafenib-(Nexavar-BAY43-9006),90,sorafenib,Tyrosine-Kinase-inhibitor
2686,Allergic_reaction,7,123,Immune_system_disorders,NCT00791778,https://clinicaltrials.gov/show/NCT00791778,Ovarian_Neoplasms,Sorafenib_(Nexavar_BAY43-9006)|Placebo|,other_events,arm0,Sorafenib-(Nexavar-BAY43-9006),90,sorafenib,Tyrosine-Kinase-inhibitor
2684,Allergic_reaction,1,123,Immune_system_disorders,NCT00791778,https://clinicaltrials.gov/show/NCT00791778,Ovarian_Neoplasms,Sorafenib_(Nexavar_BAY43-9006)|Placebo|,serious_events,arm0,Sorafenib-(Nexavar-BAY43-9006),72,bay43,Tyrosine-Kinase-inhibitor
2686,Allergic_reaction,7,123,Immune_system_disorders,NCT00791778,https://clinicaltrials.gov/show/NCT00791778,Ovarian_Neoplasms,Sorafenib_(Nexavar_BAY43-9006)|Placebo|,other_events,arm0,Sorafenib-(Nexavar-BAY43-9006),72,bay43,Tyrosine-Kinase-inhibitor
2685,Allergic_reaction,3,123,Immune_system_disorders,NCT00791778,https://clinicaltrials.gov/show/NCT00791778,Ovarian_Neoplasms,Sorafenib_(Nexavar_BAY43-9006)|Placebo|,other_events,arm1,Placebo,,,
1626,Drug_hypersensitivity,1,146,Immune_system_disorders,NCT00796757,https://clinicaltrials.gov/show/NCT00796757,Renal_Cell_Cancer,bevacizumab_[Avastin]|interferon_alfa-2a|,serious_events,arm0,Bevacizumab-+-Interferon,4,bevacizumab,monoclonal-antibody
1626,Drug_hypersensitivity,1,146,Immune_system_disorders,NCT00796757,https://clinicaltrials.gov/show/NCT00796757,Renal_Cell_Cancer,bevacizumab_[Avastin]|interferon_alfa-2a|,serious_events,arm0,Bevacizumab-+-Interferon,22,bevacizumab,monoclonal-antibody
789,Hypersensitivity,6,20,Immune_system_disorders,NCT00796991,https://clinicaltrials.gov/show/NCT00796991,Advanced_Melanoma,Ipilimumab|Carboplatin|Paclitaxel|Dacarbazine|,other_events,arm0,Paclitaxel-Carboplatin-Ipilimumab,3,carboplatin,alkalating-agent
789,Hypersensitivity,6,20,Immune_system_disorders,NCT00796991,https://clinicaltrials.gov/show/NCT00796991,Advanced_Melanoma,Ipilimumab|Carboplatin|Paclitaxel|Dacarbazine|,other_events,arm0,Paclitaxel-Carboplatin-Ipilimumab,64,ipilimumab,monoclonal-antibody
789,Hypersensitivity,6,20,Immune_system_disorders,NCT00796991,https://clinicaltrials.gov/show/NCT00796991,Advanced_Melanoma,Ipilimumab|Carboplatin|Paclitaxel|Dacarbazine|,other_events,arm0,Paclitaxel-Carboplatin-Ipilimumab,2,paclitaxel,taxane
790,Hypersensitivity,1,20,Immune_system_disorders,NCT00796991,https://clinicaltrials.gov/show/NCT00796991,Advanced_Melanoma,Ipilimumab|Carboplatin|Paclitaxel|Dacarbazine|,other_events,arm2,Ipilimumab,64,ipilimumab,monoclonal-antibody
793,Hypersensitivity,2,17,Immune_system_disorders,NCT00802737,https://clinicaltrials.gov/show/NCT00802737,Leukaemia_Lymphocytic_Chronic,Ofatumumab,other_events,arm0,2000-mg-Ofatumumab-+-DR,42,ofatumumab,monoclonal-antibody
1628,Drug_hypersensitivity,1,42,Immune_system_disorders,NCT00805142,https://clinicaltrials.gov/show/NCT00805142,Pain|Cancer|,Tapentadol_PR,serious_events,arm1,Opioid-Switch-Participants-(Tapentadol-PR),,,
1629,Drug_hypersensitivity,2,652,Immune_system_disorders,NCT00805194,https://clinicaltrials.gov/show/NCT00805194,Carcinoma_Non-Small-Cell_Lung,placebo_plus_docetaxel|BIBF_1120_plus_docetaxel|,serious_events,arm0,Nintedanib-Plus-Docetaxel,8,docetaxel,taxane
1630,Drug_hypersensitivity,2,655,Immune_system_disorders,NCT00805194,https://clinicaltrials.gov/show/NCT00805194,Carcinoma_Non-Small-Cell_Lung,placebo_plus_docetaxel|BIBF_1120_plus_docetaxel|,serious_events,arm1,Placebo-Plus-Docetaxel,8,docetaxel,taxane
794,Hypersensitivity,3,655,Immune_system_disorders,NCT00805194,https://clinicaltrials.gov/show/NCT00805194,Carcinoma_Non-Small-Cell_Lung,placebo_plus_docetaxel|BIBF_1120_plus_docetaxel|,serious_events,arm1,Placebo-Plus-Docetaxel,8,docetaxel,taxane
799,Hypersensitivity,1,33,Immune_system_disorders,NCT00816595,https://clinicaltrials.gov/show/NCT00816595,Leukemia|Lymphoma|,bevacizumab|pegfilgrastim|rituximab|cyclophosphamide|pentostatin|,other_events,arm0,Arm-A:-Pentostatin-Cyclophosphamide-Rituximab-and-Avastin,13,cyclophosphamide,alkylating-agent
799,Hypersensitivity,1,33,Immune_system_disorders,NCT00816595,https://clinicaltrials.gov/show/NCT00816595,Leukemia|Lymphoma|,bevacizumab|pegfilgrastim|rituximab|cyclophosphamide|pentostatin|,other_events,arm0,Arm-A:-Pentostatin-Cyclophosphamide-Rituximab-and-Avastin,16,rituximab,monoclonal-antibody
798,Hypersensitivity,1,33,Immune_system_disorders,NCT00816595,https://clinicaltrials.gov/show/NCT00816595,Leukemia|Lymphoma|,bevacizumab|pegfilgrastim|rituximab|cyclophosphamide|pentostatin|,other_events,arm1,Arm-B:-Pentostatin-Cyclophosphamide-and-Rituximab,13,cyclophosphamide,alkylating-agent
798,Hypersensitivity,1,33,Immune_system_disorders,NCT00816595,https://clinicaltrials.gov/show/NCT00816595,Leukemia|Lymphoma|,bevacizumab|pegfilgrastim|rituximab|cyclophosphamide|pentostatin|,other_events,arm1,Arm-B:-Pentostatin-Cyclophosphamide-and-Rituximab,16,rituximab,monoclonal-antibody
801,Hypersensitivity,1,46,Immune_system_disorders,NCT00819247,https://clinicaltrials.gov/show/NCT00819247,Prostate_Cancer,Degarelix,serious_events,arm1,Degarelix-40/40-+-40,,,
803,Hypersensitivity,1,139,Immune_system_disorders,NCT00819780,https://clinicaltrials.gov/show/NCT00819780,Colon_Cancer|Colorectal_Cancer|Rectal_Cancer|Metastatic_Colorectal_Cancer|,Panitumumab|Bevacizumab|mFOLFOX6|,serious_events,arm0,Panitumumab-Plus-mFOLFOX6,47,mfolfox6,combination-therapy-with-leucovorin-calcium--fluorouracil-and-oxaliplatin
803,Hypersensitivity,1,139,Immune_system_disorders,NCT00819780,https://clinicaltrials.gov/show/NCT00819780,Colon_Cancer|Colorectal_Cancer|Rectal_Cancer|Metastatic_Colorectal_Cancer|,Panitumumab|Bevacizumab|mFOLFOX6|,serious_events,arm0,Panitumumab-Plus-mFOLFOX6,30,panitumumab,monoclonal-antibody-and-signal-transduction-inhibitor
1635,Drug_hypersensitivity,8,583,Immune_system_disorders,NCT00820755,https://clinicaltrials.gov/show/NCT00820755,Non-Small_Cell_Lung_Cancer_(NSCLC),Cetuximab_plus_Platinum-based_Doublet_Chemotherapy|Cetuximab_500_mg/m^2|Cetuximab_250_mg/m^2|,serious_events,arm0,Cetuximab-250-mg/m^2-q1w-+-Platinum-based-Doublet-Chemotherapy,5,cetuximab,Epidermal-growth-factor-receptor-inhibitor
804,Hypersensitivity,2,583,Immune_system_disorders,NCT00820755,https://clinicaltrials.gov/show/NCT00820755,Non-Small_Cell_Lung_Cancer_(NSCLC),Cetuximab_plus_Platinum-based_Doublet_Chemotherapy|Cetuximab_500_mg/m^2|Cetuximab_250_mg/m^2|,serious_events,arm0,Cetuximab-250-mg/m^2-q1w-+-Platinum-based-Doublet-Chemotherapy,5,cetuximab,Epidermal-growth-factor-receptor-inhibitor
1638,Drug_hypersensitivity,1,26,Immune_system_disorders,NCT00823719,https://clinicaltrials.gov/show/NCT00823719,Lymphoma_Large-Cell_Diffuse,ofatumumab_+_ICE|ofatumumab_+_DHAP|,other_events,arm0,Ofatumumab-+-DHAP,42,ofatumumab,monoclonal-antibody
2134,Dermatitis_allergic,1,35,Skin_and_subcutaneous_tissue_disorders,NCT00823719,https://clinicaltrials.gov/show/NCT00823719,Lymphoma_Large-Cell_Diffuse,ofatumumab_+_ICE|ofatumumab_+_DHAP|,other_events,arm1,Ofatumumab-+-ICE,42,ofatumumab,monoclonal-antibody
2135,Dermatitis_allergic,1,61,Skin_and_subcutaneous_tissue_disorders,NCT00823719,https://clinicaltrials.gov/show/NCT00823719,Lymphoma_Large-Cell_Diffuse,ofatumumab_+_ICE|ofatumumab_+_DHAP|,other_events,arm2,Total-Ofatumumab-+-Chemotherapy,42,ofatumumab,monoclonal-antibody
1637,Drug_hypersensitivity,1,61,Immune_system_disorders,NCT00823719,https://clinicaltrials.gov/show/NCT00823719,Lymphoma_Large-Cell_Diffuse,ofatumumab_+_ICE|ofatumumab_+_DHAP|,other_events,arm2,Total-Ofatumumab-+-Chemotherapy,42,ofatumumab,monoclonal-antibody
2687,ALLERGIC_REACTION,10,76,Immune_system_disorders,NCT00825734,https://clinicaltrials.gov/show/NCT00825734,Metastatic_Breast_Cancer,Sorafenib|Ixabepilone|,other_events,arm0,Dose-Level-1a,,,
1640,Drug_Hypersensitivity,6,235,Immune_system_disorders,NCT00828841,https://clinicaltrials.gov/show/NCT00828841,Non-Small_Cell_Lung_Cancer,Cetuximab|Paclitaxel|Carboplatin|Gemcitabine|Cisplatin|,other_events,arm0,Paclitaxel-Carboplatin-Cetuximab-(Arm-A),3,carboplatin,alkalating-agent
1642,Drug_Hypersensitivity,1,235,Immune_system_disorders,NCT00828841,https://clinicaltrials.gov/show/NCT00828841,Non-Small_Cell_Lung_Cancer,Cetuximab|Paclitaxel|Carboplatin|Gemcitabine|Cisplatin|,serious_events,arm0,Paclitaxel-Carboplatin-Cetuximab-(Arm-A),3,carboplatin,alkalating-agent
810,Hypersensitivity,10,235,Immune_system_disorders,NCT00828841,https://clinicaltrials.gov/show/NCT00828841,Non-Small_Cell_Lung_Cancer,Cetuximab|Paclitaxel|Carboplatin|Gemcitabine|Cisplatin|,other_events,arm0,Paclitaxel-Carboplatin-Cetuximab-(Arm-A),3,carboplatin,alkalating-agent
812,Hypersensitivity,4,235,Immune_system_disorders,NCT00828841,https://clinicaltrials.gov/show/NCT00828841,Non-Small_Cell_Lung_Cancer,Cetuximab|Paclitaxel|Carboplatin|Gemcitabine|Cisplatin|,serious_events,arm0,Paclitaxel-Carboplatin-Cetuximab-(Arm-A),3,carboplatin,alkalating-agent
1640,Drug_Hypersensitivity,6,235,Immune_system_disorders,NCT00828841,https://clinicaltrials.gov/show/NCT00828841,Non-Small_Cell_Lung_Cancer,Cetuximab|Paclitaxel|Carboplatin|Gemcitabine|Cisplatin|,other_events,arm0,Paclitaxel-Carboplatin-Cetuximab-(Arm-A),5,cetuximab,Epidermal-growth-factor-receptor-inhibitor
1642,Drug_Hypersensitivity,1,235,Immune_system_disorders,NCT00828841,https://clinicaltrials.gov/show/NCT00828841,Non-Small_Cell_Lung_Cancer,Cetuximab|Paclitaxel|Carboplatin|Gemcitabine|Cisplatin|,serious_events,arm0,Paclitaxel-Carboplatin-Cetuximab-(Arm-A),5,cetuximab,Epidermal-growth-factor-receptor-inhibitor
810,Hypersensitivity,10,235,Immune_system_disorders,NCT00828841,https://clinicaltrials.gov/show/NCT00828841,Non-Small_Cell_Lung_Cancer,Cetuximab|Paclitaxel|Carboplatin|Gemcitabine|Cisplatin|,other_events,arm0,Paclitaxel-Carboplatin-Cetuximab-(Arm-A),5,cetuximab,Epidermal-growth-factor-receptor-inhibitor
812,Hypersensitivity,4,235,Immune_system_disorders,NCT00828841,https://clinicaltrials.gov/show/NCT00828841,Non-Small_Cell_Lung_Cancer,Cetuximab|Paclitaxel|Carboplatin|Gemcitabine|Cisplatin|,serious_events,arm0,Paclitaxel-Carboplatin-Cetuximab-(Arm-A),5,cetuximab,Epidermal-growth-factor-receptor-inhibitor
1640,Drug_Hypersensitivity,6,235,Immune_system_disorders,NCT00828841,https://clinicaltrials.gov/show/NCT00828841,Non-Small_Cell_Lung_Cancer,Cetuximab|Paclitaxel|Carboplatin|Gemcitabine|Cisplatin|,other_events,arm0,Paclitaxel-Carboplatin-Cetuximab-(Arm-A),2,paclitaxel,taxane
1642,Drug_Hypersensitivity,1,235,Immune_system_disorders,NCT00828841,https://clinicaltrials.gov/show/NCT00828841,Non-Small_Cell_Lung_Cancer,Cetuximab|Paclitaxel|Carboplatin|Gemcitabine|Cisplatin|,serious_events,arm0,Paclitaxel-Carboplatin-Cetuximab-(Arm-A),2,paclitaxel,taxane
810,Hypersensitivity,10,235,Immune_system_disorders,NCT00828841,https://clinicaltrials.gov/show/NCT00828841,Non-Small_Cell_Lung_Cancer,Cetuximab|Paclitaxel|Carboplatin|Gemcitabine|Cisplatin|,other_events,arm0,Paclitaxel-Carboplatin-Cetuximab-(Arm-A),2,paclitaxel,taxane
812,Hypersensitivity,4,235,Immune_system_disorders,NCT00828841,https://clinicaltrials.gov/show/NCT00828841,Non-Small_Cell_Lung_Cancer,Cetuximab|Paclitaxel|Carboplatin|Gemcitabine|Cisplatin|,serious_events,arm0,Paclitaxel-Carboplatin-Cetuximab-(Arm-A),2,paclitaxel,taxane
1639,Drug_Hypersensitivity,1,236,Immune_system_disorders,NCT00828841,https://clinicaltrials.gov/show/NCT00828841,Non-Small_Cell_Lung_Cancer,Cetuximab|Paclitaxel|Carboplatin|Gemcitabine|Cisplatin|,serious_events,arm1,Platinum-Gemcitabine-Cetuximab-(Arm-B),6,gemcitabine,antimetabolites
1641,Drug_Hypersensitivity,3,236,Immune_system_disorders,NCT00828841,https://clinicaltrials.gov/show/NCT00828841,Non-Small_Cell_Lung_Cancer,Cetuximab|Paclitaxel|Carboplatin|Gemcitabine|Cisplatin|,other_events,arm1,Platinum-Gemcitabine-Cetuximab-(Arm-B),6,gemcitabine,antimetabolites
809,Hypersensitivity,2,236,Immune_system_disorders,NCT00828841,https://clinicaltrials.gov/show/NCT00828841,Non-Small_Cell_Lung_Cancer,Cetuximab|Paclitaxel|Carboplatin|Gemcitabine|Cisplatin|,serious_events,arm1,Platinum-Gemcitabine-Cetuximab-(Arm-B),6,gemcitabine,antimetabolites
811,Hypersensitivity,4,236,Immune_system_disorders,NCT00828841,https://clinicaltrials.gov/show/NCT00828841,Non-Small_Cell_Lung_Cancer,Cetuximab|Paclitaxel|Carboplatin|Gemcitabine|Cisplatin|,other_events,arm1,Platinum-Gemcitabine-Cetuximab-(Arm-B),6,gemcitabine,antimetabolites
1639,Drug_Hypersensitivity,1,236,Immune_system_disorders,NCT00828841,https://clinicaltrials.gov/show/NCT00828841,Non-Small_Cell_Lung_Cancer,Cetuximab|Paclitaxel|Carboplatin|Gemcitabine|Cisplatin|,serious_events,arm1,Platinum-Gemcitabine-Cetuximab-(Arm-B),5,cetuximab,Epidermal-growth-factor-receptor-inhibitor
1641,Drug_Hypersensitivity,3,236,Immune_system_disorders,NCT00828841,https://clinicaltrials.gov/show/NCT00828841,Non-Small_Cell_Lung_Cancer,Cetuximab|Paclitaxel|Carboplatin|Gemcitabine|Cisplatin|,other_events,arm1,Platinum-Gemcitabine-Cetuximab-(Arm-B),5,cetuximab,Epidermal-growth-factor-receptor-inhibitor
809,Hypersensitivity,2,236,Immune_system_disorders,NCT00828841,https://clinicaltrials.gov/show/NCT00828841,Non-Small_Cell_Lung_Cancer,Cetuximab|Paclitaxel|Carboplatin|Gemcitabine|Cisplatin|,serious_events,arm1,Platinum-Gemcitabine-Cetuximab-(Arm-B),5,cetuximab,Epidermal-growth-factor-receptor-inhibitor
811,Hypersensitivity,4,236,Immune_system_disorders,NCT00828841,https://clinicaltrials.gov/show/NCT00828841,Non-Small_Cell_Lung_Cancer,Cetuximab|Paclitaxel|Carboplatin|Gemcitabine|Cisplatin|,other_events,arm1,Platinum-Gemcitabine-Cetuximab-(Arm-B),5,cetuximab,Epidermal-growth-factor-receptor-inhibitor
1643,Drug_Hypersensitivity,1,130,Immune_system_disorders,NCT00828841,https://clinicaltrials.gov/show/NCT00828841,Non-Small_Cell_Lung_Cancer,Cetuximab|Paclitaxel|Carboplatin|Gemcitabine|Cisplatin|,other_events,arm2,Platinum-Pemetrexed-Cetuximab-(Arm-C),15,pemetrexed,antimetabolite
808,Hypersensitivity,2,130,Immune_system_disorders,NCT00828841,https://clinicaltrials.gov/show/NCT00828841,Non-Small_Cell_Lung_Cancer,Cetuximab|Paclitaxel|Carboplatin|Gemcitabine|Cisplatin|,serious_events,arm2,Platinum-Pemetrexed-Cetuximab-(Arm-C),15,pemetrexed,antimetabolite
813,Hypersensitivity,2,130,Immune_system_disorders,NCT00828841,https://clinicaltrials.gov/show/NCT00828841,Non-Small_Cell_Lung_Cancer,Cetuximab|Paclitaxel|Carboplatin|Gemcitabine|Cisplatin|,other_events,arm2,Platinum-Pemetrexed-Cetuximab-(Arm-C),15,pemetrexed,antimetabolite
1643,Drug_Hypersensitivity,1,130,Immune_system_disorders,NCT00828841,https://clinicaltrials.gov/show/NCT00828841,Non-Small_Cell_Lung_Cancer,Cetuximab|Paclitaxel|Carboplatin|Gemcitabine|Cisplatin|,other_events,arm2,Platinum-Pemetrexed-Cetuximab-(Arm-C),5,cetuximab,Epidermal-growth-factor-receptor-inhibitor
808,Hypersensitivity,2,130,Immune_system_disorders,NCT00828841,https://clinicaltrials.gov/show/NCT00828841,Non-Small_Cell_Lung_Cancer,Cetuximab|Paclitaxel|Carboplatin|Gemcitabine|Cisplatin|,serious_events,arm2,Platinum-Pemetrexed-Cetuximab-(Arm-C),5,cetuximab,Epidermal-growth-factor-receptor-inhibitor
813,Hypersensitivity,2,130,Immune_system_disorders,NCT00828841,https://clinicaltrials.gov/show/NCT00828841,Non-Small_Cell_Lung_Cancer,Cetuximab|Paclitaxel|Carboplatin|Gemcitabine|Cisplatin|,other_events,arm2,Platinum-Pemetrexed-Cetuximab-(Arm-C),5,cetuximab,Epidermal-growth-factor-receptor-inhibitor
814,Hypersensitivity,1,490,Immune_system_disorders,NCT00829166,https://clinicaltrials.gov/show/NCT00829166,Breast_Cancer,Trastuzumab_emtansine_[Kadcyla]|Lapatinib|Capecitabine|,serious_events,arm0,Trastuzumab-Emtansine,18,trastuzumab,monoclonal-antibody
2354,Anaphylaxis,1,10,Immune_system_disorders,NCT00831844,https://clinicaltrials.gov/show/NCT00831844,Adult_Rhabdomyosarcoma|Adult_Synovial_Sarcoma|Childhood_Hepatoblastoma|Childhood_Synovial_Sarcoma|Previously_Treated_Childhood_Rhabdomyosarcoma|Recurrent_Adrenocortical_Carcinoma|Recurrent_Adult_Soft_Tissue_Sarcoma|Recurrent_Childhood_Liver_Cancer|Recurre,cixutumumab|laboratory_biomarker_analysis|,serious_events,arm0,Group-1---Recurrent-or-Refractory-Hepatoblastoma,,,
2355,Anaphylaxis,1,20,Immune_system_disorders,NCT00831844,https://clinicaltrials.gov/show/NCT00831844,Adult_Rhabdomyosarcoma|Adult_Synovial_Sarcoma|Childhood_Hepatoblastoma|Childhood_Synovial_Sarcoma|Previously_Treated_Childhood_Rhabdomyosarcoma|Recurrent_Adrenocortical_Carcinoma|Recurrent_Adult_Soft_Tissue_Sarcoma|Recurrent_Childhood_Liver_Cancer|Recurre,cixutumumab|laboratory_biomarker_analysis|,serious_events,arm5,Grp-6---Neuroblastoma-MIBG-Positive-Without-Measurable-Disease,,,
2688,Allergic_reaction,1,10,Immune_system_disorders,NCT00831844,https://clinicaltrials.gov/show/NCT00831844,Adult_Rhabdomyosarcoma|Adult_Synovial_Sarcoma|Childhood_Hepatoblastoma|Childhood_Synovial_Sarcoma|Previously_Treated_Childhood_Rhabdomyosarcoma|Recurrent_Adrenocortical_Carcinoma|Recurrent_Adult_Soft_Tissue_Sarcoma|Recurrent_Childhood_Liver_Cancer|Recurre,cixutumumab|laboratory_biomarker_analysis|,other_events,arm6,Grp-7-Neuroblastoma-With-Measurable-Disease,,,
815,Hypersensitivity,2,11,Immune_system_disorders,NCT00834678,https://clinicaltrials.gov/show/NCT00834678,Breast_Cancer,bendamustine|erlotinib|Maintenance_erlotinib|,other_events,arm0,Bendamustine-and-Erlotinib,36,bendamustine,alkylating-agent
815,Hypersensitivity,2,11,Immune_system_disorders,NCT00834678,https://clinicaltrials.gov/show/NCT00834678,Breast_Cancer,bendamustine|erlotinib|Maintenance_erlotinib|,other_events,arm0,Bendamustine-and-Erlotinib,31,erlotinib,epidermal-growth-factor-receptor-(EGFR)-inhibitor---protein-tyrosine-kinase-inhibitor
817,Hypersensitivity,2,44,Immune_system_disorders,NCT00838578,https://clinicaltrials.gov/show/NCT00838578,Colorectal_Cancer,KRN330|Irinotecan|,other_events,arm2,Phase-2:-KRN330-Weekly-+-IRI-Biweekly,,,
2689,Allergic_reaction,1,25,Immune_system_disorders,NCT00841204,https://clinicaltrials.gov/show/NCT00841204,Precancerous_Condition,sulindac|placebo|laboratory_biomarker_analysis|,other_events,arm0,Sulindac,,,
2690,Allergic_reaction,2,25,Immune_system_disorders,NCT00841204,https://clinicaltrials.gov/show/NCT00841204,Precancerous_Condition,sulindac|placebo|laboratory_biomarker_analysis|,other_events,arm1,Placebo,,,
1647,DRUG_HYPERSENSITIVITY,1,85,Immune_system_disorders,NCT00842712,https://clinicaltrials.gov/show/NCT00842712,Carcinoma_Non-Small-Cell_Lung,Cilengitide|Cilengitide|Cetuximab|Cisplatin|Cisplatin|Gemcitabine|Vinorelbine|Cilengitide|Cilengitide|Cetuximab|Chemotherapy|,serious_events,arm4,Randomized-Part:-Cil-(Once-Weekly)-+-Cetuximab-+-Chemotherapy,5,cetuximab,Epidermal-growth-factor-receptor-inhibitor
2691,Allergic_reaction,1,82,Immune_system_disorders,NCT00846027,https://clinicaltrials.gov/show/NCT00846027,Breast_Cancer,Bevacizumab|Paclitaxel|Gemcitabine|,other_events,arm0,Bevacizumab-+-Paclitaxel-+-Gemcitabine,6,gemcitabine,antimetabolites
2691,Allergic_reaction,1,82,Immune_system_disorders,NCT00846027,https://clinicaltrials.gov/show/NCT00846027,Breast_Cancer,Bevacizumab|Paclitaxel|Gemcitabine|,other_events,arm0,Bevacizumab-+-Paclitaxel-+-Gemcitabine,4,bevacizumab,monoclonal-antibody
2691,Allergic_reaction,1,82,Immune_system_disorders,NCT00846027,https://clinicaltrials.gov/show/NCT00846027,Breast_Cancer,Bevacizumab|Paclitaxel|Gemcitabine|,other_events,arm0,Bevacizumab-+-Paclitaxel-+-Gemcitabine,22,bevacizumab,monoclonal-antibody
2691,Allergic_reaction,1,82,Immune_system_disorders,NCT00846027,https://clinicaltrials.gov/show/NCT00846027,Breast_Cancer,Bevacizumab|Paclitaxel|Gemcitabine|,other_events,arm0,Bevacizumab-+-Paclitaxel-+-Gemcitabine,2,paclitaxel,taxane
2693,Allergic_reaction,1,8,Immune_system_disorders,NCT00849121,https://clinicaltrials.gov/show/NCT00849121,Prostate_Cancer,pTVG-HP_with_rhGM-CSF|pTVG-HP_with_rhGM-CSF|,other_events,arm0,1:-pTVG-HP-With-rhGM-CSF-Every-3-Months-Post-Week-12,,,
2692,Allergic_reaction,2,9,Immune_system_disorders,NCT00849121,https://clinicaltrials.gov/show/NCT00849121,Prostate_Cancer,pTVG-HP_with_rhGM-CSF|pTVG-HP_with_rhGM-CSF|,other_events,arm1,2:-pTVG-HP-With-rhGM-CSF-Variable-Dosing-Post-Week-12,,,
1650,Drug_hypersensitivity,6,116,Immune_system_disorders,NCT00851084,https://clinicaltrials.gov/show/NCT00851084,Colorectal_Neoplasms|Neoplasm_Metastasis|,aflibercept|oxaliplatin|5-FU|Folinic_Acid|,other_events,arm0,mFOLFOX6-Only,47,mfolfox6,combination-therapy-with-leucovorin-calcium--fluorouracil-and-oxaliplatin
1649,Drug_hypersensitivity,3,119,Immune_system_disorders,NCT00851084,https://clinicaltrials.gov/show/NCT00851084,Colorectal_Neoplasms|Neoplasm_Metastasis|,aflibercept|oxaliplatin|5-FU|Folinic_Acid|,serious_events,arm1,mFOLFOX6-+-Aflibercept,47,mfolfox6,combination-therapy-with-leucovorin-calcium--fluorouracil-and-oxaliplatin
1651,Drug_hypersensitivity,4,119,Immune_system_disorders,NCT00851084,https://clinicaltrials.gov/show/NCT00851084,Colorectal_Neoplasms|Neoplasm_Metastasis|,aflibercept|oxaliplatin|5-FU|Folinic_Acid|,other_events,arm1,mFOLFOX6-+-Aflibercept,47,mfolfox6,combination-therapy-with-leucovorin-calcium--fluorouracil-and-oxaliplatin
1649,Drug_hypersensitivity,3,119,Immune_system_disorders,NCT00851084,https://clinicaltrials.gov/show/NCT00851084,Colorectal_Neoplasms|Neoplasm_Metastasis|,aflibercept|oxaliplatin|5-FU|Folinic_Acid|,serious_events,arm1,mFOLFOX6-+-Aflibercept,39,aflibercept,vascular-endothelial-growth-factor-(VEGF)-inhibitor
1651,Drug_hypersensitivity,4,119,Immune_system_disorders,NCT00851084,https://clinicaltrials.gov/show/NCT00851084,Colorectal_Neoplasms|Neoplasm_Metastasis|,aflibercept|oxaliplatin|5-FU|Folinic_Acid|,other_events,arm1,mFOLFOX6-+-Aflibercept,39,aflibercept,vascular-endothelial-growth-factor-(VEGF)-inhibitor
827,HYPERSENSITIVITY,1,67,Immune_system_disorders,NCT00854308,https://clinicaltrials.gov/show/NCT00854308,Non-Small_Cell_Lung_Cancer,Erlotinib_HCl|MetMAb|placebo_(0.9__PERCENT_saline)|,serious_events,arm1,Placebo-+-Erlotinib,31,erlotinib,epidermal-growth-factor-receptor-(EGFR)-inhibitor---protein-tyrosine-kinase-inhibitor
2695,Allergic_reaction,2,40,Immune_system_disorders,NCT00859937,https://clinicaltrials.gov/show/NCT00859937,High-grade_Salivary_Gland_Mucoepidermoid_Carcinoma|Low-grade_Salivary_Gland_Mucoepidermoid_Carcinoma|Recurrent_Salivary_Gland_Cancer|Salivary_Gland_Acinic_Cell_Tumor|Salivary_Gland_Adenocarcinoma|Salivary_Gland_Adenoid_Cystic_Carcinoma|Salivary_Gland_Anap,dasatinib|laboratory_biomarker_analysis|,other_events,arm0,Adenoid-Cystic-Carcinoma,,,
835,Hypersensitivity,8,108,Immune_system_disorders,NCT00861705,https://clinicaltrials.gov/show/NCT00861705,Estrogen_Receptor_Negative|HER2/Neu_Negative|Male_Breast_Carcinoma|Progesterone_Receptor_Negative|Stage_IIA_Breast_Cancer|Stage_IIB_Breast_Cancer|Stage_IIIA_Breast_Cancer|Triple-Negative_Breast_Carcinoma|,Bevacizumab|Carboplatin|Cyclophosphamide|Doxorubicin_Hydrochloride|Laboratory_Biomarker_Analysis|Paclitaxel|,other_events,arm0,Arm-1-(Pac--->-ddAC),,,
833,Hypersensitivity,1,108,Immune_system_disorders,NCT00861705,https://clinicaltrials.gov/show/NCT00861705,Estrogen_Receptor_Negative|HER2/Neu_Negative|Male_Breast_Carcinoma|Progesterone_Receptor_Negative|Stage_IIA_Breast_Cancer|Stage_IIB_Breast_Cancer|Stage_IIIA_Breast_Cancer|Triple-Negative_Breast_Carcinoma|,Bevacizumab|Carboplatin|Cyclophosphamide|Doxorubicin_Hydrochloride|Laboratory_Biomarker_Analysis|Paclitaxel|,serious_events,arm1,Arm-2-(Pac-+-Bev--->-ddAC-+-Bev),,,
839,Hypersensitivity,11,108,Immune_system_disorders,NCT00861705,https://clinicaltrials.gov/show/NCT00861705,Estrogen_Receptor_Negative|HER2/Neu_Negative|Male_Breast_Carcinoma|Progesterone_Receptor_Negative|Stage_IIA_Breast_Cancer|Stage_IIB_Breast_Cancer|Stage_IIIA_Breast_Cancer|Triple-Negative_Breast_Carcinoma|,Bevacizumab|Carboplatin|Cyclophosphamide|Doxorubicin_Hydrochloride|Laboratory_Biomarker_Analysis|Paclitaxel|,other_events,arm1,Arm-2-(Pac-+-Bev--->-ddAC-+-Bev),,,
836,Hypersensitivity,6,109,Immune_system_disorders,NCT00861705,https://clinicaltrials.gov/show/NCT00861705,Estrogen_Receptor_Negative|HER2/Neu_Negative|Male_Breast_Carcinoma|Progesterone_Receptor_Negative|Stage_IIA_Breast_Cancer|Stage_IIB_Breast_Cancer|Stage_IIIA_Breast_Cancer|Triple-Negative_Breast_Carcinoma|,Bevacizumab|Carboplatin|Cyclophosphamide|Doxorubicin_Hydrochloride|Laboratory_Biomarker_Analysis|Paclitaxel|,other_events,arm2,Arm-3-(Pac-+-Carboplatin--->-ddAC),3,carboplatin,alkalating-agent
838,Hypersensitivity,1,109,Immune_system_disorders,NCT00861705,https://clinicaltrials.gov/show/NCT00861705,Estrogen_Receptor_Negative|HER2/Neu_Negative|Male_Breast_Carcinoma|Progesterone_Receptor_Negative|Stage_IIA_Breast_Cancer|Stage_IIB_Breast_Cancer|Stage_IIIA_Breast_Cancer|Triple-Negative_Breast_Carcinoma|,Bevacizumab|Carboplatin|Cyclophosphamide|Doxorubicin_Hydrochloride|Laboratory_Biomarker_Analysis|Paclitaxel|,serious_events,arm2,Arm-3-(Pac-+-Carboplatin--->-ddAC),3,carboplatin,alkalating-agent
834,Hypersensitivity,1,112,Immune_system_disorders,NCT00861705,https://clinicaltrials.gov/show/NCT00861705,Estrogen_Receptor_Negative|HER2/Neu_Negative|Male_Breast_Carcinoma|Progesterone_Receptor_Negative|Stage_IIA_Breast_Cancer|Stage_IIB_Breast_Cancer|Stage_IIIA_Breast_Cancer|Triple-Negative_Breast_Carcinoma|,Bevacizumab|Carboplatin|Cyclophosphamide|Doxorubicin_Hydrochloride|Laboratory_Biomarker_Analysis|Paclitaxel|,serious_events,arm3,Arm-4-(Pac-+-Carboplatin-+-Bev--->-ddAC-+-Bev),3,carboplatin,alkalating-agent
837,Hypersensitivity,12,112,Immune_system_disorders,NCT00861705,https://clinicaltrials.gov/show/NCT00861705,Estrogen_Receptor_Negative|HER2/Neu_Negative|Male_Breast_Carcinoma|Progesterone_Receptor_Negative|Stage_IIA_Breast_Cancer|Stage_IIB_Breast_Cancer|Stage_IIIA_Breast_Cancer|Triple-Negative_Breast_Carcinoma|,Bevacizumab|Carboplatin|Cyclophosphamide|Doxorubicin_Hydrochloride|Laboratory_Biomarker_Analysis|Paclitaxel|,other_events,arm3,Arm-4-(Pac-+-Carboplatin-+-Bev--->-ddAC-+-Bev),3,carboplatin,alkalating-agent
2143,Dermatitis_allergic,1,90,Skin_and_subcutaneous_tissue_disorders,NCT00862459,https://clinicaltrials.gov/show/NCT00862459,Brain_Diseases|Spinal_Cord_Diseases|,Gadobutrol~0.03_mmol/kg_BW_(Gadavist_Gadovist_BAY86-4875)|Gadobutrol~0.1_mmol/kg_BW_(Gadavist_Gadovist_BAY86-4875)|Gadobutrol~0.3_mmol/kg_BW_(Gadavist_Gadovist_BAY86-4875)|OptiMARK~0.1_mmol/kg_BW|,other_events,arm1,Gadobutrol~0.1-mmol/kg-BW-(Gadavist-BAY86-4875),,,
832,Hypersensitivity,1,14,Immune_system_disorders,NCT00862836,https://clinicaltrials.gov/show/NCT00862836,Ovarian_Cancer,Vandetanib,other_events,arm0,Vandetanib-100-mg,33,vandetanib,tyrosine-kinase-inhibitor
2696,Allergic_reaction,1,346,Immune_system_disorders,NCT00863746,https://clinicaltrials.gov/show/NCT00863746,Carcinoma|Non-Small-Cell_Lung|,Sorafenib_(Nexavar_BAY43-9006)|Placebo|,serious_events,arm0,Sorafenib-(Nexavar-BAY43-9006),97,nexavar,Tyrosine-Kinase-inhibitor
2696,Allergic_reaction,1,346,Immune_system_disorders,NCT00863746,https://clinicaltrials.gov/show/NCT00863746,Carcinoma|Non-Small-Cell_Lung|,Sorafenib_(Nexavar_BAY43-9006)|Placebo|,serious_events,arm0,Sorafenib-(Nexavar-BAY43-9006),90,sorafenib,Tyrosine-Kinase-inhibitor
2696,Allergic_reaction,1,346,Immune_system_disorders,NCT00863746,https://clinicaltrials.gov/show/NCT00863746,Carcinoma|Non-Small-Cell_Lung|,Sorafenib_(Nexavar_BAY43-9006)|Placebo|,serious_events,arm0,Sorafenib-(Nexavar-BAY43-9006),72,bay43,Tyrosine-Kinase-inhibitor
840,Hypersensitivity,2,258,Immune_system_disorders,NCT00864253,https://clinicaltrials.gov/show/NCT00864253,Malignant_Melanoma,ABI-007|Dacarbazine|,serious_events,arm1,Dacarbazine-Arm-B,,,
2147,Dermatitis_allergic,1,97,Skin_and_subcutaneous_tissue_disorders,NCT00865709,https://clinicaltrials.gov/show/NCT00865709,Metastatic_Colorectal_Cancer,Sorafenib_(Nexavar_BAY43-9006)_+_mFOLFOX6_(5-FU_levo-leucovorin_oxaliplatin)|Matching_placebo_+_mFOLFOX6_(5-FU_levo-leucovorin_oxaliplatin)|,serious_events,arm0,Sorafenib-(Nexavar-BAY43-9006)-+-mFOLFOX6,47,mfolfox6,combination-therapy-with-leucovorin-calcium--fluorouracil-and-oxaliplatin
2147,Dermatitis_allergic,1,97,Skin_and_subcutaneous_tissue_disorders,NCT00865709,https://clinicaltrials.gov/show/NCT00865709,Metastatic_Colorectal_Cancer,Sorafenib_(Nexavar_BAY43-9006)_+_mFOLFOX6_(5-FU_levo-leucovorin_oxaliplatin)|Matching_placebo_+_mFOLFOX6_(5-FU_levo-leucovorin_oxaliplatin)|,serious_events,arm0,Sorafenib-(Nexavar-BAY43-9006)-+-mFOLFOX6,97,nexavar,Tyrosine-Kinase-inhibitor
2147,Dermatitis_allergic,1,97,Skin_and_subcutaneous_tissue_disorders,NCT00865709,https://clinicaltrials.gov/show/NCT00865709,Metastatic_Colorectal_Cancer,Sorafenib_(Nexavar_BAY43-9006)_+_mFOLFOX6_(5-FU_levo-leucovorin_oxaliplatin)|Matching_placebo_+_mFOLFOX6_(5-FU_levo-leucovorin_oxaliplatin)|,serious_events,arm0,Sorafenib-(Nexavar-BAY43-9006)-+-mFOLFOX6,90,sorafenib,Tyrosine-Kinase-inhibitor
2147,Dermatitis_allergic,1,97,Skin_and_subcutaneous_tissue_disorders,NCT00865709,https://clinicaltrials.gov/show/NCT00865709,Metastatic_Colorectal_Cancer,Sorafenib_(Nexavar_BAY43-9006)_+_mFOLFOX6_(5-FU_levo-leucovorin_oxaliplatin)|Matching_placebo_+_mFOLFOX6_(5-FU_levo-leucovorin_oxaliplatin)|,serious_events,arm0,Sorafenib-(Nexavar-BAY43-9006)-+-mFOLFOX6,72,bay43,Tyrosine-Kinase-inhibitor
841,Hypersensitivity,1,101,Immune_system_disorders,NCT00865709,https://clinicaltrials.gov/show/NCT00865709,Metastatic_Colorectal_Cancer,Sorafenib_(Nexavar_BAY43-9006)_+_mFOLFOX6_(5-FU_levo-leucovorin_oxaliplatin)|Matching_placebo_+_mFOLFOX6_(5-FU_levo-leucovorin_oxaliplatin)|,serious_events,arm1,Matching-Placebo-+-mFOLFOX6,47,mfolfox6,combination-therapy-with-leucovorin-calcium--fluorouracil-and-oxaliplatin
2148,Dermatitis_allergic,1,97,Skin_and_subcutaneous_tissue_disorders,NCT00865709,https://clinicaltrials.gov/show/NCT00865709,Metastatic_Colorectal_Cancer,Sorafenib_(Nexavar_BAY43-9006)_+_mFOLFOX6_(5-FU_levo-leucovorin_oxaliplatin)|Matching_placebo_+_mFOLFOX6_(5-FU_levo-leucovorin_oxaliplatin)|,serious_events,arm2,Sorafenib-(Nexavar-BAY43-9006)-+-mFOLFOX6-(OS-Update),47,mfolfox6,combination-therapy-with-leucovorin-calcium--fluorouracil-and-oxaliplatin
2148,Dermatitis_allergic,1,97,Skin_and_subcutaneous_tissue_disorders,NCT00865709,https://clinicaltrials.gov/show/NCT00865709,Metastatic_Colorectal_Cancer,Sorafenib_(Nexavar_BAY43-9006)_+_mFOLFOX6_(5-FU_levo-leucovorin_oxaliplatin)|Matching_placebo_+_mFOLFOX6_(5-FU_levo-leucovorin_oxaliplatin)|,serious_events,arm2,Sorafenib-(Nexavar-BAY43-9006)-+-mFOLFOX6-(OS-Update),97,nexavar,Tyrosine-Kinase-inhibitor
2148,Dermatitis_allergic,1,97,Skin_and_subcutaneous_tissue_disorders,NCT00865709,https://clinicaltrials.gov/show/NCT00865709,Metastatic_Colorectal_Cancer,Sorafenib_(Nexavar_BAY43-9006)_+_mFOLFOX6_(5-FU_levo-leucovorin_oxaliplatin)|Matching_placebo_+_mFOLFOX6_(5-FU_levo-leucovorin_oxaliplatin)|,serious_events,arm2,Sorafenib-(Nexavar-BAY43-9006)-+-mFOLFOX6-(OS-Update),90,sorafenib,Tyrosine-Kinase-inhibitor
2148,Dermatitis_allergic,1,97,Skin_and_subcutaneous_tissue_disorders,NCT00865709,https://clinicaltrials.gov/show/NCT00865709,Metastatic_Colorectal_Cancer,Sorafenib_(Nexavar_BAY43-9006)_+_mFOLFOX6_(5-FU_levo-leucovorin_oxaliplatin)|Matching_placebo_+_mFOLFOX6_(5-FU_levo-leucovorin_oxaliplatin)|,serious_events,arm2,Sorafenib-(Nexavar-BAY43-9006)-+-mFOLFOX6-(OS-Update),72,bay43,Tyrosine-Kinase-inhibitor
842,Hypersensitivity,1,101,Immune_system_disorders,NCT00865709,https://clinicaltrials.gov/show/NCT00865709,Metastatic_Colorectal_Cancer,Sorafenib_(Nexavar_BAY43-9006)_+_mFOLFOX6_(5-FU_levo-leucovorin_oxaliplatin)|Matching_placebo_+_mFOLFOX6_(5-FU_levo-leucovorin_oxaliplatin)|,serious_events,arm3,Matching-Placebo-+-mFOLFOX6-(OS-Update),47,mfolfox6,combination-therapy-with-leucovorin-calcium--fluorouracil-and-oxaliplatin
1655,Drug_hypersensitivity,1,477,Immune_system_disorders,NCT00866697,https://clinicaltrials.gov/show/NCT00866697,Neoplasms_Ovarian,Pazopanib|Placebo|,serious_events,arm1,Pazopanib-800-mg,,,
2697,ALLERGIC_REACTION,10,167,Immune_system_disorders,NCT00866905,https://clinicaltrials.gov/show/NCT00866905,Breast_Cancer,Ixabepilone|Cyclophosphamide|,other_events,arm0,Ixabepilone/Cyclophosphamide,13,cyclophosphamide,alkylating-agent
2697,ALLERGIC_REACTION,10,167,Immune_system_disorders,NCT00866905,https://clinicaltrials.gov/show/NCT00866905,Breast_Cancer,Ixabepilone|Cyclophosphamide|,other_events,arm0,Ixabepilone/Cyclophosphamide,82,ixabepilone,antimicrotubule-agent
1653,Drug_hypersensitivity,1,113,Immune_system_disorders,NCT00867009,https://clinicaltrials.gov/show/NCT00867009,Non-Small-Cell_Lung_Cancer,Pemetrexed|Cisplatin|Cetuximab|,other_events,arm0,Pem/Cis-+-Cet,,,
1654,Drug_hypersensitivity,1,113,Immune_system_disorders,NCT00867009,https://clinicaltrials.gov/show/NCT00867009,Non-Small-Cell_Lung_Cancer,Pemetrexed|Cisplatin|Cetuximab|,serious_events,arm0,Pem/Cis-+-Cet,,,
843,Hypersensitivity,3,113,Immune_system_disorders,NCT00867009,https://clinicaltrials.gov/show/NCT00867009,Non-Small-Cell_Lung_Cancer,Pemetrexed|Cisplatin|Cetuximab|,other_events,arm0,Pem/Cis-+-Cet,,,
844,Hypersensitivity,1,113,Immune_system_disorders,NCT00867009,https://clinicaltrials.gov/show/NCT00867009,Non-Small-Cell_Lung_Cancer,Pemetrexed|Cisplatin|Cetuximab|,serious_events,arm0,Pem/Cis-+-Cet,,,
2394,Allergy,11,34,Immune_system_disorders,NCT00868192,https://clinicaltrials.gov/show/NCT00868192,Ovarian_Carcinoma|Primary_Peritoneal_Carcinoma|,Pemetrexed|Bevacizumab|,other_events,arm0,Pemetrexed-and-Bevacizumab,15,pemetrexed,antimetabolite
2394,Allergy,11,34,Immune_system_disorders,NCT00868192,https://clinicaltrials.gov/show/NCT00868192,Ovarian_Carcinoma|Primary_Peritoneal_Carcinoma|,Pemetrexed|Bevacizumab|,other_events,arm0,Pemetrexed-and-Bevacizumab,4,bevacizumab,monoclonal-antibody
2394,Allergy,11,34,Immune_system_disorders,NCT00868192,https://clinicaltrials.gov/show/NCT00868192,Ovarian_Carcinoma|Primary_Peritoneal_Carcinoma|,Pemetrexed|Bevacizumab|,other_events,arm0,Pemetrexed-and-Bevacizumab,22,bevacizumab,monoclonal-antibody
1656,Drug_hypersensitivity,6,42,Immune_system_disorders,NCT00873119,https://clinicaltrials.gov/show/NCT00873119,Carcinoma_of_Unknown_Primary,belinostat_carboplatin_paclitaxel|carboplatin_paclitaxel|,other_events,arm0,Arm-A---BelCaP,,,
1659,Drug_hypersensitivity,2,42,Immune_system_disorders,NCT00873119,https://clinicaltrials.gov/show/NCT00873119,Carcinoma_of_Unknown_Primary,belinostat_carboplatin_paclitaxel|carboplatin_paclitaxel|,serious_events,arm0,Arm-A---BelCaP,,,
1657,Drug_hypersensitivity,5,44,Immune_system_disorders,NCT00873119,https://clinicaltrials.gov/show/NCT00873119,Carcinoma_of_Unknown_Primary,belinostat_carboplatin_paclitaxel|carboplatin_paclitaxel|,other_events,arm1,Arm-B---CaP,,,
1658,Drug_hypersensitivity,2,44,Immune_system_disorders,NCT00873119,https://clinicaltrials.gov/show/NCT00873119,Carcinoma_of_Unknown_Primary,belinostat_carboplatin_paclitaxel|carboplatin_paclitaxel|,serious_events,arm1,Arm-B---CaP,,,
1660,Drug_hypersensitivity,24,221,Immune_system_disorders,NCT00877006,https://clinicaltrials.gov/show/NCT00877006,Non-Hodgkin's_Lymphoma|Mantle_Cell_Lymphoma|,bendamustine|rituximab|vincristine|prednisone|cyclophosphamide|doxorubicin|,other_events,arm0,Bendamustine-and-Rituximab-(BR),36,bendamustine,alkylating-agent
1661,Drug_hypersensitivity,4,221,Immune_system_disorders,NCT00877006,https://clinicaltrials.gov/show/NCT00877006,Non-Hodgkin's_Lymphoma|Mantle_Cell_Lymphoma|,bendamustine|rituximab|vincristine|prednisone|cyclophosphamide|doxorubicin|,serious_events,arm0,Bendamustine-and-Rituximab-(BR),36,bendamustine,alkylating-agent
1660,Drug_hypersensitivity,24,221,Immune_system_disorders,NCT00877006,https://clinicaltrials.gov/show/NCT00877006,Non-Hodgkin's_Lymphoma|Mantle_Cell_Lymphoma|,bendamustine|rituximab|vincristine|prednisone|cyclophosphamide|doxorubicin|,other_events,arm0,Bendamustine-and-Rituximab-(BR),16,rituximab,monoclonal-antibody
1661,Drug_hypersensitivity,4,221,Immune_system_disorders,NCT00877006,https://clinicaltrials.gov/show/NCT00877006,Non-Hodgkin's_Lymphoma|Mantle_Cell_Lymphoma|,bendamustine|rituximab|vincristine|prednisone|cyclophosphamide|doxorubicin|,serious_events,arm0,Bendamustine-and-Rituximab-(BR),16,rituximab,monoclonal-antibody
1662,Drug_hypersensitivity,8,215,Immune_system_disorders,NCT00877006,https://clinicaltrials.gov/show/NCT00877006,Non-Hodgkin's_Lymphoma|Mantle_Cell_Lymphoma|,bendamustine|rituximab|vincristine|prednisone|cyclophosphamide|doxorubicin|,other_events,arm1,R-CHOP/CVP,,,
2151,Dermatitis_allergic,1,7,Skin_and_subcutaneous_tissue_disorders,NCT00878800,https://clinicaltrials.gov/show/NCT00878800,Dose_Escalation:_Solid_Tumors|MTD:_Soft_Tissue_Sarcomas|,PXD101|Doxorubicin|,other_events,arm1,Cohort-2:-BelDox-IV-(600/75),,,
847,Hypersensitivity,1,9,Immune_system_disorders,NCT00878800,https://clinicaltrials.gov/show/NCT00878800,Dose_Escalation:_Solid_Tumors|MTD:_Soft_Tissue_Sarcomas|,PXD101|Doxorubicin|,serious_events,arm2,Cohort-3:-BelDox-IV-(800/75),,,
848,Hypersensitivity,1,9,Immune_system_disorders,NCT00878800,https://clinicaltrials.gov/show/NCT00878800,Dose_Escalation:_Solid_Tumors|MTD:_Soft_Tissue_Sarcomas|,PXD101|Doxorubicin|,other_events,arm2,Cohort-3:-BelDox-IV-(800/75),,,
849,Hypersensitivity,2,16,Immune_system_disorders,NCT00878800,https://clinicaltrials.gov/show/NCT00878800,Dose_Escalation:_Solid_Tumors|MTD:_Soft_Tissue_Sarcomas|,PXD101|Doxorubicin|,other_events,arm4,MTD-Expansion:-BelDox-IV-(1000/75),,,
2698,Allergic_reaction,1,72,Immune_system_disorders,NCT00880334,https://clinicaltrials.gov/show/NCT00880334,Transitional_Cell_Carcinoma|Bladder_Cancer|,Docetaxel|Zactima|Placebo|,serious_events,arm1,Placebo-and-Docetaxel,8,docetaxel,taxane
2699,Allergic_Reaction,4,133,Immune_system_disorders,NCT00883675,https://clinicaltrials.gov/show/NCT00883675,Non-small_Cell_Lung_Cancer,Docetaxel-Carboplatin,serious_events,arm0,Treatment,,,
851,Hypersensitivity,1,20,Immune_system_disorders,NCT00884949,https://clinicaltrials.gov/show/NCT00884949,MPS_IV_A,BMN_110,other_events,arm0,0.1-mg/kg/Week,,,
1664,Drug_hypersensitivity,1,18,Immune_system_disorders,NCT00884949,https://clinicaltrials.gov/show/NCT00884949,MPS_IV_A,BMN_110,other_events,arm2,2.0-mg/kg/Week,,,
1663,Drug_hypersensitivity,1,20,Immune_system_disorders,NCT00884949,https://clinicaltrials.gov/show/NCT00884949,MPS_IV_A,BMN_110,other_events,arm4,Entire-Study,,,
850,Hypersensitivity,1,20,Immune_system_disorders,NCT00884949,https://clinicaltrials.gov/show/NCT00884949,MPS_IV_A,BMN_110,other_events,arm4,Entire-Study,,,
1665,Drug_hypersensitivity,3,33,Immune_system_disorders,NCT00885755,https://clinicaltrials.gov/show/NCT00885755,Breast_Cancer,Standard_taxane_therapy|capecitabine_[Xeloda]|trastuzumab_[Herceptin]|,other_events,arm0,All-Participants,,,
852,Hypersensitivity,2,33,Immune_system_disorders,NCT00885755,https://clinicaltrials.gov/show/NCT00885755,Breast_Cancer,Standard_taxane_therapy|capecitabine_[Xeloda]|trastuzumab_[Herceptin]|,other_events,arm0,All-Participants,,,
2700,ALLERGIC_REACTION,4,41,Immune_system_disorders,NCT00887575,https://clinicaltrials.gov/show/NCT00887575,Breast_Cancer,Paclitaxel|Carboplatin|Sunitinib|,other_events,arm0,Dose-Level-I,,,
2701,Allergic_reaction,2,90,General_disorders,NCT00890656,https://clinicaltrials.gov/show/NCT00890656,Acute_Lymphoblastic_Leukemia,Cyclophosphamide_(CTX)|Vincristine|Doxorubicin|Decadron|G-CSF|Methotrexate_(MTX)|Ara-C|Pegaspargase|,serious_events,arm0,Augmented-Hyper-CVAD,,,
2702,Allergic_reaction,1,10,General_disorders,NCT00893997,https://clinicaltrials.gov/show/NCT00893997,Leukemia|Myelodysplastic_Syndrome|,PR-1_vaccine,other_events,arm0,PR-1-Vaccine,,,
2703,Allergic_reaction,1,10,General_disorders,NCT00893997,https://clinicaltrials.gov/show/NCT00893997,Leukemia|Myelodysplastic_Syndrome|,PR-1_vaccine,serious_events,arm0,PR-1-Vaccine,,,
2704,allergic_reaction,2,43,Immune_system_disorders,NCT00895934,https://clinicaltrials.gov/show/NCT00895934,Adult_Acute_Megakaryoblastic_Leukemia_(M7)|Adult_Acute_Minimally_Differentiated_Myeloid_Leukemia_(M0)|Adult_Acute_Monoblastic_Leukemia_(M5a)|Adult_Acute_Monocytic_Leukemia_(M5b)|Adult_Acute_Myeloblastic_Leukemia_With_Maturation_(M2)|Adult_Acute_Myeloblast,vorinostat|gemtuzumab_ozogamicin|azacitidine|,other_events,arm1,Phase-2/Selected-Dose,,,
1667,DRUG_HYPERSENSITIVITY,1,6,Immune_system_disorders,NCT00900627,https://clinicaltrials.gov/show/NCT00900627,Neoplasms|Breast_Neoplasms|Breast_Cancer|,AZD8931|Paclitaxel|Placebo|,other_events,arm0,AZD8931-40-mg-bd,,,
1669,DRUG_HYPERSENSITIVITY,5,94,Immune_system_disorders,NCT00900627,https://clinicaltrials.gov/show/NCT00900627,Neoplasms|Breast_Neoplasms|Breast_Cancer|,AZD8931|Paclitaxel|Placebo|,other_events,arm4,AZD8931-40MG-bd-+-Paclitaxel,2,paclitaxel,taxane
2156,DERMATITIS_ALLERGIC,1,95,Skin_and_subcutaneous_tissue_disorders,NCT00900627,https://clinicaltrials.gov/show/NCT00900627,Neoplasms|Breast_Neoplasms|Breast_Cancer|,AZD8931|Paclitaxel|Placebo|,other_events,arm5,Placebo-+-Paclitaxel,2,paclitaxel,taxane
1668,DRUG_HYPERSENSITIVITY,3,95,Immune_system_disorders,NCT00900627,https://clinicaltrials.gov/show/NCT00900627,Neoplasms|Breast_Neoplasms|Breast_Cancer|,AZD8931|Paclitaxel|Placebo|,other_events,arm5,Placebo-+-Paclitaxel,2,paclitaxel,taxane
855,HYPERSENSITIVITY,1,95,Immune_system_disorders,NCT00900627,https://clinicaltrials.gov/show/NCT00900627,Neoplasms|Breast_Neoplasms|Breast_Cancer|,AZD8931|Paclitaxel|Placebo|,other_events,arm5,Placebo-+-Paclitaxel,2,paclitaxel,taxane
856,Hypersensitivity,1,3,Immune_system_disorders,NCT00903006,https://clinicaltrials.gov/show/NCT00903006,Breast_Cancer,Fulvestrant|MK-0646|Dasatinib|,other_events,arm1,Group-2:-Fulvestrant-+-Dasatinib,24,dasatinib,signal-transduction-inhibitor---tyrosine-kinase-inhibitor
1670,Drug_hypersensitivity,6,85,Immune_system_disorders,NCT00904839,https://clinicaltrials.gov/show/NCT00904839,Colorectal_Neoplasms,BIBF_1120|BIBF_1120|mFolfox|Bevacizumab|mFolfox_6|bevacizumab|,other_events,arm0,Nintedanib-+-mFolfox6,47,mfolfox6,combination-therapy-with-leucovorin-calcium--fluorouracil-and-oxaliplatin
1671,Drug_hypersensitivity,4,41,Immune_system_disorders,NCT00904839,https://clinicaltrials.gov/show/NCT00904839,Colorectal_Neoplasms,BIBF_1120|BIBF_1120|mFolfox|Bevacizumab|mFolfox_6|bevacizumab|,other_events,arm1,Bevacizumab-+-mFolfox6,47,mfolfox6,combination-therapy-with-leucovorin-calcium--fluorouracil-and-oxaliplatin
1671,Drug_hypersensitivity,4,41,Immune_system_disorders,NCT00904839,https://clinicaltrials.gov/show/NCT00904839,Colorectal_Neoplasms,BIBF_1120|BIBF_1120|mFolfox|Bevacizumab|mFolfox_6|bevacizumab|,other_events,arm1,Bevacizumab-+-mFolfox6,4,bevacizumab,monoclonal-antibody
1671,Drug_hypersensitivity,4,41,Immune_system_disorders,NCT00904839,https://clinicaltrials.gov/show/NCT00904839,Colorectal_Neoplasms,BIBF_1120|BIBF_1120|mFolfox|Bevacizumab|mFolfox_6|bevacizumab|,other_events,arm1,Bevacizumab-+-mFolfox6,22,bevacizumab,monoclonal-antibody
857,Hypersensitivity,1,513,Immune_system_disorders,NCT00906399,https://clinicaltrials.gov/show/NCT00906399,Relapsing_Multiple_Sclerosis,BIIB017_(peginterferon_beta-1a)|Placebo|,serious_events,arm2,Year-1:-Peginterferon-Beta-1a-Q2W,,,
2157,Dermatitis_allergic,1,144,Skin_and_subcutaneous_tissue_disorders,NCT00908232,https://clinicaltrials.gov/show/NCT00908232,Multiple_Myeloma,Cyclophosphamide|Bortezomib|Dexamethasone|Lenalidomide|,other_events,arm0,Complete-to-Partial-Response:-Bortezomib-+-Dexamethasone,70,bortezomib,proteasome-inhibitor
2157,Dermatitis_allergic,1,144,Skin_and_subcutaneous_tissue_disorders,NCT00908232,https://clinicaltrials.gov/show/NCT00908232,Multiple_Myeloma,Cyclophosphamide|Bortezomib|Dexamethasone|Lenalidomide|,other_events,arm0,Complete-to-Partial-Response:-Bortezomib-+-Dexamethasone,79,dexamethasone,steroid
2158,Dermatitis_allergic,1,19,Skin_and_subcutaneous_tissue_disorders,NCT00908232,https://clinicaltrials.gov/show/NCT00908232,Multiple_Myeloma,Cyclophosphamide|Bortezomib|Dexamethasone|Lenalidomide|,other_events,arm1,Stable-Disease-After-4-Cycles:-VD-VDC-VDL,,,
2160,Dermatitis_allergic,1,170,Skin_and_subcutaneous_tissue_disorders,NCT00911300,https://clinicaltrials.gov/show/NCT00911300,Fibrillation_Atrial,fondaparinux|unfractionated_heparin|Vitamin-K-Antagonist|,other_events,arm1,UFH/VKA,,,
2161,Dermatitis_allergic,1,23,Skin_and_subcutaneous_tissue_disorders,NCT00912925,https://clinicaltrials.gov/show/NCT00912925,Mucopolysaccharidosis_I|Hurlers_Syndrome|Hurler-Scheie_Syndrome|,rhIDU_(recombinant_human-Alpha-L-Iduronidase)|Placebo|,other_events,arm0,Placebo***Check-Title***,,,
861,Hypersensitivity,1,8,Immune_system_disorders,NCT00915278,https://clinicaltrials.gov/show/NCT00915278,Advanced_Non-Hematologic_Malignancies,PF-04605412,serious_events,arm0,PF-04605412-7.5-mg,,,
1674,Drug_hypersensitivity,1,5,Immune_system_disorders,NCT00915278,https://clinicaltrials.gov/show/NCT00915278,Advanced_Non-Hematologic_Malignancies,PF-04605412,other_events,arm1,PF-04605412-11.25-mg,,,
859,Hypersensitivity,2,5,Immune_system_disorders,NCT00915278,https://clinicaltrials.gov/show/NCT00915278,Advanced_Non-Hematologic_Malignancies,PF-04605412,other_events,arm1,PF-04605412-11.25-mg,,,
860,Hypersensitivity,1,9,Immune_system_disorders,NCT00915278,https://clinicaltrials.gov/show/NCT00915278,Advanced_Non-Hematologic_Malignancies,PF-04605412,other_events,arm5,PF-04605412-136-mg,,,
2706,Allergic_reaction,3,41,Immune_system_disorders,NCT00924066,https://clinicaltrials.gov/show/NCT00924066,Cervical_Carcinoma|Cervical_Adenocarcinoma|Cervical_Adenosquamous_Carcinoma|Cervical_Carcinoma_Non-SquamousType|,Ixempra_(Ixabepilone_(BMS-247550)_),other_events,arm0,Adverse-Events-for-Squamous-and-Non-squamous-Participants,,,
862,Hypersensitivity,3,56,Immune_system_disorders,NCT00924352,https://clinicaltrials.gov/show/NCT00924352,Metastatic_Breast_Cancer,Dasatinib|Ixabepilone|,other_events,arm0,Ixabepilone-+-Dasatinib,82,ixabepilone,antimicrotubule-agent
862,Hypersensitivity,3,56,Immune_system_disorders,NCT00924352,https://clinicaltrials.gov/show/NCT00924352,Metastatic_Breast_Cancer,Dasatinib|Ixabepilone|,other_events,arm0,Ixabepilone-+-Dasatinib,24,dasatinib,signal-transduction-inhibitor---tyrosine-kinase-inhibitor
2164,DERMATITIS_ALLERGIC,1,66,Skin_and_subcutaneous_tissue_disorders,NCT00924443,https://clinicaltrials.gov/show/NCT00924443,Acute_Myeloid_Leukemia,clofarabine,other_events,arm0,Clofarabine,37,clofarabine,antimetabolite
863,HYPERSENSITIVITY,2,66,Immune_system_disorders,NCT00924443,https://clinicaltrials.gov/show/NCT00924443,Acute_Myeloid_Leukemia,clofarabine,other_events,arm0,Clofarabine,37,clofarabine,antimetabolite
1677,Drug_Hypersensitivity,5,58,Immune_system_disorders,NCT00929162,https://clinicaltrials.gov/show/NCT00929162,Patients_With_Advanced_Ovarian_Cancer_Sensitive_to_Platinum-based_Chemotherapy,ZD4054_Zibotentan|Paclitaxel|Carboplatin|Placebo|,serious_events,arm0,ZD4054+Paclitaxel+Carboplatin,3,carboplatin,alkalating-agent
1678,Drug_Hypersensitivity,15,58,Immune_system_disorders,NCT00929162,https://clinicaltrials.gov/show/NCT00929162,Patients_With_Advanced_Ovarian_Cancer_Sensitive_to_Platinum-based_Chemotherapy,ZD4054_Zibotentan|Paclitaxel|Carboplatin|Placebo|,other_events,arm0,ZD4054+Paclitaxel+Carboplatin,3,carboplatin,alkalating-agent
1677,Drug_Hypersensitivity,5,58,Immune_system_disorders,NCT00929162,https://clinicaltrials.gov/show/NCT00929162,Patients_With_Advanced_Ovarian_Cancer_Sensitive_to_Platinum-based_Chemotherapy,ZD4054_Zibotentan|Paclitaxel|Carboplatin|Placebo|,serious_events,arm0,ZD4054+Paclitaxel+Carboplatin,2,paclitaxel,taxane
1678,Drug_Hypersensitivity,15,58,Immune_system_disorders,NCT00929162,https://clinicaltrials.gov/show/NCT00929162,Patients_With_Advanced_Ovarian_Cancer_Sensitive_to_Platinum-based_Chemotherapy,ZD4054_Zibotentan|Paclitaxel|Carboplatin|Placebo|,other_events,arm0,ZD4054+Paclitaxel+Carboplatin,2,paclitaxel,taxane
1675,Drug_Hypersensitivity,10,58,Immune_system_disorders,NCT00929162,https://clinicaltrials.gov/show/NCT00929162,Patients_With_Advanced_Ovarian_Cancer_Sensitive_to_Platinum-based_Chemotherapy,ZD4054_Zibotentan|Paclitaxel|Carboplatin|Placebo|,other_events,arm1,Placebo+Paclitaxel+Carboplatin,3,carboplatin,alkalating-agent
1676,Drug_Hypersensitivity,4,58,Immune_system_disorders,NCT00929162,https://clinicaltrials.gov/show/NCT00929162,Patients_With_Advanced_Ovarian_Cancer_Sensitive_to_Platinum-based_Chemotherapy,ZD4054_Zibotentan|Paclitaxel|Carboplatin|Placebo|,serious_events,arm1,Placebo+Paclitaxel+Carboplatin,3,carboplatin,alkalating-agent
1675,Drug_Hypersensitivity,10,58,Immune_system_disorders,NCT00929162,https://clinicaltrials.gov/show/NCT00929162,Patients_With_Advanced_Ovarian_Cancer_Sensitive_to_Platinum-based_Chemotherapy,ZD4054_Zibotentan|Paclitaxel|Carboplatin|Placebo|,other_events,arm1,Placebo+Paclitaxel+Carboplatin,2,paclitaxel,taxane
1676,Drug_Hypersensitivity,4,58,Immune_system_disorders,NCT00929162,https://clinicaltrials.gov/show/NCT00929162,Patients_With_Advanced_Ovarian_Cancer_Sensitive_to_Platinum-based_Chemotherapy,ZD4054_Zibotentan|Paclitaxel|Carboplatin|Placebo|,serious_events,arm1,Placebo+Paclitaxel+Carboplatin,2,paclitaxel,taxane
1679,DRUG_HYPERSENSITIVITY,1,3,Immune_system_disorders,NCT00932373,https://clinicaltrials.gov/show/NCT00932373,Metastatic_Breast_Cancer,trastuzumab-MCC-DM1,other_events,arm7,Trastuzumab-MCC-DM-1.6-mg/kg-Weekly,18,trastuzumab,monoclonal-antibody
2168,Dermatitis_allergic,1,264,Skin_and_subcutaneous_tissue_disorders,NCT00933270,https://clinicaltrials.gov/show/NCT00933270,Peripheral_Vascular_Disease,SUPERA??_Nitinol_Stent_System,serious_events,arm0,Supera??-Peripheral-Stent-System-ITT,,,
2167,Dermatitis_allergic,1,38,Skin_and_subcutaneous_tissue_disorders,NCT00933335,https://clinicaltrials.gov/show/NCT00933335,Lymphoma_Non-Hodgkin|Non-Hodgkin's_Lymphoma|,Tositumomab_and_Iodine_I_131_Tositumomab,other_events,arm0,Fludarabine,66,fludarabine,antimetabolite
1681,Drug_hypersensitivity,3,38,Immune_system_disorders,NCT00933335,https://clinicaltrials.gov/show/NCT00933335,Lymphoma_Non-Hodgkin|Non-Hodgkin's_Lymphoma|,Tositumomab_and_Iodine_I_131_Tositumomab,other_events,arm0,Fludarabine,66,fludarabine,antimetabolite
2166,Dermatitis_allergic,1,38,Skin_and_subcutaneous_tissue_disorders,NCT00933335,https://clinicaltrials.gov/show/NCT00933335,Lymphoma_Non-Hodgkin|Non-Hodgkin's_Lymphoma|,Tositumomab_and_Iodine_I_131_Tositumomab,other_events,arm2,Fludarabine/TST-and-Iodine-I-131-TST-(Combined-Regimen),66,fludarabine,antimetabolite
1680,Drug_hypersensitivity,3,38,Immune_system_disorders,NCT00933335,https://clinicaltrials.gov/show/NCT00933335,Lymphoma_Non-Hodgkin|Non-Hodgkin's_Lymphoma|,Tositumomab_and_Iodine_I_131_Tositumomab,other_events,arm2,Fludarabine/TST-and-Iodine-I-131-TST-(Combined-Regimen),66,fludarabine,antimetabolite
2166,Dermatitis_allergic,1,38,Skin_and_subcutaneous_tissue_disorders,NCT00933335,https://clinicaltrials.gov/show/NCT00933335,Lymphoma_Non-Hodgkin|Non-Hodgkin's_Lymphoma|,Tositumomab_and_Iodine_I_131_Tositumomab,other_events,arm2,Fludarabine/TST-and-Iodine-I-131-TST-(Combined-Regimen),53,iodine,Class_Name_Needed
1680,Drug_hypersensitivity,3,38,Immune_system_disorders,NCT00933335,https://clinicaltrials.gov/show/NCT00933335,Lymphoma_Non-Hodgkin|Non-Hodgkin's_Lymphoma|,Tositumomab_and_Iodine_I_131_Tositumomab,other_events,arm2,Fludarabine/TST-and-Iodine-I-131-TST-(Combined-Regimen),53,iodine,Class_Name_Needed
869,Hypersensitivity,1,189,Immune_system_disorders,NCT00937560,https://clinicaltrials.gov/show/NCT00937560,Ovarian_Cancer,Bevacizumab|Paclitaxel|Carboplatin|,serious_events,arm0,Bevacizumab-+-Paclitaxel-+-Carboplatin,3,carboplatin,alkalating-agent
869,Hypersensitivity,1,189,Immune_system_disorders,NCT00937560,https://clinicaltrials.gov/show/NCT00937560,Ovarian_Cancer,Bevacizumab|Paclitaxel|Carboplatin|,serious_events,arm0,Bevacizumab-+-Paclitaxel-+-Carboplatin,4,bevacizumab,monoclonal-antibody
869,Hypersensitivity,1,189,Immune_system_disorders,NCT00937560,https://clinicaltrials.gov/show/NCT00937560,Ovarian_Cancer,Bevacizumab|Paclitaxel|Carboplatin|,serious_events,arm0,Bevacizumab-+-Paclitaxel-+-Carboplatin,22,bevacizumab,monoclonal-antibody
869,Hypersensitivity,1,189,Immune_system_disorders,NCT00937560,https://clinicaltrials.gov/show/NCT00937560,Ovarian_Cancer,Bevacizumab|Paclitaxel|Carboplatin|,serious_events,arm0,Bevacizumab-+-Paclitaxel-+-Carboplatin,2,paclitaxel,taxane
2357,Anaphylaxis,1,26,Immune_system_disorders,NCT00939627,https://clinicaltrials.gov/show/NCT00939627,Metastatic_Squamous_Neck_Cancer_With_Occult_Primary_Squamous_Cell_Carcinoma|Recurrent_Metastatic_Squamous_Neck_Cancer_With_Occult_Primary|Recurrent_Salivary_Gland_Cancer|Recurrent_Squamous_Cell_Carcinoma_of_the_Hypopharynx|Recurrent_Squamous_Cell_Carcinom,cetuximab|placebo|sorafenib_tosylate|laboratory_biomarker_analysis|quality-of-life_assessment|,other_events,arm0,Arm-A---Cetuximab,5,cetuximab,Epidermal-growth-factor-receptor-inhibitor
2359,Anaphylaxis,1,26,Immune_system_disorders,NCT00939627,https://clinicaltrials.gov/show/NCT00939627,Metastatic_Squamous_Neck_Cancer_With_Occult_Primary_Squamous_Cell_Carcinoma|Recurrent_Metastatic_Squamous_Neck_Cancer_With_Occult_Primary|Recurrent_Salivary_Gland_Cancer|Recurrent_Squamous_Cell_Carcinoma_of_the_Hypopharynx|Recurrent_Squamous_Cell_Carcinom,cetuximab|placebo|sorafenib_tosylate|laboratory_biomarker_analysis|quality-of-life_assessment|,serious_events,arm0,Arm-A---Cetuximab,5,cetuximab,Epidermal-growth-factor-receptor-inhibitor
2358,Anaphylaxis,2,27,Immune_system_disorders,NCT00939627,https://clinicaltrials.gov/show/NCT00939627,Metastatic_Squamous_Neck_Cancer_With_Occult_Primary_Squamous_Cell_Carcinoma|Recurrent_Metastatic_Squamous_Neck_Cancer_With_Occult_Primary|Recurrent_Salivary_Gland_Cancer|Recurrent_Squamous_Cell_Carcinoma_of_the_Hypopharynx|Recurrent_Squamous_Cell_Carcinom,cetuximab|placebo|sorafenib_tosylate|laboratory_biomarker_analysis|quality-of-life_assessment|,other_events,arm1,Arm-B---Cetuximab-and-Sorafenib-Tosylate,5,cetuximab,Epidermal-growth-factor-receptor-inhibitor
2358,Anaphylaxis,2,27,Immune_system_disorders,NCT00939627,https://clinicaltrials.gov/show/NCT00939627,Metastatic_Squamous_Neck_Cancer_With_Occult_Primary_Squamous_Cell_Carcinoma|Recurrent_Metastatic_Squamous_Neck_Cancer_With_Occult_Primary|Recurrent_Salivary_Gland_Cancer|Recurrent_Squamous_Cell_Carcinoma_of_the_Hypopharynx|Recurrent_Squamous_Cell_Carcinom,cetuximab|placebo|sorafenib_tosylate|laboratory_biomarker_analysis|quality-of-life_assessment|,other_events,arm1,Arm-B---Cetuximab-and-Sorafenib-Tosylate,90,sorafenib,Tyrosine-Kinase-inhibitor
873,Hypersensitivity,1,106,Immune_system_disorders,NCT00943111,https://clinicaltrials.gov/show/NCT00943111,Gaucher_Disease_Type_1,Eliglustat_tartrate|Imiglucerase|,other_events,arm0,Eliglustat,,,
2707,Allergic_reaction,4,46,General_disorders,NCT00945139,https://clinicaltrials.gov/show/NCT00945139,Ovarian_Cancer,Doxil|Avastin|,other_events,arm0,Doxil-(PLD)-+-Avastin-(Bevacizumab),4,bevacizumab,monoclonal-antibody
2707,Allergic_reaction,4,46,General_disorders,NCT00945139,https://clinicaltrials.gov/show/NCT00945139,Ovarian_Cancer,Doxil|Avastin|,other_events,arm0,Doxil-(PLD)-+-Avastin-(Bevacizumab),22,bevacizumab,monoclonal-antibody
875,Hypersensitivity,1,6,Immune_system_disorders,NCT00948389,https://clinicaltrials.gov/show/NCT00948389,Glioblastoma,Dasatinib|Lomustine|,other_events,arm0,Dasatinib-100-mg-QD/100-mg-BID-+-Lomustine-110-mg/m^2,24,dasatinib,signal-transduction-inhibitor---tyrosine-kinase-inhibitor
876,Hypersensitivity,1,166,Immune_system_disorders,NCT00948675,https://clinicaltrials.gov/show/NCT00948675,Advanced_Non-Small_Cell_Lung_Cancer,Pemetrexed|Carboplatin|Paclitaxel|Bevacizumab|,serious_events,arm1,Paclitaxel-+-Carboplatin-+-Bevacizumab,3,carboplatin,alkalating-agent
876,Hypersensitivity,1,166,Immune_system_disorders,NCT00948675,https://clinicaltrials.gov/show/NCT00948675,Advanced_Non-Small_Cell_Lung_Cancer,Pemetrexed|Carboplatin|Paclitaxel|Bevacizumab|,serious_events,arm1,Paclitaxel-+-Carboplatin-+-Bevacizumab,4,bevacizumab,monoclonal-antibody
876,Hypersensitivity,1,166,Immune_system_disorders,NCT00948675,https://clinicaltrials.gov/show/NCT00948675,Advanced_Non-Small_Cell_Lung_Cancer,Pemetrexed|Carboplatin|Paclitaxel|Bevacizumab|,serious_events,arm1,Paclitaxel-+-Carboplatin-+-Bevacizumab,22,bevacizumab,monoclonal-antibody
876,Hypersensitivity,1,166,Immune_system_disorders,NCT00948675,https://clinicaltrials.gov/show/NCT00948675,Advanced_Non-Small_Cell_Lung_Cancer,Pemetrexed|Carboplatin|Paclitaxel|Bevacizumab|,serious_events,arm1,Paclitaxel-+-Carboplatin-+-Bevacizumab,2,paclitaxel,taxane
2171,Dermatitis_allergic,1,16,Skin_and_subcutaneous_tissue_disorders,NCT00950742,https://clinicaltrials.gov/show/NCT00950742,Breast_Neoplasms,Trastuzumab|BIBW_2992|,other_events,arm0,Afatinib-20mg-+-Herceptin,,,
878,Hypersensitivity,1,41,Immune_system_disorders,NCT00950755,https://clinicaltrials.gov/show/NCT00950755,Lymphoma_Non-Hodgkin|Non-Hodgkin's_Lymphoma|,tositumomab_and_Iodine_I_131_tositumomab_(anti-B1_antibody),other_events,arm0,TST-and-Iodine-I-131-TST,53,iodine,Class_Name_Needed
2172,Dermatitis_allergic,1,18,Skin_and_subcutaneous_tissue_disorders,NCT00950911,https://clinicaltrials.gov/show/NCT00950911,Bone_Metastases_in_Men_With_Hormone-Refractory_Prostate_Cancer|Bone_Metastases_in_Subjects_With_Advanced_Breast_Cancer|Bone_Metastases_in_Subjects_With_Advanced_Cancer_or_Multiple_Myeloma|,amg_162,other_events,arm1,Denosumab-120-mg-Q4W-/-Denosumab-120-mg-Q4W,,,
2708,Allergic_Reaction,2,9,Immune_system_disorders,NCT00955721,https://clinicaltrials.gov/show/NCT00955721,Cholangiocarcinoma|Biliary_Tract_Cancer|Gallbladder_Cancer|,Gemcitabine|Oxaliplatin|Sorafenib|,other_events,arm0,Phase-1,,,
2710,Allergic_reaction,2,49,Immune_system_disorders,NCT00965250,https://clinicaltrials.gov/show/NCT00965250,Thymoma|Thymic_Carcinoma|Thymic_Carcinoid|Thymic_Neuroendocrine_Tumors|,IMC-12,other_events,arm0,IMC-A12-Monotherapy-in-Patients,,,
2711,ALLERGIC_REACTION,1,12,Immune_system_disorders,NCT00972205,https://clinicaltrials.gov/show/NCT00972205,Cervical|Ovarian|Lung|Breast|Renal|,paclitaxel|CBT-1(Registered_Trademark)|Tc_99m_sestamibi|,other_events,arm0,Paclitaxel-and-CBT-1-to-Treat-Solid-Tumors,2,paclitaxel,taxane
882,Hypersensitivity,1,7,Immune_system_disorders,NCT00975806,https://clinicaltrials.gov/show/NCT00975806,Renal_Cell_Carcinoma,Lenalidomide_(CC-5013)_in_combination_with_sunitinib|Lenalidomide|Sunitinib|,serious_events,arm1,Cohort-F,,,
887,Hypersensitivity,1,12,Immune_system_disorders,NCT00982657,https://clinicaltrials.gov/show/NCT00982657,Solid_Tumor,CVX-060_+_sunitinib|CVX-060_+_sunitinib|CVX-060_+_sunitinib|CVX-060_+_sunitinib|CVX-060_+_sunitinib|Sunitinib|,other_events,arm0,CVX-060-6-mg/kg-+-Sunitinib-50-mg,27,sunitinib,tyrosine-kinase-inhibitor-and-angiogenesis-inhibitor
2712,Allergic_reaction,1,207,Immune_system_disorders,NCT00984282,https://clinicaltrials.gov/show/NCT00984282,Thyroid_Neoplasms,Sorafenib_(Nexavar_BAY43-9006)|Placebo|,serious_events,arm0,Sorafenib-(Double-Blind-Only),90,sorafenib,Tyrosine-Kinase-inhibitor
889,Hypersensitivity,1,6,Immune_system_disorders,NCT00985959,https://clinicaltrials.gov/show/NCT00985959,Multiple_Myeloma,JNJ-26866138_0.7_mg/m2|JNJ-26866138_1.0_mg/m2|JNJ-26866138_1.3_mg/m2|Melphalan|Prednisolone|,other_events,arm1,Phase-I---JNJ-26866138-1.0-mg/m2-Group,,,
890,Hypersensitivity,8,87,Immune_system_disorders,NCT00985959,https://clinicaltrials.gov/show/NCT00985959,Multiple_Myeloma,JNJ-26866138_0.7_mg/m2|JNJ-26866138_1.0_mg/m2|JNJ-26866138_1.3_mg/m2|Melphalan|Prednisolone|,other_events,arm3,Phase-II---JNJ-26866138-1.3-mg/m2-Group,,,
2713,Allergic_reaction,1,48,Immune_system_disorders,NCT00986674,https://clinicaltrials.gov/show/NCT00986674,Recurrent_Non-small_Cell_Lung_Cancer|Stage_IIIB_Non-small_Cell_Lung_Cancer|Stage_IV_Non-small_Cell_Lung_Cancer|,cixutumumab|carboplatin|paclitaxel|cetuximab|,serious_events,arm2,Arm-III-(Carboplatin-Paclitaxel-Cetuximab-Cixutumumab),3,carboplatin,alkalating-agent
2360,Anaphylaxis,1,48,Immune_system_disorders,NCT00986674,https://clinicaltrials.gov/show/NCT00986674,Recurrent_Non-small_Cell_Lung_Cancer|Stage_IIIB_Non-small_Cell_Lung_Cancer|Stage_IV_Non-small_Cell_Lung_Cancer|,cixutumumab|carboplatin|paclitaxel|cetuximab|,serious_events,arm2,Arm-III-(Carboplatin-Paclitaxel-Cetuximab-Cixutumumab),3,carboplatin,alkalating-agent
2713,Allergic_reaction,1,48,Immune_system_disorders,NCT00986674,https://clinicaltrials.gov/show/NCT00986674,Recurrent_Non-small_Cell_Lung_Cancer|Stage_IIIB_Non-small_Cell_Lung_Cancer|Stage_IV_Non-small_Cell_Lung_Cancer|,cixutumumab|carboplatin|paclitaxel|cetuximab|,serious_events,arm2,Arm-III-(Carboplatin-Paclitaxel-Cetuximab-Cixutumumab),5,cetuximab,Epidermal-growth-factor-receptor-inhibitor
2360,Anaphylaxis,1,48,Immune_system_disorders,NCT00986674,https://clinicaltrials.gov/show/NCT00986674,Recurrent_Non-small_Cell_Lung_Cancer|Stage_IIIB_Non-small_Cell_Lung_Cancer|Stage_IV_Non-small_Cell_Lung_Cancer|,cixutumumab|carboplatin|paclitaxel|cetuximab|,serious_events,arm2,Arm-III-(Carboplatin-Paclitaxel-Cetuximab-Cixutumumab),5,cetuximab,Epidermal-growth-factor-receptor-inhibitor
2713,Allergic_reaction,1,48,Immune_system_disorders,NCT00986674,https://clinicaltrials.gov/show/NCT00986674,Recurrent_Non-small_Cell_Lung_Cancer|Stage_IIIB_Non-small_Cell_Lung_Cancer|Stage_IV_Non-small_Cell_Lung_Cancer|,cixutumumab|carboplatin|paclitaxel|cetuximab|,serious_events,arm2,Arm-III-(Carboplatin-Paclitaxel-Cetuximab-Cixutumumab),2,paclitaxel,taxane
2360,Anaphylaxis,1,48,Immune_system_disorders,NCT00986674,https://clinicaltrials.gov/show/NCT00986674,Recurrent_Non-small_Cell_Lung_Cancer|Stage_IIIB_Non-small_Cell_Lung_Cancer|Stage_IV_Non-small_Cell_Lung_Cancer|,cixutumumab|carboplatin|paclitaxel|cetuximab|,serious_events,arm2,Arm-III-(Carboplatin-Paclitaxel-Cetuximab-Cixutumumab),2,paclitaxel,taxane
894,Hypersensitivity,1,16,Immune_system_disorders,NCT00987935,https://clinicaltrials.gov/show/NCT00987935,Carcinoma_Hepatocellular,Sorafenib|BIBF_1120|,other_events,arm6,Phase-I-Group-II-Nintedanib-200-mg-Bid,,,
1689,Drug_Hypersensitivity,1,521,Immune_system_disorders,NCT00988208,https://clinicaltrials.gov/show/NCT00988208,Prostate_Cancer,Lenalidomide|Docetaxel|Prednisone|Placebo|,serious_events,arm0,Docetaxel/Prednisone/Placebo-(DP),85,prednisone,steroid
896,Hypersensitivity,1,521,Immune_system_disorders,NCT00988208,https://clinicaltrials.gov/show/NCT00988208,Prostate_Cancer,Lenalidomide|Docetaxel|Prednisone|Placebo|,serious_events,arm0,Docetaxel/Prednisone/Placebo-(DP),85,prednisone,steroid
897,Hypersensitivity,20,521,Immune_system_disorders,NCT00988208,https://clinicaltrials.gov/show/NCT00988208,Prostate_Cancer,Lenalidomide|Docetaxel|Prednisone|Placebo|,other_events,arm0,Docetaxel/Prednisone/Placebo-(DP),85,prednisone,steroid
1689,Drug_Hypersensitivity,1,521,Immune_system_disorders,NCT00988208,https://clinicaltrials.gov/show/NCT00988208,Prostate_Cancer,Lenalidomide|Docetaxel|Prednisone|Placebo|,serious_events,arm0,Docetaxel/Prednisone/Placebo-(DP),8,docetaxel,taxane
896,Hypersensitivity,1,521,Immune_system_disorders,NCT00988208,https://clinicaltrials.gov/show/NCT00988208,Prostate_Cancer,Lenalidomide|Docetaxel|Prednisone|Placebo|,serious_events,arm0,Docetaxel/Prednisone/Placebo-(DP),8,docetaxel,taxane
897,Hypersensitivity,20,521,Immune_system_disorders,NCT00988208,https://clinicaltrials.gov/show/NCT00988208,Prostate_Cancer,Lenalidomide|Docetaxel|Prednisone|Placebo|,other_events,arm0,Docetaxel/Prednisone/Placebo-(DP),8,docetaxel,taxane
1688,Drug_Hypersensitivity,1,525,Immune_system_disorders,NCT00988208,https://clinicaltrials.gov/show/NCT00988208,Prostate_Cancer,Lenalidomide|Docetaxel|Prednisone|Placebo|,serious_events,arm1,Lenalidomide/Docetaxel/Prednisone-(DPL),25,lenalidomide,immunomodulatory-agent-or-antiangiogenic-agent
895,Hypersensitivity,3,525,Immune_system_disorders,NCT00988208,https://clinicaltrials.gov/show/NCT00988208,Prostate_Cancer,Lenalidomide|Docetaxel|Prednisone|Placebo|,serious_events,arm1,Lenalidomide/Docetaxel/Prednisone-(DPL),25,lenalidomide,immunomodulatory-agent-or-antiangiogenic-agent
898,Hypersensitivity,48,525,Immune_system_disorders,NCT00988208,https://clinicaltrials.gov/show/NCT00988208,Prostate_Cancer,Lenalidomide|Docetaxel|Prednisone|Placebo|,other_events,arm1,Lenalidomide/Docetaxel/Prednisone-(DPL),25,lenalidomide,immunomodulatory-agent-or-antiangiogenic-agent
1688,Drug_Hypersensitivity,1,525,Immune_system_disorders,NCT00988208,https://clinicaltrials.gov/show/NCT00988208,Prostate_Cancer,Lenalidomide|Docetaxel|Prednisone|Placebo|,serious_events,arm1,Lenalidomide/Docetaxel/Prednisone-(DPL),85,prednisone,steroid
895,Hypersensitivity,3,525,Immune_system_disorders,NCT00988208,https://clinicaltrials.gov/show/NCT00988208,Prostate_Cancer,Lenalidomide|Docetaxel|Prednisone|Placebo|,serious_events,arm1,Lenalidomide/Docetaxel/Prednisone-(DPL),85,prednisone,steroid
898,Hypersensitivity,48,525,Immune_system_disorders,NCT00988208,https://clinicaltrials.gov/show/NCT00988208,Prostate_Cancer,Lenalidomide|Docetaxel|Prednisone|Placebo|,other_events,arm1,Lenalidomide/Docetaxel/Prednisone-(DPL),85,prednisone,steroid
1688,Drug_Hypersensitivity,1,525,Immune_system_disorders,NCT00988208,https://clinicaltrials.gov/show/NCT00988208,Prostate_Cancer,Lenalidomide|Docetaxel|Prednisone|Placebo|,serious_events,arm1,Lenalidomide/Docetaxel/Prednisone-(DPL),8,docetaxel,taxane
895,Hypersensitivity,3,525,Immune_system_disorders,NCT00988208,https://clinicaltrials.gov/show/NCT00988208,Prostate_Cancer,Lenalidomide|Docetaxel|Prednisone|Placebo|,serious_events,arm1,Lenalidomide/Docetaxel/Prednisone-(DPL),8,docetaxel,taxane
898,Hypersensitivity,48,525,Immune_system_disorders,NCT00988208,https://clinicaltrials.gov/show/NCT00988208,Prostate_Cancer,Lenalidomide|Docetaxel|Prednisone|Placebo|,other_events,arm1,Lenalidomide/Docetaxel/Prednisone-(DPL),8,docetaxel,taxane
2180,Dermatitis_allergic,1,6,Skin_and_subcutaneous_tissue_disorders,NCT00998296,https://clinicaltrials.gov/show/NCT00998296,Neoplasms,BIBW_2992|BIBF_1120|,other_events,arm0,Nintedanib-150-mg-+Afatinib-30-mg---Continuously,,,
1694,Drug_hypersensitivity,1,6,Immune_system_disorders,NCT01001221,https://clinicaltrials.gov/show/NCT01001221,Neoplasms_Malignant,cabazitaxel|gemcitabine|,other_events,arm3,Gemcitabine-+-Cabazitaxel-Dose-Level-0,6,gemcitabine,antimetabolites
905,Hypersensitivity,2,503,Immune_system_disorders,NCT01001377,https://clinicaltrials.gov/show/NCT01001377,Metastatic_Colorectal_Cancer,Cetuximab|Panitumumab|,serious_events,arm0,Cetuximab,5,cetuximab,Epidermal-growth-factor-receptor-inhibitor
904,Hypersensitivity,1,496,Immune_system_disorders,NCT01001377,https://clinicaltrials.gov/show/NCT01001377,Metastatic_Colorectal_Cancer,Cetuximab|Panitumumab|,serious_events,arm1,Panitumumab,30,panitumumab,monoclonal-antibody-and-signal-transduction-inhibitor
907,Hypersensitivity,1,4,Immune_system_disorders,NCT01004003,https://clinicaltrials.gov/show/NCT01004003,Carcinoma_Hepatocellular,Sorafenib|BIBF_1120|,other_events,arm2,Phase-I-Group-1-200mg-Nintedanib-Bid,,,
906,Hypersensitivity,1,20,Immune_system_disorders,NCT01004159,https://clinicaltrials.gov/show/NCT01004159,Colorectal_Cancer,cetuximab_with_irinotecan,serious_events,arm0,Cetuximab-With-Irinotecan,5,cetuximab,Epidermal-growth-factor-receptor-inhibitor
906,Hypersensitivity,1,20,Immune_system_disorders,NCT01004159,https://clinicaltrials.gov/show/NCT01004159,Colorectal_Cancer,cetuximab_with_irinotecan,serious_events,arm0,Cetuximab-With-Irinotecan,46,irinotecan,plant-alkaloid-and-topoisomerase-1-inhibitor
908,Hypersensitivity,1,282,Immune_system_disorders,NCT01006980,https://clinicaltrials.gov/show/NCT01006980,Malignant_Melanoma,RO5185426|dacarbazine|,serious_events,arm1,Dacarbazine,,,
2182,Dermatitis_allergic,1,66,Skin_and_subcutaneous_tissue_disorders,NCT01012258,https://clinicaltrials.gov/show/NCT01012258,Squamous_Cell_Carcinoma_of_the_Head_and_Neck,Cetuximab_+_concomitant_boost_radiotherapy,other_events,arm0,Cetuximab:-Treatment-Emergent-Phase,5,cetuximab,Epidermal-growth-factor-receptor-inhibitor
1696,Drug_hypersensitivity,1,66,Immune_system_disorders,NCT01012258,https://clinicaltrials.gov/show/NCT01012258,Squamous_Cell_Carcinoma_of_the_Head_and_Neck,Cetuximab_+_concomitant_boost_radiotherapy,other_events,arm0,Cetuximab:-Treatment-Emergent-Phase,5,cetuximab,Epidermal-growth-factor-receptor-inhibitor
1697,Drug_hypersensitivity,2,66,Immune_system_disorders,NCT01012258,https://clinicaltrials.gov/show/NCT01012258,Squamous_Cell_Carcinoma_of_the_Head_and_Neck,Cetuximab_+_concomitant_boost_radiotherapy,serious_events,arm0,Cetuximab:-Treatment-Emergent-Phase,5,cetuximab,Epidermal-growth-factor-receptor-inhibitor
910,Hypersensitivity,1,222,Immune_system_disorders,NCT01014208,https://clinicaltrials.gov/show/NCT01014208,Lymphoma_Large-Cell_Diffuse,OFATUMUMAB_+_DHAP|RITUXIMAB_+_DHAP|,serious_events,arm1,Ofatumumab-+-Chemotherapy,42,ofatumumab,monoclonal-antibody
1698,Drug_hypersensitivity,58,902,Immune_system_disorders,NCT01015118,https://clinicaltrials.gov/show/NCT01015118,Ovarian_Neoplasms|Peritoneal_Neoplasms|,Placebo|Paclitaxel|BIBF_1120|Carboplatin|Paclitaxel|Carboplatin|,other_events,arm0,Nintedanib,,,
1699,Drug_hypersensitivity,9,902,Immune_system_disorders,NCT01015118,https://clinicaltrials.gov/show/NCT01015118,Ovarian_Neoplasms|Peritoneal_Neoplasms|,Placebo|Paclitaxel|BIBF_1120|Carboplatin|Paclitaxel|Carboplatin|,serious_events,arm0,Nintedanib,,,
911,Hypersensitivity,53,902,Immune_system_disorders,NCT01015118,https://clinicaltrials.gov/show/NCT01015118,Ovarian_Neoplasms|Peritoneal_Neoplasms|,Placebo|Paclitaxel|BIBF_1120|Carboplatin|Paclitaxel|Carboplatin|,other_events,arm0,Nintedanib,,,
912,Hypersensitivity,1,902,Immune_system_disorders,NCT01015118,https://clinicaltrials.gov/show/NCT01015118,Ovarian_Neoplasms|Peritoneal_Neoplasms|,Placebo|Paclitaxel|BIBF_1120|Carboplatin|Paclitaxel|Carboplatin|,serious_events,arm0,Nintedanib,,,
1700,Drug_hypersensitivity,3,450,Immune_system_disorders,NCT01015118,https://clinicaltrials.gov/show/NCT01015118,Ovarian_Neoplasms|Peritoneal_Neoplasms|,Placebo|Paclitaxel|BIBF_1120|Carboplatin|Paclitaxel|Carboplatin|,serious_events,arm1,Placebo,,,
1701,Drug_hypersensitivity,21,450,Immune_system_disorders,NCT01015118,https://clinicaltrials.gov/show/NCT01015118,Ovarian_Neoplasms|Peritoneal_Neoplasms|,Placebo|Paclitaxel|BIBF_1120|Carboplatin|Paclitaxel|Carboplatin|,other_events,arm1,Placebo,,,
913,Hypersensitivity,1,450,Immune_system_disorders,NCT01015118,https://clinicaltrials.gov/show/NCT01015118,Ovarian_Neoplasms|Peritoneal_Neoplasms|,Placebo|Paclitaxel|BIBF_1120|Carboplatin|Paclitaxel|Carboplatin|,serious_events,arm1,Placebo,,,
914,Hypersensitivity,30,450,Immune_system_disorders,NCT01015118,https://clinicaltrials.gov/show/NCT01015118,Ovarian_Neoplasms|Peritoneal_Neoplasms|,Placebo|Paclitaxel|BIBF_1120|Carboplatin|Paclitaxel|Carboplatin|,other_events,arm1,Placebo,,,
1704,Drug_hypersensitivity,1,18,Immune_system_disorders,NCT01020006,https://clinicaltrials.gov/show/NCT01020006,Pancreatic_Cancer|Ductal_Adrenocarcinoma|Exocrine_Pancreatic_Cancer|,PCI-27483|Gemcitabine|,other_events,arm1,(PCI-27483-+-Gemcitabine)/Part-B,6,gemcitabine,antimetabolites
2185,Dermatitis_allergic,1,377,Skin_and_subcutaneous_tissue_disorders,NCT01023308,https://clinicaltrials.gov/show/NCT01023308,Multiple_Myeloma,Panobinostat|Bortezomib|,serious_events,arm1,PBO+BTZ+Dex,,,
923,Hypersensitivity,1,29,Immune_system_disorders,NCT01032291,https://clinicaltrials.gov/show/NCT01032291,Colorectal_Cancer,cetuximab|lenalidomide|,serious_events,arm1,Lenalidomide-+-Cetuximab-(Safety-Lead-in-and-Proof-of-Concept),5,cetuximab,Epidermal-growth-factor-receptor-inhibitor
923,Hypersensitivity,1,29,Immune_system_disorders,NCT01032291,https://clinicaltrials.gov/show/NCT01032291,Colorectal_Cancer,cetuximab|lenalidomide|,serious_events,arm1,Lenalidomide-+-Cetuximab-(Safety-Lead-in-and-Proof-of-Concept),25,lenalidomide,immunomodulatory-agent-or-antiangiogenic-agent
1709,DRUG_HYPERSENSITIVITY,2,54,Immune_system_disorders,NCT01040832,https://clinicaltrials.gov/show/NCT01040832,Squamous_Cell_Carcinoma_of_the_Head_and_Neck_Cancer,Cetuximab|EMD_1201081|,serious_events,arm0,Cetuximab-Plus-EMD-1201081,5,cetuximab,Epidermal-growth-factor-receptor-inhibitor
925,Hypersensitivity,1,6,Immune_system_disorders,NCT01049945,https://clinicaltrials.gov/show/NCT01049945,Refractory_Multiple_Myeloma,bendamustine_hydrochloride|lenalidomide|dexamethasone|,other_events,arm3,Phase-I-Dose-Level-4,,,
926,Hypersensitivity,4,49,Immune_system_disorders,NCT01049945,https://clinicaltrials.gov/show/NCT01049945,Refractory_Multiple_Myeloma,bendamustine_hydrochloride|lenalidomide|dexamethasone|,other_events,arm5,Phase-II-Dose-Level-4,,,
1711,Drug_hypersensitivity,1,177,Immune_system_disorders,NCT01056510,https://clinicaltrials.gov/show/NCT01056510,Lymphocytic_Leukemia_Chronic,bendamustine|chlorambucil|rituximab_[MabThera/Rituxan]|,serious_events,arm0,Rituximab-+-Bendamustine,36,bendamustine,alkylating-agent
1711,Drug_hypersensitivity,1,177,Immune_system_disorders,NCT01056510,https://clinicaltrials.gov/show/NCT01056510,Lymphocytic_Leukemia_Chronic,bendamustine|chlorambucil|rituximab_[MabThera/Rituxan]|,serious_events,arm0,Rituximab-+-Bendamustine,16,rituximab,monoclonal-antibody
2191,Dermatitis_allergic,1,95,Skin_and_subcutaneous_tissue_disorders,NCT01063907,https://clinicaltrials.gov/show/NCT01063907,Multiple_Myeloma,KW-2478|Bortezomib|,other_events,arm0,Phase-1-and-2:-KW-2478-and-Bortezomib,70,bortezomib,proteasome-inhibitor
2192,Dermatitis_allergic,1,3,Skin_and_subcutaneous_tissue_disorders,NCT01063907,https://clinicaltrials.gov/show/NCT01063907,Multiple_Myeloma,KW-2478|Bortezomib|,other_events,arm3,Phase-1-Cohort-3:-KW-2478-175-mg/m^2-and-Bortezomib-1.0-mg/m^2,70,bortezomib,proteasome-inhibitor
930,Hypersensitivity,1,20,Immune_system_disorders,NCT01069627,https://clinicaltrials.gov/show/NCT01069627,Malignant_Melanoma,bevacizumab_[Avastin]|fotemustine|,other_events,arm0,Bevacizumab-+-Fotemustine,4,bevacizumab,monoclonal-antibody
930,Hypersensitivity,1,20,Immune_system_disorders,NCT01069627,https://clinicaltrials.gov/show/NCT01069627,Malignant_Melanoma,bevacizumab_[Avastin]|fotemustine|,other_events,arm0,Bevacizumab-+-Fotemustine,22,bevacizumab,monoclonal-antibody
1713,DRUG_HYPERSENSITIVITY,1,45,Immune_system_disorders,NCT01071083,https://clinicaltrials.gov/show/NCT01071083,Relapsing_Remitting_Multiple_Sclerosis,natalizumab|interferon_beta_1-a|methylprednisolone|IV_placebo|glatiramer_acetate|,other_events,arm1,Natalizumab,,,
1714,DRUG_HYPERSENSITIVITY,1,17,Immune_system_disorders,NCT01071083,https://clinicaltrials.gov/show/NCT01071083,Relapsing_Remitting_Multiple_Sclerosis,natalizumab|interferon_beta_1-a|methylprednisolone|IV_placebo|glatiramer_acetate|,other_events,arm2,Interferon-?_-1a,,,
1716,Drug_hypersensitivity,1,54,Immune_system_disorders,NCT01072175,https://clinicaltrials.gov/show/NCT01072175,Cancer,GSK2118436|GSK1120212|,serious_events,arm7,Part-C:-Dabrafenib-150-mg-+-Trametinib-1-mg,,,
1715,Drug_hypersensitivity,8,53,Immune_system_disorders,NCT01073163,https://clinicaltrials.gov/show/NCT01073163,Non-Hodgkin's_Lymphoma|Mantle_Cell_Lymphoma|,Bendamustine|Rituximab|,other_events,arm0,Bendamustine-With-Rituximab,36,bendamustine,alkylating-agent
1715,Drug_hypersensitivity,8,53,Immune_system_disorders,NCT01073163,https://clinicaltrials.gov/show/NCT01073163,Non-Hodgkin's_Lymphoma|Mantle_Cell_Lymphoma|,Bendamustine|Rituximab|,other_events,arm0,Bendamustine-With-Rituximab,16,rituximab,monoclonal-antibody
2196,Dermatitis_allergic,1,25,Skin_and_subcutaneous_tissue_disorders,NCT01077739,https://clinicaltrials.gov/show/NCT01077739,Colorectal_Cancer,fluorouracil_(5FU)|leucovorin|bevacizumab_[Avastin]|capecitabine_[Xeloda]|oxaliplatin|,other_events,arm0,Bevacizumab-+-Oxaliplatin-+-Capecitabine,7,oxaliplatin,alkalating-agent
1719,Drug_hypersensitivity,2,25,Immune_system_disorders,NCT01077739,https://clinicaltrials.gov/show/NCT01077739,Colorectal_Cancer,fluorouracil_(5FU)|leucovorin|bevacizumab_[Avastin]|capecitabine_[Xeloda]|oxaliplatin|,other_events,arm0,Bevacizumab-+-Oxaliplatin-+-Capecitabine,7,oxaliplatin,alkalating-agent
2196,Dermatitis_allergic,1,25,Skin_and_subcutaneous_tissue_disorders,NCT01077739,https://clinicaltrials.gov/show/NCT01077739,Colorectal_Cancer,fluorouracil_(5FU)|leucovorin|bevacizumab_[Avastin]|capecitabine_[Xeloda]|oxaliplatin|,other_events,arm0,Bevacizumab-+-Oxaliplatin-+-Capecitabine,17,capecitabine,antimetabolite
1719,Drug_hypersensitivity,2,25,Immune_system_disorders,NCT01077739,https://clinicaltrials.gov/show/NCT01077739,Colorectal_Cancer,fluorouracil_(5FU)|leucovorin|bevacizumab_[Avastin]|capecitabine_[Xeloda]|oxaliplatin|,other_events,arm0,Bevacizumab-+-Oxaliplatin-+-Capecitabine,17,capecitabine,antimetabolite
2196,Dermatitis_allergic,1,25,Skin_and_subcutaneous_tissue_disorders,NCT01077739,https://clinicaltrials.gov/show/NCT01077739,Colorectal_Cancer,fluorouracil_(5FU)|leucovorin|bevacizumab_[Avastin]|capecitabine_[Xeloda]|oxaliplatin|,other_events,arm0,Bevacizumab-+-Oxaliplatin-+-Capecitabine,29,capecitabine,antimetabolite
1719,Drug_hypersensitivity,2,25,Immune_system_disorders,NCT01077739,https://clinicaltrials.gov/show/NCT01077739,Colorectal_Cancer,fluorouracil_(5FU)|leucovorin|bevacizumab_[Avastin]|capecitabine_[Xeloda]|oxaliplatin|,other_events,arm0,Bevacizumab-+-Oxaliplatin-+-Capecitabine,29,capecitabine,antimetabolite
2196,Dermatitis_allergic,1,25,Skin_and_subcutaneous_tissue_disorders,NCT01077739,https://clinicaltrials.gov/show/NCT01077739,Colorectal_Cancer,fluorouracil_(5FU)|leucovorin|bevacizumab_[Avastin]|capecitabine_[Xeloda]|oxaliplatin|,other_events,arm0,Bevacizumab-+-Oxaliplatin-+-Capecitabine,4,bevacizumab,monoclonal-antibody
1719,Drug_hypersensitivity,2,25,Immune_system_disorders,NCT01077739,https://clinicaltrials.gov/show/NCT01077739,Colorectal_Cancer,fluorouracil_(5FU)|leucovorin|bevacizumab_[Avastin]|capecitabine_[Xeloda]|oxaliplatin|,other_events,arm0,Bevacizumab-+-Oxaliplatin-+-Capecitabine,4,bevacizumab,monoclonal-antibody
2196,Dermatitis_allergic,1,25,Skin_and_subcutaneous_tissue_disorders,NCT01077739,https://clinicaltrials.gov/show/NCT01077739,Colorectal_Cancer,fluorouracil_(5FU)|leucovorin|bevacizumab_[Avastin]|capecitabine_[Xeloda]|oxaliplatin|,other_events,arm0,Bevacizumab-+-Oxaliplatin-+-Capecitabine,22,bevacizumab,monoclonal-antibody
1719,Drug_hypersensitivity,2,25,Immune_system_disorders,NCT01077739,https://clinicaltrials.gov/show/NCT01077739,Colorectal_Cancer,fluorouracil_(5FU)|leucovorin|bevacizumab_[Avastin]|capecitabine_[Xeloda]|oxaliplatin|,other_events,arm0,Bevacizumab-+-Oxaliplatin-+-Capecitabine,22,bevacizumab,monoclonal-antibody
1720,Drug_hypersensitivity,5,50,Immune_system_disorders,NCT01077739,https://clinicaltrials.gov/show/NCT01077739,Colorectal_Cancer,fluorouracil_(5FU)|leucovorin|bevacizumab_[Avastin]|capecitabine_[Xeloda]|oxaliplatin|,other_events,arm1,Bevacizumab-+-FOLFOX,4,bevacizumab,monoclonal-antibody
935,Hypersensitivity,1,50,Immune_system_disorders,NCT01077739,https://clinicaltrials.gov/show/NCT01077739,Colorectal_Cancer,fluorouracil_(5FU)|leucovorin|bevacizumab_[Avastin]|capecitabine_[Xeloda]|oxaliplatin|,other_events,arm1,Bevacizumab-+-FOLFOX,4,bevacizumab,monoclonal-antibody
1720,Drug_hypersensitivity,5,50,Immune_system_disorders,NCT01077739,https://clinicaltrials.gov/show/NCT01077739,Colorectal_Cancer,fluorouracil_(5FU)|leucovorin|bevacizumab_[Avastin]|capecitabine_[Xeloda]|oxaliplatin|,other_events,arm1,Bevacizumab-+-FOLFOX,22,bevacizumab,monoclonal-antibody
935,Hypersensitivity,1,50,Immune_system_disorders,NCT01077739,https://clinicaltrials.gov/show/NCT01077739,Colorectal_Cancer,fluorouracil_(5FU)|leucovorin|bevacizumab_[Avastin]|capecitabine_[Xeloda]|oxaliplatin|,other_events,arm1,Bevacizumab-+-FOLFOX,22,bevacizumab,monoclonal-antibody
937,Hypersensitivity,4,197,Immune_system_disorders,NCT01078675,https://clinicaltrials.gov/show/NCT01078675,Familial_Hypercholesterolaemia,rosuvastatin_calcium|rosuvastatin_calcium|rosuvastatin_calcium|,other_events,arm0,Rosuvastatin,,,
1721,Drug_hypersensitivity,1,392,Immune_system_disorders,NCT01080391,https://clinicaltrials.gov/show/NCT01080391,Relapsed_Multiple_Myeloma,Dexamethasone|Lenalidomide|Carfilzomib|,serious_events,arm1,Carfilzomib-Lenalidomide-and-Dexamethasone-(CRd),25,lenalidomide,immunomodulatory-agent-or-antiangiogenic-agent
1721,Drug_hypersensitivity,1,392,Immune_system_disorders,NCT01080391,https://clinicaltrials.gov/show/NCT01080391,Relapsed_Multiple_Myeloma,Dexamethasone|Lenalidomide|Carfilzomib|,serious_events,arm1,Carfilzomib-Lenalidomide-and-Dexamethasone-(CRd),79,dexamethasone,steroid
1722,Drug_hypersensitivity,1,33,Immune_system_disorders,NCT01081041,https://clinicaltrials.gov/show/NCT01081041,Head_and_Neck_Cancer,Cetuximab|Cisplatin|Carboplatin|5-Fluorouracil|,serious_events,arm0,Part-1:-Safety-Lead-In-(Cetuximab-Cis-or-Carbo-5-FU),5,cetuximab,Epidermal-growth-factor-receptor-inhibitor
939,Hypersensitivity,1,33,Immune_system_disorders,NCT01081041,https://clinicaltrials.gov/show/NCT01081041,Head_and_Neck_Cancer,Cetuximab|Cisplatin|Carboplatin|5-Fluorouracil|,serious_events,arm0,Part-1:-Safety-Lead-In-(Cetuximab-Cis-or-Carbo-5-FU),5,cetuximab,Epidermal-growth-factor-receptor-inhibitor
1723,Drug_Hypersensitivity,15,81,Immune_system_disorders,NCT01081951,https://clinicaltrials.gov/show/NCT01081951,Ovarian_Cancer,olaparib|paclitaxel|carboplatin|paclitaxel|Drug:_carboplatin|,other_events,arm0,Olaparib/Carboplatin-AUC4/Paclitaxel,3,carboplatin,alkalating-agent
1724,Drug_Hypersensitivity,2,81,Immune_system_disorders,NCT01081951,https://clinicaltrials.gov/show/NCT01081951,Ovarian_Cancer,olaparib|paclitaxel|carboplatin|paclitaxel|Drug:_carboplatin|,serious_events,arm0,Olaparib/Carboplatin-AUC4/Paclitaxel,3,carboplatin,alkalating-agent
1723,Drug_Hypersensitivity,15,81,Immune_system_disorders,NCT01081951,https://clinicaltrials.gov/show/NCT01081951,Ovarian_Cancer,olaparib|paclitaxel|carboplatin|paclitaxel|Drug:_carboplatin|,other_events,arm0,Olaparib/Carboplatin-AUC4/Paclitaxel,2,paclitaxel,taxane
1724,Drug_Hypersensitivity,2,81,Immune_system_disorders,NCT01081951,https://clinicaltrials.gov/show/NCT01081951,Ovarian_Cancer,olaparib|paclitaxel|carboplatin|paclitaxel|Drug:_carboplatin|,serious_events,arm0,Olaparib/Carboplatin-AUC4/Paclitaxel,2,paclitaxel,taxane
1725,Drug_Hypersensitivity,13,75,Immune_system_disorders,NCT01081951,https://clinicaltrials.gov/show/NCT01081951,Ovarian_Cancer,olaparib|paclitaxel|carboplatin|paclitaxel|Drug:_carboplatin|,other_events,arm1,Carboplatin-AUC6/Paclitaxel,3,carboplatin,alkalating-agent
1726,Drug_Hypersensitivity,2,75,Immune_system_disorders,NCT01081951,https://clinicaltrials.gov/show/NCT01081951,Ovarian_Cancer,olaparib|paclitaxel|carboplatin|paclitaxel|Drug:_carboplatin|,serious_events,arm1,Carboplatin-AUC6/Paclitaxel,3,carboplatin,alkalating-agent
1725,Drug_Hypersensitivity,13,75,Immune_system_disorders,NCT01081951,https://clinicaltrials.gov/show/NCT01081951,Ovarian_Cancer,olaparib|paclitaxel|carboplatin|paclitaxel|Drug:_carboplatin|,other_events,arm1,Carboplatin-AUC6/Paclitaxel,2,paclitaxel,taxane
1726,Drug_Hypersensitivity,2,75,Immune_system_disorders,NCT01081951,https://clinicaltrials.gov/show/NCT01081951,Ovarian_Cancer,olaparib|paclitaxel|carboplatin|paclitaxel|Drug:_carboplatin|,serious_events,arm1,Carboplatin-AUC6/Paclitaxel,2,paclitaxel,taxane
2714,Allergic_Reaction,1,80,General_disorders,NCT01082939,https://clinicaltrials.gov/show/NCT01082939,Chronic_Lymphocytic_Leukemia,Fludarabine|Cyclophosphamide|Alemtuzumab|Rituximab|,serious_events,arm0,CFAR,,,
2362,Anaphylaxis,1,89,Immune_system_disorders,NCT01084083,https://clinicaltrials.gov/show/NCT01084083,Head_and_Neck_Cancer|Precancerous_Condition|,cetuximab|intensity-modulated_radiation_therapy_(IMRT)|Paclitaxel|Cisplatin|,serious_events,arm0,All-Treated-Patients,,,
2201,Dermatitis_allergic,1,118,Skin_and_subcutaneous_tissue_disorders,NCT01084148,https://clinicaltrials.gov/show/NCT01084148,Uremic_Xerosis,V0034CR01B|V0034CR01B_vehicle|,other_events,arm0,V0034CR01B,,,
1733,Drug_hypersensitivity,3,126,Immune_system_disorders,NCT01090011,https://clinicaltrials.gov/show/NCT01090011,Carcinoma_Non-Small-Cell_Lung,Cetuximab|Cetuximab|BIBW_2992|BIBW_2992|,serious_events,arm1,Combination-Arm---Afa40+Ctx500,,,
1734,Drug_hypersensitivity,9,126,Immune_system_disorders,NCT01090011,https://clinicaltrials.gov/show/NCT01090011,Carcinoma_Non-Small-Cell_Lung,Cetuximab|Cetuximab|BIBW_2992|BIBW_2992|,other_events,arm1,Combination-Arm---Afa40+Ctx500,,,
1732,Drug_hypersensitivity,1,36,Immune_system_disorders,NCT01090011,https://clinicaltrials.gov/show/NCT01090011,Carcinoma_Non-Small-Cell_Lung,Cetuximab|Cetuximab|BIBW_2992|BIBW_2992|,other_events,arm3,Sequential-Arm---Combination-Therapy-(Afa40+Ctx500),,,
2715,Allergic_reaction,1,29,Immune_system_disorders,NCT01091259,https://clinicaltrials.gov/show/NCT01091259,Ovarian_Cancer|Fallopian_Tube_Cancer|Primary_Peritoneal_Carcinoma|,Irinotecan|Bevacizumab|,other_events,arm0,Irinotecan-With-Bevacizumab,4,bevacizumab,monoclonal-antibody
2715,Allergic_reaction,1,29,Immune_system_disorders,NCT01091259,https://clinicaltrials.gov/show/NCT01091259,Ovarian_Cancer|Fallopian_Tube_Cancer|Primary_Peritoneal_Carcinoma|,Irinotecan|Bevacizumab|,other_events,arm0,Irinotecan-With-Bevacizumab,22,bevacizumab,monoclonal-antibody
2715,Allergic_reaction,1,29,Immune_system_disorders,NCT01091259,https://clinicaltrials.gov/show/NCT01091259,Ovarian_Cancer|Fallopian_Tube_Cancer|Primary_Peritoneal_Carcinoma|,Irinotecan|Bevacizumab|,other_events,arm0,Irinotecan-With-Bevacizumab,46,irinotecan,plant-alkaloid-and-topoisomerase-1-inhibitor
2716,Allergic_reaction,1,34,Immune_system_disorders,NCT01093222,https://clinicaltrials.gov/show/NCT01093222,Extrahepatic_Bile_Duct_Adenocarcinoma|Gallbladder_Adenocarcinoma|Gallbladder_Adenocarcinoma_With_Squamous_Metaplasia|Hilar_Cholangiocarcinoma|Recurrent_Extrahepatic_Bile_Duct_Carcinoma|Recurrent_Gallbladder_Carcinoma|Undifferentiated_Gallbladder_Carcinoma,Erlotinib_Hydrochloride|Sorafenib_Tosylate|,serious_events,arm0,Sorafenib-and-Erlotinib,31,erlotinib,epidermal-growth-factor-receptor-(EGFR)-inhibitor---protein-tyrosine-kinase-inhibitor
2716,Allergic_reaction,1,34,Immune_system_disorders,NCT01093222,https://clinicaltrials.gov/show/NCT01093222,Extrahepatic_Bile_Duct_Adenocarcinoma|Gallbladder_Adenocarcinoma|Gallbladder_Adenocarcinoma_With_Squamous_Metaplasia|Hilar_Cholangiocarcinoma|Recurrent_Extrahepatic_Bile_Duct_Carcinoma|Recurrent_Gallbladder_Carcinoma|Undifferentiated_Gallbladder_Carcinoma,Erlotinib_Hydrochloride|Sorafenib_Tosylate|,serious_events,arm0,Sorafenib-and-Erlotinib,90,sorafenib,Tyrosine-Kinase-inhibitor
2717,Allergic_reaction,1,17,General_disorders,NCT01100242,https://clinicaltrials.gov/show/NCT01100242,Metastatic_Renal_Cell_Carcinoma,Velcade_and_Sorafenib,other_events,arm0,VELCADE-and-Sorafenib,90,sorafenib,Tyrosine-Kinase-inhibitor
2718,Allergic_reaction,3,19,Immune_system_disorders,NCT01100931,https://clinicaltrials.gov/show/NCT01100931,NSCLC|Solid_Tumors|,YM155|Carboplatin|Paclitaxel|,other_events,arm1,Phase-II,,,
2719,Allergic_reaction,2,500,Immune_system_disorders,NCT01103323,https://clinicaltrials.gov/show/NCT01103323,Metastatic_Colorectal_Cancer,Regorafenib_(Stivarga_BAY73-4506)|Placebo|Best_Supportive_Care_(BSC)|,serious_events,arm0,Regorafenib-(BAY73-4506)+BSC,,,
2206,Dermatitis_allergic,1,46,Skin_and_subcutaneous_tissue_disorders,NCT01105533,https://clinicaltrials.gov/show/NCT01105533,Neoplasm,PF-00337210|PF-00337210|PF-00337210|PF-00337210|PF-00337210|PF-00337210|PF-00337210|PF-00337210|PF-00337210|PF-00337210|,other_events,arm0,PF-00337210,,,
1741,Drug_hypersensitivity,5,49,Immune_system_disorders,NCT01108341,https://clinicaltrials.gov/show/NCT01108341,Non-Hodgkin's_Lymphoma_(NHL),Bendamustine_hydrochloride|Ofatumumab|,other_events,arm0,Bendamustine-and-Ofatumumab,36,bendamustine,alkylating-agent
1741,Drug_hypersensitivity,5,49,Immune_system_disorders,NCT01108341,https://clinicaltrials.gov/show/NCT01108341,Non-Hodgkin's_Lymphoma_(NHL),Bendamustine_hydrochloride|Ofatumumab|,other_events,arm0,Bendamustine-and-Ofatumumab,42,ofatumumab,monoclonal-antibody
946,Hypersensitivity,5,60,Immune_system_disorders,NCT01109524,https://clinicaltrials.gov/show/NCT01109524,Lung_Neoplasms|Carcinoma|Cancer_of_the_Lung|Non-Small-Cell_Lung_Carcinoma|,Cetuximab|Cisplatin|Vinorelbine|,other_events,arm0,Cetuximab-+-Cisplatin/Vinorelbine,9,cisplatin,alkalating-agent
946,Hypersensitivity,5,60,Immune_system_disorders,NCT01109524,https://clinicaltrials.gov/show/NCT01109524,Lung_Neoplasms|Carcinoma|Cancer_of_the_Lung|Non-Small-Cell_Lung_Carcinoma|,Cetuximab|Cisplatin|Vinorelbine|,other_events,arm0,Cetuximab-+-Cisplatin/Vinorelbine,5,cetuximab,Epidermal-growth-factor-receptor-inhibitor
2720,Allergic_reaction,14,33,Immune_system_disorders,NCT01113632,https://clinicaltrials.gov/show/NCT01113632,Chronic_Lymphocytic_Leukemia|Small_Lymphocytic_Lymphoma|,Ofatumumab,other_events,arm0,Ofatumumab-1000mg,42,ofatumumab,monoclonal-antibody
2721,Allergic_reaction,16,44,Immune_system_disorders,NCT01113632,https://clinicaltrials.gov/show/NCT01113632,Chronic_Lymphocytic_Leukemia|Small_Lymphocytic_Lymphoma|,Ofatumumab,other_events,arm1,Ofatumumab-2000mg,42,ofatumumab,monoclonal-antibody
2723,Allergic_reaction,1,59,Immune_system_disorders,NCT01117623,https://clinicaltrials.gov/show/NCT01117623,Neoplasm,Escalation_cohort:_Regorafenib_(Stivarga_BAY73-4506)_20_mg|Escalation_cohort:_Regorafenib_(Stivarga_BAY73-4506)_40_mg|Escalation_cohort:_Regorafenib_(Stivarga_BAY73-4506)_100_mg|Escalation_cohort:_Regorafenib_(Stivarga_BAY73-4506)_120_mg|Escalation_cohort,other_events,arm2,Regorafenib-(Stivarga-BAY73-4506)-100-mg,,,
2722,Allergic_reaction,1,10,Immune_system_disorders,NCT01117623,https://clinicaltrials.gov/show/NCT01117623,Neoplasm,Escalation_cohort:_Regorafenib_(Stivarga_BAY73-4506)_20_mg|Escalation_cohort:_Regorafenib_(Stivarga_BAY73-4506)_40_mg|Escalation_cohort:_Regorafenib_(Stivarga_BAY73-4506)_100_mg|Escalation_cohort:_Regorafenib_(Stivarga_BAY73-4506)_120_mg|Escalation_cohort,other_events,arm4,Escalation-Cohort:-Regorafenib-(Stivarga-BAY73-4506)-140-mg,,,
949,Hypersensitivity,1,59,Immune_system_disorders,NCT01118845,https://clinicaltrials.gov/show/NCT01118845,Non-Hodgkin's_Lymphoma|Lymphoma_Large_Cell|Diffuse_Mantle_Cell_Lymphoma_Lymphoma|Follicular_Lymphoma|Large_B-Cell_Diffuse|,SyB_L-0501|Rituximab|,other_events,arm0,SyB-L-0501,,,
951,Hypersensitivity,1,239,Immune_system_disorders,NCT01121393,https://clinicaltrials.gov/show/NCT01121393,Carcinoma_Non-Small-Cell_Lung|Adenocarcinoma|,Gemcitabine+Cisplatin|BIBW_2992|,serious_events,arm0,Afatinib-40mg,,,
952,Hypersensitivity,2,54,Immune_system_disorders,NCT01121406,https://clinicaltrials.gov/show/NCT01121406,Ovarian_Neoplasms,Paclitaxel|Gemcitabine|Topotecan|Pegylated_liposomal_doxorubicin_(PLD)|BI_6727|,other_events,arm0,Volasertib-(BI-6727),,,
1747,Drug_hypersensitivity,1,55,Immune_system_disorders,NCT01121406,https://clinicaltrials.gov/show/NCT01121406,Ovarian_Neoplasms,Paclitaxel|Gemcitabine|Topotecan|Pegylated_liposomal_doxorubicin_(PLD)|BI_6727|,serious_events,arm1,Cytotoxic,,,
953,Hypersensitivity,2,24,Immune_system_disorders,NCT01121406,https://clinicaltrials.gov/show/NCT01121406,Ovarian_Neoplasms,Paclitaxel|Gemcitabine|Topotecan|Pegylated_liposomal_doxorubicin_(PLD)|BI_6727|,other_events,arm2,Cytotoxic-to-Volasertib-Switch,,,
954,Hypersensitivity,1,6,Immune_system_disorders,NCT01121575,https://clinicaltrials.gov/show/NCT01121575,Non_Small_Cell_Lung_Cancer,PF-02341066|PF-00299804|PF-02341066|PF-00299804|,serious_events,arm1,PF-02341066-200-mg-BID/-PF-00299804-45-mg-QD,,,
2406,Allergy,2,29,Immune_system_disorders,NCT01128543,https://clinicaltrials.gov/show/NCT01128543,Cancer,lapatinib_and_Vinorelbine,other_events,arm0,Lapatinib-1250-mg-and-Vinorelbine-20-mg/m^2,21,lapatinib,signal-transduction-inhibitor
1752,Drug_hypersensitivity,1,15,Immune_system_disorders,NCT01129336,https://clinicaltrials.gov/show/NCT01129336,First_or_Second_Line_HER2-negative_Breast_Cancer|Metastatic_Disease_Without_Bone_Metastasis|,Zoledronic_acid|Standard_Therapy|,other_events,arm0,Patients-Without-Bone-Metastases,,,
1753,Drug_hypersensitivity,1,29,Immune_system_disorders,NCT01129336,https://clinicaltrials.gov/show/NCT01129336,First_or_Second_Line_HER2-negative_Breast_Cancer|Metastatic_Disease_Without_Bone_Metastasis|,Zoledronic_acid|Standard_Therapy|,other_events,arm1,Patients-With-Bone-Metastases,,,
2725,Allergic_reaction,1,9,Immune_system_disorders,NCT01132547,https://clinicaltrials.gov/show/NCT01132547,Cancer,cyproheptadine_hydrochloride|placebo|,other_events,arm0,Arm-I-Cyproheptadine-Hydrochloride,,,
959,Hypersensitivity,1,12,Immune_system_disorders,NCT01132664,https://clinicaltrials.gov/show/NCT01132664,Metastatic_Breast_Cancer|HER2+_Breast_Cancer|,BKM120|Trastuzumab|Capecitabine|,other_events,arm1,Phase-Ib-Dose-Escalation-100-mg/Day,,,
961,Hypersensitivity,1,50,Immune_system_disorders,NCT01132664,https://clinicaltrials.gov/show/NCT01132664,Metastatic_Breast_Cancer|HER2+_Breast_Cancer|,BKM120|Trastuzumab|Capecitabine|,other_events,arm2,Phase-II-Dose-Expansion-100-mg/Day,,,
960,Hypersensitivity,1,6,Immune_system_disorders,NCT01132664,https://clinicaltrials.gov/show/NCT01132664,Metastatic_Breast_Cancer|HER2+_Breast_Cancer|,BKM120|Trastuzumab|Capecitabine|,serious_events,arm4,BM-Cohort-100-mg/Day,,,
2726,Allergic_reaction,1,118,Immune_system_disorders,NCT01134614,https://clinicaltrials.gov/show/NCT01134614,Recurrent_Melanoma|Stage_III_Melanoma|Stage_IV_Melanoma|,ipilimumab|sargramostim|,serious_events,arm0,Arm-A-(Ipilimumab-and-Sargramostim),64,ipilimumab,monoclonal-antibody
1755,Drug_hypersensitivity,1,90,Immune_system_disorders,NCT01135498,https://clinicaltrials.gov/show/NCT01135498,Colorectal_Cancer,bevacizumab_[Avastin]|eloxatin|capecitabine_[Xeloda]|erlotinib_[Tarceva]|,serious_events,arm0,Bevacizumab+Eloxatin+Capecitabine/Bevacizumab+Erlotinib,17,capecitabine,antimetabolite
1756,Drug_hypersensitivity,3,90,Immune_system_disorders,NCT01135498,https://clinicaltrials.gov/show/NCT01135498,Colorectal_Cancer,bevacizumab_[Avastin]|eloxatin|capecitabine_[Xeloda]|erlotinib_[Tarceva]|,other_events,arm0,Bevacizumab+Eloxatin+Capecitabine/Bevacizumab+Erlotinib,17,capecitabine,antimetabolite
964,Hypersensitivity,3,90,Immune_system_disorders,NCT01135498,https://clinicaltrials.gov/show/NCT01135498,Colorectal_Cancer,bevacizumab_[Avastin]|eloxatin|capecitabine_[Xeloda]|erlotinib_[Tarceva]|,other_events,arm0,Bevacizumab+Eloxatin+Capecitabine/Bevacizumab+Erlotinib,17,capecitabine,antimetabolite
1755,Drug_hypersensitivity,1,90,Immune_system_disorders,NCT01135498,https://clinicaltrials.gov/show/NCT01135498,Colorectal_Cancer,bevacizumab_[Avastin]|eloxatin|capecitabine_[Xeloda]|erlotinib_[Tarceva]|,serious_events,arm0,Bevacizumab+Eloxatin+Capecitabine/Bevacizumab+Erlotinib,29,capecitabine,antimetabolite
1756,Drug_hypersensitivity,3,90,Immune_system_disorders,NCT01135498,https://clinicaltrials.gov/show/NCT01135498,Colorectal_Cancer,bevacizumab_[Avastin]|eloxatin|capecitabine_[Xeloda]|erlotinib_[Tarceva]|,other_events,arm0,Bevacizumab+Eloxatin+Capecitabine/Bevacizumab+Erlotinib,29,capecitabine,antimetabolite
964,Hypersensitivity,3,90,Immune_system_disorders,NCT01135498,https://clinicaltrials.gov/show/NCT01135498,Colorectal_Cancer,bevacizumab_[Avastin]|eloxatin|capecitabine_[Xeloda]|erlotinib_[Tarceva]|,other_events,arm0,Bevacizumab+Eloxatin+Capecitabine/Bevacizumab+Erlotinib,29,capecitabine,antimetabolite
1755,Drug_hypersensitivity,1,90,Immune_system_disorders,NCT01135498,https://clinicaltrials.gov/show/NCT01135498,Colorectal_Cancer,bevacizumab_[Avastin]|eloxatin|capecitabine_[Xeloda]|erlotinib_[Tarceva]|,serious_events,arm0,Bevacizumab+Eloxatin+Capecitabine/Bevacizumab+Erlotinib,31,erlotinib,epidermal-growth-factor-receptor-(EGFR)-inhibitor---protein-tyrosine-kinase-inhibitor
1756,Drug_hypersensitivity,3,90,Immune_system_disorders,NCT01135498,https://clinicaltrials.gov/show/NCT01135498,Colorectal_Cancer,bevacizumab_[Avastin]|eloxatin|capecitabine_[Xeloda]|erlotinib_[Tarceva]|,other_events,arm0,Bevacizumab+Eloxatin+Capecitabine/Bevacizumab+Erlotinib,31,erlotinib,epidermal-growth-factor-receptor-(EGFR)-inhibitor---protein-tyrosine-kinase-inhibitor
964,Hypersensitivity,3,90,Immune_system_disorders,NCT01135498,https://clinicaltrials.gov/show/NCT01135498,Colorectal_Cancer,bevacizumab_[Avastin]|eloxatin|capecitabine_[Xeloda]|erlotinib_[Tarceva]|,other_events,arm0,Bevacizumab+Eloxatin+Capecitabine/Bevacizumab+Erlotinib,31,erlotinib,epidermal-growth-factor-receptor-(EGFR)-inhibitor---protein-tyrosine-kinase-inhibitor
1755,Drug_hypersensitivity,1,90,Immune_system_disorders,NCT01135498,https://clinicaltrials.gov/show/NCT01135498,Colorectal_Cancer,bevacizumab_[Avastin]|eloxatin|capecitabine_[Xeloda]|erlotinib_[Tarceva]|,serious_events,arm0,Bevacizumab+Eloxatin+Capecitabine/Bevacizumab+Erlotinib,4,bevacizumab,monoclonal-antibody
1756,Drug_hypersensitivity,3,90,Immune_system_disorders,NCT01135498,https://clinicaltrials.gov/show/NCT01135498,Colorectal_Cancer,bevacizumab_[Avastin]|eloxatin|capecitabine_[Xeloda]|erlotinib_[Tarceva]|,other_events,arm0,Bevacizumab+Eloxatin+Capecitabine/Bevacizumab+Erlotinib,4,bevacizumab,monoclonal-antibody
964,Hypersensitivity,3,90,Immune_system_disorders,NCT01135498,https://clinicaltrials.gov/show/NCT01135498,Colorectal_Cancer,bevacizumab_[Avastin]|eloxatin|capecitabine_[Xeloda]|erlotinib_[Tarceva]|,other_events,arm0,Bevacizumab+Eloxatin+Capecitabine/Bevacizumab+Erlotinib,4,bevacizumab,monoclonal-antibody
1755,Drug_hypersensitivity,1,90,Immune_system_disorders,NCT01135498,https://clinicaltrials.gov/show/NCT01135498,Colorectal_Cancer,bevacizumab_[Avastin]|eloxatin|capecitabine_[Xeloda]|erlotinib_[Tarceva]|,serious_events,arm0,Bevacizumab+Eloxatin+Capecitabine/Bevacizumab+Erlotinib,22,bevacizumab,monoclonal-antibody
1756,Drug_hypersensitivity,3,90,Immune_system_disorders,NCT01135498,https://clinicaltrials.gov/show/NCT01135498,Colorectal_Cancer,bevacizumab_[Avastin]|eloxatin|capecitabine_[Xeloda]|erlotinib_[Tarceva]|,other_events,arm0,Bevacizumab+Eloxatin+Capecitabine/Bevacizumab+Erlotinib,22,bevacizumab,monoclonal-antibody
964,Hypersensitivity,3,90,Immune_system_disorders,NCT01135498,https://clinicaltrials.gov/show/NCT01135498,Colorectal_Cancer,bevacizumab_[Avastin]|eloxatin|capecitabine_[Xeloda]|erlotinib_[Tarceva]|,other_events,arm0,Bevacizumab+Eloxatin+Capecitabine/Bevacizumab+Erlotinib,22,bevacizumab,monoclonal-antibody
1755,Drug_hypersensitivity,1,90,Immune_system_disorders,NCT01135498,https://clinicaltrials.gov/show/NCT01135498,Colorectal_Cancer,bevacizumab_[Avastin]|eloxatin|capecitabine_[Xeloda]|erlotinib_[Tarceva]|,serious_events,arm0,Bevacizumab+Eloxatin+Capecitabine/Bevacizumab+Erlotinib,62,eloxatin,Xa-inhibitors
1756,Drug_hypersensitivity,3,90,Immune_system_disorders,NCT01135498,https://clinicaltrials.gov/show/NCT01135498,Colorectal_Cancer,bevacizumab_[Avastin]|eloxatin|capecitabine_[Xeloda]|erlotinib_[Tarceva]|,other_events,arm0,Bevacizumab+Eloxatin+Capecitabine/Bevacizumab+Erlotinib,62,eloxatin,Xa-inhibitors
964,Hypersensitivity,3,90,Immune_system_disorders,NCT01135498,https://clinicaltrials.gov/show/NCT01135498,Colorectal_Cancer,bevacizumab_[Avastin]|eloxatin|capecitabine_[Xeloda]|erlotinib_[Tarceva]|,other_events,arm0,Bevacizumab+Eloxatin+Capecitabine/Bevacizumab+Erlotinib,62,eloxatin,Xa-inhibitors
966,Hypersensitivity,1,345,Immune_system_disorders,NCT01139762,https://clinicaltrials.gov/show/NCT01139762,Benign_Prostatic_Hyperplasia|Enlarged_Prostate|,Tadalafil|Placebo|Finasteride|,other_events,arm1,Tadalafil,,,
2216,Dermatitis_allergic,1,277,Skin_and_subcutaneous_tissue_disorders,NCT01140347,https://clinicaltrials.gov/show/NCT01140347,Hepatocellular_Carcinoma,Placebo|Ramucirumab_DP_(IMC-1121B)|BSC|,serious_events,arm0,Ramucirumab-(IMC-1121B)-+-BSC,,,
1757,Drug_hypersensitivity,6,233,Immune_system_disorders,NCT01144364,https://clinicaltrials.gov/show/NCT01144364,Non-Hodgkin's_Lymphoma,rituximab_[Mabthera/Rituxan],other_events,arm0,Rituximab-Induction-(Induction-Phase-Only),16,rituximab,monoclonal-antibody
968,Hypersensitivity,1,233,Immune_system_disorders,NCT01144364,https://clinicaltrials.gov/show/NCT01144364,Non-Hodgkin's_Lymphoma,rituximab_[Mabthera/Rituxan],serious_events,arm0,Rituximab-Induction-(Induction-Phase-Only),16,rituximab,monoclonal-antibody
969,Hypersensitivity,11,233,Immune_system_disorders,NCT01144364,https://clinicaltrials.gov/show/NCT01144364,Non-Hodgkin's_Lymphoma,rituximab_[Mabthera/Rituxan],other_events,arm0,Rituximab-Induction-(Induction-Phase-Only),16,rituximab,monoclonal-antibody
1758,Drug_hypersensitivity,1,101,Immune_system_disorders,NCT01144364,https://clinicaltrials.gov/show/NCT01144364,Non-Hodgkin's_Lymphoma,rituximab_[Mabthera/Rituxan],other_events,arm2,Rituximab-Induction-Observation-Maintenance-(Follow-up-Phase),88,maintenance,Class_Name_Needed
970,Hypersensitivity,1,101,Immune_system_disorders,NCT01144364,https://clinicaltrials.gov/show/NCT01144364,Non-Hodgkin's_Lymphoma,rituximab_[Mabthera/Rituxan],other_events,arm2,Rituximab-Induction-Observation-Maintenance-(Follow-up-Phase),88,maintenance,Class_Name_Needed
1758,Drug_hypersensitivity,1,101,Immune_system_disorders,NCT01144364,https://clinicaltrials.gov/show/NCT01144364,Non-Hodgkin's_Lymphoma,rituximab_[Mabthera/Rituxan],other_events,arm2,Rituximab-Induction-Observation-Maintenance-(Follow-up-Phase),16,rituximab,monoclonal-antibody
970,Hypersensitivity,1,101,Immune_system_disorders,NCT01144364,https://clinicaltrials.gov/show/NCT01144364,Non-Hodgkin's_Lymphoma,rituximab_[Mabthera/Rituxan],other_events,arm2,Rituximab-Induction-Observation-Maintenance-(Follow-up-Phase),16,rituximab,monoclonal-antibody
2728,Allergic_reaction,1,63,Immune_system_disorders,NCT01145495,https://clinicaltrials.gov/show/NCT01145495,Stage_II_Grade_1_Contiguous_Follicular_Lymphoma|Stage_II_Grade_1_Non-Contiguous_Follicular_Lymphoma|Stage_II_Grade_2_Contiguous_Follicular_Lymphoma|Stage_II_Grade_2_Non-Contiguous_Follicular_Lymphoma|Stage_II_Grade_3_Contiguous_Follicular_Lymphoma|Stage_I,Laboratory_Biomarker_Analysis|Lenalidomide|Rituximab|,serious_events,arm0,Treatment-(Lenalidomide-Rituximab),25,lenalidomide,immunomodulatory-agent-or-antiangiogenic-agent
2729,Allergic_reaction,5,63,Immune_system_disorders,NCT01145495,https://clinicaltrials.gov/show/NCT01145495,Stage_II_Grade_1_Contiguous_Follicular_Lymphoma|Stage_II_Grade_1_Non-Contiguous_Follicular_Lymphoma|Stage_II_Grade_2_Contiguous_Follicular_Lymphoma|Stage_II_Grade_2_Non-Contiguous_Follicular_Lymphoma|Stage_II_Grade_3_Contiguous_Follicular_Lymphoma|Stage_I,Laboratory_Biomarker_Analysis|Lenalidomide|Rituximab|,other_events,arm0,Treatment-(Lenalidomide-Rituximab),25,lenalidomide,immunomodulatory-agent-or-antiangiogenic-agent
2728,Allergic_reaction,1,63,Immune_system_disorders,NCT01145495,https://clinicaltrials.gov/show/NCT01145495,Stage_II_Grade_1_Contiguous_Follicular_Lymphoma|Stage_II_Grade_1_Non-Contiguous_Follicular_Lymphoma|Stage_II_Grade_2_Contiguous_Follicular_Lymphoma|Stage_II_Grade_2_Non-Contiguous_Follicular_Lymphoma|Stage_II_Grade_3_Contiguous_Follicular_Lymphoma|Stage_I,Laboratory_Biomarker_Analysis|Lenalidomide|Rituximab|,serious_events,arm0,Treatment-(Lenalidomide-Rituximab),16,rituximab,monoclonal-antibody
2729,Allergic_reaction,5,63,Immune_system_disorders,NCT01145495,https://clinicaltrials.gov/show/NCT01145495,Stage_II_Grade_1_Contiguous_Follicular_Lymphoma|Stage_II_Grade_1_Non-Contiguous_Follicular_Lymphoma|Stage_II_Grade_2_Contiguous_Follicular_Lymphoma|Stage_II_Grade_2_Non-Contiguous_Follicular_Lymphoma|Stage_II_Grade_3_Contiguous_Follicular_Lymphoma|Stage_I,Laboratory_Biomarker_Analysis|Lenalidomide|Rituximab|,other_events,arm0,Treatment-(Lenalidomide-Rituximab),16,rituximab,monoclonal-antibody
972,HYPERSENSITIVITY,2,120,Immune_system_disorders,NCT01151215,https://clinicaltrials.gov/show/NCT01151215,Neoplasms|Breast_Neoplasms|Breast_Cancer|,AZD8931|anastrozole|Placebo|,other_events,arm1,AZD8931-40mg,,,
974,Hypersensitivity,1,47,Immune_system_disorders,NCT01153971,https://clinicaltrials.gov/show/NCT01153971,Non-Hodgkin's_Lymphoma,rituximab,other_events,arm0,Rituximab-+-Fludarabine-+-Cyclophosphamide,13,cyclophosphamide,alkylating-agent
974,Hypersensitivity,1,47,Immune_system_disorders,NCT01153971,https://clinicaltrials.gov/show/NCT01153971,Non-Hodgkin's_Lymphoma,rituximab,other_events,arm0,Rituximab-+-Fludarabine-+-Cyclophosphamide,66,fludarabine,antimetabolite
974,Hypersensitivity,1,47,Immune_system_disorders,NCT01153971,https://clinicaltrials.gov/show/NCT01153971,Non-Hodgkin's_Lymphoma,rituximab,other_events,arm0,Rituximab-+-Fludarabine-+-Cyclophosphamide,16,rituximab,monoclonal-antibody
2730,Allergic_reaction,1,40,Immune_system_disorders,NCT01160484,https://clinicaltrials.gov/show/NCT01160484,Multiple_Myeloma,DVD-R,serious_events,arm0,DVD-R-Single-Arm,,,
977,Hypersensitivity,1,69,Immune_system_disorders,NCT01160744,https://clinicaltrials.gov/show/NCT01160744,Carcinoma_Non-Small-Cell_Lung,IMC-1121B_(ramucirumab)|Pemetrexed|Carboplatin_(AUC_6)|Cisplatin|Gemcitabine|Carboplatin_(AUC_5)|,serious_events,arm0,Pem-+-Carb-or-Cis-(Non-Squamous),,,
1765,Drug_hypersensitivity,1,735,Immune_system_disorders,NCT01168349,https://clinicaltrials.gov/show/NCT01168349,Anemia_Neoplasms,epoetin_beta_[NeoRecormon],other_events,arm0,Solid-Tumor-Participants,,,
1764,Drug_hypersensitivity,1,1054,Immune_system_disorders,NCT01168349,https://clinicaltrials.gov/show/NCT01168349,Anemia_Neoplasms,epoetin_beta_[NeoRecormon],other_events,arm2,Anemic-Cancer-Participants-(Total-Participants),,,
1766,Drug_hypersensitivity,1,627,Immune_system_disorders,NCT01168973,https://clinicaltrials.gov/show/NCT01168973,Non-Small_Cell_Lung_Cancer,Ramucirumab|Placebo_(for_Ramucirumab)|Docetaxel|,serious_events,arm0,Ramucirumab-and-Docetaxel,8,docetaxel,taxane
1767,Drug_hypersensitivity,2,618,Immune_system_disorders,NCT01168973,https://clinicaltrials.gov/show/NCT01168973,Non-Small_Cell_Lung_Cancer,Ramucirumab|Placebo_(for_Ramucirumab)|Docetaxel|,serious_events,arm1,Placebo-and-Docetaxel,8,docetaxel,taxane
978,Hypersensitivity,1,17,Immune_system_disorders,NCT01169675,https://clinicaltrials.gov/show/NCT01169675,Neoplasms,BIBW_2992_low_dose|BIBW_2992_high_dose|pemetrexed|pemetrexed|BIBW_2992_high_dose_6_day|pemetrexed|pemetrexed|pemetrexed|pemetrexed|BIBW_2992_low_dose_6_day|BIBW_2992_medium_dose_6_day|BIBW_2992_medium_dose|,other_events,arm3,Pulsed-Afatinib-60-mg,,,
1771,Drug_hypersensitivity,1,528,Immune_system_disorders,NCT01183780,https://clinicaltrials.gov/show/NCT01183780,Colorectal_Cancer,Ramucirumab|Placebo|Irinotecan|Folinic_Acid|5-Fluorouracil|,serious_events,arm1,FOLFIRI-+-Placebo,45,folfiri,combination-drug-with-Irinotecan--Flourouracil--and-Leucovorin
2733,Allergic_reaction,1,42,Immune_system_disorders,NCT01190527,https://clinicaltrials.gov/show/NCT01190527,Non-Small_Cell_Lung_Cancer,FDG-PET,serious_events,arm0,Adaptive-Radiation,,,
988,Hypersensitivity,1,10,Immune_system_disorders,NCT01198548,https://clinicaltrials.gov/show/NCT01198548,Stage_IV_Colon_Cancer|Stage_IV_Rectal_Cancer|,leucovorin_calcium|bevacizumab|cholecalciferol|fluorouracil|oxaliplatin|pharmacological_study|,serious_events,arm0,Treatment-(FOLXFOX-Bevacizumab-Cholecalciferol),4,bevacizumab,monoclonal-antibody
988,Hypersensitivity,1,10,Immune_system_disorders,NCT01198548,https://clinicaltrials.gov/show/NCT01198548,Stage_IV_Colon_Cancer|Stage_IV_Rectal_Cancer|,leucovorin_calcium|bevacizumab|cholecalciferol|fluorouracil|oxaliplatin|pharmacological_study|,serious_events,arm0,Treatment-(FOLXFOX-Bevacizumab-Cholecalciferol),22,bevacizumab,monoclonal-antibody
2734,Allergic_reaction,1,35,Immune_system_disorders,NCT01206140,https://clinicaltrials.gov/show/NCT01206140,Recurrent_Adult_Soft_Tissue_Sarcoma|Stage_III_Adult_Soft_Tissue_Sarcoma|Stage_IV_Adult_Soft_Tissue_Sarcoma|,Laboratory_Biomarker_Analysis|Selumetinib|Temsirolimus|,other_events,arm1,Arm-II-(Selumetinib-and-Temsirolimus),,,
2735,Allergic_reaction,2,10,Immune_system_disorders,NCT01207102,https://clinicaltrials.gov/show/NCT01207102,Metastatic_Breast_Cancer,Abraxane|Carboplatin|,other_events,arm0,Abraxane-Carboplatin,3,carboplatin,alkalating-agent
2736,Allergic_reaction,1,10,Immune_system_disorders,NCT01207102,https://clinicaltrials.gov/show/NCT01207102,Metastatic_Breast_Cancer,Abraxane|Carboplatin|,serious_events,arm0,Abraxane-Carboplatin,3,carboplatin,alkalating-agent
990,Hypersensitivity,2,116,Immune_system_disorders,NCT01207388,https://clinicaltrials.gov/show/NCT01207388,B-cell_Acute_Lymphoblastic_Leukemia,Blinatumomab,serious_events,arm0,Blinatumomab,71,blinatumomab,monoclonal-antibody
1775,Drug_hypersensitivity,1,871,Immune_system_disorders,NCT01212991,https://clinicaltrials.gov/show/NCT01212991,Prostate_Cancer,Enzalutamide|Placebo|,serious_events,arm0,Enzalutamide,,,
2228,Dermatitis_Allergic,1,20,Skin_and_subcutaneous_tissue_disorders,NCT01229176,https://clinicaltrials.gov/show/NCT01229176,Typhoid_Fever,Vi-CRM197_vaccine|Vi_Polysaccharide_(PS)_vaccine|Pneumococcal_conjugate_vaccine|,other_events,arm6,Vi-CRM-Infants,,,
2227,Dermatitis_Allergic,1,19,Skin_and_subcutaneous_tissue_disorders,NCT01229176,https://clinicaltrials.gov/show/NCT01229176,Typhoid_Fever,Vi-CRM197_vaccine|Vi_Polysaccharide_(PS)_vaccine|Pneumococcal_conjugate_vaccine|,other_events,arm7,PNC13-Infants,,,
2232,Dermatitis_allergic,1,111,Skin_and_subcutaneous_tissue_disorders,NCT01236391,https://clinicaltrials.gov/show/NCT01236391,Mantle_Cell_Lymphoma,PCI-32765,other_events,arm0,PCI-32765,,,
1780,Drug_hypersensitivity,1,111,Immune_system_disorders,NCT01236391,https://clinicaltrials.gov/show/NCT01236391,Mantle_Cell_Lymphoma,PCI-32765,other_events,arm0,PCI-32765,,,
1781,Drug_hypersensitivity,1,20,Immune_system_disorders,NCT01242111,https://clinicaltrials.gov/show/NCT01242111,MPS_IV_A|Mucopolysaccharidosis_IVA|Morquio_A_Syndrome|,BMN_110,other_events,arm0,BMN-110,,,
1004,Hypersensitivity,1,211,Immune_system_disorders,NCT01245062,https://clinicaltrials.gov/show/NCT01245062,Melanoma,GSK1120212|Chemotherapy|,serious_events,arm0,Trametinib,,,
1005,Hypersensitivity,1,6,Immune_system_disorders,NCT01253525,https://clinicaltrials.gov/show/NCT01253525,Adenocarcinoma,Ramucirumab_(IMC-1121B_)|Paclitaxel|,other_events,arm0,Ramucirumab-+-Paclitaxel,2,paclitaxel,taxane
1014,Hypersensitivity,1,59,Immune_system_disorders,NCT01275066,https://clinicaltrials.gov/show/NCT01275066,MPS_IV_A,BMN_110_Weekly|Placebo|BMN_110_Every_Other_Week|,other_events,arm0,Placebo,,,
1013,Hypersensitivity,4,59,Immune_system_disorders,NCT01275066,https://clinicaltrials.gov/show/NCT01275066,MPS_IV_A,BMN_110_Weekly|Placebo|BMN_110_Every_Other_Week|,other_events,arm1,BMN110-2.0-mg/kg/Qow,,,
1012,Hypersensitivity,2,58,Immune_system_disorders,NCT01275066,https://clinicaltrials.gov/show/NCT01275066,MPS_IV_A,BMN_110_Weekly|Placebo|BMN_110_Every_Other_Week|,other_events,arm2,BMN110-2.0-mg/kg/Week,,,
1015,Hypersensitivity,1,58,Immune_system_disorders,NCT01275066,https://clinicaltrials.gov/show/NCT01275066,MPS_IV_A,BMN_110_Weekly|Placebo|BMN_110_Every_Other_Week|,serious_events,arm2,BMN110-2.0-mg/kg/Week,,,
2366,Anaphylaxis,4,20,Immune_system_disorders,NCT01283334,https://clinicaltrials.gov/show/NCT01283334,Head_and_Neck_Neoplasms|Cancer_of_the_Head_and_Neck|,Carboplatin|Cetuximab|RAD001|,other_events,arm0,Carboplatin-Cetuximab-and-Everolimus,3,carboplatin,alkalating-agent
2366,Anaphylaxis,4,20,Immune_system_disorders,NCT01283334,https://clinicaltrials.gov/show/NCT01283334,Head_and_Neck_Neoplasms|Cancer_of_the_Head_and_Neck|,Carboplatin|Cetuximab|RAD001|,other_events,arm0,Carboplatin-Cetuximab-and-Everolimus,5,cetuximab,Epidermal-growth-factor-receptor-inhibitor
2366,Anaphylaxis,4,20,Immune_system_disorders,NCT01283334,https://clinicaltrials.gov/show/NCT01283334,Head_and_Neck_Neoplasms|Cancer_of_the_Head_and_Neck|,Carboplatin|Cetuximab|RAD001|,other_events,arm0,Carboplatin-Cetuximab-and-Everolimus,32,everolimus,mTOR?inhibitor-(blocks-gene-translation)
1016,Hypersensitivity,3,70,Immune_system_disorders,NCT01289041,https://clinicaltrials.gov/show/NCT01289041,Advanced_Endometrial_Cancer,BKM120,serious_events,arm0,All-Patients,,,
2738,Allergic_reaction,4,53,Immune_system_disorders,NCT01289821,https://clinicaltrials.gov/show/NCT01289821,Colorectal_Neoplasms,Regorafenib_(Stivarga_BAY73-4506)|Oxaliplatin|Folinic_acid|5-FU_(mFOLFOX6)|,other_events,arm0,Regorafenib-+-Oxaliplatin/Folinic-Acid/5-FU-(mFOLFOX6),7,oxaliplatin,alkalating-agent
2738,Allergic_reaction,4,53,Immune_system_disorders,NCT01289821,https://clinicaltrials.gov/show/NCT01289821,Colorectal_Neoplasms,Regorafenib_(Stivarga_BAY73-4506)|Oxaliplatin|Folinic_acid|5-FU_(mFOLFOX6)|,other_events,arm0,Regorafenib-+-Oxaliplatin/Folinic-Acid/5-FU-(mFOLFOX6),47,mfolfox6,combination-therapy-with-leucovorin-calcium--fluorouracil-and-oxaliplatin
1790,Drug_hypersensitivity,2,30,Immune_system_disorders,NCT01292135,https://clinicaltrials.gov/show/NCT01292135,B-cell_Chronic_Lymphocytic_Leukemia|Small_Lymphocytic_Lymphoma|,PCI-32765,other_events,arm0,PCI-32765-Plus-Bendamustine/Rituximab-(BR),36,bendamustine,alkylating-agent
1790,Drug_hypersensitivity,2,30,Immune_system_disorders,NCT01292135,https://clinicaltrials.gov/show/NCT01292135,B-cell_Chronic_Lymphocytic_Leukemia|Small_Lymphocytic_Lymphoma|,PCI-32765,other_events,arm0,PCI-32765-Plus-Bendamustine/Rituximab-(BR),16,rituximab,monoclonal-antibody
2408,Allergy,1,3870,General_disorders,NCT01299571,https://clinicaltrials.gov/show/NCT01299571,Benign_Prostatic_Hyperplasia|Prostatic_Hyperplasia|,Dutasteride,other_events,arm0,Avodart-0.5-mg,,,
2237,DERMATITIS_ALLERGIC,1,109,Skin_and_subcutaneous_tissue_disorders,NCT01300351,https://clinicaltrials.gov/show/NCT01300351,Breast_Cancer,Fulvestrant|Placebo|,other_events,arm0,Fulvestrant-500-mg,,,
1022,Hypersensitivity,1,153,Immune_system_disorders,NCT01302392,https://clinicaltrials.gov/show/NCT01302392,Multiple_Myeloma,Carfilzomib|Best_Supportive_Care|,serious_events,arm0,Best-Supportive-Care,,,
1792,Drug_hypersensitivity,1,17,Immune_system_disorders,NCT01302860,https://clinicaltrials.gov/show/NCT01302860,Cryopyrin-associated_Periodic_Syndromes|Familial_Cold_Autoinflammatory_Syndrome|Muckle-Wells_Syndrome|Neonatal_Onset_Multisystem_Inflammatory_Disease|,ACZ885,other_events,arm0,Canakinumab,,,
2740,Allergic_reaction,2,56,Immune_system_disorders,NCT01303835,https://clinicaltrials.gov/show/NCT01303835,Malignant_Glioma,LDN|Placebo|,other_events,arm1,Placebo,,,
2741,Allergic_reaction,1,4,Immune_system_disorders,NCT01313078,https://clinicaltrials.gov/show/NCT01313078,Ovarian_Neoplasms|Fallopian_Tube_Neoplasms|Primary_Peritoneal_Neoplasms|,Pegylated_L-Asparaginase,serious_events,arm0,Pegaspargase-in-Women-With-Cancer,,,
2241,Dermatitis_allergic,1,9,Skin_and_subcutaneous_tissue_disorders,NCT01313663,https://clinicaltrials.gov/show/NCT01313663,Lung_Cancer_Small_Cell,pazopanib|pemetrexed|,other_events,arm0,Pemetrexed-500-mg/m^2,15,pemetrexed,antimetabolite
1026,Hypersensitivity,1,7,Immune_system_disorders,NCT01314105,https://clinicaltrials.gov/show/NCT01314105,Ovarian_Neoplasms|Peritoneal_Neoplasms|,BIBF_1120_+_PLD_30_mg/m2_+_CBDCA_AUC5_mg/mLmin|BIBF_1120+_PLD_30_mg/m2_+_CBDCA_AUC5_mg/mLmin|BIBF_1120_+_PLD_30_mg/m2_+_CBDCA_AUC5_mg/mLmin|,serious_events,arm0,Nintedanib-150mg,,,
1027,Hypersensitivity,1,7,Immune_system_disorders,NCT01314105,https://clinicaltrials.gov/show/NCT01314105,Ovarian_Neoplasms|Peritoneal_Neoplasms|,BIBF_1120_+_PLD_30_mg/m2_+_CBDCA_AUC5_mg/mLmin|BIBF_1120+_PLD_30_mg/m2_+_CBDCA_AUC5_mg/mLmin|BIBF_1120_+_PLD_30_mg/m2_+_CBDCA_AUC5_mg/mLmin|,other_events,arm0,Nintedanib-150mg,,,
2742,Allergic_reaction,2,36,Immune_system_disorders,NCT01334515,https://clinicaltrials.gov/show/NCT01334515,Recurrent_Neuroblastoma,hu14.18-IL2_fusion_protein|isotretinoin|sargramostim|laboratory_biomarker_analysis|,other_events,arm1,Disease-Evaluable-Only-by-I-MIBG-or-BM-Histology,,,
1796,Drug_hypersensitivity,1,160,Immune_system_disorders,NCT01345682,https://clinicaltrials.gov/show/NCT01345682,Head_and_Neck_Neoplasms|Carcinoma_Squamous_Cell|,Afatinib|Methotrexate|,serious_events,arm1,Methotrexate,23,methotrexate,antimetabolite
1034,Hypersensitivity,3,59,Immune_system_disorders,NCT01354431,https://clinicaltrials.gov/show/NCT01354431,Renal_Cell_Carcinoma,BMS-936558|BMS-936558|BMS-936558|,other_events,arm0,0.3-mg/kg-Nivolumab,,,
1032,Hypersensitivity,1,54,Immune_system_disorders,NCT01354431,https://clinicaltrials.gov/show/NCT01354431,Renal_Cell_Carcinoma,BMS-936558|BMS-936558|BMS-936558|,other_events,arm1,2.0-mg/kg-Nivolumab,,,
1033,Hypersensitivity,9,54,Immune_system_disorders,NCT01354431,https://clinicaltrials.gov/show/NCT01354431,Renal_Cell_Carcinoma,BMS-936558|BMS-936558|BMS-936558|,other_events,arm2,10.0-mg/kg-Nivolumab,,,
1799,Drug_hypersensitivity,1,152,Immune_system_disorders,NCT01362530,https://clinicaltrials.gov/show/NCT01362530,Chemotherapy_Induced_Nausea_and_Vomiting,Aprepitant_125_mg|Aprepitant_80_mg|Aprepitant_powder_for_suspension_(PFS)|Ondansetron|Placebo_for_Aprepitant_125_mg|Placebo_for_Aprepitant_80_mg|Placebo_for_Aprepitant_PFS|Emetogenic_chemotherapy|,serious_events,arm0,Aprepitant-Regimen-Cycle-1,,,
1801,Drug_hypersensitivity,1,308,Immune_system_disorders,NCT01376297,https://clinicaltrials.gov/show/NCT01376297,Chemotherapy-Induced_Nausea_and_Vomiting,Netupitant_and_Palonosetron|Aprepitant|Palonosetron|Dexamethasone|,serious_events,arm0,Netupitant-and-Palonosetron-Plus-Dexamethasone,79,dexamethasone,steroid
1037,Hypersensitivity,1,28,Immune_system_disorders,NCT01377480,https://clinicaltrials.gov/show/NCT01377480,Chagas_Disease,Posaconazole|Placebo_for_posaconazole|Benznidazole|,other_events,arm2,Posaconazole-+-Benznidazole,,,
1036,Hypersensitivity,3,30,Immune_system_disorders,NCT01377480,https://clinicaltrials.gov/show/NCT01377480,Chagas_Disease,Posaconazole|Placebo_for_posaconazole|Benznidazole|,other_events,arm3,Benznidazole-+-Placebo,,,
1038,Hypersensitivity,2,6,Immune_system_disorders,NCT01388647,https://clinicaltrials.gov/show/NCT01388647,HER-2_Positive_Breast_Cancer,eribulin|carboplatin|trastuzumab|,other_events,arm0,Eribulin-1.1-mg/m2,,,
1039,Hypersensitivity,1,242,Immune_system_disorders,NCT01394991,https://clinicaltrials.gov/show/NCT01394991,Anemia|Neoplasms|,Epoetin_alfa_450_IU/kg_once_a_week|Epoetin_alfa_150_IU/kg_3_times_a_week|Epoetin_alfa_450_IU/kg_once_a_week_(QW)|Epoetin_alfa_150_IU/kg_3_times_a_week_(TIW)|,serious_events,arm0,Epoetin-Alfa-QW,,,
2744,Allergic_reaction,1,18,Investigations,NCT01402063,https://clinicaltrials.gov/show/NCT01402063,Glioblastoma_Multiforme,PPX_(CT2103)|Temozolomide|,other_events,arm1,Radiation-+-Temozolomide-and-Maintenance,98,temozolomide,alkylating-agent
2744,Allergic_reaction,1,18,Investigations,NCT01402063,https://clinicaltrials.gov/show/NCT01402063,Glioblastoma_Multiforme,PPX_(CT2103)|Temozolomide|,other_events,arm1,Radiation-+-Temozolomide-and-Maintenance,88,maintenance,Class_Name_Needed
1042,Hypersensitivity,1,403,Immune_system_disorders,NCT01419197,https://clinicaltrials.gov/show/NCT01419197,Breast_Cancer,Trastuzumab_emtansine|Treatment_of_physician's_choice|,serious_events,arm0,Trastuzumab-Emtansine---Planned-Treatment-Period,18,trastuzumab,monoclonal-antibody
1806,Drug_hypersensitivity,1,184,Immune_system_disorders,NCT01419197,https://clinicaltrials.gov/show/NCT01419197,Breast_Cancer,Trastuzumab_emtansine|Treatment_of_physician's_choice|,serious_events,arm1,Treatment-of-Physician_??s-Choice---Planned-Treatment-Period,,,
1043,Hypersensitivity,1,21,Immune_system_disorders,NCT01420081,https://clinicaltrials.gov/show/NCT01420081,Endometrial_Neoplasms,PF-05212384|PF-05212384|PF-05212384|,other_events,arm4,PF-05212384-154-mg-(PI3K-Basal),,,
1045,Hypersensitivity,1,7,Immune_system_disorders,NCT01424930,https://clinicaltrials.gov/show/NCT01424930,Prostate_Neoplasms|Prostate_Cancer|,Abiraterone|Prednisone|,other_events,arm0,Abiraterone+Prednisone-(Low-fat-Meal),85,prednisone,steroid
1044,Hypersensitivity,1,18,Immune_system_disorders,NCT01424930,https://clinicaltrials.gov/show/NCT01424930,Prostate_Neoplasms|Prostate_Cancer|,Abiraterone|Prednisone|,other_events,arm1,Abiraterone+Prednisone-(High-fat-Meal),85,prednisone,steroid
1047,Hypersensitivity,2,20,Immune_system_disorders,NCT01437267,https://clinicaltrials.gov/show/NCT01437267,Typhoid_Fever,Vi-CRM197_vaccine|Pneumococcal_conjugate_vaccine|Vi_Polysaccharide_(PS)_vaccine|,other_events,arm4,Vi-CRM-Infants,,,
1807,Drug_hypersensitivity,1,1158,Immune_system_disorders,NCT01444456,https://clinicaltrials.gov/show/NCT01444456,Anemia|Breast_Cancer|Cancer|Colorectal_Cancer|Lung_Cancer|Ovarian_Cancer|Prostate_Cancer|Solid_Tumors|Bladder_Cancer|Endometrial_Cancer|Renal_Cancer|Pancreatic_Cancer|Esophageal_Cancer|Gastric_Cancer|,Null,other_events,arm0,Darbepoetin-Alfa-or-Other-ESA,,,
2745,Allergic_reaction,1,36,Immune_system_disorders,NCT01447927,https://clinicaltrials.gov/show/NCT01447927,Barrett_Esophagus|Esophageal_Cancer|,metformin_hydrochloride|placebo|,other_events,arm0,Placebo,,,
1810,Drug_hypersensitivity,1,1496,Immune_system_disorders,NCT01459653,https://clinicaltrials.gov/show/NCT01459653,Febrile_Neutropenia|Cancer|Breast_Cancer|Ovarian_Cancer|Lung_Cancer|Prostate_Cancer|Multiple_Myeloma|Bladder_Cancer|B-cell_Lymphoma|,Null,serious_events,arm0,EP2006,,,
2257,Dermatitis_allergic,1,304,Skin_and_subcutaneous_tissue_disorders,NCT01460342,https://clinicaltrials.gov/show/NCT01460342,Benign_Prostatic_Hyperplasia,Tadalafil|Placebo|,other_events,arm0,Placebo,,,
1055,Hypersensitivity,2,189,Immune_system_disorders,NCT01466179,https://clinicaltrials.gov/show/NCT01466179,Acute_Lymphoblastic_Leukemia,Blinatumomab,serious_events,arm0,Blinatumomab,71,blinatumomab,monoclonal-antibody
2259,Dermatitis_allergic,2,39,Skin_and_subcutaneous_tissue_disorders,NCT01478373,https://clinicaltrials.gov/show/NCT01478373,Gastrointestinal_Stromal_Tumors,Dovitinib_(TKI258),other_events,arm0,Dovitinib,,,
1813,Drug_hypersensitivity,1,177,Immune_system_disorders,NCT01478594,https://clinicaltrials.gov/show/NCT01478594,Colorectal_Cancer,Tivozanib|Bevacizumab|mFOLFOX6|,serious_events,arm0,Tivozanib-+-mFOLFOX6,47,mfolfox6,combination-therapy-with-leucovorin-calcium--fluorouracil-and-oxaliplatin
1057,Hypersensitivity,3,177,Immune_system_disorders,NCT01478594,https://clinicaltrials.gov/show/NCT01478594,Colorectal_Cancer,Tivozanib|Bevacizumab|mFOLFOX6|,other_events,arm0,Tivozanib-+-mFOLFOX6,47,mfolfox6,combination-therapy-with-leucovorin-calcium--fluorouracil-and-oxaliplatin
1059,Hypersensitivity,1,177,Immune_system_disorders,NCT01478594,https://clinicaltrials.gov/show/NCT01478594,Colorectal_Cancer,Tivozanib|Bevacizumab|mFOLFOX6|,serious_events,arm0,Tivozanib-+-mFOLFOX6,47,mfolfox6,combination-therapy-with-leucovorin-calcium--fluorouracil-and-oxaliplatin
1814,Drug_hypersensitivity,1,87,Immune_system_disorders,NCT01478594,https://clinicaltrials.gov/show/NCT01478594,Colorectal_Cancer,Tivozanib|Bevacizumab|mFOLFOX6|,serious_events,arm1,Bevacizumab-+-mFOLFOX6,47,mfolfox6,combination-therapy-with-leucovorin-calcium--fluorouracil-and-oxaliplatin
1058,Hypersensitivity,6,87,Immune_system_disorders,NCT01478594,https://clinicaltrials.gov/show/NCT01478594,Colorectal_Cancer,Tivozanib|Bevacizumab|mFOLFOX6|,other_events,arm1,Bevacizumab-+-mFOLFOX6,47,mfolfox6,combination-therapy-with-leucovorin-calcium--fluorouracil-and-oxaliplatin
1814,Drug_hypersensitivity,1,87,Immune_system_disorders,NCT01478594,https://clinicaltrials.gov/show/NCT01478594,Colorectal_Cancer,Tivozanib|Bevacizumab|mFOLFOX6|,serious_events,arm1,Bevacizumab-+-mFOLFOX6,4,bevacizumab,monoclonal-antibody
1058,Hypersensitivity,6,87,Immune_system_disorders,NCT01478594,https://clinicaltrials.gov/show/NCT01478594,Colorectal_Cancer,Tivozanib|Bevacizumab|mFOLFOX6|,other_events,arm1,Bevacizumab-+-mFOLFOX6,4,bevacizumab,monoclonal-antibody
1814,Drug_hypersensitivity,1,87,Immune_system_disorders,NCT01478594,https://clinicaltrials.gov/show/NCT01478594,Colorectal_Cancer,Tivozanib|Bevacizumab|mFOLFOX6|,serious_events,arm1,Bevacizumab-+-mFOLFOX6,22,bevacizumab,monoclonal-antibody
1058,Hypersensitivity,6,87,Immune_system_disorders,NCT01478594,https://clinicaltrials.gov/show/NCT01478594,Colorectal_Cancer,Tivozanib|Bevacizumab|mFOLFOX6|,other_events,arm1,Bevacizumab-+-mFOLFOX6,22,bevacizumab,monoclonal-antibody
1060,Hypersensitivity,1,74,Immune_system_disorders,NCT01500083,https://clinicaltrials.gov/show/NCT01500083,Indolent_Non-Hodgkin's_Lymphoma|Chronic_Lymphocytic_Leukemia|,Bendamustine_at_a_dose_of_100_mg/m2|Bendamustine_at_a_dose_of_120_mg/m2|,serious_events,arm1,Patients-With-iNHL,,,
2261,Dermatitis_allergic,1,88,Skin_and_subcutaneous_tissue_disorders,NCT01500720,https://clinicaltrials.gov/show/NCT01500720,Small_Cell_Lung_Cancer,Cabazitaxel|Topotecan|,serious_events,arm1,Topotecan,44,topotecan,topoisomerase-1-inhibitor
2263,Dermatitis_allergic,3,44,Skin_and_subcutaneous_tissue_disorders,NCT01520922,https://clinicaltrials.gov/show/NCT01520922,Leukaemia_Lymphocytic_Chronic,Ofatumumab|Bendamustine|,other_events,arm0,Ofatumumab-+-Bendamustine-90-mg/m^2,36,bendamustine,alkylating-agent
2263,Dermatitis_allergic,3,44,Skin_and_subcutaneous_tissue_disorders,NCT01520922,https://clinicaltrials.gov/show/NCT01520922,Leukaemia_Lymphocytic_Chronic,Ofatumumab|Bendamustine|,other_events,arm0,Ofatumumab-+-Bendamustine-90-mg/m^2,42,ofatumumab,monoclonal-antibody
2262,Dermatitis_allergic,5,53,Skin_and_subcutaneous_tissue_disorders,NCT01520922,https://clinicaltrials.gov/show/NCT01520922,Leukaemia_Lymphocytic_Chronic,Ofatumumab|Bendamustine|,other_events,arm1,Ofatumumab-+-Bendamustine-70-mg/m^2,36,bendamustine,alkylating-agent
1818,Drug_hypersensitivity,1,53,Immune_system_disorders,NCT01520922,https://clinicaltrials.gov/show/NCT01520922,Leukaemia_Lymphocytic_Chronic,Ofatumumab|Bendamustine|,serious_events,arm1,Ofatumumab-+-Bendamustine-70-mg/m^2,36,bendamustine,alkylating-agent
2262,Dermatitis_allergic,5,53,Skin_and_subcutaneous_tissue_disorders,NCT01520922,https://clinicaltrials.gov/show/NCT01520922,Leukaemia_Lymphocytic_Chronic,Ofatumumab|Bendamustine|,other_events,arm1,Ofatumumab-+-Bendamustine-70-mg/m^2,42,ofatumumab,monoclonal-antibody
1818,Drug_hypersensitivity,1,53,Immune_system_disorders,NCT01520922,https://clinicaltrials.gov/show/NCT01520922,Leukaemia_Lymphocytic_Chronic,Ofatumumab|Bendamustine|,serious_events,arm1,Ofatumumab-+-Bendamustine-70-mg/m^2,42,ofatumumab,monoclonal-antibody
2747,Allergic_Reaction,1,11,Immune_system_disorders,NCT01531998,https://clinicaltrials.gov/show/NCT01531998,Myeloma,Lenalidomide|Bortezomib|Siltuximab|Dexamethasone|Questionnaires|,other_events,arm0,Siltuximab-+-Bortezomib-+-Lenalidomide,25,lenalidomide,immunomodulatory-agent-or-antiangiogenic-agent
2747,Allergic_Reaction,1,11,Immune_system_disorders,NCT01531998,https://clinicaltrials.gov/show/NCT01531998,Myeloma,Lenalidomide|Bortezomib|Siltuximab|Dexamethasone|Questionnaires|,other_events,arm0,Siltuximab-+-Bortezomib-+-Lenalidomide,70,bortezomib,proteasome-inhibitor
2749,Allergic_reaction,2,44,Immune_system_disorders,NCT01557959,https://clinicaltrials.gov/show/NCT01557959,Adenocarcinoma_of_the_Lung|Adenosquamous_Cell_Lung_Cancer|Bronchoalveolar_Cell_Lung_Cancer|Large_Cell_Lung_Cancer|Non-small_Cell_Lung_Cancer|Recurrent_Non-small_Cell_Lung_Cancer|Squamous_Cell_Lung_Cancer|Stage_IIIB_Non-small_Cell_Lung_Cancer|Stage_IV_Non-,cisplatin|pegfilgrastim|erlotinib_hydrochloride|laboratory_biomarker_analysis|polymorphism_analysis|pharmacogenomic_studies|genetic_linkage_analysis|docetaxel|,serious_events,arm0,Treatment-(Chemo-Chemoprotection-Antiangiogenesis-Therapy),,,
2750,Allergic_reaction,42,44,Immune_system_disorders,NCT01557959,https://clinicaltrials.gov/show/NCT01557959,Adenocarcinoma_of_the_Lung|Adenosquamous_Cell_Lung_Cancer|Bronchoalveolar_Cell_Lung_Cancer|Large_Cell_Lung_Cancer|Non-small_Cell_Lung_Cancer|Recurrent_Non-small_Cell_Lung_Cancer|Squamous_Cell_Lung_Cancer|Stage_IIIB_Non-small_Cell_Lung_Cancer|Stage_IV_Non-,cisplatin|pegfilgrastim|erlotinib_hydrochloride|laboratory_biomarker_analysis|polymorphism_analysis|pharmacogenomic_studies|genetic_linkage_analysis|docetaxel|,other_events,arm0,Treatment-(Chemo-Chemoprotection-Antiangiogenesis-Therapy),,,
1067,Hypersensitivity,2,27,Immune_system_disorders,NCT01592045,https://clinicaltrials.gov/show/NCT01592045,Neuroblastoma,ch14.18_-NCI|ch14.18-UTC|Granulocyte-Macrophage_Colony-Stimulating_Factor_(GM-CSF)|Aldesleukin_(IL-2)|Isotretinoin|,other_events,arm0,UTC-ch14.18,,,
1068,Hypersensitivity,3,27,Immune_system_disorders,NCT01592045,https://clinicaltrials.gov/show/NCT01592045,Neuroblastoma,ch14.18_-NCI|ch14.18-UTC|Granulocyte-Macrophage_Colony-Stimulating_Factor_(GM-CSF)|Aldesleukin_(IL-2)|Isotretinoin|,other_events,arm1,NCI-ch14.18,,,
1823,Drug_hypersensitivity,1,504,Immune_system_disorders,NCT01594749,https://clinicaltrials.gov/show/NCT01594749,Chemotherapy-Induced_Nausea_and_Vomiting_(CINV),Fosaprepitant_dimeglumine|Fosaprepitant_Placebo|Dexamethasone|Ondansetron|Dexamethasone_Placebo|Ondansetron_Placebo|Rescue_Therapy|,serious_events,arm0,Fosaprepitant-Regimen,,,
1069,Hypersensitivity,1,504,Immune_system_disorders,NCT01594749,https://clinicaltrials.gov/show/NCT01594749,Chemotherapy-Induced_Nausea_and_Vomiting_(CINV),Fosaprepitant_dimeglumine|Fosaprepitant_Placebo|Dexamethasone|Ondansetron|Dexamethasone_Placebo|Ondansetron_Placebo|Rescue_Therapy|,serious_events,arm0,Fosaprepitant-Regimen,,,
1070,Hypersensitivity,1,497,Immune_system_disorders,NCT01594749,https://clinicaltrials.gov/show/NCT01594749,Chemotherapy-Induced_Nausea_and_Vomiting_(CINV),Fosaprepitant_dimeglumine|Fosaprepitant_Placebo|Dexamethasone|Ondansetron|Dexamethasone_Placebo|Ondansetron_Placebo|Rescue_Therapy|,serious_events,arm1,Control-Regimen,,,
1071,Hypersensitivity,1,2,Immune_system_disorders,NCT01596088,https://clinicaltrials.gov/show/NCT01596088,Extravasations_of_Anthracycline_Anti-cancer_Agents,Dexrazoxane,other_events,arm0,Dexrazoxane,,,
1824,Drug_hypersensitivity,1,349,Immune_system_disorders,NCT01597908,https://clinicaltrials.gov/show/NCT01597908,Melanoma,Dabrafenib|Vemurafenib|Trametinib|,serious_events,arm1,Vemurafenib,,,
1072,Hypersensitivity,1,349,Immune_system_disorders,NCT01597908,https://clinicaltrials.gov/show/NCT01597908,Melanoma,Dabrafenib|Vemurafenib|Trametinib|,serious_events,arm1,Vemurafenib,,,
2369,Anaphylaxis,1,12,Immune_system_disorders,NCT01614795,https://clinicaltrials.gov/show/NCT01614795,Childhood_Alveolar_Soft-part_Sarcoma|Childhood_Angiosarcoma|Childhood_Epithelioid_Sarcoma|Childhood_Fibrosarcoma|Childhood_Gliosarcoma|Childhood_Leiomyosarcoma|Childhood_Liposarcoma|Childhood_Neurofibrosarcoma|Childhood_Synovial_Sarcoma|Previously_Treated,cixutumumab|temsirolimus|laboratory_biomarker_analysis|,serious_events,arm3,Group-4-Relapsed-or-Refractory-Non-rhabdo-Soft-Tissue-Sarcoma,,,
2751,Allergic_reaction,1,16,Immune_system_disorders,NCT01623869,https://clinicaltrials.gov/show/NCT01623869,Adult_Angiosarcoma|Recurrent_Adult_Soft_Tissue_Sarcoma|Stage_III_Adult_Soft_Tissue_Sarcoma|Stage_IV_Adult_Soft_Tissue_Sarcoma|,Laboratory_Biomarker_Analysis|Trebananib|,other_events,arm0,Treatment-(Trebananib),,,
1077,Hypersensitivity,1,8,Immune_system_disorders,NCT01649791,https://clinicaltrials.gov/show/NCT01649791,B-cell_Chronic_Lymphocytic_Leukemia|Chronic_Lymphocytic_Leukemia|Stage_0_Chronic_Lymphocytic_Leukemia|Stage_I_Chronic_Lymphocytic_Leukemia|Stage_II_Chronic_Lymphocytic_Leukemia|,lenalidomide|laboratory_biomarker_analysis|lymph_node_biopsy|bone_marrow_aspiration|pharmacological_study|flow_cytometry|,other_events,arm0,Treatment-(Lenalidomide-as-Chemoprevention),25,lenalidomide,immunomodulatory-agent-or-antiangiogenic-agent
1078,Hypersensitivity,1,3,Immune_system_disorders,NCT01653158,https://clinicaltrials.gov/show/NCT01653158,Advanced_Non-Hematologic_Malignancies,CP-751871|Docetaxel|,other_events,arm2,CP-751871-0.8-mg/kg-+-Docetaxel,8,docetaxel,taxane
1828,Drug_hypersensitivity,1,19,Immune_system_disorders,NCT01653158,https://clinicaltrials.gov/show/NCT01653158,Advanced_Non-Hematologic_Malignancies,CP-751871|Docetaxel|,other_events,arm7,CP-751871-20-mg/kg-+-Docetaxel,8,docetaxel,taxane
2752,Allergic_reaction,2,39,Immune_system_disorders,NCT01656031,https://clinicaltrials.gov/show/NCT01656031,Leukemia,clofarabine|cytarabine|,serious_events,arm0,High-Dose-Cytarabine-and-Clofarabine,37,clofarabine,antimetabolite
2752,Allergic_reaction,2,39,Immune_system_disorders,NCT01656031,https://clinicaltrials.gov/show/NCT01656031,Leukemia,clofarabine|cytarabine|,serious_events,arm0,High-Dose-Cytarabine-and-Clofarabine,52,cytarabine,antimetabolite
1079,Hypersensitivity,1,120,Immune_system_disorders,NCT01656161,https://clinicaltrials.gov/show/NCT01656161,Prostate_Cancer,Triptorelin_embonate_22.5_mg,serious_events,arm0,Triptorelin-Embonate-22.5-mg,,,
1829,Drug_hypersensitivity,1,30,Immune_system_disorders,NCT01663714,https://clinicaltrials.gov/show/NCT01663714,Lymphoma_Non-Hodgkin,cycolophosphamide_vacristine_and_pednisone_(CVP)_x6_cycles_followed_by_tositumomab_and_iodine_I_131_tositumomab.,other_events,arm0,Period-After-CVP,,,
1830,Drug_hypersensitivity,1,30,Immune_system_disorders,NCT01663714,https://clinicaltrials.gov/show/NCT01663714,Lymphoma_Non-Hodgkin,cycolophosphamide_vacristine_and_pednisone_(CVP)_x6_cycles_followed_by_tositumomab_and_iodine_I_131_tositumomab.,other_events,arm2,Combined-Regimen-Period,,,
2753,Allergic_reaction,1,11,Immune_system_disorders,NCT01681368,https://clinicaltrials.gov/show/NCT01681368,Epithelial_Ovarian_Cancer|Peritoneal_Neoplasms|Fallopian_Tube_Neoplasms|,Birinapant_(TL32711),other_events,arm0,Birinapant-for-Advanced-OvarianFallopian-Tube-&-Peritoneal-Ca,,,
2279,Dermatitis_allergic,1,6,Skin_and_subcutaneous_tissue_disorders,NCT01685216,https://clinicaltrials.gov/show/NCT01685216,Gaucher_Disease_Type_3,velaglucerase_alfa,other_events,arm0,Velaglucerase-Alfa,,,
1083,HYPERSENSITIVITY,3,247,Hepatobiliary_disorders,NCT01689519,https://clinicaltrials.gov/show/NCT01689519,Malignant_Melanoma,Placebo|Vemurafenib|Cobimetinib|,serious_events,arm1,Cobimetinib-+-Vemurafenib,,,
1086,Hypersensitivity,1,117,Immune_system_disorders,NCT01721759,https://clinicaltrials.gov/show/NCT01721759,Squamous_Cell_Non-small_Cell_Lung_Cancer,Nivolumab,serious_events,arm0,NivolumAB-3-mg/kg,,,
1831,Drug_hypersensitivity,1,9,Immune_system_disorders,NCT01741792,https://clinicaltrials.gov/show/NCT01741792,Diffuse_Large_B-cell_Lymphoma,Blinatumomab,other_events,arm0,Cohort-1:-Blinatumomab-9/28/112-??g/d,71,blinatumomab,monoclonal-antibody
2283,Dermatitis_allergic,1,2,Skin_and_subcutaneous_tissue_disorders,NCT01741792,https://clinicaltrials.gov/show/NCT01741792,Diffuse_Large_B-cell_Lymphoma,Blinatumomab,other_events,arm1,Cohort-2:-Blinatumomab-112-??g/d,71,blinatumomab,monoclonal-antibody
1834,Drug_hypersensitivity,1,2,Immune_system_disorders,NCT01741792,https://clinicaltrials.gov/show/NCT01741792,Diffuse_Large_B-cell_Lymphoma,Blinatumomab,other_events,arm1,Cohort-2:-Blinatumomab-112-??g/d,71,blinatumomab,monoclonal-antibody
1832,Drug_hypersensitivity,1,23,Immune_system_disorders,NCT01741792,https://clinicaltrials.gov/show/NCT01741792,Diffuse_Large_B-cell_Lymphoma,Blinatumomab,other_events,arm3,Cohort-1+3:-Blinatumomab-9/28/112??g/d,71,blinatumomab,monoclonal-antibody
2282,Dermatitis_allergic,1,25,Skin_and_subcutaneous_tissue_disorders,NCT01741792,https://clinicaltrials.gov/show/NCT01741792,Diffuse_Large_B-cell_Lymphoma,Blinatumomab,other_events,arm4,Blinatumomab-Overall,71,blinatumomab,monoclonal-antibody
1833,Drug_hypersensitivity,2,25,Immune_system_disorders,NCT01741792,https://clinicaltrials.gov/show/NCT01741792,Diffuse_Large_B-cell_Lymphoma,Blinatumomab,other_events,arm4,Blinatumomab-Overall,71,blinatumomab,monoclonal-antibody
2413,allergy,1,38,Immune_system_disorders,NCT01757561,https://clinicaltrials.gov/show/NCT01757561,Cerebral_Hypoxia|Postoperative_Cognitive_Dysfunction|,propofol|sevoflurane|,other_events,arm0,Propofol-Abnormal,,,
2412,allergy,2,34,Immune_system_disorders,NCT01757561,https://clinicaltrials.gov/show/NCT01757561,Cerebral_Hypoxia|Postoperative_Cognitive_Dysfunction|,propofol|sevoflurane|,other_events,arm3,Sevoflurane-Normal,,,
1091,Hypersensitivity,1,5,Immune_system_disorders,NCT01808326,https://clinicaltrials.gov/show/NCT01808326,Leukaemia_Lymphoblastic,chlorambucil_tablets,other_events,arm0,Chlorambucil-10-mg/m^2,,,
2286,Dermatitis_allergic,1,22,Skin_and_subcutaneous_tissue_disorders,NCT01857622,https://clinicaltrials.gov/show/NCT01857622,Non-valvular_Atrial_Fibrillation,DU-176b_15mg|DU-176b_30mg|DU-176b_60mg|,other_events,arm1,Normal/MiRI-Low-dose-Group,,,
1093,Hypersensitivity,1,6,Immune_system_disorders,NCT01928940,https://clinicaltrials.gov/show/NCT01928940,Solid_Tumours,dabrafenib|trametinib|,other_events,arm0,Phase-I:-GSK2118436-150-mg-+-GSK1120212-2-mg,,,
2373,Anaphylaxis,1,104,Immune_system_disorders,NCT01989572,https://clinicaltrials.gov/show/NCT01989572,Local_Recurrence_of_Malignant_Melanoma_of_Skin|Stage_IV_Melanoma|,sargramostim|peptide_vaccine|GM-CSF_placebo|peptide_placebo|,serious_events,arm0,Arm-I-(GM-CSF-Peptide-Vaccine),,,
2372,Anaphylaxis,1,110,Immune_system_disorders,NCT01989572,https://clinicaltrials.gov/show/NCT01989572,Local_Recurrence_of_Malignant_Melanoma_of_Skin|Stage_IV_Melanoma|,sargramostim|peptide_vaccine|GM-CSF_placebo|peptide_placebo|,serious_events,arm1,Arm-II-(GM-CSF-Placebo-Peptide-Vaccine),,,
2375,Anaphylaxis,1,107,Immune_system_disorders,NCT01989572,https://clinicaltrials.gov/show/NCT01989572,Local_Recurrence_of_Malignant_Melanoma_of_Skin|Stage_IV_Melanoma|,sargramostim|peptide_vaccine|GM-CSF_placebo|peptide_placebo|,serious_events,arm2,Arm-III-(GM-CSF-Peptide-Placebo),,,
2374,Anaphylaxis,1,186,Immune_system_disorders,NCT01989572,https://clinicaltrials.gov/show/NCT01989572,Local_Recurrence_of_Malignant_Melanoma_of_Skin|Stage_IV_Melanoma|,sargramostim|peptide_vaccine|GM-CSF_placebo|peptide_placebo|,serious_events,arm4,Arm-V-(GM-CSF),,,
1095,Hypersensitivity,1,20,Immune_system_disorders,NCT01990859,https://clinicaltrials.gov/show/NCT01990859,Melanoma,Ipilimumab,other_events,arm0,3-MG/KG-IPILIMUMAB,64,ipilimumab,monoclonal-antibody
2755,Allergic_reaction,3,1797,Immune_system_disorders,NCT01996332,https://clinicaltrials.gov/show/NCT01996332,Non-Small_Cell_Lung_Cancer,erlotinib_[Tarceva],other_events,arm0,Erlotinib-150-mg/Day,31,erlotinib,epidermal-growth-factor-receptor-(EGFR)-inhibitor---protein-tyrosine-kinase-inhibitor
1097,Hypersensitivity,1,115,Immune_system_disorders,NCT01998906,https://clinicaltrials.gov/show/NCT01998906,Breast_Cancer,Trastuzumab|Doxorubicin|Paclitaxel|CMF|,other_events,arm0,HER2+-TC,,,
1098,Hypersensitivity,4,112,Immune_system_disorders,NCT01998906,https://clinicaltrials.gov/show/NCT01998906,Breast_Cancer,Trastuzumab|Doxorubicin|Paclitaxel|CMF|,other_events,arm1,HER2+-C,,,
1096,Hypersensitivity,5,99,Immune_system_disorders,NCT01998906,https://clinicaltrials.gov/show/NCT01998906,Breast_Cancer,Trastuzumab|Doxorubicin|Paclitaxel|CMF|,other_events,arm2,HER2--C,,,
2288,Dermatitis_allergic,1,79,Skin_and_subcutaneous_tissue_disorders,NCT01998919,https://clinicaltrials.gov/show/NCT01998919,Non-Small_Cell_Lung_Cancer,erlotinib_[Tarceva]|placebo|gemcitabine|cisplatin|carboplatin|,other_events,arm0,Placebo-Plus-Chemotherapy,,,
1099,Hypersensitivity,1,79,Immune_system_disorders,NCT01998919,https://clinicaltrials.gov/show/NCT01998919,Non-Small_Cell_Lung_Cancer,erlotinib_[Tarceva]|placebo|gemcitabine|cisplatin|carboplatin|,other_events,arm0,Placebo-Plus-Chemotherapy,,,
1848,Drug_hypersensitivity,11,75,Immune_system_disorders,NCT02004093,https://clinicaltrials.gov/show/NCT02004093,Ovarian_Cancer,pertuzumab|paclitaxel|gemcitabine|carboplatin|,other_events,arm0,Chemotherapy-+-Pertuzumab,40,pertuzumab,monoclonal-antibody
1850,Drug_hypersensitivity,4,75,Immune_system_disorders,NCT02004093,https://clinicaltrials.gov/show/NCT02004093,Ovarian_Cancer,pertuzumab|paclitaxel|gemcitabine|carboplatin|,serious_events,arm0,Chemotherapy-+-Pertuzumab,40,pertuzumab,monoclonal-antibody
1849,Drug_hypersensitivity,13,74,Immune_system_disorders,NCT02004093,https://clinicaltrials.gov/show/NCT02004093,Ovarian_Cancer,pertuzumab|paclitaxel|gemcitabine|carboplatin|,other_events,arm1,Chemotherapy,,,
1100,Hypersensitivity,1,6,Immune_system_disorders,NCT02005484,https://clinicaltrials.gov/show/NCT02005484,Gastric_Cancer,Trastuzumab,other_events,arm0,Trastuzumab-Monotherapy,18,trastuzumab,monoclonal-antibody
1101,Hypersensitivity,1,6,Immune_system_disorders,NCT02005484,https://clinicaltrials.gov/show/NCT02005484,Gastric_Cancer,Trastuzumab,serious_events,arm0,Trastuzumab-Monotherapy,18,trastuzumab,monoclonal-antibody
1851,Drug_hypersensitivity,1,43,Immune_system_disorders,NCT02013817,https://clinicaltrials.gov/show/NCT02013817,Lymphocytic_Leukemia_Chronic,rituximab_[MabThera/Rituxan]|fludarabine|cyclophosphamide|,other_events,arm0,Rituximab-Fludarabine-Cyclophosphamide,13,cyclophosphamide,alkylating-agent
1102,Hypersensitivity,1,43,Immune_system_disorders,NCT02013817,https://clinicaltrials.gov/show/NCT02013817,Lymphocytic_Leukemia_Chronic,rituximab_[MabThera/Rituxan]|fludarabine|cyclophosphamide|,other_events,arm0,Rituximab-Fludarabine-Cyclophosphamide,13,cyclophosphamide,alkylating-agent
1851,Drug_hypersensitivity,1,43,Immune_system_disorders,NCT02013817,https://clinicaltrials.gov/show/NCT02013817,Lymphocytic_Leukemia_Chronic,rituximab_[MabThera/Rituxan]|fludarabine|cyclophosphamide|,other_events,arm0,Rituximab-Fludarabine-Cyclophosphamide,66,fludarabine,antimetabolite
1102,Hypersensitivity,1,43,Immune_system_disorders,NCT02013817,https://clinicaltrials.gov/show/NCT02013817,Lymphocytic_Leukemia_Chronic,rituximab_[MabThera/Rituxan]|fludarabine|cyclophosphamide|,other_events,arm0,Rituximab-Fludarabine-Cyclophosphamide,66,fludarabine,antimetabolite
1851,Drug_hypersensitivity,1,43,Immune_system_disorders,NCT02013817,https://clinicaltrials.gov/show/NCT02013817,Lymphocytic_Leukemia_Chronic,rituximab_[MabThera/Rituxan]|fludarabine|cyclophosphamide|,other_events,arm0,Rituximab-Fludarabine-Cyclophosphamide,16,rituximab,monoclonal-antibody
1102,Hypersensitivity,1,43,Immune_system_disorders,NCT02013817,https://clinicaltrials.gov/show/NCT02013817,Lymphocytic_Leukemia_Chronic,rituximab_[MabThera/Rituxan]|fludarabine|cyclophosphamide|,other_events,arm0,Rituximab-Fludarabine-Cyclophosphamide,16,rituximab,monoclonal-antibody
1852,Drug_hypersensitivity,1,69,Immune_system_disorders,NCT02015676,https://clinicaltrials.gov/show/NCT02015676,Breast_Cancer,trastuzumab|paclitaxel|Myocet|,other_events,arm0,Trastuzumab-Doxorubicin-Paclitaxel;-Phase-I-&-II,38,doxorubicin,anthracycline-antibiotic
1852,Drug_hypersensitivity,1,69,Immune_system_disorders,NCT02015676,https://clinicaltrials.gov/show/NCT02015676,Breast_Cancer,trastuzumab|paclitaxel|Myocet|,other_events,arm0,Trastuzumab-Doxorubicin-Paclitaxel;-Phase-I-&-II,18,trastuzumab,monoclonal-antibody
1852,Drug_hypersensitivity,1,69,Immune_system_disorders,NCT02015676,https://clinicaltrials.gov/show/NCT02015676,Breast_Cancer,trastuzumab|paclitaxel|Myocet|,other_events,arm0,Trastuzumab-Doxorubicin-Paclitaxel;-Phase-I-&-II,2,paclitaxel,taxane
2756,Allergic_reaction,2,28,Immune_system_disorders,NCT02127372,https://clinicaltrials.gov/show/NCT02127372,Non-small_Cell_Lung_Cancer,Docetaxel_Cisplatin_and_STI571|Docetaxel|Cisplatin|,other_events,arm1,Phase-2,,,
1105,Hypersensitivity,2,99,Immune_system_disorders,NCT02461290,https://clinicaltrials.gov/show/NCT02461290,Follicular_Lymphoma,Chemotherapy|Rituximab|,serious_events,arm0,Rituximab-+-Chemotherapy,16,rituximab,monoclonal-antibody
1106,Hypersensitivity,4,99,Immune_system_disorders,NCT02461290,https://clinicaltrials.gov/show/NCT02461290,Follicular_Lymphoma,Chemotherapy|Rituximab|,other_events,arm0,Rituximab-+-Chemotherapy,16,rituximab,monoclonal-antibody
